Microinjection	O
of	O
ritanserin	D016713
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	D012601
-	O
induced	O
amnesia	D000647
in	O
adult	O
male	O
rats	10116
.	O

The	O
effect	O
of	O
ritanserin	D016713
(	O
5	29595
-	O
HT2	29595
antagonist	O
)	O
on	O
scopolamine	D012601
(	O
muscarinic	25229
cholinergic	25229
antagonist	O
)	O
-	O
induced	O
amnesia	D000647
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O

Rats	10116
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	D004121
,	O
saline	O
+	O
DMSO	D004121
)	O
,	O
scopolamine	D012601
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
saline	O
/	O
side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	D016713
(	O
2	O
,	O
4	O
and	O
8	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	D004121
/	O
side	O
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	D012601
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
;	O
30	O
min	O
before	O
ritanserin	D016713
injection	O
)	O
+	O
ritanserin	D016713
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	D004121
)	O
through	O
cannulae	O
each	O
day	O
.	O

Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial	O
/	O
day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O

In	O
the	O
fifth	O
day	O
,	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
,	O
motivational	O
and	O
visual	O
systems	O
.	O

The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	D012601
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O

Ritanserin	D016713
-	O
treated	O
rats	10116
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	D004121
-	O
treated	O
group	O
.	O

However	O
,	O
scopolamine	D012601
and	O
ritanserin	D016713
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	D012601
-	O
treated	O
rats	10116
.	O

Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	D016713
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	D012601
-	O
induced	O
amnesia	D000647
.	O
P2RX7	5027
:	O
A	O
bipolar	D001714,D003866
and	D001714,D003866
unipolar	D001714,D003866
disorder	D001714,D003866
candidate	O
susceptibility	O
gene?	O
The	O
chromosomal	O
region	O
12q24	O
has	O
been	O
previously	O
implicated	O
by	O
linkage	O
studies	O
of	O
both	O
bipolar	D001714
disorder	D001714
and	O
unipolar	D003866,D019964
mood	D003866,D019964
disorder	D003866,D019964
and	O
we	O
have	O
reported	O
two	O
pedigrees	O
segregating	O
both	O
bipolar	D001714
disorder	D001714
and	O
Darier	D007644
'	O
s	D007644
disease	D007644
that	O
show	O
linkage	O
across	O
this	O
region	O
.	O

The	O
gene	O
P2RX7	5027
is	O
located	O
in	O
this	O
chromosomal	O
region	O
and	O
has	O
been	O
recently	O
reported	O
as	O
a	O
susceptibility	O
gene	O
for	O
bipolar	D001714
disorder	D001714
and	O
unipolar	D003866
depression	D003866
.	O

The	O
non	O
-	O
synonymous	O
SNP	O
rs2230912	rs2230912
(	O
resulting	O
in	O
amino	O
-	O
acid	O
polymorphism	O
Q460R	rs2230912
)	O
showed	O
the	O
strongest	O
association	O
and	O
has	O
been	O
postulated	O
to	O
be	O
pathogenically	O
relevant	O
.	O

We	O
have	O
investigated	O
this	O
gene	O
in	O
a	O
large	O
UK	O
case	O
-	O
control	O
sample	O
(	O
bipolar	D001714
I	D001714
disorder	D001714
N	O
=	O
687	O
,	O
unipolar	D003865
recurrent	D003865
major	D003865
depression	D003865
N	O
=	O
1	O
,	O
036	O
,	O
controls	O
N	O
=	O
1	O
,	O
204	O
)	O
.	O

Neither	O
rs2230912	rs2230912
nor	O
any	O
of	O
8	O
other	O
SNPs	O
genotyped	O
across	O
P2RX7	5027
was	O
found	O
to	O
be	O
associated	O
with	O
mood	D019964
disorder	D019964
in	O
general	O
,	O
nor	O
specifically	O
with	O
bipolar	D001714,D003866
or	D001714,D003866
unipolar	D001714,D003866
disorder	D001714,D003866
.	O

Further	O
,	O
sequencing	O
of	O
our	O
two	O
chromosome	O
12	O
-	O
linked	O
bipolar	O
-	O
Darier	O
families	O
showed	O
no	O
evidence	O
of	O
rare	O
variants	O
at	O
P2RX7	5027
that	O
could	O
explain	O
the	O
linkage	O
.	O

Our	O
data	O
do	O
not	O
provide	O
support	O
for	O
rs2230912	rs2230912
or	O
the	O
other	O
polymorphisms	O
studied	O
within	O
the	O
P2RX7	5027
locus	O
,	O
being	O
involved	O
in	O
susceptibility	O
to	O
mood	D019964
disorders	D019964
.	O
Pilocarpine	D010862
seizures	D012640
cause	O
age	O
-	O
dependent	O
impairment	D001308
in	D001308
auditory	D001308
location	D001308
discrimination	D001308
.	O

Children	O
who	O
have	O
status	D013226
epilepticus	D013226
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	D012640
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O

The	O
extent	O
to	O
which	O
status	D013226
epilepticus	D013226
causes	O
deficits	D001308
in	D001308
auditory	D001308
discrimination	D001308
is	O
unknown	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	D013226
epilepticus	D013226
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	10116
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	D010862
on	O
P20	O
or	O
P45	O
.	O

Pilocarpine	D010862
on	O
either	O
day	O
induced	O
status	D013226
epilepticus	D013226
;	O
status	D013226
epilepticus	D013226
at	O
P45	O
resulted	O
in	O
CA3	10090
cell	O
loss	O
and	O
spontaneous	O
seizures	D012640
,	O
whereas	O
P20	O
rats	10116
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	D012640
.	O

Mature	O
rats	10116
were	O
trained	O
with	O
sound	O
-	O
source	O
location	O
and	O
sound	O
-	O
silence	O
discriminations	O
.	O

Control	O
(	O
saline	O
P20	O
)	O
rats	10116
acquired	O
both	O
discriminations	O
immediately	O
.	O

In	O
status	D013226
epilepticus	D013226
(	O
P20	O
)	O
rats	10116
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O

Status	D013226
epilepticus	D013226
(	O
P45	O
)	O
rats	10116
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O

Status	D013226
epilepticus	D013226
in	O
rat	10116
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	D001308
in	D001308
auditory	D001308
discrimination	D001308
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	D001308
auditory	D001308
location	D001308
discrimination	D001308
in	O
humans	9606
.	O
The	O
first	O
founder	O
DGUOK	1716
mutation	O
associated	O
with	O
hepatocerebral	C580039
mitochondrial	C580039
DNA	C580039
depletion	C580039
syndrome	C580039
.	O

Deoxyguanosine	C580039
kinase	C580039
(	O
dGK	C580039
)	O
deficiency	C580039
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	C580039
DNA	C580039
depletion	C580039
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	1716
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	1716
patients	9606
.	O

This	O
new	O
DGUOK	1716
homozygous	O
mutation	O
(	O
c	c|SUB|C|444-62|A
.	O
444	c|SUB|C|444-62|A
-	O
62C	c|SUB|C|444-62|A
>	O
A	c|SUB|C|444-62|A
)	O
was	O
identified	O
in	O
three	O
patients	9606
from	O
two	O
North	O
-	O
African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	D028361
chain	D028361
deficiencies	D028361
and	O
mitochondrial	C580039
DNA	C580039
depletion	C580039
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	1716
patients	9606
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	-
abnormal	-
myelination	-
and	O
moderate	D006973
hyperintensity	D006973
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	9606
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-	O
62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	1716
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	D003853
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
)	O
,	O
which	O
span	O
4	O
.	O
6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	1716
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	1716
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	1716
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North	O
-	O
African	O
population	O
.	O
Atypical	O
GH	D046150
insensitivity	D046150
syndrome	D046150
and	O
severe	O
insulin	C563867
-	O
like	C563867
growth	C563867
factor	C563867
-	O
I	C563867
deficiency	C563867
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	2690
receptor	2690
,	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
GH	D046150
insensitivity	D046150
and	O
IGF	C563867
deficiency	C563867
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	2690
receptor	2690
(	O
GHR	2690
)	O
.	O

We	O
describe	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
modest	O
growth	D006130
failure	D006130
and	O
normal	O
serum	O
concentrations	O
of	O
GH	2690
-	O
binding	2690
protein	2690
(	O
GHBP	2690
)	O
,	O
but	O
clinical	O
evidence	O
of	O
GH	D046150
insensitivity	D046150
.	O

METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-	O
4	O
SD	O
,	O
elevated	O
serum	O
GH	2688
concentrations	O
,	O
abnormally	O
low	O
serum	O
IGF	3479
-	O
I	3479
and	O
IGFBP	3486
-	O
3	3486
concentrations	O
and	O
normal	O
GHBP	2690
concentrations	O
.	O

DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	2690
,	O
including	O
a	O
previously	O
reported	O
R211H	p|SUB|R|211|H
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
(	O
899dupC	c|DUP|899|C|
)	O
,	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O

Treatment	O
with	O
recombinant	O
DNA	O
-	O
derived	O
IGF	3479
-	O
I	3479
resulted	O
in	O
growth	O
acceleration	O
.	O

CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	2690
can	O
result	O
in	O
GH	D046150
insensitivity	D046150
and	O
IGF	C563867
deficiency	C563867
,	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	2690
.	O

The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	2688
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	2690
,	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	2690
concentrations	O
.	O
Safety	O
of	O
capecitabine	D000069287
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	-
,	O
in	O
particular	O
5	D005472
-	O
fluorouracil	D005472
(	O
5	D005472
-	O
FU	D005472
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	D009369
,	O
including	O
colorectal	D001943,D006258,D015179
,	O
breast	D001943,D006258,D015179
and	D001943,D006258,D015179
head	D001943,D006258,D015179
and	D001943,D006258,D015179
neck	D001943,D006258,D015179
cancers	D001943,D006258,D015179
,	O
for	O
>	O
40	O
years	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	D000069287
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	D000069287
in	O
special	O
populations	O
such	O
as	O
patients	9606
with	O
advanced	O
age	O
,	O
renal	D007674
and	D007674
kidney	D007674
disease	D007674
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	D000069287
administration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	D000069287
is	O
an	O
oral	O
prodrug	O
of	O
5	D005472
-	O
FU	D005472
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	D001943,D002292,D006258,D010190,D013274,D015179
,	O
breast	D001943,D002292,D006258,D010190,D013274,D015179
,	O
pancreaticobiliary	D001943,D002292,D006258,D010190,D013274,D015179
,	O
gastric	D001943,D002292,D006258,D010190,D013274,D015179
,	O
renal	D001943,D002292,D006258,D010190,D013274,D015179
cell	D001943,D002292,D006258,D010190,D013274,D015179
and	D001943,D002292,D006258,D010190,D013274,D015179
head	D001943,D002292,D006258,D010190,D013274,D015179
and	D001943,D002292,D006258,D010190,D013274,D015179
neck	D001943,D002292,D006258,D010190,D013274,D015179
cancers	D001943,D002292,D006258,D010190,D013274,D015179
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	D000069287
are	O
diarrhea	D003967
,	O
nausea	D009325
,	O
vomiting	D014839
,	O
stomatitis	D013280
and	O
hand	D060831
-	O
foot	D060831
syndrome	D060831
.	O

Capecitabine	D000069287
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	9606
with	O
advanced	O
age	O
,	O
hepatic	D007674,D008107
and	D007674,D008107
renal	D007674,D008107
dysfunctions	D007674,D008107
.	O
Fluoxetine	D005473
improves	O
the	O
memory	D008569
deficits	D008569
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	D005472
-	O
fluorouracil	D005472
.	O

Cancer	D009369
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O

A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5	D005472
-	O
fluorouracil	D005472
(	O
5	D005472
-	O
FU	D005472
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O

In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O

In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	D017367
antidepressant	O
Fluoxetine	D005473
.	O

In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	D005472
-	O
FU	D005472
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	D005473
either	O
separately	O
or	O
in	O
combination	O
with	O
5	D005472
-	O
FU	D005472
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	10116
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	D005472
-	O
FU	D005472
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O

Animals	O
treated	O
only	O
with	O
5	D005472
-	O
FU	D005472
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	D005473
improved	O
their	O
performance	O
.	O

5	D005472
-	O
FU	D005472
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	D005473
was	O
co	O
administered	O
with	O
5	D005472
-	O
FU	D005472
.	O

Fluoxetine	D005473
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O

These	O
findings	O
suggest	O
that	O
5	D005472
-	O
FU	D005472
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	D005473
.	O
TIEG1	21847
deficiency	O
confers	O
enhanced	O
myocardial	O
protection	O
in	O
the	O
infarcted	D009203
heart	D009203
by	O
mediating	O
the	O
Pten	19211
/	O
Akt	11651
signalling	O
pathway	O
.	O

The	O
transforming	21847
growth	21847
factor	21847
(	O
TGF	21847
)	O
-	O
b	21847
-	O
inducible	21847
early	21847
gene	21847
-	O
1	21847
(	O
TIEG1	21847
)	O
plays	O
a	O
crucial	O
role	O
in	O
modulating	O
cell	O
apoptosis	O
and	O
proliferation	O
in	O
a	O
number	O
of	O
diseases	O
,	O
including	O
pancreatic	D010190
cancer	D010190
,	O
leukaemia	D007938
and	O
osteoporosis	D010024
.	O

However	O
,	O
the	O
functional	O
role	O
of	O
TIEG1	21847
in	O
the	O
heart	O
has	O
not	O
been	O
fully	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
the	O
role	O
of	O
TIEG1	21847
in	O
ischaemic	D017202
heart	D017202
disease	D017202
.	O

For	O
in	O
vitro	O
experiments	O
,	O
cardiomyocytes	O
were	O
isolated	O
from	O
both	O
TIEG1	21847
knockout	O
(	O
KO	O
)	O
and	O
wile	O
-	O
type	O
(	O
WT	O
)	O
mice	10090
,	O
and	O
the	O
apoptotic	O
ratios	O
were	O
evaluated	O
after	O
a	O
48	O
-	O
h	O
ischaemic	O
insult	O
.	O

A	O
cell	O
proliferation	O
assay	O
was	O
performed	O
after	O
7	O
days	O
of	O
incubation	O
under	O
normoxic	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
angiogenic	O
capacity	O
of	O
endothelial	O
cells	O
was	O
determined	O
by	O
tube	O
formation	O
assay	O
.	O

For	O
in	O
vivo	O
experiments	O
,	O
a	O
model	O
of	O
myocardial	D009203
infarction	D009203
(	O
MI	D009203
)	O
was	O
established	O
using	O
both	O
TIEG1	21847
KO	O
and	O
WT	O
mice	10090
.	O

Echocardiography	O
was	O
performed	O
at	O
3	O
and	O
28	O
days	O
post	O
-	O
MI	D009203
,	O
whereas	O
the	O
haemodynamics	O
test	O
was	O
performed	O
28	O
days	O
post	O
-	O
MI	D009203
.	O

Histological	O
analyses	O
of	O
apoptosis	O
,	O
proliferation	O
,	O
angiogenesis	O
and	O
infarct	D007238
zone	O
assessments	O
were	O
performed	O
using	O
terminal	1791
deoxynucleotidyltransferase	1791
-	O
mediated	O
dUTP	C027078
nick	O
-	O
end	O
labelling	O
(	O
TUNEL	O
)	O
staining	O
,	O
BrdU	O
immunostaining	O
,	O
a	11475
-	O
smooth	11475
muscle	11475
actin	11475
(	O
a	11475
-	O
SMA	11475
)	O
/	O
CD31	18613
immunostaining	O
and	O
Masson	O
'	O
s	O
trichrome	O
staining	O
,	O
respectively	O
.	O

Changes	O
in	O
the	O
expression	O
of	O
related	O
proteins	O
caused	O
by	O
TIEG1	21847
deficiency	O
were	O
confirmed	O
using	O
both	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
absence	O
of	O
TIEG1	21847
prevented	O
cardiomyocytes	O
from	O
undergoing	O
apoptosis	O
and	O
promoted	O
higher	O
proliferation	O
;	O
it	O
stimulated	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Improved	O
cardiac	O
function	O
and	O
less	O
scar	O
formation	O
were	O
observed	O
in	O
TIEG1	21847
KO	O
mice	10090
,	O
and	O
we	O
also	O
observed	O
the	O
altered	O
expression	O
of	O
phosphatase	19211
and	19211
tensin	19211
homolog	19211
(	O
Pten	19211
)	O
,	O
Akt	11651
and	O
Bcl	12043
-	O
2	12043
/	O
Bax	12028
,	O
as	O
well	O
as	O
vascular	22339
endothelial	22339
growth	22339
factor	22339
(	O
VEGF	22339
)	O
.	O

On	O
the	O
whole	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
absence	O
of	O
TIEG1	21847
plays	O
a	O
cardioprotective	O
role	O
in	O
ischaemic	D017202
heart	D017202
disease	D017202
by	O
promoting	O
changes	O
in	O
Pten	19211
/	O
Akt	11651
signalling	O
.	O
Long	O
-	O
Lived	O
CD4	12504
+	O
IFN	15978
-	O
g	15978
+	O
T	O
Cells	O
rather	O
than	O
Short	O
-	O
Lived	O
CD4	12504
+	O
IFN	15978
-	O
g	15978
+	O
IL	16153
-	O
10	16153
+	O
T	O
Cells	O
Initiate	O
Rapid	O
IL	16153
-	O
10	16153
Production	O
To	O
Suppress	O
Anamnestic	O
T	O
Cell	O
Responses	O
during	O
Secondary	O
Malaria	D008288
Infection	D008288
.	O

CD4	12504
(	O
+	O
)	O
T	O
cells	O
that	O
produce	O
IFN	15978
-	O
g	15978
are	O
the	O
source	O
of	O
host	O
-	O
protective	O
IL	16153
-	O
10	16153
during	O
primary	O
infection	D007239
with	O
a	O
number	O
of	O
different	O
pathogens	O
,	O
including	O
Plasmodium	O
spp	O
.	O

The	O
fate	O
of	O
these	O
CD4	12504
(	O
+	O
)	O
IFN	15978
-	O
g	15978
(	O
+	O
)	O
IL	16153
-	O
10	16153
(	O
+	O
)	O
T	O
cells	O
following	O
clearance	O
of	O
primary	O
infection	D007239
and	O
their	O
subsequent	O
influence	O
on	O
the	O
course	O
of	O
repeated	O
infections	O
is	O
,	O
however	O
,	O
presently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
IFN	15978
-	O
g	15978
-	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
and	O
IL	16153
-	O
10	16153
-	O
GFP	O
dual	O
reporter	O
mice	10090
,	O
we	O
show	O
that	O
primary	O
malaria	D008288
infection	D008288
-	O
induced	O
CD4	12504
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
have	O
limited	O
memory	O
potential	O
,	O
do	O
not	O
stably	O
express	O
IL	16153
-	O
10	16153
,	O
and	O
are	O
disproportionately	O
lost	O
from	O
the	O
Ag	O
-	O
experienced	O
CD4	12504
(	O
+	O
)	O
T	O
cell	O
memory	O
population	O
during	O
the	O
maintenance	O
phase	O
postinfection	O
.	O

CD4	12504
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
generally	O
exhibited	O
a	O
short	O
-	O
lived	O
effector	O
rather	O
than	O
effector	O
memory	O
T	O
cell	O
phenotype	O
postinfection	O
and	O
expressed	O
high	O
levels	O
of	O
PD	18566
-	O
1	18566
,	O
Lag	16768
-	O
3	16768
,	O
and	O
TIGIT	100043314
,	O
indicative	O
of	O
cellular	O
exhaustion	O
.	O

Consistently	O
,	O
the	O
surviving	O
CD4	12504
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
were	O
unresponsive	O
and	O
failed	O
to	O
proliferate	O
during	O
the	O
early	O
phase	O
of	O
secondary	O
infection	D007239
.	O

In	O
contrast	O
,	O
CD4	12504
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
-	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
expanded	O
rapidly	O
and	O
upregulated	O
IL	16153
-	O
10	16153
expression	O
during	O
secondary	O
infection	D007239
.	O

Correspondingly	O
,	O
CD4	12504
(	O
+	O
)	O
T	O
cells	O
were	O
the	O
major	O
producers	O
within	O
an	O
accelerated	O
and	O
amplified	O
IL	16153
-	O
10	16153
response	O
during	O
the	O
early	O
stage	O
of	O
secondary	O
malaria	D008288
infection	D008288
.	O

Notably	O
,	O
IL	16153
-	O
10	16153
exerted	O
quantitatively	O
stronger	O
regulatory	O
effects	O
on	O
innate	O
and	O
CD4	12504
(	O
+	O
)	O
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
infections	O
,	O
respectively	O
.	O

The	O
results	O
in	O
this	O
study	O
significantly	O
improve	O
our	O
understanding	O
of	O
the	O
durability	O
of	O
IL	16153
-	O
10	16153
-	O
producing	O
CD4	12504
(	O
+	O
)	O
T	O
cells	O
postinfection	O
and	O
provide	O
information	O
on	O
how	O
IL	16153
-	O
10	16153
may	O
contribute	O
to	O
optimized	O
parasite	O
control	O
and	O
prevention	O
of	O
immune	O
-	O
mediated	O
pathology	O
during	O
repeated	O
malaria	D008288
infections	D008288
.	O
Chloroacetaldehyde	C004656
as	O
a	O
sulfhydryl	D013439
reagent	D013439
:	O
the	O
role	O
of	O
critical	O
thiol	D013438
groups	O
in	O
ifosfamide	D007069
nephropathy	D007674
.	O

Chloroacetaldehyde	C004656
(	O
CAA	C004656
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	D000477
agent	D000477
ifosfamide	D007069
(	O
IFO	D007069
)	O
and	O
putatively	O
responsible	O
for	O
renal	D007674
damage	D007674
following	O
anti	O
-	O
tumor	D009369
therapy	O
with	O
IFO	D007069
.	O

Depletion	O
of	O
sulfhydryl	D013439
(	O
SH	D013439
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
work	O
the	O
effect	O
of	O
CAA	C004656
on	O
human	9606
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	9606
)	O
was	O
investigated	O
.	O

Toxicity	D064420
of	O
CAA	C004656
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	D007770
release	O
,	O
trypan	D014343
blue	D014343
exclusion	O
assay	O
and	O
caspase	836
-	O
3	836
activity	O
.	O

Free	O
thiols	D013438
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O

CAA	C004656
reduced	O
hRPTEC	9606
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	D013438
and	O
an	O
increase	O
in	O
necrosis	D009336
markers	O
.	O

CAA	C004656
but	O
not	O
acrolein	D000171
inhibited	O
the	O
cysteine	1508,836,841
proteases	1508,836,841
caspase	836
-	O
3	836
,	O
caspase	841
-	O
8	841
and	O
cathepsin	1508
B	1508
.	O

Caspase	836,841
activation	O
by	O
cisplatin	D002945
was	O
inhibited	O
by	O
CAA	C004656
.	O

In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	C004656
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O

The	O
effects	O
of	O
CAA	C004656
on	O
cysteine	1508,836,841
protease	1508,836,841
activities	O
and	O
thiols	D013438
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	C004656
with	O
thiol	D013438
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	C004656
on	O
necrosis	D009336
markers	O
,	O
thiol	D013438
depletion	O
and	O
cysteine	1508,836,841
protease	1508,836,841
inhibition	O
in	O
living	O
cells	O
.	O

Thus	O
,	O
CAA	C004656
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	D013438
,	O
mediating	O
its	O
toxicity	D064420
on	O
hRPTEC	9606
.	O

This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O

Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	D007069
nephropathy	D007674
in	O
patients	9606
.	O
Absence	O
of	O
PKC	18750
-	O
alpha	18750
attenuates	O
lithium	D008094
-	O
induced	O
nephrogenic	D018500
diabetes	D018500
insipidus	D018500
.	O

Lithium	D008094
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	D018500
diabetes	D018500
insipidus	D018500
(	O
NDI	D018500
)	O
in	O
40%	O
of	O
patients	9606
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	D008094
acutely	O
disrupting	O
the	O
cAMP	D000242
pathway	O
and	O
chronically	O
reducing	O
urea	27411
transporter	27411
(	O
UT	27411
-	O
A1	27411
)	O
and	O
water	O
channel	O
(	O
AQP2	11827
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	18750
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	D008094
-	O
induced	O
polyuria	D011141
.	O

PKC	18750
-	O
alpha	18750
null	O
mice	10090
(	O
PKCa	18750
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	D008094
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

WT	O
mice	10090
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	18750
KO	O
mice	10090
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	11827
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	10090
;	O
however	O
,	O
AQP2	11827
was	O
unchanged	O
in	O
PKCa	18750
KO	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT	27411
-	O
A1	27411
expression	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	D008094
for	O
6	O
weeks	O
.	O

Lithium	D008094
-	O
treated	O
WT	O
mice	10090
had	O
19	O
-	O
fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	18750
KO	O
animals	O
had	O
a	O
4	O
-	O
fold	O
increase	O
in	O
output	O
.	O

AQP2	11827
and	O
UT	27411
-	O
A1	27411
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	D008094
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	18750
KO	O
mice	10090
,	O
AQP2	11827
was	O
only	O
reduced	O
by	O
2	O
-	O
fold	O
and	O
UT	27411
-	O
A1	27411
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	D012964
,	O
potassium	D011188
and	O
calcium	D002118
were	O
elevated	O
in	O
lithium	D008094
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	D008094
-	O
fed	O
PKCa	18750
KO	O
mice	10090
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	18750
preserves	O
AQP2	11827
and	O
UT	27411
-	O
A1	27411
protein	O
expression	O
and	O
localization	O
in	O
lithium	D008094
-	O
induced	O
NDI	D018500
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	D011141
associated	O
with	O
lithium	D008094
therapy	O
.	O
H3	11255
histamine	11255
receptor	11255
-	O
mediated	O
activation	O
of	O
protein	5578
kinase	5578
Calpha	5578
inhibits	O
the	O
growth	O
of	O
cholangiocarcinoma	D018281
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Histamine	D006632
regulates	O
functions	O
via	O
four	O
receptors	O
(	O
HRH1	3269
,	O
HRH2	3274
,	O
HRH3	11255
,	O
and	O
HRH4	59340
)	O
.	O

The	O
d	D015544
-	O
myo	D015544
-	O
inositol	D015544
1	D015544
,	O
4	D015544
,	O
5	D015544
-	O
trisphosphate	D015544
(	O
IP	D015544
(	O
3	D015544
)	O
)	O
/	O
Ca	D002118
(	O
2	D002118
+	O
)	O
/	O
protein	5578
kinase	5578
C	5578
(	O
PKC	5578
)	O
/	O
mitogen	5594,5595
-	O
activated	5594,5595
protein	5594,5595
kinase	5594,5595
pathway	O
regulates	O
cholangiocarcinoma	D018281
growth	O
.	O

We	O
evaluated	O
the	O
role	O
of	O
HRH3	11255
in	O
the	O
regulation	O
of	O
cholangiocarcinoma	D018281
growth	O
.	O

Expression	O
of	O
HRH3	11255
in	O
intrahepatic	O
and	O
extrahepatic	O
cell	O
lines	O
,	O
normal	O
cholangiocytes	O
,	O
and	O
human	9606
tissue	O
arrays	O
was	O
measured	O
.	O

In	O
Mz	9606
-	O
ChA	9606
-	O
1	9606
cells	O
stimulated	O
with	O
(	O
R	C069357
)	O
-	O
(	O
alpha	C069357
)	O
-	O
(	O
-	O
)	O
-	O
methylhistamine	C069357
dihydrobromide	C069357
(	O
RAMH	C069357
)	O
,	O
we	O
measured	O
(	O
a	O
)	O
cell	O
growth	O
,	O
(	O
b	O
)	O
IP	D015544
(	O
3	D015544
)	O
and	O
cyclic	D000242
AMP	D000242
levels	O
,	O
and	O
(	O
c	O
)	O
phosphorylation	O
of	O
PKC	5578
and	O
mitogen	5594,5595
-	O
activated	5594,5595
protein	5594,5595
kinase	5594,5595
isoforms	O
.	O

Localization	O
of	O
PKCalpha	5578
was	O
visualized	O
by	O
immunofluorescence	O
in	O
cell	O
smears	O
and	O
immunoblotting	O
for	O
PKCalpha	5578
in	O
cytosol	O
and	O
membrane	O
fractions	O
.	O

Following	O
knockdown	O
of	O
PKCalpha	5578
,	O
Mz	9606
-	O
ChA	9606
-	O
1	9606
cells	O
were	O
stimulated	O
with	O
RAMH	C069357
before	O
evaluating	O
cell	O
growth	O
and	O
extracellular	5595;5594
signal	5595;5594
-	O
regulated	5595;5594
kinase	5595;5594
(	O
ERK	5595;5594
)	O
-	O
1	5595;5594
/	O
2	5595;5594
phosphorylation	O
.	O

In	O
vivo	O
experiments	O
were	O
done	O
in	O
BALB	10090
/	O
c	10090
nude	O
mice	10090
.	O

Mice	10090
were	O
treated	O
with	O
saline	O
or	O
RAMH	C069357
for	O
44	O
days	O
and	O
tumor	D009369
volume	O
was	O
measured	O
.	O

Tumors	D009369
were	O
excised	O
and	O
evaluated	O
for	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
expression	O
of	O
PKCalpha	5578
,	O
vascular	7422
endothelial	7422
growth	7422
factor	7422
(	O
VEGF	7422
)	O
-	O
A	7422
,	O
VEGF	7424
-	O
C	7424
,	O
VEGF	3791
receptor	3791
2	3791
,	O
and	O
VEGF	2324
receptor	2324
3	2324
.	O

HRH3	11255
expression	O
was	O
found	O
in	O
all	O
cells	O
.	O

RAMH	C069357
inhibited	O
the	O
growth	O
of	O
cholangiocarcinoma	D018281
cells	O
.	O

RAMH	C069357
increased	O
IP	D015544
(	O
3	D015544
)	O
levels	O
and	O
PKCalpha	5578
phosphorylation	O
and	O
decreased	O
ERK1	5595;5594
/	O
2	5595;5594
phosphorylation	O
.	O

RAMH	C069357
induced	O
a	O
shift	O
in	O
the	O
localization	O
of	O
PKCalpha	5578
expression	O
from	O
the	O
cytosolic	O
domain	O
into	O
the	O
membrane	O
region	O
of	O
Mz	9606
-	O
ChA	9606
-	O
1	9606
cells	O
.	O

Silencing	O
of	O
PKCalpha	5578
prevented	O
RAMH	C069357
inhibition	O
of	O
Mz	9606
-	O
ChA	9606
-	O
1	9606
cell	O
growth	O
and	O
ablated	O
RAMH	C069357
effects	O
on	O
ERK1	5595;5594
/	O
2	5595;5594
phosphorylation	O
.	O

In	O
vivo	O
,	O
RAMH	C069357
decreased	O
tumor	D009369
growth	O
and	O
expression	O
of	O
VEGF	7422;7424
and	O
its	O
receptors	O
;	O
PKCalpha	5578
expression	O
was	O
increased	O
.	O

RAMH	C069357
inhibits	O
cholangiocarcinoma	D018281
growth	O
by	O
PKCalpha	5578
-	O
dependent	O
ERK1	5595;5594
/	O
2	5595;5594
dephosphorylation	O
.	O

Modulation	O
of	O
PKCalpha	5578
by	O
histamine	11255,3269,3274,59340
receptors	11255,3269,3274,59340
may	O
be	O
important	O
in	O
regulating	O
cholangiocarcinoma	D018281
growth	O
.	O
The	O
G51S	rs1049564
purine	4860
nucleoside	4860
phosphorylase	4860
polymorphism	O
is	O
associated	O
with	O
cognitive	D003072
decline	D003072
in	O
Alzheimer	D000544
'	O
s	D000544
disease	D000544
patients	9606
.	O

Alzheimer	D000544
'	O
s	D000544
disease	D000544
(	O
AD	D000544
)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
,	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
,	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O

Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O

Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
,	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
,	O
apoptosis	O
,	O
and	O
inflammatory	D007249
responses	O
.	O

These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	D000544
.	O

In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G	rs1049564
/	O
A	rs1049564
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
purine	4860
nucleoside	4860
phosphorylase	4860
(	O
PNP	4860
)	O
gene	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	rs1049564
to	rs1049564
glycine	rs1049564
at	rs1049564
position	rs1049564
51	rs1049564
(	O
G51S	rs1049564
)	O
,	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	D000544
patients	9606
(	O
n	O
=	O
321	O
)	O
and	O
non	O
-	O
demented	O
control	O
(	O
n	O
=	O
208	O
)	O
.	O

The	O
PNP	4860
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	9606
and	O
controls	O
.	O

The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	D000544
patients	9606
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	D003072
decline	D003072
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O

An	O
increased	O
representation	O
of	O
the	O
PNP	4860
AA	O
genotype	O
was	O
observed	O
in	O
AD	D000544
patients	9606
with	O
fast	O
cognitive	D003072
deterioration	D003072
in	O
comparison	O
with	O
that	O
from	O
patients	9606
with	O
slow	O
deterioration	O
rate	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
G51S	rs1049564
PNP	4860
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	D003072
decline	D003072
in	O
AD	D000544
patients	9606
,	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	D019636
disorder	D019636
.	O
Antithrombotic	D005343
drug	D005343
use	O
,	O
cerebral	D002543
microbleeds	D002543
,	O
and	O
intracerebral	D002543
hemorrhage	D002543
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	D002543
microbleeds	D002543
(	O
MB	D002543
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	D002543
hemorrhage	D002543
(	O
ICH	D002543
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	D005343
drugs	D005343
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	D002543
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	D002543
and	O
ischemic	D002544
stroke	D002544
(	O
IS	D002544
)	O
/	O
transient	D002546
ischemic	D002546
attack	D002546
(	O
TIA	D002546
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	D020521
or	O
TIA	D002546
to	O
compare	O
the	O
presence	O
of	O
MB	D002543
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	D002543
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	D002544
/	O
TIA	D002546
;	O
and	O
(	O
3	O
)	O
ICH	D002543
vs	O
ischemic	D007511
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O

We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	D002543
in	O
antithrombotic	O
users	O
with	O
MB	D002543
.	O

RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	D002543
and	O
3817	O
IS	D002544
/	O
TIA	D002546
,	O
MB	D002543
were	O
more	O
frequent	O
in	O
ICH	D002543
vs	O
IS	D002544
/	O
TIA	D002546
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2	O
.	O
8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfarin	D014859
users	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
excess	O
of	O
MB	D002543
in	O
warfarin	D014859
users	O
vs	O
nonusers	O
with	O
ICH	D002543
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
warfarin	D014859
users	O
with	O
IS	D002544
/	O
TIA	D002546
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	D002543
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	D002543
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	D002544
/	O
TIA	D002546
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	D002543
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	D002543
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	D002543
in	O
warfarin	D014859
users	O
with	O
ICH	D002543
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	D002543
increase	O
the	O
risk	O
of	O
warfarin	D014859
-	O
associated	O
ICH	D002543
.	O

Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O
Efficacy	O
of	O
everolimus	D000068338
(	O
RAD001	D000068338
)	O
in	O
patients	9606
with	O
advanced	O
NSCLC	D002289
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	1956
inhibitors	O
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	D002289
-	O
small	D002289
-	O
cell	D002289
lung	D002289
cancer	D002289
(	O
NSCLC	D002289
)	O
patients	9606
.	O

RAD001	D000068338
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	2475
target	2475
of	2475
rapamycin	2475
(	O
mTOR	2475
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	D002289
.	O

METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	D002289
patients	9606
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	D010984
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	1956
growth	1956
factor	1956
receptor	1956
tyrosine	1956
kinase	1956
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	D000068338
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	D064420
.	O

Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	2475
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	D009369
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	9606
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O

ORR	O
was	O
4	O
.	O
7%	O
(	O
7	O
.	O
1%	O
stratum	O
1	O
;	O
2	O
.	O
3%	O
stratum	O
2	O
)	O
.	O

Overall	O
disease	O
control	O
rate	O
was	O
47	O
.	O
1%	O
.	O

Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2	O
.	O
6	O
(	O
stratum	O
1	O
)	O
and	O
2	O
.	O
7	O
months	O
(	O
stratum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	D005221
,	O
dyspnea	D004417
,	O
stomatitis	D013280
,	O
anemia	D000740
,	O
and	O
thrombocytopenia	D013921
.	O

Pneumonitis	D011014
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25%	O
.	O

Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	207
(	O
pAKT	207
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	D000068338
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	D002289
.	O

Evaluation	O
of	O
RAD001	D000068338
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	D002289
continues	O
.	O
Decreased	O
Whole	O
-	O
Body	O
Fat	O
Mass	O
Produced	O
by	O
Chronic	O
Alcohol	D000438
Consumption	O
is	O
Associated	O
with	O
Activation	O
of	O
S6K1	72508
-	O
Mediated	O
Protein	O
Synthesis	O
and	O
Increased	O
Autophagy	O
in	O
Epididymal	O
White	O
Adipose	O
Tissue	O
.	O

BACKGROUND	O
:	O
Chronic	O
alcohol	D000438
consumption	O
leads	O
to	O
a	O
loss	O
of	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
but	O
the	O
underlying	O
mechanisms	O
for	O
this	O
lipodystrophy	D008060
are	O
not	O
fully	O
elucidated	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
reduction	O
in	O
WAT	O
mass	O
in	O
chronic	O
alcohol	D000438
-	O
fed	O
mice	10090
is	O
associated	O
with	O
a	O
decreased	O
protein	O
synthesis	O
specifically	O
related	O
to	O
impaired	O
function	O
of	O
mammalian	56717
target	56717
of	56717
rapamycin	56717
(	O
mTOR	56717
)	O
.	O

METHODS	O
:	O
Adult	O
male	O
mice	10090
were	O
provided	O
an	O
alcohol	D000438
-	O
containing	O
liquid	O
diet	O
for	O
24	O
weeks	O
or	O
an	O
isonitrogenous	O
isocaloric	O
control	O
diet	O
.	O

In	O
vivo	O
protein	O
synthesis	O
was	O
determined	O
at	O
this	O
time	O
and	O
thereafter	O
epididymal	O
WAT	O
(	O
eWAT	O
)	O
was	O
excised	O
for	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
central	O
to	O
controling	O
protein	O
synthesis	O
and	O
degradation	O
.	O

RESULTS	O
:	O
While	O
chronic	O
alcohol	D000438
feeding	O
decreased	O
whole	O
-	O
body	O
and	O
eWAT	O
mass	O
,	O
this	O
was	O
associated	O
with	O
a	O
discordant	O
increase	O
in	O
protein	O
synthesis	O
in	O
eWAT	O
.	O

This	O
increase	O
was	O
not	O
associated	O
with	O
a	O
change	O
in	O
mTOR	56717
,	O
4E	13685
-	O
BP1	13685
,	O
Akt	11651
,	O
or	O
PRAS40	67605
phosphorylation	O
.	O

Instead	O
,	O
a	O
selective	O
increase	O
in	O
phosphorylation	O
of	O
S6K1	72508
and	O
its	O
downstream	O
substrates	O
,	O
S6	20104
and	O
eIF4B	75705
was	O
detected	O
in	O
alcohol	D000438
-	O
fed	O
mice	10090
.	O

Alcohol	D000438
also	O
increased	O
eEF2K	13631
phosphorylation	O
and	O
decreased	O
eEF2	13629
phosphorylation	O
consistent	O
with	O
increased	O
translation	O
elongation	O
.	O

Alcohol	D000438
increased	O
Atg12	11793,67526
-	O
5	11793,67526
,	O
LC3B	67443
-	O
I	67443
and	67443
-	O
II	67443
,	O
and	O
ULK1	22241
S555	p|Allele|S|555
phosphorylation	O
,	O
suggesting	O
increased	O
autophagy	O
,	O
while	O
markers	O
of	O
apoptosis	O
(	O
cleaved	O
caspase	12367,12371
-	O
3	12367,12371
and	12367,12371
-	O
9	12367,12371
,	O
and	O
PARP	11545
)	O
were	O
unchanged	O
.	O

Lipolytic	O
enzymes	O
(	O
ATGL	66853
and	O
HSL	16890
phosphorylation	O
)	O
were	O
increased	O
and	O
lipogenic	O
regulators	O
(	O
PPARgamma	19016
and	O
C	12606
/	O
EBPalpha	12606
)	O
were	O
decreased	O
in	O
eWAT	O
by	O
alcohol	D000438
.	O

Although	O
alcohol	D000438
increased	O
TNF	21926
-	O
alpha	21926
,	O
IL	16193
-	O
6	16193
,	O
and	O
IL	16176
-	O
1beta	16176
mRNA	O
,	O
no	O
change	O
in	O
key	O
components	O
of	O
the	O
NLRP3	216799
inflammasome	O
(	O
NLRP3	216799
,	O
ACS	66824
,	O
and	O
cleaved	O
caspase	12362
-	O
1	12362
)	O
was	O
detected	O
suggesting	O
alcohol	D000438
did	O
not	O
increase	O
pyroptosis	O
.	O

Plasma	O
insulin	16334
did	O
not	O
differ	O
between	O
groups	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
the	O
alcohol	D000438
-	O
induced	O
decrease	O
in	O
whole	O
-	O
body	O
fat	O
mass	O
resulted	O
in	O
part	O
from	O
activation	O
of	O
autophagy	O
in	O
eWAT	O
as	O
protein	O
synthesis	O
was	O
increased	O
and	O
mediated	O
by	O
the	O
specific	O
increase	O
in	O
the	O
activity	O
of	O
S6K1	72508
.	O
A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	9365
gene	O
may	O
be	O
associated	O
with	O
essential	D000075222
hypertension	D000075222
in	O
the	O
Chinese	O
Han	O
population	O
.	O

BACKGROUND	O
:	O
Mice	10090
with	O
defects	O
in	O
the	O
Klotho	16591
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	D001161
.	O

We	O
hypothesised	O
that	O
the	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	9606
Klotho	9365
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	D000075222
Hypertension	D000075222
(	O
EH	D000075222
)	O
.	O

METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
of	O
Klotho	9365
is	O
associated	O
with	O
EH	D000075222
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	9606
with	O
EH	D000075222
and	O
220	O
non	O
-	O
hypertensive	D006973
subjects	O
.	O

We	O
also	O
tested	O
whether	O
a	O
G	rs1207568
/	O
A	rs1207568
substitution	O
at	O
the	O
G	rs1207568
-	O
395A	rs1207568
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
.	O

RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
between	O
the	O
EH	D000075222
and	O
non	O
-	O
hypertension	D006973
groups	O
are	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
032	O
)	O
.	O

There	O
are	O
differential	O
effects	O
of	O
age	O
,	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
with	O
EH	D000075222
;	O
the	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	D000075222
in	O
subjects	O
over	O
60years	O
old	O
,	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	D000075222
in	O
the	O
-	O
395A	rs1207568
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0	O
.	O
593	O
(	O
P	O
=	O
0	O
.	O
024	O
)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O

The	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-	O
395A	rs1207568
carrier	O
of	O
a	O
498	O
-	O
bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G	rs1207568
-	O
395A	rs1207568
site	O
)	O
upstream	O
of	O
the	O
Klotho	9365
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-	O
395G	rs1207568
carrier	O
.	O

CONCLUSIONS	O
:	O
The	O
G	rs1207568
-	O
395A	rs1207568
polymorphism	O
of	O
the	O
human	9606
Klotho	9365
gene	O
is	O
associated	O
with	O
EH	D000075222
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O
Protective	O
effects	O
of	O
antithrombin	D000991
on	O
puromycin	D011692
aminonucleoside	D011692
nephrosis	D009401
in	O
rats	10116
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	D000991
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	10116
with	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
nephrosis	D009401
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	9606
nephrotic	D009404
syndrome	D009404
.	O

Antithrombin	D000991
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
was	O
administered	O
to	O
rats	10116
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	D011692
aminonucleoside	D011692
(	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
.	O

Treatment	O
with	O
antithrombin	D000991
attenuated	O
the	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
hematological	D006402
abnormalities	D006402
.	O

Puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
renal	D007674
dysfunction	D007674
and	O
hyperlipidemia	D006949
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	D007674
damage	D007674
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	10116
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	D000991
-	O
treated	O
rats	10116
.	O

In	O
addition	O
,	O
antithrombin	D000991
treatment	O
markedly	O
suppressed	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	29251
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
nephrotic	D009404
syndrome	D009404
.	O

Treatment	O
with	O
antithrombin	D000991
may	O
be	O
clinically	O
effective	O
in	O
patients	9606
with	O
nephrotic	D009404
syndrome	D009404
.	O
A	O
single	O
amino	O
acid	O
substitution	O
confers	O
B	O
-	O
cell	O
clonogenic	O
activity	O
to	O
the	O
HIV	11676
-	O
1	11676
matrix	O
protein	O
p17	155348
.	O

Recent	O
data	O
highlight	O
the	O
presence	O
,	O
in	O
HIV	D006679
-	O
1	D006679
-	O
seropositive	D006679
patients	9606
with	O
lymphoma	D008223
,	O
of	O
p17	155348
variants	O
(	O
vp17s	O
)	O
endowed	O
with	O
B	O
-	O
cell	O
clonogenicity	O
,	O
suggesting	O
a	O
role	O
of	O
vp17s	O
in	O
lymphomagenesis	D008223
.	O

We	O
investigated	O
the	O
mechanisms	O
responsible	O
for	O
the	O
functional	O
disparity	O
on	O
B	O
cells	O
between	O
a	O
wild	O
-	O
type	O
p17	155348
(	O
refp17	O
)	O
and	O
a	O
vp17	O
named	O
S75X	p|SUB|S|75|X
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
single	O
Arginine	p|SUB|R|76|G
(	O
R	p|SUB|R|76|G
)	O
to	p|SUB|R|76|G
Glycine	p|SUB|R|76|G
(	O
G	p|SUB|R|76|G
)	O
mutation	p|SUB|R|76|G
at	p|SUB|R|76|G
position	p|SUB|R|76|G
76	p|SUB|R|76|G
in	O
the	O
refp17	O
backbone	O
(	O
p17R76G	155348
)	O
,	O
as	O
in	O
the	O
S75X	p|SUB|S|75|X
variant	O
,	O
is	O
per	O
se	O
sufficient	O
to	O
confer	O
a	O
B	O
-	O
cell	O
clonogenic	O
potential	O
to	O
the	O
viral	O
protein	O
and	O
modulate	O
,	O
through	O
activation	O
of	O
the	O
PTEN	5728
/	O
PI3K	5291
/	O
Akt	207
signaling	O
pathway	O
,	O
different	O
molecules	O
involved	O
in	O
apoptosis	O
inhibition	O
(	O
CASP	842
-	O
9	842
,	O
CASP	840
-	O
7	840
,	O
DFF	1676
-	O
45	1676
,	O
NPM	4869
,	O
YWHAZ	7534
,	O
Src	6714
,	O
PAX2	5076
,	O
MAPK8	5599
)	O
,	O
cell	O
cycle	O
promotion	O
and	O
cancer	D009369
progression	O
(	O
CDK1	983
,	O
CDK2	1017
,	O
CDK8	1024
,	O
CHEK1	1111
,	O
CHEK2	11200
,	O
GSK	2932
-	O
3	2932
beta	2932
,	O
NPM	4869
,	O
PAK1	5058
,	O
PP2C	5494
-	O
alpha	5494
)	O
.	O

Moreover	O
,	O
the	O
only	O
R	p|SUB|R|76|G
to	p|SUB|R|76|G
G	p|SUB|R|76|G
mutation	p|SUB|R|76|G
at	p|SUB|R|76|G
position	p|SUB|R|76|G
76	p|SUB|R|76|G
was	O
found	O
to	O
strongly	O
impact	O
on	O
protein	O
folding	O
and	O
oligomerization	O
by	O
altering	O
the	O
hydrogen	O
bond	O
network	O
.	O

This	O
generates	O
a	O
conformational	O
shift	O
in	O
the	O
p17	155348
R76G	p|SUB|R|76|G
mutant	O
which	O
enables	O
a	O
functional	O
epitope	O
(	O
s	O
)	O
,	O
masked	O
in	O
refp17	O
,	O
to	O
elicit	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
signals	O
after	O
its	O
interaction	O
with	O
a	O
still	O
unknown	O
receptor	O
(	O
s	O
)	O
.	O

Our	O
findings	O
offer	O
new	O
opportunities	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
accounting	O
for	O
the	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
activity	O
of	O
vp17s	O
.	O
Mutation	O
analysis	O
of	O
CHRNA1	1134
,	O
CHRNB1	1140
,	O
CHRND	1144
,	O
and	O
RAPSN	5913
genes	O
in	O
multiple	C537377
pterygium	C537377
syndrome	C537377
/	O
fetal	C536647
akinesia	C536647
patients	9606
.	O

Multiple	C537377
pterygium	C537377
syndromes	C537377
(	O
MPS	C537377
)	O
comprise	O
a	O
group	O
of	O
multiple	O
congenital	D000013
anomaly	D000013
disorders	D000013
characterized	O
by	O
webbing	O
(	O
pterygia	O
)	O
of	O
the	O
neck	O
,	O
elbows	O
,	O
and	O
/	O
or	O
knees	O
and	O
joint	D003286
contractures	D003286
(	O
arthrogryposis	D001176
)	O
.	O

MPS	C537377
are	O
phenotypically	O
and	O
genetically	O
heterogeneous	O
but	O
are	O
traditionally	O
divided	O
into	O
prenatally	O
lethal	O
and	O
nonlethal	O
(	O
Escobar	O
)	O
types	O
.	O

Previously	O
,	O
we	O
and	O
others	O
reported	O
that	O
recessive	O
mutations	O
in	O
the	O
embryonal	1146
acetylcholine	1146
receptor	1146
g	1146
subunit	1146
(	O
CHRNG	1146
)	O
can	O
cause	O
both	O
lethal	O
and	O
nonlethal	O
MPS	C537377
,	O
thus	O
demonstrating	O
that	O
pterygia	O
resulted	O
from	O
fetal	C536647
akinesia	C536647
.	O

We	O
hypothesized	O
that	O
mutations	O
in	O
acetylcholine	O
receptor	O
-	O
related	O
genes	O
might	O
also	O
result	O
in	O
a	O
MPS	C537377
/	O
fetal	C536647
akinesia	C536647
phenotype	O
and	O
so	O
we	O
analyzed	O
15	O
cases	O
of	O
lethal	O
MPS	C537377
/	O
fetal	C536647
akinesia	C536647
without	O
CHRNG	1146
mutations	O
for	O
mutations	O
in	O
the	O
CHRNA1	1134
,	O
CHRNB1	1140
,	O
CHRND	1144
,	O
and	O
rapsyn	5913
(	O
RAPSN	5913
)	O
genes	O
.	O

No	O
CHRNA1	1134
,	O
CHRNB1	1140
,	O
or	O
CHRND	1144
mutations	O
were	O
detected	O
,	O
but	O
a	O
homozygous	O
RAPSN	5913
frameshift	O
mutation	O
,	O
c	c|DEL|1177_1178|AA
.	O
1177	c|DEL|1177_1178|AA
-	O
1178delAA	c|DEL|1177_1178|AA
,	O
was	O
identified	O
in	O
a	O
family	O
with	O
three	O
children	O
affected	O
with	O
lethal	O
fetal	C536647
akinesia	C536647
sequence	C536647
.	O

Previously	O
,	O
RAPSN	5913
mutations	O
have	O
been	O
reported	O
in	O
congenital	D020294
myasthenia	D020294
.	O

Functional	O
studies	O
were	O
consistent	O
with	O
the	O
hypothesis	O
that	O
whereas	O
incomplete	O
loss	O
of	O
rapsyn	5913
function	O
may	O
cause	O
congenital	D020294
myasthenia	D020294
,	O
more	O
severe	O
loss	O
of	O
function	O
can	O
result	O
in	O
a	O
lethal	O
fetal	C536647
akinesia	C536647
phenotype	O
.	O
Comparison	O
of	O
sequential	O
cytomegalovirus	10358
isolates	O
in	O
a	O
patient	9606
with	O
lymphoma	D008223
and	O
failing	O
antiviral	O
therapy	O
.	O

BACKGROUND	O
:	O
Long	D003586
-	O
term	D003586
anti	D003586
-	O
cytomegalovirus	D003586
(	O
CMV	D003586
)	O
treatments	O
in	O
immunocompromised	O
patients	9606
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O

Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	D003586
isolates	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	D003586
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain	O
-	O
specific	O
variability	O
in	O
a	O
patient	9606
with	O
non	D008228
-	O
Hodgkin	D008228
'	O
s	D008228
lymphoma	D008228
in	O
whom	O
successive	O
anti	O
-	O
CMV	D003586
treatments	O
failed	O
.	O

STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	D003586
isolates	O
collected	O
from	O
one	O
patient	9606
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
period	O
were	O
retrospectively	O
analysed	O
.	O

In	O
parallel	O
,	O
we	O
used	O
glycoprotein	2813
B	2813
(	O
gB	2813
)	O
genotyping	O
,	O
and	O
a	O
-	O
and	O
UL10	O
-	O
13	O
-	O
sequence	O
analysis	O
to	O
study	O
CMV	D003586
interstrain	O
variability	O
.	O

RESULTS	O
:	O
The	O
patient	9606
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	D003586
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O

Resistance	O
to	O
ganciclovir	D015774
,	O
cidofovir	D000077404
and	O
foscarnet	D017245
was	O
successively	O
detected	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

UL97	3077517
protein	3077517
kinase	3077517
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	D015774
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
,	O
and	O
then	O
at	O
position	O
594	O
.	O

Decreased	O
sensitivity	O
to	O
foscarnet	D017245
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495K	p|SUB|N|495|K
in	O
DNA	O
polymerase	O
,	O
whereas	O
cross	O
-	O
resistance	O
to	O
ganciclovir	D015774
and	O
cidofovir	D000077404
was	O
due	O
to	O
the	O
L501I	p|SUB|L|501|I
substitution	O
.	O

CONCLUSIONS	O
:	O
The	O
CMV	D003586
isolates	O
obtained	O
from	O
our	O
patient	9606
were	O
complex	O
mixtures	O
of	O
strains	O
.	O

Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O
Bortezomib	D000069286
and	O
dexamethasone	D003907
as	O
salvage	O
therapy	O
in	O
patients	9606
with	O
relapsed	O
/	O
refractory	O
multiple	D009101
myeloma	D009101
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O

Bortezomib	D000069286
(	O
bort	D000069286
)	O
-	O
dexamethasone	D003907
(	O
dex	D003907
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	D009101
myeloma	D009101
(	O
MM	D009101
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	D000069286
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	D003907
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	D000069286
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	9606
with	O
R	O
/	O
R	O
MM	D009101
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	9606
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	D000069286
-	O
dex	D003907
.	O

The	O
median	O
number	O
of	O
bort	D000069286
-	O
dex	D003907
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	9606
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
months	O
,	O
respectively	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	D010523
neuropathy	D010523
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	9606
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	9606
achieving	O
CR	O
and	O
receiving	O
bort	D000069286
-	O
dex	D003907
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort	D000069286
-	O
dex	D003907
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	D009101
patients	9606
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O
Adenosine	135
A	135
(	O
2A	135
)	O
receptor	135
gene	O
(	O
ADORA2A	135
)	O
variants	O
may	O
increase	O
autistic	D001321
symptoms	D001321
and	O
anxiety	D001008
in	O
autism	D000067877
spectrum	D000067877
disorder	D000067877
.	O

Autism	D000067877
spectrum	D000067877
disorders	D000067877
(	O
ASDs	D000067877
)	O
are	O
heterogeneous	O
disorders	O
presenting	O
with	O
increased	O
rates	O
of	O
anxiety	D001008
.	O

The	O
adenosine	135
A	135
(	O
2A	135
)	O
receptor	135
gene	O
(	O
ADORA2A	135
)	O
is	O
associated	O
with	O
panic	D016584
disorder	D016584
and	O
is	O
located	O
on	O
chromosome	O
22q11	O
.	O
23	O
.	O

Its	O
gene	O
product	O
,	O
the	O
adenosine	135
A	135
(	O
2A	135
)	O
receptor	135
,	O
is	O
strongly	O
expressed	O
in	O
the	O
caudate	O
nucleus	O
,	O
which	O
also	O
is	O
involved	O
in	O
ASD	D000067877
.	O

As	O
autistic	D001321
symptoms	D001321
are	O
increased	O
in	O
individuals	O
with	O
22q11	D004062
.	O
2	D004062
deletion	D004062
syndrome	D004062
,	O
and	O
large	O
22q11	D004062
.	O
2	D004062
deletions	D004062
and	O
duplications	O
have	O
been	O
observed	O
in	O
ASD	D000067877
individuals	O
,	O
in	O
this	O
study	O
,	O
98	O
individuals	O
with	O
ASD	D000067877
and	O
234	O
control	O
individuals	O
were	O
genotyped	O
for	O
eight	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
ADORA2A	135
.	O

Nominal	O
association	O
with	O
the	O
disorder	O
was	O
observed	O
for	O
rs2236624	rs2236624
-	O
CC	O
,	O
and	O
phenotypic	O
variability	O
in	O
ASD	D000067877
symptoms	O
was	O
influenced	O
by	O
rs3761422	rs3761422
,	O
rs5751876	rs5751876
and	O
rs35320474	rs35320474
.	O

In	O
addition	O
,	O
association	O
of	O
ADORA2A	135
variants	O
with	O
anxiety	D001008
was	O
replicated	O
for	O
individuals	O
with	O
ASD	D000067877
.	O

Findings	O
point	O
toward	O
a	O
possible	O
mediating	O
role	O
of	O
ADORA2A	135
variants	O
on	O
phenotypic	O
expression	O
in	O
ASD	D000067877
that	O
need	O
to	O
be	O
replicated	O
in	O
a	O
larger	O
sample	O
.	O
Hypoxia	D000860
in	O
renal	D007674
disease	D007674
with	O
proteinuria	D011507
and	O
/	O
or	O
glomerular	O
hypertension	D006973
.	O

Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
,	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia	D000860
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	D000860
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	83785
endothelial	83785
growth	83785
factor	83785
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	D000860
-	O
sensing	O
transgenic	O
rat	10116
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	D000860
in	O
the	O
diseased	D007674
kidney	D007674
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	D000860
in	O
the	O
puromycin	D011692
aminonucleoside	D011692
-	O
induced	O
nephrotic	D009404
syndrome	D009404
and	O
focal	O
and	O
segmental	O
hypoxia	D000860
in	O
the	O
remnant	O
kidney	O
model	O
.	O

Expression	O
of	O
the	O
hypoxia	D000860
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2	O
.	O
2	O
-	O
fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	D011692
aminonucleoside	D011692
model	O
and	O
2	O
.	O
6	O
-	O
fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	83785
endothelial	83785
growth	83785
factor	83785
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O

The	O
degree	O
of	O
hypoxia	D000860
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	D007674
injury	D007674
in	O
both	O
models	O
.	O

Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
,	O
ED	302424
-	O
1	302424
-	O
positive	O
,	O
and	O
terminal	O
dUTP	C027078
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	D000860
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	D000860
and	O
progressive	O
glomerular	D007674
diseases	D007674
.	O
Anxiogenic	D001008
potential	O
of	O
ciprofloxacin	D002939
and	O
norfloxacin	D009643
in	O
rats	10116
.	O

INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	D001008
effects	O
of	O
fluoroquinolones	D024841
,	O
namely	O
ciprofloxacin	D002939
and	O
norfloxacin	D009643
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	10116
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g	O
.	O

METHODS	O
:	O
The	O
drugs	O
were	O
given	O
orally	O
,	O
in	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O

The	O
tests	O
included	O
open	O
-	O
field	O
exploratory	O
behaviour	O
,	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
,	O
social	O
interaction	O
and	O
novelty	O
-	O
suppressed	O
feeding	O
latency	O
behaviour	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin	D002939
-	O
and	O
norfloxacin	D009643
-	O
treated	O
rats	10116
showed	O
anxious	D001008
behaviour	D001008
in	O
comparison	O
to	O
control	O
rats	10116
in	O
all	O
the	O
parameters	O
studied	O
.	O

However	O
,	O
ciprofloxacin	D002939
-	O
and	O
norfloxacin	D009643
-	O
treated	O
rats	10116
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O

CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	D001008
potential	O
of	O
ciprofloxacin	D002939
and	O
norfloxacin	D009643
.	O
Cytochrome	1543
p4501A1	1543
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	D011471
cancer	D011471
.	O

CYP1A1	1543
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	D011471
cancer	D011471
.	O

To	O
evaluate	O
this	O
phenomenon	O
,	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	rs1048943
to	rs1048943
G	rs1048943
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	rs1048943
and	O
T3801C	g|SUB|T|3801|C
at	O
3	O
'	O
UTR	O
)	O
of	O
CYP1A1	1543
gene	O
in	O
prostate	D011471
cancer	D011471
were	O
analyzed	O
in	O
a	O
case	O
-	O
control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O

The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1	O
/	O
m1	O
genotype	O
at	O
3	O
'	O
UTR	O
of	O
CYP1A1	1543
gene	O
(	O
OR	O
-	O
4	O
.	O
64	O
;	O
95%CI	O
=	O
1	O
.	O
51	O
-	O
14	O
.	O
86	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
whereas	O
the	O
CYP1A1	1543
Ile	rs1048943
/	O
Val	rs1048943
genotype	O
(	O
w2	O
/	O
m2	O
)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	D011471
cancer	D011471
(	O
OR	O
-	O
0	O
.	O
17	O
;	O
95%CI	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	D009369
grade	O
showed	O
the	O
w1	O
/	O
m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
;	O
however	O
the	O
tumor	D009369
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O

Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1	O
/	O
m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2	O
/	O
m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	D011471
cancer	D011471
.	O
Four	O
novel	O
mutations	O
in	O
the	O
thiazide	D049971
-	O
sensitive	O
Na	6559
-	O
Cl	6559
co	6559
-	O
transporter	6559
gene	O
in	O
Japanese	O
patients	9606
with	O
Gitelman	D053579
'	O
s	D053579
syndrome	D053579
.	O

BACKGROUND	O
:	O
Gitelman	D053579
'	O
s	D053579
syndrome	D053579
(	O
GS	D053579
)	O
is	O
an	O
autosomal	D030342
recessive	D030342
disorder	D030342
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide	D049971
-	O
sensitive	O
Na	6559
-	O
Cl	6559
co	6559
-	O
transporter	6559
(	O
NCCT	6559
)	O
gene	O
.	O

To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O

It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population	O
-	O
specific	O
distribution	O
of	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	6559
gene	O
of	O
seven	O
Japanese	O
patients	9606
with	O
GS	D053579
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	9606
with	O
GS	D053579
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O

A	O
mutation	O
analysis	O
of	O
the	O
NCCT	6559
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
DNA	O
products	O
.	O

In	O
patients	9606
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O

Five	O
of	O
them	O
[	O
c	rs371443644
.	O
185C	rs371443644
>	O
T	rs371443644
(	O
Thr60Met	rs371443644
)	O
,	O
c	rs79351185
.	O
1712C	rs79351185
>	O
T	rs79351185
(	O
Ala569Val	rs79351185
)	O
,	O
c	rs200697179
.	O
1930C	rs200697179
>	O
T	rs200697179
(	O
Arg642Cys	rs200697179
)	O
,	O
c	rs185927948
.	O
2552T	rs185927948
>	O
A	rs185927948
(	O
Leu849His	rs185927948
)	O
and	O
c	c|DEL|1932|C
.	O
1932delC	c|DEL|1932|C
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	9606
,	O
but	O
not	O
in	O
GS	D053579
patients	9606
from	O
other	O
ethnic	O
groups	O
.	O

The	O
remaining	O
four	O
mutations	O
[	O
c	c|SUB|A|7|T
.	O
7A	c|SUB|A|7|T
>	O
T	c|SUB|A|7|T
(	O
Met1Leu	p|SUB|M|1|L
)	O
,	O
c	c|DEL|1181_1186+20|26
.	O
1181_1186	c|DEL|1181_1186+20|26
+	O
20del26	c|DEL|1181_1186+20|26
,	O
c	c|DEL|1811_1812|AT
.	O
1811_1812delAT	c|DEL|1811_1812|AT
and	O
IVS16	c|SUB|G|IVS16+1|A
+	O
1G	c|SUB|G|IVS16+1|A
>	O
A	c|SUB|G|IVS16+1|A
]	O
were	O
novel	O
.	O

In	O
cDNA	O
derived	O
from	O
a	O
patient	9606
with	O
c	c|DEL|1181_1186+20|26
.	O
1181_1186	c|DEL|1181_1186+20|26
+	O
20del26	c|DEL|1181_1186+20|26
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O

In	O
cDNA	O
derived	O
from	O
patients	9606
with	O
IVS16	c|SUB|G|IVS16+1|A
+	O
1G	c|SUB|G|IVS16+1|A
>	O
A	c|SUB|G|IVS16+1|A
,	O
an	O
additional	O
96	c|INS||96
bp	c|INS||96
insertion	c|INS||96
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O

Six	O
out	O
of	O
seven	O
patients	9606
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	6559
gene	O
in	O
seven	O
Japanese	O
patients	9606
with	O
GS	D053579
.	O

Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	6559
gene	O
in	O
Japanese	O
GS	D053579
patients	9606
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O
Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	5972
in	O
a	O
kindred	O
with	O
anemia	D000740
,	O
hyperuricemia	D033461
,	O
and	O
CKD	D051436
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	5972
(	O
REN	5972
)	O
cause	O
renal	C537048
tubular	C537048
dysgenesis	C537048
,	O
which	O
is	O
characterized	O
by	O
death	D003643
in	O
utero	O
due	O
to	O
kidney	D051437
failure	D051437
and	O
pulmonary	D008171
hypoplasia	D008171
.	O

The	O
phenotype	O
resembles	O
the	O
fetopathy	C576203
caused	O
by	O
angiotensin	D000806
-	O
converting	D000806
enzyme	D000806
inhibitor	D000806
or	O
angiotensin	D057911
receptor	D057911
blocker	D057911
intake	O
during	O
pregnancy	O
.	O

Recently	O
,	O
heterozygous	O
REN	5972
mutations	O
were	O
shown	O
to	O
result	O
in	O
early	O
-	O
onset	O
hyperuricemia	D033461
,	O
anemia	D000740
,	O
and	O
chronic	D051436
kidney	D051436
disease	D051436
(	O
CKD	D051436
)	O
.	O

To	O
date	O
,	O
only	O
3	O
different	O
heterozygous	O
REN	5972
mutations	O
have	O
been	O
published	O
.	O

We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	5972
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	D033461
and	O
CKD	D051436
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	7369
(	O
uromodulin	7369
)	O
and	O
HNF1B	6928
(	O
hepatocyte	6928
nuclear	6928
factor	6928
1b	6928
)	O
genes	O
.	O

We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	c|SUB|T|28|C
to	c|SUB|T|28|C
cytosine	c|SUB|T|28|C
mutation	c|SUB|T|28|C
at	c|SUB|T|28|C
position	c|SUB|T|28|C
28	c|SUB|T|28|C
in	O
the	O
REN	5972
complementary	O
DNA	O
,	O
corresponding	O
to	O
a	O
tryptophan	p|SUB|W|10|R
to	p|SUB|W|10|R
arginine	p|SUB|W|10|R
substitution	p|SUB|W|10|R
at	p|SUB|W|10|R
amino	p|SUB|W|10|R
acid	p|SUB|W|10|R
10	p|SUB|W|10|R
,	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c	c|SUB|T|28|C
.	O
28T	c|SUB|T|28|C
>	O
C	c|SUB|T|28|C
;	O
p	p|SUB|W|10|R
.	O
W10R	p|SUB|W|10|R
)	O
.	O

On	O
this	O
basis	O
,	O
we	O
conclude	O
that	O
REN	5972
mutations	O
are	O
rare	O
events	O
in	O
patients	9606
with	O
CKD	D051436
.	O

Within	O
the	O
kindred	O
,	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	5972
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	D000740
,	O
hyperuricemia	D033461
,	O
and	O
CKD	D051436
.	O

Anemia	D000740
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O

Because	O
all	O
heterozygous	O
REN	5972
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
,	O
screening	O
of	O
the	O
REN	5972
gene	O
for	O
patients	9606
with	O
CKD	D051436
with	O
hyperuricemia	D033461
and	O
anemia	D000740
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
,	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O
A	O
Critical	O
Role	O
for	O
the	O
Type	288264,686326
I	288264,686326
Interferon	288264,686326
Receptor	288264,686326
in	O
Virus	O
-	O
Induced	O
Autoimmune	D003922
Diabetes	D003922
in	O
Rats	10116
.	O

The	O
pathogenesis	O
of	O
human	9606
type	D003922
1	D003922
diabetes	D003922
,	O
characterized	O
by	O
immune	O
-	O
mediated	O
damage	O
of	O
insulin	3630
-	O
producing	O
b	O
-	O
cells	O
of	O
pancreatic	O
islets	O
,	O
may	O
involve	O
viral	D014777
infection	D014777
.	O

Essential	O
components	O
of	O
the	O
innate	O
immune	O
antiviral	O
response	O
,	O
including	O
type	3456
I	3456
interferon	3456
(	O
IFN	3439
)	O
and	O
IFN	3454
receptor	3454
-	O
mediated	O
signaling	O
pathways	O
,	O
are	O
candidates	O
for	O
determining	O
susceptibility	O
to	O
human	9606
type	D003922
1	D003922
diabetes	D003922
.	O

Numerous	O
aspects	O
of	O
human	9606
type	D003922
1	D003922
diabetes	D003922
pathogenesis	O
are	O
recapitulated	O
in	O
the	O
LEW	O
.	O
1WR1	O
rat	10116
model	O
.	O

Diabetes	D003920
can	O
be	O
induced	O
in	O
LEW	O
.	O
1WR1	O
weanling	O
rats	10116
challenged	O
with	O
virus	O
or	O
with	O
the	O
viral	O
mimetic	O
polyinosinic	D011070
:	O
polycytidylic	D011070
acid	D011070
(	O
poly	D011070
I	D011070
:	O
C	D011070
)	O
.	O

We	O
hypothesized	O
that	O
disrupting	O
the	O
cognate	O
type	288264,686326
I	288264,686326
IFN	288264,686326
receptor	288264,686326
(	O
type	288264,686326
I	288264,686326
IFN	288264,686326
a	288264,686326
/	O
b	288264,686326
receptor	288264,686326
[	O
IFNAR	288264,686326
]	O
)	O
to	O
interrupt	O
IFN	25712
signaling	O
would	O
prevent	O
or	O
delay	O
the	O
development	O
of	O
virus	O
-	O
induced	O
diabetes	D003920
.	O

We	O
generated	O
IFNAR1	288264
subunit	O
-	O
deficient	O
LEW	O
.	O
1WR1	O
rats	10116
using	O
CRISPR	O
-	O
Cas9	O
(	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein	O
9	O
)	O
genome	O
editing	O
and	O
confirmed	O
functional	O
disruption	O
of	O
the	O
Ifnar1	288264
gene	O
.	O

IFNAR1	288264
deficiency	O
significantly	O
delayed	O
the	O
onset	O
and	O
frequency	O
of	O
diabetes	D003920
and	O
greatly	O
reduced	O
the	O
intensity	O
of	O
insulitis	D007410
after	O
poly	D011070
I	D011070
:	O
C	D011070
treatment	O
.	O

The	O
occurrence	O
of	O
Kilham	12441
rat	12441
virus	12441
-	O
induced	O
diabetes	D003920
was	O
also	O
diminished	O
in	O
IFNAR1	288264
-	O
deficient	O
animals	O
.	O

These	O
findings	O
firmly	O
establish	O
that	O
alterations	O
in	O
innate	O
immunity	O
influence	O
the	O
course	O
of	O
autoimmune	D003922
diabetes	D003922
and	O
support	O
the	O
use	O
of	O
targeted	O
strategies	O
to	O
limit	O
or	O
prevent	O
the	O
development	O
of	O
type	D003922
1	D003922
diabetes	D003922
.	O
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	C416835
acetate	C416835
(	O
BIA	C416835
2	C416835
-	O
093	C416835
)	O
on	O
seizures	D012640
induced	O
by	O
microperfusion	O
of	O
picrotoxin	D010852
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	10116
.	O

Eslicarbazepine	C416835
acetate	C416835
(	O
BIA	C416835
2	C416835
-	O
093	C416835
,	O
S	C416835
-	O
(	O
-	O
)	O
-	O
10	C416835
-	O
acetoxy	C416835
-	O
10	C416835
,	O
11	C416835
-	O
dihydro	C416835
-	O
5H	C416835
-	O
dibenzo	C416835
/	O
b	C416835
,	O
f	C416835
/	O
azepine	C416835
-	O
5	C416835
-	O
carboxamide	C416835
)	O
is	O
a	O
novel	O
antiepileptic	D000927
drug	D000927
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	D002220
(	O
CBZ	D002220
)	O
and	O
oxcarbazepine	C036006
(	O
OXC	C036006
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	C416835
acetate	C416835
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	D012640
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	D012640
patterns	O
.	O

In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	D010852
,	O
the	O
average	O
number	O
of	O
seizures	D012640
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
average	O
seizure	D012640
duration	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	D010852
microperfusion	O
prevented	O
seizures	D012640
in	O
the	O
75%	O
of	O
the	O
rats	10116
.	O

Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	D012640
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	D012640
duration	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizure	D012640
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
adverse	O
effects	O
of	O
eslicarbazepine	C416835
acetate	C416835
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O
Hypomorphic	O
mutations	O
in	O
meckelin	91147
(	O
MKS3	91147
/	O
TMEM67	91147
)	O
cause	O
nephronophthisis	OMIM:613550
with	OMIM:613550
liver	OMIM:613550
fibrosis	OMIM:613550
(	O
NPHP11	OMIM:613550
)	O
.	O

BACKGROUND	O
:	O
Nephronophthisis	C537699
(	O
NPHP	C537699
)	O
,	O
a	O
rare	O
recessive	O
cystic	D052177
kidney	D052177
disease	D052177
,	O
is	O
the	O
most	O
frequent	O
genetic	O
cause	O
of	O
chronic	D007676
renal	D007676
failure	D007676
in	O
children	O
and	O
young	O
adults	O
.	O

Mutations	O
in	O
nine	O
genes	O
(	O
NPHP1	23322,261734,27031,27130,284086,4867,80184,84662,9657
-	O
9	23322,261734,27031,27130,284086,4867,80184,84662,9657
)	O
have	O
been	O
identified	O
.	O

NPHP	C537699
can	O
be	O
associated	O
with	O
retinal	D012162
degeneration	D012162
(	O
Senior	C537580
-	O
Loken	C537580
syndrome	C537580
)	O
,	O
brainstem	O
and	O
cerebellar	D002526
anomalies	D002526
(	O
Joubert	C536293
syndrome	C536293
)	O
,	O
or	O
liver	D008103
fibrosis	D008103
.	O

METHODS	O
:	O
To	O
identify	O
a	O
causative	O
gene	O
for	O
the	O
subset	O
of	O
patients	9606
with	O
associated	O
liver	D008103
fibrosis	D008103
,	O
the	O
authors	O
performed	O
a	O
genome	O
wide	O
linkage	O
search	O
in	O
a	O
consanguineous	O
family	O
with	O
three	O
affected	O
patients	9606
using	O
50K	O
SNP	O
microarrays	O
and	O
homozygosity	O
mapping	O
.	O

RESULTS	O
:	O
The	O
authors	O
obtained	O
a	O
significant	O
maximum	O
parametric	O
LOD	O
(	O
logarithm	O
of	O
odds	O
)	O
score	O
of	O
Z	O
(	O
max	O
)	O
=	O
3	O
.	O
72	O
on	O
chromosome	O
8q22	O
and	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
in	O
the	O
gene	O
MKS3	91147
/	O
TMEM67	91147
.	O

When	O
examining	O
a	O
worldwide	O
cohort	O
of	O
62	O
independent	O
patients	9606
with	O
NPHP	C537699
and	O
associated	O
liver	D008103
fibrosis	D008103
we	O
identified	O
altogether	O
four	O
novel	O
mutations	O
(	O
p	rs267607117
.	O
W290L	rs267607117
,	O
p	rs201893408
.	O
C615R	rs201893408
,	O
p	rs267607116
.	O
G821S	rs267607116
,	O
and	O
p	rs267607116
.	O
G821R	rs267607116
)	O
in	O
five	O
of	O
them	O
.	O

Mutations	O
of	O
MKS3	91147
/	O
TMEM67	91147
,	O
found	O
recently	O
in	O
Meckel	C536132
-	O
Gruber	C536132
syndrome	C536132
(	O
MKS	C536132
)	O
type	C536132
3	C536132
and	O
Joubert	C537689
syndrome	C537689
(	O
JBTS	C537689
)	O
type	C537689
6	C537689
,	O
are	O
predominantly	O
truncating	O
mutations	O
.	O

In	O
contrast	O
,	O
the	O
mutations	O
detected	O
here	O
in	O
patients	9606
with	O
NPHP	C537699
and	O
associated	O
liver	D008103
fibrosis	D008103
are	O
exclusively	O
missense	O
mutations	O
.	O

This	O
suggests	O
that	O
they	O
may	O
represent	O
hypomorphic	O
alleles	O
,	O
leading	O
to	O
a	O
milder	O
phenotype	O
compared	O
with	O
the	O
more	O
severe	O
MKS	C536133
or	O
JBTS	C536293
phenotype	O
.	O

Additionally	O
,	O
mutation	O
analysis	O
for	O
MKS3	91147
/	O
TMEM67	91147
in	O
120	O
patients	9606
with	O
JBTS	C536293
yielded	O
seven	O
different	O
(	O
four	O
novel	O
)	O
mutations	O
in	O
five	O
patients	9606
,	O
four	O
of	O
whom	O
also	O
presented	O
with	O
congenital	O
liver	D008103
fibrosis	D008103
.	O

CONCLUSIONS	O
:	O
Hypomorphic	O
MKS3	91147
/	O
TMEM67	91147
mutations	O
cause	O
NPHP	OMIM:613550
with	OMIM:613550
liver	OMIM:613550
fibrosis	OMIM:613550
(	O
NPHP11	OMIM:613550
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
MKS3	91147
mutations	O
in	O
patients	9606
with	O
no	O
vermian	O
agenesis	O
and	O
without	O
neurological	O
signs	O
.	O

Thus	O
NPHP	C537699
,	O
JBTS	C536293
,	O
and	O
MKS	C536133
represent	O
allelic	D030342
disorders	D030342
.	O
Genetic	O
variants	O
of	O
the	O
T	26762
-	O
cell	26762
immunoglobulin	26762
mucin	26762
1	26762
but	O
not	O
the	O
T	84868
-	O
cell	84868
immunoglobulin	84868
mucin	84868
3	84868
gene	O
are	O
associated	O
with	O
asthma	D001249
in	O
an	O
African	O
American	O
population	O
.	O

BACKGROUND	O
:	O
The	O
T	26762,84868
-	O
cell	26762,84868
immunoglobulin	26762,84868
mucin	26762,84868
(	O
TIM	26762,84868
)	O
proteins	O
and	O
their	O
genetic	O
variants	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
regulating	O
allergic	D004342
diseases	D004342
.	O

OBJECTIVE	O
:	O
Genetic	O
association	O
of	O
the	O
sequence	O
variants	O
for	O
TIM	26762
-	O
1	26762
and	O
TIM	84868
-	O
3	84868
genes	O
with	O
asthma	D001249
in	O
an	O
African	O
American	O
population	O
was	O
investigated	O
.	O

METHODS	O
:	O
Both	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
association	O
analyses	O
were	O
performed	O
for	O
a	O
total	O
of	O
7	O
polymorphisms	O
,	O
including	O
3	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
and	O
1	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
TIM	26762,84868
-	O
1	26762,84868
and	26762,84868
3	26762,84868
SNPs	O
in	O
the	O
TIM	84868
-	O
3	84868
genes	O
.	O

The	O
exposure	O
to	O
hepatitis	208726
A	208726
virus	208726
as	O
judged	O
by	O
seropositivity	O
was	O
also	O
examined	O
.	O

RESULTS	O
:	O
In	O
the	O
case	O
-	O
control	O
design	O
,	O
the	O
frequencies	O
of	O
the	O
TT	O
genotype	O
for	O
SNP	O
rs2277025	rs2277025
and	O
the	O
homozygous	O
deletion	O
variant	O
(	O
157delMTTTVP	p|DEL|157|MTTTVP
)	O
in	O
the	O
fourth	O
exon	O
of	O
the	O
TIM	26762
-	O
1	26762
gene	O
were	O
higher	O
among	O
patients	9606
with	O
patients	9606
with	O
asthma	D001249
compared	O
with	O
the	O
controls	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
2	O
.	O
779	O
,	O
P	O
=	O
.	O
016	O
;	O
and	O
OR	O
,	O
3	O
.	O
09	O
,	O
P	O
=	O
.	O
022	O
,	O
respectively	O
)	O
.	O

This	O
association	O
was	O
substantiated	O
by	O
haplotype	O
analysis	O
of	O
these	O
and	O
2	O
additional	O
SNPs	O
(	O
OR	O
,	O
2	O
.	O
48	O
;	O
P	O
=	O
.	O
004	O
)	O
,	O
and	O
also	O
by	O
family	O
-	O
based	O
tests	O
for	O
the	O
allele	O
and	O
haplotype	O
carrying	O
157delMTTTVP	p|DEL|157|MTTTVP
(	O
P	O
=	O
.	O
009	O
and	O
P	O
=	O
.	O
048	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
this	O
association	O
seems	O
to	O
exist	O
even	O
in	O
the	O
hepatitis	208726
A	208726
virus	208726
-	O
seronegative	O
subjects	O
in	O
our	O
data	O
.	O

None	O
of	O
the	O
3	O
variants	O
in	O
TIM	84868
-	O
3	84868
genes	O
yielded	O
significant	O
association	O
with	O
either	O
asthma	D001249
or	O
asthma	D001249
-	O
related	O
phenotypes	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
genetic	O
variants	O
of	O
the	O
TIM	26762
-	O
1	26762
but	O
not	O
the	O
TIM	84868
-	O
3	84868
gene	O
contribute	O
to	O
asthma	D001249
susceptibility	O
in	O
this	O
African	O
-	O
American	O
population	O
.	O
Identification	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
prolactin	5618
receptor	5618
in	O
women	9606
with	O
benign	D001943
breast	D001943
tumors	D001943
.	O

There	O
is	O
currently	O
no	O
known	O
genetic	D030342
disease	D030342
linked	O
to	O
prolactin	5617
(	O
Prl	5617
)	O
or	O
its	O
receptor	O
(	O
PrlR	5618
)	O
in	O
humans	9606
.	O

Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
,	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl	5617
/	O
PrlR	5618
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	D001941
diseases	D001941
with	O
high	O
proliferative	O
potential	O
.	O

Multiple	D018226
fibroadenomas	D018226
(	O
MFA	D018226
)	O
are	O
benign	D001943
breast	D001943
tumors	D001943
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	9606
,	O
including	O
at	O
puberty	O
,	O
when	O
Prl	5617
has	O
well	O
-	O
recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O

In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	D018226
patients	9606
and	O
170	O
control	O
subjects	O
,	O
we	O
identified	O
four	O
patients	9606
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	5618
gene	O
,	O
encoding	O
Ile	rs72478580
(	O
146	rs72478580
)	O
-	O
-	O
>	O
Leu	rs72478580
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O

This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
(	O
PrlR	19116
(	O
I146L	rs72478580
)	O
)	O
,	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba	10090
/	O
F3	10090
,	O
HEK293	9606
and	O
MCF	9606
-	O
7	9606
cells	O
)	O
by	O
Prl	5617
-	O
independent	O
(	O
i	O
)	O
PrlR	5618
tyrosine	O
phosphorylation	O
,	O
(	O
ii	O
)	O
activation	O
of	O
signal	6776
transducer	6776
and	6776
activator	6776
of	6776
transcription	6776
5	6776
(	O
STAT5	6776
)	O
signaling	O
,	O
(	O
iii	O
)	O
transcriptional	O
activity	O
toward	O
a	O
Prl	5617
-	O
responsive	O
reporter	O
gene	O
,	O
and	O
(	O
iv	O
)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O

Constitutive	O
activity	O
of	O
PrlR	5618
(	O
I146L	rs72478580
)	O
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	9606
was	O
supported	O
by	O
increased	O
STAT5	6776
signaling	O
.	O

This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	5618
associated	O
with	O
a	O
human	9606
disease	O
.	O

Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	-
antagonist	-
,	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	D018226
,	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O
Polymorphic	O
Alu	O
insertions	O
and	O
the	O
genetic	O
structure	O
of	O
Iberian	O
Basques	O
.	O

Eight	O
Alu	O
sequences	O
(	O
ACE	1636
,	O
TPA25	-
,	O
PV92	-
,	O
APO	84909
,	O
FXIIIB	2165
,	O
D1	-
,	O
A25	28936
and	O
B65	-
)	O
were	O
analyzed	O
in	O
two	O
samples	O
from	O
Navarre	O
and	O
Guipuzcoa	O
provinces	O
(	O
Basque	O
Country	O
,	O
Spain	O
)	O
.	O

Alu	O
data	O
for	O
other	O
European	O
,	O
Caucasus	O
and	O
North	O
African	O
populations	O
were	O
compiled	O
from	O
the	O
literature	O
for	O
comparison	O
purposes	O
to	O
assess	O
the	O
genetic	O
relationships	O
of	O
the	O
Basques	O
in	O
a	O
broader	O
geographic	O
context	O
.	O

Results	O
of	O
both	O
MDS	O
plot	O
and	O
AMOVA	O
revealed	O
spatial	O
heterogeneity	O
among	O
these	O
three	O
population	O
clusters	O
clearly	O
defined	O
by	O
geography	O
.	O

On	O
the	O
contrary	O
,	O
no	O
substantial	O
genetic	O
heterogeneity	O
was	O
found	O
between	O
the	O
Basque	O
samples	O
,	O
or	O
between	O
Basques	O
and	O
other	O
Europeans	O
(	O
excluding	O
Caucasus	O
populations	O
)	O
.	O

Moreover	O
,	O
the	O
genetic	O
information	O
obtained	O
from	O
Alu	O
data	O
conflicts	O
with	O
hypotheses	O
linking	O
the	O
origin	O
of	O
Basques	O
with	O
populations	O
from	O
North	O
Africa	O
(	O
Berbers	O
)	O
or	O
from	O
the	O
Caucasus	O
region	O
(	O
Georgia	O
)	O
.	O

In	O
order	O
to	O
explain	O
the	O
reduced	O
genetic	O
heterogeneity	O
detected	O
by	O
Alu	O
insertions	O
among	O
Basque	O
subpopulations	O
,	O
values	O
of	O
the	O
Wright	O
'	O
s	O
F	O
(	O
ST	O
)	O
statistic	O
were	O
estimated	O
for	O
both	O
Alu	O
markers	O
and	O
a	O
set	O
of	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
in	O
terms	O
of	O
two	O
geographical	O
scales	O
:	O
(	O
1	O
)	O
the	O
Basque	O
Country	O
,	O
(	O
2	O
)	O
Europe	O
(	O
including	O
Basques	O
)	O
.	O

In	O
the	O
Basque	O
area	O
,	O
estimates	O
of	O
Wahlund	O
'	O
s	O
effect	O
for	O
both	O
genetic	O
markers	O
showed	O
no	O
statistical	O
difference	O
between	O
Basque	O
subpopulations	O
.	O

However	O
,	O
when	O
this	O
analysis	O
was	O
performed	O
on	O
a	O
European	O
scale	O
,	O
F	O
(	O
ST	O
)	O
values	O
were	O
significantly	O
higher	O
for	O
Alu	O
insertions	O
than	O
for	O
STR	O
alleles	O
.	O

From	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
spatial	O
heterogeneity	O
of	O
the	O
Basque	O
gene	O
pool	O
identified	O
in	O
previous	O
polymorphism	O
studies	O
is	O
relatively	O
recent	O
and	O
probably	O
caused	O
by	O
a	O
differential	O
process	O
of	O
genetic	O
admixture	O
with	O
non	O
-	O
Basque	O
neighboring	O
populations	O
modulated	O
by	O
the	O
effect	O
of	O
a	O
linguistic	O
barrier	O
to	O
random	O
mating	O
.	O
Phosphatidylinositol	55300
4	55300
-	O
kinase	55300
IIb	55300
negatively	O
regulates	O
invadopodia	O
formation	O
and	O
suppresses	O
an	O
invasive	O
cellular	O
phenotype	O
.	O

The	O
type	55300,55361
II	55300,55361
phosphatidylinositol	55300,55361
4	55300,55361
-	O
kinase	55300,55361
(	O
PI4KII	55300,55361
)	O
enzymes	O
synthesize	O
the	O
lipid	D008055
phosphatidylinositol	C037178
4	C037178
-	O
phosphate	C037178
(	O
PI	C037178
(	O
4	C037178
)	O
P	C037178
)	O
,	O
which	O
has	O
been	O
detected	O
at	O
the	O
Golgi	O
complex	O
and	O
endosomal	O
compartments	O
and	O
recruits	O
clathrin	1213
adaptors	O
.	O

Despite	O
common	O
mechanistic	O
similarities	O
between	O
the	O
isoforms	O
,	O
the	O
extent	O
of	O
their	O
redundancy	O
is	O
unclear	O
.	O

We	O
found	O
that	O
depletion	O
of	O
PI4KIIa	55361
and	O
PI4KIIb	55300
using	O
small	O
interfering	O
RNA	O
led	O
to	O
actin	60
remodeling	O
.	O

Depletion	O
of	O
PI4KIIb	55300
also	O
induced	O
the	O
formation	O
of	O
invadopodia	O
containing	O
membrane	4323
type	4323
I	4323
matrix	4323
metalloproteinase	4323
(	O
MT1	4323
-	O
MMP	4323
)	O
.	O

Depletion	O
of	O
PI4KII	55300,55361
isoforms	O
also	O
differentially	O
affected	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
pools	O
of	O
PI	C037178
(	O
4	C037178
)	O
P	C037178
and	O
post	O
-	O
TGN	O
traffic	O
.	O

PI4KIIb	55300
depletion	O
caused	O
increased	O
MT1	4323
-	O
MMP	4323
trafficking	O
to	O
invasive	O
structures	O
at	O
the	O
plasma	O
membrane	O
and	O
was	O
accompanied	O
by	O
reduced	O
colocalization	O
of	O
MT1	4323
-	O
MMP	4323
with	O
membranes	O
containing	O
the	O
endosomal	O
markers	O
Rab5	5868
and	O
Rab7	338382
but	O
increased	O
localization	O
with	O
the	O
exocytic	O
Rab8	4218
.	O

Depletion	O
of	O
PI4KIIb	55300
was	O
sufficient	O
to	O
confer	O
an	O
aggressive	O
invasive	O
phenotype	O
on	O
minimally	O
invasive	O
HeLa	9606
and	O
MCF	9606
-	O
7	9606
cell	O
lines	O
.	O

Mining	O
oncogenomic	O
databases	O
revealed	O
that	O
loss	O
of	O
the	O
PI4K2B	55300
allele	O
and	O
underexpression	O
of	O
PI4KIIb	55300
mRNA	O
are	O
associated	O
with	O
human	9606
cancers	D009369
.	O

This	O
finding	O
supports	O
the	O
cell	O
data	O
and	O
suggests	O
that	O
PI4KIIb	55300
may	O
be	O
a	O
clinically	O
significant	O
suppressor	O
of	O
invasion	O
.	O

We	O
propose	O
that	O
PI4KIIb	55300
synthesizes	O
a	O
pool	O
of	O
PI	C037178
(	O
4	C037178
)	O
P	C037178
that	O
maintains	O
MT1	4323
-	O
MMP	4323
traffic	O
in	O
the	O
degradative	O
pathway	O
and	O
suppresses	O
the	O
formation	O
of	O
invadopodia	O
.	O
Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	D001943
cancer	D001943
.	O

PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	D001943
cancer	D001943
varies	O
considerably	O
among	O
individuals	O
,	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	D017382
oxygen	D017382
species	D017382
(	O
ROS	D017382
)	O
because	O
ROS	D017382
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	D009369
.	O

PATIENTS	9606
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
05	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	847
,	O
SOD1	6647
,	O
SOD2	6648
,	O
GPX1	2876
,	O
GPX4	2879
,	O
GSR	2936
,	O
TXN	7295
,	O
TXN2	25828
,	O
TXNRD1	7296
,	O
and	O
TXNRD2	10587
)	O
and	O
survival	O
in	O
4	O
,	O
470	O
women	9606
with	O
breast	D001943
cancer	D001943
.	O

RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
GPX4	2879
(	O
rs713041	rs713041
and	O
rs757229	rs757229
)	O
were	O
associated	O
with	O
all	O
-	O
cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.	O
0041	O
and	O
P	O
=	O
.	O
0035	O
)	O
.	O

These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0	O
.	O
61	O
)	O
.	O

GPX4	2879
rs713041	rs713041
is	O
located	O
near	O
the	O
selenocysteine	D017279
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	2879
3	O
'	O
untranslated	O
region	O
,	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	D003643
,	O
with	O
a	O
hazard	O
ratio	O
of	O
1	O
.	O
27	O
per	O
rare	O
allele	O
carried	O
(	O
95%	O
CI	O
,	O
1	O
.	O
13	O
to	O
11	O
.	O
43	O
)	O
.	O

This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	D009369
stage	O
,	O
grade	O
,	O
or	O
estrogen	2099
receptor	2099
status	O
.	O

We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
,	O
normal	O
breast	O
,	O
and	O
breast	D001943
tumors	D001943
compared	O
with	O
the	O
rare	O
allele	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	2879
mRNA	O
across	O
genotypes	O
.	O

CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	2879
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	D001943
cancer	D001943
.	O
A	O
novel	O
IRF6	3664
nonsense	O
mutation	O
(	O
Y67X	p|SUB|Y|67|X
)	O
in	O
a	O
German	O
family	O
with	O
Van	C536528
der	C536528
Woude	C536528
syndrome	C536528
.	O

Van	C536528
der	C536528
Woude	C536528
syndrome	C536528
(	O
VWS	C536528
)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	D002972
orofacial	D002972
cleft	D002972
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	D002971,D002972
lip	D002971,D002972
and	D002971,D002972
palate	D002971,D002972
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	C536528
pits	C536528
,	O
cleft	D002971
lip	D002971
and	O
cleft	D002972
palate	D002972
,	O
and	O
hypodontia	D000848
.	O

VWS	C536528
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	3664
regulatory	3664
factor	3664
6	3664
(	O
IRF6	3664
)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	3664
gene	O
in	O
exons	O
2	O
-	O
9	O
have	O
been	O
found	O
in	O
VWS	C536528
patients	9606
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	3664
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	3664
gene	O
.	O

All	O
5	O
patients	9606
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c	c|SUB|C|201|A
.	O
201C	c|SUB|C|201|A
>	O
A	c|SUB|C|201|A
changing	O
the	O
tyrosine	p|SUB|Y|67|X
codon	p|SUB|Y|67|X
at	p|SUB|Y|67|X
amino	p|SUB|Y|67|X
acid	p|SUB|Y|67|X
position	p|SUB|Y|67|X
67	p|SUB|Y|67|X
into	p|SUB|Y|67|X
a	p|SUB|Y|67|X
stop	p|SUB|Y|67|X
codon	O
(	O
p	p|SUB|Y|67|X
.	O
Y67X	p|SUB|Y|67|X
)	O
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad	4086
-	O
interferon	3664
regulatory	3664
factor	3664
-	O
binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	4086
transcription	O
factors	O
.	O
Late	O
-	O
onset	O
metachromatic	D007966
leukodystrophy	D007966
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	410
A	410
(	O
ARSA	410
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	D007966
leukodystrophy	D007966
(	O
MLD	D007966
)	O
.	O

In	O
that	O
allele	O
arginine84	rs74315458
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	410
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	D007966
,	O
the	O
arginine84	rs74315458
to	rs74315458
glutamine	rs74315458
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	410
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	410
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	9606
with	O
MLD	D007966
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	410
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	D007966
.	O
Families	O
with	O
the	O
risk	O
allele	O
of	O
DISC1	27185
reveal	O
a	O
link	O
between	O
schizophrenia	D012559
and	O
another	O
component	O
of	O
the	O
same	O
molecular	O
pathway	O
,	O
NDE1	54820
.	O

We	O
have	O
previously	O
reported	O
a	O
robust	O
association	O
between	O
an	O
allelic	O
haplotype	O
of	O
'	O
Disrupted	27185
in	27185
Schizophrenia	27185
1	27185
'	O
(	O
DISC1	27185
)	O
and	O
schizophrenia	D012559
in	O
a	O
nationwide	O
collection	O
of	O
Finnish	O
schizophrenia	D012559
families	O
.	O

This	O
specific	O
DISC1	27185
allele	O
was	O
later	O
identified	O
to	O
associate	O
with	O
visual	O
working	O
memory	O
,	O
selectively	O
in	O
males	O
.	O

DISC1	27185
association	O
to	O
schizophrenia	D012559
has	O
since	O
been	O
replicated	O
in	O
multiple	O
independent	O
study	O
samples	O
from	O
different	O
populations	O
.	O

In	O
this	O
study	O
,	O
we	O
conditioned	O
our	O
sample	O
of	O
Finnish	O
families	O
for	O
the	O
presence	O
of	O
the	O
Finnish	O
tentative	O
risk	O
allele	O
for	O
DISC1	27185
and	O
re	O
-	O
analyzed	O
our	O
genome	O
-	O
wide	O
scan	O
data	O
of	O
443	O
markers	O
on	O
the	O
basis	O
of	O
this	O
stratification	O
.	O

Two	O
additional	O
loci	O
displayed	O
an	O
evidence	O
of	O
linkage	O
(	O
LOD	O
>	O
3	O
)	O
and	O
included	O
a	O
locus	O
on	O
16p13	O
,	O
proximal	O
to	O
the	O
gene	O
encoding	O
NDE1	54820
,	O
which	O
has	O
been	O
shown	O
to	O
biologically	O
interact	O
with	O
DISC1	27185
.	O

Although	O
none	O
of	O
the	O
observed	O
linkages	O
remained	O
significant	O
after	O
multiple	O
test	O
correction	O
through	O
simulation	O
,	O
further	O
analysis	O
of	O
NDE1	54820
revealed	O
an	O
association	O
between	O
a	O
tag	O
-	O
haplotype	O
and	O
schizophrenia	D012559
(	O
P	O
=	O
0	O
.	O
00046	O
)	O
specific	O
to	O
females	O
,	O
which	O
proved	O
to	O
be	O
significant	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
after	O
multiple	O
test	O
correction	O
.	O

Our	O
finding	O
would	O
support	O
the	O
concept	O
that	O
initial	O
gene	O
findings	O
in	O
multifactorial	O
diseases	O
will	O
assist	O
in	O
the	O
identification	O
of	O
other	O
components	O
of	O
complex	O
genetic	O
etiology	O
.	O

Notably	O
,	O
this	O
and	O
other	O
converging	O
lines	O
of	O
evidence	O
underline	O
the	O
importance	O
of	O
DISC1	27185
-	O
related	O
functional	O
pathways	O
in	O
the	O
etiology	O
of	O
schizophrenia	D012559
.	O
CenpH	26886
regulates	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
modulating	O
the	O
APC	56371
/	O
CCdh1	56371
-	O
cyclin	268697
B1	268697
pathway	O
in	O
oocytes	O
.	O

Meiotic	O
resumption	O
(	O
G2	O
/	O
M	O
transition	O
)	O
and	O
progression	O
through	O
meiosis	O
I	O
(	O
MI	O
)	O
are	O
two	O
key	O
stages	O
for	O
producing	O
fertilization	O
-	O
competent	O
eggs	O
.	O

Here	O
,	O
we	O
report	O
that	O
CenpH	26886
,	O
a	O
component	O
of	O
the	O
kinetochore	O
inner	O
plate	O
,	O
is	O
responsible	O
for	O
G2	O
/	O
M	O
transition	O
in	O
meiotic	O
mouse	10090
oocytes	O
.	O

Depletion	O
of	O
CenpH	26886
by	O
morpholino	D060172
injection	O
decreased	O
cyclin	268697
B1	268697
levels	O
,	O
resulting	O
in	O
attenuation	O
of	O
maturation	268697
-	O
promoting	268697
factor	268697
(	O
MPF	268697
)	O
activation	O
,	O
and	O
severely	O
compromised	O
meiotic	O
resumption	O
.	O

CenpH	26886
protects	O
cyclin	268697
B1	268697
from	O
destruction	O
by	O
competing	O
with	O
the	O
action	O
of	O
APC	56371
/	O
C	56371
(	O
Cdh1	56371
)	O
Impaired	O
G2	O
/	O
M	O
transition	O
after	O
CenpH	26886
depletion	O
could	O
be	O
rescued	O
by	O
expression	O
of	O
exogenous	O
cyclin	268697
B1	268697
.	O

Unexpectedly	O
,	O
blocking	O
CenpH	26886
did	O
not	O
affect	O
spindle	O
organization	O
and	O
meiotic	O
cell	O
cycle	O
progression	O
after	O
germinal	O
vesicle	O
breakdown	O
.	O

Our	O
findings	O
reveal	O
a	O
novel	O
role	O
of	O
CenpH	26886
in	O
regulating	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
acting	O
via	O
the	O
APC	56371
/	O
C	56371
(	O
Cdh1	56371
)	O
-	O
cyclin	268697
B1	268697
pathway	O
.	O
The	O
fibrinogen	2266
gamma	2266
10034C	rs2066865
>	O
T	rs2066865
polymorphism	O
is	O
not	O
associated	O
with	O
Peripheral	D058729
Arterial	D058729
Disease	D058729
.	O

Conversion	O
of	O
fibrinogen	2243,2244,2266
to	O
fibrin	2243,2244,2266
plays	O
an	O
essential	O
role	O
in	O
hemostasis	O
and	O
results	O
in	O
stabilization	O
of	O
the	O
fibrin	2243,2244,2266
clot	O
.	O

Fibrinogen	2243,2244,2266
consists	O
of	O
three	O
pairs	O
of	O
non	O
-	O
identical	O
polypeptide	O
chains	O
,	O
encoded	O
by	O
different	O
genes	O
(	O
fibrinogen	2243
alpha	2243
[	O
FGA	2243
]	O
,	O
fibrinogen	2244
beta	2244
[	O
FGB	2244
]	O
and	O
fibrinogen	2266
gamma	2266
[	O
FGG	2266
]	O
)	O
.	O

A	O
functional	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
FGG	2266
gene	O
(	O
FGG	2266
10034C	rs2066865
>	O
T	rs2066865
,	O
rs2066865	rs2066865
)	O
has	O
been	O
associated	O
with	O
deep	D020246
venous	D020246
thrombosis	D020246
and	O
myocardial	D009203
infarction	D009203
.	O

Aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
this	O
polymorphism	O
in	O
peripheral	D058729
arterial	D058729
disease	D058729
(	O
PAD	D058729
)	O
.	O

The	O
study	O
was	O
designed	O
as	O
case	O
-	O
control	O
study	O
including	O
891	O
patients	9606
with	O
documented	O
PAD	D058729
and	O
777	O
control	O
subjects	O
.	O

FGG	2266
genotypes	O
were	O
determined	O
by	O
exonuclease	O
(	O
TaqMan	O
)	O
assays	O
.	O

FGG	2266
genotype	O
frequencies	O
were	O
not	O
significantly	O
different	O
between	O
PAD	D058729
patients	9606
(	O
CC	O
:	O
57	O
.	O
3%	O
,	O
CT	O
:	O
36	O
.	O
7%	O
,	O
TT	O
:	O
5	O
.	O
8%	O
)	O
and	O
control	O
subjects	O
(	O
CC	O
:	O
60	O
.	O
9%	O
,	O
CT	O
:	O
33	O
.	O
5%	O
,	O
TT	O
5	O
.	O
6%	O
;	O
p	O
=	O
0	O
.	O
35	O
)	O
.	O

In	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
including	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
diabetes	D003920
,	O
arterial	O
hypertension	D006973
and	O
hypercholesterolemia	D006937
,	O
the	O
FGG	2266
10034	rs2066865
T	rs2066865
variant	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
PAD	D058729
(	O
Odds	O
ratio	O
1	O
.	O
07	O
,	O
95%	O
confidence	O
interval	O
0	O
.	O
84	O
-	O
1	O
.	O
37	O
;	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O

The	O
FGG	2266
10034C	rs2066865
>	O
T	rs2066865
polymorphism	O
was	O
furthermore	O
not	O
associated	O
with	O
age	O
at	O
onset	O
of	O
PAD	D058729
.	O

We	O
conclude	O
that	O
the	O
thrombophilic	O
FGG	2266
10034	rs2066865
T	rs2066865
gene	O
variant	O
does	O
not	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
to	O
PAD	D058729
.	O
Concordance	O
between	O
PIK3CA	5290
mutations	O
in	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
of	O
esophageal	D000077277
squamous	D000077277
cell	D000077277
carcinoma	D000077277
.	O

BACKGROUND	O
:	O
PIK3CA	5290
mutations	O
are	O
expected	O
to	O
be	O
potential	O
therapeutic	O
targets	O
for	O
esophageal	D000077277
squamous	D000077277
cell	D000077277
carcinoma	D000077277
(	O
ESCC	D000077277
)	O
.	O

We	O
aimed	O
to	O
clarify	O
the	O
concordance	O
between	O
PIK3CA	5290
mutations	O
detected	O
in	O
endoscopic	O
biopsy	O
specimens	O
and	O
corresponding	O
surgically	O
resected	O
specimens	O
.	O

METHODS	O
:	O
We	O
examined	O
five	O
hotspot	O
mutations	O
in	O
the	O
PIK3CA	5290
gene	O
(	O
E542K	rs121913273
,	O
E545K	rs104886003
,	O
E546K	p|SUB|E|546|K
,	O
H1047R	rs121913279
,	O
and	O
H1047L	rs121913279
)	O
in	O
formalin	D005557
-	O
fixed	O
and	O
paraffin	D010232
-	O
embedded	O
tissue	O
sections	O
of	O
paired	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
181	O
patients	9606
undergoing	O
curative	O
resection	O
for	O
ESCC	D000077277
between	O
2000	O
and	O
2011	O
using	O
a	O
Luminex	O
technology	O
-	O
based	O
multiplex	O
gene	O
mutation	O
detection	O
kit	O
.	O

RESULTS	O
:	O
Mutation	O
analyses	O
were	O
successfully	O
performed	O
for	O
both	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
in	O
all	O
the	O
cases	O
.	O

A	O
PIK3CA	5290
mutation	O
was	O
detected	O
in	O
either	O
type	O
of	O
specimen	O
in	O
13	O
cases	O
(	O
7	O
.	O
2%	O
,	O
95%	O
confidence	O
interval	O
:	O
3	O
.	O
9	O
-	O
12	O
.	O
0	O
)	O
.	O

The	O
overall	O
concordance	O
rate	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
were	O
98	O
.	O
3%	O
(	O
178	O
/	O
181	O
)	O
,	O
90	O
.	O
9%	O
(	O
10	O
/	O
11	O
)	O
,	O
and	O
98	O
.	O
8%	O
(	O
168	O
/	O
170	O
)	O
,	O
respectively	O
.	O

Among	O
patients	9606
with	O
a	O
PIK3CA	5290
mutation	O
detected	O
in	O
both	O
types	O
of	O
specimens	O
,	O
the	O
concordance	O
between	O
PIK3CA	5290
mutation	O
genotypes	O
was	O
100%	O
.	O

There	O
were	O
three	O
cases	O
with	O
a	O
discordant	O
mutation	O
status	O
between	O
the	O
types	O
of	O
specimens	O
(	O
PIK3CA	5290
mutation	O
in	O
surgically	O
resected	O
specimen	O
and	O
wild	O
-	O
type	O
in	O
biopsy	O
specimen	O
in	O
two	O
cases	O
,	O
and	O
the	O
opposite	O
pattern	O
in	O
one	O
case	O
)	O
,	O
suggesting	O
possible	O
intratumoral	O
heterogeneity	O
in	O
the	O
PIK3CA	5290
mutation	O
status	O
.	O

CONCLUSIONS	O
:	O
The	O
PIK3CA	5290
mutation	O
status	O
was	O
highly	O
concordant	O
between	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
the	O
same	O
patient	9606
,	O
suggesting	O
that	O
endoscopic	O
biopsy	O
specimens	O
can	O
be	O
clinically	O
used	O
to	O
detect	O
PIK3CA	5290
mutations	O
in	O
patients	9606
with	O
ESCC	D000077277
.	O
Paraoxonase	5444
1	5444
polymorphisms	O
and	O
survival	O
.	O

The	O
antioxidant	O
enzyme	O
paraoxonase	5444
1	5444
(	O
PON1	5444
)	O
has	O
previously	O
been	O
suggested	O
to	O
confer	O
protection	O
against	O
coronary	D003327
heart	D003327
disease	D003327
(	O
CHD	D003327
)	O
,	O
one	O
of	O
the	O
main	O
causes	O
of	O
death	D003643
in	O
the	O
Western	O
world	O
.	O

Two	O
coding	O
polymorphisms	O
,	O
55M	p|SUB|M|55|L
/	O
L	p|SUB|M|55|L
and	O
192Q	p|SUB|Q|192|R
/	O
R	p|SUB|Q|192|R
,	O
and	O
a	O
promoter	O
variant	O
,	O
-	O
107C	c|SUB|C|-107|T
/	O
T	c|SUB|C|-107|T
,	O
has	O
been	O
extensively	O
studied	O
with	O
respect	O
to	O
susceptibility	O
to	O
CHD	D003327
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
impact	O
of	O
these	O
three	O
polymorphisms	O
on	O
mortality	O
using	O
a	O
sample	O
of	O
1932	O
Danish	O
individuals	O
aged	O
47	O
-	O
93	O
years	O
,	O
previously	O
used	O
in	O
gene	O
-	O
longevity	O
studies	O
.	O

A	O
cross	O
-	O
sectional	O
study	O
comparing	O
the	O
genotype	O
distribution	O
of	O
the	O
three	O
polymorphisms	O
separately	O
as	O
well	O
as	O
the	O
haplotype	O
distribution	O
in	O
different	O
age	O
groups	O
did	O
not	O
reveal	O
any	O
difference	O
.	O

However	O
,	O
a	O
longitudinal	O
follow	O
-	O
up	O
study	O
on	O
survival	O
in	O
the	O
same	O
sample	O
indicated	O
that	O
192RR	p|Allele|R|192
homozygotes	O
have	O
a	O
poorer	O
survival	O
compared	O
to	O
QQ	O
homozygotes	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

We	O
hereafter	O
used	O
an	O
independent	O
sample	O
of	O
541	O
Danish	O
individuals	O
from	O
the	O
oldest	O
cohort	O
and	O
confirmed	O
the	O
initial	O
findings	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

In	O
both	O
samples	O
,	O
the	O
effect	O
was	O
most	O
pronounced	O
in	O
women	9606
.	O

Using	O
self	O
-	O
reported	O
data	O
on	O
ischemic	D017202
heart	D017202
disease	D017202
to	O
evaluate	O
the	O
impact	O
of	O
the	O
PON	5444
192Q	p|SUB|Q|192|R
/	O
R	p|SUB|Q|192|R
polymorphism	O
on	O
susceptibility	O
to	O
CHD	D003327
,	O
we	O
found	O
only	O
a	O
nonsignificant	O
trend	O
of	O
192RR	p|Allele|R|192
homozygosity	O
in	O
women	9606
being	O
a	O
risk	O
factor	O
.	O

Our	O
results	O
thus	O
indicates	O
that	O
PON1	5444
192RR	p|Allele|R|192
homozygosity	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
women	9606
in	O
the	O
second	O
half	O
of	O
life	O
and	O
that	O
this	O
increased	O
mortality	O
is	O
possibly	O
related	O
to	O
CHD	D003327
severity	O
and	O
survival	O
after	O
CHD	D003327
rather	O
than	O
susceptibility	O
to	O
development	O
of	O
CHD	D003327
.	O
The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	D010862
on	O
animal	O
models	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	D010862
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine	D000157
-	O
induced	O
rat	10116
and	O
ouabain	D010042
-	O
induced	O
guinea	10141
pig	10141
arrhythmia	D001145
models	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	D002118
concentrations	O
(	O
[	O
Ca	D002118
(	O
2	D002118
+	O
)	O
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	D010862
significantly	O
delayed	O
onset	O
of	O
arrhythmias	D001145
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	D017180|D014693
tachycardia	D017180|D014693
and	D017180|D014693
fibrillation	D017180|D014693
,	O
reduced	O
arrhythmia	D001145
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	D001145
rats	10116
and	O
guinea	10141
pigs	10141
.	O

[	O
Ca	D002118
(	O
2	D002118
+	O
)	O
]	O
(	O
i	O
)	O
overload	O
induced	O
by	O
aconitine	D000157
or	O
ouabain	D010042
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	D010862
.	O

Moreover	O
,	O
M	100379235,24260
(	O
3	100379235,24260
)	O
-	O
muscarinic	100379235,24260
acetylcholine	100379235,24260
receptor	100379235,24260
(	O
mAChR	100379235,24260
)	O
antagonist	O
4	C042375
-	O
DAMP	C042375
(	O
4	C042375
-	O
diphenylacetoxy	C042375
-	O
N	C042375
-	O
methylpiperidine	C042375
-	O
methiodide	C042375
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	D010862
.	O

These	O
data	O
suggest	O
that	O
pilocarpine	D010862
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	D001145
rat	10116
and	O
guinea	10141
pig	10141
models	O
induced	O
by	O
aconitine	D000157
or	O
ouabain	D010042
via	O
stimulating	O
the	O
cardiac	O
M	100379235,24260
(	O
3	100379235,24260
)	O
-	O
mAChR	100379235,24260
.	O

The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	D002118
(	O
2	D002118
+	O
)	O
handling	O
.	O
Arginase	11846
1	11846
deletion	O
in	O
myeloid	O
cells	O
affects	O
the	O
inflammatory	D007249
response	O
in	O
allergic	O
asthma	D001249
,	O
but	O
not	O
lung	O
mechanics	O
,	O
in	O
female	O
mice	10090
.	O

BACKGROUND	O
:	O
(	O
Over	O
-	O
)	O
expression	O
of	O
arginase	11846
may	O
limit	O
local	O
availability	O
of	O
arginine	O
for	O
nitric	D009569
oxide	D009569
synthesis	O
.	O

We	O
investigated	O
the	O
significance	O
of	O
arginase1	11846
(	O
ARG1	11846
)	O
for	O
the	O
development	O
of	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
and	O
lung	D011014
inflammation	D011014
in	O
female	O
mice	10090
with	O
ovalbumin	66222
(	O
OVA	66222
)	O
-	O
induced	O
allergic	O
asthma	D001249
.	O

METHODS	O
:	O
Arg1	11846
was	O
ablated	O
in	O
the	O
lung	O
by	O
crossing	O
Arg1	11846
fl	O
/	O
fl	O
and	O
Tie2Cre	O
tg	O
/	O
-	O
mice	10090
.	O

OVA	66222
sensitization	O
and	O
challenge	O
were	O
conducted	O
,	O
and	O
AHR	O
to	O
methacholine	D016210
was	O
determined	O
using	O
the	O
Flexivent	O
system	O
.	O

Changes	O
in	O
gene	O
expression	O
,	O
chemokine	O
and	O
cytokine	O
secretion	O
,	O
plasma	O
IgE	629822
,	O
and	O
lung	O
histology	O
were	O
quantified	O
using	O
RT	O
-	O
qPCR	O
,	O
ELISA	O
,	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Arg1	11846
ablation	O
had	O
no	O
influence	O
on	O
the	O
development	O
of	O
OVA	66222
-	O
induced	O
AHR	O
,	O
but	O
attenuated	O
OVA	66222
-	O
induced	O
increases	O
in	O
expression	O
of	O
Arg2	11847
and	O
Nos2	18126
,	O
Slc7a1	11987
,	O
Slc7a2	11988
,	O
and	O
Slc7a7	20540
(	O
arginine	11987,11988,20540
transporters	11987,11988,20540
)	O
,	O
Il4	16189
,	O
Il5	16191
and	O
Il13	16163
(	O
TH2	16163,16189,16191
-	O
type	16163,16189,16191
cytokines	16163,16189,16191
)	O
,	O
Ccl2	20296
and	O
Ccl11	20292
(	O
chemokines	20292,20296
)	O
,	O
Ifng	15978
(	O
TH1	15978
-	O
type	15978
cytokine	15978
)	O
,	O
Clca3	23844
and	O
Muc5ac	17833
(	O
goblet	O
cell	O
markers	O
)	O
,	O
and	O
OVA	66222
-	O
specific	O
IgE	629822
.	O

Pulmonary	O
IL	16153
-	O
10	16153
protein	O
content	O
increased	O
,	O
but	O
IL	16189
-	O
4	16189
,	O
IL	16191
-	O
5	16191
,	O
IL	16163
-	O
13	16163
,	O
TNFalpha	21926
and	O
IFNgamma	15978
content	O
,	O
and	O
lung	O
histopathology	O
,	O
were	O
not	O
affected	O
.	O

Arg1	11846
elimination	O
also	O
decreased	O
number	O
and	O
tightness	O
of	O
correlations	O
between	O
adaptive	O
changes	O
in	O
lung	O
function	O
and	O
inflammatory	D007249
parameters	O
in	O
OVA	66222
/	O
OVA	66222
-	O
treated	O
female	O
mice	10090
.	O

OVA	66222
/	O
OVA	66222
-	O
treated	O
female	O
mice	10090
mounted	O
a	O
higher	O
OVA	66222
-	O
IgE	629822
response	O
than	O
males	O
,	O
but	O
the	O
correlation	O
between	O
lung	O
function	O
and	O
inflammation	D007249
was	O
lower	O
.	O

Arg1	11846
-	O
deficient	O
OVA	66222
/	O
OVA	66222
-	O
treated	O
females	O
differed	O
from	O
males	O
in	O
a	O
more	O
pronounced	O
decline	O
of	O
arginine	O
-	O
metabolizing	O
and	O
-	O
transporting	O
genes	O
,	O
higher	O
plasma	O
arginine	O
levels	O
,	O
a	O
smaller	O
OVA	66222
-	O
specific	O
IgE	629822
response	O
,	O
and	O
no	O
improvement	O
of	O
peripheral	O
lung	O
function	O
.	O

CONCLUSION	O
:	O
Complete	O
ablation	O
of	O
Arg1	11846
in	O
the	O
lung	O
affects	O
mRNA	O
abundance	O
of	O
arginine	O
-	O
transporting	O
and	O
-	O
metabolizing	O
genes	O
,	O
and	O
pro	O
-	O
inflammatory	D007249
genes	O
,	O
but	O
not	O
methacholine	D016210
responsiveness	O
or	O
accumulation	O
of	O
inflammatory	D007249
cells	O
.	O
Valproic	D014635
acid	D014635
I	O
:	O
time	O
course	O
of	O
lipid	D008055
peroxidation	O
biomarkers	O
,	O
liver	D056486
toxicity	D056486
,	O
and	O
valproic	D014635
acid	D014635
metabolite	O
levels	O
in	O
rats	10116
.	O

A	O
single	O
dose	O
of	O
valproic	D014635
acid	D014635
(	O
VPA	D014635
)	O
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	D000927
drug	D000927
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	10116
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15	C075750
-	O
F	C075750
(	O
2t	C075750
)	O
-	O
isoprostane	C075750
(	O
15	C075750
-	O
F	C075750
(	O
2t	C075750
)	O
-	O
IsoP	C075750
)	O
.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	D014635
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	D056486
,	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	10116
were	O
treated	O
ip	O
with	O
VPA	D014635
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0	O
.	O
9%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15	C075750
-	O
F	C075750
(	O
2t	C075750
)	O
-	O
IsoP	C075750
,	O
lipid	D008054
hydroperoxides	D008054
(	O
LPO	D008054
)	O
,	O
and	O
thiobarbituric	D017392
acid	D017392
reactive	D017392
substances	D017392
(	O
TBARs	D017392
)	O
.	O

Plasma	O
and	O
liver	O
15	C075750
-	O
F	C075750
(	O
2t	C075750
)	O
-	O
IsoP	C075750
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	D014635
treatment	O
compared	O
to	O
control	O
.	O

Liver	O
LPO	D008054
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1	O
.	O
8	O
-	O
fold	O
versus	O
control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	O
and	O
plasma	O
TBARs	D017392
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2	O
-	O
fold	O
vs	O
.	O

control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	D056486
toxicity	D056486
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	24421
-	O
glutathione	24421
S	24421
-	O
transferase	24421
(	O
alpha	24421
-	O
GST	24421
)	O
and	O
by	O
histology	O
.	O

Serum	O
alpha	24421
-	O
GST	24421
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	D056486
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	D006505
of	D006505
the	D006505
liver	D006505
capsule	D006505
,	O
necrosis	D009336
,	O
and	O
steatosis	D005234
throughout	O
the	O
study	O
.	O

The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	D014635
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4	C045022
-	O
ene	C045022
-	O
VPA	C045022
and	O
(	O
E	O
)	O
-	O
2	C556631
,	O
4	C556631
-	O
diene	C556631
-	O
VPA	C556631
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	D014635
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15	C075750
-	O
F	C075750
(	O
2t	C075750
)	O
-	O
IsoP	C075750
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	D009336
,	O
steatosis	D005234
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	24421
-	O
GST	24421
.	O
Delineation	O
of	O
the	O
clinical	O
phenotype	O
associated	O
with	O
OPHN1	4983
mutations	O
based	O
on	O
the	O
clinical	O
and	O
neuropsychological	O
evaluation	O
of	O
three	O
families	O
.	O

Recent	O
reports	O
have	O
demonstrated	O
that	O
mutations	O
in	O
the	O
OPHN1	4983
gene	O
were	O
responsible	O
for	O
a	O
syndromic	O
rather	O
than	O
non	O
-	O
specific	O
mental	D008607
retardation	D008607
.	O

Abnormalities	O
of	O
the	O
posterior	O
fossa	O
with	O
cerebellar	C562568
hypoplasia	C562568
have	O
been	O
demonstrated	O
in	O
all	O
male	O
patients	9606
reported	O
to	O
date	O
.	O

We	O
report	O
here	O
a	O
new	O
family	O
with	O
X	D038901
-	O
linked	D038901
mental	D038901
retardation	D038901
due	O
to	O
mutation	O
in	O
OPHN1	4983
and	O
present	O
unpublished	O
data	O
about	O
two	O
families	O
previously	O
reported	O
,	O
concerning	O
the	O
facial	O
and	O
psychological	O
phenotype	O
of	O
affected	O
males	O
and	O
carrier	O
females	O
.	O

Our	O
study	O
confirms	O
that	O
cerebellar	C562568
hypoplasia	C562568
is	O
a	O
hallmark	O
of	O
this	O
syndrome	O
.	O

In	O
addition	O
,	O
affected	O
males	O
display	O
facial	O
similarities	O
that	O
can	O
help	O
the	O
diagnosis	O
.	O

Most	O
carrier	O
females	O
have	O
mild	O
mental	D008607
retardation	D008607
and	O
subtle	O
facial	O
changes	O
.	O
Serum	O
levels	O
of	O
chemokines	3576,6347,6348,6351,6352,6374
CCL4	6351
and	O
CCL5	6352
in	O
cirrhotic	D008103
patients	9606
indicate	O
the	O
presence	O
of	O
hepatocellular	D006528
carcinoma	D006528
.	O

BACKGROUND	O
:	O
Most	O
hepatocellular	D006528
carcinomas	D006528
(	O
HCCs	D006528
)	O
are	O
diagnosed	O
at	O
an	O
advanced	O
stage	O
.	O

The	O
prognostic	O
value	O
of	O
serum	O
tumour	D009369
markers	O
alpha	174
-	O
fetoprotein	174
(	O
AFP	174
)	O
and	O
des	2147
-	O
gamma	2147
-	O
carboxy	2147
prothrombin	2147
(	O
DCP	2147
)	O
is	O
limited	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
diagnostic	O
value	O
of	O
serum	O
growth	O
factors	O
,	O
apoptotic	O
and	O
inflammatory	D007249
mediators	O
of	O
cirrhotic	D008103
patients	9606
with	O
and	O
without	O
HCC	D006528
.	O

METHODS	O
:	O
Serum	O
samples	O
were	O
collected	O
from	O
cirrhotic	D008103
potential	O
liver	O
transplant	O
patients	9606
(	O
LTx	O
)	O
with	O
(	O
n	O
=	O
61	O
)	O
and	O
without	O
HCC	D006528
(	O
n	O
=	O
78	O
)	O
as	O
well	O
as	O
from	O
healthy	O
controls	O
(	O
HCs	O
;	O
n	O
=	O
39	O
)	O
.	O

Serum	O
concentrations	O
of	O
CRP	1401
,	O
neopterin	D019798
and	O
IL	3569
-	O
6	3569
as	O
markers	O
of	O
inflammation	D007249
and	O
thrombopoietin	7066
(	O
TPO	7066
)	O
,	O
GCSF	1440
,	O
FGF	2247
basic	2247
and	O
VEGF	7422
,	O
HMGB1	3146
,	O
CK	3875
-	O
18	3875
(	O
M65	O
)	O
and	O
CK18	3875
fragment	O
(	O
M30	O
)	O
and	O
a	O
panel	O
of	O
proinflammatory	3576,6347,6348,6351,6352,6374
chemokines	3576,6347,6348,6351,6352,6374
(	O
CCL2	6347
,	O
CCL3	6348
,	O
CCL4	6351
,	O
CCL5	6352
,	O
CXCL5	6374
and	O
IL	3576
-	O
8	3576
)	O
were	O
measured	O
.	O

Chi	O
square	O
,	O
Fisher	O
exact	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
ROC	O
curve	O
analysis	O
and	O
forward	O
stepwise	O
logistic	O
regression	O
analyses	O
were	O
applied	O
.	O

RESULTS	O
:	O
Patients	9606
with	O
HCC	D006528
had	O
higher	O
serum	O
TPO	7066
and	O
chemokines	3576,6347,6348,6351,6352,6374
(	O
P	O
<	O
0	O
.	O
001	O
for	O
TPO	7066
,	O
CCL4	6351
,	O
CCL5	6352
and	O
CXCL5	6374
)	O
and	O
lower	O
CCL2	6347
(	O
P	O
=	O
0	O
.	O
008	O
)	O
levels	O
than	O
cirrhotic	D008103
patients	9606
without	O
HCC	D006528
.	O

Multivariate	O
forward	O
stepwise	O
regression	O
analysis	O
for	O
significant	O
parameters	O
showed	O
that	O
among	O
the	O
studied	O
parameters	O
CCL4	6351
and	O
CCL5	6352
(	O
P	O
=	O
0	O
.	O
001	O
)	O
are	O
diagnostic	O
markers	O
of	O
HCC	D006528
.	O

Serum	O
levels	O
of	O
TPO	7066
and	O
chemokines	3576,6347,6348,6351,6352,6374
were	O
lower	O
,	O
whereas	O
M30	O
was	O
significantly	O
higher	O
in	O
cirrhotic	D008103
patients	9606
than	O
in	O
HCs	O
.	O

CONCLUSIONS	O
:	O
High	O
serum	O
levels	O
of	O
inflammatory	D007249
chemokines	3576,6347,6348,6351,6352,6374
such	O
as	O
CCL4	6351
and	O
CCL5	6352
in	O
the	O
serum	O
of	O
cirrhotic	D008103
patients	9606
indicate	O
the	O
presence	O
of	O
HCC	D006528
.	O
Over	O
-	O
expression	O
of	O
BMP4	652
and	O
BMP5	653
in	O
a	O
child	O
with	O
axial	D001848
skeletal	D001848
malformations	D001848
and	O
heterotopic	D009999
ossification	D009999
:	O
a	O
new	O
syndrome	O
.	O

Bone	649,650,652,653
morphogenetic	649,650,652,653
proteins	649,650,652,653
(	O
BMPs	649,650,652,653
)	O
are	O
a	O
highly	O
conserved	O
class	O
of	O
signaling	O
molecules	O
that	O
induce	O
ectopic	D001847,D002357
cartilage	D001847,D002357
and	D001847,D002357
bone	D001847,D002357
formation	D001847,D002357
in	O
vivo	O
.	O

Dysregulated	O
expression	O
of	O
bone	652
morphogenetic	652
protein	652
4	652
(	O
BMP4	652
)	O
is	O
found	O
in	O
the	O
cells	O
of	O
patients	9606
who	O
have	O
fibrodysplasia	D009221
ossificans	D009221
progressiva	D009221
(	O
FOP	D009221
)	O
,	O
a	O
genetic	O
disorder	O
of	O
axial	D001848
and	D001848
appendicular	D001848
skeletal	D001848
malformation	D001848
and	O
progressive	O
heterotopic	D009999
ossification	D009999
.	O

Loss	O
of	O
function	O
mutations	O
in	O
the	O
bone	653
morphogenetic	653
protein	653
5	653
(	O
bmp5	653
)	O
gene	O
leading	O
to	O
under	O
-	O
expression	O
of	O
BMP5	653
cause	O
the	O
murine	10090
short	D004427
ear	D004427
syndrome	D004427
,	O
characterized	O
by	O
small	O
malformed	O
ears	O
and	O
a	O
broad	O
range	O
of	O
axial	D001848
skeletal	D001848
malformations	D001848
.	O

We	O
found	O
features	O
reminiscent	O
of	O
both	O
the	O
short	O
ear	O
mouse	10090
and	O
FOP	D009221
in	O
a	O
child	O
with	O
malformed	D004426
external	D004426
ears	D004426
,	O
multiple	D001848
malformations	D001848
of	D001848
the	D001848
axial	D001848
skeleton	D001848
,	O
and	O
progressive	O
heterotopic	D009999
ossification	D009999
in	O
the	O
neck	O
and	O
back	O
.	O

We	O
examined	O
BMP	649,650,652,653
mRNA	O
expression	O
in	O
transformed	O
lymphocytes	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
and	O
protein	O
expression	O
by	O
ELISA	O
assays	O
and	O
immunohistochemistry	O
.	O

Elevated	O
levels	O
of	O
BMP4	652
and	O
BMP5	653
mRNA	O
and	O
protein	O
were	O
detected	O
in	O
the	O
patient	9606
'	O
s	O
cells	O
while	O
levels	O
of	O
BMP2	650
mRNA	O
were	O
unchanged	O
.	O

Our	O
data	O
suggest	O
that	O
dysregulated	O
expression	O
of	O
BMP4	652
and	O
BMP5	653
genes	O
is	O
associated	O
with	O
an	O
array	O
of	O
human	9606
axial	D001848
skeletal	D001848
abnormalities	D001848
similar	O
to	O
the	O
short	O
ear	O
mouse	10090
and	O
FOP	D009221
.	O
The	O
activation	O
of	O
spinal	O
N	24408
-	O
methyl	24408
-	O
D	24408
-	O
aspartate	24408
receptors	24408
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	D009020
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	D020760
cord	D020760
ischemia	D020760
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N	24408
-	O
methyl	24408
-	O
d	24408
-	O
aspartate	24408
(	O
NMDA	24408
)	O
receptors	24408
after	O
neuraxial	O
morphine	D009020
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	D001157
occlusion	D001157
in	O
rats	10116
.	O

Spinal	D020760
cord	D020760
ischemia	D020760
was	O
induced	O
by	O
aortic	D001157
occlusion	D001157
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8	O
)	O
or	O
30	O
mug	O
of	O
morphine	D009020
(	O
group	O
M	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0	O
.	O
5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	D009020
(	O
group	O
SM	O
;	O
n	O
=	O
8	O
)	O
or	O
10	O
muL	O
of	O
saline	O
(	O
group	O
SC	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
IT	O
0	O
.	O
5	O
h	O
after	O
sham	O
operation	O
.	O

Microdialysis	O
samples	O
were	O
collected	O
preischemia	O
,	O
before	O
IT	O
injection	O
,	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
(	O
after	O
IT	O
injection	O
)	O
.	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK	D016291
-	O
801	D016291
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine	D009020
-	O
induced	O
spastic	D020336
paraparesis	D020336
.	O

After	O
IT	O
morphine	D009020
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	D018698
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
increase	O
persisted	O
for	O
8	O
hrs	O
.	O

IT	O
MK	D016291
-	O
801	D016291
significantly	O
reduced	O
the	O
number	O
of	O
dark	O
-	O
stained	O
alpha	O
-	O
motoneurons	O
after	O
morphine	D009020
-	O
induced	O
spastic	D020336
paraparesis	D020336
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	D009020
induces	O
spastic	D020336
paraparesis	D020336
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	D018698
,	O
which	O
is	O
involved	O
in	O
NMDA	24408
receptor	24408
activation	O
.	O

We	O
suggest	O
that	O
opioids	D000701
may	O
be	O
neurotoxic	D020258
in	O
the	O
setting	O
of	O
spinal	D020760
cord	D020760
ischemia	D020760
via	O
NMDA	24408
receptor	24408
activation	O
.	O
Association	O
of	O
DRD2	1813
polymorphisms	O
and	O
chlorpromazine	D002746
-	O
induced	O
extrapyramidal	D001480
syndrome	D001480
in	O
Chinese	O
schizophrenic	D012559
patients	9606
.	O

AIM	O
:	O
Extrapyramidal	D001480
syndrome	D001480
(	O
EPS	D001480
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	D014150
drugs	D014150
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	1813
receptor	1813
.	O

Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	1813
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	D012559
patients	9606
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	1813
plays	O
in	O
chlorpromazine	D002746
-	O
induced	O
EPS	D001480
in	O
schizophrenic	D012559
patients	9606
.	O

METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(	O
-	O
141Cins	c|INDEL|0141|C
>	O
del	c|INDEL|0141|C
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	c|SUB|S|311|C
,	O
rs6275	rs6275
,	O
rs6277	rs6277
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	1813
gene	O
in	O
146	O
schizophrenic	D012559
inpatients	9606
(	O
59	O
with	O
EPS	D001480
and	O
87	O
without	O
EPS	D001480
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	D002746
after	O
8	O
weeks	O
.	O

The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O

RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	c|SUB|S|311|C
and	O
rs6277	rs6277
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O

No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-	O
141Cins	c|INDEL|0141|C
>	O
del	c|INDEL|0141|C
,	O
TaqIB	O
,	O
rs6275	rs6275
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	rs6275
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	1813
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	D002746
,	O
at	O
least	O
in	O
Chinese	O
patients	9606
with	O
schizophrenia	D012559
.	O

Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	1813
and	O
EPS	D001480
in	O
Caucasians	O
.	O
Does	O
domperidone	D004294
potentiate	O
mirtazapine	D000078785
-	O
associated	O
restless	D012148
legs	D012148
syndrome?	D012148
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	D012148
legs	D012148
syndrome	D012148
(	O
RLS	D012148
)	O
.	O

For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	D012148
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	D007980
and	O
dopamine	D004298
agonists	O
,	O
whereas	O
central	O
dopamine	D065127
D2	D065127
receptor	D065127
antagonists	D065127
can	O
induce	O
or	O
aggravate	O
RLS	D012148
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	D004294
,	O
a	O
peripheral	O
dopamine	1813
D2	1813
receptor	1813
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	D012148
.	O

Mirtazapine	D000078785
,	O
the	O
first	O
noradrenergic	D000928
and	D000928
specific	D000928
serotonergic	D000928
antidepressant	D000928
(	O
NaSSA	D000928
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	D012148
in	O
several	O
recent	O
publications	O
.	O

The	O
authors	O
report	O
here	O
a	O
depressed	D003866
patient	9606
comorbid	O
with	O
postprandial	D004415
dyspepsia	D004415
who	O
developed	O
RLS	D012148
after	O
mirtazapine	D000078785
had	O
been	O
added	O
to	O
his	O
domperidone	D004294
therapy	O
.	O

Our	O
patient	9606
started	O
to	O
have	O
symptoms	O
of	O
RLS	D012148
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	D000078785
,	O
and	O
his	O
RLS	D012148
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	D000078785
.	O

Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	D000078785
and	O
the	O
symptoms	O
of	O
RLS	D012148
in	O
our	O
patient	9606
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	D004294
on	O
mirtazapine	D000078785
-	O
associated	O
RLS	D012148
.	O

However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	D000078785
can	O
be	O
associated	O
with	O
RLS	D012148
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	D065127
D2	D065127
receptor	D065127
antagonists	D065127
.	O
End	D007676
-	O
stage	D007676
renal	D007676
disease	D007676
(	O
ESRD	D007676
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	5530
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	5530
inhibitors	O
cyclosporine	D016572
and	O
tacrolimus	D016559
are	O
both	O
known	O
to	O
be	O
nephrotoxic	D007674
.	O

Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	9606
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	D007676
-	O
stage	D007676
renal	D007676
disease	D007676
(	O
ESRD	D007676
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	D007676
and	O
chronic	D007676
renal	D007676
failure	D007676
(	O
CRF	D007676
)	O
in	O
OLTX	O
patients	9606
.	O

METHODS	O
:	O
Patients	9606
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O

Patients	9606
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	D007676
or	O
ESRD	D007676
,	O
n	O
=	O
748	O
;	O
CRF	D007676
,	O
sustained	O
serum	O
creatinine	D003404
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	D007676
,	O
n	O
=	O
45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	D007676
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	D007676
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	D007674
dysfunction	D007674
was	O
18	O
.	O
1%	O
(	O
CRF	D007676
8	O
.	O
6%	O
and	O
ESRD	D007676
9	O
.	O
5%	O
)	O
.	O

Compared	O
with	O
control	O
patients	9606
,	O
CRF	D007676
and	O
ESRD	D007676
patients	9606
had	O
higher	O
preoperative	O
serum	O
creatinine	D003404
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	9606
with	O
hepatorenal	D006530
syndrome	D006530
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	D003404
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	D003404
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	D007676
or	O
ESRD	D007676
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	9606
who	O
had	O
ESRD	D007676
was	O
only	O
28	O
.	O
2%	O
compared	O
with	O
54	O
.	O
6%	O
in	O
the	O
control	O
group	O
.	O

Patients	9606
developing	O
ESRD	D007676
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	D007676
of	O
27%	O
for	O
the	O
patients	9606
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4%	O
for	O
the	O
patients	9606
developing	O
ESRD	D007676
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	9606
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	D007676
and	O
ESRD	D007676
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	D007676
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	9606
treated	O
with	O
dialysis	O
only	O
.	O

Patients	9606
who	O
develop	O
ESRD	D007676
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	D003404
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	D006530
syndrome	D006530
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	D003404
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	D007676
or	O
ESRD	D007676
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O
Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O

Approximately	O
30%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(	O
PTCs	O
)	O
,	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O

However	O
,	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O

Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(	O
indel	O
)	O
of	O
three	O
nucleotides	O
.	O

We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	D003550
fibrosis	D003550
patients	9606
homozygous	O
for	O
the	O
E831X	rs397508387
mutation	O
(	O
2623G	rs397508387
>	O
T	rs397508387
)	O
in	O
the	O
CFTR	1080
gene	O
.	O

Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
,	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O

Structure	O
-	O
function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
,	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease	O
-	O
causing	O
UAG	O
stop	O
codon	O
.	O

This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O

This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O
Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	p|SUB|G|145|R
and	O
P120T	c|SUB|P|120|T
on	O
the	O
replication	O
of	O
lamivudine	D019259
-	O
resistant	O
hepatitis	D006513
B	D006513
virus	D006513
e	D006513
antigen	D006513
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	10407
B	10407
virus	10407
(	O
HBV	10407
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	10407
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	D019259
(	O
LAM	D019259
)	O
and	O
/	O
or	O
HBeAg	D006513
negativity	O
.	O

Replication	O
-	O
competent	O
HBV	10407
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	D019259
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	D006513
-	O
positive	O
and	O
an	O
HBeAg	D006513
-	O
negative	O
background	O
with	O
precore	944568
(	O
PC	944568
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	D006514
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	D019259
-	O
resistant	O
HBV	10407
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	10407
,	O
and	O
PC	944568
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	D006514
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	D019259
-	O
resistant	O
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	D006513
negativity	O
(	O
PC	944568
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	D019259
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	10407
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	D019259
resistance	O
mutations	O
,	O
the	O
nucleotide	O
analogues	O
adefovir	C053001
and	O
tenofovir	D000068698
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O

These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	10407
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O
Bilateral	O
haemorrhagic	D002543,D020520
infarction	D002543,D020520
of	D002543,D020520
the	D002543,D020520
globus	D002543,D020520
pallidus	D002543,D020520
after	O
cocaine	D003042
and	O
alcohol	D000431
intoxication	O
.	O

Cocaine	D003042
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	D002544,D020521
and	D002544,D020521
haemorrhagic	D002544,D020521
stroke	D002544,D020521
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
man	9606
with	O
bilateral	O
ischemia	D002545
of	D002545
the	D002545
globus	D002545
pallidus	D002545
after	O
excessive	O
alcohol	D000431
and	O
intranasal	O
cocaine	D003042
use	O
.	O

Drug	O
-	O
related	O
globus	D020520
pallidus	D020520
infarctions	D020520
are	O
most	O
often	O
associated	O
with	O
heroin	D003932
.	O

Bilateral	O
basal	D020520
ganglia	D020520
infarcts	D020520
after	O
the	O
use	O
of	O
cocaine	D003042
,	O
without	O
concurrent	O
heroin	D003932
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	9606
,	O
transient	O
cardiac	D001145
arrhythmia	D001145
or	O
respiratory	D012131
dysfunction	D012131
related	O
to	O
cocaine	D003042
and	O
/	O
or	O
ethanol	D000431
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	D002545
hypoperfusion	D002545
.	O
Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	D010406
-	O
induced	O
epileptiform	D004827
activity	D004827
in	O
anesthetized	O
rats	10116
.	O

Penicillin	D010406
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	D004827
research	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	D010406
-	O
induced	O
epileptiform	D004827
activity	D004827
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	10116
.	O

Male	O
Wistar	O
rats	10116
were	O
anesthetized	O
with	O
i	O
.	O
p	O
.	O

urethane	D014520
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O

After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	D004827
focus	O
was	O
induced	O
by	O
injecting	O
400IU	O
/	O
2	O
microl	O
penicillin	D010400
-	O
G	D010400
potassium	D010400
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	D010406
-	O
induced	O
epileptiform	D004827
activity	D004827
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha	O
-	O
sigma	O
,	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	D004827
activity	D004827
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	D004827
activity	D004827
)	O
.	O

Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	D004827
.	O
Exaggerated	O
expression	O
of	O
inflammatory	D007249
mediators	O
in	O
vasoactive	22353
intestinal	22353
polypeptide	22353
knockout	O
(	O
VIP	22353
-	O
/	O
-	O
)	O
mice	10090
with	O
cyclophosphamide	D003520
(	O
CYP	D003520
)	O
-	O
induced	O
cystitis	D003556
.	O

Vasoactive	22353
intestinal	22353
polypeptide	22353
(	O
VIP	22353
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	D003520
(	O
CYP	D003520
)	O
-	O
induced	O
cystitis	D003556
.	O

Given	O
VIP	22353
'	O
s	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	D007249
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
would	O
exhibit	O
enhanced	O
inflammatory	D007249
mediator	O
expression	O
after	O
cystitis	D003556
.	O

A	O
mouse	10090
inflammatory	D007249
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
with	O
or	O
without	O
CYP	D003520
-	O
induced	O
cystitis	D003556
(	O
150	O
mg	O
/	O
kg	O
;	O
i	O
.	O
p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	D003520
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	D003520
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	D003520
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
with	O
CYP	D003520
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1	O
.	O
5	O
-	O
fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0	O
.	O
05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL	16176
-	O
1beta	16176
and	O
CXCL1	14825
.	O

CYP	D003520
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
increased	O
expression	O
of	O
CXCL1	14825
and	O
IL	16176
-	O
1beta	16176
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
,	O
but	O
expression	O
in	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
with	O
CYP	D003520
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
greater	O
(	O
4	O
.	O
2	O
-	O
to	O
13	O
-	O
fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3	O
.	O
6	O
-	O
to	O
5	O
-	O
fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
with	O
bladder	D003556
inflammation	D003556
,	O
inflammatory	D007249
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	D003520
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	D001745
dysfunction	D001745
in	O
VIP	22353
(	O
-	O
/	O
-	O
)	O
mice	10090
with	O
bladder	D003556
inflammation	D003556
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O
Seizures	D012640
associated	O
with	O
levofloxacin	D064704
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	9606
who	O
developed	O
seizures	D012640
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	D064704
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	1544
P450	1544
(	O
CYP	1544
)	O
1A2	1544
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin	D064704
-	O
induced	O
seizures	D012640
.	O

METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
,	O
Cochrane	O
and	O
Ovid	O
.	O

The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	D064704
.	O

The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O

RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin	D064704
-	O
induced	O
seizures	D012640
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	1544
by	O
levofloxacin	D064704
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	D064704
therapy	O
in	O
patients	9606
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	1544
substrates	O
.	O
Takotsubo	D054549
syndrome	D054549
(	O
or	O
apical	D054549
ballooning	D054549
syndrome	D054549
)	O
secondary	O
to	O
Zolmitriptan	C089750
.	O

Takotsubo	D054549
syndrome	D054549
(	O
TS	D054549
)	O
,	O
also	O
known	O
as	O
broken	D054549
heart	D054549
syndrome	D054549
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	D054058
coronary	D054058
syndrome	D054058
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	9606
with	O
medical	O
history	O
of	O
mitral	D008945
valve	D008945
prolapse	D008945
and	O
migraines	D008881
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	D002637
pain	D002637
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I	O
.	O

Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	D009041
abnormalities	D009041
consistent	O
with	O
TS	D054549
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	9606
took	O
zolmitriptan	C089750
sparingly	O
only	O
when	O
she	O
had	O
migraines	D008881
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	C089750
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	D008881
headache	D008881
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	9796
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	D008881
migrainosus	D008881
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	D003329
artery	D003329
vasospasm	D003329
secondary	O
to	O
zolmitriptan	C089750
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	D054549
.	O
Characterization	O
of	O
Bietti	C535440
crystalline	C535440
dystrophy	C535440
patients	9606
with	O
CYP4V2	285440
mutations	O
.	O

PURPOSE	O
:	O
Mutations	O
of	O
the	O
CYP4V2	285440
gene	O
,	O
a	O
novel	O
family	O
member	O
of	O
the	O
cytochrome	285440
P450	285440
genes	O
on	O
chromosome	O
4q35	O
,	O
have	O
recently	O
been	O
identified	O
in	O
patients	9606
with	O
Bietti	C535440
crystalline	C535440
dystrophy	C535440
(	O
BCD	C535440
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
BCD	C535440
patients	9606
from	O
Singapore	O
,	O
and	O
to	O
characterize	O
their	O
phenotype	O
.	O

METHODS	O
:	O
Nine	O
patients	9606
with	O
BCD	C535440
from	O
six	O
families	O
were	O
recruited	O
into	O
the	O
study	O
.	O

The	O
11	O
exons	O
of	O
the	O
CYP4V2	285440
gene	O
were	O
amplified	O
from	O
genomic	O
DNA	O
of	O
patients	9606
by	O
polymerase	O
chain	O
reaction	O
and	O
then	O
sequenced	O
.	O

Detailed	O
characterization	O
of	O
the	O
patients	9606
'	O
phenotype	O
was	O
performed	O
with	O
fundal	O
photography	O
,	O
visual	O
field	O
testing	O
,	O
fundal	O
fluorescein	O
angiography	O
,	O
and	O
electroretinography	O
(	O
ERG	O
)	O
.	O

RESULTS	O
:	O
Three	O
pathogenic	O
mutations	O
were	O
identified	O
;	O
two	O
mutations	O
,	O
S482X	rs146494374
and	O
K386T	rs199476200
,	O
were	O
novel	O
and	O
found	O
in	O
three	O
patients	9606
.	O

The	O
third	O
mutation	O
,	O
a	O
previously	O
identified	O
15	c|DEL||15
-	O
bp	c|DEL||15
deletion	c|DEL||15
that	O
included	O
the	O
3	O
'	O
splice	O
site	O
for	O
exon	O
7	O
,	O
was	O
found	O
in	O
all	O
nine	O
patients	9606
,	O
with	O
six	O
patients	9606
carrying	O
the	O
deletion	O
in	O
the	O
homozygous	O
state	O
.	O

Haplotype	O
analysis	O
in	O
patients	9606
and	O
controls	O
indicated	O
a	O
founder	O
effect	O
for	O
this	O
deletion	O
mutation	O
in	O
exon	O
7	O
.	O

Clinical	O
heterogeneity	O
was	O
present	O
in	O
the	O
patients	9606
.	O

Compound	O
heterozygotes	O
for	O
the	O
deletion	O
in	O
exon	O
7	O
seemed	O
to	O
have	O
more	O
severe	O
disease	O
compared	O
to	O
patients	9606
homozygous	O
for	O
the	O
deletion	O
.	O

There	O
was	O
good	O
correlation	O
between	O
clinical	O
stage	O
of	O
disease	O
and	O
ERG	O
changes	O
,	O
but	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
identified	O
novel	O
mutations	O
in	O
the	O
CYP4V2	285440
gene	O
as	O
a	O
cause	O
of	O
BCD	C535440
.	O

A	O
high	O
carrier	O
frequency	O
for	O
the	O
15	c|DEL||15
-	O
bp	c|DEL||15
deletion	c|DEL||15
in	O
exon	O
7	O
may	O
exist	O
in	O
the	O
Singapore	O
population	O
.	O

Phenotype	O
characterization	O
showed	O
clinical	O
heterogeneity	O
,	O
and	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O
Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	729238
protein	729238
-	O
A2	729238
increases	O
susceptibility	O
to	O
meningococcal	D008589
disease	D008589
.	O

BACKGROUND	O
:	O
Meningococcal	D008589
disease	D008589
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	D006069
meningitidis	D006069
.	O

Surfactant	653509,729238
protein	653509,729238
(	O
SP	653509,729238
)	O
-	O
A	653509,729238
and	O
SP	6441
-	O
D	6441
are	O
pattern	O
-	O
recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	D007249
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	D000073893
.	O

Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O

METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP	653509
-	O
A1	653509
,	O
SP	729238
-	O
A2	729238
,	O
and	O
SP	6441
-	O
D	6441
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	9606
with	O
microbiologically	O
proven	O
meningococcal	D008589
disease	D008589
,	O
including	O
18	O
patients	9606
who	O
died	D003643
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP	729238
-	O
A2	729238
increased	O
the	O
risk	O
of	O
meningococcal	D008589
disease	D008589
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
7	O
.	O
4	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
42	O
.	O
4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0	O
.	O
3	O
;	O
95%	O
CI	O
,	O
0	O
.	O
1	O
-	O
0	O
.	O
97	O
)	O
.	O

An	O
analysis	O
of	O
the	O
multiple	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
SP	653509,729238
-	O
A	653509,729238
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	c|SUB|Q|223|K
(	O
in	c|SUB|Q|223|K
1A1	c|SUB|Q|223|K
)	O
rather	c|SUB|Q|223|K
than	c|SUB|Q|223|K
glutamine	c|SUB|Q|223|K
(	O
in	c|SUB|Q|223|K
1A5	c|SUB|Q|223|K
)	O
at	c|SUB|Q|223|K
amino	c|SUB|Q|223|K
acid	c|SUB|Q|223|K
223	c|SUB|Q|223|K
in	O
the	O
carbohydrate	D002241
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	D008589
disease	D008589
(	O
OR	O
,	O
6	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
4	O
-	O
31	O
.	O
5	O
)	O
.	O

Carriage	O
of	O
alleles	O
encoding	O
lysine	c|Allele|K|223
at	c|Allele|K|223
residue	c|Allele|K|223
223	c|Allele|K|223
was	O
found	O
in	O
61%	O
of	O
patients	9606
who	O
died	D003643
,	O
compared	O
with	O
35%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2	O
.	O
9	O
;	O
95%	O
CI	O
,	O
1	O
.	O
1	O
-	O
7	O
.	O
7	O
)	O
.	O

Genetic	O
variation	O
of	O
SP	653509
-	O
A1	653509
and	O
SP	6441
-	O
D	6441
was	O
not	O
associated	O
with	O
meningococcal	D008589
disease	D008589
.	O

CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	c|SUB|Q|223|K
with	c|SUB|Q|223|K
lysine	c|SUB|Q|223|K
at	c|SUB|Q|223|K
residue	c|SUB|Q|223|K
223	c|SUB|Q|223|K
in	O
the	O
carbohydrate	D002241
recognition	O
domain	O
of	O
SP	729238
-	O
A2	729238
increases	O
susceptibility	O
to	O
meningococcal	D008589
disease	D008589
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	D003643
.	O
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	D007980
-	O
induced	O
dyskinesia	D004409
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
.	O

Chronic	O
pulsatile	O
levodopa	D007980
therapy	O
for	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
(	O
PD	D010300
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	D004409
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	D007980
-	O
induced	O
dyskinesia	D004409
among	O
multiethnic	O
Malaysian	O
patients	9606
with	O
PD	D010300
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	9606
with	O
PD	D010300
on	O
uninterrupted	O
levodopa	D007980
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O

The	O
predictors	O
of	O
dyskinesia	D004409
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
years	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
years	O
.	O

The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O

Dyskinesia	D004409
was	O
present	O
in	O
44%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	D007980
therapy	O
of	O
3	O
years	O
.	O

There	O
were	O
64	O
.	O
3%	O
Chinese	O
,	O
31%	O
Malays	O
,	O
and	O
3	O
.	O
7%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patients	9606
with	O
dyskinesia	D004409
had	O
clinical	O
fluctuations	O
.	O

Patients	9606
with	O
dyskinesia	D004409
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	D007980
therapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	D007980
dose	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
patients	9606
without	O
dyskinesia	D004409
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	D004409
were	O
duration	O
of	O
levodopa	D007980
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	D007980
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	D007980
-	O
induced	O
dyskinesia	D004409
in	O
our	O
patients	9606
was	O
44%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	D007980
therapy	O
,	O
total	O
daily	O
levodopa	D007980
dose	O
,	O
and	O
onset	O
age	O
.	O
Novel	O
CACNA1S	779
mutation	O
causes	O
autosomal	O
dominant	O
hypokalemic	D020514
periodic	D020514
paralysis	D020514
in	O
a	O
South	O
American	O
family	O
.	O

Hypokalaemic	D020514
periodic	D020514
paralysis	D020514
(	O
HypoPP	D020514
)	O
is	O
an	O
autosomal	D030342
dominant	D030342
disorder	D030342
,	O
which	O
is	O
characterized	O
by	O
periodic	O
attacks	O
of	O
muscle	D018908
weakness	D018908
associated	O
with	O
a	O
decrease	O
in	O
the	O
serum	O
potassium	D011188
level	O
.	O

A	O
major	O
disease	O
-	O
causing	O
gene	O
for	O
HypoPP	D020514
has	O
been	O
identified	O
as	O
CACNA1S	779
,	O
which	O
encodes	O
the	O
skeletal	779
muscle	779
calcium	779
channel	779
alpha	779
-	O
subunit	779
with	O
four	O
transmembrane	O
domains	O
(	O
I	O
-	O
IV	O
)	O
,	O
each	O
with	O
six	O
transmembrane	O
segments	O
(	O
S1	O
-	O
S6	O
)	O
.	O

To	O
date	O
,	O
all	O
CACNA1S	779
mutations	O
identified	O
in	O
HypoPP	D020514
patients	9606
are	O
located	O
within	O
the	O
voltage	O
-	O
sensor	O
S4	O
segment	O
.	O

In	O
this	O
study	O
we	O
report	O
a	O
novel	O
CACNA1S	779
mutation	O
in	O
a	O
new	O
region	O
of	O
the	O
protein	O
,	O
the	O
S3	O
segment	O
of	O
domain	O
III	O
.	O

We	O
characterized	O
a	O
four	O
-	O
generation	O
South	O
American	O
family	O
with	O
HypoPP	D020514
.	O

Genetic	O
analysis	O
identified	O
a	O
novel	O
V876E	rs267606698
mutation	O
in	O
all	O
HypoPP	D020514
patients	9606
in	O
the	O
family	O
,	O
but	O
not	O
in	O
normal	O
family	O
members	O
or	O
160	O
control	O
people	O
.	O

Clinical	O
analysis	O
indicates	O
that	O
mutation	O
V876E	rs267606698
is	O
associated	O
with	O
a	O
severe	O
outcome	O
as	O
characterized	O
by	O
a	O
very	O
early	O
age	O
of	O
onset	O
,	O
complete	O
penetrance	O
and	O
a	O
severe	O
prognosis	O
including	O
death	D003643
.	O

These	O
results	O
identify	O
a	O
new	O
mutation	O
in	O
CACNA1S	779
and	O
expand	O
the	O
spectrum	O
of	O
CACNA1S	779
mutations	O
associated	O
with	O
HypoPP	D020514
.	O
Elevation	O
of	O
ADAM10	29650
,	O
ADAM17	57027
,	O
MMP	81686
-	O
2	81686
and	O
MMP	81687
-	O
9	81687
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	D002122
-	O
induced	O
thoracic	D017545
aortic	D017545
aneurysm	D017545
in	O
a	O
rat	10116
model	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	10116
model	O
of	O
thoracic	D017545
aortic	D017545
aneurysm	D017545
(	O
TAA	D017545
)	O
by	O
calcium	D002122
chloride	D002122
(	O
CaCl	D002122
(	O
2	D002122
)	O
)	O
-	O
induced	O
arterial	D014652
injury	D014652
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	29650,57027
disintegrin	29650,57027
and	29650,57027
metalloproteinase	29650,57027
(	O
ADAM	29650,57027
)	O
,	O
matrix	81686;81687
metalloproteinases	81686;81687
(	O
MMPs	81686;81687
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	D017545
formation	O
.	O

METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	10116
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	D002122
(	O
2	D002122
)	O
or	O
normal	O
saline	O
(	O
NaCl	D012965
)	O
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
,	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	D012965
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

MMP	81686;81687
-	O
TIMP	116510
and	O
ADAM	29650,57027
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
,	O
non	O
-	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
and	O
NaCl	D012965
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100%	O
)	O
were	O
demonstrated	O
in	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
segments	O
.	O

MMP	81686
-	O
2	81686
,	O
MMP	81687
-	O
9	81687
,	O
ADAM	29650
-	O
10	29650
and	O
ADAM	57027
-	O
17	57027
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	D012965
-	O
treated	O
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	81686
-	O
2	81686
,	O
MMP	81687
-	O
9	81687
,	O
ADAM	29650
-	O
10	29650
and	O
ADAM	57027
-	O
17	57027
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	D002122
(	O
2	D002122
)	O
-	O
treated	O
segments	O
.	O

TIMP	116510
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O

CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	D017545
model	O
by	O
periarterial	O
CaCl	D002122
(	O
2	D002122
)	O
exposure	O
in	O
rats	10116
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	81686
-	O
2	81686
,	O
MMP	81687
-	O
9	81687
,	O
ADAM10	29650
and	O
ADAM17	57027
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O
Expanding	O
clinical	O
spectrum	O
of	O
non	C563786
-	O
autoimmune	C563786
hyperthyroidism	C563786
due	O
to	O
an	O
activating	O
germline	O
mutation	O
,	O
p	rs121908864
.	O
M453T	rs121908864
,	O
in	O
the	O
thyrotropin	7253
receptor	7253
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non	C563786
-	O
autoimmune	C563786
hyperthyroidism	C563786
(	O
NAH	C563786
)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	7253
receptor	7253
(	O
TSHR	7253
)	O
gene	O
.	O

PATIENTS	9606
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O

Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O

GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	7253
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	rs121908864
to	rs121908864
C	rs121908864
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	7253
gene	O
(	O
c	rs121908864
.	O
1358T	rs121908864
-	O
-	O
>	O
C	rs121908864
)	O
resulting	O
in	O
the	O
substitution	O
of	O
methionine	rs121908864
(	O
ATG	rs121908864
)	O
by	rs121908864
threonine	rs121908864
(	O
ACG	rs121908864
)	O
at	rs121908864
codon	rs121908864
453	rs121908864
(	O
p	rs121908864
.	O
M453T	rs121908864
)	O
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O

They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O

In	O
addition	O
to	O
hyperthyroidism	D006980
,	O
ventriculomegaly	D006849
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Ventriculomegaly	D006849
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	C563786
because	O
of	O
an	O
activating	O
TSHR	7253
germline	O
mutation	O
.	O

In	O
addition	O
,	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
,	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O
Identification	O
of	O
a	O
novel	O
FBN1	2200
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	D008382
syndrome	D008382
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin	2200
-	O
1	2200
gene	O
(	O
FBN1	2200
)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	D008382
syndrome	D008382
(	O
MFS	D008382
)	O
.	O

METHODS	O
:	O
Patients	9606
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	2200
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4	O
.	O
0	O
.	O
1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
c	c|SUB|T|3703|C
.	O
3703T	c|SUB|T|3703|C
>	O
C	c|SUB|T|3703|C
change	O
in	O
exon	O
29	O
of	O
FBN1	2200
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	p|SUB|S|1235|P
by	p|SUB|S|1235|P
proline	p|SUB|S|1235|P
at	p|SUB|S|1235|P
codon	p|SUB|S|1235|P
1235	p|SUB|S|1235|P
(	O
p	p|SUB|S|1235|P
.	O
S1235P	p|SUB|S|1235|P
)	O
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	D002118
binding	O
epidermal	1956
growth	1956
factor	1956
-	O
like	O
#	O
15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
p	p|SUB|S|1235|P
.	O
S1235P	p|SUB|S|1235|P
mutation	O
in	O
FBN1	2200
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	D008382
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	2200
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	D008382
syndrome	D008382
.	O
CD72	971
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	9606
systemic	D008180
lupus	D008180
erythematosus	D008180
through	O
epistatic	O
interaction	O
with	O
FCGR2B	2213
.	O

We	O
previously	O
reported	O
association	O
of	O
FCGR2B	2213
-	O
Ile232Thr	rs1050501
with	O
systemic	D008180
lupus	D008180
erythematosus	D008180
(	O
SLE	D008180
)	O
in	O
three	O
Asian	O
populations	O
.	O

Because	O
polymorphism	O
of	O
CD72	12517
,	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
,	O
was	O
associated	O
with	O
murine	10090
SLE	D008180
,	O
we	O
identified	O
human	9606
CD72	971
polymorphisms	O
,	O
tested	O
their	O
association	O
with	O
SLE	D008180
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	2213
in	O
the	O
Japanese	O
(	O
160	O
SLE	D008180
,	O
277	O
controls	O
)	O
,	O
Thais	O
(	O
87	O
SLE	D008180
,	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	D008180
members	O
)	O
.	O

Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O

The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*	O
1	O
and	O
*	O
2	O
,	O
respectively	O
)	O
.	O

Although	O
association	O
with	O
susceptibility	O
to	O
SLE	D008180
was	O
not	O
detected	O
,	O
the	O
*	O
1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	D009393
among	O
the	O
Japanese	O
patients	9606
(	O
P	O
=	O
0	O
.	O
024	O
)	O
.	O

RT	O
-	O
PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(	O
AS	O
)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS	9606
-	O
7	9606
transfectants	O
.	O

The	O
ratio	O
of	O
AS	O
/	O
common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*	O
2	O
/	O
*	O
2	O
genotype	O
when	O
compared	O
with	O
*	O
1	O
/	O
*	O
1	O
(	O
P	O
=	O
0	O
.	O
000038	O
)	O
or	O
*	O
1	O
/	O
*	O
2	O
(	O
P	O
=	O
0	O
.	O
0085	O
)	O
genotypes	O
.	O

Using	O
the	O
two	O
Asian	O
cohorts	O
,	O
significant	O
association	O
of	O
FCGR2B	2213
-	O
232Thr	rs1050501
/	O
Thr	O
with	O
SLE	D008180
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72	971
-	O
*	O
1	O
/	O
*	O
1	O
genotype	O
(	O
OR	O
4	O
.	O
63	O
,	O
95%	O
CI	O
1	O
.	O
47	O
-	O
14	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
009	O
versus	O
FCGR2B	2213
-	O
232Ile	rs1050501
/	O
Ile	O
plus	O
CD72	971
-	O
*	O
2	O
/	O
*	O
2	O
)	O
.	O

Minigene	O
assays	O
demonstrated	O
that	O
the	O
13	O
-	O
nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O

The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
,	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane	O
-	O
distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
,	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72	12517
(	O
c	O
)	O
allele	O
associated	O
with	O
murine	10090
SLE	D008180
.	O

These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72	971
-	O
*	O
2	O
allele	O
decreases	O
risk	O
for	O
human	9606
SLE	D008180
conferred	O
by	O
FCGR2B	2213
-	O
232Thr	rs1050501
,	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	971
.	O
Vaccine	O
candidates	O
derived	O
from	O
a	O
novel	O
infectious	O
cDNA	O
clone	O
of	O
an	O
American	O
genotype	O
dengue	11060
virus	11060
type	11060
2	11060
.	O

BACKGROUND	O
:	O
A	O
dengue	11060
virus	11060
type	11060
2	11060
(	O
DEN	11060
-	O
2	11060
Tonga	O
/	O
74	O
)	O
isolated	O
from	O
a	O
1974	O
epidemic	O
was	O
characterized	O
by	O
mild	O
illness	O
and	O
belongs	O
to	O
the	O
American	O
genotype	O
of	O
DEN	11060
-	O
2	11060
viruses	O
.	O

To	O
prepare	O
a	O
vaccine	O
candidate	O
,	O
a	O
previously	O
described	O
30	c|DEL||30
nucleotide	c|DEL||30
deletion	c|DEL||30
(	O
Delta30	c|DEL||30
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
DEN	11070
-	O
4	11070
has	O
been	O
engineered	O
into	O
the	O
DEN	11060
-	O
2	11060
isolate	O
.	O

METHODS	O
:	O
A	O
full	O
-	O
length	O
cDNA	O
clone	O
was	O
generated	O
from	O
the	O
DEN	11060
-	O
2	11060
virus	O
and	O
used	O
to	O
produce	O
recombinant	O
DEN	11060
-	O
2	11060
(	O
rDEN	11060
-	O
2	11060
)	O
and	O
rDEN2Delta30	11060
.	O

Viruses	O
were	O
evaluated	O
for	O
replication	O
in	O
SCID	O
mice	10090
transplanted	O
with	O
human	9606
hepatoma	D006528
cells	O
(	O
SCID	9606
-	O
HuH	9606
-	O
7	9606
mice	10090
)	O
,	O
in	O
mosquitoes	O
,	O
and	O
in	O
rhesus	9544
monkeys	9544
.	O

Neutralizing	O
antibody	O
induction	O
and	O
protective	O
efficacy	O
were	O
also	O
assessed	O
in	O
rhesus	9544
monkeys	9544
.	O

RESULTS	O
:	O
The	O
rDEN2Delta30	11060
virus	O
was	O
ten	O
-	O
fold	O
reduced	O
in	O
replication	O
in	O
SCID	9606
-	O
HuH	9606
-	O
7	9606
mice	10090
when	O
compared	O
to	O
the	O
parent	O
virus	O
.	O

The	O
rDEN	11060
-	O
2	11060
viruses	O
were	O
not	O
infectious	O
for	O
Aedes	1245352
mosquitoes	1245352
,	O
but	O
both	O
readily	O
infected	O
Toxorynchites	2498889
mosquitoes	2498889
.	O

In	O
rhesus	9544
monkeys	9544
,	O
rDEN2Delta30	11060
appeared	O
to	O
be	O
slightly	O
attenuated	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
as	O
measured	O
by	O
duration	O
and	O
peak	O
of	O
viremia	D014766
and	O
neutralizing	O
antibody	O
induction	O
.	O

A	O
derivative	O
of	O
rDEN2Delta30	11060
,	O
designated	O
rDEN2Delta30	11060
-	O
4995	c|DEL|4995|30
,	O
was	O
generated	O
by	O
incorporation	O
of	O
a	O
point	O
mutation	O
previously	O
identified	O
in	O
the	O
NS3	5130010
gene	O
of	O
DEN	11070
-	O
4	11070
and	O
was	O
found	O
to	O
be	O
more	O
attenuated	O
than	O
rDEN2Delta30	11060
in	O
SCID	9606
-	O
HuH	9606
-	O
7	9606
mice	10090
.	O

CONCLUSIONS	O
:	O
The	O
rDEN2Delta30	11060
and	O
rDEN2Delta30	11060
-	O
4995	c|DEL|4995|30
viruses	O
can	O
be	O
considered	O
for	O
evaluation	O
in	O
humans	9606
and	O
for	O
inclusion	O
in	O
a	O
tetravalent	O
dengue	D003715
vaccine	O
.	O
The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	D020849
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	1361
,	O
tPA	5327
,	O
and	O
PAI	5054
-	O
1	5054
.	O

BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	1361
-	O
activatable	1361
fibrinolysis	1361
inhibitor	1361
(	O
TAFI	1361
)	O
,	O
tissue	5327
-	O
type	5327
plasminogen	5327
activator	5327
(	O
tPA	5327
)	O
,	O
and	O
plasminogen	5054
activator	5054
inhibitor	5054
-	O
1	5054
(	O
PAI	5054
-	O
1	5054
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	D020849
administration	O
in	O
postmenopausal	O
women	9606
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	9606
with	O
osteopenia	D001851
or	O
osteoporosis	D010024
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty	O
-	O
five	O
women	9606
were	O
given	O
raloxifene	D020849
hydrochloride	D020849
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	D002118
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	D002118
.	O

Plasma	O
TAFI	1361
,	O
tPA	5327
,	O
and	O
PAI	5054
-	O
1	5054
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O

Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
'	O
s	O
test	O
.	O

Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	D020849
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	1361
antigen	O
concentrations	O
(	O
16%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	5327
antigen	O
concentrations	O
(	O
25%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	1361
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	D054556
thromboembolism	D054556
due	O
to	O
raloxifene	D020849
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	5327
levels	O
,	O
but	O
not	O
TAFI	1361
levels	O
.	O
NEK2	4751
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
hepatocellular	D006528
carcinoma	D006528
.	O

Never	4751
in	4751
mitosis	4751
gene	4751
A	4751
(	O
NIMA	4751
)	O
-	O
related	4751
kinase	4751
2	4751
(	O
NEK2	4751
)	O
is	O
a	O
microtubule	4130
-	O
associated	4130
protein	4130
that	O
regulates	O
spindle	O
assembly	O
in	O
human	9606
cells	O
and	O
is	O
overexpressed	O
in	O
various	O
malignancies	D009369
.	O

However	O
,	O
the	O
role	O
of	O
NEK2	4751
in	O
hepatocellular	D006528
carcinoma	D006528
(	O
HCC	D006528
)	O
remains	O
undetermined	O
.	O

We	O
performed	O
RNA	O
-	O
seq	O
of	O
the	O
HCC	D006528
cell	O
line	O
SMMC	9606
-	O
7721	9606
and	O
the	O
normal	O
liver	O
cell	O
line	O
HL	9606
-	O
7702	9606
using	O
the	O
Ion	O
Proton	O
System	O
.	O

NEK2	4751
expression	O
was	O
detected	O
using	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
two	O
cell	O
lines	O
and	O
5	O
matched	O
HCC	D006528
and	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

The	O
correlation	O
between	O
survival	O
and	O
NEK2	4751
expression	O
was	O
analyzed	O
in	O
359	O
patients	9606
with	O
HCC	D006528
using	O
RNASeqV2	O
data	O
available	O
from	O
The	O
Cancer	D009369
Genome	O
Atlas	O
(	O
TCGA	O
)	O
website	O
(	O
https	O
:	O
/	O
/	O
tcga	O
-	O
data	O
.	O
nci	O
.	O
nih	O
.	O
gov	O
/	O
tcga	O
/	O
)	O
.	O

The	O
expression	O
of	O
NEK2	4751
,	O
phospho	O
-	O
AKT	207
and	O
MMP	4130
-	O
2	4130
was	O
evaluated	O
by	O
immunohistochemistry	O
in	O
63	O
cases	O
of	O
HCC	D006528
and	O
matched	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

Relationships	O
between	O
protein	O
expression	O
and	O
clinicopathological	O
parameters	O
were	O
assessed	O
,	O
and	O
the	O
correlations	O
between	O
NEK2	4751
with	O
phospho	O
-	O
AKT	207
and	O
MMP	4130
-	O
2	4130
expressions	O
were	O
evaluated	O
.	O

A	O
total	O
of	O
610	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
revealed	O
in	O
the	O
transcriptome	O
comparison	O
,	O
297	O
of	O
which	O
were	O
upregulated	O
and	O
313	O
were	O
downregulated	O
in	O
HCC	D006528
.	O

NEK2	4751
,	O
as	O
the	O
most	O
obviously	O
different	O
DEG	O
in	O
cells	O
and	O
tissues	O
from	O
the	O
RNA	O
-	O
seq	O
data	O
,	O
was	O
listed	O
as	O
an	O
HCC	D006528
candidate	O
biomarker	O
for	O
further	O
verification	O
.	O

NEK2	4751
was	O
overexpressed	O
in	O
HCC	D006528
cells	O
and	O
tissues	O
(	O
P	O
=	O
0	O
.	O
002	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
and	O
HCC	D006528
patients	9606
with	O
a	O
high	O
expression	O
of	O
NEK2	4751
had	O
a	O
poor	O
prognosis	O
(	O
P	O
=	O
0	O
.	O
0145	O
)	O
.	O

Clinical	O
analysis	O
indicated	O
that	O
the	O
overexpression	O
of	O
NEK2	4751
in	O
HCC	D006528
was	O
significantly	O
correlated	O
with	O
diolame	O
complete	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tumor	D009369
nodule	O
number	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
recurrence	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

NEK2	4751
expression	O
was	O
positively	O
correlated	O
with	O
the	O
expression	O
of	O
phospho	O
-	O
AKT	207
(	O
r	O
=	O
0	O
.	O
883	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
MMP	4130
-	O
2	4130
(	O
r	O
=	O
0	O
.	O
781	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Overexpression	O
of	O
NEK2	4751
was	O
associated	O
with	O
clinicopathological	O
characteristics	O
and	O
poor	O
patient	9606
outcomes	O
,	O
suggesting	O
that	O
NEK2	4751
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
HCC	D006528
.	O

Alteration	O
of	O
NEK2	4751
protein	O
levels	O
may	O
contribute	O
to	O
invasion	O
and	O
metastasis	D006528,D009362
of	D006528,D009362
HCC	D006528,D009362
,	O
which	O
may	O
occur	O
through	O
activation	O
of	O
AKT	207
signaling	O
and	O
promotion	O
of	O
MMP	4130
-	O
2	4130
expression	O
.	O
The	O
number	O
of	O
lymph	D009362
node	D009362
metastases	D009362
in	O
gastric	D013274
cancer	D013274
correlates	O
with	O
the	O
angiotensin	1636
I	1636
-	O
converting	1636
enzyme	1636
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
.	O

PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	1636
I	1636
-	O
converting	1636
enzyme	1636
(	O
ACE	1636
)	O
on	O
gastric	D013274
cancer	D013274
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	D013274
cancer	D013274
progression	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O

Amplified	O
ACE	1636
gene	O
fragments	O
were	O
separated	O
on	O
agarose	D012685
gels	O
.	O

D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190	O
-	O
or	O
490	O
-	O
bp	O
fragments	O
,	O
respectively	O
.	O

Local	O
expression	O
of	O
ACE	1636
was	O
investigated	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
of	O
113	O
(	O
21%	O
)	O
gastric	D013274
cancer	D013274
patients	9606
had	O
the	O
II	O
,	O
57	O
(	O
51%	O
)	O
the	O
ID	O
,	O
and	O
32	O
(	O
28%	O
)	O
the	O
DD	O
genotype	O
.	O

The	O
distribution	O
of	O
the	O
ACE	1636
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	9606
without	O
gastric	D013274
cancer	D013274
.	O

However	O
,	O
the	O
ACE	1636
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	D009362
node	D009362
metastases	D009362
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(	O
UICC	O
)	O
tumor	D009369
stage	O
.	O

Patients	9606
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	D009362
node	D009362
metastases	D009362
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	D009369
stage	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
than	O
patients	9606
with	O
the	O
DD	O
genotype	O
.	O

No	O
correlation	O
was	O
found	O
between	O
tumor	D009369
type	O
,	O
tumor	D009369
location	O
,	O
local	O
tumor	D009369
growth	O
,	O
distant	O
metastases	D009362
,	O
and	O
the	O
ACE	1636
genotype	O
.	O

The	O
expression	O
of	O
ACE	1636
in	O
gastric	D013274
cancer	D013274
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	9606
.	O

ACE	1636
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(	O
100%	O
)	O
specimens	O
and	O
by	O
tumor	D009369
cells	O
in	O
56	O
(	O
56%	O
)	O
specimens	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	1636
is	O
expressed	O
locally	O
in	O
gastric	D013274
cancer	D013274
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O
POLG	5428
mutations	O
associated	O
with	O
Alpers	D002549
'	O
syndrome	D002549
and	O
mitochondrial	D028361
DNA	D028361
depletion	D028361
.	O

Alpers	D002549
'	O
syndrome	D002549
is	O
a	O
fatal	O
neurogenetic	D009422
disorder	D009422
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	O
,	O
developmental	O
mitochondrial	D028361
DNA	D028361
depletion	D028361
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	5428
polymerase	5428
gamma	5428
(	O
POLG	5428
)	O
catalytic	O
activity	O
,	O
refractory	O
seizures	D012640
,	O
neurodegeneration	D019636
,	O
and	O
liver	D008107
disease	D008107
.	O

In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers	D002549
'	O
syndrome	D002549
,	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	5428
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	rs121918047
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	rs113994095
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	rs113994095
substitution	O
in	O
POLG	5428
,	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O
Zebrafish	7955
chordin	563085
-	O
like	563085
and	O
chordin	30161
are	O
functionally	O
redundant	O
in	O
regulating	O
patterning	O
of	O
the	O
dorsoventral	O
axis	O
.	O

Chordin	30161
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
cysteine	25884,30161,373985,419054,563085,69121,83453,91851
-	O
rich	25884,30161,373985,419054,563085,69121,83453,91851
domain	25884,30161,373985,419054,563085,69121,83453,91851
-	O
containing	25884,30161,373985,419054,563085,69121,83453,91851
proteins	25884,30161,373985,419054,563085,69121,83453,91851
that	O
bind	O
and	O
modulate	O
signaling	O
of	O
various	O
TGFbeta	359834
-	O
like	O
ligands	O
.	O

Chordin	373985,83453,91851;25884,419054,69121
-	O
like	373985,83453,91851;25884,419054,69121
1	373985,83453,91851;25884,419054,69121
and	373985,83453,91851;25884,419054,69121
2	373985,83453,91851;25884,419054,69121
(	O
CHL1	373985,83453,91851;25884,419054,69121
and	373985,83453,91851;25884,419054,69121
2	373985,83453,91851;25884,419054,69121
)	O
are	O
two	O
members	O
of	O
this	O
group	O
that	O
have	O
been	O
described	O
in	O
human	9606
,	O
mouse	10090
,	O
and	O
chick	9031
.	O

However	O
,	O
in	O
vivo	O
roles	O
for	O
CHL1	373985,83453,91851;25884,419054,69121
and	373985,83453,91851;25884,419054,69121
2	373985,83453,91851;25884,419054,69121
in	O
early	O
development	O
are	O
unknown	O
due	O
to	O
lack	O
of	O
loss	O
-	O
of	O
-	O
function	O
analysis	O
.	O

Here	O
we	O
identify	O
and	O
characterize	O
zebrafish	7955
,	O
Danio	7955
rerio	7955
,	O
CHL	563085
(	O
Chl	563085
)	O
.	O

The	O
chl	563085
gene	O
is	O
on	O
a	O
region	O
of	O
chromosome	O
21	O
syntenic	O
with	O
the	O
area	O
of	O
murine	10090
chromosome	O
7	O
bearing	O
the	O
CHL2	69121
gene	O
.	O

Inability	O
to	O
identify	O
a	O
separate	O
zebrafish	7955
gene	O
corresponding	O
to	O
the	O
mammalian	O
CHL1	91851
gene	O
suggests	O
that	O
Chl	563085
may	O
serve	O
roles	O
in	O
zebrafish	7955
distributed	O
between	O
CHL1	91851
and	O
CHL2	25884
in	O
other	O
species	O
.	O

Chl	563085
is	O
a	O
maternal	O
factor	O
that	O
is	O
also	O
zygotically	O
expressed	O
later	O
in	O
development	O
and	O
has	O
spatiotemporal	O
expression	O
patterns	O
that	O
differ	O
from	O
but	O
overlap	O
those	O
of	O
zebrafish	7955
chordin	30161
(	O
Chd	30161
)	O
,	O
suggesting	O
differences	O
but	O
also	O
possible	O
overlap	O
in	O
developmental	O
roles	O
of	O
the	O
two	O
proteins	O
.	O

Chl	563085
,	O
like	O
Chd	30161
,	O
dorsalizes	O
embryos	O
upon	O
overexpression	O
and	O
is	O
cleaved	O
by	O
BMP1	30204
,	O
which	O
antagonizes	O
this	O
activity	O
.	O

Loss	O
-	O
of	O
-	O
function	O
experiments	O
demonstrate	O
that	O
Chl	563085
serves	O
as	O
a	O
BMP	30204
antagonist	O
with	O
functions	O
that	O
overlap	O
and	O
are	O
redundant	O
with	O
those	O
of	O
Chd	30161
in	O
forming	O
the	O
dorsoventral	O
axis	O
.	O
Polymorphic	O
forms	O
of	O
prostate	354
specific	354
antigen	354
and	O
their	O
interaction	O
with	O
androgen	367
receptor	367
trinucleotide	O
repeats	O
in	O
prostate	D011471
cancer	D011471
.	O

BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	354
specific	354
antigen	354
(	O
PSA	354
)	O
may	O
increase	O
prostate	D011471
cancer	D011471
(	O
PC	D011471
)	O
risk	O
.	O

The	O
PSA	354
gene	O
contains	O
a	O
G	c|SUB|G||A
/	O
A	c|SUB|G||A
substitution	O
in	O
the	O
androgen	D000728
response	O
element	O
(	O
ARE	O
)	O
1	O
region	O
.	O

The	O
androgen	367
receptor	367
(	O
AR	367
)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	D011471
risk	O
.	O

The	O
effect	O
on	O
PC	D011471
risks	O
from	O
PSA	354
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	367
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O

METHODS	O
:	O
One	O
hundred	O
PC	D011471
patients	9606
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	D011470
prostate	D011470
hyperplasia	D011470
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA	354
/	O
ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O

PCR	O
products	O
were	O
cut	O
with	O
Nhe	6548
1	6548
restriction	O
enzyme	O
to	O
distinguish	O
G	c|SUB|G||A
/	O
A	c|SUB|G||A
alleles	O
.	O

AR	367
/	O
CAG	c|DUP||CAG_GGC|
and	c|DUP||CAG_GGC|
GGC	c|DUP||CAG_GGC|
repeat	c|DUP||CAG_GGC|
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA	354
/	O
GG	O
distribution	O
in	O
PC	D011471
(	O
30%	O
)	O
than	O
either	O
benign	D011470
prostatic	D011470
hyperplasia	D011470
(	O
BPH	D011470
)	O
(	O
18%	O
)	O
or	O
population	O
controls	O
(	O
16%	O
)	O
(	O
P	O
=	O
0	O
.	O
025	O
)	O
.	O

Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	9606
(	O
<	O
65	O
years	O
;	O
42%	O
;	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

Additionally	O
,	O
when	O
PSA	354
genotype	O
was	O
cross	O
classified	O
with	O
CAG	c|DUP||CAG|
repeat	c|DUP||CAG|
,	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	D011470
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(	O
<	O
22	O
)	O
CAG	O
/	O
GG	O
genotype	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA	354
/	O
ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	D011471
especially	O
among	O
younger	O
men	9606
.	O

Moreover	O
,	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	c|DUP||G|
repeat	c|DUP||G|
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	D009369
disease	D009369
.	O
A	O
homozygous	O
mutation	O
in	O
LYRM7	90624
/	O
MZM1L	90624
associated	O
with	O
early	O
onset	O
encephalopathy	D001927
,	O
lactic	D000140
acidosis	D000140
,	O
and	O
severe	O
reduction	C565128
of	C565128
mitochondrial	C565128
complex	C565128
III	C565128
activity	O
.	O

Mutations	O
in	O
nuclear	O
genes	O
associated	O
with	O
defective	C565128
complex	C565128
III	C565128
(	O
cIII	C565128
)	O
of	C565128
the	C565128
mitochondrial	C565128
respiratory	O
chain	O
are	O
rare	O
,	O
having	O
been	O
found	O
in	O
only	O
two	O
cIII	617
assembly	O
factors	O
and	O
,	O
as	O
private	O
changes	O
in	O
single	O
families	O
,	O
three	O
cIII	617
structural	O
subunits	O
.	O

Recently	O
,	O
human	9606
LYRM7	90624
/	O
MZM1L	90624
,	O
the	O
ortholog	O
of	O
yeast	4932
MZM1	852104
,	O
has	O
been	O
identified	O
as	O
a	O
new	O
assembly	O
factor	O
for	O
cIII	617
.	O

In	O
a	O
baby	O
patient	9606
with	O
early	O
onset	O
,	O
severe	O
encephalopathy	D001927
,	O
lactic	D000140
acidosis	D000140
and	O
profound	O
,	O
isolated	O
cIII	C565128
deficiency	C565128
in	O
skeletal	O
muscle	O
,	O
we	O
identified	O
a	O
disease	O
-	O
segregating	O
homozygous	O
mutation	O
(	O
c	rs587777433
.	O
73G	rs587777433
>	O
A	rs587777433
)	O
in	O
LYRM7	90624
/	O
MZM1L	90624
,	O
predicting	O
a	O
drastic	O
change	O
in	O
a	O
highly	O
conserved	O
amino	O
-	O
acid	O
residue	O
(	O
p	rs587777433
.	O
Asp25Asn	rs587777433
)	O
.	O

In	O
a	O
mzm1D	852104
yeast	4932
strain	O
,	O
the	O
expression	O
of	O
a	O
mzm1	852104
(	O
D25N	rs587777433
)	O
mutant	O
allele	O
caused	O
temperature	O
-	O
sensitive	O
respiratory	D012131
growth	D012131
defect	D012131
,	O
decreased	O
oxygen	D010100
consumption	O
,	O
impaired	O
maturation	O
/	O
stabilization	O
of	O
the	O
Rieske	856689
Fe	856689
-	O
S	856689
protein	856689
,	O
and	O
reduced	O
complex	617
III	617
activity	O
and	O
amount	O
.	O

LYRM7	90624
/	O
MZM1L	90624
is	O
a	O
novel	O
disease	O
gene	O
,	O
causing	O
cIII	C565128
-	O
defective	C565128
,	O
early	O
onset	O
,	O
severe	O
mitochondrial	C538525
encephalopathy	C538525
.	O
cDNA	O
sequence	O
and	O
chromosomal	O
localization	O
of	O
the	O
remaining	O
three	O
human	9606
nuclear	4720,4722,4726
encoded	4720,4722,4726
iron	4720,4722,4726
sulphur	4720,4722,4726
protein	4720,4722,4726
(	O
IP	4720,4722,4726
)	O
subunits	4720,4722,4726
of	4720,4722,4726
complex	4720,4722,4726
I	4720,4722,4726
:	O
the	O
human	9606
IP	4720,4722,4726
fraction	O
is	O
completed	O
.	O

NADH	4720,4722,4726
:	O
ubiquinone	4720,4722,4726
oxidoreductase	4720,4722,4726
(	O
complex	4720,4722,4726
I	4720,4722,4726
)	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
can	O
be	O
fragmented	O
in	O
a	O
flavoprotein	-
(	O
FP	-
)	O
,	O
iron	4720,4722,4726
-	O
sulfur	4720,4722,4726
protein	4720,4722,4726
(	O
IP	4720,4722,4726
)	O
,	O
and	O
hydrophobic	-
protein	-
(	O
HP	-
)	O
subfraction	O
.	O

The	O
IP	4720,4722,4726
subfraction	O
is	O
hypothesized	O
to	O
be	O
significant	O
,	O
since	O
it	O
contains	O
important	O
prosthetic	O
groups	O
highly	O
conserved	O
among	O
species	O
.	O

We	O
cloned	O
the	O
cDNA	O
of	O
three	O
remaining	O
human	9606
NADH	4720,4722,4726
:	O
ubiquinone	4720,4722,4726
oxidoreductase	4720,4722,4726
subunits	4720,4722,4726
of	O
this	O
IP	4720,4722,4726
fraction	O
:	O
the	O
NDUFS2	4720
(	O
49	O
kDa	O
)	O
,	O
NDUFS3	4722
(	O
30	O
kDa	O
)	O
,	O
and	O
NDUFS6	4726
(	O
13	O
kDa	O
)	O
subunits	O
.	O

All	O
presented	O
cDNAs	O
include	O
the	O
complete	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
,	O
which	O
consist	O
of	O
1392	O
,	O
795	O
,	O
and	O
375	O
base	O
pairs	O
,	O
coding	O
for	O
463	O
,	O
264	O
,	O
and	O
124	O
amino	O
acids	O
,	O
respectively	O
.	O

The	O
latter	O
show	O
96	O
,	O
90	O
,	O
and	O
83%	O
homology	O
with	O
the	O
corresponding	O
bovine	9913
translation	O
products	O
.	O

The	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
complete	O
in	O
all	O
three	O
cDNAs	O
.	O

Polymerase	O
chain	O
reaction	O
performed	O
with	O
DNA	O
isolated	O
from	O
somatic	O
human	9606
-	O
rodent	O
cell	O
hybrids	O
containing	O
defined	O
human	9606
chromosomes	O
as	O
template	O
gave	O
a	O
human	9606
-	O
specific	O
signal	O
which	O
mapped	O
the	O
NDUFS2	4720
and	O
NDUFS3	4722
subunits	O
to	O
chromosomes	O
1	O
and	O
11	O
,	O
respectively	O
.	O

In	O
the	O
case	O
of	O
the	O
NDUFS6	4726
subunit	O
a	O
pseudogene	O
may	O
be	O
present	O
since	O
signals	O
were	O
seen	O
in	O
the	O
lanes	O
containing	O
chromosomes	O
5	O
and	O
6	O
.	O

The	O
NDUFS2	4720
contains	O
a	O
highly	O
conserved	O
protein	5578
kinase	5578
C	5578
phosphorylation	O
site	O
and	O
the	O
NDUFS3	4722
subunit	O
contains	O
a	O
highly	O
conserved	O
casein	1457
kinase	1457
II	1457
phosphorylation	O
site	O
which	O
make	O
them	O
strong	O
candidates	O
for	O
future	O
mutation	O
detection	O
studies	O
in	O
enzymatic	C537475
complex	C537475
I	C537475
-	O
deficient	C537475
patients	9606
.	O
The	O
FH	2271
mutation	O
database	O
:	O
an	O
online	O
database	O
of	O
fumarate	2271
hydratase	2271
mutations	O
involved	O
in	O
the	O
MCUL	C535516
(	O
HLRCC	C535516
)	O
tumor	D009369
syndrome	D009369
and	O
congenital	O
fumarase	C538191
deficiency	C538191
.	O

BACKGROUND	O
:	O
Fumarate	2271
hydratase	2271
(	O
HGNC	O
approved	O
gene	O
symbol	O
-	O
FH	2271
)	O
,	O
also	O
known	O
as	O
fumarase	2271
,	O
is	O
an	O
enzyme	O
of	O
the	O
tricarboxylic	D014233
acid	D014233
(	O
TCA	D014233
)	O
cycle	O
,	O
involved	O
in	O
fundamental	O
cellular	O
energy	O
production	O
.	O

First	O
described	O
by	O
Zinn	O
et	O
al	O
in	O
1986	O
,	O
deficiency	C538191
of	C538191
FH	C538191
results	O
in	O
early	O
onset	O
,	O
severe	O
encephalopathy	D001927
.	O

In	O
2002	O
,	O
the	O
Multiple	O
Leiomyoma	D007889
Consortium	O
identified	O
heterozygous	O
germline	O
mutations	O
of	O
FH	2271
in	O
patients	9606
with	O
multiple	C535516
cutaneous	C535516
and	C535516
uterine	C535516
leiomyomas	C535516
,	O
(	O
MCUL	C535516
:	O
OMIM	C535516
150800	C535516
)	O
.	O

In	O
some	O
families	O
renal	D002292
cell	D002292
cancer	D002292
also	O
forms	O
a	O
component	O
of	O
the	O
complex	O
and	O
as	O
such	O
has	O
been	O
described	O
as	O
hereditary	C535516
leiomyomatosis	C535516
and	C535516
renal	C535516
cell	C535516
cancer	C535516
(	O
HLRCC	C535516
:	O
OMIM	C535516
605839	C535516
)	O
.	O

The	O
identification	O
of	O
FH	2271
as	O
a	O
tumor	D009369
suppressor	O
was	O
an	O
unexpected	O
finding	O
and	O
following	O
the	O
identification	O
of	O
subunits	O
of	O
succinate	O
dehydrogenase	O
in	O
2000	O
and	O
2001	O
,	O
was	O
only	O
the	O
second	O
description	O
of	O
the	O
involvement	O
of	O
an	O
enzyme	O
of	O
intermediary	O
metabolism	O
in	O
tumorigenesis	D009369
.	O

DESCRIPTION	O
:	O
The	O
FH	2271
mutation	O
database	O
is	O
a	O
part	O
of	O
the	O
TCA	D014233
cycle	O
gene	O
mutation	O
database	O
(	O
formerly	O
the	O
succinate	O
dehydrogenase	O
gene	O
mutation	O
database	O
)	O
and	O
is	O
based	O
on	O
the	O
Leiden	O
Open	O
(	O
source	O
)	O
Variation	O
Database	O
(	O
LOVD	O
)	O
system	O
.	O

The	O
variants	O
included	O
in	O
the	O
database	O
were	O
derived	O
from	O
the	O
published	O
literature	O
and	O
annotated	O
to	O
conform	O
to	O
current	O
mutation	O
nomenclature	O
.	O

The	O
FH	2271
database	O
applies	O
HGVS	O
nomenclature	O
guidelines	O
,	O
and	O
will	O
assist	O
researchers	O
in	O
applying	O
these	O
guidelines	O
when	O
directly	O
submitting	O
new	O
sequence	O
variants	O
online	O
.	O

Since	O
the	O
first	O
molecular	O
characterization	O
of	O
an	O
FH	2271
mutation	O
by	O
Bourgeron	O
et	O
al	O
in	O
1994	O
,	O
a	O
series	O
of	O
reports	O
of	O
both	O
FH	C538191
deficiency	C538191
patients	9606
and	O
patients	9606
with	O
MCUL	C535516
/	O
HLRRC	C535516
have	O
described	O
107	O
variants	O
,	O
of	O
which	O
93	O
are	O
thought	O
to	O
be	O
pathogenic	O
.	O

The	O
most	O
common	O
type	O
of	O
mutation	O
is	O
missense	O
(	O
57%	O
)	O
,	O
followed	O
by	O
frameshifts	O
&	O
nonsense	O
(	O
27%	O
)	O
,	O
and	O
diverse	O
deletions	O
,	O
insertions	O
and	O
duplications	O
.	O

Here	O
we	O
introduce	O
an	O
online	O
database	O
detailing	O
all	O
reported	O
FH	2271
sequence	O
variants	O
.	O

CONCLUSION	O
:	O
The	O
FH	2271
mutation	O
database	O
strives	O
to	O
systematically	O
unify	O
all	O
current	O
genetic	O
knowledge	O
of	O
FH	2271
variants	O
.	O

We	O
believe	O
that	O
this	O
knowledge	O
will	O
assist	O
clinical	O
geneticists	O
and	O
treating	O
physicians	O
when	O
advising	O
patients	9606
and	O
their	O
families	O
,	O
will	O
provide	O
a	O
rapid	O
and	O
convenient	O
resource	O
for	O
research	O
scientists	O
,	O
and	O
may	O
eventually	O
assist	O
in	O
gaining	O
novel	O
insights	O
into	O
FH	2271
and	O
its	O
related	O
clinical	O
syndromes	O
.	O
Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	D001151
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O

BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	D001152
arsenic	D001152
(	O
iAs	D001152
)	O
in	O
their	O
drinking	O
water	O
.	O

Inorganic	D001152
As	D001152
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	D001152
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	D009369
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	D009369
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	D001152
exposure	O
.	O

DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	D009369
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	D001152
exposure	O
elicits	O
latent	O
carcinogenic	D009369
effects	O
.	O

CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	D001152
exposure	O
and	O
cancer	D009369
development	O
later	O
in	O
life	O
.	O

Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	9606
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O
Two	O
novel	O
mutations	O
in	O
SRY	6736
gene	O
form	O
Chinese	O
sex	OMIM:400044
reversal	OMIM:400044
XY	OMIM:400044
females	O
.	O

The	O
SRY	6736
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O

SRY	6736
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG	O
-	O
box	O
motif	O
(	O
high	O
-	O
mobility	O
group	O
-	O
box	O
)	O
,	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O

Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	6736
are	O
among	O
the	O
known	O
causes	O
of	O
XY	OMIM:400044
sex	OMIM:400044
reversal	OMIM:400044
.	O

Here	O
,	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	9606
who	O
presented	O
with	O
46	OMIM:400044
,	O
XY	OMIM:400044
sex	OMIM:400044
reversal	OMIM:400044
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
SRY	6736
gene	O
.	O

DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O

A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	6736
gene	O
was	O
amplified	O
,	O
using	O
primers	O
XES	O
-	O
2	O
and	O
XES	O
-	O
7	O
.	O

The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm	O
-	O
T	O
vectors	O
,	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377	O
-	O
3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O

PCR	O
-	O
restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O

In	O
two	O
patients	9606
,	O
de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O

An	O
A	c|SUB|A|CODON38|G
was	c|SUB|A|CODON38|G
replaced	c|SUB|A|CODON38|G
by	c|SUB|A|CODON38|G
a	c|SUB|A|CODON38|G
G	c|SUB|A|CODON38|G
in	c|SUB|A|CODON38|G
codon	c|SUB|A|CODON38|G
38	c|SUB|A|CODON38|G
upstream	O
of	O
the	O
5	O
'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	6736
gene	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	p|SUB|E||G
by	p|SUB|E||G
glycine	p|SUB|E||G
.	O

Another	O
heterozygous	O
T	c|SUB|T|387|A
to	c|SUB|T|387|A
A	c|SUB|T|387|A
transition	c|SUB|T|387|A
at	c|SUB|T|387|A
the	c|SUB|T|387|A
nucleotide	c|SUB|T|387|A
position	c|SUB|T|387|A
+	O
387	c|SUB|T|387|A
which	O
encodes	O
for	O
a	O
Tyrosine	c|SUB|Y||X
(	O
Tyr	c|SUB|Y||X
)	O
instead	c|SUB|Y||X
of	c|SUB|Y||X
a	c|SUB|Y||X
Term	c|SUB|Y||X
,	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild	O
-	O
type	O
sequence	O
.	O

These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR	O
-	O
restrict	O
enzyme	O
method	O
.	O

As	O
demonstrated	O
by	O
the	O
Human	9606
Gene	O
Mutation	O
Database	O
analysis	O
,	O
homology	O
search	O
,	O
and	O
review	O
of	O
the	O
literature	O
,	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	6736
gene	O
nucleotide	O
substitutions	O
(	O
missense	O
/	O
nonsense	O
)	O
to	O
45	O
.	O

These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	OMIM:400044
reversal	OMIM:400044
,	O
not	O
only	O
inside	O
the	O
HMG	O
-	O
box	O
but	O
also	O
outside	O
the	O
HMG	O
-	O
box	O
.	O

The	O
two	O
novel	O
mutations	O
in	O
SRY	6736
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	9606
with	O
46	OMIM:400044
,	O
XY	OMIM:400044
female	OMIM:400044
sex	OMIM:400044
reversal	OMIM:400044
.	O
Superoxide	20655
dismutase	20655
1	20655
overexpression	O
in	O
mice	10090
abolishes	O
maternal	D016640
diabetes	D016640
-	O
induced	O
endoplasmic	O
reticulum	O
stress	O
in	O
diabetic	D003920
embryopathy	D005315
.	O

OBJECTIVE	O
:	O
Both	O
oxidative	O
stress	O
and	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
are	O
causal	O
events	O
in	O
diabetic	D003920
embryopathy	D005315
.	O

We	O
tested	O
whether	O
oxidative	O
stress	O
causes	O
ER	O
stress	O
.	O

STUDY	O
DESIGN	O
:	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
superoxide	20655
dismutase	20655
1	20655
(	O
SOD1	20655
)	O
-	O
overexpressing	O
day	O
8	O
.	O
75	O
embryos	O
from	O
nondiabetic	O
WT	O
control	O
with	O
SOD1	20655
transgenic	O
male	O
and	O
diabetic	D003920
WT	O
female	O
with	O
SOD1	20655
transgenic	O
male	O
were	O
analyzed	O
for	O
ER	O
stress	O
markers	O
:	O
C	13198
/	O
EBP	13198
-	O
homologous	13198
protein	13198
(	O
CHOP	13198
)	O
,	O
calnexin	12330
,	O
eukaryotic	229317
initiation	229317
factor	229317
2a	229317
(	O
eIF2a	229317
)	O
,	O
protein	13666
kinase	13666
ribonucleic	13666
acid	13666
(	O
RNA	13666
)	O
-	O
like	13666
ER	13666
kinase	13666
(	O
PERK	13666
)	O
,	O
binding	14828
immunoglobulin	14828
protein	14828
,	O
protein	14827
disulfide	14827
isomerase	14827
family	14827
A	14827
member	14827
3	14827
,	O
kinases	78943
inositol	78943
-	O
requiring	78943
protein	78943
-	O
1a	78943
(	O
IRE1a	78943
)	O
,	O
and	O
the	O
X	22433
-	O
box	22433
binding	22433
protein	22433
(	O
XBP1	22433
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
splicing	O
.	O

RESULTS	O
:	O
Maternal	D016640
diabetes	D016640
significantly	O
increased	O
the	O
levels	O
of	O
CHOP	13198
,	O
calnexin	12330
,	O
phosphorylated	O
(	O
p	O
)	O
-	O
eIF2a	229317
,	O
p	O
-	O
PERK	13666
,	O
and	O
p	O
-	O
IRE1a	78943
;	O
triggered	O
XBP1	22433
mRNA	O
splicing	O
;	O
and	O
enhanced	O
ER	O
chaperone	O
gene	O
expression	O
in	O
WT	O
embryos	O
.	O

SOD1	20655
overexpression	O
blocked	O
these	O
diabetes	D003920
-	O
induced	O
ER	O
stress	O
markers	O
.	O

CONCLUSION	O
:	O
Mitigating	O
oxidative	O
stress	O
via	O
SOD1	20655
overexpression	O
blocks	O
maternal	D016640
diabetes	D016640
-	O
induced	O
ER	O
stress	O
in	O
vivo	O
.	O
The	O
human	9606
AHR	196
:	O
identification	O
of	O
single	O
nucleotide	O
polymorphisms	O
from	O
six	O
ethnic	O
populations	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
2	D000072317
,	O
3	D000072317
,	O
7	D000072317
,	O
8	D000072317
-	O
tetrachlorodibenzo	D000072317
-	O
p	D000072317
-	O
dioxin	D000072317
and	O
related	O
dioxin	D004147
-	O
like	O
chemicals	O
are	O
mediated	O
through	O
binding	O
-	O
dependent	O
activation	O
of	O
the	O
cytosolic	O
aryl	196
hydrocarbon	196
receptor	196
(	O
AHR	196
)	O
.	O

The	O
human	9606
AHR	196
is	O
a	O
low	O
-	O
affinity	O
receptor	O
relative	O
to	O
most	O
rodents	O
,	O
but	O
some	O
reports	O
suggest	O
that	O
there	O
may	O
be	O
individuals	O
with	O
polymorphic	O
high	O
-	O
affinity	O
receptors	O
,	O
thereby	O
possibly	O
increasing	O
the	O
sensitivity	O
to	O
dioxins	D004147
in	O
such	O
people	O
.	O

METHODS	O
:	O
Although	O
no	O
polymorphisms	O
have	O
been	O
reported	O
in	O
the	O
ligand	O
binding	O
region	O
of	O
the	O
AHR	196
in	O
the	O
over	O
100	O
reported	O
sequences	O
,	O
we	O
sequenced	O
108	O
additional	O
human	9606
AHR	196
genes	O
in	O
an	O
effort	O
to	O
further	O
identify	O
single	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
the	O
open	O
reading	O
frames	O
of	O
the	O
AHR	196
locus	O
.	O

The	O
DNA	O
was	O
sequenced	O
from	O
six	O
ethnic	O
populations	O
that	O
included	O
Japanese	O
,	O
Chinese	O
,	O
European	O
/	O
Caucasian	O
,	O
African	O
-	O
American	O
,	O
South	O
East	O
Asian	O
,	O
and	O
Hispanic	O
.	O

RESULTS	O
:	O
Six	O
exonic	O
SNPs	O
were	O
identified	O
;	O
four	O
had	O
been	O
described	O
as	O
previously	O
reported	O
and	O
two	O
seem	O
to	O
be	O
novel	O
.	O

Four	O
of	O
the	O
SNPs	O
identified	O
lead	O
to	O
amino	O
acid	O
changes	O
in	O
the	O
AHR	196
protein	O
and	O
two	O
of	O
the	O
SNPs	O
lead	O
to	O
synonymous	O
substitutions	O
.	O

An	O
additional	O
four	O
SNPs	O
have	O
been	O
reported	O
elsewhere	O
that	O
were	O
not	O
identified	O
in	O
the	O
current	O
analysis	O
.	O

With	O
these	O
new	O
sequences	O
,	O
more	O
than	O
200	O
human	9606
AHR	196
gene	O
sequences	O
have	O
been	O
analyzed	O
for	O
SNPs	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
very	O
limited	O
presence	O
of	O
polymorphisms	O
in	O
the	O
core	O
ligand	O
binding	O
region	O
of	O
the	O
human	9606
AHR	196
.	O

Other	O
regions	O
,	O
such	O
as	O
the	O
transactivation	O
domain	O
,	O
seem	O
to	O
be	O
slightly	O
more	O
polymorphic	O
in	O
the	O
human	9606
population	O
and	O
the	O
impact	O
on	O
functionality	O
should	O
be	O
further	O
examined	O
.	O
A	O
Cys	rs6318
23	rs6318
-	O
Ser	rs6318
23	rs6318
substitution	O
in	O
the	O
5	3358
-	O
HT	3358
(	O
2C	3358
)	O
receptor	3358
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	D016574
affective	D016574
disorder	D016574
:	O
an	O
Austrian	O
-	O
Canadian	O
collaborative	O
study	O
.	O

Most	O
females	O
with	O
seasonal	D016574
affective	D016574
disorder	D016574
(	O
SAD	D016574
)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	D015430
gain	D015430
when	D015430
depressed	D015430
.	O

The	O
serotonin	3358
2C	3358
receptor	3358
(	O
5	3358
-	O
HT	3358
(	O
2C	3358
)	O
)	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O

A	O
5	3358
-	O
HT	3358
(	O
2C	3358
)	O
Cys	rs6318
23	rs6318
Ser	rs6318
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	rs6318
23	rs6318
Ser	rs6318
)	O
within	O
the	O
5	3358
-	O
HT	3358
(	O
2C	3358
)	O
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5	3358
-	O
HT	3358
(	O
2C	3358
)	O
function	O
.	O

We	O
hypothesized	O
that	O
Cys	rs6318
23	rs6318
Ser	rs6318
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	D016574
.	O

Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	D016574
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	D016574
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	rs6318
23	rs6318
Ser	rs6318
.	O

Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	9606
with	O
atypical	O
features	O
.	O

In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	9606
and	O
controls	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
and	O
Cys	rs6318
23	rs6318
Ser	rs6318
was	O
associated	O
with	O
weight	O
(	O
p	O
=	O
0	O
.	O
039	O
)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p	O
=	O
0	O
.	O
038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
.	O

All	O
values	O
were	O
highest	O
in	O
Cys	O
/	O
Cys	O
,	O
intermediate	O
in	O
Cys	O
/	O
Ser	O
,	O
and	O
lowest	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O

In	O
Canadian	O
patients	9606
,	O
Cys	rs6318
23	rs6318
Ser	rs6318
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
,	O
with	O
lowest	O
values	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
Cys	rs6318
23	rs6318
Ser	rs6318
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	D016574
,	O
and	O
the	O
gene	O
-	O
dose	O
effect	O
-	O
like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	rs6318
23	rs6318
Ser	rs6318
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O
Rab6c	84084
,	O
a	O
new	O
member	O
of	O
the	O
rab	5870,84084
gene	O
family	O
,	O
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	9606
/	O
AdrR	9606
cells	O
.	O

A	O
new	O
Rab6	5870
homolog	O
cDNA	O
,	O
Rab6c	84084
,	O
was	O
discovered	O
by	O
a	O
hypermethylated	O
DNA	O
fragment	O
probe	O
that	O
was	O
isolated	O
from	O
a	O
human	9606
multidrug	O
resistant	O
(	O
MDR	O
)	O
breast	D001943
cancer	D001943
cell	O
line	O
,	O
MCF7	9606
/	O
AdrR	9606
,	O
by	O
the	O
methylation	O
sensitive	O
-	O
representational	O
difference	O
analysis	O
(	O
MS	O
-	O
RDA	O
)	O
technique	O
.	O

Rab6c	84084
was	O
found	O
to	O
be	O
under	O
-	O
expressed	O
in	O
MCF7	9606
/	O
AdrR	9606
and	O
MES	9606
-	O
SA	9606
/	O
Dx5	9606
(	O
a	O
human	9606
MDR	O
uterine	D014594
sarcoma	D014594
cell	O
line	O
)	O
compared	O
with	O
their	O
non	O
-	O
MDR	O
parental	O
cell	O
lines	O
.	O

MCF7	9606
/	O
AdrR	9606
cells	O
expressing	O
the	O
exogenous	O
Rab6c	84084
exhibited	O
less	O
resistance	O
to	O
several	O
anti	O
-	O
cancer	O
drugs	O
,	O
such	O
as	O
doxorubicin	D004317
(	O
DOX	D004317
)	O
,	O
taxol	D017239
,	O
vinblastine	D014747
,	O
and	O
vincristine	D014750
,	O
than	O
the	O
control	O
cells	O
containing	O
the	O
empty	O
vector	O
.	O

Flow	O
cytometry	O
experiments	O
confirmed	O
that	O
the	O
transfectants	O
'	O
diminished	O
resistance	O
to	O
DOX	D004317
was	O
caused	O
by	O
increased	O
drug	O
accumulation	O
induced	O
by	O
the	O
exogenous	O
Rab6c	84084
.	O

These	O
results	O
indicate	O
that	O
Rab6c	84084
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	9606
/	O
AdrR	9606
cells	O
.	O
Genome	O
-	O
wide	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
screening	O
identifies	O
opioid	4988
receptor	4988
u1	4988
as	O
a	O
key	O
regulator	O
of	O
L	D001215
-	O
asparaginase	D001215
resistance	O
in	O
pediatric	O
acute	D054198
lymphoblastic	D054198
leukemia	D054198
.	O

L	D001215
-	O
asparaginase	D001215
is	O
a	O
critical	O
chemotherapeutic	O
agent	O
for	O
acute	D054198
lymphoblastic	D054198
leukemia	D054198
(	O
ALL	D054198
)	O
.	O

It	O
hydrolyzes	O
plasma	O
asparagine	D001216
into	O
aspartate	D001224
and	O
NH3	D000641
,	O
causing	O
asparagine	OMIM:615574
deficit	OMIM:615574
and	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
eventually	O
,	O
leukemic	D007938
cell	O
death	O
.	O

However	O
,	O
patient	9606
relapse	O
often	O
occurs	O
due	O
to	O
development	O
of	O
resistance	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ALL	D054198
cells	O
acquire	O
resistance	O
to	O
L	D001215
-	O
asparaginase	D001215
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
identify	O
genes	O
that	O
are	O
involved	O
in	O
L	D001215
-	O
asparaginase	D001215
resistance	O
in	O
primary	O
leukemic	D007938
cells	O
.	O

By	O
unbiased	O
genome	O
-	O
wide	O
RNAi	O
screening	O
,	O
we	O
found	O
that	O
among	O
10	O
resistant	O
ALL	D054198
clones	O
,	O
six	O
hits	O
were	O
for	O
opioid	4988
receptor	4988
mu	4988
1	4988
(	O
oprm1	4988
)	O
,	O
two	O
hits	O
were	O
for	O
carbonic	759
anhydrase	759
1	759
(	O
ca1	759
)	O
and	O
another	O
two	O
hits	O
were	O
for	O
ubiquitin	11065
-	O
conjugating	11065
enzyme	11065
E2C	11065
(	O
ube2c	11065
)	O
.	O

We	O
also	O
found	O
that	O
OPRM1	4988
is	O
expressed	O
in	O
all	O
leukemic	D007938
cells	O
tested	O
.	O

Specific	O
knockdown	O
of	O
OPRM1	4988
confers	O
L	D001215
-	O
asparaginase	D001215
resistance	O
,	O
validating	O
our	O
genome	O
-	O
wide	O
retroviral	O
shRNA	O
library	O
screening	O
data	O
.	O

Methadone	D008691
,	O
an	O
agonist	O
of	O
OPRM1	4988
,	O
enhances	O
the	O
sensitivity	O
of	O
parental	O
leukemic	D007938
cells	O
,	O
but	O
not	O
OPRM1	4988
-	O
depleted	O
cells	O
,	O
to	O
L	D001215
-	O
asparaginase	D001215
treatment	O
,	O
indicating	O
that	O
OPRM1	4988
is	O
required	O
for	O
the	O
synergistic	O
action	O
of	O
L	D001215
-	O
asparaginase	D001215
and	O
methadone	D008691
,	O
and	O
that	O
OPRM1	4988
loss	O
promotes	O
leukemic	D007938
cell	O
survival	O
likely	O
through	O
downregulation	O
of	O
the	O
OPRM1	4988
-	O
mediated	O
apoptotic	O
pathway	O
.	O

Consistent	O
with	O
this	O
premise	O
,	O
patient	9606
leukemic	D007938
cells	O
with	O
relatively	O
high	O
levels	O
of	O
OPRM1	4988
are	O
more	O
sensitive	O
to	O
L	D001215
-	O
asparaginase	D001215
treatment	O
compared	O
to	O
OPRM1	4988
-	O
depleted	O
leukemic	D007938
cells	O
,	O
further	O
indicating	O
that	O
OPRM1	4988
loss	O
has	O
a	O
crucial	O
role	O
in	O
L	D001215
-	O
asparaginase	D001215
resistance	O
in	O
leukemic	D007938
patients	9606
.	O

Thus	O
,	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
OPRM1	4988
-	O
mediated	O
mechanism	O
for	O
L	D001215
-	O
asparaginase	D001215
resistance	O
in	O
ALL	D054198
,	O
and	O
identifies	O
OPRM1	4988
as	O
a	O
functional	O
biomarker	O
for	O
defining	O
high	O
-	O
risk	O
subpopulations	O
and	O
for	O
the	O
detection	O
of	O
evolving	O
resistant	O
clones	O
.	O

Oprm1	4988
may	O
also	O
be	O
utilized	O
for	O
effective	O
treatment	O
of	O
L	D001215
-	O
asparaginase	D001215
-	O
resistant	O
ALL	D054198
.	O
Oncogene	O
advance	O
online	O
publication	O
,	O
26	O
June	O
2017	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
onc	O
.	O
2017	O
.	O
211	O
.	O
rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	D004409
in	O
Parkinson	D010300
disease	D010300
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa	D007980
-	O
induced	O
dyskinesia	D004409
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	9606
with	O
advanced	O
Parkinson	D010300
disease	D010300
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	D004409
state	O
induced	O
by	O
continuous	O
apomorphine	D001058
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	D004409
-	O
induced	D004409
dyskinesias	D004409
,	O
whereas	O
5	O
-	O
Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O
Two	O
novel	O
mutations	O
in	O
the	O
MEN1	4221
gene	O
in	O
subjects	O
with	O
multiple	D018761
endocrine	D018761
neoplasia	D018761
-	O
1	D018761
.	O

Multiple	D018761
endocrine	D018761
neoplasia	D018761
type	D018761
1	D018761
(	O
MEN1	D018761
)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	C535650,D010911
endocrine	C535650,D010911
and	C535650,D010911
pituitary	C535650,D010911
adenomas	C535650,D010911
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	4221
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	4221
with	O
novel	O
mutations	O
in	O
the	O
MEN1	4221
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	9606
had	O
primary	D049950
hyperparathyroidism	D049950
(	O
PHPT	D049950
)	O
plus	O
a	O
prolactinoma	D015175
;	O
three	O
relatives	O
had	O
PHPT	D049950
only	O
.	O

The	O
index	O
patient	9606
in	O
the	O
second	O
family	O
was	O
a	O
46	O
-	O
yr	O
-	O
old	O
woman	9606
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	9606
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	D010146
and	O
watery	O
diarrhea	D003967
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	D007516
islet	D007516
cell	D007516
tumor	D007516
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	D015175
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	4221
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	9606
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	p|SUB|K|557|E
to	p|SUB|K|557|E
G	p|SUB|K|557|E
transition	p|SUB|K|557|E
at	p|SUB|K|557|E
codon	p|SUB|K|557|E
557	p|SUB|K|557|E
(	O
AAG	p|SUB|K|557|E
-	O
-	O
>	O
GAG	p|SUB|K|557|E
)	O
of	O
exon	O
10	O
of	O
MEN1	4221
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	p|SUB|K||E
by	p|SUB|K||E
glutamic	p|SUB|K||E
acid	p|SUB|K||E
.	O

The	O
Chinese	O
index	O
patient	9606
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	p|SUB|D|418|Y
at	p|SUB|D|418|Y
codon	p|SUB|D|418|Y
418	p|SUB|D|418|Y
of	p|SUB|D|418|Y
exon	p|SUB|D|418|Y
9	p|SUB|D|418|Y
(	O
GAC	p|SUB|D|418|Y
-	O
-	O
>	O
TAT	p|SUB|D|418|Y
)	O
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	p|SUB|D||Y
acid	p|SUB|D||Y
by	p|SUB|D||Y
tyrosine	p|SUB|D||Y
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	4221
gene	O
.	O
Sex	O
-	O
differential	O
genetic	O
effect	O
of	O
phosphodiesterase	5144
4D	5144
(	O
PDE4D	5144
)	O
on	O
carotid	D002340
atherosclerosis	D002340
.	O

BACKGROUND	O
:	O
The	O
phosphodiesterase	5144
4D	5144
(	O
PDE4D	5144
)	O
gene	O
was	O
reported	O
as	O
a	O
susceptibility	O
gene	O
to	O
stroke	D020521
.	O

The	O
genetic	O
effect	O
might	O
be	O
attributed	O
to	O
its	O
role	O
in	O
modulating	O
the	O
atherogenic	D050197
process	O
in	O
the	O
carotid	O
arteries	O
.	O

Using	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
and	O
plaque	O
index	O
as	O
phenotypes	O
,	O
the	O
present	O
study	O
sought	O
to	O
determine	O
the	O
influence	O
of	O
this	O
gene	O
on	O
subclinical	O
atherosclerosis	D050197
.	O

METHODS	O
:	O
Carotid	O
ultrasonography	O
was	O
performed	O
on	O
1013	O
stroke	D020521
-	O
free	O
subjects	O
who	O
participated	O
in	O
the	O
health	O
screening	O
programs	O
(	O
age	O
52	O
.	O
6	O
+	O
/	O
-	O
12	O
.	O
2	O
;	O
47	O
.	O
6%	O
men	9606
)	O
.	O

Genotype	O
distribution	O
was	O
compared	O
among	O
the	O
high	O
-	O
risk	O
(	O
plaque	O
index	O
>	O
or	O
=	O
4	O
)	O
,	O
low	O
-	O
risk	O
(	O
index	O
=	O
1	O
-	O
3	O
)	O
,	O
and	O
reference	O
(	O
index	O
=	O
0	O
)	O
groups	O
.	O

We	O
analyzed	O
continuous	O
IMT	O
data	O
and	O
further	O
dichotomized	O
IMT	O
data	O
using	O
mean	O
plus	O
one	O
standard	O
deviation	O
as	O
the	O
cutoff	O
level	O
.	O

Because	O
the	O
plaque	O
prevalence	O
and	O
IMT	O
values	O
displayed	O
a	O
notable	O
difference	O
between	O
men	9606
and	O
women	9606
,	O
we	O
carried	O
out	O
sex	O
-	O
specific	O
analyses	O
in	O
addition	O
to	O
analyzing	O
the	O
overall	O
data	O
.	O

Rs702553	rs702553
at	O
the	O
PDE4D	5144
gene	O
was	O
selected	O
because	O
it	O
conferred	O
a	O
risk	O
for	O
young	O
stroke	D020521
in	O
our	O
previous	O
report	O
.	O

Previous	O
young	O
stroke	D020521
data	O
(	O
190	O
cases	O
and	O
211	O
controls	O
)	O
with	O
an	O
additional	O
532	O
control	O
subjects	O
without	O
ultrasonic	O
data	O
were	O
shown	O
as	O
a	O
cross	O
-	O
validation	O
for	O
the	O
genetic	O
effect	O
.	O

RESULTS	O
:	O
In	O
the	O
overall	O
analyses	O
,	O
the	O
rare	O
homozygote	O
of	O
rs702553	rs702553
led	O
to	O
an	O
OR	O
of	O
3	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
034	O
)	O
for	O
a	O
plaque	O
index	O
>	O
or	O
=	O
4	O
.	O

When	O
subjects	O
were	O
stratified	O
by	O
sex	O
,	O
the	O
genetic	O
effect	O
was	O
only	O
evident	O
in	O
men	9606
but	O
not	O
in	O
women	9606
.	O

Comparing	O
male	O
subjects	O
with	O
plaque	O
index	O
>	O
or	O
=	O
4	O
and	O
those	O
with	O
plaque	O
index	O
=	O
0	O
,	O
the	O
TT	O
genotype	O
was	O
over	O
-	O
represented	O
(	O
27	O
.	O
6%	O
vs	O
.	O

13	O
.	O
4%	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

For	O
dichotomized	O
IMT	O
data	O
in	O
men	9606
,	O
the	O
TT	O
genotype	O
had	O
an	O
OR	O
of	O
2	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
for	O
a	O
thicker	O
IMT	O
at	O
the	O
common	O
carotid	O
artery	O
compared	O
with	O
the	O
(	O
AA	O
+	O
AT	O
)	O
genotypes	O
.	O

In	O
women	9606
,	O
neither	O
IMT	O
nor	O
plaque	O
index	O
was	O
associated	O
with	O
rs702553	rs702553
.	O

Similarly	O
,	O
SNP	O
rs702553	rs702553
was	O
only	O
significant	O
in	O
young	O
stroke	D020521
men	9606
(	O
OR	O
=	O
1	O
.	O
8	O
,	O
p	O
=	O
0	O
.	O
025	O
)	O
but	O
not	O
in	O
women	9606
(	O
p	O
=	O
0	O
.	O
27	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
a	O
sex	O
-	O
differential	O
effect	O
of	O
PDE4D	5144
on	O
IMT	O
,	O
plaque	O
index	O
and	O
stroke	D020521
,	O
which	O
highlights	O
its	O
influence	O
on	O
various	O
aspects	O
of	O
atherogenesis	D050197
.	O
Reduced	O
adiponectin	11450
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	11668
and	O
further	O
retinoic	19401,19411,20181
acid	19401,19411,20181
receptor	19401,19411,20181
signaling	O
in	O
adipose	O
tissue	O
.	O

Adiponectin	11450
is	O
an	O
adipocyte	O
-	O
derived	O
adipokine	11450
with	O
potent	O
antidiabetic	O
,	O
anti	O
-	O
inflammatory	D007249
,	O
and	O
antiatherogenic	O
activity	O
.	O

Long	O
-	O
term	O
,	O
high	O
-	O
fat	O
diet	O
results	O
in	O
gain	O
of	O
body	O
weight	O
,	O
adiposity	D009765
,	O
further	O
inflammatory	D007249
-	O
based	O
cardiovascular	D002318
diseases	D002318
,	O
and	O
reduced	O
adiponectin	11450
secretion	O
.	O

Vitamin	D014801
A	D014801
derivatives	O
/	O
retinoids	D012176
are	O
involved	O
in	O
several	O
of	O
these	O
processes	O
,	O
which	O
mainly	O
take	O
place	O
in	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
adiponectin	11450
expression	O
as	O
a	O
function	O
of	O
dietary	O
high	O
-	O
fat	O
and	O
high	O
-	O
vitamin	D014801
A	D014801
conditions	O
in	O
mice	10090
.	O

A	O
decrease	O
of	O
adiponectin	11450
expression	O
in	O
addition	O
to	O
an	O
up	O
-	O
regulation	O
of	O
aldehyde	11668
dehydrogenase	11668
A1	11668
(	O
ALDH1A1	11668
)	O
,	O
retinoid	O
signaling	O
,	O
and	O
retinoic	D014212
acid	D014212
response	O
element	O
signaling	O
was	O
selectively	O
observed	O
in	O
WAT	O
of	O
mice	10090
fed	O
a	O
normal	O
-	O
vitamin	D014801
A	D014801
,	O
high	O
-	O
fat	O
diet	O
.	O

Reduced	O
adiponectin	11450
expression	O
in	O
WAT	O
was	O
also	O
observed	O
in	O
mice	10090
fed	O
a	O
high	O
-	O
vitamin	D014801
A	D014801
diet	O
.	O

Adipocyte	O
cell	O
culture	O
revealed	O
that	O
endogenous	O
and	O
synthetic	O
retinoic	19401
acid	19401
receptor	19401
(	O
RAR	19401
)	O
a	19401
-	O
and	O
RARg	19411
-	O
selective	O
agonists	O
,	O
as	O
well	O
as	O
a	O
synthetic	O
retinoid	20181
X	20181
receptor	20181
agonist	O
,	O
efficiently	O
reduced	O
adiponectin	11450
expression	O
,	O
whereas	O
ALDH1A1	11668
expression	O
only	O
increased	O
with	O
RAR	19401,19411,20181
agonists	O
.	O

We	O
conclude	O
that	O
reduced	O
adiponectin	11450
expression	O
under	O
high	O
-	O
fat	O
dietary	O
conditions	O
is	O
dependent	O
on	O
1	O
)	O
increased	O
ALDH1A1	11668
expression	O
in	O
adipocytes	O
,	O
which	O
does	O
not	O
increase	O
all	O
-	O
trans	O
-	O
retinoic	D014212
acid	D014212
levels	O
;	O
2	O
)	O
further	O
RAR	19401,19411,20181
ligand	O
-	O
induced	O
,	O
WAT	O
-	O
selective	O
,	O
increased	O
retinoic	D014212
acid	D014212
response	O
element	O
-	O
mediated	O
signaling	O
;	O
and	O
3	O
)	O
RAR	19401,19411,20181
ligand	O
-	O
dependent	O
reduction	O
of	O
adiponectin	11450
expression	O
.	O
-	O
Landrier	O
,	O
J	O
.	O
-	O
F	O
.	O
,	O
Kasiri	O
,	O
E	O
.	O
,	O
Karkeni	O
,	O
E	O
.	O
,	O
Mihaly	O
,	O
J	O
.	O
,	O
Beke	O
,	O
G	O
.	O
,	O
Weiss	O
,	O
K	O
.	O
,	O
Lucas	O
,	O
R	O
.	O
,	O
Aydemir	O
,	O
G	O
.	O
,	O
Salles	O
,	O
J	O
.	O
,	O
Walrand	O
,	O
S	O
.	O
,	O
de	O
Lera	O
,	O
A	O
.	O

R	O
.	O
,	O
Ruhl	O
,	O
R	O
.	O

Reduced	O
adiponectin	11450
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	11668
and	O
further	O
retinoic	19401,19411,20181
acid	19401,19411,20181
receptor	19401,19411,20181
signaling	O
in	O
adipose	O
tissue	O
.	O
Effect	O
of	O
the	O
abrogation	O
of	O
TGF	4052
-	O
beta1	4052
by	O
antisense	O
oligonucleotides	D009841
on	O
the	O
expression	O
of	O
TGF	7046,7048
-	O
beta	7046,7048
-	O
isoforms	7046,7048
and	7046,7048
their	7046,7048
receptors	7046,7048
I	7046,7048
and	7046,7048
II	7046,7048
in	O
isolated	O
fibroblasts	O
from	O
keloid	D007627
scars	D007627
.	O

Disequilibrium	O
of	O
dermal	O
wound	O
repair	O
can	O
result	O
in	O
continued	O
accumulation	O
of	O
ECM	O
and	O
excessive	O
scar	O
formation	O
.	O

In	O
susceptible	O
genetically	O
predisposed	O
individuals	O
,	O
keloid	D007627
formation	O
can	O
be	O
observed	O
.	O

Keloid	D007627
disease	D007627
represents	O
a	O
benign	O
dermal	O
fibroproliferative	O
tumor	D009369
that	O
is	O
unique	O
to	O
humans	9606
.	O

TGF	7040,7042,7043
-	O
beta	7040,7042,7043
is	O
known	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
which	O
is	O
still	O
not	O
fully	O
understood	O
.	O

The	O
isoforms	O
TGF	4052
-	O
beta1	4052
and	O
TGF	7042
-	O
beta2	7042
have	O
profibrotic	O
properties	O
,	O
whereas	O
TGF	7043
-	O
beta3	7043
may	O
have	O
antifibrotic	O
functions	O
.	O

TGF	7040,7042,7043
-	O
beta	7040,7042,7043
exerts	O
its	O
influence	O
by	O
binding	O
to	O
type	7046,7048
I	7046,7048
and	7046,7048
type	7046,7048
II	7046,7048
TGF	7046,7048
-	O
beta	7046,7048
receptors	7046,7048
,	O
thereby	O
forming	O
a	O
complex	O
and	O
activating	O
specific	O
downstream	O
effector	O
molecules	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
TGF	4052
-	O
beta1	4052
targeting	O
by	O
antisense	O
oligonucleotides	D009841
on	O
the	O
RNA	O
synthesis	O
and	O
protein	O
expression	O
of	O
TGF	7040,7042,7043
-	O
beta	7040,7042,7043
isoforms	O
and	O
their	O
receptors	O
in	O
keloid	D007627
-	O
derived	O
fibroblasts	O
.	O

In	O
tissue	O
samples	O
with	O
normal	O
fibroblasts	O
(	O
NFs	O
)	O
serving	O
as	O
control	O
samples	O
,	O
expression	O
of	O
TGF	4052,7042
-	O
beta1	4052,7042
and	4052,7042
-	O
beta2	4052,7042
was	O
decreased	O
when	O
compared	O
to	O
keloid	D007627
fibroblasts	O
(	O
KFs	O
)	O
,	O
while	O
expression	O
of	O
TGF	7043
-	O
beta3	7043
and	O
of	O
TGF	7048
-	O
betaRII	7048
was	O
significantly	O
higher	O
in	O
NFs	O
.	O

In	O
the	O
ELISA	O
assay	O
,	O
abrogation	O
of	O
TGF	4052
-	O
beta1	4052
led	O
to	O
a	O
significant	O
decrease	O
in	O
TGF	4052,7042
-	O
beta1	4052,7042
and	4052,7042
-	O
beta2	4052,7042
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Expression	O
of	O
TGF	7042
-	O
beta2	7042
mRNA	O
was	O
reduced	O
.	O

Expression	O
of	O
TGF	7043
-	O
beta3	7043
mRNA	O
revealed	O
contrary	O
patterns	O
in	O
KFs	O
from	O
different	O
patients	9606
while	O
expression	O
of	O
TGF	7046
-	O
betaRI	7046
was	O
found	O
to	O
be	O
equal	O
during	O
the	O
measurement	O
period	O
.	O

TGF	7048
-	O
betaRII	7048
mRNA	O
expression	O
was	O
increased	O
after	O
48	O
and	O
72	O
h	O
respectively	O
.	O

There	O
is	O
growing	O
evidence	O
for	O
a	O
regulatory	O
mechanism	O
between	O
TGF	4052
-	O
beta1	4052
and	O
its	O
receptors	O
.	O

Our	O
findings	O
support	O
this	O
theory	O
by	O
suggesting	O
interrelations	O
between	O
the	O
different	O
TGF	7040,7042,7043
-	O
beta	7040,7042,7043
isoforms	O
and	O
their	O
receptors	O
.	O

Abnormal	O
response	O
of	O
KFs	O
to	O
TGF	O
-	O
betamight	O
reflect	O
a	O
modification	O
in	O
the	O
regulatory	O
pathway	O
that	O
occurs	O
at	O
the	O
receptor	O
level	O
or	O
during	O
intracellular	O
trans	O
-	O
duction	O
.	O

Improving	O
the	O
understanding	O
of	O
TGF	7040,7042,7043
-	O
beta	7040,7042,7043
in	O
keloid	D007627
disease	D007627
could	O
lead	O
to	O
the	O
development	O
of	O
clinically	O
useful	O
therapeutic	O
modalities	O
for	O
treatment	O
of	O
keloid	D007627
disease	D007627
or	O
even	O
allow	O
identification	O
of	O
preventive	O
strategies	O
.	O
TAK1	26409
is	O
an	O
essential	O
regulator	O
of	O
BMP	12159
signalling	O
in	O
cartilage	O
.	O

TGFbeta	26409
activated	26409
kinase	26409
1	26409
(	O
TAK1	26409
)	O
,	O
a	O
member	O
of	O
the	O
MAPKKK	26409
family	O
,	O
controls	O
diverse	O
functions	O
ranging	O
from	O
innate	O
and	O
adaptive	O
immune	O
system	O
activation	O
to	O
vascular	O
development	O
and	O
apoptosis	O
.	O

To	O
analyse	O
the	O
in	O
vivo	O
function	O
of	O
TAK1	26409
in	O
cartilage	O
,	O
we	O
generated	O
mice	10090
with	O
a	O
conditional	O
deletion	O
of	O
Tak1	26409
driven	O
by	O
the	O
collagen	12824
2	12824
promoter	O
.	O

Tak1	26409
(	O
col2	12824
)	O
mice	10090
displayed	O
severe	O
chondrodysplasia	D010009
with	O
runting	O
,	O
impaired	O
formation	O
of	O
secondary	O
centres	O
of	O
ossification	O
,	O
and	O
joint	D007592
abnormalities	D007592
including	O
elbow	D004204
dislocation	D004204
and	O
tarsal	D000070604
fusion	D000070604
.	O

This	O
phenotype	O
resembled	O
that	O
of	O
bone	12166
morphogenetic	12166
protein	12166
receptor	12166
(	O
BMPR	12166
)	O
1	12166
and	O
Gdf5	14563
-	O
deficient	O
mice	10090
.	O

BMPR	12166
signalling	O
was	O
markedly	O
impaired	O
in	O
TAK1	26409
-	O
deficient	O
chondrocytes	O
as	O
evidenced	O
by	O
reduced	O
expression	O
of	O
known	O
BMP	12159
target	O
genes	O
as	O
well	O
as	O
reduced	O
phosphorylation	O
of	O
Smad1	17125,17129,55994
/	O
5	17125,17129,55994
/	O
8	17125,17129,55994
and	O
p38	26416
/	O
Jnk	26419
/	O
Erk	26413
MAP	26413,26416,26419
kinases	26413,26416,26419
.	O

TAK1	26409
mediates	O
Smad1	17125
phosphorylation	O
at	O
C	O
-	O
terminal	O
serine	O
residues	O
.	O

These	O
findings	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
in	O
a	O
mammalian	O
system	O
that	O
TAK1	26409
is	O
required	O
for	O
BMP	12159
signalling	O
and	O
functions	O
as	O
an	O
upstream	O
activating	O
kinase	O
for	O
Smad1	17125,17129,55994
/	O
5	17125,17129,55994
/	O
8	17125,17129,55994
in	O
addition	O
to	O
its	O
known	O
role	O
in	O
regulating	O
MAP	26413,26416,26419
kinase	26413,26416,26419
pathways	O
.	O

Our	O
experiments	O
reveal	O
an	O
essential	O
role	O
for	O
TAK1	26409
in	O
the	O
morphogenesis	O
,	O
growth	O
,	O
and	O
maintenance	O
of	O
cartilage	O
.	O
Promoter	O
insertion	O
/	O
deletion	O
in	O
the	O
IRF5	3663
gene	O
is	O
highly	O
associated	O
with	O
susceptibility	O
to	O
systemic	D008180
lupus	D008180
erythematosus	D008180
in	O
distinct	O
populations	O
,	O
but	O
exerts	O
a	O
modest	O
effect	O
on	O
gene	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
examined	O
the	O
genetic	O
association	O
of	O
the	O
promoter	O
insertion	O
/	O
deletion	O
(	O
indel	O
)	O
in	O
IRF5	3663
gene	O
with	O
systemic	D008180
lupus	D008180
erythematosus	D008180
(	O
SLE	D008180
)	O
in	O
distinct	O
populations	O
and	O
assessed	O
its	O
role	O
in	O
gene	O
expression	O
.	O

METHODS	O
:	O
Four	O
IRF5	3663
polymorphisms	O
were	O
genotyped	O
in	O
1488	O
SLE	D008180
patients	9606
and	O
1466	O
controls	O
.	O

Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
RNA	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

RESULTS	O
:	O
The	O
promoter	O
indel	O
and	O
rs2070197	rs2070197
had	O
independent	O
genetic	O
effects	O
,	O
which	O
accounted	O
for	O
the	O
association	O
of	O
rs2004640	rs2004640
and	O
rs10954213	rs10954213
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
rs10954213	rs10954213
exerted	O
the	O
greatest	O
influence	O
on	O
IRF5	3663
transcript	O
levels	O
.	O

CONCLUSION	O
:	O
We	O
corroborated	O
the	O
association	O
of	O
the	O
promoter	O
indel	O
with	O
SLE	D008180
in	O
5	O
different	O
populations	O
and	O
revealed	O
that	O
rs10954213	rs10954213
is	O
the	O
main	O
single	O
-	O
nucleotide	O
polymorphism	O
responsible	O
for	O
altered	O
IRF5	3663
expression	O
in	O
PBMC	O
.	O
Tissue	O
-	O
Specific	O
Ablation	O
of	O
the	O
LIF	16880
Receptor	16880
in	O
the	O
Murine	10090
Uterine	O
Epithelium	O
Results	O
in	O
Implantation	O
Failure	O
.	O

The	O
cytokine	O
leukemia	16878
inhibitory	16878
factor	16878
(	O
LIF	16878
)	O
is	O
essential	O
for	O
rendering	O
the	O
uterus	O
receptive	O
for	O
blastocyst	O
implantation	O
.	O

In	O
mice	10090
,	O
LIF	16880
receptor	16880
expression	O
(	O
LIFR	16880
)	O
is	O
largely	O
restricted	O
to	O
the	O
uterine	O
luminal	O
epithelium	O
(	O
LE	O
)	O
.	O

LIF	16878
,	O
secreted	O
from	O
the	O
endometrial	O
glands	O
(	O
GEs	O
)	O
,	O
binds	O
to	O
the	O
LIFR	16880
,	O
activating	O
the	O
Janus	16452
kinase	16452
-	O
signal	20848
transducer	20848
and	20848
activation	20848
of	20848
transcription	20848
(	O
STAT	20848
)	O
3	20848
(	O
Jak	16452
-	O
Stat3	20848
)	O
signaling	O
pathway	O
in	O
the	O
LE	O
.	O

JAK	16452
-	O
STAT	20848
activation	O
converts	O
the	O
LE	O
to	O
a	O
receptive	O
state	O
so	O
that	O
juxtaposed	O
blastocysts	O
begin	O
to	O
implant	O
.	O

To	O
specifically	O
delete	O
the	O
LIFR	16880
in	O
the	O
LE	O
,	O
we	O
derived	O
a	O
line	O
of	O
mice	10090
in	O
which	O
Cre	O
recombinase	O
was	O
inserted	O
into	O
the	O
endogenous	O
lactoferrin	17002
gene	O
(	O
Ltf	16878
-	O
Cre	O
)	O
.	O

Lactoferrin	17002
expression	O
in	O
the	O
LE	O
is	O
induced	O
by	O
E2	O
,	O
and	O
we	O
demonstrate	O
that	O
Cre	O
recombinase	O
activity	O
is	O
restricted	O
to	O
the	O
LE	O
and	O
GE	O
.	O

To	O
determine	O
the	O
requirement	O
of	O
the	O
LIFR	16880
in	O
implantation	O
,	O
we	O
derived	O
an	O
additional	O
mouse	10090
line	O
carrying	O
a	O
conditional	O
(	O
floxed	O
)	O
Lifr	16880
flx	O
/	O
flx	O
gene	O
.	O

Crossing	O
Ltf	16878
-	O
Cre	O
mice	10090
with	O
Lifr	16880
flx	O
/	O
flx	O
mice	10090
generated	O
Lifr	16880
flx	O
/	O
D	O
:	O
Ltf	16878
Cre	O
/	O
+	O
females	O
that	O
were	O
overtly	O
normal	O
but	O
infertile	O
.	O

Many	O
of	O
these	O
females	O
,	O
despite	O
repeated	O
matings	O
,	O
did	O
not	O
become	O
pregnant	O
.	O

Unimplanted	O
blastocysts	O
were	O
recovered	O
from	O
the	O
Lifr	16880
flx	O
/	O
D	O
:	O
Ltf	16878
Cre	O
/	O
+	O
uteri	O
and	O
,	O
when	O
transferred	O
to	O
wild	O
-	O
type	O
recipients	O
,	O
implanted	O
normally	O
,	O
indicating	O
that	O
uterine	O
receptivity	O
rather	O
than	O
the	O
embryo	O
'	O
s	O
competency	O
is	O
compromised	O
.	O

The	O
loss	O
of	O
Lifr	16880
results	O
in	O
both	O
the	O
failure	O
for	O
STAT3	20848
to	O
translocate	O
to	O
the	O
LE	O
nuclei	O
and	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
LIF	16878
regulated	O
gene	O
Msx1	17701
that	O
regulates	O
uterine	O
receptivity	O
.	O

These	O
results	O
reveal	O
that	O
uterine	O
expression	O
of	O
the	O
LIFR	16880
is	O
essential	O
for	O
embryo	O
implantation	O
and	O
further	O
define	O
the	O
components	O
of	O
the	O
LIF	16878
signaling	O
pathway	O
necessary	O
for	O
effective	O
implantation	O
.	O
Psoriasin	6278
promotes	O
invasion	O
,	O
aggregation	O
and	O
survival	O
of	O
pancreatic	D010190
cancer	D010190
cells	O
;	O
association	O
with	O
disease	O
progression	O
.	O

Psoriasin	6278
(	O
S100A7	6278
)	O
is	O
an	O
11	O
-	O
kDa	O
small	O
calcium	6278
binding	6278
protein	6278
initially	O
isolated	O
from	O
psoriatic	D011565
skin	D011565
lesions	D011565
.	O

It	O
belongs	O
to	O
the	O
S100	6278
family	O
of	O
proteins	O
which	O
play	O
an	O
important	O
role	O
in	O
a	O
range	O
of	O
cell	O
functions	O
including	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
.	O

Aberrant	O
Psoriasin	6278
expression	O
has	O
been	O
implicated	O
in	O
a	O
range	O
of	O
cancers	D009369
and	O
is	O
often	O
associated	O
with	O
poor	O
prognosis	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
Psoriasin	6278
on	O
pancreatic	D010190
cancer	D010190
cell	O
functions	O
and	O
the	O
implication	O
in	O
progression	O
of	O
the	O
disease	O
.	O

Expression	O
of	O
Psoriasin	6278
was	O
determined	O
in	O
a	O
cohort	O
of	O
pancreatic	O
tissues	O
comprised	O
of	O
126	O
pancreatic	D010190
tumours	D010190
and	O
114	O
adjacent	O
non	O
-	O
tumour	O
pancreatic	O
tissues	O
.	O

Knockdown	O
and	O
overexpression	O
of	O
Psoriasin	6278
in	O
pancreatic	D010190
cancer	D010190
cells	O
was	O
performed	O
using	O
specifically	O
constructed	O
plasmids	O
,	O
which	O
either	O
had	O
anti	O
-	O
Psoriasin	6278
ribozyme	O
transgene	O
or	O
the	O
full	O
length	O
human	9606
Psoriasin	6278
coding	O
sequence	O
.	O

Psoriasin	6278
knockdown	O
and	O
overexpression	O
was	O
verified	O
using	O
conventional	O
RT	O
-	O
PCR	O
and	O
qPCR	O
.	O

The	O
effect	O
of	O
manipulating	O
Psoriasin	6278
expression	O
on	O
pancreatic	D010190
cancer	D010190
cell	O
functions	O
was	O
assessed	O
using	O
several	O
in	O
vitro	O
cell	O
function	O
assays	O
.	O

Local	O
invasive	O
pancreatic	D010190
cancers	D010190
extended	O
beyond	O
the	O
pancreas	O
expressed	O
higher	O
levels	O
of	O
Psoriasin	6278
transcripts	O
compared	O
with	O
the	O
cancers	D009369
confined	O
to	O
the	O
pancreas	O
.	O

Primary	D009369
tumours	D009369
with	O
distant	O
metastases	D009362
exhibited	O
a	O
reduced	O
expression	O
of	O
Psoriasin	6278
.	O

Psoriasin	6278
overexpression	O
cell	O
lines	O
exhibited	O
significantly	O
increased	O
growth	O
and	O
migration	O
compared	O
to	O
control	O
cells	O
.	O

In	O
addition	O
,	O
Psoriasin	6278
overexpression	O
resulted	O
in	O
increased	O
pancreatic	D010190
cancer	D010190
cell	O
invasion	O
which	O
was	O
associated	O
with	O
upregulation	O
of	O
matrix	4313
metalloproteinase	4313
-	O
2	4313
(	O
MMP	4313
-	O
2	4313
)	O
and	O
MMP	4318
-	O
9	4318
.	O

Overexpression	O
of	O
Psoriasin	6278
also	O
promoted	O
aggregation	O
and	O
survival	O
of	O
pancreatic	D010190
cancer	D010190
cells	O
when	O
they	O
lost	O
anchorage	O
.	O

Taken	O
together	O
,	O
higher	O
expression	O
of	O
Psoriasin	6278
was	O
associated	O
with	O
local	O
invasion	O
in	O
pancreatic	D010190
cancers	D010190
.	O

Psoriasin	6278
expression	O
is	O
associated	O
with	O
pancreatic	D010190
cancer	D010190
cell	O
growth	O
,	O
migration	O
,	O
cell	O
-	O
matrix	O
adhesion	O
,	O
and	O
invasion	O
via	O
regulation	O
of	O
MMPs	4313,4318
.	O

As	O
such	O
,	O
the	O
proposed	O
implications	O
of	O
Psoriasin	6278
in	O
invasion	O
,	O
disease	O
progression	O
and	O
as	O
a	O
potential	O
therapeutic	O
target	O
warrant	O
further	O
investigation	O
.	O
Influence	O
of	O
interleukin	3593
12B	3593
(	O
IL12B	3593
)	O
polymorphisms	O
on	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
hepatitis	D006526
C	D006526
virus	D006526
infection	D006526
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Interleukin	3593
-	O
12	3593
(	O
IL	3593
-	O
12	3593
)	O
governs	O
the	O
Th1	O
-	O
type	O
immune	O
response	O
,	O
affecting	O
the	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
HCV	D006526
-	O
infection	D006526
.	O

We	O
investigated	O
whether	O
the	O
IL12B	3593
polymorphisms	O
within	O
the	O
promoter	O
region	O
(	O
4	c|INDEL||4
bp	c|INDEL||4
insertion	c|INDEL||4
/	O
deletion	c|INDEL||4
)	O
and	O
the	O
3	O
'	O
-	O
UTR	O
(	O
1188	c|SUB|A|1188|C
-	O
A	c|SUB|A|1188|C
/	O
C	c|SUB|A|1188|C
)	O
,	O
which	O
have	O
been	O
reported	O
to	O
influence	O
IL	3593
-	O
12	3593
synthesis	O
,	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
HCV	D006526
infection	D006526
.	O

METHODS	O
:	O
We	O
analyzed	O
186	O
individuals	O
with	O
spontaneous	O
HCV	11103
clearance	O
,	O
501	O
chronically	O
HCV	D006526
infected	D006526
patients	9606
,	O
and	O
217	O
healthy	O
controls	O
.	O

IL12B	3593
3	O
'	O
-	O
UTR	O
and	O
promoter	O
genotyping	O
was	O
performed	O
by	O
Taqman	O
-	O
based	O
assays	O
with	O
allele	O
-	O
specific	O
oligonucleotide	D009841
probes	O
and	O
PCR	O
-	O
based	O
allele	O
-	O
specific	O
DNA	O
-	O
amplification	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
proportion	O
of	O
IL12B	3593
promoter	O
and	O
3	O
'	O
-	O
UTR	O
genotypes	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
different	O
cohorts	O
.	O

However	O
,	O
HCV	D006526
genotype	D006526
1	D006526
-	O
infected	D006526
patients	9606
with	O
high	O
baseline	O
viremia	D014766
carrying	O
the	O
IL12B	3593
3	O
'	O
-	O
UTR	O
1188	c|Allele|C|1188
-	O
C	c|Allele|C|1188
-	O
allele	O
showed	O
significantly	O
higher	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
rates	O
(	O
25	O
.	O
3%	O
vs	O
.	O

46%	O
vs	O
.	O

54	O
.	O
5%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
)	O
due	O
to	O
reduced	O
relapse	O
rates	O
(	O
24	O
.	O
2%	O
vs	O
.	O

12%	O
vs	O
.	O

zero	O
%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
)	O
.	O

CONCLUSIONS	O
:	O
IL12B	3593
3	O
'	O
-	O
UTR	O
1188	c|Allele|C|1188
-	O
C	c|Allele|C|1188
-	O
allele	O
carriers	O
appear	O
to	O
be	O
capable	O
of	O
responding	O
more	O
efficiently	O
to	O
antiviral	O
combination	O
therapy	O
as	O
a	O
consequence	O
of	O
a	O
reduced	O
relapse	O
rate	O
.	O

No	O
association	O
of	O
IL12B	3593
polymorphisms	O
and	O
self	O
-	O
limited	O
HCV	D006526
infection	D006526
could	O
be	O
demonstrated	O
.	O
Neurofibromin	4763
1	4763
(	O
NF1	4763
)	O
defects	O
are	O
common	O
in	O
human	9606
ovarian	D010051
serous	D010051
carcinomas	D010051
and	O
co	O
-	O
occur	O
with	O
TP53	7157
mutations	O
.	O

Ovarian	D010051
serous	D010051
carcinoma	D010051
(	O
OSC	D010051
)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	D002277
epithelial	D002277
malignancy	D002277
.	O

Mutations	O
of	O
TP53	7157
and	O
dysfunction	O
of	O
the	O
Brca1	672
and	O
/	O
or	O
Brca2	675
tumor	D009369
-	O
suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	D010051
,	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well	O
-	O
established	O
tumor	D009369
-	O
suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O

Using	O
a	O
genome	O
-	O
wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	D010051
,	O
we	O
identified	O
two	O
tumors	D009369
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	4763
gene	O
.	O

Subsequently	O
,	O
18	O
ovarian	D010051
carcinoma	D010051
-	O
derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	D010051
were	O
evaluated	O
for	O
NF1	4763
alterations	O
.	O

Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	4763
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
,	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
,	O
NF1	4763
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and	O
/	O
or	O
aberrant	O
splicing	O
of	O
NF1	4763
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	4763
expression	O
.	O

Similarly	O
,	O
NF1	4763
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(	O
22%	O
)	O
of	O
41	O
primary	O
OSCs	D010051
.	O

As	O
expected	O
,	O
tumors	D009369
and	O
cell	O
lines	O
with	O
NF1	4763
defects	O
lacked	O
mutations	O
in	O
KRAS	3845
or	O
BRAF	673
but	O
showed	O
Ras	3845
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	5594
(	O
primary	O
tumors	D009369
)	O
or	O
increased	O
levels	O
of	O
GTP	D006160
-	O
bound	O
Ras	3845
(	O
cell	O
lines	O
)	O
.	O

The	O
TP53	7157
tumor	D009369
-	O
suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	D010051
with	O
documented	O
NF1	4763
mutation	O
,	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor	D009369
-	O
suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	D010051
carcinomas	D010051
with	O
serous	O
differentiation	O
.	O
Drug	O
-	O
induced	O
long	D008133
QT	D008133
syndrome	D008133
in	O
injection	O
drug	O
users	O
receiving	O
methadone	D008691
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	9606
and	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	D008133
QT	D008133
syndrome	D008133
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O

Methadone	D008691
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
the	O
inpatient	9606
setting	O
,	O
the	O
frequency	O
of	O
QT	D008133
interval	D008133
prolongation	D008133
with	O
methadone	D008691
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	D008691
and	O
those	O
not	O
receiving	O
methadone	D008691
among	O
all	O
patients	9606
hospitalized	O
over	O
a	O
5	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

A	O
total	O
of	O
167	O
patients	9606
receiving	O
methadone	D008691
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	D008691
.	O

In	O
addition	O
to	O
methadone	D008691
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	D008133
prolongation	D008133
.	O

RESULTS	O
:	O
Among	O
167	O
methadone	D008691
maintenance	O
patients	9606
,	O
the	O
prevalence	O
of	O
QTc	D008133
prolongation	D008133
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2%	O
compared	O
with	O
0%	O
in	O
80	O
control	O
subjects	O
.	O

Six	O
patients	9606
(	O
3	O
.	O
6%	O
)	O
in	O
the	O
methadone	D008691
group	O
presented	O
torsades	D016171
de	D016171
pointes	D016171
.	O

QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	D008691
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31	O
.	O
8%	O
of	O
QTc	O
variability	O
to	O
methadone	D008691
dose	O
,	O
cytochrome	1576
P	1576
-	O
450	1576
3A4	1576
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	D007008
,	O
and	O
altered	O
liver	O
function	O
.	O

CONCLUSIONS	O
:	O
QT	D008133
interval	D008133
prolongation	D008133
in	O
methadone	D008691
maintenance	O
patients	9606
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O

Methadone	D008691
dose	O
,	O
presence	O
of	O
cytochrome	D065692
P	D065692
-	O
450	D065692
3A4	D065692
inhibitors	D065692
,	O
potassium	D011188
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	D008133
prolongation	D008133
.	O

Long	D008133
QT	D008133
syndrome	D008133
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	D008691
.	O
Upregulation	O
of	O
centrosomal	55165
protein	55165
55	55165
is	O
associated	O
with	O
unfavorable	O
prognosis	O
and	O
tumor	D009369
invasion	O
in	O
epithelial	D000077216
ovarian	D000077216
carcinoma	D000077216
.	O

Centrosomal	55165
protein	55165
55	55165
(	O
CEP55	55165
)	O
is	O
a	O
cell	O
cycle	O
regulator	O
implicated	O
in	O
development	O
of	O
certain	O
cancers	D009369
.	O

However	O
,	O
characteristics	O
of	O
CEP55	55165
expression	O
and	O
its	O
clinical	O
/	O
prognostic	O
significance	O
are	O
unclear	O
in	O
human	9606
epithelial	D000077216
ovarian	D000077216
carcinoma	D000077216
(	O
EOC	D000077216
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
clinicopathological	O
significance	O
of	O
CEP55	55165
in	O
patients	9606
with	O
EOC	D000077216
and	O
its	O
role	O
in	O
regulating	O
invasion	O
and	O
metastasis	D010051
of	D010051
ovarian	D010051
cell	O
lines	O
.	O

CEP55	55165
mRNA	O
and	O
protein	O
expression	O
levels	O
were	O
detected	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
,	O
Western	O
blotting	O
,	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Potential	O
associations	O
of	O
CEP55	55165
expression	O
scores	O
with	O
clinical	O
parameters	O
and	O
patient	9606
survival	O
were	O
evaluated	O
.	O

CEP55	55165
function	O
was	O
investigated	O
further	O
using	O
RNA	O
interference	O
,	O
wound	O
healing	O
assay	O
,	O
transwell	O
assay	O
,	O
immunofluorescence	O
analysis	O
,	O
qRT	O
-	O
PCR	O
,	O
and	O
Western	O
blotting	O
.	O

CEP55	55165
was	O
significantly	O
upregulated	O
in	O
ovarian	D010051
cancer	D010051
cell	O
lines	O
and	O
lesions	O
compared	O
with	O
normal	O
cells	O
and	O
adjacent	O
noncancerous	O
ovarian	O
tissues	O
.	O

In	O
the	O
213	O
EOC	D000077216
samples	O
,	O
CEP55	55165
protein	O
levels	O
were	O
positively	O
correlated	O
with	O
clinical	O
stage	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
lymph	D008207
node	D008207
metastasis	D008207
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
intraperitoneal	D009362
metastasis	D009362
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tumor	D009369
recurrence	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
differentiation	O
grade	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
residual	O
tumor	D009369
size	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
ascites	D001201
see	O
tumor	D009369
cells	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
,	O
and	O
serum	O
CA153	4582
level	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
patients	9606
with	O
aberrant	O
CEP55	55165
protein	O
expression	O
showed	O
tendencies	O
to	O
receive	O
neoadjuvant	O
chemotherapy	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
cytoreductive	O
surgery	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

By	O
contrast	O
,	O
no	O
significant	O
correlation	O
was	O
detected	O
between	O
the	O
protein	O
levels	O
and	O
patient	9606
age	O
,	O
histological	O
type	O
,	O
or	O
serum	O
CA125	94025
,	O
CA199	94025
,	O
CA724	94025
,	O
NSE	2026
,	O
CEA	1084
,	O
and	O
b	93659
-	O
HCG	93659
levels	O
.	O

Patients	9606
with	O
high	O
CEP55	55165
protein	O
expression	O
had	O
shorter	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
compared	O
with	O
those	O
with	O
low	O
CEP55	55165
expression	O
.	O

Multivariate	O
analysis	O
implicated	O
CEP55	55165
as	O
an	O
independent	O
prognostic	O
indicator	O
for	O
EOC	D000077216
patients	9606
.	O

Additionally	O
,	O
downregulation	O
of	O
CEP55	55165
in	O
ovarian	D010051
cancer	D010051
cells	O
remarkably	O
inhibited	O
cellular	O
motility	O
and	O
invasion	O
.	O

Aberrant	O
CEP55	55165
expression	O
may	O
predict	O
unfavorable	O
clinical	O
outcomes	O
in	O
EOC	D000077216
patients	9606
and	O
play	O
an	O
important	O
role	O
in	O
regulating	O
invasion	O
in	O
ovarian	D010051
cancer	D010051
cells	O
.	O

Thus	O
,	O
CEP55	55165
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
and	O
therapeutic	O
target	O
for	O
EOC	D000077216
.	O
Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood	O
-	O
onset	O
systemic	D008180
lupus	D008180
erythematosus	D008180
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O

OBJECTIVE	O
:	O
Childhood	O
-	O
onset	O
systemic	D008180
lupus	D008180
erythematosus	D008180
(	O
SLE	D008180
)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	9606
for	O
genetic	O
study	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	D008180
,	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	9606
with	O
childhood	O
-	O
onset	O
SLE	D008180
and	O
both	O
of	O
their	O
parents	O
.	O

METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
,	O
a	O
platform	O
of	O
9	O
,	O
412	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
from	O
1	O
,	O
204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O

Molecular	O
inversion	O
probes	O
and	O
high	O
-	O
throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O

Seven	O
hundred	O
fifty	O
three	O
subjects	O
,	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood	O
-	O
onset	O
SLE	D008180
families	O
,	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(	O
TDT	O
)	O
and	O
multitest	O
corrections	O
.	O

RESULTS	O
:	O
Family	O
-	O
based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	D008180
with	O
a	O
N673S	rs3917815
polymorphism	O
in	O
the	O
P	6403
-	O
selectin	6403
gene	O
(	O
SELP	6403
)	O
(	O
P	O
=	O
5	O
.	O
74	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
and	O
a	O
C203S	rs10127175
polymorphism	O
in	O
the	O
interleukin	3654
-	O
1	3654
receptor	3654
-	O
associated	3654
kinase	3654
1	3654
gene	O
(	O
IRAK1	3654
)	O
(	O
P	O
=	O
9	O
.	O
58	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
.	O

These	O
2	O
SNPs	O
had	O
a	O
false	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<	O
0	O
.	O
05	O
,	O
and	O
therefore	O
a	O
>	O
95%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O

Furthermore	O
,	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<	O
0	O
.	O
5	O
,	O
suggesting	O
association	O
with	O
SLE	D008180
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O

These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	355
(	O
Fas	355
)	O
and	O
IRF5	3663
,	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	D008180
pathogenesis	O
.	O

CONCLUSION	O
:	O
SELP	6403
and	O
IRAK1	3654
were	O
identified	O
as	O
novel	O
SLE	D008180
-	O
associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
,	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	D008180
.	O

The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O
A	O
novel	O
compound	O
,	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
,	O
attenuates	O
cognitive	D003072
deficits	D003072
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	D003704
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
by	O
the	O
esterification	O
of	O
maltol	C008316
and	O
p	C495469
-	O
coumaric	C495469
acid	C495469
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
could	O
improve	O
cognitive	D003072
decline	D003072
in	O
scopolamine	D012601
-	O
injected	O
rats	10116
and	O
in	O
amyloid	C544092
beta	C544092
peptide	C544092
(	O
1	C544092
-	O
42	C544092
)	O
-	O
infused	O
rats	10116
.	O

Maltolyl	C524754
p	C524754
-	O
coumarate	C524754
was	O
found	O
to	O
attenuate	O
cognitive	D003072
deficits	D003072
in	O
both	O
rat	10116
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	C544092
beta	C544092
peptide	C544092
(	O
1	C544092
-	O
42	C544092
)	O
-	O
infused	O
rats	10116
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
in	O
vitro	O
using	O
SH	9606
-	O
SY5Y	9606
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
,	O
before	O
exposed	O
to	O
amyloid	C544092
beta	C544092
peptide	C544092
(	O
1	C544092
-	O
42	C544092
)	O
,	O
glutamate	D018698
or	O
H2O2	D006861
.	O

We	O
found	O
that	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	D017382
oxygen	D017382
species	D017382
,	O
cytochrome	D045304
c	D045304
release	O
,	O
and	O
caspase	25402
3	25402
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	C524754
p	C524754
-	O
coumarate	C524754
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	D000544
'	O
s	D000544
disease	D000544
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	D009410
death	D009410
and	O
progressive	O
decline	D003072
of	D003072
cognitive	D003072
function	D003072
.	O
Anticipation	O
in	O
familial	O
lattice	C537881
corneal	C537881
dystrophy	C537881
type	C537881
I	C537881
with	O
R124C	rs121909210
mutation	O
in	O
the	O
TGFBI	7045
(	O
BIGH3	7045
)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
,	O
ophthalmic	O
,	O
and	O
genetic	O
characteristics	O
for	O
lattice	C537881
corneal	C537881
dystrophy	C537881
type	C537881
I	C537881
(	O
LCDI	C537881
)	O
in	O
a	O
Chilean	O
family	O
.	O

METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
,	O
color	O
cornea	O
photography	O
,	O
applanation	O
tonography	O
,	O
and	O
fundoscopy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	C537881
corneal	C537881
dystrophy	C537881
type	C537881
I	C537881
.	O

Exon	O
4	O
of	O
the	O
transforming	7045
growth	7045
factor	7045
-	O
induced	7045
gene	7045
(	O
TGFBI	7045
)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
,	O
R124C	rs121909210
,	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O

We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
,	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	6690
restriction	O
enzyme	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O

RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	C537881
corneal	C537881
dystrophy	C537881
.	O

Six	O
participants	O
demonstrated	O
LCD1	C537881
in	O
both	O
eyes	O
,	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O

Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3	O
-	O
42	O
years	O
old	O
)	O
.	O

Moreover	O
,	O
in	O
this	O
family	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O

Visual	O
acuity	O
varied	O
from	O
1	O
.	O
0	O
to	O
0	O
.	O
13	O
.	O

Two	O
patients	9606
,	O
ages	O
69	O
and	O
44	O
years	O
old	O
,	O
demonstrated	O
a	O
degree	O
of	O
severity	O
""""	O
Bad	O
""""	O
according	O
to	O
best	O
-	O
corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O

The	O
exon	O
4	O
sequence	O
of	O
TGFBI	7045
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single	O
-	O
nucleotide	O
mutation	O
,	O
C417T	rs121909210
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
(	O
R124C	rs121909210
)	O
in	O
the	O
encoded	O
TGF	7045
-	O
induced	7045
protein	7045
.	O

Using	O
PCR	O
-	O
RFLP	O
,	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
R124C	rs121909210
mutation	O
in	O
TGFBI	7045
cosegregated	O
with	O
LCD	C537881
type	C537881
I	C537881
in	O
the	O
investigated	O
family	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	C537881
type	C537881
I	C537881
in	O
Chilean	O
patients	9606
.	O

The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O
A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	D018967
and	O
selective	D017367
serotonin	D017367
reuptake	D017367
inhibitors	D017367
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	D018967
-	O
induced	O
hyperprolactinemia	D006966
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O

METHOD	O
:	O
Medically	O
healthy	O
7	O
-	O
to	O
17	O
-	O
year	O
-	O
old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	D018967
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	9606
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O

Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O

The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
,	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O

Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
,	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O

RESULTS	O
:	O
Hyperprolactinemia	D006966
was	O
present	O
in	O
49%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	D018967
for	O
a	O
mean	O
of	O
2	O
.	O
9	O
years	O
.	O

Serum	O
testosterone	D013739
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	D006966
.	O

As	O
expected	O
,	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O

After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
,	O
serum	O
prolactin	5617
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.	O
03	O
)	O
.	O

Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	D017367
serotonin	D017367
reuptake	D017367
inhibitors	D017367
(	O
SSRIs	D017367
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.	O
03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non	O
-	O
Hispanic	O
white	O
patients	9606
.	O

Of	O
13	O
documented	O
fractures	D050723
,	O
3	O
occurred	O
after	O
risperidone	D018967
and	O
SSRIs	D017367
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	9606
with	O
hyperprolactinemia	D006966
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	D018967
-	O
induced	O
hyperprolactinemia	D006966
and	O
SSRI	D017367
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O

Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	D050723
rate	O
ensues	O
.	O
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	10090
pretreated	O
with	O
garcinielliptone	C573355
FC	C573355
in	O
pilocarpine	D010862
-	O
induced	O
seizures	D012640
.	O

Garcinielliptone	C573355
FC	C573355
(	O
GFC	C573355
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	198787
insignis	198787
Mart	198787
.	O

It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	D012871
diseases	D012871
in	O
both	O
humans	9606
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	D003967
and	O
inflammatory	D007249
diseases	D007249
.	O

However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	C573355
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	C573355
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	D012640
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	O
acid	O
(	O
r	D005680
-	O
aminobutyric	D005680
acid	D005680
(	O
GABA	D005680
)	O
,	O
glutamine	D018698
,	O
aspartate	D001224
and	O
glutathione	D005978
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	11423
(	O
AChE	11423
)	O
activity	O
in	O
mice	10090
hippocampus	O
after	O
seizures	D012640
.	O

GFC	C573355
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	D012640
,	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	10090
.	O

In	O
addition	O
,	O
GABA	D005680
content	O
of	O
mice	10090
hippocampus	O
treated	O
with	O
GFC75	C573355
plus	O
P400	D010862
showed	O
an	O
increase	O
of	O
46	O
.	O
90%	O
when	O
compared	O
with	O
seized	O
mice	10090
.	O

In	O
aspartate	D001224
,	O
glutamine	D018698
and	O
glutamate	D018698
levels	O
detected	O
a	O
decrease	O
of	O
5	O
.	O
21%	O
,	O
13	O
.	O
55%	O
and	O
21	O
.	O
80%	O
,	O
respectively	O
in	O
mice	10090
hippocampus	O
treated	O
with	O
GFC75	C573355
plus	O
P400	D010862
when	O
compared	O
with	O
seized	O
mice	10090
.	O

Hippocampus	O
mice	10090
treated	O
with	O
GFC75	C573355
plus	O
P400	D010862
showed	O
an	O
increase	O
in	O
AChE	11423
activity	O
(	O
63	O
.	O
30%	O
)	O
when	O
compared	O
with	O
seized	O
mice	10090
.	O

The	O
results	O
indicate	O
that	O
GFC	C573355
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	D010862
-	O
induced	O
status	D013226
epilepticus	D013226
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	D012640
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	C573355
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	D010862
model	O
by	O
modulating	O
the	O
GABA	D005680
and	O
glutamate	D018698
contents	O
and	O
of	O
AChE	11423
activity	O
in	O
seized	O
mice	10090
hippocampus	O
.	O

This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O
Gastrointestinal	D005768
hormones	D005768
/	O
neurotransmitters	D018377
and	O
growth	O
factors	O
can	O
activate	O
P21	29432
activated	29432
kinase	29432
2	29432
in	O
pancreatic	O
acinar	O
cells	O
by	O
novel	O
mechanisms	O
.	O

P	292756,29431,29432,29433,296078,311450
-	O
21	292756,29431,29432,29433,296078,311450
-	O
activated	292756,29431,29432,29433,296078,311450
kinases	292756,29431,29432,29433,296078,311450
(	O
PAKs	292756,29431,29432,29433,296078,311450
)	O
are	O
serine	292756,29431,29432,29433,296078,311450
/	O
threonine	292756,29431,29432,29433,296078,311450
kinases	292756,29431,29432,29433,296078,311450
comprising	O
six	O
isoforms	O
divided	O
in	O
two	O
groups	O
,	O
group	O
-	O
I	O
(	O
PAK1	29431,29432,29433
-	O
3	29431,29432,29433
)	O
/	O
group	O
-	O
II	O
(	O
PAK4	292756,296078,311450
-	O
6	292756,296078,311450
)	O
which	O
play	O
important	O
roles	O
in	O
cell	O
cytoskeletal	O
dynamics	O
,	O
survival	O
,	O
secretion	O
and	O
proliferation	O
and	O
are	O
activated	O
by	O
diverse	O
stimuli	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
PAKs	292756,29431,29432,29433,296078,311450
ability	O
to	O
be	O
activated	O
by	O
gastrointestinal	D005768
(	O
GI	D005768
)	O
hormones	D005768
/	O
neurotransmitters	D018377
/	O
growth	O
-	O
factors	O
.	O

We	O
used	O
rat	10116
pancreatic	O
acini	O
to	O
explore	O
the	O
ability	O
of	O
GI	D005768
-	O
hormones	D005768
/	O
neurotransmitters	D018377
/	O
growth	O
-	O
factors	O
to	O
activate	O
Group	29431,29432,29433
-	O
I	29431,29432,29433
-	O
PAKs	29431,29432,29433
and	O
the	O
signaling	O
cascades	O
involved	O
.	O

Only	O
PAK2	29432
was	O
present	O
in	O
acini	O
.	O

PAK2	29432
was	O
activated	O
by	O
some	O
pancreatic	25266,25313,54250
growth	25266,25313,54250
-	O
factors	25266,25313,54250
[	O
EGF	25313
,	O
PDGF	25266
,	O
bFGF	54250
]	O
,	O
by	O
secretagogues	O
activating	O
phospholipase	24655
-	O
C	24655
(	O
PLC	24655
)	O
[	O
CCK	25298
,	O
carbachol	D002217
,	O
bombesin	D001839
]	O
and	O
by	O
post	O
-	O
receptor	O
stimulants	O
activating	O
PKC	24681
[	O
TPA	D013755
]	O
,	O
but	O
not	O
agents	O
only	O
mobilizing	O
cellular	O
calcium	D002118
or	O
increasing	O
cyclic	D000242
AMP	D000242
.	O

CCK	25298
-	O
activation	O
of	O
PAK2	29432
required	O
both	O
high	O
-	O
and	O
low	O
-	O
affinity	O
-	O
CCK1	24889
-	O
receptor	24889
-	O
state	O
activation	O
.	O

It	O
was	O
partially	O
reduced	O
by	O
PKC	24681
-	O
or	O
Src	83805
-	O
inhibition	O
,	O
but	O
not	O
with	O
PI3K	298947
-	O
inhibitors	O
(	O
wortmannin	D000077191
,	O
LY294002	C085911
)	O
or	O
thapsigargin	D019284
.	O

IPA	C541795
-	O
3	C541795
,	O
which	O
prevents	O
PAK2	29432
binding	O
to	O
small	363875,64465
-	O
GTPases	363875,64465
partially	O
inhibited	O
PAK2	29432
-	O
activation	O
,	O
as	O
well	O
as	O
reduced	O
CCK	25298
-	O
induced	O
ERK1	116590,50689
/	O
2	116590,50689
activation	O
and	O
amylase	24203
release	O
induced	O
by	O
CCK	25298
or	O
bombesin	D001839
.	O

This	O
study	O
demonstrates	O
pancreatic	O
acini	O
,	O
possess	O
only	O
one	O
Group	29431,29432,29433
-	O
I	29431,29432,29433
-	O
PAK	29431,29432,29433
,	O
PAK2	29432
.	O

CCK	25298
and	O
other	O
GI	D005768
-	O
hormones	D005768
/	O
neurotransmitters	D018377
/	O
growth	O
-	O
factors	O
activate	O
PAK2	29432
via	O
small	363875,64465
GTPases	363875,64465
(	O
CDC42	64465
/	O
Rac1	363875
)	O
,	O
PKC	24681
and	O
SFK	83805
but	O
not	O
cytosolic	O
calcium	D002118
or	O
PI3K	298947
.	O

CCK	25298
-	O
activation	O
of	O
PAK2	29432
showed	O
several	O
novel	O
features	O
being	O
dependent	O
on	O
both	O
receptor	O
-	O
activation	O
states	O
,	O
having	O
PLC	24655
-	O
and	O
PKC	24681
-	O
dependent	O
/	O
independent	O
components	O
and	O
small	363875,64465
-	O
GTPase	363875,64465
-	O
dependent	O
/	O
independent	O
components	O
.	O

These	O
results	O
show	O
that	O
PAK2	29432
is	O
important	O
in	O
signaling	O
cascades	O
activated	O
by	O
numerous	O
pancreatic	O
stimuli	O
which	O
mediate	O
their	O
various	O
physiological	O
/	O
pathophysiological	O
responses	O
and	O
thus	O
could	O
be	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
therapies	O
in	O
some	O
pancreatic	D010182
disorders	D010182
such	O
as	O
pancreatitis	D010195
.	O

Evaluation	O
of	O
RGS4	5999
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	D012559
.	O

Several	O
studies	O
have	O
suggested	O
that	O
the	O
regulator	5999
of	5999
G	5999
-	O
protein	5999
signaling	5999
4	5999
(	O
RGS4	5999
)	O
may	O
be	O
a	O
positional	O
and	O
functional	O
candidate	O
gene	O
for	O
schizophrenia	D012559
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
located	O
at	O
the	O
promoter	O
region	O
(	O
SNP4	O
and	O
SNP7	O
)	O
and	O
the	O
intron	O
1	O
(	O
SNP18	O
)	O
of	O
RGS4	5999
have	O
been	O
verified	O
in	O
different	O
ethnic	O
groups	O
.	O

Positive	O
results	O
have	O
been	O
reported	O
in	O
these	O
SNPs	O
with	O
different	O
numbers	O
of	O
SNP	O
combinatory	O
haplotypes	O
.	O

In	O
this	O
study	O
,	O
these	O
three	O
SNP	O
markers	O
were	O
genotyped	O
in	O
218	O
schizophrenia	D012559
pedigrees	O
of	O
Taiwan	O
(	O
864	O
individuals	O
)	O
for	O
association	O
analysis	O
.	O

Among	O
these	O
three	O
SNPs	O
,	O
neither	O
SNP4	O
,	O
SNP7	O
,	O
SNP18	O
has	O
shown	O
significant	O
association	O
with	O
schizophrenia	D012559
in	O
single	O
locus	O
association	O
analysis	O
,	O
nor	O
any	O
compositions	O
of	O
the	O
three	O
SNP	O
haplotypes	O
has	O
shown	O
significantly	O
associations	O
with	O
the	O
DSM	O
-	O
IV	O
diagnosed	O
schizophrenia	D012559
.	O

Our	O
results	O
fail	O
to	O
support	O
the	O
RGS4	5999
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	D012559
when	O
evaluated	O
from	O
these	O
three	O
SNP	O
markers	O
.	O
Gastrointestinal	O
tolerability	O
of	O
etoricoxib	D000077613
in	O
rheumatoid	D001172
arthritis	D001172
patients	9606
:	O
results	O
of	O
the	O
etoricoxib	D000077613
vs	O
diclofenac	D004008
sodium	D004008
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	D000077613
and	O
diclofenac	D004008
in	O
patients	9606
with	O
rheumatoid	D001172
arthritis	D001172
(	O
RA	D001172
)	O
.	O

PATIENTS	9606
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	9606
(	O
mean	O
age	O
60	O
.	O
8	O
years	O
)	O
diagnosed	O
with	O
RA	D001172
were	O
enrolled	O
and	O
received	O
etoricoxib	D000077613
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	D004008
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	D001241
was	O
allowed	O
.	O

The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	9606
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	D005767
adverse	D005767
experiences	D005767
(	O
AEs	O
)	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	D002318
cardiovascular	D002318
event	O
data	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	9606
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
;	O
0	O
-	O
4	O
point	O
scale	O
)	O
.	O

RESULTS	O
:	O
Mean	O
(	O
SD	O
;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19	O
.	O
3	O
(	O
10	O
.	O
3	O
;	O
32	O
.	O
9	O
)	O
and	O
19	O
.	O
1	O
(	O
10	O
.	O
4	O
;	O
33	O
.	O
1	O
)	O
months	O
in	O
the	O
etoricoxib	D000077613
and	O
diclofenac	D004008
groups	O
,	O
respectively	O
.	O

The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	D005767
AEs	D005767
was	O
significantly	O
lower	O
with	O
etoricoxib	D000077613
than	O
diclofenac	D004008
(	O
5	O
.	O
2	O
vs	O
8	O
.	O
5	O
events	O
per	O
100	O
patient	9606
-	O
years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0	O
.	O
62	O
(	O
95%	O
CI	O
:	O
0	O
.	O
47	O
,	O
0	O
.	O
81	O
;	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
)	O
.	O

The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	D006973
-	O
related	O
and	O
oedema	D004487
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	D000077613
(	O
2	O
.	O
5%	O
and	O
1	O
.	O
1%	O
respectively	O
)	O
compared	O
with	O
diclofenac	D004008
(	O
1	O
.	O
5%	O
and	O
0	O
.	O
4%	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
for	O
hypertension	D006973
and	O
p	O
<	O
0	O
.	O
01	O
for	O
oedema	D004487
)	O
.	O

Etoricoxib	D000077613
and	O
diclofenac	D004008
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-	O
0	O
.	O
62	O
vs	O
-	O
0	O
.	O
58	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Etoricoxib	D000077613
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	D005767
AEs	D005767
compared	O
with	O
diclofenac	D004008
150	O
mg	O
.	O

Discontinuations	O
from	O
renovascular	O
AEs	O
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	D005767
AEs	D005767
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	D000077613
.	O
Putative	O
Prostate	D011471
Cancer	D011471
Risk	O
SNP	O
in	O
an	O
Androgen	367
Receptor	367
-	O
Binding	O
Site	O
of	O
the	O
Melanophilin	79083
Gene	O
Illustrates	O
Enrichment	O
of	O
Risk	O
SNPs	O
in	O
Androgen	367
Receptor	367
Target	O
Sites	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
genomic	O
loci	O
,	O
whose	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
predispose	O
to	O
prostate	D011471
cancer	D011471
(	O
PCa	D011471
)	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
most	O
of	O
these	O
variants	O
are	O
largely	O
unknown	O
.	O

We	O
integrated	O
chromatin	O
-	O
immunoprecipitation	O
-	O
coupled	O
sequencing	O
and	O
microarray	O
expression	O
profiling	O
in	O
TMPRSS2	7113
-	O
ERG	2078
gene	O
rearrangement	O
positive	O
DUCaP	9606
cells	O
with	O
the	O
GWAS	O
PCa	D011471
risk	O
SNPs	O
catalog	O
to	O
identify	O
disease	O
susceptibility	O
SNPs	O
localized	O
within	O
functional	O
androgen	367
receptor	367
-	O
binding	O
sites	O
(	O
ARBSs	367
)	O
.	O

Among	O
the	O
48	O
GWAS	O
index	O
risk	O
SNPs	O
and	O
3	O
,	O
917	O
linked	O
SNPs	O
,	O
80	O
were	O
found	O
located	O
in	O
ARBSs	367
.	O

Of	O
these	O
,	O
rs11891426	rs11891426
:	O
T	rs11891426
>	O
G	rs11891426
in	O
an	O
intron	O
of	O
the	O
melanophilin	79083
gene	O
(	O
MLPH	79083
)	O
was	O
within	O
a	O
novel	O
putative	O
auxiliary	O
AR	367
-	O
binding	O
motif	O
,	O
which	O
is	O
enriched	O
in	O
the	O
neighborhood	O
of	O
canonical	O
androgen	D000728
-	O
responsive	O
elements	O
.	O

T	rs11891426
>	O
G	rs11891426
exchange	O
attenuated	O
the	O
transcriptional	O
activity	O
of	O
the	O
ARBS	367
in	O
an	O
AR	367
reporter	O
gene	O
assay	O
.	O

The	O
expression	O
of	O
MLPH	79083
in	O
primary	O
prostate	D011471
tumors	D011471
was	O
significantly	O
lower	O
in	O
those	O
with	O
the	O
G	O
compared	O
with	O
the	O
T	O
allele	O
and	O
correlated	O
significantly	O
with	O
AR	367
protein	O
.	O

Higher	O
melanophilin	79083
level	O
in	O
prostate	O
tissue	O
of	O
patients	9606
with	O
a	O
favorable	O
PCa	D011471
risk	O
profile	O
points	O
out	O
a	O
tumor	D009369
-	O
suppressive	O
effect	O
.	O

These	O
results	O
unravel	O
a	O
hidden	O
link	O
between	O
AR	367
and	O
a	O
functional	O
putative	O
PCa	D011471
risk	O
SNP	O
,	O
whose	O
allele	O
alteration	O
affects	O
androgen	D000728
regulation	O
of	O
its	O
host	O
gene	O
MLPH	79083
.	O
Cultured	-
mycelium	-
Cordyceps	-
sinensis	-
protects	O
liver	O
sinusoidal	O
endothelial	O
cells	O
in	O
acute	O
liver	D008107
injured	D008107
mice	10090
.	O

Cultured	-
mycelium	-
Cordyceps	-
sinensis	-
(	O
CMCS	-
)	O
was	O
widely	O
used	O
for	O
a	O
variety	O
of	O
diseases	O
including	O
liver	D008107
injury	D008107
,	O
the	O
current	O
study	O
aims	O
to	O
investigate	O
the	O
protective	O
effects	O
of	O
CMCS	-
on	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSECs	O
)	O
in	O
acute	O
injury	D008107
liver	D008107
and	O
related	O
action	O
mechanisms	O
.	O

The	O
mice	10090
were	O
injected	O
intraperitoneally	O
with	O
lipopolysaccharide	D008070
(	O
LPS	D008070
)	O
and	O
D	D005688
-	O
galactosamine	D005688
(	O
D	D005688
-	O
GalN	D005688
)	O
.	O

39	O
male	O
BABL	10090
/	O
c	10090
mice	10090
were	O
randomly	O
divided	O
into	O
four	O
groups	O
:	O
normal	O
control	O
,	O
model	O
control	O
,	O
CMCS	-
treatment	O
and	O
1	C025205
,	O
10	C025205
-	O
phenanthroline	C025205
treatment	O
groups	O
.	O

The	O
Serum	O
liver	O
function	O
parameters	O
including	O
alanine	76282
aminotransferase	76282
(	O
ALT	76282
)	O
and	O
aspartate	14718
aminotransferase	14718
(	O
AST	14718
)	O
levels	O
were	O
assayed	O
with	O
the	O
commercial	O
kit	O
.	O

The	O
inflammation	D007249
and	O
scaffold	O
structure	O
in	O
liver	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
silver	O
staining	O
respectively	O
.	O

The	O
LSECs	O
and	O
sub	O
-	O
endothelial	O
basement	O
membrane	O
were	O
observed	O
with	O
the	O
scanning	O
and	O
transmission	O
electronic	O
microscope	O
.	O

The	O
protein	O
expressions	O
of	O
intercellular	15894
adhesion	15894
molecule	15894
-	O
1	15894
(	O
ICAM	15894
-	O
1	15894
)	O
and	O
vascular	22329
cell	22329
adhesion	22329
molecule	22329
-	O
1	22329
(	O
VCAM	22329
-	O
1	22329
)	O
in	O
liver	O
were	O
analyzed	O
with	O
Western	O
blotting	O
.	O

Expression	O
of	O
von	22371
Willebrand	22371
factor	22371
(	O
vWF	22371
)	O
was	O
investigated	O
with	O
immunofluorescence	O
staining	O
.	O

The	O
lipid	D008055
peroxidation	O
indicators	O
including	O
antisuperoxideanion	O
(	O
ASAFR	O
)	O
,	O
hydroxyl	D017665
free	D017665
radical	D017665
(	O
.	O
OH	D017665
)	O
,	O
superoxide	20655
dismutase	20655
(	O
SOD	20655
)	O
,	O
malondialdehyde	D008315
and	O
glutathione	54486
S	54486
-	O
transferase	54486
(	O
GST	14870
)	O
were	O
determined	O
with	O
kits	O
,	O
and	O
matrix	17390,17395
metalloproteinase	17390,17395
-	O
2	17390,17395
and	17390,17395
9	17390,17395
(	O
MMP	17390,17395
-	O
2	17390,17395
/	O
9	17390,17395
)	O
activities	O
in	O
liver	O
were	O
analyzed	O
with	O
gelatin	O
zymography	O
and	O
in	O
situ	O
fluorescent	O
zymography	O
respectively	O
.	O

The	O
model	O
mice	10090
had	O
much	O
higher	O
serum	O
levels	O
of	O
ALT	76282
and	O
AST	14718
than	O
the	O
normal	O
mice	10090
.	O

Compared	O
to	O
that	O
in	O
the	O
normal	O
control	O
,	O
more	O
severe	O
liver	D008107
inflammation	D008107
and	O
hepatocyte	O
apoptosis	O
,	O
worse	O
hepatic	O
lipid	D008055
peroxidation	O
demonstrated	O
by	O
the	O
increased	O
ASAFR	O
,	O
.	O
OH	D017665
and	O
MDA	D008315
,	O
but	O
decreased	O
SOD	20655
and	O
GST	54486
,	O
increased	O
MMP	17390,17395
-	O
2	17390,17395
/	O
9	17390,17395
activities	O
and	O
VCAM	22329
-	O
1	22329
,	O
ICAM	15894
-	O
1	15894
and	O
vWF	22371
expressions	O
,	O
which	O
revealed	O
obvious	O
LSEC	D008107
injury	D008107
and	O
scaffold	O
structure	O
broken	O
,	O
were	O
shown	O
in	O
the	O
model	O
control	O
.	O

Compared	O
with	O
the	O
model	O
group	O
,	O
CMCS	-
and	O
1	C025205
,	O
10	C025205
-	O
phenanthroline	C025205
significantly	O
improved	O
serum	O
ALT	76282
/	O
AST	14718
,	O
attenuated	O
hepatic	D008107
inflammation	D008107
and	O
improved	O
peroxidative	O
injury	D008107
in	D008107
liver	D008107
,	O
decreased	O
MMP	17390,17395
-	O
2	17390,17395
/	O
9	17390,17395
activities	O
in	O
liver	O
tissue	O
,	O
improved	O
integration	O
of	O
scaffold	O
structure	O
,	O
and	O
decreased	O
protein	O
expression	O
of	O
VCAM	22329
-	O
1	22329
and	O
ICAM	15894
-	O
1	15894
.	O

CMCS	-
could	O
protect	O
LSECs	D008107
from	D008107
injury	D008107
and	O
maintain	O
the	O
microvasculature	O
integration	O
in	O
acute	O
injured	D008107
liver	D008107
of	O
mice	10090
induced	O
by	O
LPS	D008070
/	O
D	D005688
-	O
GalN	D005688
.	O

Its	O
action	O
mechanism	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
MMP	17390,17395
-	O
2	17390,17395
/	O
9	17390,17395
activities	O
and	O
inhibition	O
of	O
peroxidation	O
in	O
injured	D008107
liver	D008107
.	O
Defining	O
an	O
EPOR	13857
-	O
regulated	O
transcriptome	O
for	O
primary	O
progenitors	O
,	O
including	O
Tnfr	72049
-	O
sf13c	72049
as	O
a	O
novel	O
mediator	O
of	O
EPO	13856
-	O
dependent	O
erythroblast	O
formation	O
.	O

Certain	O
concepts	O
concerning	O
EPO	13856
/	O
EPOR	13857
action	O
modes	O
have	O
been	O
challenged	O
by	O
in	O
vivo	O
studies	O
:	O
Bcl	12048
-	O
x	12048
levels	O
are	O
elevated	O
in	O
maturing	O
erythroblasts	O
,	O
but	O
not	O
in	O
their	O
progenitors	O
;	O
truncated	O
EPOR	13857
alleles	O
that	O
lack	O
a	O
major	O
p85	18708
/	O
PI3K	18708
recruitment	O
site	O
nonetheless	O
promote	O
polycythemia	D011086
;	O
and	O
Erk1	26417
disruption	O
unexpectedly	O
bolsters	O
erythropoiesis	O
.	O

To	O
discover	O
novel	O
EPO	13856
/	O
EPOR	13857
action	O
routes	O
,	O
global	O
transcriptome	O
analyses	O
presently	O
are	O
applied	O
to	O
interrogate	O
EPO	13856
/	O
EPOR	13857
effects	O
on	O
primary	O
bone	O
marrow	O
-	O
derived	O
CFUe	O
-	O
like	O
progenitors	O
.	O

Overall	O
,	O
160	O
EPO	13856
/	O
EPOR	13857
target	O
transcripts	O
were	O
significantly	O
modulated	O
2	O
-	O
to	O
21	O
.	O
8	O
-	O
fold	O
.	O

A	O
unique	O
set	O
of	O
EPO	13856
-	O
regulated	O
survival	O
factors	O
included	O
Lyl1	17095
,	O
Gas5	14455
,	O
Pim3	223775
,	O
Pim1	18712
,	O
Bim	12125
,	O
Trib3	228775
and	O
Serpina	20715
3g	20715
.	O

EPO	13856
/	O
EPOR	13857
-	O
modulated	O
cell	O
cycle	O
mediators	O
included	O
Cdc25a	12530
,	O
Btg3	12228
,	O
Cyclin	12444
-	O
d2	12444
,	O
p27	12576
-	O
kip1	12576
,	O
Cyclin	12452
-	O
g2	12452
and	O
CyclinB1	239083
-	O
IP	239083
-	O
1	239083
.	O

EPO	13856
regulation	O
of	O
signal	O
transduction	O
factors	O
was	O
also	O
interestingly	O
complex	O
.	O

For	O
example	O
,	O
not	O
only	O
Socs3	12702
plus	O
Socs2	216233
but	O
also	O
Spred2	114716
,	O
Spred1	114715
and	O
Eaf1	74427
were	O
EPO	13856
-	O
induced	O
as	O
negative	O
-	O
feedback	O
components	O
.	O

Socs2	216233
,	O
plus	O
five	O
additional	O
targets	O
,	O
further	O
proved	O
to	O
comprise	O
new	O
EPOR	13857
/	O
Jak2	16452
/	O
Stat5	20850
response	O
genes	O
(	O
which	O
are	O
important	O
for	O
erythropoiesis	O
during	O
anemia	D000740
)	O
.	O

Among	O
receptors	O
,	O
an	O
atypical	O
TNF	72049
-	O
receptor	72049
Tnfr	72049
-	O
sf13c	72049
was	O
up	O
-	O
modulated	O
>	O
5	O
-	O
fold	O
by	O
EPO	13856
.	O

Functionally	O
,	O
Tnfr	72049
-	O
sf13c	72049
ligation	O
proved	O
to	O
both	O
promote	O
proerythroblast	O
survival	O
,	O
and	O
substantially	O
enhance	O
erythroblast	O
formation	O
.	O

The	O
EPOR	13857
therefore	O
engages	O
a	O
sophisticated	O
set	O
of	O
transcriptome	O
response	O
circuits	O
,	O
with	O
Tnfr	72049
-	O
sf13c	72049
deployed	O
as	O
one	O
novel	O
positive	O
regulator	O
of	O
proerythroblast	O
formation	O
.	O
Novel	O
CRELD1	78987
gene	O
mutations	O
in	O
patients	9606
with	O
atrioventricular	C562831
septal	C562831
defect	C562831
.	O

BACKGROUND	O
:	O
Atrioventricular	C562831
septal	C562831
defects	C562831
(	O
AVSDs	C562831
)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
,	O
as	O
autosomal	D030342
dominant	D030342
defects	D030342
,	O
and	O
as	O
sporadically	O
occurring	O
malformations	D000013
.	O

Consequently	O
,	O
there	O
is	O
genetic	O
heterogeneity	O
,	O
but	O
until	O
recently	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	C562831
.	O

CRELD1	78987
gene	O
,	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	C562831
.	O

METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	9606
with	O
AVSD	C562831
and	O
200	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O

CRELD1	78987
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
specific	O
primers	O
.	O

The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	9606
and	O
controls	O
.	O

RESULTS	O
:	O
In	O
a	O
patient	9606
,	O
a	O
C	c|SUB|C|857|G
-	O
to	c|SUB|C|857|G
-	O
G	c|SUB|C|857|G
transition	c|SUB|C|857|G
was	c|SUB|C|857|G
identified	c|SUB|C|857|G
at	c|SUB|C|857|G
nucleotide	c|SUB|C|857|G
857	c|SUB|C|857|G
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	p|SUB|A|286|P
for	p|SUB|A|286|P
proline	p|SUB|A|286|P
at	p|SUB|A|286|P
amino	p|SUB|A|286|P
acid	p|SUB|A|286|P
286	p|SUB|A|286|P
in	O
the	O
first	O
calcium	D002118
-	O
binding	O
EGF	1950
domain	O
.	O

This	O
patient	9606
had	O
an	O
isolated	O
partial	O
AVSD	C562831
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O

Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	9606
with	O
a	O
partial	O
AVSD	C562831
and	O
evidence	O
of	O
Down	D004314
syndrome	D004314
.	O

The	O
heterozygous	O
c	rs755981922
.	O
973G	rs755981922
>	O
A	rs755981922
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	rs755981922
for	rs755981922
glutamic	rs755981922
acid	rs755981922
at	rs755981922
amino	rs755981922
acid	rs755981922
325	rs755981922
(	O
E325K	rs755981922
)	O
in	O
the	O
second	O
calcium	D002118
-	O
binding	O
EGF	1950
domain	O
.	O

CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	78987
mutations	O
were	O
identified	O
in	O
the	O
calcium	D002118
-	O
binding	O
EGF	1950
domain	O
in	O
patients	9606
with	O
AVSD	C562831
.	O

CRELD1	78987
is	O
likely	O
to	O
be	O
an	O
AVSD	C562831
-	O
susceptibility	O
gene	O
and	O
CRELD1	78987
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	D006331
defect	D006331
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O
The	O
differential	O
effects	O
of	O
bupivacaine	D002045
and	O
lidocaine	D008012
on	O
prostaglandin	5732
E2	5732
release	O
,	O
cyclooxygenase	4512,4513
gene	O
expression	O
and	O
pain	D010146
in	O
a	O
clinical	O
pain	D010146
model	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	D007249
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	D002045
on	O
local	O
prostaglandin	5732
E2	5732
(	O
PGE2	5732
)	O
production	O
and	O
cyclooxygenase	4512,4513
(	O
COX	4512,4513
)	O
gene	O
expression	O
that	O
increases	O
postoperative	D010149
pain	D010149
in	O
human	9606
subjects	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2%	O
lidocaine	D008012
or	O
0	O
.	O
5%	O
bupivacaine	D002045
before	O
surgery	O
and	O
either	O
rofecoxib	C116926
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	5732
and	O
thromboxane	D013929
B2	D013929
(	O
TXB2	D013929
)	O
measurements	O
.	O

RESULTS	O
:	O
The	O
bupivacaine	D002045
/	O
rofecoxib	C116926
group	O
reported	O
significantly	O
less	O
pain	D010146
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
bupivacaine	D002045
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	D010146
at	O
24	O
h	O
and	O
PGE2	5732
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O

Moreover	O
,	O
bupivacaine	D002045
significantly	O
increased	O
COX	4513
-	O
2	4513
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	D008012
/	O
placebo	O
group	O
.	O

Thromboxane	D013931
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX	4513
-	O
2	4513
,	O
but	O
not	O
COX	4512
-	O
1	4512
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	D002045
stimulates	O
COX	4513
-	O
2	4513
gene	O
expression	O
after	O
tissue	D017695
injury	D017695
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	5732
production	O
and	O
pain	D010146
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O
Syncope	D013575
and	O
QT	D008133
prolongation	D008133
among	O
patients	9606
treated	O
with	O
methadone	D008691
for	O
heroin	D006556
dependence	D006556
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

BACKGROUND	O
:	O
Methadone	D008691
is	O
prescribed	O
to	O
heroin	D006556
addicts	D006556
to	O
decrease	O
illicit	O
opioid	D000701
use	O
.	O

Prolongation	D008133
of	D008133
the	D008133
QT	D008133
interval	D008133
in	O
the	O
ECG	O
of	O
patients	9606
with	O
torsade	D016171
de	D016171
pointes	D016171
(	O
TdP	D016171
)	O
has	O
been	O
reported	O
in	O
methadone	D008691
users	O
.	O

As	O
heroin	D006556
addicts	D006556
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	D013575
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	D016171
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	D008691
.	O

METHODS	O
:	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	D006556
addicts	D006556
treated	O
with	O
methadone	D008691
or	O
buprenorphine	D002047
on	O
a	O
daily	O
basis	O
.	O

Of	O
the	O
patients	9606
at	O
the	O
Drug	O
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	O
52%	O
)	O
were	O
included	O
.	O

The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	O
ECGs	O
.	O

All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	D013575
.	O

The	O
association	O
between	O
opioid	D000701
dose	O
and	O
QT	O
,	O
and	O
methadone	D008691
dose	O
and	O
reporting	O
of	O
syncope	D013575
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Methadone	D008691
dose	O
was	O
associated	O
with	O
longer	D008133
QT	D008133
interval	D008133
of	O
0	O
.	O
140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

No	O
association	O
between	O
buprenorphine	D002047
and	O
QTc	O
was	O
found	O
.	O

Among	O
the	O
subjects	O
treated	O
with	O
methadone	D008691
,	O
28%	O
men	9606
and	O
32%	O
women	9606
had	O
prolonged	D008133
QTc	D008133
interval	D008133
.	O

None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	D002047
had	O
QTc	O
interval	O
>	O
0	O
.	O
440	O
s	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
.	O

A	O
50	O
mg	O
higher	O
methadone	D008691
dose	O
was	O
associated	O
with	O
a	O
1	O
.	O
2	O
(	O
95%	O
CI	O
1	O
.	O
1	O
to	O
1	O
.	O
4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	D013575
.	O

CONCLUSIONS	O
:	O
Methadone	D008691
is	O
associated	O
with	O
QT	D008133
prolongation	D008133
and	O
higher	O
reporting	O
of	O
syncope	D013575
in	O
a	O
population	O
of	O
heroin	D006556
addicts	D006556
.	O
Clusters	O
of	O
multidrug	O
-	O
resistant	O
Mycobacterium	1773
tuberculosis	1773
cases	O
,	O
Europe	O
.	O

Molecular	O
surveillance	O
of	O
multidrug	D018088
-	O
resistant	D018088
tuberculosis	D018088
(	O
MDR	D018088
TB	D018088
)	O
was	O
implemented	O
in	O
Europe	O
as	O
case	O
reporting	O
in	O
2005	O
.	O

For	O
all	O
new	O
MDR	D018088
TB	D018088
cases	O
detected	O
from	O
January	O
2003	O
through	O
June	O
2007	O
,	O
countries	O
reported	O
case	O
-	O
based	O
epidemiologic	O
data	O
and	O
DNA	O
fingerprint	O
patterns	O
of	O
MDR	D018088
TB	D018088
strains	O
when	O
available	O
.	O

International	O
clusters	O
were	O
detected	O
and	O
analyzed	O
.	O

From	O
2003	O
through	O
mid	O
-	O
2007	O
in	O
Europe	O
,	O
2	O
,	O
494	O
cases	O
of	O
MDR	D018088
TB	D018088
were	O
reported	O
from	O
24	O
European	O
countries	O
.	O

Epidemiologic	O
and	O
molecular	O
data	O
were	O
linked	O
for	O
593	O
(	O
39%	O
)	O
cases	O
,	O
and	O
672	O
insertion	O
sequence	O
6110	O
DNA	O
fingerprint	O
patterns	O
were	O
reported	O
from	O
19	O
countries	O
.	O

Of	O
these	O
patterns	O
,	O
288	O
(	O
43%	O
)	O
belonged	O
to	O
18	O
European	O
clusters	O
;	O
7	O
clusters	O
(	O
242	O
/	O
288	O
cases	O
,	O
84%	O
)	O
were	O
characterized	O
by	O
strains	O
of	O
the	O
Beijing	O
genotype	O
family	O
,	O
including	O
the	O
largest	O
cluster	O
(	O
175	O
/	O
288	O
cases	O
,	O
61%	O
)	O
.	O

Both	O
clustering	O
and	O
the	O
Beijing	O
genotype	O
were	O
associated	O
with	O
strains	O
originating	O
in	O
eastern	O
European	O
countries	O
.	O

Molecular	O
cluster	O
detection	O
contributes	O
to	O
identification	O
of	O
transmission	O
profile	O
,	O
risk	O
factors	O
,	O
and	O
control	O
measures	O
.	O
Association	O
study	O
of	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	1815
with	O
schizophrenia	D012559
,	O
depression	D003866
,	O
and	O
heroin	D006556
addiction	D006556
.	O

This	O
study	O
investigated	O
the	O
possible	O
association	O
between	O
three	O
functional	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
dopamine	1815
D4	1815
receptor	1815
(	O
DRD4	1815
)	O
gene	O
and	O
schizophrenia	D012559
,	O
depression	D003866
,	O
and	O
heroin	D006556
addiction	D006556
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
venous	O
blood	O
leukocytes	O
of	O
322	O
unrelated	O
patients	9606
with	O
schizophrenia	D012559
,	O
156	O
patients	9606
with	O
depression	D003866
,	O
300	O
patients	9606
with	O
heroin	D006556
addiction	D006556
,	O
and	O
300	O
healthy	O
unrelated	O
individuals	O
.	O

Polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	1815
(	O
-	O
120	c|DUP|-120||
bp	c|DUP|-120||
duplication	c|DUP|-120||
,	O
-	O
616C	rs747302
/	O
G	rs747302
,	O
and	O
-	O
521C	rs1800955
/	O
T	rs1800955
)	O
were	O
genotyped	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Genotype	O
and	O
allele	O
were	O
analyzed	O
using	O
SPSS	O
11	O
.	O
5	O
software	O
.	O

Results	O
of	O
this	O
analysis	O
indicated	O
that	O
there	O
is	O
a	O
strong	O
finding	O
of	O
-	O
120	c|DUP|-120||
bp	c|DUP|-120||
duplication	c|DUP|-120||
allele	O
frequencies	O
with	O
schizophrenia	D012559
(	O
p	O
=	O
0	O
.	O
008	O
)	O
and	O
weak	O
finding	O
with	O
-	O
1240	p|SUB|L|-1240|S
L	p|SUB|L|-1240|S
/	O
S	p|SUB|L|-1240|S
and	O
for	O
paranoid	D012563
schizophrenia	D012563
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O

Interestingly	O
,	O
there	O
is	O
a	O
stronger	O
finding	O
with	O
-	O
521	rs1800955
C	rs1800955
/	O
T	rs1800955
allele	O
frequencies	O
with	O
heroin	D006556
dependence	D006556
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
-	O
120	c|DUP|-120||
-	O
bp	c|DUP|-120||
duplication	c|DUP|-120||
polymorphism	O
of	O
DRD4	1815
is	O
associated	O
with	O
schizophrenia	D012559
and	O
that	O
the	O
-	O
521	rs1800955
C	rs1800955
/	O
T	rs1800955
polymorphism	O
is	O
associated	O
with	O
heroin	D006556
addiction	D006556
.	O
Lack	O
of	O
major	O
involvement	O
of	O
human	9606
uroplakin	11045,7380
genes	O
in	O
vesicoureteral	C564042
reflux	C564042
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O

BACKGROUND	O
:	O
Primary	O
vesicoureteral	C564042
reflux	C564042
(	O
VUR	C564042
)	O
is	O
a	O
hereditary	D030342
disorder	D030342
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O

It	O
affects	O
about	O
1%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	D030342
diseases	D030342
.	O

Its	O
associated	O
nephropathy	D007674
is	O
an	O
important	O
cause	O
of	O
end	D007676
-	O
stage	D007676
renal	D007676
failure	D007676
in	O
children	O
and	O
adults	O
.	O

Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	10090
uroplakin	22270
(	O
UP	22270
)	O
III	22270
gene	O
,	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial	O
-	O
specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
,	O
causes	O
VUR	C564042
and	O
hydronephrosis	D006869
.	O

METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	11045,7380
genes	O
might	O
play	O
a	O
role	O
in	O
human	9606
VUR	C564042
,	O
we	O
genotyped	O
all	O
four	O
UP	11045,7380
genes	O
in	O
76	O
patients	9606
with	O
radiologically	O
proven	O
primary	O
VUR	C564042
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O

RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
identified	O
,	O
seven	O
of	O
which	O
were	O
missense	O
,	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O

Since	O
healthy	O
relatives	O
of	O
the	O
VUR	C564042
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	C564042
,	O
we	O
used	O
a	O
population	O
of	O
90	O
race	O
-	O
matched	O
,	O
healthy	O
individuals	O
,	O
unrelated	O
to	O
the	O
VUR	C564042
patients	9606
,	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O

Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	C564042
.	O

However	O
,	O
SNP1	O
of	O
UP	11045
Ia	11045
gene	O
affecting	O
a	O
C	rs373513519
to	rs373513519
T	rs373513519
conversion	O
and	O
an	O
Ala7Val	rs373513519
change	O
,	O
and	O
SNP7	O
of	O
UP	7380
III	7380
affecting	O
a	O
C	c|SUB|C||G
to	c|SUB|C||G
G	c|SUB|C||G
conversion	O
and	O
a	O
Pro154Ala	p|SUB|P|154|A
change	O
,	O
were	O
marginally	O
associated	O
with	O
VUR	C564042
(	O
both	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
,	O
in	O
combination	O
with	O
the	O
first	O
set	O
,	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	7380
III	7380
SNP7	O
in	O
VUR	C564042
(	O
P	O
=	O
0	O
.	O
036	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs	O
.	O

controls	O
)	O
.	O

CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	11045,7380
genes	O
cannot	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	C564042
in	O
humans	9606
,	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O

The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	C564042
patients	9606
,	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	22270
III	22270
knockout	O
mice	10090
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	C564042
,	O
but	O
also	O
severe	O
hydronephrosis	D006869
and	O
neonatal	D066087
death	D066087
,	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	11045,7380
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	9606
.	O
Midline	O
B3	O
serotonin	D012701
nerves	O
in	O
rat	10116
medulla	O
are	O
involved	O
in	O
hypotensive	D007022
effect	O
of	O
methyldopa	D008750
.	O

Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	D008750
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	D012701
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	D007022
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	D012701
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

In	O
spontaneously	O
hypertensive	D006973
,	O
stroke	D020521
-	O
prone	O
rats	10116
,	O
microinjection	O
of	O
methyldopa	D008750
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	D012701
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	D007022
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	D012701
neurotoxin	O
5	D015116
,	O
7	D015116
-	O
dihydroxytryptamine	D015116
(	O
5	D015116
,	O
7	D015116
-	O
DHT	D015116
)	O
injected	O
intracerebroventricularly	O
.	O

However	O
,	O
intraspinal	O
injection	O
of	O
5	D015116
,	O
7	D015116
-	O
DHT	D015116
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	D012701
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	D007022
.	O

Further	O
,	O
5	D015116
,	O
7	D015116
-	O
DHT	D015116
lesion	O
of	O
serotonin	D012701
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	D012701
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	D012701
methyldopa	D008750
injection	O
.	O

It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	D008750
-	O
induced	O
hypotension	D007022
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	D012701
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	D007022
action	O
of	O
methyldopa	D008750
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O
A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers	D004535
-	O
Danlos	D004535
Syndrome	D004535
,	O
vascular	D004535
type	D004535
by	O
high	O
-	O
resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers	D004535
-	O
Danlos	D004535
syndrome	D004535
,	O
vascular	D004535
type	D004535
(	O
vEDS	D004535
)	O
(	O
MIM	D004535
#	O
130050	D004535
)	O
is	O
an	O
autosomal	D030342
dominant	D030342
disorder	D030342
caused	O
by	O
type	1281
III	1281
procollagen	1281
gene	O
(	O
COL3A1	1281
)	O
mutations	O
.	O

Most	O
COL3A1	1281
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient	9606
-	O
derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High	O
-	O
resolution	O
melting	O
curve	O
analysis	O
(	O
hrMCA	O
)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post	O
-	O
PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost	O
-	O
effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	1281
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	1281
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	D004535
patients	9606
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	1281
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	1281
mutations	O
,	O
including	O
one	O
deletion	O
(	O
c	c|DEL|2187|A
.	O
2187delA	c|DEL|2187|A
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
c	c|SUB|C|2992|T
.	O
2992C	c|SUB|C|2992|T
>	O
T	c|SUB|C|2992|T
)	O
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(	O
SAG	O
)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding	O
-	O
region	O
SNPs	O
(	O
rs1800255	rs1800255
:	O
G	rs1800255
>	O
A	rs1800255
,	O
rs1801184	rs1801184
:	O
T	rs1801184
>	O
C	rs1801184
,	O
and	O
rs2271683	rs2271683
:	O
A	rs2271683
>	O
G	rs2271683
)	O
in	O
COL3A1	1281
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	1281
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
COL3A1	1281
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O
Quinine	D011803
-	O
induced	O
arrhythmia	D001145
in	O
a	O
patient	O
with	O
severe	D016778
malaria	D016778
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	D016778
malaria	D016778
patient	O
with	O
jaundice	D007565
who	O
presented	O
with	O
arrhythmia	D001145
(	O
premature	D018879
ventricular	D018879
contraction	D018879
)	O
while	O
getting	O
quinine	D011803
infusion	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	D005334
,	O
chill	D023341
,	O
vomiting	D014839
,	O
jaundice	D007565
.	O

The	O
patient	O
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	5833
falciparum	5833
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	D001663
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	D001663
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	D001663
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potassium	D011188
3	O
.	O
52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	D016778
malaria	D016778
with	O
jaundice	D007565
and	O
got	O
quinine	D011803
infusion	O
in	O
dextrose	D005947
5%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	D014839
,	O
diarrhea	D003967
,	O
tinnitus	D014012
,	O
loss	D034381
of	D034381
hearing	D034381
.	O

After	O
30	O
hours	O
of	O
quinine	D011803
infusion	O
the	O
patient	O
felt	O
palpitation	D006331
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	D018879
ventricular	D018879
contraction	D018879
(	O
PVC	D018879
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
-	O
-	O
sinoatrial	D012848
block	D012848
,	O
positive	O
U	O
wave	O
.	O

He	O
was	O
treated	O
with	O
lidocaine	D008012
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	D005947
5%	O
/	O
24	O
hour	O
and	O
potassium	D001224
aspartate	D001224
tablet	O
.	O

Quinine	D011803
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	D011803
tablets	O
.	O

Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	D018879
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	D011188
level	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O

He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O

Quinine	D011803
,	O
like	O
quinidine	D011802
,	O
is	O
a	O
chincona	-
alkaloid	-
that	O
has	O
anti	O
-	O
arrhythmic	D001145
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	D001145
that	O
can	O
cause	O
various	O
arrhythmias	D001145
,	O
including	O
severe	O
arrhythmia	D001145
such	O
as	O
multiple	O
PVC	D018879
.	O

Administration	O
of	O
parenteral	O
quinine	D011803
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	D001145
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	D006331
diseases	D006331
or	O
patients	O
with	O
electrolyte	D014883
disorder	D014883
(	O
hypokalemia	D007008
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	D014839
and	O
or	O
diarrhea	D003967
in	O
malaria	D008288
cases	O
.	O
Low	O
frequency	O
of	O
deafness	D003638
-	O
associated	O
GJB2	2706
variants	O
in	O
Kenya	O
and	O
Sudan	O
and	O
novel	O
GJB2	2706
variants	O
.	O

A	O
large	O
proportion	O
of	O
non	C567134
-	O
syndromic	C567134
autosomal	C567134
recessive	C567134
deafness	C567134
(	O
NSARD	C567134
)	O
in	O
many	O
populations	O
is	O
caused	O
by	O
variants	O
of	O
the	O
GJB2	2706
gene	O
.	O

Here	O
,	O
the	O
frequency	O
of	O
GJB2	2706
variants	O
was	O
studied	O
in	O
406	O
and	O
183	O
apparently	O
unrelated	O
children	O
from	O
Kenya	O
and	O
Sudan	O
,	O
respectively	O
,	O
with	O
mostly	O
severe	O
to	O
profound	O
non	D003638
-	O
syndromic	D003638
deafness	D003638
.	O

Nine	O
(	O
2	O
.	O
2	O
%	O
)	O
Kenyan	O
and	O
12	O
(	O
6	O
.	O
6	O
%	O
)	O
of	O
the	O
Sudanese	O
children	O
only	O
were	O
carriers	O
of	O
variants	O
within	O
the	O
coding	O
sequence	O
of	O
the	O
GJB2	2706
gene	O
.	O

Variants	O
in	O
the	O
5	O
'	O
-	O
adjacent	O
region	O
were	O
detected	O
in	O
further	O
115	O
individuals	O
.	O

A	O
total	O
of	O
10	O
novel	O
variants	O
was	O
recognized	O
,	O
among	O
them	O
four	O
variants	O
in	O
the	O
adjacent	O
5	O
'	O
-	O
region	O
of	O
the	O
GJB2	2706
coding	O
exon	O
2	O
(	O
g	g|SUB|T|3318-6|A
.	O
3318	g|SUB|T|3318-6|A
-	O
6T	g|SUB|T|3318-6|A
>	O
A	g|SUB|T|3318-6|A
,	O
g	g|SUB|C|3318-15|T
.	O
3318	g|SUB|C|3318-15|T
-	O
15C	g|SUB|C|3318-15|T
>	O
T	g|SUB|C|3318-15|T
,	O
g	g|SUB|C|3318-34|T
.	O
3318	g|SUB|C|3318-34|T
-	O
34C	g|SUB|C|3318-34|T
>	O
T	g|SUB|C|3318-34|T
,	O
g	g|SUB|T|3318-35|G
.	O
3318	g|SUB|T|3318-35|G
-	O
35T	g|SUB|T|3318-35|G
>	O
G	g|SUB|T|3318-35|G
)	O
,	O
a	O
6	O
base	O
-	O
pair	O
deletion	O
(	O
g	g|DEL|3455_3460|
.	O
3455_3460del	g|DEL|3455_3460|
[	O
p	p|INDEL|46_48|Glu
.	O
Asp46_Gln48delinsGlu	p|INDEL|46_48|Glu
]	O
)	O
,	O
a	O
variant	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
g	rs763572195
.	O
3512C	rs763572195
>	O
A	rs763572195
[	O
p	rs763572195
.	O
Tyr65X	rs763572195
]	O
)	O
,	O
synonymous	O
variants	O
(	O
g	g|SUB|C|3395|T
.	O
3395C	g|SUB|C|3395|T
>	O
T	g|SUB|C|3395|T
[	O
p	p|Allele|T|26
.	O
Thr26	p|Allele|T|26
]	O
,	O
g	g|SUB|C|3503|T
.	O
3503C	g|SUB|C|3503|T
>	O
T	g|SUB|C|3503|T
[	O
p	p|Allele|N|62
.	O
Asn62	p|Allele|N|62
]	O
,	O
g	g|SUB|A|3627|C
.	O
3627A	g|SUB|A|3627|C
>	O
C	g|SUB|A|3627|C
[	O
p	p|Allele|R|104
.	O
Arg104	p|Allele|R|104
]	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
variant	O
(	O
g	rs111033360
.	O
3816C	rs111033360
>	O
A	rs111033360
[	O
p	rs111033360
.	O
Val167Met	rs111033360
]	O
)	O
.	O

In	O
addition	O
,	O
the	O
previously	O
described	O
variants	O
g	g|DEL|3352|G
.	O
3352delG	g|DEL|3352|G
(	O
commonly	O
designated	O
30delG	c|DEL|30|G
or	O
35	c|DEL|35|G
delG	c|DEL|35|G
)	O
,	O
g	rs72474224
.	O
3426G	rs72474224
>	O
A	rs72474224
[	O
p	rs72474224
.	O
Val37Ile	rs72474224
]	O
,	O
g	rs111033196
.	O
3697G	rs111033196
>	O
A	rs111033196
[	O
p	rs111033196
.	O
Arg127His	rs111033196
]	O
,	O
g	rs111033186
.	O
3774G	rs111033186
>	O
A	rs111033186
[	O
p	rs111033186
.	O
Val153Ile	rs111033186
]	O
,	O
and	O
g	rs34988750
.	O
3795G	rs34988750
>	O
A	rs34988750
[	O
p	rs34988750
.	O
Gly160Ser	rs34988750
]	O
were	O
identified	O
.	O

With	O
the	O
exception	O
of	O
g	g|SUB|C|3318-34|T
.	O
3318	g|SUB|C|3318-34|T
-	O
34C	g|SUB|C|3318-34|T
>	O
T	g|SUB|C|3318-34|T
and	O
g	g|DEL|3352|G
.	O
3352delG	g|DEL|3352|G
,	O
all	O
variants	O
occurred	O
heterozygously	O
.	O

For	O
most	O
of	O
the	O
variants	O
identified	O
in	O
the	O
Kenyan	O
and	O
Sudanese	O
study	O
population	O
,	O
a	O
causative	O
association	O
with	O
NSARD	C567134
appears	O
to	O
be	O
unlikely	O
.	O

Compared	O
to	O
many	O
other	O
ethnic	O
groups	O
,	O
deafness	D003638
-	O
associated	O
variants	O
of	O
the	O
coding	O
region	O
of	O
GJB2	2706
are	O
rare	O
in	O
Sudan	O
and	O
Kenya	O
,	O
suggesting	O
a	O
role	O
of	O
other	O
genetic	O
,	O
or	O
epigenetic	O
factors	O
as	O
a	O
cause	O
for	O
deafness	D003638
in	O
these	O
countries	O
.	O
A	O
novel	O
point	O
mutation	O
in	O
helix	O
10	O
of	O
the	O
human	9606
glucocorticoid	2908
receptor	2908
causes	O
generalized	O
glucocorticoid	C564221
resistance	C564221
by	O
disrupting	O
the	O
structure	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
.	O

CONTEXT	O
:	O
Generalized	O
glucocorticoid	C564221
resistance	C564221
syndrome	O
is	O
a	O
rare	O
familial	O
or	O
sporadic	O
condition	O
characterized	O
by	O
partial	O
insensitivity	O
to	O
glucocorticoids	D005938
,	O
caused	O
by	O
mutations	O
in	O
the	O
glucocorticoid	2908
receptor	2908
(	O
GR	2908
)	O
gene	O
.	O

Most	O
of	O
the	O
reported	O
cases	O
are	O
adults	O
,	O
demonstrating	O
symptoms	O
associated	O
with	O
mineralocorticoid	D008901
and	O
/	O
or	O
adrenal	O
androgen	D000728
excess	O
caused	O
by	O
compensatively	O
increased	O
secretion	O
of	O
the	O
adrenocorticotropic	O
hormone	O
.	O

PATIENT	9606
:	O
We	O
identified	O
a	O
new	O
2	O
-	O
yr	O
-	O
old	O
female	O
case	O
of	O
generalized	O
glucocorticoid	C564221
resistance	C564221
syndrome	O
.	O

The	O
patient	9606
(	O
TJ	O
)	O
presented	O
with	O
a	O
generalized	O
seizure	D012640
associated	O
with	O
hypoglycemia	D007003
and	O
hypokalemia	D007008
.	O

She	O
also	O
had	O
hypertension	D006973
and	O
premature	C567552
pubarche	C567552
,	O
whereas	O
dexamethasone	D003907
effectively	O
suppressed	O
these	O
clinical	O
manifestations	O
.	O

RESULTS	O
:	O
The	O
patient	9606
'	O
s	O
GR	2908
gene	O
had	O
a	O
heterozygotic	O
mutation	O
(	O
G	c|SUB|G|2141|A
-	O
-	O
>	O
A	c|SUB|G|2141|A
)	O
at	c|SUB|G|2141|A
nucleotide	c|SUB|G|2141|A
position	c|SUB|G|2141|A
2141	c|SUB|G|2141|A
(	O
exon	O
8	O
)	O
,	O
which	O
resulted	O
in	O
substitution	O
of	O
arginine	c|SUB|R|714|Q
by	c|SUB|R|714|Q
glutamine	c|SUB|R|714|Q
at	c|SUB|R|714|Q
amino	c|SUB|R|714|Q
acid	c|SUB|R|714|Q
position	c|SUB|R|714|Q
714	c|SUB|R|714|Q
in	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
the	O
GR	2908
alpha	2908
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
mutant	O
receptor	O
had	O
significantly	O
impaired	O
transactivation	O
activity	O
with	O
a	O
2	O
-	O
fold	O
reduction	O
in	O
affinity	O
to	O
ligand	O
.	O

It	O
showed	O
attenuated	O
transactivation	O
of	O
the	O
activation	O
function	O
(	O
AF	O
)	O
-	O
2	O
and	O
reduced	O
binding	O
to	O
a	O
p160	8648
nuclear	8648
receptor	8648
coactivator	8648
.	O

Computer	O
-	O
based	O
structural	O
analysis	O
revealed	O
that	O
replacement	O
of	O
arginine	c|SUB|R|714|Q
by	c|SUB|R|714|Q
glutamine	c|SUB|R|714|Q
at	c|SUB|R|714|Q
position	c|SUB|R|714|Q
714	c|SUB|R|714|Q
transmitted	O
a	O
conformational	O
change	O
to	O
the	O
LBD	O
and	O
the	O
AF	O
-	O
2	O
transactivation	O
surface	O
,	O
resulting	O
in	O
a	O
decreased	O
binding	O
affinity	O
to	O
ligand	O
and	O
to	O
the	O
LXXLL	O
coactivator	O
motif	O
.	O

CONCLUSIONS	O
:	O
Dexamethasone	D003907
treatment	O
is	O
effective	O
in	O
controlling	O
the	O
premature	C567552
pubarche	C567552
,	O
hypoglycemia	D007003
,	O
hypertension	D006973
,	O
and	O
hypokalemia	D007008
in	O
this	O
child	O
case	O
,	O
wherein	O
arginine	c|Allele|R|714
714	c|Allele|R|714
plays	O
a	O
key	O
role	O
in	O
the	O
proper	O
formation	O
of	O
the	O
ligand	O
-	O
binding	O
pocket	O
and	O
the	O
AF	O
-	O
2	O
surface	O
of	O
the	O
GR	2908
alpha	2908
LBD	O
.	O
Inactivation	O
of	O
Sag	19823
/	O
Rbx2	19823
/	O
Roc2	19823
e3	19823
ubiquitin	19823
ligase	19823
triggers	O
senescence	O
and	O
inhibits	O
kras	16653
-	O
induced	O
immortalization	O
.	O

Our	O
recent	O
study	O
showed	O
that	O
SAG	19823
/	O
RBX2	19823
E3	19823
ubiquitin	19823
ligase	19823
regulates	O
apoptosis	O
and	O
vasculogenesis	O
by	O
promoting	O
degradation	O
of	O
NOXA	58801
and	O
NF1	18015
,	O
and	O
co	O
-	O
operates	O
with	O
Kras	16653
to	O
promote	O
lung	D008175
tumorigenesis	D008175
by	O
activating	O
NFkappaB	18033
and	O
mTOR	56717
pathways	O
via	O
targeted	O
degradation	O
of	O
tumor	D009369
suppressive	O
substrates	O
including	O
IkappaB	18033
,	O
DEPTOR	97998
,	O
p21	12575
and	O
p27	12576
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
Sag	19823
/	O
Rbx2	19823
E3	19823
ligase	19823
in	O
cellular	O
senescence	O
and	O
immortalization	O
of	O
mouse	10090
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
report	O
that	O
Sag	19823
is	O
required	O
for	O
proper	O
cell	O
proliferation	O
and	O
Kras	16653
(	O
G12D	rs121913529
)	O
-	O
induced	O
immortalization	O
.	O

Sag	19823
inactivation	O
by	O
genetic	O
deletion	O
remarkably	O
suppresses	O
cell	O
proliferation	O
by	O
inducing	O
senescence	O
,	O
which	O
is	O
associated	O
with	O
accumulation	O
of	O
p16	12578
,	O
but	O
not	O
p53	22059
.	O

Mechanistically	O
,	O
Sag	19823
deletion	O
caused	O
accumulation	O
of	O
Jun	16477
-	O
B	16477
,	O
a	O
substrate	O
of	O
Sag	19823
-	O
Fbxw7	50754
E3	19823
ligase	19823
and	O
a	O
transcription	O
factor	O
that	O
drives	O
p16	12578
transcription	O
.	O

Importantly	O
,	O
senescence	O
triggered	O
by	O
Sag	19823
deletion	O
can	O
be	O
largely	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	12578
,	O
the	O
p16	12578
encoding	O
gene	O
,	O
indicating	O
its	O
causal	O
role	O
.	O

Furthermore	O
,	O
Kras	16653
(	O
G12D	rs121913529
)	O
-	O
induced	O
immortalization	O
can	O
also	O
be	O
abrogated	O
by	O
Sag	19823
deletion	O
via	O
senescence	O
induction	O
,	O
which	O
is	O
again	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	12578
.	O

Finally	O
,	O
we	O
found	O
that	O
Sag	19823
deletion	O
inactivates	O
Kras	16653
(	O
G12D	rs121913529
)	O
activity	O
and	O
block	O
the	O
MAPK	26413
signaling	O
pathway	O
,	O
together	O
with	O
accumulated	O
p16	12578
,	O
to	O
induce	O
senescence	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
Sag	19823
is	O
a	O
Kras	16653
(	O
G12D	rs121913529
)	O
-	O
cooperating	O
oncogene	O
required	O
for	O
Kras	16653
(	O
G12D	rs121913529
)	O
-	O
induced	O
immortalization	O
and	O
transformation	O
,	O
and	O
targeting	O
SAG	19823
-	O
SCF	50754
E3	19823
ligase	19823
may	O
,	O
therefore	O
,	O
have	O
therapeutic	O
value	O
for	O
senescence	O
-	O
based	O
cancer	D009369
treatment	O
.	O
In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	D014640
-	O
induced	O
nephrotoxicity	D007674
:	O
protection	O
by	O
erdosteine	C048498
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	D014640
(	O
VCM	D014640
)	O
-	O
induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	D017382
oxygen	D017382
species	D017382
(	O
ROS	D017382
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	C048498
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	D000975
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	D014640
-	O
induced	O
renal	D007674
impairment	D007674
in	O
rats	10116
.	O

Rats	10116
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	D014640
and	O
VCM	D014640
plus	O
erdosteine	C048498
.	O

VCM	D014640
was	O
administrated	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O

Erdosteine	C048498
was	O
administered	O
orally	O
.	O

VCM	D014640
administration	O
to	O
control	O
rats	10116
significantly	O
increased	O
renal	O
malondialdehyde	D008315
(	O
MDA	D008315
)	O
and	O
urinary	O
N	154968
-	O
acetyl	154968
-	O
beta	154968
-	O
d	154968
-	O
glucosaminidase	154968
(	O
NAG	154968
,	O
a	O
marker	O
of	O
renal	D007674
tubular	D007674
injury	D007674
)	O
excretion	O
but	O
decreased	O
superoxide	D013482
dismutase	D013482
(	O
SOD	D013482
)	O
and	O
catalase	24248
(	O
CAT	24248
)	O
activities	O
.	O

Erdosteine	C048498
administration	O
with	O
VCM	D014640
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	D008315
and	O
urinary	O
NAG	154968
excretion	O
,	O
and	O
increased	O
SOD	D013482
activity	O
,	O
but	O
not	O
CAT	24248
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	D014640
alone	O
.	O

Erdosteine	C048498
showed	O
histopathological	O
protection	O
against	O
VCM	D014640
-	O
induced	O
nephrotoxicity	D007674
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	D001284
,	O
desquamation	D012871
,	O
and	O
necrosis	D009336
in	O
VCM	D014640
-	O
treated	O
rats	10116
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	C048498
groups	O
.	O

Erdosteine	C048498
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	D014640
-	O
induced	O
nephrotoxicity	D007674
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	C048498
reduces	O
the	O
VCM	D014640
-	O
induced	O
kidney	D007674
damage	D007674
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O
Bone	652
morphogenetic	652
protein	652
-	O
4	652
interacts	O
with	O
activin	3624,83729
and	O
GnRH	14714
to	O
modulate	O
gonadotrophin	12640,14308
secretion	O
in	O
LbetaT2	10090
gonadotrophs	O
.	O

We	O
have	O
shown	O
previously	O
that	O
,	O
in	O
sheep	9940
primary	O
pituitary	O
cells	O
,	O
bone	443502
morphogenetic	443502
proteins	443502
(	O
BMP	443502
)	O
-	O
4	443502
inhibits	O
FSHbeta	443387
mRNA	O
expression	O
and	O
FSH	443387,443538
release	O
.	O

In	O
contrast	O
,	O
in	O
mouse	10090
LbetaT2	10090
gonadotrophs	O
,	O
others	O
have	O
shown	O
a	O
stimulatory	O
effect	O
of	O
BMPs	652
on	O
basal	O
or	O
activin	16323
-	O
stimulated	O
FSHbeta	14308
promoter	O
-	O
driven	O
transcription	O
.	O

As	O
a	O
species	O
comparison	O
with	O
our	O
previous	O
results	O
,	O
we	O
used	O
LbetaT2	10090
cells	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	652
-	O
4	652
on	O
gonadotrophin	12640,14308
mRNA	O
and	O
secretion	O
modulated	O
by	O
activin	16323
and	O
GnRH	14714
.	O

BMP	652
-	O
4	652
alone	O
had	O
no	O
effect	O
on	O
FSH	443387,443538
production	O
,	O
but	O
enhanced	O
the	O
activin	16323
+	O
GnRH	14714
-	O
induced	O
stimulation	O
of	O
FSHbeta	14308
mRNA	O
and	O
FSH	443387,443538
secretion	O
,	O
without	O
any	O
effect	O
on	O
follistatin	14313
mRNA	O
.	O

BMP	652
-	O
4	652
reduced	O
LHbeta	16866
mRNA	O
up	O
-	O
regulation	O
in	O
response	O
to	O
GnRH	14714
(	O
+	O
/	O
-	O
activin	16323
)	O
and	O
decreased	O
GnRH	14715
receptor	14715
expression	O
,	O
which	O
would	O
favour	O
FSH	443387,443538
,	O
rather	O
than	O
LH	12640,16866
,	O
synthesis	O
and	O
secretion	O
.	O

In	O
contrast	O
to	O
sheep	9940
pituitary	O
gonadotrophs	O
,	O
which	O
express	O
only	O
BMP	101103793,101112282
receptor	101103793,101112282
types	101103793,101112282
IA	101103793,101112282
(	O
BMPRIA	101103793,101112282
)	O
and	101103793,101112282
II	101103793,101112282
(	O
BMPRII	101103793,101112282
)	O
,	O
LbetaT2	10090
cells	O
also	O
express	O
BMPRIB	12167
.	O

Smad1	17125,17129
/	O
5	17125,17129
phosphorylation	O
induced	O
by	O
BMP	652
-	O
4	652
,	O
indicating	O
activation	O
of	O
BMP	12159
signalling	O
,	O
was	O
the	O
same	O
whether	O
BMP	652
-	O
4	652
was	O
used	O
alone	O
or	O
combined	O
with	O
activin	16323
+	O
/	O
-	O
GnRH	14714
.	O

We	O
hypothesized	O
that	O
activin	16323
and	O
/	O
or	O
GnRH	14714
pathways	O
may	O
be	O
modulated	O
by	O
BMP	652
-	O
4	652
,	O
but	O
neither	O
the	O
activin	16323
-	O
stimulated	O
phosphorylation	O
of	O
Smad2	17126,17127
/	O
3	17126,17127
nor	O
the	O
GnRH	14714
-	O
induced	O
ERK1	26413,26417
/	O
2	26413,26417
or	O
cAMP	12912
response	12912
element	12912
-	O
binding	12912
phosphorylation	O
were	O
modified	O
.	O

However	O
,	O
the	O
GnRH	14714
-	O
induced	O
activation	O
of	O
p38	26416
MAPK	26416
was	O
decreased	O
by	O
BMP	652
-	O
4	652
.	O

This	O
was	O
associated	O
with	O
increased	O
FSHbeta	14308
mRNA	O
levels	O
and	O
FSH	443387,443538
secretion	O
,	O
but	O
decreased	O
LHbeta	16866
mRNA	O
levels	O
.	O

These	O
results	O
confirm	O
1	O
.	O

BMPs	652
as	O
important	O
modulators	O
of	O
activin	16323
and	O
/	O
or	O
GnRH	14714
-	O
stimulated	O
gonadotrophin	12640,14308
synthesis	O
and	O
release	O
and	O
2	O
.	O

important	O
species	O
differences	O
in	O
these	O
effects	O
,	O
which	O
could	O
relate	O
to	O
differences	O
in	O
BMP	101103793,101112282,12167
receptor	101103793,101112282,12167
expression	O
in	O
gonadotrophs	O
.	O
Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	3172
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	D003924
2	D003924
diabetes	D003924
mellitus	D003924
:	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O

Hepatocyte	3172
nuclear	3172
factor	3172
4alpha	3172
(	O
HNF4alpha	3172
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	9606
liver	O
and	O
pancreatic	O
islets	O
.	O

We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
HNF4A	3172
,	O
encoding	O
HNF4alpha	3172
,	O
influenced	O
the	O
conversion	O
from	O
impaired	D018149
glucose	D018149
tolerance	D018149
(	O
IGT	D018149
)	O
to	O
type	D003924
2	D003924
diabetes	D003924
mellitus	D003924
in	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O

This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	D020909
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	D003924
2	D003924
diabetes	D003924
mellitus	D003924
.	O

Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	3172
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O

Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	rs4810424
,	O
rs1884614	rs1884614
,	O
and	O
rs2144908	rs2144908
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D	O
'	O
>	O
0	O
.	O
97	O
,	O
r	O
(	O
2	O
)	O
>	O
0	O
.	O
95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	rs4810424
was	O
included	O
in	O
further	O
analyses	O
.	O

Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	rs4810424
had	O
a	O
1	O
.	O
7	O
-	O
fold	O
elevated	O
risk	O
[	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
09	O
-	O
2	O
.	O
66	O
;	O
P	O
=	O
0	O
.	O
020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	D003920
compared	O
to	O
women	9606
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	D020909
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O

No	O
association	O
was	O
found	O
in	O
men	9606
.	O

Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	rs4810424
,	O
rs2071197	rs2071197
,	O
and	O
rs3818247	rs3818247
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	D003924
2	D003924
diabetes	D003924
mellitus	D003924
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	9606
.	O

Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	3172
and	O
their	O
haplotypes	O
predispose	O
to	O
type	D003924
2	D003924
diabetes	D003924
mellitus	D003924
in	O
female	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
study	O
population	O
.	O
Identification	O
of	O
three	O
F5	2153
gene	O
mutations	O
associated	O
with	O
inherited	D005166
coagulation	D005166
factor	D005166
V	D005166
deficiency	D005166
in	O
two	O
Chinese	O
pedigrees	O
.	O

To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	D005166
factor	D005166
V	D005166
(	O
FV	D005166
)	O
deficiency	D005166
.	O

A	O
37	O
-	O
year	O
-	O
old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	D005166
coagulation	D005166
FV	D005166
deficiency	D005166
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	2153
activity	O
and	O
antigen	O
.	O

All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	2153
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O

The	O
homozygous	O
deletion	O
IVS8	c|SUB|A|IVS8-2|G
-	O
2A	c|SUB|A|IVS8-2|G
>	O
G	c|SUB|A|IVS8-2|G
was	O
identified	O
in	O
the	O
F5	2153
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O

The	O
insertion	p|INS||8
introduced	p|INS||8
eight	p|INS||8
additional	p|INS||8
amino	p|INS||8
acids	p|INS||8
(	O
AA	O
)	O
into	O
the	O
FV	2153
protein	O
.	O

Two	O
heterozygous	O
mutations	O
of	O
F5	2153
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O

The	O
2238	c|DEL|2238_2239|AG
-	O
9del	c|DEL|2238_2239|AG
AG	c|DEL|2238_2239|AG
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	c|Allele|A|689
AA	c|Allele|A|689
and	O
the	O
substitution	O
of	O
G6410	g|SUB|G|6410|T
by	g|SUB|G|6410|T
T	g|SUB|G|6410|T
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	p|SUB|G|2079|V
.	O

Three	O
F5	2153
gene	O
mutations	O
,	O
IVS8	c|SUB|A|IVS8-2|G
-	O
2A	c|SUB|A|IVS8-2|G
>	O
G	c|SUB|A|IVS8-2|G
,	O
2238	c|DEL|2238_2239|AG
-	O
9del	c|DEL|2238_2239|AG
AG	c|DEL|2238_2239|AG
and	O
G6410T	g|SUB|G|6410|T
,	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	D005166
FV	D005166
deficiency	D005166
,	O
respectively	O
.	O
Gene	O
therapy	O
for	O
cystic	D003550
fibrosis	D003550
airway	O
disease	O
-	O
is	O
clinical	O
success	O
imminent?	O
Cystic	D003550
fibrosis	D003550
(	O
CF	D003550
)	O
was	O
one	O
of	O
the	O
first	O
inherited	D030342
disorders	D030342
for	O
which	O
gene	O
therapy	O
was	O
seriously	O
considered	O
as	O
a	O
realistic	O
option	O
for	O
treatment	O
,	O
and	O
as	O
such	O
,	O
it	O
has	O
long	O
provided	O
a	O
paradigm	O
for	O
gene	O
therapy	O
of	O
inherited	D030342
diseases	D030342
.	O

However	O
,	O
despite	O
the	O
cloning	O
of	O
the	O
cystic	1080
fibrosis	1080
transmembrane	1080
conductance	1080
regulator	1080
gene	O
in	O
1989	O
,	O
over	O
15	O
years	O
later	O
a	O
practical	O
gene	O
therapy	O
for	O
CF	D003550
has	O
not	O
eventuated	O
.	O

There	O
are	O
a	O
number	O
of	O
reasons	O
for	O
this	O
,	O
and	O
analysis	O
of	O
the	O
specific	O
issues	O
that	O
have	O
delayed	O
the	O
successful	O
development	O
of	O
gene	O
therapy	O
for	O
CF	D003550
also	O
provides	O
general	O
insights	O
into	O
the	O
practical	O
complexities	O
involved	O
in	O
the	O
development	O
of	O
gene	O
therapy	O
for	O
inherited	D030342
disorders	D030342
.	O

The	O
issues	O
which	O
have	O
prevented	O
the	O
application	O
of	O
gene	O
therapy	O
for	O
CF	D003550
to	O
date	O
include	O
the	O
lack	O
of	O
suitable	O
gene	O
delivery	O
technologies	O
,	O
the	O
complexities	O
of	O
the	O
interactions	O
between	O
the	O
host	O
and	O
vector	O
,	O
the	O
biology	O
of	O
the	O
lung	O
airways	O
,	O
and	O
the	O
nature	O
of	O
the	O
pathology	O
found	O
in	O
individuals	O
with	O
CF	D003550
.	O

We	O
will	O
discuss	O
the	O
history	O
of	O
CF	D003550
gene	O
therapy	O
with	O
specific	O
reference	O
to	O
these	O
and	O
other	O
issues	O
that	O
pre	O
-	O
occupy	O
the	O
field	O
at	O
present	O
:	O
namely	O
,	O
the	O
question	O
of	O
what	O
vectors	O
appear	O
to	O
be	O
suitable	O
for	O
airway	O
gene	O
delivery	O
in	O
CF	D003550
,	O
what	O
cells	O
must	O
be	O
targeted	O
,	O
how	O
airway	O
epithelium	O
defences	O
can	O
be	O
overcome	O
or	O
eluded	O
to	O
allow	O
efficient	O
gene	O
delivery	O
,	O
how	O
to	O
ensure	O
safe	O
and	O
long	O
-	O
term	O
transgene	O
expression	O
and	O
the	O
need	O
to	O
identify	O
relevant	O
surrogate	O
success	O
measures	O
that	O
can	O
be	O
used	O
to	O
assess	O
the	O
outcome	O
of	O
gene	O
therapy	O
in	O
CF	D003550
patients	9606
.	O
Amisulpride	D000077582
related	O
tic	-
-	O
like	-
symptoms	-
in	O
an	O
adolescent	O
schizophrenic	D012559
.	O

Tic	D013981
disorders	D013981
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	D014150
such	O
as	O
risperidone	D018967
,	O
olanzapine	D000077152
and	O
ziprasidone	C092292
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	-
-	O
like	-
symptoms	-
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	D000069348
or	O
clozapine	D003024
.	O

We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	D012559
who	O
developed	O
frequent	O
involuntary	D020820
eye	D020820
-	O
blinking	D020820
movements	D020820
after	O
5	O
months	O
of	O
amisulpride	D000077582
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	-
-	O
like	-
symptoms	-
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	D000077582
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	D011605
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	D000069348
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic	-
-	O
like	-
symptoms	-
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	9606
suggests	O
that	O
tic	-
-	O
like	-
symptoms	-
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	D014150
such	O
as	O
quetiapine	D000069348
,	O
clozapine	D003024
,	O
or	O
amisulpride	D000077582
.	O
Context	O
-	O
and	O
cell	O
-	O
dependent	O
effects	O
of	O
Delta	54485
-	O
like	54485
4	54485
targeting	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
.	O

Delta	54485
-	O
like	54485
4	54485
(	O
Dll4	54485
)	O
is	O
a	O
ligand	O
of	O
the	O
Notch	18128
pathway	O
family	O
which	O
has	O
been	O
widely	O
studied	O
in	O
the	O
context	O
of	O
tumor	D009369
angiogenesis	O
,	O
its	O
blockade	O
shown	O
to	O
result	O
in	O
non	O
-	O
productive	O
angiogenesis	O
and	O
halted	O
tumor	D009369
growth	O
.	O

As	O
Dll4	54485
inhibitors	O
enter	O
the	O
clinic	O
,	O
there	O
is	O
an	O
emerging	O
need	O
to	O
understand	O
their	O
side	O
effects	O
,	O
namely	O
the	O
systemic	O
consequences	O
of	O
Dll4	54485
:	O
Notch	18128
blockade	O
in	O
tissues	O
other	O
than	O
tumors	D009369
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	54485
targeting	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
microenvironment	O
.	O

Here	O
we	O
show	O
that	O
Dll4	54485
blockade	O
with	O
monoclonal	O
antibodies	O
perturbs	O
the	O
BM	O
vascular	O
niche	O
of	O
sub	O
-	O
lethally	O
irradiated	O
mice	10090
,	O
resulting	O
in	O
increased	O
CD31	18613
(	O
+	O
)	O
,	O
VE	12562
-	O
Cadherin	12562
(	O
+	O
)	O
and	O
c	16590
-	O
kit	16590
(	O
+	O
)	O
vessel	O
density	O
,	O
and	O
also	O
increased	O
megakaryocytes	O
,	O
whereas	O
CD105	13805
(	O
+	O
)	O
,	O
VEGFR3	14257
(	O
+	O
)	O
,	O
SMA	11475
(	O
+	O
)	O
and	O
lectin	-
(	O
+	O
)	O
vessel	O
density	O
remained	O
unaltered	O
.	O

We	O
investigated	O
also	O
the	O
expression	O
of	O
angiocrine	O
genes	O
upon	O
Dll4	54485
treatment	O
in	O
vivo	O
,	O
and	O
demonstrate	O
that	O
IGFbp2	16008
,	O
IGFbp3	16009
,	O
Angpt2	11601
,	O
Dll4	54485
,	O
DHH	13363
and	O
VEGF	22339
-	O
A	22339
are	O
upregulated	O
,	O
while	O
FGF1	14164
and	O
CSF2	12981
are	O
reduced	O
.	O

In	O
vitro	O
treatment	O
of	O
endothelial	O
cells	O
with	O
anti	O
-	O
Dll4	54485
reduced	O
Akt	11651
phosphorylation	O
while	O
maintaining	O
similar	O
levels	O
of	O
Erk	26413,26417
1	26413,26417
/	O
2	26413,26417
phosphorylation	O
.	O

Besides	O
its	O
effects	O
in	O
the	O
BM	O
vascular	O
niche	O
,	O
anti	O
-	O
Dll4	54485
treatment	O
perturbed	O
hematopoiesis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloid	O
(	O
CD11b	16409
(	O
+	O
)	O
)	O
,	O
decreased	O
B	O
(	O
B220	19264
(	O
+	O
)	O
)	O
and	O
T	O
(	O
CD3	12501
(	O
+	O
)	O
)	O
lymphoid	O
BM	O
content	O
of	O
treated	O
mice	10090
,	O
with	O
a	O
corresponding	O
increase	O
in	O
myeloid	O
circulating	O
cells	O
.	O

Moreover	O
,	O
anti	O
-	O
Dll4	54485
treatment	O
also	O
increased	O
the	O
number	O
of	O
CFU	O
-	O
M	O
and	O
-	O
G	O
colonies	O
in	O
methylcellulose	O
assays	O
,	O
independently	O
of	O
Notch1	18128
.	O

Finally	O
,	O
anti	O
-	O
Dll4	54485
treatment	O
of	O
donor	O
BM	O
improved	O
the	O
hematopoietic	O
recovery	O
of	O
lethally	O
irradiated	O
recipients	O
in	O
a	O
transplant	O
setting	O
.	O

Together	O
,	O
our	O
data	O
reveals	O
the	O
hematopoietic	O
(	O
BM	O
)	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	54485
treatment	O
result	O
from	O
qualitative	O
vascular	O
changes	O
and	O
also	O
direct	O
hematopoietic	O
cell	O
modulation	O
,	O
which	O
may	O
be	O
favorable	O
in	O
a	O
transplant	O
setting	O
.	O
Impact	O
of	O
CCR5delta32	1234
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
HIV	11676
-	O
1	11676
intrahost	O
evolutionary	O
processes	O
:	O
efficient	O
hypothesis	O
testing	O
through	O
hierarchical	O
phylogenetic	O
models	O
.	O

The	O
interplay	O
between	O
C	1234
-	O
C	1234
chemokine	1234
receptor	1234
type	1234
5	1234
(	O
CCR5	1234
)	O
host	O
genetic	O
background	O
,	O
disease	O
progression	O
,	O
and	O
intrahost	O
HIV	11676
-	O
1	11676
evolutionary	O
dynamics	O
remains	O
unclear	O
because	O
differences	O
in	O
viral	O
evolution	O
between	O
hosts	O
limit	O
the	O
ability	O
to	O
draw	O
conclusions	O
across	O
hosts	O
stratified	O
into	O
clinically	O
relevant	O
populations	O
.	O

Similar	O
inference	O
problems	O
are	O
proliferating	O
across	O
many	O
measurably	O
evolving	O
pathogens	O
for	O
which	O
intrahost	O
sequence	O
samples	O
are	O
readily	O
available	O
.	O

To	O
this	O
end	O
,	O
we	O
propose	O
novel	O
hierarchical	O
phylogenetic	O
models	O
(	O
HPMs	O
)	O
that	O
incorporate	O
fixed	O
effects	O
to	O
test	O
for	O
differences	O
in	O
dynamics	O
across	O
host	O
populations	O
in	O
a	O
formal	O
statistical	O
framework	O
employing	O
stochastic	O
search	O
variable	O
selection	O
and	O
model	O
averaging	O
.	O

To	O
clarify	O
the	O
role	O
of	O
CCR5	1234
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
viral	O
evolutionary	O
patterns	O
,	O
we	O
obtain	O
gp120	3700
envelope	O
sequences	O
from	O
clonal	O
HIV	11676
-	O
1	11676
variants	O
isolated	O
at	O
multiple	O
time	O
points	O
in	O
the	O
course	O
of	O
infection	D007239
from	O
populations	O
of	O
HIV	D015658
-	O
1	D015658
-	O
infected	D015658
individuals	O
who	O
only	O
harbored	O
CCR5	1234
-	O
using	O
HIV	11676
-	O
1	11676
variants	O
at	O
all	O
time	O
points	O
.	O

Presence	O
or	O
absence	O
of	O
a	O
CCR5	1234
wt	O
/	O
DD32	c|DEL||32
genotype	O
and	O
progressive	O
or	O
long	O
-	O
term	O
nonprogressive	O
course	O
of	O
infection	D007239
stratify	O
the	O
clinical	O
populations	O
in	O
a	O
two	O
-	O
way	O
design	O
.	O

As	O
compared	O
with	O
the	O
standard	O
approach	O
of	O
analyzing	O
sequences	O
from	O
each	O
patient	9606
independently	O
,	O
the	O
HPM	O
provides	O
more	O
efficient	O
estimation	O
of	O
evolutionary	O
parameters	O
such	O
as	O
nucleotide	O
substitution	O
rates	O
and	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
rate	O
ratios	O
,	O
as	O
shown	O
by	O
significant	O
shrinkage	O
of	O
the	O
estimator	O
variance	O
.	O

The	O
fixed	O
effects	O
also	O
correct	O
for	O
nonindependence	O
of	O
data	O
between	O
populations	O
and	O
results	O
in	O
even	O
further	O
shrinkage	O
of	O
individual	O
patient	9606
estimates	O
.	O

Model	O
selection	O
suggests	O
an	O
association	O
between	O
nucleotide	O
substitution	O
rate	O
and	O
disease	O
progression	O
,	O
but	O
a	O
role	O
for	O
CCR5	1234
genotype	O
remains	O
elusive	O
.	O

Given	O
the	O
absence	O
of	O
clear	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
differences	O
between	O
patient	9606
groups	O
,	O
delayed	O
onset	O
of	O
AIDS	D000163
symptoms	O
appears	O
to	O
be	O
solely	O
associated	O
with	O
lower	O
viral	O
replication	O
rates	O
rather	O
than	O
with	O
differences	O
in	O
selection	O
on	O
amino	O
acid	O
fixation	O
.	O
Phenylephrine	D010656
but	O
not	O
ephedrine	D004809
reduces	O
frontal	O
lobe	O
oxygenation	O
following	O
anesthesia	O
-	O
induced	O
hypotension	D007022
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	D007022
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	D010656
and	O
ephedrine	D004809
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	D007022
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	D005283
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	D015742
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	9606
received	O
phenylephrine	D010656
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	9606
received	O
ephedrine	D004809
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	D020521
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	O
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	D010656
,	O
MAP	O
increased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14%	O
(	O
from	O
70	O
+	O
/	O
-	O
8%	O
to	O
60	O
+	O
/	O
-	O
7%	O
)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
administration	O
of	O
ephedrine	D004809
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	D010656
to	O
correct	O
hypotension	D007022
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	D004809
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O
Interleukin	3569
6	3569
(	O
IL	3569
-	O
6	3569
)	O
and	O
Tumor	7124
Necrosis	7124
Factor	7124
alpha	7124
(	O
TNF	7124
-	O
alpha	7124
)	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
SNPs	O
)	O
,	O
Inflammation	D007249
and	O
Metabolism	O
in	O
Gestational	D016640
Diabetes	D016640
Mellitus	D016640
in	O
Inner	O
Mongolia	O
.	O

BACKGROUND	O
Gestational	D016640
diabetes	D016640
mellitus	D016640
(	O
GDM	D016640
)	O
is	O
common	O
all	O
over	O
the	O
world	O
.	O

GDM	D016640
women	9606
are	O
with	O
inflammatory	D007249
and	O
metabolisms	D008659
abnormalities	D008659
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
association	O
of	O
IL	3569
-	O
65	3569
-	O
72C	rs1800796
/	O
G	rs1800796
and	O
TNF	7124
-	O
alpha	7124
-	O
857C	rs1799724
/	O
T	rs1799724
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
inflammatory	D007249
biomarkers	O
,	O
and	O
metabolic	O
indexes	O
in	O
women	9606
with	O
GDM	D016640
,	O
especially	O
in	O
the	O
Inner	O
Mongolia	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
of	O
IL	3569
-	O
65	3569
-	O
72C	rs1800796
/	O
G	rs1800796
and	O
TNF	7124
-	O
alpha	7124
-	O
857C	rs1799724
/	O
T	rs1799724
SNPs	O
,	O
and	O
inflammation	D007249
and	O
metabolic	O
biomarkers	O
in	O
women	9606
with	O
GDM	D016640
pregnancies	O
.	O

MATERIAL	O
AND	O
METHODS	O
Blood	O
samples	O
and	O
placentas	O
from	O
140	O
women	9606
with	O
GDM	D016640
and	O
140	O
women	9606
with	O
healthy	O
pregnancies	O
were	O
collected	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
and	O
MassARRAY	O
-	O
IPLEX	O
were	O
performed	O
to	O
analyze	O
IL	3569
-	O
65	3569
-	O
72C	rs1800796
/	O
G	rs1800796
and	O
TNF	7124
-	O
alpha	7124
-	O
857C	rs1799724
/	O
T	rs1799724
SNPs	O
.	O

Enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
to	O
analyze	O
inflammatory	D007249
biomarkers	O
and	O
adipokines	3952,9370
.	O

RESULTS	O
Distribution	O
frequency	O
of	O
TNF	7124
-	O
alpha	7124
-	O
857CT	rs1799724
(	O
OR	O
=	O
3	O
.	O
316	O
,	O
95%	O
CI	O
=	O
1	O
.	O
092	O
-	O
8	O
.	O
304	O
,	O
p	O
=	O
0	O
.	O
025	O
)	O
in	O
women	9606
with	O
GDM	D016640
pregnancies	O
were	O
obviously	O
higher	O
than	O
that	O
in	O
women	9606
with	O
healthy	O
pregnancies	O
.	O

Women	9606
with	O
GDM	D016640
were	O
of	O
older	O
maternal	O
age	O
,	O
had	O
higher	O
BMI	O
,	O
were	O
more	O
nulliparous	O
,	O
and	O
had	O
T2DM	D003924
and	O
GDM	D016640
history	O
,	O
compared	O
to	O
women	9606
with	O
healthy	O
pregnancies	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Inflammatory	D007249
biomarkers	O
in	O
serum	O
(	O
hs	O
-	O
CRP	1401
,	O
IL	3569
-	O
6	3569
,	O
IL	3576
-	O
8	3576
,	O
IL	3569
-	O
6	3569
/	O
IL	3586
-	O
10	3586
ratio	O
)	O
and	O
placental	O
(	O
NF	4790
-	O
kappaB	4790
,	O
IL	3569
-	O
6	3569
,	O
IL	3576
-	O
8	3576
,	O
IL	3569
-	O
6	3569
/	O
IL	3586
-	O
10	3586
ratio	O
,	O
IL	3553
-	O
1b	3553
,	O
TNF	7124
-	O
alpha	7124
)	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
women	9606
with	O
GDM	D016640
and	O
women	9606
with	O
healthy	O
pregnancies	O
.	O

Differences	O
were	O
found	O
for	O
serum	O
FBG	O
,	O
FINS	O
,	O
HOMA	O
-	O
IR	O
,	O
and	O
HOMA	O
-	O
beta	O
,	O
and	O
placental	O
IRS	3667
-	O
1	3667
,	O
IRS	8660
-	O
2	8660
,	O
leptin	3952
,	O
adiponectin	9370
,	O
visfatin	10135
,	O
RBP	5950
-	O
4	5950
,	O
chemerin	5919
,	O
nesfatin	4925
-	O
1	4925
,	O
FATP	10999
-	O
4	10999
,	O
EL	9388
,	O
LPL	4023
,	O
FABP	2168
-	O
1	2168
,	O
FABP	2170
-	O
3	2170
,	O
FABP	2167
-	O
4	2167
,	O
and	O
FABP	2171
-	O
5	2171
.	O

CONCLUSIONS	O
TNF	7124
-	O
alpha	7124
-	O
857C	rs1799724
/	O
T	rs1799724
SNP	O
,	O
hs	O
-	O
CRP	1401
,	O
IL	3569
-	O
6	3569
,	O
IL	3576
-	O
8	3576
,	O
and	O
IL	3569
-	O
6	3569
/	O
IL	3586
-	O
10	3586
were	O
associated	O
with	O
GDM	D016640
in	O
women	9606
from	O
Inner	O
Mongolia	O
,	O
as	O
was	O
serious	O
inflammation	D007249
and	O
disordered	D044882,D052439
lipid	D044882,D052439
and	D044882,D052439
glucose	D044882,D052439
metabolisms	D044882,D052439
.	O
Estrogen	D004967
prevents	O
cholesteryl	D002788
ester	D002788
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	-
protease	-
inhibitor	O
ritonavir	D019438
.	O

Individuals	O
with	O
HIV	11676
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	D019438
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	D050197
atherosclerosis	D050197
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	D019438
treatment	O
increases	O
atherosclerotic	D050197
lesion	D050197
formation	O
in	O
male	O
mice	10090
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	10090
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	D019438
-	O
treated	O
females	O
had	O
less	O
cholesteryl	D002788
ester	D002788
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	D002784
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	-
protease	-
inhibitor	O
ritonavir	D019438
.	O

We	O
have	O
utilized	O
the	O
human	9606
monocyte	O
cell	O
line	O
,	O
THP	9606
-	O
1	9606
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	D004958
-	O
estradiol	D004958
(	O
E2	D004958
)	O
,	O
100	O
nM	O
progesterone	D011374
or	O
vehicle	O
(	O
0	O
.	O
01%	O
ethanol	D000431
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	D019438
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	D008055
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	D004958
decreased	O
the	O
accumulation	O
of	O
cholesteryl	D002788
esters	D002788
in	O
macrophages	O
following	O
ritonavir	D019438
treatment	O
.	O

Ritonavir	D019438
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	948
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	D019438
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	5468
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	948
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	D004958
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	D004958
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	948
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	D004958
modifies	O
the	O
expression	O
of	O
CD36	948
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	D002788
ester	D002788
accumulation	O
following	O
ritonavir	D019438
treatment	O
.	O
Single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
the	O
FMR1	2332
gene	O
in	O
autistic	D001321
and	O
mentally	D008607
retarded	D008607
children	O
in	O
Japan	O
.	O

Fragile	D005600
X	D005600
syndrome	D005600
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	D008607
retardation	D008607
in	O
males	O
,	O
and	O
patients	9606
with	O
fragile	D005600
X	D005600
syndrome	D005600
occasionally	O
develop	O
autism	D001321
.	O

It	O
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
the	O
trinucleotide	O
repeat	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
FMR1	2332
gene	O
,	O
but	O
in	O
a	O
small	O
number	O
of	O
patients	9606
deletions	O
and	O
point	O
mutations	O
have	O
been	O
identified	O
.	O

We	O
screened	O
all	O
17	O
exons	O
of	O
the	O
FMR1	2332
gene	O
for	O
mutations	O
in	O
90	O
autistic	D001321
or	O
mentally	D008607
retarded	D008607
children	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
.	O

No	O
mutations	O
were	O
found	O
in	O
76	O
male	O
patients	9606
.	O

However	O
,	O
one	O
female	O
patient	9606
was	O
heterozygous	O
for	O
a	O
normal	O
allele	O
and	O
a	O
mutant	O
allele	O
with	O
an	O
A	rs782013865
to	rs782013865
C	rs782013865
substitution	rs782013865
at	rs782013865
nucleotide	rs782013865
879	rs782013865
in	O
exon	O
9	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
50	O
controls	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
revealed	O
that	O
a	O
large	O
proportion	O
of	O
the	O
mutant	O
transcripts	O
were	O
spliced	O
aberrantly	O
,	O
causing	O
premature	O
termination	O
of	O
the	O
protein	O
synthesis	O
.	O

Although	O
uncommon	O
,	O
point	O
mutations	O
in	O
the	O
FMR1	2332
gene	O
may	O
be	O
a	O
cause	O
of	O
autism	D001321
and	O
mental	D008607
retardation	D008607
in	O
Japanese	O
patients	9606
.	O
Homozygously	O
deleted	O
gene	O
DACH1	1602
regulates	O
tumor	D009369
-	O
initiating	O
activity	O
of	O
glioma	D005910
cells	O
.	O

Loss	O
or	O
reduction	O
in	O
function	O
of	O
tumor	D009369
suppressor	O
genes	O
contributes	O
to	O
tumorigenesis	D009369
.	O

Here	O
,	O
by	O
allelic	O
DNA	O
copy	O
number	O
analysis	O
using	O
single	O
-	O
nucleotide	O
polymorphism	O
genotyping	O
array	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
homozygous	O
deletion	O
in	O
glioblastoma	D005909
multiformes	O
at	O
chromosome	O
13q21	O
,	O
where	O
DACH1	1602
gene	O
is	O
located	O
.	O

We	O
found	O
decreased	O
cell	O
proliferation	O
of	O
a	O
series	O
of	O
glioma	D005910
cell	O
lines	O
by	O
forced	O
expression	O
of	O
DACH1	1602
.	O

We	O
then	O
generated	O
U87TR	9606
-	O
Da	9606
glioma	D005910
cells	O
,	O
where	O
DACH1	1602
expression	O
could	O
be	O
activated	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
doxycycline	D004318
.	O

Both	O
ex	O
vivo	O
cellular	O
proliferation	O
and	O
in	O
vivo	O
growth	O
of	O
s	O
.	O
c	O
.	O

transplanted	O
tumors	D009369
in	O
mice	10090
are	O
reduced	O
in	O
U87TR	9606
-	O
Da	9606
cells	O
with	O
DACH1	1602
expression	O
(	O
U87	9606
-	O
DACH1	1602
-	O
high	O
)	O
,	O
compared	O
with	O
DACH1	1602
-	O
nonexpressing	O
U87TR	9606
-	O
Da	9606
cells	O
(	O
U87	9606
-	O
DACH1	1602
-	O
low	O
)	O
.	O

U87	9606
-	O
DACH1	1602
-	O
low	O
cells	O
form	O
spheroids	O
with	O
CD133	8842
and	O
Nestin	10763
expression	O
in	O
serum	O
-	O
free	O
medium	O
but	O
U87	9606
-	O
DACH1	1602
-	O
high	O
cells	O
do	O
not	O
.	O

Compared	O
with	O
spheroid	O
-	O
forming	O
U87	9606
-	O
DACH1	1602
-	O
low	O
cells	O
,	O
adherent	O
U87	9606
-	O
DACH1	1602
-	O
high	O
cells	O
display	O
lower	O
tumorigenicity	O
,	O
indicating	O
DACH1	1602
decreases	O
the	O
number	O
of	O
tumor	D009369
-	O
initiating	O
cells	O
.	O

Gene	O
expression	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
reveal	O
that	O
fibroblast	2247
growth	2247
factor	2247
2	2247
(	O
FGF2	2247
/	O
bFGF	2247
)	O
is	O
transcriptionally	O
repressed	O
by	O
DACH1	1602
,	O
especially	O
in	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Exogenous	O
bFGF	2247
rescues	O
spheroid	O
-	O
forming	O
activity	O
and	O
tumorigenicity	O
of	O
the	O
U87	9606
-	O
DACH1	1602
-	O
high	O
cells	O
,	O
suggesting	O
that	O
loss	O
of	O
DACH1	1602
increases	O
the	O
number	O
of	O
tumor	D009369
-	O
initiating	O
cells	O
through	O
transcriptional	O
activation	O
of	O
bFGF	2247
.	O

These	O
results	O
illustrate	O
that	O
DACH1	1602
is	O
a	O
distinctive	O
tumor	D009369
suppressor	O
,	O
which	O
does	O
not	O
only	O
suppress	O
growth	O
of	O
tumor	D009369
cells	O
but	O
also	O
regulates	O
bFGF	2247
-	O
mediated	O
tumor	D009369
-	O
initiating	O
activity	O
of	O
glioma	D005910
cells	O
.	O
Focal	D005489
dermal	D005489
hypoplasia	D005489
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
,	O
p	p|SUB|E|300|X
.	O
E300X	p|SUB|E|300|X
,	O
in	O
the	O
PORCN	64840
gene	O
.	O

BACKGROUND	O
:	O
Focal	D005489
dermal	D005489
hypoplasia	D005489
(	O
FDH	D005489
)	O
(	O
OMIM	D005489
305600	D005489
)	O
is	O
an	O
X	D040181
-	O
linked	D040181
dominant	D040181
disorder	D040181
of	O
ecto	O
-	O
mesodermal	O
development	O
.	O

Also	O
known	O
as	O
Goltz	D005489
syndrome	D005489
,	O
FDH	D005489
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	D005489
dermis	D005489
and	O
variable	O
abnormalities	O
of	O
bone	O
,	O
nails	O
,	O
hair	O
,	O
limbs	O
,	O
teeth	O
and	O
eyes	O
.	O

The	O
molecular	O
basis	O
of	O
FDH	D005489
involves	O
mutations	O
in	O
the	O
PORCN	64840
gene	O
,	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	D005489
in	O
a	O
2	O
-	O
year	O
-	O
old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	D003866
,	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
,	O
sparse	O
brittle	O
hair	O
,	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
,	O
dental	D003731
caries	D003731
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O

METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	64840
gene	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G	c|SUB|G|898|T
>	O
T	c|SUB|G|898|T
substitution	c|SUB|G|898|T
at	c|SUB|G|898|T
nucleotide	c|SUB|G|898|T
c	c|SUB|G|898|T
.	O
898	c|SUB|G|898|T
within	O
exon	O
10	O
(	O
NM_203475	O
.	O
1	O
)	O
,	O
converting	O
a	O
glutamic	p|SUB|E||X
acid	p|SUB|E||X
residue	p|SUB|E||X
(	O
GAA	p|SUB|E||X
)	O
to	p|SUB|E||X
a	p|SUB|E||X
premature	p|SUB|E||X
termination	p|SUB|E||X
codon	p|SUB|E||X
(	O
TAA	p|SUB|E||X
)	O
.	O

This	O
mutation	O
,	O
designated	O
p	p|SUB|E|300|X
.	O
E300X	p|SUB|E|300|X
,	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O

CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	D005489
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	64840
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O
Human	9606
mu	4988
opiate	4988
receptor	4988
.	O

cDNA	O
and	O
genomic	O
clones	O
,	O
pharmacologic	O
characterization	O
and	O
chromosomal	O
assignment	O
.	O

A	O
human	9606
mu	4988
opiate	4988
receptor	4988
cDNA	O
has	O
been	O
identified	O
from	O
a	O
cerebral	O
cortical	O
cDNA	O
library	O
using	O
sequences	O
from	O
the	O
rat	10116
mu	25601
opiate	25601
receptor	25601
cDNA	O
.	O

The	O
human	9606
mu	4988
opiate	4988
receptor	4988
(	O
h	4988
mu	4988
OR1	4988
)	O
shares	O
95%	O
amino	O
acid	O
identity	O
with	O
the	O
rat	10116
sequence	O
.	O

The	O
expressed	O
mu	25601
OR1	25601
recognized	O
tested	O
opiate	D053610
drugs	O
and	O
opioid	D018847
peptides	D018847
in	O
a	O
sodium	D012964
-	O
and	O
GTP	D006160
-	O
sensitive	O
fashion	O
with	O
affinities	O
virtually	O
identical	O
to	O
those	O
displayed	O
by	O
the	O
rat	10116
mu	25601
opiate	25601
receptor	25601
.	O

Effects	O
on	O
cyclic	D000242
AMP	D000242
are	O
similar	O
to	O
those	O
noted	O
for	O
the	O
rat	10116
mu	25601
opiate	25601
receptor	25601
.	O

An	O
18	O
kb	O
genomic	O
clone	O
hybridizing	O
with	O
the	O
h	4988
mu	4988
OR1	4988
cDNA	O
contains	O
63	O
and	O
489	O
bp	O
exonic	O
sequences	O
flanked	O
by	O
splice	O
donor	O
/	O
acceptor	O
sequences	O
.	O

Analysis	O
of	O
hybridization	O
to	O
DNA	O
prepared	O
from	O
human	9606
rodent	O
hybrid	O
cell	O
lines	O
and	O
chromosomal	O
in	O
situ	O
hybridization	O
studies	O
indicate	O
localization	O
to	O
6q24	O
-	O
25	O
.	O

An	O
MspI	O
polymorphism	O
,	O
producing	O
a	O
3	O
.	O
7	O
kb	O
band	O
,	O
may	O
prove	O
useful	O
in	O
assessing	O
this	O
gene	O
'	O
s	O
involvement	O
in	O
neuropsychiatric	D001523
disorders	D001523
involving	O
opiatergic	O
systems	O
.	O
An	O
Ag	3047
-	O
globin	3047
G	rs368698783
-	O
>	O
A	rs368698783
gene	O
polymorphism	O
associated	O
with	O
b	3043
(	O
0	3043
)	O
39	3043
thalassemia	3043
globin	3043
gene	O
and	O
high	O
fetal	3040,3048
hemoglobin	3040,3048
production	O
.	O

BACKGROUND	O
:	O
Increase	O
of	O
the	O
expression	O
of	O
g	3047,3048
-	O
globin	3047,3048
gene	O
and	O
high	O
production	O
of	O
fetal	3040,3048
hemoglobin	3040,3048
(	O
HbF	3040,3048
)	O
in	O
b	D017086
-	O
thalassemia	D017086
patients	9606
is	O
widely	O
accepted	O
as	O
associated	O
with	O
a	O
milder	O
or	O
even	O
asymptomatic	O
disease	O
.	O

The	O
search	O
for	O
HbF	3040,3048
-	O
associated	O
polymorphisms	O
(	O
such	O
as	O
the	O
XmnI	O
,	O
BCL11A	53335
and	O
MYB	4602
polymorphisms	O
)	O
has	O
recently	O
gained	O
great	O
attention	O
,	O
in	O
order	O
to	O
stratify	O
b	D017086
-	O
thalassemia	D017086
patients	9606
with	O
respect	O
to	O
expectancy	O
of	O
the	O
first	O
transfusion	O
,	O
need	O
for	O
annual	O
intake	O
of	O
blood	O
,	O
response	O
to	O
HbF	3040,3048
inducers	O
(	O
the	O
most	O
studied	O
of	O
which	O
is	O
hydroxyurea	O
)	O
.	O

METHODS	O
:	O
Ag	3047
-	O
globin	3047
gene	O
sequencing	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
a	O
total	O
of	O
75	O
b	D017086
-	O
thalassemia	D017086
patients	9606
,	O
including	O
31	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
0	O
)	O
39	O
,	O
33	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
9	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
one	O
b	O
(	O
0	O
)	O
IVSI	O
-	O
1	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
and	O
one	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
rs368698783	rs368698783
polymorphism	O
is	O
present	O
in	O
b	D017086
-	O
thalassemia	D017086
patients	9606
in	O
the	O
5	O
'	O
UTR	O
sequence	O
(	O
+	O
25	O
)	O
of	O
the	O
Ag	3047
-	O
globin	3047
gene	O
,	O
known	O
to	O
affect	O
the	O
LYAR	55646
(	O
human	9606
homologue	O
of	O
mouse	10090
Ly	17089
-	O
1	17089
antibody	17089
reactive	17089
clone	17089
)	O
binding	O
site	O
5	O
'	O
-	O
GGTTAT	O
-	O
3	O
'	O
.	O

This	O
Ag	3047
(	O
+	O
25	rs368698783
G	rs368698783
-	O
>	O
A	rs368698783
)	O
polymorphism	O
is	O
associated	O
with	O
the	O
Gg	3048
-	O
globin	3048
-	O
XmnI	O
polymorphism	O
and	O
both	O
are	O
linked	O
with	O
the	O
b	3043
(	O
0	3043
)	O
39	3043
-	O
globin	3043
gene	O
,	O
but	O
not	O
with	O
the	O
b	3043
(	O
+	O
)	O
IVSI	3043
-	O
110	3043
-	O
globin	3043
gene	O
.	O

In	O
agreement	O
with	O
the	O
expectation	O
that	O
this	O
mutation	O
alters	O
the	O
LYAR	55646
binding	O
activity	O
,	O
we	O
found	O
that	O
the	O
Ag	3047
(	O
+	O
25	rs368698783
G	rs368698783
-	O
>	O
A	rs368698783
)	O
and	O
Gg	3048
-	O
globin	3048
-	O
XmnI	O
polymorphisms	O
are	O
associated	O
with	O
high	O
HbF	3040,3048
in	O
erythroid	O
precursor	O
cells	O
isolated	O
from	O
b	D017086
(	O
0	D017086
)	O
39	D017086
/	O
b	D017086
(	O
0	D017086
)	O
39	D017086
thalassemia	D017086
patients	9606
.	O

CONCLUSIONS	O
:	O
As	O
a	O
potential	O
explanation	O
of	O
our	O
findings	O
,	O
we	O
hypothesize	O
that	O
in	O
b	D017086
-	O
thalassemia	D017086
the	O
Gg	3048
-	O
globin	3048
-	O
XmnI	O
/	O
Ag	3047
-	O
globin	3047
-	O
(	O
G	rs368698783
-	O
>	O
A	rs368698783
)	O
genotype	O
is	O
frequently	O
under	O
genetic	O
linkage	O
with	O
b	D017086
(	O
0	D017086
)	O
-	O
thalassemia	D017086
mutations	O
,	O
but	O
not	O
with	O
the	O
b	D017086
(	O
+	O
)	O
-	O
thalassemia	D017086
mutation	O
here	O
studied	O
(	O
i	O
.	O
e	O
.	O

b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
)	O
and	O
that	O
this	O
genetic	O
combination	O
has	O
been	O
selected	O
within	O
the	O
population	O
of	O
b	D017086
(	O
0	D017086
)	O
-	O
thalassemia	D017086
patients	9606
,	O
due	O
to	O
functional	O
association	O
with	O
high	O
HbF	3040,3048
.	O

Here	O
we	O
describe	O
the	O
characterization	O
of	O
the	O
rs368698783	rs368698783
(	O
+	O
25	rs368698783
G	rs368698783
-	O
>	O
A	rs368698783
)	O
polymorphism	O
of	O
the	O
Ag	3047
-	O
globin	3047
gene	O
associated	O
in	O
b	D017086
(	O
0	D017086
)	O
39	D017086
thalassemia	D017086
patients	9606
with	O
high	O
HbF	3040,3048
in	O
erythroid	O
precursor	O
cells	O
.	O
Alcohol	D000438
consumption	O
and	O
prostate	D011471
cancer	D011471
incidence	O
and	O
progression	O
:	O
A	O
Mendelian	O
randomisation	O
study	O
.	O

Prostate	D011471
cancer	D011471
is	O
the	O
most	O
common	O
cancer	D009369
in	O
men	9606
in	O
developed	O
countries	O
,	O
and	O
is	O
a	O
target	O
for	O
risk	O
reduction	O
strategies	O
.	O

The	O
effects	O
of	O
alcohol	D000438
consumption	O
on	O
prostate	D011471
cancer	D011471
incidence	O
and	O
survival	O
remain	O
unclear	O
,	O
potentially	O
due	O
to	O
methodological	O
limitations	O
of	O
observational	O
studies	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
associations	O
of	O
genetic	O
variants	O
in	O
alcohol	D000438
-	O
metabolising	O
genes	O
with	O
prostate	D011471
cancer	D011471
incidence	O
and	O
survival	O
.	O

We	O
analysed	O
data	O
from	O
23	O
,	O
868	O
men	9606
with	O
prostate	D011471
cancer	D011471
and	O
23	O
,	O
051	O
controls	O
from	O
25	O
studies	O
within	O
the	O
international	O
PRACTICAL	O
Consortium	O
.	O

Study	O
-	O
specific	O
associations	O
of	O
68	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
8	O
alcohol	D000438
-	O
metabolising	O
genes	O
(	O
Alcohol	125
Dehydrogenases	125
(	O
ADHs	125
)	O
and	O
Aldehyde	8854
Dehydrogenases	8854
(	O
ALDHs	8854
)	O
)	O
with	O
prostate	D011471
cancer	D011471
diagnosis	O
and	O
prostate	D011471
cancer	D011471
-	O
specific	O
mortality	O
,	O
by	O
grade	O
,	O
were	O
assessed	O
using	O
logistic	O
and	O
Cox	O
regression	O
models	O
,	O
respectively	O
.	O

The	O
data	O
across	O
the	O
25	O
studies	O
were	O
meta	O
-	O
analysed	O
using	O
fixed	O
-	O
effect	O
and	O
random	O
-	O
effects	O
models	O
.	O

We	O
found	O
little	O
evidence	O
that	O
variants	O
in	O
alcohol	D000438
metabolising	O
genes	O
were	O
associated	O
with	O
prostate	D011471
cancer	D011471
diagnosis	O
.	O

Four	O
variants	O
in	O
two	O
genes	O
exceeded	O
the	O
multiple	O
testing	O
threshold	O
for	O
associations	O
with	O
prostate	D011471
cancer	D011471
mortality	O
in	O
fixed	O
-	O
effect	O
meta	O
-	O
analyses	O
.	O

SNPs	O
within	O
ALDH1A2	8854
associated	O
with	O
prostate	D011471
cancer	D011471
mortality	O
were	O
rs1441817	rs1441817
(	O
fixed	O
effects	O
hazard	O
ratio	O
,	O
HRfixed	O
=	O
0	O
.	O
78	O
;	O
95%	O
confidence	O
interval	O
(	O
95%CI	O
)	O
:	O
0	O
.	O
66	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
;	O
rs12910509	rs12910509
,	O
HRfixed	O
=	O
0	O
.	O
76	O
;	O
95%CI	O
:	O
0	O
.	O
64	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
003	O
)	O
;	O
and	O
rs8041922	rs8041922
(	O
HRfixed	O
=	O
0	O
.	O
76	O
;	O
95%CI	O
:	O
0	O
.	O
64	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
.	O

These	O
SNPs	O
were	O
in	O
linkage	O
disequilibrium	O
with	O
each	O
other	O
.	O

In	O
ALDH1B1	219
,	O
rs10973794	rs10973794
(	O
HRfixed	O
=	O
1	O
.	O
43	O
;	O
95%CI	O
:	O
1	O
.	O
14	O
,	O
1	O
.	O
79	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
was	O
associated	O
with	O
prostate	D011471
cancer	D011471
mortality	O
in	O
men	9606
with	O
low	O
-	O
grade	O
prostate	D011471
cancer	D011471
.	O

These	O
results	O
suggest	O
that	O
alcohol	D000438
consumption	O
is	O
unlikely	O
to	O
affect	O
prostate	D011471
cancer	D011471
incidence	O
,	O
but	O
it	O
may	O
influence	O
disease	O
progression	O
.	O
Novel	O
somatic	O
MEN1	4221
gene	O
alterations	O
in	O
sporadic	O
primary	D049950
hyperparathyroidism	D049950
and	O
correlation	O
with	O
clinical	O
characteristics	O
.	O

Primary	D049950
hyperparathyroidism	D049950
(	O
pHPT	D049950
)	O
is	O
a	O
common	O
endocrine	D004700
disease	D004700
that	O
in	O
more	O
than	O
95%	O
of	O
cases	O
is	O
sporadic	O
and	O
only	O
in	O
some	O
cases	O
is	O
caused	O
by	O
inherited	D030342
disorders	D030342
,	O
isolated	O
or	O
as	O
part	O
of	O
multiple	D009377
endocrine	D009377
neoplasia	D009377
(	O
MEN1	D018761,D018813
and	D018761,D018813
2	D018761,D018813
)	O
.	O

Somatic	O
mutations	O
of	O
MEN1	4221
gene	O
have	O
also	O
been	O
described	O
in	O
sporadic	O
parathyroid	D010282
tumors	D010282
.	O

In	O
our	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	4221
gene	O
in	O
a	O
series	O
of	O
39	O
patients	9606
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
pHPT	D049950
(	O
35	O
with	O
parathyroid	D010282
adenoma	D010282
or	D010282
hyperplasia	D010282
,	O
4	O
with	O
a	O
carcinoma	D002277
)	O
.	O

A	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
also	O
analysed	O
.	O

After	O
DNA	O
extraction	O
from	O
paraffin	D010232
-	O
embedded	O
tissues	O
,	O
we	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
the	O
exons	O
2	O
-	O
10	O
of	O
the	O
MEN1	4221
gene	O
.	O

Somatic	O
MEN1	4221
mutations	O
were	O
detected	O
in	O
6	O
of	O
the	O
35	O
patients	9606
with	O
a	O
benign	D010279
parathyroid	D010279
lesion	D010279
examined	O
(	O
17	O
.	O
1%	O
)	O
,	O
whereas	O
no	O
alterations	O
were	O
found	O
in	O
the	O
carcinomas	D002277
.	O

Four	O
novel	O
MEN1	4221
gene	O
mutations	O
were	O
identified	O
as	O
follows	O
:	O
one	O
frameshift	O
mutation	O
(	O
222insT	c|INS|222|T
,	O
exon	O
2	O
)	O
,	O
one	O
frameshift	O
deletion	O
(	O
912delTA	c|DEL|912|TA
,	O
exon	O
5	O
)	O
,	O
one	O
in	O
-	O
frame	O
deletion	O
(	O
835del18	c|DEL|835|18
,	O
exon	O
4	O
)	O
and	O
one	O
missense	O
mutation	O
(	O
P291A	p|SUB|P|291|A
,	O
exon	O
6	O
)	O
.	O

In	O
addition	O
,	O
one	O
missense	O
mutation	O
(	O
L89R	p|SUB|L|89|R
,	O
exon	O
2	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
Q536X	p|SUB|Q|536|X
,	O
exon	O
10	O
)	O
were	O
previously	O
reported	O
.	O

Moreover	O
,	O
two	O
polymorphisms	O
were	O
also	O
found	O
:	O
one	O
allele	O
carried	O
a	O
R171Q	rs607969
polymorphism	O
(	O
1	O
/	O
39	O
tumors	D009369
)	O
,	O
while	O
a	O
D418D	rs2071313
polymorphism	O
(	O
GAC	rs2071313
/	O
GAT	rs2071313
)	O
was	O
found	O
in	O
15	O
and	O
8	O
tumors	D009369
in	O
hetero	O
(	O
CT	O
)	O
and	O
homozygosity	O
(	O
TT	O
)	O
,	O
respectively	O
.	O

In	O
no	O
case	O
(	O
mutations	O
and	O
/	O
or	O
polymorphisms	O
)	O
did	O
we	O
find	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
the	O
presence	O
of	O
somatic	O
alterations	O
of	O
the	O
MEN1	4221
tumor	D009369
suppressor	O
gene	O
in	O
about	O
one	O
fifth	O
of	O
benign	O
sporadic	O
parathyroid	D010282
tumors	D010282
.	O

The	O
absence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
however	O
,	O
suggests	O
the	O
involvement	O
of	O
other	O
genetic	O
/	O
epigenetic	O
factors	O
for	O
the	O
full	O
expression	O
of	O
the	O
disease	O
.	O
Lack	O
of	O
association	O
between	O
ADRA2B	151
-	O
4825	c|INDEL|-4825||
gene	c|INDEL|-4825||
insertion	c|INDEL|-4825||
/	O
deletion	c|INDEL|-4825||
polymorphism	O
and	O
migraine	D008881
in	O
Chinese	O
Han	O
population	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	D008881
and	O
the	O
12	c|INDEL||12
-	O
nucleotide	c|INDEL||12
insertion	c|INDEL||12
/	O
deletion	c|INDEL||12
(	O
indel	c|INDEL||12
)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha	151
(	O
2B	151
)	O
-	O
adrenergic	151
receptor	151
gene	O
(	O
ADRA2B	151
)	O
.	O

METHODS	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	D008881
and	O
517	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O

Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	D008881
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	D008881
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	151
indel	c|INDEL|-4825||
polymorphism	c|INDEL|-4825||
at	c|INDEL|-4825||
position	c|INDEL|-4825||
-	O
4825	c|INDEL|-4825||
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	D008881
subjects	O
.	O
Aryl	9049
hydrocarbon	9049
receptor	9049
interacting	9049
protein	9049
(	O
AIP	9049
)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	D010911
adenomas	D010911
.	O

OBJECTIVE	O
:	O
Pituitary	D010911
adenomas	D010911
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O

Pituitary	D010911
adenoma	D010911
predisposition	O
(	O
PAP	O
)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	9049
hydrocarbon	9049
receptor	9049
interacting	9049
protein	9049
(	O
AIP	9049
)	O
gene	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	9049
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	D010911
adenomas	D010911
.	O

DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	9049
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O

PATIENTS	9606
:	O
A	O
population	O
-	O
based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	D010911
adenoma	D010911
patients	9606
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O

Patients	9606
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	D000236
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
Y248del	rs267606574
(	O
c	rs267606574
.	O
742_744delTAC	rs267606574
)	O
was	O
identified	O
in	O
one	O
GH	D049912
-	O
secreting	D049912
adenoma	D049912
patient	9606
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
analysis	O
of	O
tumour	D009369
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
.	O

First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O

CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non	O
-	O
GH	D049912
-	O
secreting	D049912
adenoma	D049912
patients	9606
,	O
germline	O
AIP	9049
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH	D049912
-	O
secreting	D049912
tumours	D049912
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O

The	O
present	O
study	O
reports	O
the	O
AIP	9049
mutation	O
analysis	O
results	O
on	O
patients	9606
of	O
a	O
single	O
ethnic	O
origin	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	9049
in	O
paediatric	O
pituitary	D010911
adenomas	D010911
.	O
A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	9606
PAX9	5083
causes	O
oligodontia	C538049
.	O

PAX9	5083
and	O
MSX1	4487
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O

In	O
humans	9606
,	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	C538049
and	C538049
syndromic	C538049
oligodontia	C538049
,	O
respectively	O
.	O

We	O
screened	O
one	O
family	O
with	O
nonsyndromic	C538049
oligodontia	C538049
for	O
mutations	O
in	O
PAX9	5083
and	O
MSX1	4487
.	O

Single	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139T	rs121917720
transition	O
in	O
PAX9	5083
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O

There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	4487
.	O

The	O
C139T	rs121917720
mutation	O
,	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	rs121917720
by	rs121917720
a	rs121917720
tryptophan	rs121917720
(	O
R47W	rs121917720
)	O
in	O
the	O
N	O
-	O
terminal	O
subdomain	O
,	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	5083
paired	O
domain	O
.	O

To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	C538049
phenotype	C538049
caused	O
by	O
this	O
mutation	O
,	O
we	O
analyzed	O
the	O
binding	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
PAX9	5083
paired	O
domain	O
protein	O
to	O
double	O
-	O
stranded	O
DNA	O
targets	O
.	O

The	O
R47W	rs121917720
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O
Availability	O
of	O
human	9606
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	D008133
prolongation	D008133
.	O

Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	9606
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	D002121,D026902
(	O
+	O
)	O
channel	D002121,D026902
and	D002121,D026902
Ca	D002121,D026902
(	O
2	D002121,D026902
+	O
)	O
channel	D002121,D026902
blocker	D002121,D026902
effects	O
on	O
QT	O
interval	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	D008133
prolongation	D008133
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	D008133
prolongation	D008133
induced	O
by	O
multichannel	O
blockers	O
.	O

hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O

IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	D002121
(	O
2	D002121
+	O
)	O
channel	D002121
blockers	D002121
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O

Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	D000638
,	O
Paroxetine	D017374
,	O
Terfenadine	D016593
and	O
Citalopram	D015283
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	D016593
and	O
Citalopram	D015283
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	D016171
de	D016171
Pointes	D016171
(	O
TdP	D016171
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O

hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	D016171
potential	O
.	O
A	O
novel	O
splicing	O
mutation	O
in	O
SLC12A3	6559
associated	O
with	O
Gitelman	D053579
syndrome	D053579
and	O
idiopathic	D011559
intracranial	D011559
hypertension	D011559
.	O

We	O
report	O
a	O
case	O
of	O
Gitelman	D053579
syndrome	D053579
(	O
GS	D053579
)	O
in	O
a	O
dizygotic	O
twin	O
who	O
presented	O
at	O
12	O
years	O
of	O
age	O
with	O
growth	D006130
delay	D006130
,	O
metabolic	D000471
alkalosis	D000471
,	O
hypomagnesemia	C537153
and	O
hypokalemia	D007008
with	O
inappropriate	O
kaliuresis	O
,	O
and	O
idiopathic	D011559
intracranial	D011559
hypertension	D011559
with	O
bilateral	D010211
papilledema	D010211
(	O
pseudotumor	D011559
cerebri	D011559
)	O
.	O

The	O
patient	9606
,	O
her	O
twin	O
sister	O
,	O
and	O
her	O
mother	O
also	O
presented	O
with	O
cerebral	D002543
cavernous	D002543
malformations	D002543
.	O

Based	O
on	O
the	O
early	O
onset	O
and	O
normocalciuria	O
,	O
Bartter	D001477
syndrome	D001477
was	O
diagnosed	O
first	O
.	O

However	O
,	O
mutation	O
analysis	O
showed	O
that	O
the	O
proband	O
is	O
a	O
compound	O
heterozygote	O
for	O
2	O
mutations	O
in	O
SLC12A3	6559
:	O
a	O
substitution	O
of	O
serine	rs148038173
by	rs148038173
leucine	rs148038173
at	rs148038173
amino	rs148038173
acid	rs148038173
position	rs148038173
555	rs148038173
(	O
p	rs148038173
.	O
Ser555Leu	rs148038173
)	O
and	O
a	O
novel	O
guanine	c|SUB|G||C
to	c|SUB|G||C
cytosine	c|SUB|G||C
transition	O
at	O
the	O
5	O
'	O
splice	O
site	O
of	O
intron	O
22	O
(	O
c	c|SUB|G|2633+1|C
.	O
2633	c|SUB|G|2633+1|C
+	O
1G	c|SUB|G|2633+1|C
>	O
C	c|SUB|G|2633+1|C
)	O
,	O
providing	O
the	O
molecular	O
diagnosis	O
of	O
GS	D053579
.	O

These	O
mutations	O
were	O
not	O
detected	O
in	O
200	O
normal	O
chromosomes	O
and	O
cosegregated	O
within	O
the	O
family	O
.	O

Analysis	O
of	O
complementary	O
DNA	O
showed	O
that	O
the	O
heterozygous	O
nucleotide	O
change	O
c	c|SUB|G|2633+1|C
.	O
2633	c|SUB|G|2633+1|C
+	O
1G	c|SUB|G|2633+1|C
>	O
C	c|SUB|G|2633+1|C
caused	O
the	O
appearance	O
of	O
2	O
RNA	O
molecules	O
,	O
1	O
normal	O
transcript	O
and	O
1	O
skipping	O
the	O
entire	O
exon	O
22	O
(	O
r	r|DEL|2521_2634|
.	O
2521_2634del	r|DEL|2521_2634|
)	O
.	O

Supplementation	O
with	O
potassium	D011188
and	O
magnesium	D008274
improved	O
clinical	O
symptoms	O
and	O
resulted	O
in	O
catch	O
-	O
up	O
growth	O
,	O
but	O
vision	O
remained	O
impaired	O
.	O

Three	O
similar	O
associations	O
of	O
Bartter	D001477
syndrome	D001477
/	O
GS	D053579
with	O
pseudotumor	D011559
cerebri	D011559
were	O
found	O
in	O
the	O
literature	O
,	O
suggesting	O
that	O
electrolyte	D014883
abnormalities	D014883
and	O
secondary	D001477
aldosteronism	D001477
may	O
have	O
a	O
role	O
in	O
idiopathic	D011559
intracranial	D011559
hypertension	D011559
.	O

This	O
study	O
provides	O
further	O
evidence	O
for	O
the	O
phenotypical	O
heterogeneity	O
of	O
GS	D053579
and	O
its	O
association	O
with	O
severe	O
manifestations	O
in	O
children	O
.	O

It	O
also	O
shows	O
the	O
independent	O
segregation	O
of	O
familial	D006392
cavernomatosis	D006392
and	O
GS	D053579
.	O
Regulation	O
of	O
lung	O
endothelial	O
permeability	O
and	O
inflammatory	D007249
responses	O
by	O
prostaglandin	C100008
A2	C100008
:	O
role	O
of	O
EP4	19219
receptor	19219
.	O

The	O
role	O
of	O
prostaglandin	C100008
A2	C100008
(	O
PGA2	C100008
)	O
in	O
modulation	O
of	O
vascular	O
endothelial	O
function	O
is	O
unknown	O
.	O

We	O
investigated	O
effects	O
of	O
PGA2	C100008
on	O
pulmonary	O
endothelial	O
cell	O
(	O
EC	O
)	O
permeability	O
and	O
inflammatory	D007249
activation	O
and	O
identified	O
a	O
receptor	O
mediating	O
these	O
effects	O
.	O

PGA2	C100008
enhanced	O
the	O
EC	O
barrier	O
and	O
protected	O
against	O
barrier	O
dysfunction	O
caused	O
by	O
vasoactive	O
peptide	O
thrombin	14061
and	O
proinflammatory	D007249
bacterial	O
wall	O
lipopolysaccharide	D008070
(	O
LPS	D008070
)	O
.	O

Receptor	O
screening	O
using	O
pharmacological	O
and	O
molecular	O
inhibitory	O
approaches	O
identified	O
EP4	5734
as	O
a	O
novel	O
PGA2	5734
receptor	5734
.	O

EP4	5734
mediated	O
barrier	O
-	O
protective	O
effects	O
of	O
PGA2	C100008
by	O
activating	O
Rap1	5879,5906
/	O
Rac1	5879,5906
GTPase	5879,5906
and	O
protein	5566
kinase	5566
A	5566
targets	O
at	O
cell	O
adhesions	O
and	O
cytoskeleton	O
:	O
VE	1003
-	O
cadherin	1003
,	O
p120	1500
-	O
catenin	1500
,	O
ZO	7082
-	O
1	7082
,	O
cortactin	2017
,	O
and	O
VASP	7408
.	O

PGA2	C100008
also	O
suppressed	O
LPS	D008070
-	O
induced	O
inflammatory	D007249
signaling	O
by	O
inhibiting	O
the	O
NFkB	19697
pathway	O
and	O
expression	O
of	O
EC	3383,7412
adhesion	3383,7412
molecules	3383,7412
ICAM1	3383
and	O
VCAM1	7412
.	O

These	O
effects	O
were	O
abolished	O
by	O
pharmacological	O
or	O
molecular	O
inhibition	O
of	O
EP4	5734
.	O

In	O
vivo	O
,	O
PGA2	C100008
was	O
protective	O
in	O
two	O
distinct	O
models	O
of	O
acute	D055371
lung	D055371
injury	D055371
(	O
ALI	D055371
)	O
:	O
LPS	D008070
-	O
induced	O
inflammatory	D007249
injury	D007249
and	O
two	O
-	O
hit	O
ALI	D055371
caused	O
by	O
suboptimal	O
mechanical	O
ventilation	O
and	O
injection	O
of	O
thrombin	14062
receptor	14062
-	O
activating	O
peptide	O
.	O

These	O
protective	O
effects	O
were	O
abolished	O
in	O
mice	10090
with	O
endothelial	O
-	O
specific	O
EP4	19219
knockout	O
.	O

The	O
results	O
suggest	O
a	O
novel	O
role	O
for	O
the	O
PGA2	C100008
-	O
EP4	5734
axis	O
in	O
vascular	O
EC	O
protection	O
that	O
is	O
critical	O
for	O
improvement	O
of	O
pathological	O
states	O
associated	O
with	O
increased	O
vascular	O
leakage	O
and	O
inflammation	D007249
.	O
Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	874
reductase	874
3	874
gene	O
CBR3	874
and	O
the	O
NAD	1728
(	O
P	1728
)	O
H	1728
:	O
quinone	1728
oxidoreductase	1728
1	1728
gene	O
NQO1	1728
in	O
patients	9606
who	O
developed	O
anthracycline	D018943
-	O
related	O
congestive	D006333
heart	D006333
failure	D006333
after	O
childhood	O
cancer	D009369
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	D018943
as	O
part	O
of	O
cancer	D009369
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	D006333
heart	D006333
failure	D006333
(	O
CHF	D006333
)	O
.	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline	D018943
-	O
related	O
CHF	D006333
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	D018943
(	O
in	O
particular	O
,	O
the	O
nicotinamide	1728
adenine	1728
dinucleotide	1728
phosphate	1728
:	O
quinone	1728
oxidoreductase	1728
1	1728
gene	O
NQO1	1728
and	O
the	O
carbonyl	874
reductase	874
3	874
gene	O
CBR3	874
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	D018943
-	O
related	O
CHF	D006333
.	O

METHODS	O
:	O
A	O
nested	O
case	O
-	O
control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	9606
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	D018943
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	9606
with	O
CHF	D006333
(	O
cases	O
)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	1728
(	O
NQO1	1728
*	O
2	O
)	O
and	O
CBR3	874
(	O
the	O
CBR3	874
valine	rs1056892
[	O
V	rs1056892
]	O
to	rs1056892
methionine	rs1056892
[	O
M	rs1056892
]	O
substitution	rs1056892
at	rs1056892
position	rs1056892
244	rs1056892
[	O
V244M	rs1056892
]	O
)	O
.	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	874
isoforms	O
(	O
CBR3	874
V244	rs1056892
and	O
CBR3	874
M244	rs1056892
)	O
and	O
the	O
anthracycline	D018943
substrate	O
doxorubicin	D004317
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	874
V244M	rs1056892
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1	1728
*	O
2	O
and	O
CBR3	874
V244M	rs1056892
)	O
and	O
the	O
risk	O
of	O
CHF	D006333
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1	1728
*	O
2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline	D018943
-	O
related	O
CHF	D006333
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1	O
.	O
04	O
;	O
P	O
=	O
.	O
97	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	874
V244M	rs1056892
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	D006333
(	O
OR	O
,	O
8	O
.	O
16	O
;	O
P	O
=	O
.	O
056	O
for	O
G	O
/	O
G	O
vs	O
A	O
/	O
A	O
;	O
OR	O
,	O
5	O
.	O
44	O
;	O
P	O
=	O
.	O
092	O
for	O
G	O
/	O
A	O
vs	O
A	O
/	O
A	O
)	O
.	O

In	O
line	O
,	O
recombinant	O
CBR3	874
V244	rs1056892
(	O
G	O
allele	O
)	O
synthesized	O
2	O
.	O
6	O
-	O
fold	O
more	O
cardiotoxic	D066126
doxorubicinol	C010013
per	O
unit	O
of	O
time	O
than	O
CBR3	874
M244	rs1056892
(	O
A	O
allele	O
;	O
CBR3	874
V244	rs1056892
[	O
8	O
.	O
26	O
+	O
/	O
-	O
3	O
.	O
57	O
nmol	O
/	O
hour	O
.	O
mg	O
]	O
vs	O
CBR3	874
M244	rs1056892
[	O
3	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
67	O
nmol	O
/	O
hour	O
.	O
mg	O
]	O
;	O
P	O
=	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	874
V244M	rs1056892
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	D018943
-	O
related	O
CHF	D006333
among	O
childhood	O
cancer	D009369
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	D066126
anthracycline	D000438,D018943
alcohol	D000438,D018943
metabolites	O
.	O

Larger	O
confirmatory	O
case	O
-	O
control	O
studies	O
are	O
warranted	O
.	O
A	O
polymorphism	O
of	O
C	rs1143627
-	O
to	rs1143627
-	O
T	rs1143627
substitution	rs1143627
at	rs1143627
-	O
31	rs1143627
IL1B	3553
is	O
associated	O
with	O
the	O
risk	O
of	O
advanced	O
gastric	D013274
adenocarcinoma	D013274
in	O
a	O
Japanese	O
population	O
.	O

Proinflammatory	3553
cytokine	3553
gene	O
polymorphisms	O
have	O
been	O
demonstrated	O
to	O
associate	O
with	O
gastric	D013274
cancer	D013274
risk	O
,	O
of	O
which	O
IL1B	3553
-	O
31T	rs1143627
/	O
C	rs1143627
and	O
-	O
511C	rs1143634
/	O
T	rs1143634
changes	O
have	O
been	O
well	O
investigated	O
due	O
to	O
the	O
possibility	O
that	O
they	O
may	O
alter	O
the	O
IL1B	3553
transcription	O
.	O

The	O
signal	O
transduction	O
target	O
upon	O
interleukin	3553
1	3553
beta	3553
(	O
IL1beta	3553
)	O
stimulation	O
,	O
the	O
nuclear	4790
factor	4790
of	4790
kappa	4790
B	4790
(	O
NFkappaB	4790
)	O
activation	O
,	O
supports	O
cancer	D009369
development	O
,	O
signal	O
transduction	O
in	O
which	O
is	O
mediated	O
by	O
FS	355
-	O
7	355
cell	355
-	O
associated	355
cell	355
surface	355
antigen	355
(	O
FAS	355
)	O
signaling	O
.	O

Based	O
on	O
recent	O
papers	O
describing	O
the	O
prognostic	O
roles	O
of	O
the	O
polymorphisms	O
and	O
the	O
NFkappaB	4790
functions	O
on	O
cancer	D009369
development	O
,	O
we	O
sought	O
to	O
determine	O
if	O
Japanese	O
gastric	D013274
cancer	D013274
patients	9606
were	O
affected	O
by	O
the	O
IL1B	3553
-	O
31	O
/	O
-	O
511	O
and	O
FAS	355
-	O
670	O
polymorphisms	O
.	O

A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
on	O
incident	O
gastric	D013274
adenocarcinoma	D013274
patients	9606
(	O
n	O
=	O
271	O
)	O
and	O
age	O
-	O
gender	O
frequency	O
-	O
matched	O
control	O
subjects	O
(	O
n	O
=	O
271	O
)	O
.	O

We	O
observed	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
T	rs1143634
allele	rs1143634
at	rs1143634
-	O
511	rs1143634
and	O
the	O
C	rs1143627
allele	rs1143627
at	rs1143627
-	O
31	rs1143627
and	O
between	O
the	O
C	rs1143634
allele	rs1143634
at	rs1143634
-	O
511	rs1143634
and	O
the	O
T	rs1143627
allele	rs1143627
at	rs1143627
-	O
31	rs1143627
in	O
IL1B	3553
in	O
both	O
the	O
cases	O
and	O
controls	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
94	O
)	O
.	O

Neither	O
IL1B	3553
-	O
31	O
,	O
-	O
511	O
nor	O
FAS	355
-	O
670	O
polymorphisms	O
showed	O
significantly	O
different	O
risks	O
of	O
gastric	D013274
adenocarcinoma	D013274
.	O

Though	O
FAS	355
-	O
670	O
polymorphisms	O
did	O
not	O
show	O
any	O
significant	O
difference	O
,	O
the	O
proportion	O
of	O
subjects	O
with	O
IL1B	3553
-	O
31TT	rs1143627
(	O
or	O
IL1B	3553
-	O
511CC	rs1143634
)	O
increased	O
according	O
to	O
stage	O
(	O
trend	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

In	O
particular	O
,	O
subjects	O
with	O
stage	O
IV	O
had	O
a	O
two	O
times	O
higher	O
probability	O
of	O
having	O
either	O
IL1B	3553
-	O
31TT	rs1143627
(	O
or	O
IL1B	3553
-	O
511CC	rs1143634
)	O
genotype	O
compared	O
with	O
stage	O
I	O
subjects	O
.	O

These	O
observations	O
suggest	O
that	O
IL1B	3553
-	O
31TT	rs1143627
and	O
IL1B	3553
-	O
511CC	rs1143634
are	O
associated	O
with	O
disease	O
progression	O
.	O
On	O
the	O
pivotal	O
role	O
of	O
PPARa	19013
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	D000860
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	D000860
injury	O
.	O

The	O
role	O
of	O
peroxisome	19013
proliferator	19013
-	O
activated	19013
receptor	19013
a	19013
(	O
PPARa	19013
)	O
-	O
mediated	O
metabolic	O
remodeling	O
in	O
cardiac	O
adaptation	O
to	O
hypoxia	D000860
has	O
yet	O
to	O
be	O
defined	O
.	O

Here	O
,	O
mice	10090
were	O
housed	O
in	O
hypoxia	D000860
for	O
3	O
wk	O
before	O
in	O
vivo	O
contractile	O
function	O
was	O
measured	O
using	O
cine	O
MRI	O
.	O

In	O
isolated	O
,	O
perfused	O
hearts	O
,	O
energetics	O
were	O
measured	O
using	O
(	O
31	O
)	O
P	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
,	O
and	O
glycolysis	O
and	O
fatty	D005227
acid	D005227
oxidation	O
were	O
measured	O
using	O
[	O
(	O
3	D014316
)	O
H	D014316
]	O
labeling	O
.	O

Compared	O
with	O
a	O
normoxic	O
,	O
chow	O
-	O
fed	O
control	O
mouse	10090
heart	O
,	O
hypoxia	D000860
decreased	O
PPARa	19013
expression	O
,	O
fatty	D005227
acid	D005227
oxidation	O
,	O
and	O
mitochondrial	22229
uncoupling	22229
protein	22229
3	22229
(	O
UCP3	22229
)	O
levels	O
,	O
while	O
increasing	O
glycolysis	O
,	O
all	O
of	O
which	O
served	O
to	O
maintain	O
normal	O
ATP	D000255
concentrations	O
(	O
[	O
ATP	D000255
]	O
)	O
and	O
thereby	O
,	O
ejection	O
fractions	O
.	O

A	O
high	O
-	O
fat	O
diet	O
increased	O
cardiac	O
PPARa	19013
expression	O
,	O
fatty	D005227
acid	D005227
oxidation	O
,	O
and	O
UCP3	22229
levels	O
with	O
decreased	O
glycolysis	O
.	O

Hypoxia	D000860
was	O
unable	O
to	O
alter	O
the	O
high	O
PPARa	19013
expression	O
or	O
reverse	O
the	O
metabolic	O
changes	O
caused	O
by	O
the	O
high	O
-	O
fat	O
diet	O
,	O
with	O
the	O
result	O
that	O
[	O
ATP	D000255
]	O
and	O
contractile	O
function	O
decreased	O
significantly	O
.	O

The	O
adaptive	O
metabolic	O
changes	O
caused	O
by	O
hypoxia	D000860
in	O
control	O
mouse	10090
hearts	O
were	O
found	O
to	O
have	O
occurred	O
already	O
in	O
PPARa	19013
-	O
deficient	O
(	O
PPARa	19013
(	O
-	O
/	O
-	O
)	O
)	O
mouse	10090
hearts	O
and	O
sustained	O
function	O
in	O
hypoxia	D000860
despite	O
an	O
inability	O
for	O
further	O
metabolic	O
remodeling	O
.	O

We	O
conclude	O
that	O
decreased	O
cardiac	O
PPARa	19013
expression	O
is	O
essential	O
for	O
adaptive	O
metabolic	O
remodeling	O
in	O
hypoxia	D000860
,	O
but	O
is	O
prevented	O
by	O
dietary	O
fat	O
.	O
-	O
Cole	O
,	O
M	O
.	O

A	O
.	O
,	O
Abd	O
Jamil	O
,	O
A	O
.	O

H	O
.	O
,	O
Heather	O
,	O
L	O
.	O

C	O
.	O
,	O
Murray	O
,	O
A	O
.	O

J	O
.	O
,	O
Sutton	O
,	O
E	O
.	O

R	O
.	O
,	O
Slingo	O
,	O
M	O
.	O
,	O
Sebag	O
-	O
Montefiore	O
,	O
L	O
.	O
,	O
Tan	O
,	O
S	O
.	O

C	O
.	O
,	O
Aksentijevic	O
,	O
D	O
.	O
,	O
Gildea	O
,	O
O	O
.	O

S	O
.	O
,	O
Stuckey	O
,	O
D	O
.	O

J	O
.	O
,	O
Yeoh	O
,	O
K	O
.	O

K	O
.	O
,	O
Carr	O
,	O
C	O
.	O

A	O
.	O
,	O
Evans	O
,	O
R	O
.	O

D	O
.	O
,	O
Aasum	O
,	O
E	O
.	O
,	O
Schofield	O
,	O
C	O
.	O

J	O
.	O
,	O
Ratcliffe	O
,	O
P	O
.	O

J	O
.	O
,	O
Neubauer	O
,	O
S	O
.	O
,	O
Robbins	O
,	O
P	O
.	O

A	O
.	O
,	O
Clarke	O
,	O
K	O
.	O

On	O
the	O
pivotal	O
role	O
of	O
PPARa	19013
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	D000860
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	D000860
injury	O
.	O
High	O
-	O
dose	O
tranexamic	D014148
Acid	D014148
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	D012640
in	O
cardiac	O
surgical	O
patients	9606
.	O

BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	D012640
seizures	D012640
from	O
1	O
.	O
3%	O
to	O
3	O
.	O
8%	O
in	O
patients	9606
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	D014148
acid	D014148
(	O
TXA	D014148
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	D014148
usage	O
and	O
seizures	D012640
after	O
cardiac	O
surgery	O
.	O

METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	9606
who	O
developed	O
perioperative	O
seizures	D012640
.	O

Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	9606
,	O
and	O
all	O
patients	9606
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	9606
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	D001930
ischemic	D001930
injury	D001930
,	O
but	O
seizures	D012640
were	O
likely	O
due	O
to	O
ischemic	D001930
brain	D001930
injury	D001930
in	O
3	O
patients	9606
.	O

All	O
patients	9606
with	O
seizures	D012640
did	O
not	O
have	O
permanent	O
neurological	D009422
abnormalities	D009422
.	O

All	O
24	O
patients	9606
with	O
seizures	D012640
received	O
high	O
doses	O
of	O
TXA	D014148
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69	O
.	O
9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

All	O
but	O
one	O
patient	9606
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O

No	O
evidence	O
of	O
brain	D002546
ischemic	D002546
,	O
metabolic	O
,	O
or	O
hyperthermia	D005334
-	O
induced	O
causes	O
for	O
their	O
seizures	D012640
was	O
apparent	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	D014148
in	O
older	O
patients	9606
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	D012640
in	O
susceptible	O
patients	9606
.	O
Cardioprotective	O
effect	O
of	O
tincture	C007145
of	C007145
Crataegus	C007145
on	O
isoproterenol	D007545
-	O
induced	O
myocardial	D009203
infarction	D009203
in	O
rats	10116
.	O

Tincture	C007145
of	C007145
Crataegus	C007145
(	O
TCR	C007145
)	O
,	O
an	O
alcoholic	C007145
extract	C007145
of	C007145
the	C007145
berries	C007145
of	C007145
hawthorn	C007145
(	O
Crataegus	C007145
oxycantha	C007145
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	C007145
on	O
experimentally	O
induced	O
myocardial	D009203
infarction	D009203
in	O
rats	10116
.	O

Pretreatment	O
of	O
TCR	C007145
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	D008055
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	D007545
-	O
induced	O
rats	10116
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O

c	O
.	O

for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	C007145
prevented	O
the	O
isoproterenol	D007545
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	D000244
-	O
stimulated	O
oxygen	D010100
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	C007145
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	D007545
in	O
rat	10116
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	C007145
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	D007545
in	O
rat	10116
heart	O
.	O
Transgelin	6876
increases	O
metastatic	O
potential	O
of	O
colorectal	D015179
cancer	D015179
cells	O
in	O
vivo	O
and	O
alters	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
motility	O
.	O

BACKGROUND	O
:	O
Transgelin	6876
is	O
an	O
actin	21345,6876
-	O
binding	21345,6876
protein	21345,6876
that	O
promotes	O
motility	O
in	O
normal	O
cells	O
.	O

Although	O
the	O
role	O
of	O
transgelin	6876
in	O
cancer	D009369
is	O
controversial	O
,	O
a	O
number	O
of	O
studies	O
have	O
shown	O
that	O
elevated	O
levels	O
correlate	O
with	O
aggressive	O
tumor	D009369
behavior	O
,	O
advanced	O
stage	O
,	O
and	O
poor	O
prognosis	O
.	O

Here	O
we	O
sought	O
to	O
determine	O
the	O
role	O
of	O
transgelin	6876
more	O
directly	O
by	O
determining	O
whether	O
experimental	O
manipulation	O
of	O
transgelin	6876
levels	O
in	O
colorectal	D015179
cancer	D015179
(	O
CRC	D015179
)	O
cells	O
led	O
to	O
changes	O
in	O
metastatic	O
potential	O
in	O
vivo	O
.	O

METHODS	O
:	O
Isogenic	O
CRC	D015179
cell	O
lines	O
that	O
differ	O
in	O
transgelin	6876
expression	O
were	O
characterized	O
using	O
in	O
vitro	O
assays	O
of	O
growth	O
and	O
invasiveness	O
and	O
a	O
mouse	10090
tail	O
vein	O
assay	O
of	O
experimental	O
metastasis	O
.	O

Downstream	O
effects	O
of	O
transgelin	6876
overexpression	O
were	O
investigated	O
by	O
gene	O
expression	O
profiling	O
and	O
quantitative	O
PCR	O
.	O

RESULTS	O
:	O
Stable	O
overexpression	O
of	O
transgelin	6876
in	O
RKO	9606
cells	O
,	O
which	O
have	O
low	O
endogenous	O
levels	O
,	O
led	O
to	O
increased	O
invasiveness	O
,	O
growth	O
at	O
low	O
density	O
,	O
and	O
growth	O
in	O
soft	O
agar	O
.	O

Overexpression	O
also	O
led	O
to	O
an	O
increase	O
in	O
the	O
number	O
and	O
size	O
of	O
lung	D008175
metastases	D008175
in	O
the	O
mouse	10090
tail	O
vein	O
injection	O
model	O
.	O

Similarly	O
,	O
attenuation	O
of	O
transgelin	6876
expression	O
in	O
HCT116	9606
cells	O
,	O
which	O
have	O
high	O
endogenous	O
levels	O
,	O
decreased	O
metastases	D009362
in	O
the	O
same	O
model	O
.	O

Investigation	O
of	O
mRNA	O
expression	O
patterns	O
showed	O
that	O
transgelin	6876
overexpression	O
altered	O
the	O
levels	O
of	O
approximately	O
250	O
other	O
transcripts	O
,	O
with	O
over	O
-	O
representation	O
of	O
genes	O
that	O
affect	O
function	O
of	O
actin	60
or	O
other	O
cytoskeletal	51361,55740,6876,7145
proteins	51361,55740,6876,7145
.	O

Changes	O
included	O
increases	O
in	O
HOOK1	51361
,	O
SDCCAG8	10806
,	O
ENAH	55740
/	O
Mena	55740
,	O
and	O
TNS1	7145
and	O
decreases	O
in	O
EMB	133418
,	O
BCL11B	64919
,	O
and	O
PTPRD	5789
.	O

CONCLUSIONS	O
:	O
Increases	O
or	O
decreases	O
in	O
transgelin	6876
levels	O
have	O
reciprocal	O
effects	O
on	O
tumor	D009369
cell	O
behavior	O
,	O
with	O
higher	O
expression	O
promoting	O
metastasis	O
.	O

Chronic	O
overexpression	O
influences	O
steady	O
-	O
state	O
levels	O
of	O
mRNAs	O
for	O
metastasis	O
-	O
related	O
genes	O
.	O
Vitamin	D014810
E	D014810
reduces	O
cardiovascular	D002318
disease	D002318
in	O
individuals	O
with	O
diabetes	D003920
mellitus	D003920
and	O
the	O
haptoglobin	3240
2	O
-	O
2	O
genotype	O
.	O

AIMS	O
:	O
Individuals	O
with	O
both	O
diabetes	D003920
mellitus	D003920
(	O
DM	D003920
)	O
and	O
the	O
Haptoglobin	3240
(	O
Hp	3240
)	O
2	O
-	O
2	O
genotype	O
are	O
at	O
increased	O
risk	O
of	O
cardiovascular	D002318
disease	D002318
.	O

As	O
the	O
antioxidant	O
function	O
of	O
the	O
Hp	3240
2	O
-	O
2	O
protein	O
is	O
impaired	O
,	O
we	O
sought	O
to	O
test	O
the	O
pharmacogenomic	O
hypothesis	O
that	O
antioxidant	D000975
vitamin	D014810
E	D014810
supplementation	O
would	O
provide	O
cardiovascular	O
protection	O
to	O
Hp	3240
2	O
-	O
2	O
DM	D003920
individuals	O
.	O

MATERIALS	O
&	O
METHODS	O
:	O
We	O
determined	O
the	O
Hp	3240
genotype	O
on	O
DM	D003920
participants	O
from	O
two	O
trials	O
(	O
HOPE	O
and	O
ICARE	O
)	O
and	O
assessed	O
the	O
effect	O
of	O
vitamin	D014810
E	D014810
by	O
Hp	3240
genotype	O
on	O
their	O
common	O
prespecified	O
outcome	O
,	O
the	O
composite	O
of	O
stroke	D020521
,	O
myocardial	D009203
infarction	D009203
and	O
cardiovascular	D002318
death	D002318
.	O

Data	O
was	O
analyzed	O
with	O
a	O
fixed	O
-	O
effect	O
model	O
.	O

These	O
results	O
were	O
input	O
into	O
a	O
simulation	O
model	O
,	O
the	O
Evidence	O
Based	O
Medicine	O
Integrator	O
,	O
in	O
order	O
to	O
estimate	O
their	O
long	O
-	O
term	O
implications	O
in	O
a	O
real	O
-	O
world	O
population	O
from	O
Kaiser	O
Permanente	O
(	O
CA	O
,	O
USA	O
)	O
.	O

RESULTS	O
:	O
Meta	O
-	O
analysis	O
of	O
the	O
two	O
trials	O
demonstrated	O
a	O
significant	O
overall	O
reduction	O
in	O
the	O
composite	O
end	O
point	O
in	O
Hp	3240
2	O
-	O
2	O
DM	D003920
individuals	O
with	O
vitamin	D014810
E	D014810
(	O
odds	O
ratio	O
:	O
0	O
.	O
58	O
;	O
95%	O
CI	O
:	O
0	O
.	O
40	O
-	O
0	O
.	O
86	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
interaction	O
between	O
the	O
Hp	3240
genotype	O
and	O
vitamin	D014810
E	D014810
on	O
the	O
composite	O
end	O
point	O
.	O

In	O
these	O
trials	O
,	O
Hp	3240
typing	O
of	O
69	O
DM	D003920
individuals	O
and	O
treating	O
those	O
with	O
the	O
Hp	3240
2	O
-	O
2	O
with	O
vitamin	D014810
E	D014810
prevented	O
one	O
myocardial	D009203
infarct	D009203
,	O
stroke	D020521
or	O
cardiovascular	D002318
death	D002318
.	O

Lifelong	O
administration	O
of	O
vitamin	D014810
E	D014810
to	O
Hp	3240
2	O
-	O
2	O
DM	D003920
individuals	O
in	O
the	O
Kaiser	O
population	O
would	O
increase	O
their	O
life	O
expectancy	O
by	O
3	O
years	O
.	O

CONCLUSION	O
:	O
A	O
pharmacogenomic	O
strategy	O
of	O
screening	O
DM	D003920
individuals	O
for	O
the	O
Hp	3240
genotype	O
and	O
treating	O
those	O
with	O
Hp	3240
2	O
-	O
2	O
with	O
vitamin	D014810
E	D014810
appears	O
to	O
be	O
highly	O
clinically	O
effective	O
.	O
Clopidogrel	D000077144
pharmacogenomics	O
and	O
risk	O
of	O
inadequate	O
platelet	O
inhibition	O
:	O
US	O
FDA	O
recommendations	O
.	O

Antiplatelet	O
therapy	O
with	O
clopidogrel	D000077144
is	O
the	O
current	O
standard	O
of	O
care	O
for	O
coronary	D003324
artery	D003324
disease	D003324
patients	9606
undergoing	O
a	O
percutaneous	O
coronary	O
intervention	O
.	O

However	O
,	O
approximately	O
25%	O
of	O
patients	9606
experience	O
a	O
subtherapeutic	O
antiplatelet	O
response	O
.	O

Clopidogrel	D000077144
is	O
a	O
prodrug	O
that	O
undergoes	O
hepatic	O
biotransformation	O
by	O
CYP2C19	1557
into	O
its	O
active	O
metabolite	O
.	O

Several	O
studies	O
have	O
reported	O
that	O
,	O
compared	O
with	O
wild	O
-	O
type	O
individuals	O
,	O
CYP2C19	1557
variant	O
allele	O
carriers	O
exhibit	O
a	O
significantly	O
lower	O
capacity	O
to	O
metabolize	O
clopidogrel	D000077144
into	O
its	O
active	O
metabolite	O
and	O
inhibit	O
platelet	O
activation	O
,	O
and	O
are	O
therefore	O
at	O
significantly	O
higher	O
risk	O
of	O
adverse	O
cardiovascular	O
events	O
.	O

Consequently	O
,	O
the	O
US	O
FDA	O
has	O
recently	O
changed	O
clopidogrel	D000077144
'	O
s	O
prescribing	O
information	O
to	O
highlight	O
the	O
impact	O
of	O
CYP2C19	1557
genotype	O
on	O
clopidogrel	D000077144
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
clinical	O
response	O
.	O

Future	O
studies	O
remain	O
necessary	O
to	O
develop	O
effective	O
personalized	O
therapeutic	O
strategies	O
for	O
CYP2C19	1557
variant	O
allele	O
carriers	O
and	O
other	O
individuals	O
at	O
risk	O
for	O
clopidogrel	D000077144
nonresponsiveness	O
.	O
Myc	17869
enhances	O
B	16019
-	O
cell	16019
receptor	16019
signaling	O
in	O
precancerous	D011230
B	O
cells	O
and	O
confers	O
resistance	O
to	O
Btk	12229
inhibition	O
.	O

Dysregulation	O
of	O
the	O
oncogenic	O
transcription	O
factor	O
MYC	17869
induces	O
B	O
-	O
cell	O
transformation	O
and	O
is	O
a	O
driver	O
for	O
B	D016393
-	O
cell	D016393
non	D016393
-	O
Hodgkin	D016393
lymphoma	D016393
(	O
B	D016393
-	O
NHL	D016393
)	O
.	O

MYC	17869
overexpression	O
in	O
B	D016393
-	O
NHL	D016393
is	O
associated	O
with	O
more	O
aggressive	O
phenotypes	O
and	O
poor	O
prognosis	O
.	O

Although	O
genomic	O
studies	O
suggest	O
a	O
link	O
between	O
MYC	17869
overexpression	O
and	O
B	16019
-	O
cell	16019
receptor	16019
(	O
BCR	16019
)	O
signaling	O
molecules	O
in	O
B	D016393
-	O
NHL	D016393
,	O
signaling	O
pathways	O
essential	O
to	O
Myc	17869
-	O
mediated	O
B	O
-	O
cell	O
transformation	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
utilized	O
intracellular	O
phospho	O
-	O
flow	O
cytometry	O
to	O
investigate	O
the	O
relationship	O
between	O
Myc	17869
and	O
BCR	16019
signaling	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
.	O

Utilizing	O
the	O
Eu	O
-	O
myc	17869
mouse	10090
model	O
,	O
where	O
Myc	17869
is	O
overexpressed	O
specifically	O
in	O
B	O
cells	O
,	O
both	O
basal	O
and	O
stimulated	O
BCR	16019
signaling	O
were	O
increased	O
in	O
precancerous	D011230
B	O
lymphocytes	O
from	O
Eu	O
-	O
myc	17869
mice	10090
compared	O
with	O
wild	O
-	O
type	O
littermates	O
.	O

B	O
cells	O
overexpressing	O
Myc	17869
displayed	O
constitutively	O
higher	O
levels	O
of	O
activated	O
CD79a	12518
,	O
Btk	12229
,	O
Plcg2	234779
and	O
Erk1	26413,26417
/	O
2	26413,26417
.	O

Notably	O
,	O
Myc	17869
-	O
overexpressing	O
B	O
cells	O
maintained	O
elevated	O
BCR	16019
signaling	O
despite	O
treatment	O
with	O
ibrutinib	C551803
,	O
a	O
Bruton	695
'	O
s	695
tyrosine	695
kinase	695
inhibitor	O
.	O

Furthermore	O
,	O
PI3K	18708
/	O
Akt	11651
pathway	O
signaling	O
was	O
also	O
increased	O
in	O
Eu	O
-	O
myc	17869
B	O
cells	O
,	O
and	O
this	O
increase	O
was	O
partially	O
suppressed	O
with	O
ibrutinib	C551803
.	O

In	O
addition	O
,	O
experiments	O
with	O
Btk	12229
-	O
null	O
B	O
cells	O
revealed	O
off	O
-	O
target	O
effects	O
of	O
ibrutinib	C551803
on	O
BCR	16019
signaling	O
.	O

Our	O
data	O
show	O
that	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
,	O
Myc	17869
overexpression	O
is	O
sufficient	O
to	O
activate	O
BCR	16019
and	O
PI3K	18708
/	O
Akt	11651
signaling	O
pathways	O
and	O
further	O
enhances	O
signaling	O
following	O
BCR	16019
ligation	O
.	O

Therefore	O
,	O
our	O
results	O
indicate	O
that	O
precancerous	D011230
B	O
cells	O
have	O
already	O
acquired	O
enhanced	O
survival	O
and	O
growth	O
capabilities	O
before	O
transformation	O
,	O
and	O
that	O
elevated	O
MYC	17869
levels	O
confer	O
resistance	O
to	O
pharmacologic	O
inhibitors	O
of	O
BCR	16019
signaling	O
,	O
which	O
has	O
significant	O
implications	O
for	O
B	D016393
-	O
NHL	D016393
treatment	O
.	O
Genetic	O
investigation	O
of	O
four	O
meiotic	O
genes	O
in	O
women	9606
with	O
premature	D016649
ovarian	D016649
failure	D016649
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
mutations	O
of	O
meiotic	O
genes	O
,	O
such	O
as	O
disrupted	O
meiotic	O
cDNA	O
(	O
DMC1	11144
)	O
,	O
MutS	850545
homolog	O
(	O
MSH4	4438
)	O
,	O
MSH5	4439
,	O
and	O
S	4932
.	O

cerevisiae	4932
homolog	O
(	O
SPO11	856364
)	O
,	O
were	O
associated	O
with	O
premature	D016649
ovarian	D016649
failure	D016649
(	O
POF	D016649
)	O
.	O

DESIGN	O
:	O
Case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
Blood	O
sampling	O
,	O
karyotype	O
,	O
hormonal	O
dosage	O
,	O
ultrasound	O
,	O
and	O
ovarian	O
biopsy	O
were	O
carried	O
out	O
on	O
most	O
patients	9606
.	O

However	O
,	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
samples	O
of	O
41	O
women	9606
with	O
POF	D016649
and	O
36	O
fertile	O
women	9606
(	O
controls	O
)	O
.	O

RESULTS	O
:	O
A	O
single	O
heterozygous	O
missense	O
mutation	O
,	O
substitution	O
of	O
a	O
cytosine	rs2075789
residue	rs2075789
with	rs2075789
thymidine	rs2075789
in	O
exon	O
2	O
of	O
MSH5	4439
,	O
was	O
found	O
in	O
two	O
Caucasian	O
women	9606
in	O
whom	O
POF	D016649
developed	O
at	O
18	O
and	O
36	O
years	O
of	O
age	O
.	O

This	O
mutation	O
resulted	O
in	O
replacement	O
of	O
a	O
non	O
-	O
polar	O
amino	O
acid	O
(	O
proline	rs2075789
)	O
with	rs2075789
a	rs2075789
polar	rs2075789
amino	rs2075789
acid	rs2075789
(	O
serine	rs2075789
)	O
at	rs2075789
position	rs2075789
29	rs2075789
(	O
P29S	rs2075789
)	O
.	O

Neither	O
36	O
control	O
women	9606
nor	O
39	O
other	O
patients	9606
with	O
POF	D016649
possessed	O
this	O
genetic	O
perturbation	O
.	O

Another	O
POF	D016649
patient	9606
of	O
African	O
origin	O
showed	O
a	O
homozygous	O
nucleotide	O
change	O
in	O
the	O
tenth	O
of	O
DMC1	11144
gene	O
that	O
led	O
to	O
an	O
alteration	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
(	O
M200V	rs2227914
)	O
.	O

CONCLUSIONS	O
:	O
The	O
symptoms	O
of	O
infertility	D007247
observed	O
in	O
the	O
DMC1	11144
homozygote	O
mutation	O
carrier	O
and	O
in	O
both	O
patients	9606
with	O
a	O
heterozygous	O
substitution	O
in	O
exon	O
2	O
of	O
the	O
MSH5	4439
gene	O
provide	O
indirect	O
evidence	O
of	O
the	O
role	O
of	O
genes	O
involved	O
in	O
meiotic	O
recombination	O
in	O
the	O
regulation	O
of	O
ovarian	O
function	O
.	O

MSH5	4439
and	O
DMC1	11144
mutations	O
may	O
be	O
one	O
explanation	O
for	O
POF	D016649
,	O
albeit	O
uncommon	O
.	O
Nicotine	D009538
antagonizes	O
caffeine	D002110
-	O
but	O
not	O
pentylenetetrazole	D010433
-	O
induced	O
anxiogenic	D001008
effect	D001008
in	O
mice	10090
.	O

RATIONALE	O
:	O
Nicotine	D009538
and	O
caffeine	D002110
are	O
widely	O
consumed	O
licit	O
psychoactive	D011619
drugs	D011619
worldwide	O
.	O

Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	D001008
responses	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	D009538
on	O
anxiety	D001008
induced	O
by	O
caffeine	D002110
and	O
another	O
anxiogenic	D014151
drug	D014151
,	O
pentylenetetrazole	D010433
,	O
in	O
mice	10090
.	O

The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	D001008
.	O

METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	10090
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	D009538
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	D002110
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentylenetetrazole	D010433
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
injections	O
.	O

After	O
15	O
min	O
,	O
mice	10090
were	O
evaluated	O
for	O
their	O
open	O
-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O

Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O

RESULTS	O
:	O
Nicotine	D009538
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	D002110
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	D010433
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	D001008
effect	D001008
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O

Nicotine	D009538
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	D002110
-	O
but	O
not	O
pentylenetetrazole	D010433
-	O
induced	O
anxiety	D001008
.	O

Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	D009538
on	O
caffeine	D002110
-	O
induced	O
anxiety	D001008
is	O
specific	O
to	O
caffeine	D002110
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	D009538
and	O
caffeine	D002110
.	O
Behavioral	O
effects	O
of	O
pubertal	O
anabolic	D045165
androgenic	D045165
steroid	D045165
exposure	O
in	O
male	O
rats	10116
with	O
low	O
serotonin	D012701
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	D045165
androgenic	D045165
steroid	D045165
(	O
AAS	D045165
)	O
exposure	O
and	O
brain	O
serotonin	D012701
(	O
5	D012701
-	O
hydroxytryptamine	D012701
,	O
5	D012701
-	O
HT	D012701
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	10116
.	O

Serotonin	D012701
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	D010134
(	O
PCPA	D010134
100	O
mg	O
/	O
kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O

At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	D010134
-	O
treated	O
rats	10116
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	10116
began	O
treatment	O
with	O
testosterone	D013739
(	O
T	D013739
,	O
5	O
mg	O
/	O
kg	O
,	O
5	O
days	O
/	O
week	O
)	O
.	O

Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	D001523
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	D001523
.	O

Animals	O
were	O
tested	O
for	O
aggression	D001523
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O

Brain	O
levels	O
of	O
5	D012701
-	O
HT	D012701
and	O
its	O
metabolite	O
,	O
5	D006897
-	O
hydroxyindoleacetic	D006897
acid	D006897
(	O
5	D006897
-	O
HIAA	D006897
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O

PCPA	D010134
significantly	O
and	O
substantially	O
depleted	O
5	D012701
-	O
HT	D012701
and	O
5	D006897
-	O
HIAA	D006897
in	O
all	O
brain	O
regions	O
examined	O
.	O

Chronic	O
T	D013739
treatment	O
significantly	O
decreased	O
5	D012701
-	O
HT	D012701
and	O
5	D006897
-	O
HIAA	D006897
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	D010134
.	O

Chronic	O
exposure	O
to	O
PCPA	D010134
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	D001523
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	D001523
.	O

T	D013739
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	D001523
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	D001523
.	O

The	O
most	O
striking	O
effect	O
of	O
combining	O
T	D013739
+	O
PCPA	D010134
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	D045165
users	O
with	O
low	O
central	O
5	D012701
-	O
HT	D012701
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	D001523
behavior	D001523
.	O
DNA	O
damage	O
and	O
repair	O
in	O
gastric	D013274
cancer	D013274
-	O
-	O
a	O
correlation	O
with	O
the	O
hOGG1	4968
and	O
RAD51	5888
genes	O
polymorphisms	O
.	O

The	O
cell	O
'	O
s	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	D009369
induction	O
,	O
promotion	O
and	O
progression	O
.	O

Both	O
the	O
mutagens	O
'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
,	O
including	O
DNA	O
repair	O
genes	O
.	O

The	O
hOGG1	4968
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	5888
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O

Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
,	O
which	O
can	O
contribute	O
to	O
stomach	D013274
cancer	D013274
.	O

In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	D006861
peroxide	D006861
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	D013274
cancer	D013274
patients	9606
and	O
30	O
healthy	O
individuals	O
.	O

The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	4968
and	O
RAD51	5888
genes	O
:	O
a	O
G	rs1052133
-	O
-	O
>	O
C	rs1052133
transversion	rs1052133
at	rs1052133
1245	rs1052133
position	rs1052133
of	O
the	O
hOGG1	4968
gene	O
producing	O
a	O
Ser	rs1052133
-	O
-	O
>	O
Cys	rs1052133
substitution	rs1052133
at	rs1052133
the	rs1052133
codon	rs1052133
326	rs1052133
(	O
the	O
Ser326Cys	rs1052133
polymorphism	O
)	O
and	O
a	O
G	g|SUB|G|135|C
-	O
-	O
>	O
C	g|SUB|G|135|C
substitution	g|SUB|G|135|C
at	g|SUB|G|135|C
position	g|SUB|G|135|C
135	g|SUB|G|135|C
(	O
5	O
'	O
-	O
untranslated	O
region	O
)	O
of	O
the	O
RAD51	5888
gene	O
(	O
the	O
G135C	g|SUB|G|135|C
polymorphism	O
)	O
.	O

DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	4913
III	4913
(	O
Nth	4913
)	O
and	O
formamidopyrimidine	79661
-	O
DNA	79661
glycosylase	79661
(	O
Fpg	79661
)	O
,	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O

The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O

We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	D013274
cancer	D013274
occurrence	O
,	O
impaired	O
DNA	O
repair	O
in	O
human	9606
lymphocytes	O
and	O
the	O
G	g|SUB|G||C
/	O
C	g|SUB|G||C
genotype	O
of	O
the	O
G135C	g|SUB|G|135|C
polymorphism	O
of	O
the	O
RAD51	5888
gene	O
.	O

Moreover	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	D013274
cancer	D013274
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	rs1052133
polymorphism	O
of	O
the	O
hOGG1	4968
gene	O
and	O
gastric	D013274
cancer	D013274
,	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and	O
/	O
or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O

Therefore	O
,	O
our	O
result	O
suggest	O
that	O
the	O
G135C	g|SUB|G|135|C
polymorphism	O
of	O
the	O
RAD51	5888
gene	O
may	O
be	O
linked	O
with	O
gastric	D013274
cancer	D013274
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or	O
/	O
and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O
Ca2	D002118
+	O
dependence	O
of	O
the	O
Ca2	D002118
+	O
-	O
selective	O
TRPV6	55503
channel	O
.	O

Microfluorimetry	O
and	O
patch	O
-	O
clamp	O
experiments	O
were	O
performed	O
on	O
TRPV6	55503
-	O
expressing	O
HEK	9606
cells	O
to	O
determine	O
whether	O
this	O
Ca	D002118
(	O
2	D002118
+	O
)	O
-	O
sensing	O
Ca	D002118
(	O
2	D002118
+	O
)	O
channel	O
is	O
constitutively	O
active	O
.	O

Intact	O
cells	O
loaded	O
with	O
fura	D016257
-	O
2	D016257
had	O
an	O
elevated	O
intracellular	O
free	O
Ca	D002118
(	O
2	D002118
+	O
)	O
concentration	O
(	O
(	O
i	O
)	O
)	O
,	O
which	O
decreased	O
to	O
the	O
same	O
level	O
such	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
if	O
external	O
Ca	D002118
(	O
2	D002118
+	O
)	O
was	O
chelated	O
by	O
EGTA	D004533
.	O

Whole	O
cell	O
recordings	O
from	O
non	O
-	O
transfected	O
HEK	9606
cells	O
and	O
cells	O
expressing	O
human	9606
TRPV6	55503
revealed	O
the	O
presence	O
of	O
a	O
basal	O
inward	O
current	O
in	O
both	O
types	O
of	O
cells	O
when	O
the	O
internal	O
solution	O
contained	O
0	O
.	O
1	O
mm	O
EGTA	D004533
and	O
100	O
nm	O
(	O
i	O
)	O
or	O
if	O
the	O
cytosolic	O
Ca	D002118
(	O
2	D002118
+	O
)	O
buffering	O
remained	O
undisturbed	O
in	O
perforated	O
patch	O
-	O
clamp	O
experiments	O
.	O

If	O
recombinantly	O
expressed	O
TRPV6	55503
forms	O
open	O
channels	O
,	O
one	O
would	O
expect	O
Ca	D002118
(	O
2	D002118
+	O
)	O
-	O
induced	O
current	O
inhibition	O
,	O
because	O
TRPV6	55503
is	O
negatively	O
regulated	O
by	O
internal	O
Ca	D002118
(	O
2	D002118
+	O
)	O
.	O

However	O
,	O
dialyzing	O
solutions	O
with	O
high	O
such	O
as	O
1	O
microm	O
into	O
TRPV6	55503
-	O
expressing	O
cells	O
did	O
not	O
block	O
the	O
basal	O
inward	O
current	O
,	O
which	O
was	O
not	O
different	O
from	O
the	O
recordings	O
from	O
non	O
-	O
transfected	O
cells	O
.	O

In	O
contrast	O
,	O
dialyzing	O
0	O
.	O
5	O
mm	O
EGTA	D004533
into	O
TRPV6	55503
-	O
expressing	O
cells	O
readily	O
activated	O
Ca	D002118
(	O
2	D002118
+	O
)	O
inward	O
currents	O
,	O
which	O
were	O
undetectable	O
in	O
non	O
-	O
transfected	O
cells	O
.	O

Interestingly	O
,	O
monovalent	O
cations	O
permeated	O
the	O
TRPV6	55503
channels	O
under	O
conditions	O
where	O
no	O
Ca	D002118
(	O
2	D002118
+	O
)	O
permeation	O
was	O
detectable	O
,	O
indicating	O
that	O
divalent	O
cations	O
block	O
TRPV6	55503
channels	O
from	O
the	O
extracellular	O
side	O
.	O

Like	O
human	9606
TRPV6	55503
,	O
the	O
truncated	O
human	9606
TRPV6	55503
(	O
Delta695	p|DEL|695-725|
-	O
725	p|DEL|695-725|
)	O
,	O
which	O
lacks	O
the	O
C	O
-	O
terminal	O
domain	O
required	O
for	O
Ca	D002118
(	O
2	D002118
+	O
)	O
-	O
calmodulin	O
binding	O
,	O
does	O
not	O
form	O
constitutive	O
active	O
channels	O
,	O
whereas	O
the	O
human	9606
TRPV6	55503
(	O
D542A	p|SUB|D|542|A
)	O
,	O
carrying	O
a	O
point	O
mutation	O
in	O
the	O
presumed	O
pore	O
region	O
,	O
does	O
not	O
function	O
as	O
a	O
channel	O
.	O

In	O
summary	O
,	O
no	O
constitutive	O
open	O
TRPV6	55503
channels	O
were	O
detected	O
in	O
patch	O
-	O
clamp	O
experiments	O
from	O
transfected	O
HEK	9606
cells	O
.	O

However	O
,	O
channel	O
activity	O
is	O
highly	O
regulated	O
by	O
intracellular	O
and	O
extracellular	O
divalent	O
cations	O
.	O
Memory	O
function	O
and	O
serotonin	6532
transporter	6532
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	D018817
(	O
MDMA	D018817
)	O
users	O
.	O

Although	O
3	D018817
,	O
4	D018817
-	O
methylenedioxymethamphetamine	D018817
(	O
MDMA	D018817
or	O
ecstasy	D018817
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	D012701
(	O
5	D012701
-	O
HT	D012701
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	9606
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	D018817
-	O
induced	O
5	D012701
-	O
HT	D012701
neurotoxic	D020258
lesions	D020258
on	O
functions	O
in	O
which	O
5	D012701
-	O
HT	D012701
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

Because	O
5	D012701
-	O
HT	D012701
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5	D012701
-	O
HT	D012701
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5	6532
-	O
HT	6532
transporter	6532
promoter	6532
gene	6532
region	6532
(	O
5	6532
-	O
HTTLPR	6532
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	D018817
as	O
well	O
as	O
cognitive	O
functioning	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	D018817
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	D018817
,	O
in	O
subjects	O
genotyped	O
for	O
5	6532
-	O
HTTLPR	6532
.	O

A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O

Fifteen	O
moderate	O
MDMA	D018817
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA	D018817
+	O
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex	O
-	O
MDMA	D018817
+	O
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O

DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5	6532
-	O
HTTLPR	6532
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods	O
.	O
A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0	O
.	O
61	O
)	O
or	O
attention	O
/	O
executive	O
functioning	O
(	O
p	O
=	O
0	O
.	O
59	O
)	O
.	O

Heavy	O
and	O
ex	O
-	O
MDMA	D018817
+	O
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	D008569
impairment	D008569
was	O
observed	O
in	O
moderate	O
MDMA	D018817
users	O
.	O

No	O
significant	O
effect	O
of	O
5	6532
-	O
HTTLPR	6532
or	O
gender	O
was	O
observed	O
.	O

While	O
the	O
use	O
of	O
MDMA	D018817
in	O
quantities	O
that	O
may	O
be	O
considered	O
""""	O
moderate	O
""""	O
is	O
not	O
associated	O
with	O
impaired	D008569
memory	D008569
functioning	D008569
,	O
heavy	O
use	O
of	O
MDMA	D018817
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	D008569
impairments	D008569
.	O

No	O
effect	O
of	O
5	6532
-	O
HTTLPR	6532
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	D018817
use	O
was	O
observed	O
.	O
Effects	O
of	O
common	O
germline	O
genetic	O
variation	O
in	O
cell	O
cycle	O
control	O
genes	O
on	O
breast	D001943
cancer	D001943
survival	O
:	O
results	O
from	O
a	O
population	O
-	O
based	O
cohort	O
.	O

INTRODUCTION	O
:	O
Somatic	O
alterations	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
breast	D001943
cancer	D001943
prognosis	O
and	O
survival	O
,	O
but	O
less	O
is	O
known	O
about	O
the	O
effects	O
of	O
common	O
inherited	O
genetic	O
variation	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
cell	O
cycle	O
pathways	O
,	O
which	O
regulate	O
cell	O
division	O
.	O

METHODS	O
:	O
We	O
examined	O
associations	O
between	O
common	O
germline	O
genetic	O
variation	O
in	O
13	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
(	O
CCND1	595
,	O
CCND2	894
,	O
CCND3	896
,	O
CCNE1	898
,	O
CDK2	1017
[	O
p33	1017
]	O
,	O
CDK4	1019
,	O
CDK6	1021
,	O
CDKN1A	1026
[	O
p21	1026
,	O
Cip1	1026
]	O
,	O
CDKN1B	1027
[	O
p27	1027
,	O
Kip1	1027
]	O
,	O
CDKN2A	1029
[	O
p16	1029
]	O
,	O
CDKN2B	1030
[	O
p15	1030
]	O
,	O
CDKN2C	1031
[	O
p18	1031
]	O
,	O
and	O
CDKN2D	1032
[	O
p19	1029
]	O
)	O
and	O
survival	O
among	O
women	9606
diagnosed	O
with	O
invasive	D001943
breast	D001943
cancer	D001943
participating	O
in	O
the	O
SEARCH	O
(	O
Studies	O
of	O
Epidemiology	O
and	O
Risk	O
factors	O
in	O
Cancer	O
Heredity	O
)	O
breast	D001943
cancer	D001943
study	O
.	O

DNA	O
from	O
up	O
to	O
4	O
,	O
470	O
women	9606
was	O
genotyped	O
for	O
85	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
polymorphisms	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
05	O
)	O
in	O
the	O
genes	O
.	O

The	O
genotypes	O
of	O
each	O
polymorphism	O
were	O
tested	O
for	O
association	O
with	O
survival	O
using	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
rare	O
allele	O
of	O
the	O
tagging	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
rs2479717	rs2479717
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	D003643
(	O
hazard	O
ratio	O
=	O
1	O
.	O
26	O
per	O
rare	O
allele	O
carried	O
,	O
95%	O
confidence	O
interval	O
:	O
1	O
.	O
12	O
to	O
1	O
.	O
42	O
;	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
which	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumour	D009369
stage	O
,	O
grade	O
,	O
and	O
treatment	O
.	O

This	O
SNP	O
is	O
part	O
of	O
a	O
large	O
linkage	O
disequilibrium	O
block	O
,	O
which	O
contains	O
CCND3	896
,	O
BYSL	705
,	O
TRFP	55031
,	O
USP49	25862
,	O
C6ofr49	29964
,	O
FRS3	10817
,	O
and	O
PGC	5225
.	O

We	O
evaluated	O
the	O
association	O
of	O
survival	O
and	O
somatic	O
expression	O
of	O
these	O
genes	O
in	O
breast	D001943
tumours	D001943
using	O
expression	O
microarray	O
data	O
from	O
seven	O
published	O
datasets	O
.	O

Elevated	O
expression	O
of	O
the	O
C6orf49	29964
transcript	O
was	O
associated	O
with	O
breast	D001943
cancer	D001943
survival	O
,	O
adding	O
biological	O
interest	O
to	O
the	O
finding	O
.	O

CONCLUSION	O
:	O
It	O
is	O
possible	O
that	O
CCND3	896
rs2479717	rs2479717
,	O
or	O
another	O
variant	O
it	O
tags	O
,	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	D001943
cancer	D001943
.	O

Further	O
study	O
is	O
required	O
to	O
validate	O
this	O
finding	O
.	O
Disruption	O
of	O
a	O
synaptotagmin	255928
(	O
SYT14	255928
)	O
associated	O
with	O
neurodevelopmental	D009421
abnormalities	D009421
.	O

We	O
report	O
cytogenetic	O
and	O
molecular	O
studies	O
of	O
a	O
de	O
novo	O
,	O
apparently	O
balanced	O
t	O
(	O
1	O
;	O
3	O
)	O
(	O
q32	O
.	O
1	O
;	O
q25	O
.	O
1	O
)	O
identified	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
female	O
(	O
designated	O
DGAP128	O
)	O
with	O
cerebral	D001927
atrophy	D001927
,	O
macrocephaly	D058627
seizures	D012640
,	O
and	O
developmental	D002658
delay	D002658
.	O

A	O
combination	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
Southern	O
blot	O
analysis	O
demonstrated	O
disruption	O
of	O
a	O
synaptotagmin	255928
gene	O
(	O
SYT14	255928
)	O
at	O
the	O
1q32	O
breakpoint	O
.	O

Expression	O
of	O
SYT14	255928
in	O
human	9606
brain	O
was	O
confirmed	O
using	O
Northern	O
analysis	O
.	O

Because	O
members	O
of	O
the	O
synaptotagmin	255928
family	O
of	O
proteins	O
function	O
as	O
sensors	O
that	O
link	O
changes	O
in	O
calcium	D002118
levels	O
with	O
a	O
variety	O
of	O
biological	O
processes	O
,	O
including	O
neurotransmission	O
and	O
hormone	O
-	O
responsiveness	O
,	O
SYT14	255928
is	O
an	O
intriguing	O
candidate	O
gene	O
for	O
the	O
abnormal	O
development	O
in	O
this	O
child	O
.	O

This	O
is	O
the	O
first	O
known	O
constitutional	O
rearrangement	O
of	O
SYT14	255928
,	O
and	O
further	O
systematic	O
genetic	O
analysis	O
and	O
clinical	O
studies	O
of	O
DGAP128	O
may	O
offer	O
unique	O
insights	O
into	O
the	O
role	O
of	O
SYT14	255928
in	O
neurodevelopment	O
.	O
Atorvastatin	D000069059
prevented	O
and	O
reversed	O
dexamethasone	D003907
-	O
induced	O
hypertension	D006973
in	O
the	O
rat	10116
.	O

To	O
assess	O
the	O
antioxidant	D000975
effects	O
of	O
atorvastatin	D000069059
(	O
atorva	D000069059
)	O
on	O
dexamethasone	D003907
(	O
dex	D003907
)	O
-	O
induced	O
hypertension	D006973
,	O
60	O
male	O
Sprague	O
-	O
Dawley	O
rats	10116
were	O
treated	O
with	O
atorva	D000069059
30	O
mg	O
/	O
kg	O
/	O
day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	D003907
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+	O
/	O
-	O
1	O
.	O
8	O
to	O
135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
and	O
plasma	O
superoxide	D013481
(	O
5711	O
+	O
/	O
-	O
284	O
.	O
9	O
saline	O
,	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
U	O
/	O
ml	O
dex	D003907
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	D000069059
+	O
dex	D003907
group	O
was	O
increased	O
from	O
115	O
+	O
/	O
-	O
0	O
.	O
4	O
to	O
124	O
+	O
/	O
-	O
1	O
.	O
5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex	D003907
-	O
only	O
group	O
(	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	D000069059
reversed	O
dex	D003907
-	O
induced	O
hypertension	D006973
(	O
129	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
,	O
vs	O
.	O

135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
and	O
decreased	O
plasma	O
superoxide	D013481
(	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
dex	D003907
,	O
1187	O
+	O
/	O
-	O
441	O
.	O
2	O
atorva	D000069059
+	O
dex	D003907
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Plasma	O
nitrate	D009566
/	O
nitrite	D009573
(	O
NOx	D009589
)	O
was	O
decreased	O
in	O
dex	D003907
-	O
treated	O
rats	10116
compared	O
to	O
saline	O
-	O
treated	O
rats	10116
(	O
11	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
08	O
microm	O
,	O
15	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
17	O
microm	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	D000069059
affected	O
neither	O
plasma	O
NOx	D009589
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	D000069059
prevented	O
and	O
reversed	O
dexamethasone	D003907
-	O
induced	O
hypertension	D006973
in	O
the	O
rat	10116
.	O
Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	D010300
Parkinson	D010300
'	O
s	D010300
disease	D010300
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	D010300
Parkinson	D010300
'	O
s	D010300
disease	D010300
(	O
PD	D010300
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

Ten	O
consecutive	O
patients	9606
(	O
mean	O
age	O
,	O
58	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
8	O
years	O
;	O
7	O
men	9606
,	O
3	O
women	9606
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
,	O
8	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	D007980
-	O
induced	O
dyskinesias	D004409
were	O
selected	O
.	O

All	O
patients	9606
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	D007980
equivalent	O
dosing	O
were	O
analysed	O
.	O

Six	O
patients	9606
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	D010300
'	O
s	D010300
Disease	D010300
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn_Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'	O
-	O
and	O
'	O
off	O
'	O
-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	D010300
motor	O
signs	O
in	O
all	O
patients	9606
followed	O
for	O
6	O
months	O
.	O

Levodopa	D007980
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O

Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O

Complications	O
were	O
observed	O
in	O
two	O
patients	9606
:	O
one	O
had	O
a	O
left	O
homonymous	D006423
hemianopsia	D006423
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	D014635
1000	O
mg	O
/	O
day	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	9606
with	O
advanced	O
PD	D010300
refractory	O
to	O
medical	O
treatment	O
.	O
Cholecystokinin	D012844
-	O
octapeptide	D012844
restored	O
morphine	D009020
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	10116
.	O

Cholecystokinin	D012844
-	O
octapeptide	D012844
(	O
CCK	D012844
-	O
8	D012844
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	D012844
-	O
8	D012844
significantly	O
alleviated	O
morphine	D009020
-	O
induced	O
amnesia	D000647
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	D009020
-	O
treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	D012844
-	O
8	D012844
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-	O
granule	O
cell	O
synapse	O
of	O
rat	10116
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	D009020
-	O
treated	O
rats	10116
.	O

Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O

Acute	O
morphine	D009020
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK	D012844
-	O
8	D012844
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	D009020
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK	D012844
-	O
8	D012844
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rats	10116
.	O

Pre	O
-	O
treatment	O
of	O
the	O
CCK2	25706
receptor	25706
antagonist	O
L	C058121
-	O
365	C058121
,	O
260	C058121
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK	D012844
-	O
8	D012844
,	O
but	O
the	O
CCK1	24889
receptor	24889
antagonist	O
L	D020109
-	O
364	D020109
,	O
718	D020109
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK	D012844
-	O
8	D012844
attenuates	O
the	O
effect	O
of	O
morphine	D009020
on	O
hippocampal	O
LTP	O
through	O
CCK2	25706
receptors	25706
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	D012844
-	O
8	D012844
on	O
morphine	D009020
-	O
induced	O
memory	D008569
impairment	D008569
.	O
Distinct	O
patterns	O
of	O
germ	O
-	O
line	O
deletions	O
in	O
MLH1	4292
and	O
MSH2	4436
:	O
the	O
implication	O
of	O
Alu	O
repetitive	O
element	O
in	O
the	O
genetic	O
etiology	O
of	O
Lynch	D003123
syndrome	D003123
(	O
HNPCC	D003123
)	O
.	O

A	O
relatively	O
high	O
frequency	O
of	O
germ	O
-	O
line	O
genomic	O
rearrangements	O
in	O
MLH1	4292
and	O
MSH2	4436
has	O
been	O
reported	O
among	O
Lynch	D003123
Syndrome	D003123
(	O
HNPCC	D003123
)	O
patients	9606
from	O
different	O
ethnic	O
populations	O
.	O

To	O
investigate	O
the	O
underlying	O
molecular	O
mechanisms	O
,	O
we	O
characterized	O
the	O
DNA	O
breakpoints	O
of	O
11	O
germ	O
-	O
line	O
deletions	O
,	O
six	O
for	O
MLH1	4292
and	O
five	O
for	O
MSH2	4436
.	O

Distinct	O
deletion	O
patterns	O
were	O
found	O
for	O
the	O
two	O
genes	O
.	O

The	O
five	O
cases	O
of	O
MSH2	4436
deletions	O
result	O
exclusively	O
from	O
intragenic	O
unequal	O
recombination	O
mediated	O
by	O
repetitive	O
Alu	O
sequences	O
.	O

In	O
contrast	O
,	O
five	O
out	O
of	O
the	O
six	O
MLH1	4292
deletions	O
are	O
due	O
to	O
recombinations	O
involving	O
sequences	O
of	O
no	O
significant	O
homology	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
DNA	O
breakpoints	O
in	O
the	O
two	O
genes	O
,	O
previously	O
characterized	O
by	O
other	O
groups	O
,	O
validated	O
the	O
observation	O
that	O
Alu	O
-	O
mediated	O
unequal	O
recombination	O
is	O
the	O
main	O
type	O
of	O
deletion	O
in	O
MSH2	4436
(	O
n	O
=	O
34	O
)	O
,	O
but	O
not	O
in	O
MLH1	4292
(	O
n	O
=	O
21	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Plotting	O
the	O
distribution	O
of	O
known	O
DNA	O
breakpoints	O
among	O
the	O
introns	O
of	O
the	O
two	O
genes	O
showed	O
that	O
,	O
the	O
highest	O
breakpoint	O
density	O
is	O
co	O
-	O
localized	O
with	O
the	O
highest	O
Alu	O
density	O
.	O

Our	O
study	O
suggests	O
that	O
Alu	O
is	O
a	O
promoting	O
factor	O
for	O
the	O
genomic	O
recombinations	O
in	O
both	O
MLH1	4292
and	O
MSH2	4436
,	O
and	O
the	O
local	O
Alu	O
density	O
may	O
be	O
involved	O
in	O
shaping	O
the	O
deletion	O
pattern	O
.	O
Vitamin	7421
D	7421
receptor	7421
expression	O
is	O
associated	O
with	O
PIK3CA	5290
and	O
KRAS	3845
mutations	O
in	O
colorectal	D015179
cancer	D015179
.	O

Vitamin	D014807
D	D014807
is	O
associated	O
with	O
decreased	O
risks	O
of	O
various	O
cancers	D009369
,	O
including	O
colon	D015179
cancer	D015179
.	O

The	O
vitamin	7421
D	7421
receptor	7421
(	O
VDR	7421
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
cellular	O
differentiation	O
and	O
inhibition	O
of	O
proliferation	O
.	O

A	O
link	O
between	O
VDR	7421
and	O
the	O
RAS	3845
-	O
mitogen	1432
-	O
activated	1432
protein	1432
kinase	1432
(	O
MAPK	1432
)	O
or	O
phosphatidylinositol	5290
3	5290
-	O
kinase	5290
(	O
PI3K	5290
)	O
-	O
AKT	207
pathway	O
has	O
been	O
suggested	O
.	O

However	O
,	O
the	O
prognostic	O
role	O
of	O
VDR	7421
expression	O
or	O
its	O
relationship	O
with	O
PIK3CA	5290
or	O
KRAS	3845
mutation	O
remains	O
uncertain	O
.	O

Among	O
619	O
colorectal	D015179
cancers	D015179
in	O
two	O
prospective	O
cohort	O
studies	O
,	O
233	O
(	O
38%	O
)	O
tumors	D009369
showed	O
VDR	7421
overexpression	O
by	O
immunohistochemistry	O
.	O

We	O
analyzed	O
for	O
PIK3CA	5290
and	O
KRAS	3845
mutations	O
and	O
LINE	O
-	O
1	O
methylation	O
by	O
Pyrosequencing	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
DNA	O
methylation	O
(	O
epigenetic	O
changes	O
)	O
in	O
eight	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP	O
)	O
-	O
specific	O
promoters	O
[	O
CACNA1G	8913
,	O
CDKN2A	1029
(	O
p16	1029
)	O
,	O
CRABP1	1381
,	O
IGF2	3481
,	O
MLH1	4292
,	O
NEUROG1	4762
,	O
RUNX3	864
,	O
and	O
SOCS1	8651
]	O
by	O
MethyLight	O
(	O
real	O
-	O
time	O
PCR	O
)	O
.	O

VDR	7421
overexpression	O
was	O
significantly	O
associated	O
with	O
KRAS	3845
mutation	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
55	O
;	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
11	O
-	O
2	O
.	O
16	O
)	O
and	O
PIK3CA	5290
mutation	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
17	O
;	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
36	O
-	O
3	O
.	O
47	O
)	O
,	O
both	O
of	O
which	O
persisted	O
in	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

VDR	7421
was	O
not	O
independently	O
associated	O
with	O
body	O
mass	O
index	O
,	O
family	O
history	O
of	O
colorectal	D015179
cancer	D015179
,	O
tumor	D009369
location	O
(	O
colon	O
versus	O
rectum	O
)	O
,	O
stage	O
,	O
tumor	D009369
grade	O
,	O
signet	O
ring	O
cells	O
,	O
CIMP	O
,	O
MSI	O
,	O
LINE	O
-	O
1	O
hypomethylation	O
,	O
BRAF	673
,	O
p53	7157
,	O
p21	1026
,	O
beta	1499
-	O
catenin	1499
,	O
or	O
cyclooxygenase	5743
-	O
2	5743
.	O

VDR	7421
expression	O
was	O
not	O
significantly	O
related	O
with	O
patient	9606
survival	O
,	O
prognosis	O
,	O
or	O
clinical	O
outcome	O
.	O

In	O
conclusion	O
,	O
VDR	7421
overexpression	O
in	O
colorectal	D015179
cancer	D015179
is	O
independently	O
associated	O
with	O
PIK3CA	5290
and	O
KRAS	3845
mutations	O
.	O

Our	O
data	O
support	O
potential	O
interactions	O
between	O
the	O
VDR	7421
,	O
RAS	3845
-	O
MAPK	1432
and	O
PI3K	5290
-	O
AKT	207
pathways	O
,	O
and	O
possible	O
influence	O
by	O
KRAS	3845
or	O
PIK3CA	5290
mutation	O
on	O
therapy	O
or	O
chemoprevention	O
targeting	O
VDR	7421
.	O
Identification	O
of	O
novel	O
type	O
VII	1294
collagen	1294
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	D016108
dystrophic	D016108
epidermolysis	D016108
bullosa	D016108
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch	O
/	O
German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	1294
collagen	1294
gene	O
leading	O
to	O
recessive	D016108
dystrophic	D016108
epidermolysis	D016108
bullosa	D016108
,	O
Hallopeau	D016108
-	O
Siemens	D016108
variant	O
(	O
HS	D016108
-	O
RDEB	D016108
)	O
.	O

The	O
maternal	O
mutation	O
is	O
a	O
single	c|DEL||C
base	c|DEL||C
pair	c|DEL||C
deletion	c|DEL||C
of	c|DEL||C
a	c|DEL||C
cytosine	c|DEL||C
nucleotide	c|DEL||C
in	O
exon	O
26	O
,	O
designated	O
3472delC	c|DEL|3472|C
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(	O
PTC	O
)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O

The	O
paternal	O
mutation	O
is	O
a	O
G	c|SUB|G||A
-	O
-	O
>	O
A	c|SUB|G||A
transition	O
located	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
IVS51	c|SUB|G|IVS51+1|A
+	O
1G	c|SUB|G|IVS51+1|A
-	O
-	O
>	O
A	c|SUB|G|IVS51+1|A
.	O

This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out	O
-	O
of	O
-	O
frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O

To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS	D016108
-	O
RDEB	D016108
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O
Detection	O
of	O
EGFR	1956
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	D008175
cancer	D008175
patients	9606
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	D009369
EGFR	1956
status	O
and	O
response	O
to	O
EGFR	1956
inhibitors	O
.	O

AIMS	O
:	O
EGFR	1956
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR	1956
-	O
targeted	O
therapy	O
in	O
lung	D008175
cancer	D008175
.	O

However	O
,	O
standard	O
EGFR	1956
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	D009369
tissue	O
,	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(	O
Sequenom	O
)	O
with	O
a	O
mutant	O
-	O
enriched	O
PCR	O
(	O
ME	O
-	O
PCR	O
)	O
to	O
detect	O
EGFR	1956
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	9606
with	O
lung	D008175
cancer	D008175
.	O

METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	9606
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	1956
Exon	O
19	O
deletion	O
and	O
EGFR	1956
L858R	rs121434568
mutation	O
.	O

Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	1956
mutation	O
status	O
obtained	O
in	O
tumor	D009369
DNA	O
(	O
18	O
/	O
31	O
EGFR	1956
mutant	O
)	O
.	O

The	O
relationship	O
of	O
EGFR	1956
mutation	O
status	O
in	O
tumor	D009369
and	O
/	O
or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O

RESULTS	O
:	O
The	O
EGFR	1956
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	D009369
in	O
61%	O
of	O
patients	9606
(	O
19	O
/	O
31	O
)	O
.	O

By	O
mass	O
spectrometry	O
genotyping	O
,	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5	O
/	O
14	O
EGFR	1956
Exon	O
19	O
deletions	O
and	O
3	O
/	O
4	O
EGFR	1956
L858R	rs121434568
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	D009369
.	O

Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	D009369
tissue	O
.	O

Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME	O
-	O
PCR	O
.	O

For	O
patients	9606
treated	O
with	O
erlotinib	D000069347
,	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	1956
mutation	O
in	O
plasma	O
and	O
/	O
or	O
tumor	D009369
tissue	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
with	O
the	O
two	O
patients	9606
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	1956
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME	O
-	O
PCR	O
is	O
feasible	O
.	O

A	O
positive	O
EGFR	1956
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	D009369
EGFR	1956
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR	1956
-	O
targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	9606
with	O
insufficient	O
or	O
unavailable	O
tumor	D009369
specimens	O
.	O
Dynamic	O
subunit	O
turnover	O
in	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
assemblies	O
is	O
regulated	O
by	O
Vps4	27183,9525
to	O
mediate	O
membrane	O
remodelling	O
during	O
cytokinesis	O
.	O

The	O
endosomal	128866,27243,51652
sorting	128866,27243,51652
complex	128866,27243,51652
required	128866,27243,51652
for	128866,27243,51652
transport	128866,27243,51652
(	O
ESCRT	128866,27243,51652
)	O
-	O
III	128866,27243,51652
mediates	O
membrane	O
fission	O
in	O
fundamental	O
cellular	O
processes	O
,	O
including	O
cytokinesis	O
.	O

ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
is	O
thought	O
to	O
form	O
persistent	O
filaments	O
that	O
over	O
time	O
increase	O
their	O
curvature	O
to	O
constrict	O
membranes	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
at	O
the	O
midbody	O
of	O
human	9606
cells	O
rapidly	O
turns	O
over	O
subunits	O
with	O
cytoplasmic	O
pools	O
while	O
gradually	O
forming	O
larger	O
assemblies	O
.	O

ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
turnover	O
depended	O
on	O
the	O
ATPase	27183,9525
VPS4	27183,9525
,	O
which	O
accumulated	O
at	O
the	O
midbody	O
simultaneously	O
with	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
subunits	O
,	O
and	O
was	O
required	O
for	O
assembly	O
of	O
functional	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
structures	O
.	O

In	O
vitro	O
,	O
the	O
Vps2	27243
/	O
Vps24	51652
subunits	O
of	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
formed	O
side	O
-	O
by	O
-	O
side	O
filaments	O
with	O
Snf7	128866,29082
and	O
inhibited	O
further	O
polymerization	O
,	O
but	O
the	O
growth	O
inhibition	O
was	O
alleviated	O
by	O
the	O
addition	O
of	O
Vps4	27183,9525
and	O
ATP	D000255
.	O

High	O
-	O
speed	O
atomic	O
force	O
microscopy	O
further	O
revealed	O
highly	O
dynamic	O
arrays	O
of	O
growing	O
and	O
shrinking	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
spirals	O
in	O
the	O
presence	O
of	O
Vps4	27183,9525
.	O

Continuous	O
ESCRT	128866,27243,51652
-	O
III	128866,27243,51652
remodelling	O
by	O
subunit	O
turnover	O
might	O
facilitate	O
shape	O
adaptions	O
to	O
variable	O
membrane	O
geometries	O
,	O
with	O
broad	O
implications	O
for	O
diverse	O
cellular	O
processes	O
.	O
Acute	O
effects	O
of	O
N	C108761
-	O
(	O
2	C108761
-	O
propylpentanoyl	C108761
)	O
urea	C108761
on	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
in	O
pilocarpine	D010862
-	O
induced	O
seizure	D012640
in	O
rats	10116
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
(	O
glutamate	D018698
,	O
aspartate	D001224
,	O
glycine	D005998
and	O
GABA	D005680
)	O
of	O
N	C108761
-	O
(	O
2	C108761
-	O
propylpentanoyl	C108761
)	O
urea	C108761
(	O
VPU	C108761
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	D014635
acid	D014635
(	O
VPA	D014635
)	O
.	O

VPU	C108761
was	O
more	O
potent	O
than	O
VPA	D014635
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	10116
against	O
pilocarpine	D010862
-	O
induced	O
seizure	D012640
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	D014635
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	D010862
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	D018698
and	O
aspartate	D001224
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	D005998
and	O
GABA	D005680
.	O

Pretreatment	O
with	O
either	O
VPU	C108761
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	D014635
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	D010862
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	D018698
and	O
aspartate	D001224
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	D005680
and	O
glycine	D005998
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	D018698
and	O
aspartate	D001224
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	C108761
and	O
VPA	D014635
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	D010862
-	O
induced	O
seizure	D012640
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	O
acid	O
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	D018698
and	O
aspartate	D001224
.	O

Therefore	O
,	O
like	O
VPA	D014635
,	O
the	O
finding	O
that	O
VPU	C108761
could	O
drastically	O
reduce	O
pilocarpine	D010862
-	O
induced	O
increases	O
in	O
glutamate	D018698
and	O
aspartate	D001224
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	D010862
-	O
induced	O
seizure	D012640
in	O
experimental	O
animals	O
.	O

Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O
Carrier	O
frequency	O
of	O
mutation	O
657del5	c|DEL|657|5
in	O
the	O
NBS1	4683
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	9606
with	O
sporadic	D008223
lymphoid	D008223
malignancies	D008223
.	O

Nijmegen	D049932
breakage	D049932
syndrome	D049932
(	O
NBS	D049932
)	O
is	O
a	O
human	9606
autosomal	D030342
recessive	D030342
disease	D030342
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	D009369
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	D008223
and	O
leukemia	D007938
.	O

Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	4683
mutation	O
,	O
657del5	c|DEL|657|5
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	D008223
lymphoid	D008223
malignancies	D008223
,	O
and	O
in	O
Polish	O
adults	O
with	O
non	D008228
-	O
Hodgkin	D008228
lymphoma	D008228
(	O
NHL	D008228
)	O
.	O

In	O
addition	O
,	O
the	O
substitution	O
643C	c|SUB|C|643|T
>	O
T	c|SUB|C|643|T
(	O
R215W	p|SUB|R|215|W
)	O
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	D054198
lymphoblastic	D054198
leukemia	D054198
(	O
ALL	D054198
)	O
.	O

In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	D008223
lymphoid	D008223
malignancies	D008223
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	9606
.	O

The	O
NBS1	4683
mutation	O
657del5	c|DEL|657|5
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	9606
with	O
ALL	D054198
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	D008228
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	9606
with	O
Hodgkin	D006689
lymphoma	D006689
(	O
HL	D006689
)	O
.	O

No	O
carriers	O
of	O
the	O
variant	O
R215W	p|SUB|R|215|W
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O

The	O
relative	O
frequency	O
of	O
the	O
657del5	c|DEL|657|5
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6	O
,	O
984	O
controls	O
matched	O
by	O
place	O
of	O
patient	9606
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
the	O
analyzed	O
population	O
with	O
malignancies	D009369
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	c|DEL|657|5
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1	O
.	O
48	O
-	O
1	O
.	O
85	O
,	O
95%	O
confidence	O
interval	O
1	O
.	O
18	O
-	O
2	O
.	O
65	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	9606
with	O
ALL	D054198
and	O
NHL	D008228
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Nonetheless	O
,	O
NBS1	4683
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	D008223
malignancies	D008223
in	O
childhood	O
and	O
adolescence	O
.	O
TNFR	22030
-	O
associated	22030
factor	22030
2	22030
deficiency	O
in	O
B	O
lymphocytes	O
predisposes	O
to	O
chronic	D015451
lymphocytic	D015451
leukemia	D015451
/	O
small	D015451
lymphocytic	D015451
lymphoma	D015451
in	O
mice	10090
.	O

We	O
have	O
previously	O
shown	O
that	O
transgenic	O
(	O
tg	O
)	O
mice	10090
expressing	O
in	O
B	O
lymphocytes	O
both	O
BCL	596
-	O
2	596
and	O
a	O
TNFR	22030
-	O
associated	22030
factor	22030
2	22030
(	O
TRAF2	22030
)	O
mutant	O
lacking	O
the	O
really	O
interesting	O
new	O
gene	O
and	O
zinc	O
finger	O
domains	O
(	O
TRAF2DN	O
)	O
develop	O
small	D015451
lymphocytic	D015451
lymphoma	D015451
and	O
chronic	D015451
lymphocytic	D015451
leukemia	D015451
with	O
high	O
incidence	O
(	O
Zapata	O
et	O
al	O
.	O

2004	O
.	O

Proc	O
.	O

Nat	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
101	O
:	O
16600	O
-	O
16605	O
)	O
.	O

Further	O
analysis	O
of	O
the	O
expression	O
of	O
TRAF2	22030
and	O
TRAF2DN	O
in	O
purified	O
B	O
cells	O
demonstrated	O
that	O
expression	O
of	O
both	O
endogenous	O
TRAF2	22030
and	O
tg	O
TRAF2DN	O
was	O
negligible	O
in	O
Traf2DN	10090
-	O
tg	10090
B	10090
cells	O
compared	O
with	O
wild	O
-	O
type	O
mice	10090
.	O

This	O
was	O
the	O
result	O
of	O
proteasome	16912
-	O
dependent	O
degradation	O
,	O
and	O
rendered	O
TRAF2DN	O
B	O
cells	O
as	O
bona	O
fide	O
TRAF2	22030
-	O
deficient	O
B	O
cells	O
.	O

Similar	O
to	O
B	O
cells	O
with	O
targeted	O
Traf2	22030
deletion	O
,	O
Traf2DN	10090
-	O
tg	10090
mice	10090
show	O
expanded	O
marginal	O
zone	O
B	O
cell	O
population	O
and	O
have	O
constitutive	O
p100	18034
NF	18034
-	O
kappaB2	18034
processing	O
.	O

Also	O
,	O
TRAF3	22031
,	O
X	11798
-	O
linked	11798
inhibitor	11798
of	11798
apoptosis	11798
,	O
and	O
Bcl	12048
-	O
X	12048
(	O
L	12048
)	O
expression	O
levels	O
were	O
increased	O
,	O
whereas	O
cellular	11796,11797
inhibitors	11796,11797
of	11796,11797
apoptosis	11796,11797
1	11796,11797
and	11796,11797
2	11796,11797
levels	O
were	O
drastically	O
reduced	O
compared	O
with	O
those	O
found	O
in	O
wild	O
-	O
type	O
B	O
cells	O
.	O

Moreover	O
,	O
consistent	O
with	O
previous	O
results	O
,	O
we	O
also	O
show	O
that	O
TRAF2	22030
was	O
required	O
for	O
efficient	O
JNK	26419
and	O
ERK	26413
activation	O
in	O
response	O
to	O
CD40	21939
engagement	O
.	O

However	O
,	O
TRAF2	22030
was	O
deleterious	O
for	O
BCR	12518
-	O
mediated	O
activation	O
of	O
these	O
kinases	O
.	O

In	O
contrast	O
,	O
TRAF2	22030
deficiency	O
had	O
no	O
effect	O
on	O
CD40	21939
-	O
mediated	O
p38	26416
MAPK	26416
activation	O
but	O
significantly	O
reduced	O
BCR	12518
-	O
mediated	O
p38	26416
activation	O
.	O

Finally	O
,	O
we	O
further	O
confirm	O
that	O
TRAF2	22030
was	O
required	O
for	O
CD40	21939
-	O
mediated	O
proliferation	O
,	O
but	O
its	O
absence	O
relieved	O
B	O
cells	O
of	O
the	O
need	O
for	O
B	24099
cell	24099
activating	24099
factor	24099
for	O
survival	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
TRAF2	22030
deficiency	O
cooperates	O
with	O
BCL	596
-	O
2	596
in	O
promoting	O
chronic	D015451
lymphocytic	D015451
leukemia	D015451
/	O
small	D015451
lymphocytic	D015451
lymphoma	D015451
in	O
mice	10090
,	O
possibly	O
by	O
specifically	O
enforcing	O
marginal	O
zone	O
B	O
cell	O
accumulation	O
,	O
increasing	O
X	11798
-	O
linked	11798
inhibitor	11798
of	11798
apoptosis	11798
expression	O
,	O
and	O
rendering	O
B	O
cells	O
independent	O
of	O
B	24099
cell	24099
activating	24099
factor	24099
for	O
survival	O
.	O
Association	O
of	O
adipocyte	O
genes	O
with	O
ASP	718
expression	O
:	O
a	O
microarray	O
analysis	O
of	O
subcutaneous	O
and	O
omental	O
adipose	O
tissue	O
in	O
morbidly	O
obese	D009765
subjects	O
.	O

BACKGROUND	O
:	O
Prevalence	O
of	O
obesity	D009765
is	O
increasing	O
to	O
pandemic	O
proportions	O
.	O

However	O
,	O
obese	D009765
subjects	O
differ	O
in	O
insulin	D007333
resistance	D007333
,	O
adipokine	9370
production	O
and	O
co	O
-	O
morbidities	O
.	O

Based	O
on	O
fasting	O
plasma	O
analysis	O
,	O
obese	D009765
subjects	O
were	O
grouped	O
as	O
Low	O
Acylation	718
Stimulating	718
protein	718
(	O
ASP	718
)	O
and	O
Triglyceride	D014280
(	O
TG	D014280
)	O
(	O
LAT	O
)	O
vs	O
High	O
ASP	718
and	O
TG	D014280
(	O
HAT	O
)	O
.	O

Subcutaneous	O
(	O
SC	O
)	O
and	O
omental	O
(	O
OM	O
)	O
adipose	O
tissues	O
(	O
n	O
=	O
21	O
)	O
were	O
analysed	O
by	O
microarray	O
,	O
and	O
biologic	O
pathways	O
in	O
lipid	D008055
metabolism	O
and	O
inflammation	D007249
were	O
specifically	O
examined	O
.	O

METHODS	O
:	O
LAT	O
and	O
HAT	O
groups	O
were	O
matched	O
in	O
age	O
,	O
obesity	D009765
,	O
insulin	3630
,	O
and	O
glucose	D005947
,	O
and	O
had	O
similar	O
expression	O
of	O
insulin	3630
-	O
related	O
genes	O
(	O
InsR	3643
,	O
IRS	3667
-	O
1	3667
)	O
.	O

ASP	718
related	O
genes	O
tended	O
to	O
be	O
increased	O
in	O
the	O
HAT	O
group	O
and	O
were	O
correlated	O
(	O
factor	629
B	629
,	O
adipsin	1675
,	O
complement	718
C3	718
,	O
p	O
<	O
0	O
.	O
01	O
each	O
)	O
.	O

Differences	O
between	O
LAT	O
and	O
HAT	O
group	O
were	O
almost	O
exclusively	O
in	O
SC	O
tissue	O
,	O
with	O
little	O
difference	O
in	O
OM	O
tissue	O
.	O

Increased	O
C5L2	27202
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
an	O
ASP	27202
receptor	27202
,	O
in	O
HAT	O
suggests	O
a	O
compensatory	O
ASP	718
pathway	O
,	O
associated	O
with	O
increased	O
TG	D014280
storage	O
.	O

RESULTS	O
:	O
HAT	O
adipose	O
tissue	O
demonstrated	O
increased	O
lipid	D008055
related	O
genes	O
for	O
storage	O
(	O
CD36	948
,	O
DGAT1	8694
,	O
DGAT2	84649
,	O
SCD1	6319
,	O
FASN	2194
,	O
and	O
LPL	4023
)	O
,	O
lipolysis	O
(	O
HSL	3991
,	O
CES1	1066
,	O
perilipin	5346
)	O
,	O
fatty	2168,2170
acid	2168,2170
binding	2168,2170
proteins	2168,2170
(	O
FABP1	2168
,	O
FABP3	2170
)	O
and	O
adipocyte	O
differentiation	O
markers	O
(	O
CEBPalpha	1050
,	O
CEBPbeta	1051
,	O
PPARgamma	5468
)	O
.	O

By	O
contrast	O
,	O
oxidation	O
related	O
genes	O
were	O
decreased	O
(	O
AMPK	5562
,	O
UCP1	7350
,	O
CPT1	1374
,	O
FABP7	2173
)	O
.	O

HAT	O
subjects	O
had	O
increased	O
anti	O
-	O
inflammatory	D007249
genes	O
TGFB1	7040
,	O
TIMP1	7076
,	O
TIMP3	7078
,	O
and	O
TIMP4	7079
while	O
proinflammatory	D007249
PIG7	9516
and	O
MMP2	4313
were	O
also	O
significantly	O
increased	O
;	O
all	O
genes	O
,	O
p	O
<	O
0	O
.	O
025	O
.	O

CONCLUSION	O
:	O
Taken	O
together	O
,	O
the	O
profile	O
of	O
C5L2	27202
receptor	O
,	O
ASP	718
gene	O
expression	O
and	O
metabolic	O
factors	O
in	O
adipose	O
tissue	O
from	O
morbidly	O
obese	D009765
HAT	O
subjects	O
suggests	O
a	O
compensatory	O
response	O
associated	O
with	O
the	O
increased	O
plasma	O
ASP	718
and	O
TG	D014280
.	O
MHC	3123,720
region	O
and	O
risk	O
of	O
systemic	D008180
lupus	D008180
erythematosus	D008180
in	O
African	O
American	O
women	9606
.	O

The	O
major	3123,720
histocompatibility	3123,720
complex	3123,720
(	O
MHC	3123,720
)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	D008180
lupus	D008180
erythematosus	D008180
(	O
SLE	D008180
)	O
.	O

Although	O
SLE	D008180
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
,	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	3123,720
region	O
in	O
relationship	O
to	O
SLE	D008180
in	O
African	O
Americans	O
.	O

We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	3123,720
region	O
for	O
1	O
,	O
536	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	720
gene	O
in	O
a	O
SLE	D008180
case	O
-	O
control	O
study	O
(	O
380	O
cases	O
,	O
765	O
age	O
-	O
matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women	9606
'	O
s	O
Health	O
Study	O
.	O

We	O
also	O
genotyped	O
1	O
,	O
509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O

The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	D008180
was	O
the	O
rs9271366	rs9271366
(	O
odds	O
ratio	O
,	O
OR	O
=	O
1	O
.	O
70	O
,	O
p	O
=	O
5	O
.	O
6	O
10	O
(	O
-	O
5	O
)	O
)	O
near	O
the	O
HLA	3123
-	O
DRB1	3123
gene	O
.	O

Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
,	O
rs204890	rs204890
(	O
OR	O
=	O
1	O
.	O
86	O
,	O
p	O
=	O
1	O
.	O
2	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
rs2071349	rs2071349
(	O
OR	O
=	O
1	O
.	O
53	O
,	O
p	O
=	O
1	O
.	O
0	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
and	O
rs2844580	rs2844580
(	O
OR	O
=	O
1	O
.	O
43	O
,	O
p	O
=	O
1	O
.	O
3	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
to	O
be	O
associated	O
with	O
SLE	D008180
independent	O
of	O
the	O
rs9271366	rs9271366
SNP	O
.	O

In	O
univariate	O
analysis	O
,	O
the	O
OR	O
for	O
the	O
C4A	720
deletion	O
was	O
1	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
075	O
,	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1	O
.	O
01	O
,	O
p	O
=	O
0	O
.	O
98	O
.	O

A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high	O
-	O
risk	O
alleles	O
(	O
OR	O
=	O
1	O
.	O
67	O
per	O
high	O
-	O
risk	O
allele	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Our	O
strongest	O
signal	O
,	O
the	O
rs9271366	rs9271366
SNP	O
,	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	D008180
in	O
a	O
previous	O
Chinese	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
.	O

In	O
addition	O
,	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	9606
were	O
confirmed	O
in	O
our	O
study	O
,	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	D008180
with	O
European	O
and	O
Chinese	O
subjects	O
.	O

In	O
summary	O
,	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	3123,720
region	O
associated	O
with	O
risk	O
of	O
SLE	D008180
in	O
African	O
American	O
women	9606
.	O
Polymorphic	O
MLH1	4292
and	O
risk	O
of	O
cancer	D009369
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	D006689
lymphoma	D006689
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	D006689
lymphoma	D006689
,	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	D009369
.	O

Cytotoxicity	D064420
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
system	O
.	O

Loss	O
of	O
MLH1	4292
,	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
,	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	D064420
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O

We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	4292
(	O
position	O
-	O
93	O
,	O
rs1800734	rs1800734
)	O
modifies	O
the	O
risk	O
of	O
cancer	D009369
after	O
methylating	O
chemotherapy	O
.	O

METHODS	O
:	O
133	O
patients	9606
who	O
developed	O
cancer	D009369
following	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)	O
,	O
420	O
patients	9606
diagnosed	O
with	O
de	O
novo	O
myeloid	D007938
leukaemia	D007938
,	O
242	O
patients	9606
diagnosed	O
with	O
primary	D006689
Hodgkin	D006689
lymphoma	D006689
,	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	4292
-	O
93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O

Odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
for	O
cancer	D009369
risk	O
by	O
MLH1	4292
-	O
93	O
polymorphism	O
status	O
,	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
,	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	4292
-	O
93	O
variant	O
was	O
higher	O
in	O
patients	9606
who	O
developed	O
therapy	O
related	O
acute	D015470
myeloid	D015470
leukaemia	D015470
(	O
t	O
-	O
AML	D015470
)	O
(	O
75	O
.	O
0%	O
,	O
n	O
=	O
12	O
)	O
or	O
breast	D001943
cancer	D001943
(	O
53	O
.	O
3%	O
.	O

n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	D006689
lymphoma	D006689
compared	O
to	O
patients	9606
without	O
previous	O
methylating	O
exposure	O
(	O
t	O
-	O
AML	D015470
,	O
30	O
.	O
4%	O
,	O
n	O
=	O
69	O
;	O
breast	D001943
cancer	D001943
patients	9606
,	O
27	O
.	O
2%	O
,	O
n	O
=	O
22	O
)	O
.	O

The	O
MLH1	4292
-	O
93	O
variant	O
allele	O
was	O
also	O
over	O
-	O
represented	O
in	O
t	O
-	O
AML	D015470
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	D015470
cases	O
(	O
36	O
.	O
9%	O
,	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36	O
.	O
3%	O
,	O
n	O
=	O
952	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t	O
-	O
AML	D015470
(	O
odds	O
ratio	O
5	O
.	O
31	O
,	O
95%	O
confidence	O
interval	O
1	O
.	O
40	O
to	O
20	O
.	O
15	O
)	O
,	O
but	O
only	O
in	O
patients	9606
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-	O
93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	4292
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	D009369
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	D006689
lymphoma	D006689
.	O

However	O
,	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O
Genetic	O
variation	O
in	O
the	O
COX	4513
-	O
2	4513
gene	O
and	O
the	O
association	O
with	O
prostate	D011471
cancer	D011471
risk	O
.	O

COX	4513
-	O
2	4513
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	D016718
acid	D016718
to	O
prostaglandins	D011453
.	O

The	O
prostaglandins	D011453
produced	O
by	O
COX	4513
-	O
2	4513
are	O
involved	O
in	O
inflammation	D007249
and	O
pain	D010146
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O

Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
,	O
chemical	O
carcinogen	O
-	O
induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX	4513
-	O
2	4513
plays	O
a	O
role	O
in	O
human	9606
carcinogenesis	D009369
and	O
is	O
overexpressed	O
in	O
prostate	D011471
cancer	D011471
tissue	O
.	O

We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX	4513
-	O
2	4513
gene	O
are	O
associated	O
with	O
prostate	D011471
cancer	D011471
risk	O
.	O

We	O
analyzed	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
cancer	D011471
prostate	D011471
in	O
Sweden	O
(	O
CAPS	O
)	O
consisting	O
of	O
1	O
,	O
378	O
cases	O
and	O
782	O
controls	O
.	O

We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
spanning	O
the	O
entire	O
COX	4513
-	O
2	4513
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O

Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	9606
and	O
control	O
subjects	O
and	O
gene	O
-	O
specific	O
haplotypes	O
were	O
constructed	O
.	O

A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(	O
+	O
3100	c|SUB|T|+3100|G
T	c|SUB|T|+3100|G
/	O
G	c|SUB|T|+3100|G
and	O
+	O
8365	c|SUB|C|+8365|T
C	c|SUB|C|+8365|T
/	O
T	c|SUB|C|+8365|T
)	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
78	O
(	O
95%	O
CI	O
=	O
0	O
.	O
64	O
-	O
0	O
.	O
96	O
)	O
and	O
0	O
.	O
65	O
(	O
95%	O
CI	O
=	O
0	O
.	O
45	O
-	O
0	O
.	O
94	O
)	O
respectively	O
.	O

In	O
the	O
haplotype	O
analysis	O
,	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+	O
3100	c|SUB|T|+3100|G
T	c|SUB|T|+3100|G
/	O
G	c|SUB|T|+3100|G
and	O
+	O
8365	c|SUB|C|+8365|T
C	c|SUB|C|+8365|T
/	O
T	c|SUB|C|+8365|T
,	O
with	O
a	O
population	O
frequency	O
of	O
3%	O
,	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	D011471
cancer	D011471
(	O
p	O
=	O
0	O
.	O
036	O
,	O
global	O
simulated	O
p	O
-	O
value	O
=	O
0	O
.	O
046	O
)	O
.	O

This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	D007249
is	O
involved	O
in	O
prostate	D011471
carcinogenesis	D011471
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX	4513
-	O
2	4513
gene	O
influence	O
the	O
risk	O
of	O
prostate	D011471
cancer	D011471
.	O
Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	24408
receptors	24408
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	D006220
-	O
induced	O
catalepsy	D002375
.	O

The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O

Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	O
acid	O
microinjection	O
causes	O
freezing	O
,	O
escape	O
-	O
like	O
behavior	O
,	O
and	O
immobility	O
.	O

However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O

The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	O
acid	O
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	D002375
induced	O
by	O
the	O
dopamine	24316
receptor	24316
blocker	O
haloperidol	D006220
administered	O
systemically	O
(	O
1	O
or	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
in	O
rats	10116
.	O

Haloperidol	D006220
-	O
induced	O
catalepsy	D002375
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	24408
NMDA	24408
receptor	24408
antagonists	O
,	O
MK	D016291
-	O
801	D016291
(	O
15	O
or	O
30	O
mmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
and	O
AP7	C031231
(	O
10	O
or	O
20	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	24408
receptor	24408
agonist	O
N	D016202
-	O
methyl	D016202
-	O
d	D016202
-	O
aspartate	D016202
(	O
NMDA	D016202
,	O
20	O
or	O
30	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
.	O

The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK	D016291
-	O
801	D016291
and	O
AP7	C031231
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	D006220
significantly	O
attenuated	O
the	O
catalepsy	D002375
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O

Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	D016202
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O

These	O
findings	O
suggest	O
that	O
glutamate	D018698
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	D006220
-	O
induced	O
catalepsy	D002375
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O
Antioxidant	D000975
effects	O
of	O
bovine	9913
lactoferrin	301034
on	O
dexamethasone	D003907
-	O
induced	O
hypertension	D006973
in	O
rat	10116
.	O

Dexamethasone	D003907
-	O
(	O
Dex	D003907
-	O
)	O
induced	O
hypertension	D006973
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	301034
(	O
LF	301034
)	O
is	O
an	O
iron	D007501
-	O
binding	O
glycoprotein	11820
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	301034
on	O
oxidative	O
stress	O
and	O
hypertension	D006973
upon	O
Dex	D003907
administration	O
.	O

Male	O
Wistar	O
rats	10116
were	O
treated	O
by	O
Dex	D003907
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O

Oral	O
bovine	9913
LF	301034
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

In	O
a	O
prevention	O
study	O
,	O
rats	10116
received	O
4	O
days	O
of	O
LF	301034
treatment	O
followed	O
by	O
Dex	D003907
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	D005938
activity	O
.	O

Plasma	O
hydrogen	D006861
peroxide	D006861
(	O
H2O2	D006861
)	O
concentration	O
and	O
ferric	D007501
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	D003907
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	D006861
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	301034
lowered	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	D003907
-	O
induced	O
hypertension	D006973
.	O

LF	301034
prevented	O
body	O
weight	D015431
loss	D015431
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	D006861
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	301034
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	D017382
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	D003907
-	O
induced	O
hypertension	D006973
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	301034
.	O
Role	O
of	O
protein	10419
arginine	10419
methyltransferase	10419
5	10419
in	O
inflammation	D007249
and	O
migration	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
in	O
rheumatoid	D001172
arthritis	D001172
.	O

To	O
probe	O
the	O
role	O
of	O
protein	10419
arginine	10419
methyltransferase	10419
5	10419
(	O
PRMT5	10419
)	O
in	O
regulating	O
inflammation	D007249
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
(	O
FLSs	O
)	O
from	O
patients	9606
with	O
rheumatoid	D001172
arthritis	D001172
(	O
RA	D001172
)	O
.	O

FLSs	O
were	O
separated	O
from	O
synovial	O
tissues	O
(	O
STs	O
)	O
from	O
patients	9606
with	O
RA	D001172
and	O
osteoarthritis	D010003
(	O
OA	D010003
)	O
.	O

An	O
inhibitor	O
of	O
PRMT5	10419
(	O
EPZ015666	C000599896
)	O
and	O
short	O
interference	O
RNA	O
(	O
siRNA	O
)	O
against	O
PRMT5	10419
were	O
used	O
to	O
inhibit	O
PRMT5	10419
expression	O
.	O

The	O
standard	O
of	O
protein	O
was	O
measured	O
by	O
Western	O
blot	O
or	O
immunofluorescence	O
.	O

The	O
excretion	O
and	O
genetic	O
expression	O
of	O
inflammatory	D007249
factors	O
were	O
,	O
respectively	O
,	O
estimated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

Migration	O
and	O
invasion	O
in	O
vitro	O
were	O
detected	O
by	O
Boyden	O
chamber	O
assay	O
.	O

FLSs	O
proliferation	O
was	O
detected	O
by	O
BrdU	O
incorporation	O
.	O

Increased	O
PRMT5	10419
was	O
discovered	O
in	O
STs	O
and	O
FLSs	O
from	O
patients	9606
with	O
RA	D001172
.	O

In	O
RA	D001172
FLSs	O
,	O
the	O
level	O
of	O
PRMT5	10419
was	O
up	O
-	O
regulated	O
by	O
stimulation	O
with	O
IL	3553
-	O
1b	3553
and	O
TNF	7124
-	O
a	7124
.	O

Inhibition	O
of	O
PRMT5	10419
by	O
EPZ015666	C000599896
and	O
siRNA	O
-	O
mediated	O
knockdown	O
reduced	O
IL	3569
-	O
6	3569
and	O
IL	3576
-	O
8	3576
production	O
,	O
and	O
proliferation	O
of	O
RA	D001172
FLSs	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
PRMT5	10419
decreased	O
in	O
vitro	O
migration	O
and	O
invasion	O
of	O
RA	D001172
FLSs	O
.	O

Furthermore	O
,	O
EPZ015666	C000599896
restrained	O
the	O
phosphorylation	O
of	O
IkB	3551
kinaseb	3551
and	O
IkBa	4792
,	O
as	O
well	O
as	O
nucleus	O
transsituation	O
of	O
p65	5970
as	O
well	O
as	O
AKT	207
in	O
FLSs	O
.	O

PRMT5	10419
regulated	O
the	O
production	O
of	O
inflammatory	D007249
factors	O
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
RA	D001172
FLS	O
,	O
which	O
was	O
mediated	O
by	O
the	O
NF	5970
-	O
kB	5970
and	O
AKT	207
pathways	O
.	O

Our	O
data	O
suggested	O
that	O
targeting	O
PRMT5	10419
to	O
prevent	O
synovial	D013585
inflammation	D013585
and	O
destruction	O
might	O
be	O
a	O
promising	O
therapy	O
for	O
RA	D001172
.	O
Protein	5578
kinase	5578
C	5578
alpha	5578
-	O
dependent	O
signaling	O
mediates	O
endometrial	D016889
cancer	D016889
cell	O
growth	O
and	O
tumorigenesis	D009369
.	O

Endometrial	D016889
cancer	D016889
is	O
the	O
most	O
common	O
invasive	O
gynecologic	D005833
malignancy	D005833
,	O
yet	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
underlying	O
its	O
etiology	O
and	O
pathophysiology	O
remain	O
poorly	O
characterized	O
.	O

We	O
sought	O
to	O
define	O
a	O
functional	O
role	O
for	O
the	O
protein	5578
kinase	5578
C	5578
(	O
PKC	5578
)	O
isoform	O
,	O
PKCalpha	5578
,	O
in	O
an	O
established	O
cell	O
model	O
of	O
endometrial	D016889
adenocarcinoma	D016889
.	O

Ishikawa	9606
cells	O
depleted	O
of	O
PKCalpha	5578
protein	O
grew	O
slower	O
,	O
formed	O
fewer	O
colonies	O
in	O
anchorage	O
-	O
independent	O
growth	O
assays	O
and	O
exhibited	O
impaired	O
xenograft	O
tumor	D009369
formation	O
in	O
nude	O
mice	10090
.	O

Consistent	O
with	O
impaired	O
growth	O
,	O
PKCalpha	5578
knockdown	O
increased	O
levels	O
of	O
the	O
cyclin	983
-	O
dependent	983
kinase	983
(	O
CDK	983
)	O
inhibitors	O
p21	1026
(	O
Cip1	1026
/	O
WAF1	1026
)	O
(	O
p21	1026
)	O
and	O
p27	1027
(	O
Kip1	1027
)	O
(	O
p27	1027
)	O
.	O

Despite	O
the	O
absence	O
of	O
functional	O
phosphatase	5728
and	5728
tensin	5728
homolog	5728
(	O
PTEN	5728
)	O
protein	O
in	O
Ishikawa	9606
cells	O
,	O
PKCalpha	5578
knockdown	O
reduced	O
Akt	207
phosphorylation	O
at	O
serine	p|Allele|S|473
473	p|Allele|S|473
and	O
concomitantly	O
inhibited	O
phosphorylation	O
of	O
the	O
Akt	207
target	O
,	O
glycogen	2932
synthase	2932
kinase	2932
-	O
3beta	2932
(	O
GSK	2932
-	O
3beta	2932
)	O
.	O

PKCalpha	5578
knockdown	O
also	O
resulted	O
in	O
decreased	O
basal	O
ERK	5594
phosphorylation	O
and	O
attenuated	O
ERK	5594
activation	O
following	O
EGF	1950
stimulation	O
.	O

p21	1026
and	O
p27	1027
expression	O
was	O
not	O
increased	O
by	O
treatment	O
of	O
Ishikawa	9606
cells	O
with	O
ERK	5594
and	O
Akt	207
inhibitors	O
,	O
suggesting	O
that	O
PKCalpha	5578
regulates	O
CDK	983
expression	O
independently	O
of	O
Akt	207
and	O
ERK	5594
.	O

Immunohistochemical	O
analysis	O
of	O
Grade	O
1	O
endometrioid	D016889
adenocarcinoma	D016889
revealed	O
aberrant	O
PKCalpha	5578
expression	O
,	O
with	O
foci	O
of	O
elevated	O
PKCalpha	5578
staining	O
,	O
not	O
observed	O
in	O
normal	O
endometrium	O
.	O

These	O
studies	O
demonstrate	O
a	O
critical	O
role	O
for	O
PKCalpha	5578
signaling	O
in	O
endometrial	O
tumorigenesis	D009369
by	O
regulating	O
expression	O
of	O
CDK	983
inhibitors	O
p21	1026
and	O
p27	1027
and	O
activation	O
of	O
Akt	207
and	O
ERK	5594
-	O
dependent	O
proliferative	O
pathways	O
.	O

Thus	O
,	O
targeting	O
PKCalpha	5578
may	O
provide	O
novel	O
therapeutic	O
options	O
in	O
endometrial	D016889
tumors	D016889
.	O
Common	O
BRCA2	675
variants	O
and	O
modification	O
of	O
breast	D001943,D010051
and	D001943,D010051
ovarian	D001943,D010051
cancer	D001943,D010051
risk	O
in	O
BRCA1	672
mutation	O
carriers	O
.	O

The	O
HH	O
genotype	O
of	O
the	O
nonconservative	O
amino	O
acid	O
substitution	O
polymorphism	O
N372H	rs144848
in	O
the	O
BRCA2	675
gene	O
was	O
reported	O
to	O
be	O
associated	O
with	O
a	O
1	O
.	O
3	O
-	O
to	O
1	O
.	O
5	O
-	O
fold	O
increase	O
in	O
risk	O
of	O
both	O
breast	D001943,D010051
and	D001943,D010051
ovarian	D001943,D010051
cancer	D001943,D010051
.	O

As	O
these	O
studies	O
concerned	O
sporadic	O
cancer	D009369
cases	O
,	O
we	O
investigated	O
whether	O
N372H	rs144848
and	O
another	O
common	O
variant	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
203G	g|SUB|G|203|A
>	O
A	g|SUB|G|203|A
)	O
of	O
the	O
BRCA2	675
gene	O
modify	O
breast	D001943,D010051
or	D001943,D010051
ovarian	D001943,D010051
cancer	D001943,D010051
risk	O
in	O
BRCA1	672
mutation	O
carriers	O
.	O

The	O
study	O
includes	O
778	O
women	9606
carrying	O
a	O
BRCA1	672
germ	O
-	O
line	O
mutation	O
belonging	O
to	O
403	O
families	O
.	O

The	O
two	O
BRCA2	675
variants	O
were	O
analyzed	O
by	O
the	O
TaqMan	O
allelic	O
discrimination	O
technique	O
.	O

Genotypes	O
were	O
analyzed	O
by	O
disease	O
-	O
free	O
survival	O
analysis	O
using	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

We	O
found	O
no	O
evidence	O
of	O
a	O
significant	O
modification	O
of	O
breast	D001943
cancer	D001943
penetrance	O
in	O
BRCA1	672
mutation	O
carriers	O
by	O
either	O
polymorphism	O
.	O

In	O
respect	O
of	O
ovarian	D010051
cancer	D010051
risk	O
,	O
we	O
also	O
saw	O
no	O
effect	O
with	O
the	O
N372H	rs144848
variant	O
but	O
we	O
did	O
observe	O
a	O
borderline	O
association	O
with	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
203A	g|Allele|A|203
allele	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
43	O
;	O
CI	O
,	O
1	O
.	O
01	O
-	O
2	O
.	O
00	O
)	O
.	O

In	O
contrast	O
to	O
the	O
result	O
of	O
Healey	O
et	O
al	O
.	O

on	O
newborn	O
females	O
and	O
adult	O
female	O
controls	O
,	O
we	O
found	O
no	O
departure	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
the	O
distribution	O
of	O
N372H	rs144848
alleles	O
for	O
our	O
female	O
BRCA1	672
carriers	O
.	O

We	O
conclude	O
that	O
if	O
these	O
single	O
-	O
nucleotide	O
polymorphisms	O
do	O
modify	O
the	O
risk	O
of	O
cancer	D009369
in	O
BRCA1	672
mutation	O
carriers	O
,	O
their	O
effects	O
are	O
not	O
significantly	O
larger	O
than	O
that	O
of	O
N372H	rs144848
previously	O
observed	O
in	O
the	O
general	O
population	O
.	O
New	O
mutations	O
,	O
hotspots	O
,	O
and	O
founder	O
effects	O
in	O
Brazilian	O
patients	9606
with	O
steroid	C535830
5alpha	C535830
-	O
reductase	C535830
deficiency	C535830
type	C535830
2	C535830
.	O

Mutations	O
of	O
the	O
steroid	6716
5alpha	6716
-	O
reductase	6716
type	6716
2	6716
(	O
SRD5A2	6716
)	O
gene	O
in	O
46	O
,	O
XY	O
subjects	O
cause	O
masculinization	O
defects	O
of	O
varying	O
degrees	O
,	O
due	O
to	O
reduced	O
or	O
impaired	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
sequence	O
abnormalities	O
of	O
the	O
SRD5A2	6716
gene	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
specific	O
primers	O
and	O
automated	O
sequencing	O
analysis	O
in	O
DNA	O
samples	O
from	O
20	O
patients	9606
with	O
suspected	O
steroid	C535830
5alpha	C535830
-	O
reductase	C535830
type	C535830
2	C535830
deficiency	C535830
from	O
18	O
Brazilian	O
families	O
.	O

Eleven	O
subjects	O
presented	O
SRD5A2	6716
homozygous	O
single	O
-	O
base	O
mutations	O
(	O
two	O
first	O
cousins	O
and	O
four	O
unrelated	O
patients	9606
with	O
G183S	rs121434247
,	O
two	O
with	O
R246W	rs121434244
,	O
one	O
with	O
del642T	c|DEL|642|T
,	O
one	O
with	O
G196S	rs121434250
,	O
and	O
one	O
with	O
217_218insC	c|INS|217_218|C
plus	O
the	O
A49T	rs9282858
variant	O
in	O
heterozygosis	O
)	O
,	O
whereas	O
four	O
were	O
compound	O
heterozygotes	O
(	O
one	O
with	O
Q126R	rs368386747
/	O
IVS3	c|SUB|G|IVS3+1|A
+	O
1G	c|SUB|G|IVS3+1|A
>	O
A	c|SUB|G|IVS3+1|A
,	O
one	O
with	O
Q126R	rs368386747
/	O
del418T	c|DEL|418|T
,	O
and	O
two	O
brothers	O
with	O
Q126R	rs368386747
/	O
G158R	p|SUB|G|158|R
)	O
.	O

Three	O
patients	9606
were	O
heterozygous	O
for	O
A207D	rs767564684
,	O
G196S	rs121434250
,	O
and	O
R266W	p|SUB|R|266|W
substitutions	O
.	O

The	O
V89L	rs523349
polymorphism	O
was	O
found	O
in	O
heterozygosis	O
in	O
one	O
of	O
them	O
(	O
with	O
A207D	rs767564684
)	O
and	O
in	O
one	O
case	O
with	O
an	O
otherwise	O
normal	O
gene	O
sequence	O
.	O

The	O
A49T	rs9282858
variant	O
was	O
also	O
detected	O
in	O
heterozygosis	O
in	O
the	O
second	O
case	O
without	O
other	O
sequencing	O
abnormalities	O
.	O

Four	O
patients	9606
harbor	O
yet	O
non	O
-	O
described	O
SRD5A2	6716
gene	O
mutations	O
:	O
a	O
single	O
nucleotide	O
deletion	O
(	O
del642T	c|DEL|642|T
)	O
,	O
a	O
G158R	p|SUB|G|158|R
amino	O
acid	O
substitution	O
,	O
a	O
splice	O
junction	O
mutation	O
(	O
IVS3	c|SUB|G|IVS3+1|A
+	O
1G	c|SUB|G|IVS3+1|A
>	O
A	c|SUB|G|IVS3+1|A
)	O
,	O
and	O
the	O
insertion	O
of	O
a	O
cytosine	O
(	O
217_218insC	c|INS|217_218|C
)	O
occurring	O
at	O
a	O
CCCC	O
motif	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
single	O
-	O
nucleotide	O
insertion	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
SRD5A2	6716
gene	O
.	O

In	O
addition	O
to	O
these	O
new	O
mutations	O
,	O
this	O
investigation	O
reveals	O
the	O
prevalence	O
of	O
G183S	rs121434247
substitution	O
among	O
a	O
subset	O
of	O
African	O
-	O
Brazilian	O
patients	9606
and	O
presents	O
evidences	O
of	O
the	O
recurrence	O
of	O
already	O
known	O
mutations	O
.	O
Effects	O
of	O
ginsenosides	D036145
on	O
opioid	D000701
-	O
induced	O
hyperalgesia	D006930
in	O
mice	10090
.	O

Opioid	D000701
-	O
induced	O
hyperalgesia	D006930
(	O
OIH	D006930
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	D000701
use	O
.	O

OIH	D006930
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	D000701
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	D009293
addiction	D009293
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	C035054,C049864,C442759
,	O
Rg1	C035054,C049864,C442759
,	O
and	C035054,C049864,C442759
Rb1	C035054,C049864,C442759
ginsenosides	C035054,C049864,C442759
,	O
the	O
bioactive	O
components	O
of	O
ginseng	4054
,	O
on	O
OIH	D006930
.	O

OIH	D006930
was	O
achieved	O
in	O
mice	10090
after	O
subcutaneous	O
administration	O
of	O
morphine	D009020
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O

During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	10090
were	O
administered	O
Re	C049864
,	O
Rg1	C035054
,	O
or	O
Rb1	C442759
intragastrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	10090
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	D019342
acid	D019342
-	O
induced	O
writhing	O
test	O
.	O

Re	C049864
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	D006930
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	D019342
acid	D019342
-	O
induced	O
writhing	O
test	O
.	O

However	O
,	O
the	O
Rg1	C035054,C442759
and	C035054,C442759
Rb1	C035054,C442759
ginsenosides	C035054,C442759
failed	O
to	O
prevent	O
OIH	D006930
in	O
either	O
test	O
.	O

Furthermore	O
,	O
Rg1	C035054
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	D006930
in	O
the	O
acetic	D019342
acid	D019342
-	O
induced	O
writhing	O
test	O
.	O

Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	C049864
Re	C049864
,	O
but	O
not	O
Rg1	C035054
or	O
Rb1	C442759
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	D006930
.	O
Association	O
study	O
of	O
complement	3075
factor	3075
H	3075
,	O
C2	717
,	O
CFB	629
,	O
and	O
C3	718
and	O
age	D008268
-	O
related	D008268
macular	D008268
degeneration	D008268
in	O
a	O
Han	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	3075
factor	3075
H	3075
(	O
CFH	3075
)	O
,	O
C2	629,717
/	O
BF	629,717
,	O
and	O
C3	718
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age	D008268
-	O
related	D008268
macular	D008268
degeneration	D008268
(	O
AMD	D008268
)	O
.	O

Genetic	O
variants	O
,	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
in	O
these	O
genes	O
were	O
geno	O
-	O
typed	O
for	O
a	O
case	O
-	O
control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty	O
-	O
eight	O
patients	9606
with	O
wet	O
AMD	D008268
,	O
80	O
patients	9606
with	O
soft	O
drusen	D005128
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O

Seven	O
SNPs	O
in	O
CFH	3075
and	O
two	O
SNPs	O
in	O
C2	717
,	O
CFB	629
'	O
,	O
and	O
C3	718
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O

A	O
deletion	O
of	O
84	O
,	O
682	O
base	O
pairs	O
covering	O
the	O
CFHR1	3078
and	O
CFHR3	10878
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	rs3753394
(	O
P	O
=	O
0	O
.	O
0276	O
)	O
,	O
rs800292	rs800292
(	O
P	O
=	O
0	O
.	O
0266	O
)	O
,	O
rs1061170	rs1061170
(	O
P	O
=	O
0	O
.	O
00514	O
)	O
,	O
and	O
rs1329428	rs1329428
(	O
P	O
=	O
0	O
.	O
0089	O
)	O
,	O
in	O
CFH	3075
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	D008268
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(	O
CATA	O
)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	D008268
with	O
a	O
P	O
value	O
of	O
0	O
.	O
0005	O
and	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
29	O
(	O
95%	O
confidence	O
interval	O
:	O
0	O
.	O
15	O
-	O
0	O
.	O
60	O
)	O
.	O

Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	rs2274700
and	O
rs1410996	rs1410996
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	D008268
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O

None	O
of	O
the	O
SNPs	O
in	O
CFH	3075
showed	O
a	O
significant	O
association	O
with	O
drusen	D005128
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	3075
,	O
C2	717
,	O
CFB	629
,	O
and	O
C3	718
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	D008268
or	O
drusen	D005128
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

The	O
CFHR1	3078
and	O
CFHR3	10878
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	D008268
or	O
drusen	D005128
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	rs3753394
(	O
P	O
=	O
0	O
.	O
0276	O
)	O
,	O
rs800292	rs800292
(	O
P	O
=	O
0	O
.	O
0266	O
)	O
,	O
rs1061170	rs1061170
(	O
P	O
=	O
0	O
.	O
00514	O
)	O
,	O
and	O
rs1329428	rs1329428
(	O
P	O
=	O
0	O
.	O
0089	O
)	O
,	O
but	O
not	O
rs7535263	rs7535263
,	O
rs1410996	rs1410996
,	O
or	O
rs2274700	rs2274700
,	O
in	O
CFH	3075
were	O
significantly	O
associated	O
with	O
wet	O
AMD	D008268
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

This	O
study	O
showed	O
that	O
CFH	3075
was	O
more	O
likely	O
to	O
be	O
AMD	D008268
susceptibility	O
gene	O
at	O
Chr	O
.	O
1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	3078
and	O
CFHR3	10878
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	D008268
in	O
a	O
white	O
population	O
in	O
C2	717
,	O
CFB	629
,	O
and	O
C3	718
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	D008268
.	O
Seven	O
novel	O
and	O
six	O
de	O
novo	O
PHEX	5251
gene	O
mutations	O
in	O
patients	9606
with	O
hypophosphatemic	D063730
rickets	D063730
.	O

Inactivating	O
mutations	O
in	O
phosphate	5251
-	O
regulating	5251
gene	5251
with	5251
homologies	5251
to	5251
endopeptidase	5251
on	5251
the	5251
X	5251
chromosome	5251
(	O
PHEX	5251
)	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
X	D053098
-	O
linked	D053098
hypophosphatemic	D053098
rickets	D053098
(	O
XLH	D053098
;	O
OMIM	D053098
307800	D053098
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
enrolled	O
43	O
patients	9606
from	O
18	O
unrelated	O
families	O
clinically	O
diagnosed	O
with	O
hypophosphatemic	D063730
rickets	D063730
and	O
250	O
healthy	O
controls	O
.	O

For	O
each	O
available	O
individual	O
,	O
all	O
22	O
exons	O
with	O
their	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
PHEX	5251
gene	O
were	O
directly	O
sequenced	O
.	O

The	O
levels	O
of	O
serum	O
fibroblast	8074
growth	8074
factor	8074
23	8074
(	O
FGF23	8074
)	O
were	O
measured	O
as	O
well	O
.	O

Sequencing	O
analysis	O
detected	O
17	O
different	O
PHEX	5251
gene	O
mutations	O
,	O
and	O
7	O
of	O
these	O
were	O
identified	O
as	O
novel	O
:	O
3	O
missense	O
mutations	O
,	O
including	O
c	c|SUB|G|304|A
.	O
304G	c|SUB|G|304|A
>	O
A	c|SUB|G|304|A
(	O
p	p|SUB|G|102|R
.	O
Gly102Arg	p|SUB|G|102|R
)	O
in	O
exon	O
3	O
,	O
c	c|SUB|T|229|C
.	O
229T	c|SUB|T|229|C
>	O
C	c|SUB|T|229|C
(	O
p	p|SUB|C|77|R
.	O
Cys77Arg	p|SUB|C|77|R
)	O
in	O
exon	O
3	O
and	O
c	c|SUB|T|284|C
.	O
824T	c|SUB|T|284|C
>	O
C	c|SUB|T|284|C
(	O
p	p|SUB|L|275|P
.	O
Leu275Pro	p|SUB|L|275|P
)	O
in	O
exon	O
7	O
;	O
2	O
deletion	O
mutations	O
,	O
including	O
c	c|DEL|528|T
.	O
528delT	c|DEL|528|T
(	O
p	p|SUB|E|177|K|44
.	O
Glu177LysfsX44	p|SUB|E|177|K|44
)	O
in	O
exon	O
5	O
and	O
c	c|DEL|1234|A
.	O
1234delA	c|DEL|1234|A
(	O
p	p|SUB|S|412|V|12
.	O
Ser412ValfsX12	p|SUB|S|412|V|12
)	O
in	O
exon	O
11	O
;	O
and	O
2	O
alternative	O
splicing	O
mutations	O
,	O
including	O
c	c|DEL|436_436+1|AG
.	O
436_436	c|DEL|436_436+1|AG
+	O
1delAG	c|DEL|436_436+1|AG
in	O
intron	O
4	O
at	O
splicing	O
donor	O
sites	O
and	O
c	c|SUB|G|1483-1|C
.	O
1483	c|SUB|G|1483-1|C
-	O
1G	c|SUB|G|1483-1|C
>	O
C	c|SUB|G|1483-1|C
in	O
intron	O
13	O
at	O
splicing	O
acceptor	O
sites	O
.	O

Moreover	O
,	O
6	O
mutations	O
were	O
proven	O
to	O
be	O
de	O
novo	O
in	O
6	O
sporadic	O
cases	O
and	O
the	O
probands	O
were	O
all	O
females	O
.	O

No	O
mutations	O
were	O
found	O
in	O
the	O
250	O
healthy	O
controls	O
.	O

The	O
serum	O
levels	O
of	O
FGF23	8074
varied	O
widely	O
among	O
the	O
patients	9606
with	O
XLH	D053098
,	O
and	O
no	O
significant	O
difference	O
was	O
found	O
when	O
compared	O
with	O
those	O
of	O
the	O
healthy	O
controls	O
.	O

On	O
the	O
whole	O
,	O
the	O
findings	O
of	O
this	O
study	O
provide	O
new	O
insight	O
into	O
the	O
spectrum	O
of	O
PHEX	5251
mutations	O
and	O
provide	O
potential	O
evidence	O
of	O
a	O
critical	O
domain	O
in	O
PHEX	5251
protein	O
.	O

In	O
addition	O
,	O
the	O
finding	O
of	O
an	O
overlap	O
of	O
the	O
serum	O
FGF23	8074
levels	O
between	O
the	O
patients	9606
with	O
XLH	D053098
and	O
the	O
healthy	O
controls	O
indicates	O
its	O
limited	O
diagnostic	O
value	O
in	O
XLH	D053098
.	O
Hepatocyte	3175
nuclear	3175
factor	3175
-	O
6	3175
:	O
associations	O
between	O
genetic	O
variability	O
and	O
type	D003924
II	D003924
diabetes	D003924
and	O
between	O
genetic	O
variability	O
and	O
estimates	O
of	O
insulin	3630
secretion	O
.	O

The	O
transcription	O
factor	O
hepatocyte	3175
nuclear	3175
factor	3175
(	O
HNF	3175
)	O
-	O
6	3175
is	O
an	O
upstream	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
maturity	D003924
-	O
onset	D003924
diabetes	D003924
of	O
the	O
young	O
.	O

We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
variability	O
in	O
the	O
HNF	3175
-	O
6	3175
gene	O
is	O
associated	O
with	O
subsets	O
of	O
Type	D003924
II	D003924
(	O
non	D003924
-	O
insulin	D003924
-	O
dependent	D003924
)	O
diabetes	D003924
mellitus	D003924
and	O
estimates	O
of	O
insulin	3630
secretion	O
in	O
glucose	D005947
tolerant	O
subjects	O
.	O

We	O
cloned	O
the	O
coding	O
region	O
as	O
well	O
as	O
the	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
HNF	3175
-	O
6	3175
gene	O
.	O

We	O
then	O
examined	O
them	O
on	O
genomic	O
DNA	O
in	O
six	O
MODY	3172,3651,6927
probands	O
without	O
mutations	O
in	O
the	O
MODY1	3172
,	O
MODY3	6927
and	O
MODY4	3651
genes	O
and	O
in	O
54	O
patients	9606
with	O
late	O
-	O
onset	O
Type	D003924
II	D003924
diabetes	D003924
by	O
combined	O
single	O
strand	O
conformational	O
polymorphism	O
-	O
heteroduplex	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
of	O
identified	O
variants	O
.	O

An	O
identified	O
missense	O
variant	O
was	O
examined	O
in	O
association	O
studies	O
and	O
genotype	O
-	O
phenotype	O
studies	O
.	O

We	O
identified	O
two	O
silent	O
and	O
one	O
missense	O
(	O
Pro75	rs74805019
Ala	rs74805019
)	O
variant	O
.	O

In	O
an	O
association	O
study	O
the	O
allelic	O
frequency	O
of	O
the	O
Pro75Ala	rs74805019
polymorphism	O
was	O
3	O
.	O
2%	O
(	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
9	O
-	O
4	O
.	O
5	O
)	O
in	O
330	O
patients	9606
with	O
Type	D003924
II	D003924
diabetes	D003924
mellitus	D003924
compared	O
with	O
4	O
.	O
2%	O
(	O
2	O
.	O
4	O
-	O
6	O
.	O
0	O
)	O
in	O
238	O
age	O
-	O
matched	O
glucose	D005947
tolerant	O
control	O
subjects	O
.	O

Moreover	O
,	O
in	O
studies	O
of	O
238	O
middle	O
-	O
aged	O
glucose	D005947
tolerant	O
subjects	O
,	O
of	O
226	O
glucose	D005947
tolerant	O
offspring	O
of	O
Type	D003924
II	D003924
diabetic	D003924
patients	9606
and	O
of	O
367	O
young	O
healthy	O
subjects	O
,	O
the	O
carriers	O
of	O
the	O
polymorphism	O
did	O
not	O
differ	O
from	O
non	O
-	O
carriers	O
in	O
glucose	D005947
induced	O
serum	O
insulin	3630
or	O
C	3630
-	O
peptide	3630
responses	O
.	O

Mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
HNF	3175
-	O
6	3175
gene	O
are	O
not	O
associated	O
with	O
Type	D003924
II	D003924
diabetes	D003924
or	O
with	O
changes	O
in	O
insulin	3630
responses	O
to	O
glucose	D005947
among	O
the	O
Caucasians	O
examined	O
.	O
Pethidine	D008614
-	O
associated	O
seizure	D012640
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	D008614
for	O
postoperative	D010149
pain	D010149
control	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	D008614
via	O
a	O
patient	9606
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	D010149
pain	D010149
control	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	D012640
.	O

Both	O
plasma	O
pethidine	D008614
and	O
norpethidine	C002752
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	D064420
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	D008614
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	D008614
and	O
norpethidine	C002752
.	O

The	O
routine	O
use	O
of	O
pethidine	D008614
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	D010149
analgesia	D010149
should	O
be	O
reconsidered	O
.	O
Smoking	O
of	O
crack	D016578
cocaine	D016578
as	O
a	O
risk	O
factor	O
for	O
HIV	D015658
infection	D015658
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	D016578
cocaine	D016578
has	O
on	O
the	O
incidence	O
of	O
HIV	D015658
infection	D015658
.	O

Given	O
the	O
increasing	O
use	O
of	O
crack	D016578
cocaine	D016578
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	D015658
infection	D015658
.	O

METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	D015658
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O

To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	D006679
seroconversion	D006679
among	O
daily	O
smokers	O
of	O
crack	D016578
cocaine	D016578
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	D015658
infection	D015658
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	D016578
cocaine	D016578
increased	O
from	O
11	O
.	O
6%	O
in	O
period	O
1	O
to	O
39	O
.	O
7%	O
in	O
period	O
3	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	D006679
seroconversion	D006679
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	D016578
cocaine	D016578
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
period	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoking	O
of	O
crack	D016578
cocaine	D016578
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	D006679
seroconversion	D006679
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O

This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	D016578
cocaine	D016578
.	O
Common	O
dihydrofolate	1719
reductase	1719
19	c|DEL||19
-	O
base	c|DEL||19
pair	c|DEL||19
deletion	c|DEL||19
allele	O
:	O
a	O
novel	O
risk	O
factor	O
for	O
preterm	D047928
delivery	D047928
.	O

BACKGROUND	O
:	O
Folate	D005492
is	O
critical	O
for	O
cell	O
division	O
,	O
a	O
major	O
feature	O
of	O
in	O
utero	O
development	O
.	O

Dihydrofolate	1719
reductase	1719
(	O
DHFR	1719
)	O
is	O
required	O
to	O
convert	O
the	O
folic	D005492
acid	D005492
used	O
in	O
supplements	O
and	O
for	O
food	O
fortification	O
and	O
the	O
dihydrofolate	C010920
produced	O
by	O
thymidylate	7298
synthase	7298
during	O
DNA	O
synthesis	O
to	O
the	O
reduced	O
folate	D005492
forms	O
used	O
by	O
the	O
cell	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
whether	O
a	O
common	O
,	O
recently	O
discovered	O
deletion	O
polymorphism	O
in	O
the	O
DHFR	1719
gene	O
is	O
a	O
risk	O
factor	O
for	O
preterm	D047928
delivery	D047928
or	O
low	O
birth	O
weight	O
.	O

DESIGN	O
:	O
We	O
studied	O
324	O
pregnant	O
women	9606
from	O
Camden	O
,	O
NJ	O
.	O

Folate	D005492
intake	O
was	O
computed	O
from	O
folate	D005492
supplement	O
intake	O
plus	O
the	O
mean	O
of	O
two	O
24	O
-	O
h	O
recalls	O
completed	O
during	O
the	O
course	O
of	O
pregnancy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
women	9606
'	O
s	O
leukocytes	O
and	O
genotyped	O
.	O

RESULTS	O
:	O
Women	9606
with	O
a	O
deletion	O
allele	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	D047928
delivery	D047928
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
:	O
3	O
.	O
0	O
;	O
95%	O
CI	O
:	O
1	O
.	O
0	O
,	O
8	O
.	O
8	O
;	O
P	O
<	O
0	O
.	O
05	O
]	O
than	O
did	O
those	O
without	O
a	O
deletion	O
allele	O
.	O

Women	9606
with	O
both	O
a	O
DHFR	1719
deletion	O
allele	O
and	O
low	O
folate	D005492
intake	O
(	O
<	O
400	O
microg	O
/	O
d	O
from	O
diet	O
plus	O
supplements	O
)	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	D047928
delivery	D047928
(	O
AOR	O
:	O
5	O
.	O
5	O
;	O
95%	O
CI	O
:	O
1	O
.	O
5	O
,	O
20	O
.	O
4	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
a	O
significantly	O
greater	O
risk	O
of	O
having	O
an	O
infant	O
with	O
a	O
low	O
birth	O
weight	O
(	O
AOR	O
:	O
8	O
.	O
3	O
;	O
95%	O
CI	O
:	O
1	O
.	O
8	O
,	O
38	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
than	O
did	O
women	9606
without	O
a	O
deletion	O
allele	O
and	O
with	O
a	O
folate	D005492
intake	O
>	O
/	O
=	O
400	O
microg	O
/	O
d	O
.	O

CONCLUSIONS	O
:	O
The	O
DHFR	1719
19	c|DEL||19
-	O
base	c|DEL||19
pair	c|DEL||19
deletion	c|DEL||19
allele	O
may	O
be	O
a	O
risk	O
factor	O
for	O
preterm	D047928
delivery	D047928
.	O

In	O
the	O
presence	O
of	O
low	O
dietary	O
folate	D005492
,	O
the	O
allele	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
.	O

This	O
may	O
be	O
a	O
gene	O
-	O
environment	O
interaction	O
.	O
Nefiracetam	C058876
(	O
DM	C058876
-	O
9384	C058876
)	O
reverses	O
apomorphine	D001058
-	O
induced	O
amnesia	D000647
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O

Nefiracetam	C058876
is	O
a	O
novel	O
pyrrolidone	D011760
derivative	O
which	O
attenuates	O
scopolamine	D012601
-	O
induced	O
learning	D007859
and	D007859
post	D007859
-	O
training	D007859
consolidation	D007859
deficits	D007859
.	O

Given	O
that	O
apomorphine	D001058
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	C058876
to	O
attenuate	O
amnesia	D000647
induced	O
by	O
dopaminergic	D018491
agonism	D018491
.	O

A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	C058876
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	D001058
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O

Co	O
-	O
administration	O
of	O
nefiracetam	C058876
and	O
apomorphine	D001058
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	D000647
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	C058876
during	O
training	O
completely	O
reversed	O
the	O
amnesia	D000647
induced	O
by	O
apomorphine	D001058
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	C058876
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	D014316
]	O
SCH	C534628
23390	C534628
or	O
[	O
3H	D014316
]	O
spiperone	D013134
binding	O
from	O
D1	1812,1813
or	1812,1813
D2	1812,1813
dopamine	1812,1813
receptor	1812,1813
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	C058876
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O
Angiotensin	11607
II	11607
subtype	11607
1a	11607
receptor	11607
signaling	O
in	O
resident	O
hepatic	O
macrophages	O
induces	O
liver	D008113
metastasis	D008113
formation	O
.	O

Liver	D008113
metastases	D008113
from	O
colorectal	D015179
cancer	D015179
(	O
CRC	D015179
)	O
are	O
a	O
clinically	O
significant	O
problem	O
.	O

The	O
renin	19701
-	O
angiotensin	11606
system	O
is	O
involved	O
in	O
tumor	D009369
growth	O
and	O
metastases	D009362
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
role	O
of	O
angiotensin	11607
II	11607
subtype	11607
receptor	11607
1a	11607
(	O
AT1a	11607
)	O
in	O
the	O
formation	O
of	O
liver	D008113
metastasis	D008113
in	O
CRC	D015179
.	O

A	O
model	O
of	O
liver	D008113
metastasis	D008113
was	O
developed	O
by	O
intrasplenic	O
injection	O
of	O
mouse	10090
colon	D015179
cancer	D015179
(	O
CMT	10090
-	O
93	10090
)	O
into	O
AT1a	11607
knockout	O
mice	10090
(	O
AT1aKO	11607
)	O
and	O
wild	O
-	O
type	O
(	O
C57BL	10090
/	O
6	10090
)	O
mice	10090
(	O
WT	O
)	O
.	O

Compared	O
with	O
WT	O
mice	10090
,	O
the	O
liver	O
weight	O
and	O
liver	D008113
metastatic	D008113
rate	O
were	O
significantly	O
lower	O
in	O
AT1aKO	11607
.	O

The	O
mRNA	O
levels	O
of	O
CD31	18613
,	O
transforming	21803
growth	21803
factor	21803
-	O
b1	21803
(	O
TGF	21803
-	O
b1	21803
)	O
,	O
and	O
F4	13733
/	O
80	13733
were	O
suppressed	O
in	O
AT1aKO	11607
compared	O
with	O
WT	O
.	O

Double	O
immunofluorescence	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
accumulated	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
expressing	O
TGF	21803
-	O
b1	21803
in	O
metastatic	O
areas	O
was	O
higher	O
in	O
WT	O
than	O
in	O
AT1aKO	11607
.	O

The	O
AT1aKO	11607
bone	O
marrow	O
(	O
BM	O
)	O
(	O
AT1aKO	11607
-	O
BM	O
)	O
>	O
WT	O
showed	O
suppressed	O
formation	O
of	O
liver	D008113
metastasis	D008113
compared	O
with	O
WT	O
-	O
BM	O
>	O
WT	O
.	O

However	O
,	O
the	O
formation	O
of	O
metastasis	D009362
was	O
further	O
suppressed	O
in	O
WT	O
-	O
BM	O
>	O
AT1aKO	11607
compared	O
with	O
AT1aKO	11607
-	O
BM	O
>	O
WT	O
.	O

In	O
addition	O
,	O
accumulated	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
in	O
the	O
liver	D008113
metastasis	D008113
were	O
not	O
BM	O
-	O
derived	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
,	O
but	O
mainly	O
resident	O
hepatic	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
,	O
and	O
these	O
resident	O
hepatic	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
were	O
positive	O
for	O
TGF	21803
-	O
b1	21803
.	O

Angiotensin	11606
II	11606
enhanced	O
TGF	21803
-	O
b1	21803
expression	O
in	O
Kupffer	O
cells	O
.	O

Treatment	O
of	O
WT	O
with	O
clodronate	D004002
liposomes	O
suppressed	O
liver	D008113
metastasis	D008113
by	O
diminishing	O
TGF	21803
-	O
b1	21803
(	O
+	O
)	O
F4	13733
/	O
80	13733
(	O
+	O
)	O
cells	O
accumulation	O
.	O

The	O
formation	O
of	O
liver	D008113
metastasis	D008113
correlated	O
with	O
collagen	12842
deposition	O
in	O
the	O
metastatic	O
area	O
,	O
which	O
was	O
dependent	O
on	O
AT1a	11607
signaling	O
.	O

These	O
results	O
suggested	O
that	O
resident	O
hepatic	O
macrophages	O
induced	O
liver	D008113
metastasis	D008113
formation	O
by	O
induction	O
of	O
TGF	21803
-	O
b1	21803
through	O
AT1a	11607
signaling	O
.	O
Isoproterenol	D007545
induces	O
primary	O
loss	O
of	O
dystrophin	24907
in	O
rat	10116
hearts	O
:	O
correlation	O
with	O
myocardial	D009202
injury	D009202
.	O

The	O
mechanism	O
of	O
isoproterenol	D007545
-	O
induced	O
myocardial	D009202
damage	D009202
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	D010100
supply	O
vs	O
.	O

demand	O
following	O
coronary	O
hypotension	D007022
and	O
myocardial	D009202
hyperactivity	D009202
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	D007545
.	O

Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	24907
-	O
glycoprotein	11820
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	60
and	O
laminin	309368
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	D007545
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O

We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	D007545
subcutaneous	O
administration	O
.	O

Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	24907
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	60
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O

The	O
sarcomeric	O
actin	60
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	24907
.	O

Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma	305941
-	O
sarcoglycan	305941
,	O
beta	114489
-	O
dystroglycan	114489
,	O
beta1	24511
-	O
integrin	24511
,	O
and	O
laminin	309368
alpha	309368
-	O
2	309368
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	D007545
to	O
rats	10116
results	O
in	O
primary	O
loss	O
of	O
dystrophin	24907
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	D007511
injury	D007511
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	D007545
.	O
The	O
-	O
930A	rs9932581
>	O
G	rs9932581
polymorphism	O
of	O
the	O
CYBA	1535
gene	O
is	O
associated	O
with	O
premature	O
coronary	D003324
artery	D003324
disease	D003324
.	O

A	O
case	O
-	O
control	O
study	O
and	O
gene	O
-	O
risk	O
factors	O
interactions	O
.	O

Reactive	D017382
oxygen	D017382
species	D017382
(	O
ROS	D017382
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	D050197
and	O
coronary	D003324
artery	D003324
disease	D003324
(	O
CAD	D003324
)	O
.	O

NADPH	1666
oxidases	1666
are	O
the	O
main	O
source	O
of	O
ROS	D017382
in	O
the	O
vasculature	O
.	O

p22phox	1535
is	O
a	O
critical	O
component	O
of	O
vascular	O
NADPH	1666
oxidases	1666
and	O
is	O
encoded	O
by	O
the	O
CYBA	1535
(	O
cytochrome	1535
b245	1535
alpha	1535
)	O
gene	O
.	O

The	O
-	O
930A	rs9932581
>	O
G	rs9932581
CYBA	1535
polymorphism	O
(	O
rs9932581	rs9932581
:	O
A	rs9932581
>	O
G	rs9932581
)	O
modulates	O
the	O
activity	O
of	O
the	O
CYBA	1535
promoter	O
,	O
and	O
influences	O
CYBA	1535
transcriptional	O
activity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
a	O
possible	O
association	O
between	O
the	O
-	O
930A	rs9932581
>	O
G	rs9932581
polymorphism	O
and	O
CAD	D003324
and	O
to	O
search	O
for	O
gene	O
-	O
traditional	O
risk	O
factors	O
interactions	O
.	O

480	O
subjects	O
were	O
studied	O
:	O
240	O
patients	9606
with	O
premature	O
CAD	D003324
,	O
240	O
age	O
and	O
sex	O
matched	O
blood	O
donors	O
.	O

The	O
-	O
930A	rs9932581
>	O
G	rs9932581
polymorphism	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
-	O
Pre	O
-	O
designed	O
SNP	O
Genotyping	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
-	O
930G	rs9932581
allele	O
carrier	O
state	O
was	O
a	O
risk	O
factor	O
for	O
CAD	D003324
(	O
OR	O
2	O
.	O
03	O
,	O
95%	O
CI	O
1	O
.	O
21	O
-	O
3	O
.	O
44	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

A	O
synergistic	O
effect	O
of	O
the	O
-	O
930G	rs9932581
allele	O
with	O
overweight	D050177
/	O
obesity	D009765
(	O
BMI	O
-	O
-	O
25	O
)	O
and	O
cigarette	O
smoking	O
was	O
found	O
.	O

The	O
estimated	O
CAD	D003324
risk	O
for	O
BMI	O
-	O
-	O
25	O
and	O
the	O
-	O
930G	rs9932581
allele	O
interaction	O
was	O
about	O
160%	O
greater	O
than	O
that	O
predicted	O
by	O
assuming	O
additivity	O
of	O
the	O
effects	O
,	O
and	O
about	O
40%	O
greater	O
for	O
interaction	O
of	O
cigarette	O
smoking	O
and	O
the	O
-	O
930G	rs9932581
allele	O
.	O

Overweight	D050177
/	O
obesity	D009765
was	O
a	O
risk	O
factor	O
for	O
CAD	D003324
only	O
in	O
the	O
-	O
930G	rs9932581
allele	O
carriers	O
(	O
P	O
<	O
10	O
(	O
-	O
10	O
)	O
)	O
but	O
not	O
in	O
the	O
AA	O
homozygotes	O
(	O
P	O
=	O
1	O
.	O
00	O
)	O
.	O

In	O
conclusion	O
the	O
-	O
930A	rs9932581
>	O
G	rs9932581
CYBA	1535
polymorphism	O
is	O
associated	O
with	O
CAD	D003324
in	O
the	O
Polish	O
population	O
.	O

The	O
-	O
930G	rs9932581
allele	O
carriers	O
are	O
particularly	O
at	O
risk	O
of	O
consequences	O
of	O
obesity	D009765
and	O
tobacco	4097
smoke	O
exposure	O
.	O
Segregation	O
of	O
a	O
M404V	rs771966860
mutation	O
of	O
the	O
p62	8878
/	O
sequestosome	8878
1	8878
(	O
p62	8878
/	O
SQSTM1	8878
)	O
gene	O
with	O
polyostotic	O
Paget	C538098
'	O
s	C538098
disease	C538098
of	C538098
bone	C538098
in	O
an	O
Italian	O
family	O
.	O

Mutations	O
of	O
the	O
p62	8878
/	O
Sequestosome	8878
1	8878
gene	O
(	O
p62	8878
/	O
SQSTM1	8878
)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget	C538098
'	O
s	C538098
disease	C538098
of	C538098
bone	C538098
(	O
PDB	C538098
)	O
.	O

We	O
originally	O
described	O
a	O
methionine	rs771966860
-	O
-	O
>	O
valine	rs771966860
substitution	rs771966860
at	rs771966860
codon	rs771966860
404	rs771966860
(	O
M404V	rs771966860
)	O
of	O
exon	O
8	O
,	O
in	O
the	O
ubiquitin	O
protein	O
-	O
binding	O
domain	O
of	O
p62	8878
/	O
SQSTM1	8878
gene	O
in	O
an	O
Italian	O
PDB	C538098
patient	9606
.	O

The	O
collection	O
of	O
data	O
from	O
the	O
patient	9606
'	O
s	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	C538098
.	O

Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	rs771966860
mutation	O
with	O
the	O
polyostotic	O
PDB	C538098
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O

DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
,	O
4	O
PDB	C538098
patients	9606
and	O
18	O
clinically	O
unaffected	O
members	O
.	O

Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
,	O
four	O
possessed	O
the	O
M404V	rs771966860
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	C538098
,	O
except	O
one	O
patient	9606
with	O
a	O
single	O
X	O
-	O
ray	O
-	O
assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	D005357
disease	D005357
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O

By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
,	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	rs771966860
mutation	O
,	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	D000469
phosphatase	D000469
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
M404V	rs771966860
mutation	O
in	O
the	O
p62	8878
/	O
SQSTM1	8878
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	C538098
in	O
this	O
family	O
.	O

The	O
high	O
penetrance	O
of	O
the	O
PDB	C538098
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62	8878
/	O
SQSTM1	8878
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	C538098
.	O
Osteogenesis	C536044
imperfecta	C536044
type	C536044
III	C536044
with	O
intracranial	D020300
hemorrhage	D020300
and	O
brachydactyly	D059327
associated	O
with	O
mutations	O
in	O
exon	O
49	O
of	O
COL1A2	1278
.	O

Osteogenesis	D010013
imperfecta	D010013
(	O
OI	D010013
)	O
is	O
a	O
heritable	O
bone	D001847
disorder	D001847
characterized	O
by	O
fractures	D050723
with	O
minimal	O
trauma	D014947
.	O

Intracranial	D020300
hemorrhage	D020300
has	O
been	O
reported	O
in	O
a	O
small	O
number	O
of	O
OI	D010013
patients	9606
.	O

Here	O
we	O
describe	O
three	O
patients	9606
,	O
a	O
boy	O
(	O
aged	O
15	O
years	O
)	O
and	O
two	O
girls	O
(	O
aged	O
17	O
and	O
7	O
years	O
)	O
with	O
OI	C536044
type	C536044
III	C536044
who	O
suffered	O
intracranial	D020300
hemorrhage	D020300
and	O
in	O
addition	O
had	O
brachydactyly	D059327
and	O
nail	D009260
hypoplasia	D009260
.	O

In	O
all	O
of	O
these	O
patients	9606
,	O
OI	D010013
was	O
caused	O
by	O
glycine	O
mutations	O
affecting	O
exon	O
49	O
of	O
the	O
COL1A2	1278
gene	O
,	O
which	O
codes	O
for	O
the	O
most	O
carboxy	O
-	O
terminal	O
part	O
of	O
the	O
triple	O
-	O
helical	O
domain	O
of	O
the	O
collagen	1278
type	1278
I	1278
alpha	1278
2	1278
chain	O
.	O

These	O
observations	O
suggest	O
that	O
mutations	O
in	O
this	O
region	O
of	O
the	O
collagen	1278
type	1278
I	1278
alpha	1278
2	1278
chain	O
carry	O
a	O
high	O
risk	O
of	O
abnormal	D009140
limb	D009140
development	D009140
and	O
intracranial	D020300
bleeding	D020300
.	O
SLURP1	57152
mutation	O
-	O
impaired	O
T	O
-	O
cell	O
activation	O
in	O
a	O
family	O
with	O
mal	D007645
de	D007645
Meleda	D007645
.	O

BACKGROUND	O
:	O
Mal	D007645
de	D007645
Meleda	D007645
(	O
MDM	D007645
)	O
is	O
palmoplantar	C563781
erythrokeratoderma	C563781
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP	57152
-	O
1	57152
(	O
lymphocyte	57152
antigen	57152
6	57152
/	O
urokinase	57152
-	O
type	57152
plasminogen	57152
activator	57152
receptor	57152
related	57152
protein	57152
-	O
1	57152
)	O
.	O

SLURP	57152
-	O
1	57152
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	1137
acetylcholine	1137
receptor	1137
(	O
nAchR	1137
)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O

In	O
addition	O
,	O
murine	10090
studies	O
have	O
shown	O
that	O
nAchR	11441
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
function	O
.	O

Among	O
the	O
family	O
members	O
,	O
patients	9606
with	O
the	O
homozygous	O
SLURP1	57152
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	D008545
and	O
viral	D014777
infection	D014777
,	O
which	O
might	O
link	O
to	O
defective	O
T	O
-	O
cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	57152
gene	O
mutation	O
with	O
T	O
-	O
cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	D007645
.	O

To	O
test	O
that	O
SLURP	57152
-	O
1	57152
is	O
essential	O
for	O
T	O
-	O
cell	O
activation	O
.	O

METHODS	O
:	O
Human	9606
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	D007645
family	O
bearing	O
the	O
G	rs28937888
to	rs28937888
A	rs28937888
substitution	rs28937888
in	rs28937888
nucleotide	rs28937888
256	rs28937888
in	O
the	O
SLURP1	57152
gene	O
,	O
corresponding	O
to	O
a	O
glycine	rs28937888
to	rs28937888
arginine	rs28937888
substitution	rs28937888
at	rs28937888
amino	rs28937888
acid	rs28937888
86	rs28937888
(	O
G86R	rs28937888
)	O
in	O
the	O
SLURP	57152
-	O
1	57152
protein	O
.	O

PBMCs	O
from	O
homozygotes	O
and	O
wild	O
-	O
type	O
controls	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	915
/	O
anti	O
-	O
CD28	940
antibodies	O
and	O
the	O
level	O
of	O
T	O
-	O
cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O

RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP	57152
-	O
1	57152
G86R	rs28937888
mutation	O
had	O
defective	O
T	O
-	O
cell	O
activation	O
.	O

This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
5	O
ug	O
mL	O
(	O
-	O
1	O
)	O
recombinant	O
human	9606
SLURP	57152
-	O
1	57152
protein	O
.	O

CONCLUSIONS	O
:	O
Patients	9606
with	O
MDM	D007645
with	O
the	O
homozygous	O
SLURP	57152
-	O
1	57152
G86R	rs28937888
mutation	O
may	O
have	O
an	O
impaired	O
T	O
-	O
cell	O
activation	O
.	O

The	O
presence	O
of	O
wild	O
-	O
type	O
SLURP	57152
-	O
1	57152
is	O
essential	O
for	O
normal	O
T	O
-	O
cell	O
activation	O
.	O
Molecular	O
diagnosis	O
of	O
46	D058490
,	O
XY	D058490
DSD	D058490
and	O
identification	O
of	O
a	O
novel	O
8	c|DEL||8
nucleotide	c|DEL||8
deletion	c|DEL||8
in	O
exon	O
1	O
of	O
the	O
SRD5A2	6716
gene	O
.	O

Phenotypic	O
presentation	O
of	O
46	D058490
,	O
XY	D058490
DSD	D058490
depends	O
on	O
the	O
underlying	O
defects	O
.	O

Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O

Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O

Mutational	O
analysis	O
of	O
androgen	367
receptor	367
(	O
AR	367
)	O
and	O
SRD5A2	6716
genes	O
was	O
performed	O
in	O
29	O
patients	9606
with	O
46	D058490
,	O
XY	D058490
DSD	D058490
,	O
by	O
PCR	O
-	O
SSCP	O
.	O

The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O

Interestingly	O
,	O
six	O
patients	9606
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle	O
/	O
nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	6716
gene	O
.	O

In	O
five	O
patients	9606
p	rs9332967
.	O
R246Q	rs9332967
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g	g|DEL|80_87|TCGCGAAG
.	O
80_87delT	g|DEL|80_87|TCGCGAAG
CGCGAAG	g|DEL|80_87|TCGCGAAG
(	O
p	p|FS|A|27||132
.	O
A27fsX132	p|FS|A|27||132
)	O
and	O
p	rs9332967
.	O
R246Q	rs9332967
.	O

Another	O
patient	9606
with	O
isolated	C536649
micropenis	C536649
harbored	O
a	O
heterozygous	O
p	rs121434250
.	O
G196S	rs121434250
missense	O
mutation	O
.	O

No	O
AR	367
gene	O
mutation	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
p	rs9332967
.	O
R246Q	rs9332967
mutation	O
is	O
common	O
amongst	O
patients	9606
with	O
SRD5A2	6716
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O

Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	6716
gene	O
in	O
a	O
patient	9606
with	O
severe	O
hypospadias	D007021
.	O
People	O
aged	O
over	O
75	O
in	O
atrial	D001281
fibrillation	D001281
on	O
warfarin	D014859
:	O
the	O
rate	O
of	O
major	O
hemorrhage	D006470
and	O
stroke	D020521
in	O
more	O
than	O
500	O
patient	9606
-	O
years	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	D006470
and	O
stroke	D020521
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	D001281
fibrillation	D001281
on	O
adjusted	O
-	O
dose	O
warfarin	D014859
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O

SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	9606
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	D001281
fibrillation	D001281
on	O
warfarin	D014859
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	D006470
episodes	O
,	O
strokes	D020521
,	O
and	O
warfarin	D014859
use	O
was	O
obtained	O
from	O
patients	9606
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	9606
(	O
42%	O
men	9606
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfarin	D014859
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhages	D006470
,	O
for	O
an	O
annual	O
rate	O
of	O
10	O
.	O
0%	O
,	O
including	O
24	O
(	O
45	O
.	O
3%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4%	O
)	O
fatal	O
bleeds	D006470
.	O

The	O
annual	O
stroke	D020521
rate	O
after	O
initiation	O
of	O
warfarin	D014859
was	O
2	O
.	O
6%	O
.	O

CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	D006470
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	D020521
rate	O
on	O
warfarin	D014859
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	D014859
treatment	O
is	O
.	O
Apomorphine	D001058
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
.	O

Apomorphine	D001058
was	O
the	O
first	O
dopaminergic	D004298
drug	D004298
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
by	O
subcutaneous	O
administration	O
of	O
apomorphine	D001058
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	D001058
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	D007980
and	O
that	O
apomorphine	D001058
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	9606
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	D001058
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50%	O
in	O
this	O
group	O
of	O
patients	9606
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	D018491
agonists	D018491
or	O
COMT	D065098
inhibitors	D065098
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	D001058
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	D001058
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	D007980
-	O
induced	O
dyskinesias	D004409
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	D001058
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	D001523
complications	D001523
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	D001058
treatment	O
in	O
fluctuating	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O
Interleukin	112744
-	O
17F	112744
gene	O
polymorphism	O
in	O
patients	9606
with	O
chronic	D016553
immune	D016553
thrombocytopenia	D016553
.	O

INTRODUCTION	O
:	O
IL	112744
-	O
17F	112744
is	O
a	O
novel	O
inflammatory	112744
cytokine	112744
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	D001327
diseases	D001327
.	O

We	O
investigated	O
the	O
association	O
between	O
chronic	D016553
ITP	D016553
and	O
the	O
frequency	O
of	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs763780	rs763780
(	O
7488T	rs763780
/	O
C	rs763780
)	O
,	O
which	O
causes	O
a	O
His	rs763780
-	O
to	rs763780
-	O
Arg	rs763780
substitution	rs763780
at	rs763780
amino	rs763780
acid	rs763780
161	rs763780
.	O

PATIENTS	9606
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	9606
(	O
men	9606
/	O
women	9606
,	O
40	O
/	O
62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	D016553
ITP	D016553
and	O
188	O
healthy	O
controls	O
(	O
men	9606
/	O
women	9606
,	O
78	O
/	O
110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O

Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
technique	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	9606
with	O
chronic	D016553
ITP	D016553
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL	112744
-	O
17F	112744
7488CC	rs763780
genotype	O
(	O
0%	O
vs	O
.	O

4	O
.	O
8%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
number	O
of	O
IL	112744
-	O
17F	112744
7488C	rs763780
alleles	O
among	O
the	O
patients	9606
with	O
chronic	D016553
ITP	D016553
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8	O
.	O
7%	O
vs	O
.	O

15	O
.	O
2%	O
OR	O
=	O
0	O
.	O
48	O
,	O
95%CI	O
=	O
0	O
.	O
27	O
-	O
0	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
016	O
)	O
.	O

Furthermore	O
,	O
patients	9606
with	O
the	O
IL	112744
-	O
17F	112744
7488TT	rs763780
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	D011696
state	O
(	O
platelet	O
count	O
<	O
10	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL	112744
-	O
17F	112744
7488TC	rs763780
genotype	O
(	O
20	O
.	O
9%	O
vs	O
.	O

0%	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL	112744
-	O
17F	112744
7488	rs763780
T	rs763780
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	D016553
ITP	D016553
,	O
suggesting	O
a	O
role	O
for	O
IL	112744
-	O
17F	112744
in	O
the	O
pathogenesis	O
of	O
chronic	D016553
ITP	D016553
.	O
Identification	O
of	O
the	O
BRAF	673
V600E	rs113488022
mutation	O
in	O
gastroenteropancreatic	C535650
neuroendocrine	C535650
tumors	C535650
.	O

Genomic	O
profiles	O
of	O
gastroenteropancreatic	C535650
neuroendocrine	C535650
tumors	C535650
(	O
GEP	C535650
-	O
NETs	C535650
)	O
are	O
still	O
insufficiently	O
understood	O
,	O
and	O
the	O
genetic	O
alterations	O
associated	O
with	O
drug	O
responses	O
have	O
not	O
been	O
studied	O
.	O

Here	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
of	O
12	O
GEP	C535650
-	O
NETs	C535650
from	O
patients	9606
enrolled	O
in	O
a	O
nonrandomized	O
,	O
open	O
-	O
labeled	O
,	O
single	O
-	O
center	O
phase	O
II	O
study	O
for	O
pazopanib	C516667
,	O
and	O
integrated	O
our	O
results	O
with	O
previously	O
published	O
results	O
on	O
pancreas	O
(	O
n	O
=	O
12	O
)	O
and	O
small	O
intestine	D007414
NETs	D007414
(	O
n	O
=	O
50	O
)	O
.	O

The	O
mean	O
numbers	O
of	O
somatic	O
mutations	O
in	O
each	O
case	O
varied	O
widely	O
from	O
20	O
to	O
4682	O
.	O

Among	O
12	O
GEP	C535650
-	O
NETs	C535650
,	O
eight	O
showed	O
mutations	O
of	O
more	O
than	O
one	O
cancer	D009369
-	O
related	O
gene	O
,	O
including	O
TP53	7157
,	O
CNBD1	168975
,	O
RB1	5925
,	O
APC	324
,	O
BCOR	54880
,	O
BRAF	673
,	O
CTNNB1	1499
,	O
EGFR	1956
,	O
EP300	2033
,	O
ERBB3	2065
,	O
KDM6A	7403
,	O
KRAS	3845
,	O
MGA	23269
,	O
MLL3	58508
,	O
PTEN	5728
,	O
RASA1	5921
,	O
SMARCB1	6598
,	O
SPEN	23013
,	O
TBC1D12	23232
,	O
and	O
VHL	7428
.	O

TP53	7157
was	O
recurrently	O
mutated	O
in	O
three	O
cases	O
,	O
whereas	O
CNBD1	168975
and	O
RB1	5925
mutations	O
were	O
identified	O
in	O
two	O
cases	O
.	O

Three	O
GEP	C535650
-	O
NET	C535650
patients	9606
with	O
TP53	7157
mutations	O
demonstrated	O
a	O
durable	O
response	O
and	O
one	O
small	O
intestinal	D007414
grade	D007414
(	O
G	D007414
)	O
1	D007414
NET	D007414
patient	9606
with	O
BRAF	673
V600E	rs113488022
mutation	O
showed	O
progression	O
after	O
pazopanib	C516667
treatment	O
.	O

We	O
found	O
BRAF	673
V600E	rs113488022
(	O
G1	O
NET	D018358
from	O
rectum	O
and	O
two	O
G3	O
NETs	D018358
from	O
colon	O
)	O
and	O
BRAF	673
G593S	p.G593S
(	O
G2	O
NET	D018358
from	O
pancreas	O
)	O
missense	O
mutations	O
(	O
9	O
.	O
1%	O
)	O
in	O
an	O
independent	O
cohort	O
of	O
44	O
GEP	C535650
-	O
NETs	C535650
from	O
the	O
rectum	O
(	O
n	O
=	O
26	O
)	O
,	O
colon	O
(	O
n	O
=	O
7	O
)	O
,	O
pancreas	O
(	O
n	O
=	O
4	O
)	O
,	O
small	O
intestine	O
(	O
n	O
=	O
3	O
)	O
,	O
stomach	O
(	O
n	O
=	O
3	O
)	O
and	O
appendix	O
(	O
n	O
=	O
1	O
)	O
by	O
Sanger	O
sequencing	O
.	O

All	O
tumor	D009369
specimens	O
were	O
obtained	O
before	O
chemotherapy	O
.	O

In	O
conclusion	O
,	O
BRAF	673
V600E	rs113488022
mutation	O
is	O
likely	O
to	O
result	O
in	O
resistance	O
to	O
pazopanib	C516667
but	O
may	O
be	O
a	O
potentianally	O
actionable	O
mutation	O
in	O
metastatic	O
GEP	C535650
-	O
NETs	C535650
patients	9606
.	O
A	O
novel	O
apolipoprotein	348
E	348
mutation	O
,	O
ApoE	348
Osaka	O
(	O
Arg158	p|SUB|R|158|P
Pro	p|SUB|R|158|P
)	O
,	O
in	O
a	O
dyslipidemic	D050171
patient	9606
with	O
lipoprotein	C567089
glomerulopathy	C567089
.	O

Lipoprotein	C567089
glomerulopathy	C567089
(	O
LPG	C567089
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
thrombuslike	O
deposition	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
is	O
often	O
accompanied	O
by	O
an	O
increased	O
serum	O
apolipoprotein	348
E	348
(	O
apoE	348
)	O
level	O
.	O

Several	O
gene	O
mutations	O
of	O
apoE	348
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
LPG	C567089
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
an	O
LPG	C567089
patient	9606
with	O
a	O
novel	O
apoE	348
mutation	O
,	O
apoE	348
Osaka	O
.	O

The	O
patient	9606
was	O
a	O
45	O
-	O
year	O
-	O
old	O
man	9606
who	O
was	O
hospitalized	O
due	O
to	O
nephrotic	D009404
syndrome	D009404
.	O

Light	O
and	O
electron	O
microscopic	O
observations	O
of	O
renal	O
biopsy	O
clearly	O
showed	O
characteristic	O
findings	O
of	O
LPG	C567089
,	O
including	O
lamellate	D013927
thrombi	D013927
in	O
the	O
lumen	O
of	O
dilated	O
glomerular	O
capillaries	O
.	O

His	O
apoE	348
phenotype	O
was	O
apoE3	348
/	O
2	348
and	O
he	O
had	O
mild	O
dyslipidemia	D050171
with	O
a	O
mid	O
-	O
band	O
on	O
polyacrylamide	-
gel	O
electrophoresis	O
.	O

It	O
is	O
intriguing	O
that	O
the	O
serum	O
apoE	348
level	O
was	O
within	O
normal	O
limits	O
.	O

We	O
determined	O
the	O
sequence	O
of	O
the	O
apoE	348
gene	O
using	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O

ApoE	348
gene	O
analysis	O
showed	O
a	O
nucleotide	O
substitution	O
of	O
G	c|SUB|G|CODON158|C
to	c|SUB|G|CODON158|C
C	c|SUB|G|CODON158|C
at	c|SUB|G|CODON158|C
codon	c|SUB|G|CODON158|C
158	c|SUB|G|CODON158|C
of	O
exon	O
4	O
.	O

This	O
mutation	O
denoted	O
an	O
amino	O
acid	O
substitution	O
of	O
arginine	p|SUB|R|158|P
residue	p|SUB|R|158|P
for	p|SUB|R|158|P
the	p|SUB|R|158|P
proline	p|SUB|R|158|P
residue	p|SUB|R|158|P
at	p|SUB|R|158|P
position	p|SUB|R|158|P
158	p|SUB|R|158|P
of	O
apoE	348
.	O

The	O
result	O
of	O
PCR	O
associated	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
suggested	O
that	O
this	O
mutation	O
is	O
heterozygous	O
.	O

It	O
is	O
possible	O
that	O
apoE	348
Osaka	O
mutation	O
causes	O
a	O
conformational	O
change	O
of	O
apoE	348
protein	O
and	O
affects	O
the	O
interaction	O
between	O
abnormal	O
apoE	348
-	O
containing	O
lipoproteins	O
and	O
the	O
endothelial	O
cells	O
of	O
glomerular	O
capillaries	O
.	O

The	O
precise	O
mechanism	O
of	O
LPG	C567089
related	O
with	O
apoE	348
Osaka	O
,	O
however	O
,	O
remains	O
to	O
be	O
elucidated	O
.	O
Hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
tilt	O
test	O
in	O
relation	O
to	O
gene	O
polymorphism	O
of	O
renin	5972
-	O
angiotensin	183
and	O
serotonin	D012701
system	O
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
renin	5972
-	O
angiotensin	183
system	O
and	O
serotonin	6532
transporter	6532
gene	O
polymorphisms	O
in	O
relation	O
to	O
hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
head	O
-	O
up	O
tilt	O
test	O
(	O
HUT	O
)	O
in	O
patients	9606
with	O
vasovagal	D019462
syncope	D019462
.	O

METHODS	O
:	O
DNA	O
was	O
collected	O
from	O
191	O
patients	9606
(	O
mean	O
age	O
44	O
+	O
/	O
-	O
18	O
years	O
,	O
61	O
men	9606
,	O
130	O
women	9606
)	O
.	O

The	O
following	O
gene	O
polymorphisms	O
were	O
determined	O
in	O
genomic	O
DNA	O
:	O
angiotensin	1636
-	O
converting	1636
enzyme	1636
insertion	O
/	O
deletion	O
polymorphism	O
(	O
I	O
/	O
D	O
ACE	1636
)	O
,	O
angiotensinogen	183
gene	O
polymorphism	O
(	O
M	p|Allele|M|235
235	p|Allele|M|235
)	O
,	O
angiotensin	185
II	185
receptor	185
type	185
1	185
(	O
ATR1	185
)	O
polymorphism	O
(	O
A	rs5186
11666C	rs5186
)	O
,	O
and	O
polymorphism	O
of	O
serotonin	6532
transporter	6532
gene	O
(	O
5HTTLPR	6532
)	O
.	O
Heart	O
rate	O
variability	O
during	O
HUT	O
was	O
assessed	O
in	O
5	O
-	O
minute	O
intervals	O
by	O
low	O
frequency	O
,	O
high	O
frequency	O
,	O
standard	O
deviation	O
of	O
the	O
normal	O
-	O
to	O
-	O
normal	O
(	O
SDNN	O
)	O
,	O
and	O
root	O
mean	O
square	O
successive	O
difference	O
parameters	O
.	O

RESULTS	O
:	O
AA	O
genotype	O
of	O
A	rs5186
1166C	rs5186
polymorphism	O
was	O
associated	O
with	O
lower	O
minimal	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
during	O
HUT	O
compared	O
with	O
other	O
genotypes	O
(	O
minimal	O
SBP	O
:	O
AA	O
59	O
.	O
6	O
+	O
/	O
-	O
21	O
,	O
8	O
,	O
AC	O
79	O
.	O
9	O
+	O
/	O
-	O
22	O
.	O
7	O
,	O
CC	O
65	O
.	O
4	O
+	O
/	O
-	O
22	O
.	O
7	O
mmHg	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
(	O
minimal	O
DBP	O
:	O
AA	O
36	O
.	O
4	O
+	O
/	O
-	O
22	O
.	O
7	O
,	O
AC	O
52	O
.	O
3	O
+	O
/	O
-	O
22	O
.	O
9	O
,	O
CC	O
45	O
.	O
4	O
+	O
/	O
-	O
19	O
.	O
5	O
mmHg	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O
AA	O
genotype	O
was	O
also	O
associated	O
with	O
higher	O
SDNN	O
compared	O
to	O
other	O
genotypes	O
in	O
the	O
early	O
phase	O
of	O
HUT	O
(	O
SDNN	O
in	O
5	O
minutes	O
of	O
tilt	O
:	O
AA	O
59	O
.	O
7	O
+	O
/	O
-	O
24	O
.	O
6	O
,	O
AC	O
50	O
.	O
6	O
+	O
/	O
-	O
20	O
.	O
6	O
,	O
CC	O
46	O
.	O
0	O
+	O
/	O
-	O
13	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
at	O
syncope	D013575
occurrence	O
(	O
SDNN	O
:	O
AA	O
71	O
.	O
0	O
+	O
/	O
-	O
20	O
.	O
9	O
,	O
AC	O
58	O
.	O
2	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
CC	O
58	O
+	O
/	O
-	O
10	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
CONCLUSION	O
:	O
AA	O
genotype	O
of	O
A	rs5186
1166C	rs5186
polymorphism	O
in	O
the	O
ATR1	185
gene	O
may	O
be	O
associated	O
with	O
hypotension	D007022
and	O
decline	O
in	O
sympathetic	O
tone	O
during	O
HUT	O
.	O

Its	O
role	O
in	O
genetic	O
predisposition	O
to	O
vasovagal	D019462
syncope	D019462
cannot	O
be	O
excluded	O
.	O
Founder	O
mutations	O
in	O
the	O
BRCA1	672
gene	O
in	O
Polish	O
families	O
with	O
breast	D061325
-	O
ovarian	D061325
cancer	D061325
.	O

We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
,	O
to	O
identify	O
possible	O
BRCA1	672
and	O
BRCA2	675
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O

The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	D009369
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	D001943,D010051
or	D001943,D010051
ovarian	D001943,D010051
cancer	D001943,D010051
and	O
who	O
had	O
cancer	D009369
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O

A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	D001943,D010051
and	D001943,D010051
ovarian	D001943,D010051
cancers	D001943,D010051
,	O
4	O
families	O
had	O
ovarian	D010051
cancers	D010051
only	O
,	O
and	O
36	O
families	O
had	O
breast	D001943
cancers	D001943
only	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	9606
from	O
each	O
family	O
.	O

The	O
entire	O
coding	O
region	O
of	O
BRCA1	672
and	O
BRCA2	675
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O

Mutations	O
were	O
found	O
in	O
35	O
(	O
53%	O
)	O
of	O
the	O
66	O
families	O
studied	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	672
gene	O
.	O

BRCA1	OMIM:604370
abnormalities	OMIM:604370
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	D010051
cancer	D010051
only	O
,	O
in	O
67%	O
of	O
27	O
families	O
with	O
both	O
breast	D001943,D010051
and	D001943,D010051
ovarian	D001943,D010051
cancer	D001943,D010051
,	O
and	O
in	O
34%	O
of	O
35	O
families	O
with	O
breast	D001943
cancer	D001943
only	O
.	O

The	O
single	O
family	O
with	O
a	O
BRCA2	675
mutation	O
had	O
the	O
breast	D061325
-	O
ovarian	D061325
cancer	D061325
syndrome	D061325
.	O

Seven	O
distinct	O
mutations	O
were	O
identified	O
;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O

In	O
total	O
,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94%	O
)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O

Three	O
BRCA1	OMIM:604370
abnormalities	OMIM:604370
-	O
5382insC	c|INS|5382|C
,	O
C61G	rs28897672
,	O
and	O
4153delA	c|DEL|4153|A
-	O
accounted	O
for	O
51%	O
,	O
20%	O
,	O
and	O
11%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
Allelic	O
expression	O
imbalance	O
of	O
human	9606
mu	4988
opioid	4988
receptor	4988
(	O
OPRM1	4988
)	O
caused	O
by	O
variant	O
A118G	rs1799971
.	O

As	O
a	O
primary	O
target	O
for	O
opioid	O
drugs	O
and	O
peptides	O
,	O
the	O
mu	4988
opioid	4988
receptor	4988
(	O
OPRM1	4988
)	O
plays	O
a	O
key	O
role	O
in	O
pain	D010146
perception	O
and	O
addiction	O
.	O

Genetic	O
variants	O
of	O
OPRM1	4988
have	O
been	O
implicated	O
in	O
predisposition	O
to	O
drug	D019966
addiction	D019966
,	O
in	O
particular	O
the	O
single	O
nucleotide	O
polymorphism	O
A118G	rs1799971
,	O
leading	O
to	O
an	O
N40D	rs1799971
substitution	O
,	O
with	O
an	O
allele	O
frequency	O
of	O
10	O
-	O
32%	O
,	O
and	O
uncertain	O
functions	O
.	O

We	O
have	O
measured	O
allele	O
-	O
specific	O
mRNA	O
expression	O
of	O
OPRM1	4988
in	O
human	9606
autopsy	O
brain	O
tissues	O
,	O
using	O
A118G	rs1799971
as	O
a	O
marker	O
.	O

In	O
8	O
heterozygous	O
samples	O
measured	O
,	O
the	O
A118	rs1799971
mRNA	O
allele	O
was	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
-	O
fold	O
more	O
abundant	O
than	O
the	O
G118	rs1799971
allele	O
.	O

Transfection	O
into	O
Chinese	10029
hamster	10029
ovary	O
cells	O
of	O
a	O
cDNA	O
representing	O
only	O
the	O
coding	O
region	O
of	O
OPRM1	100770962
,	O
carrying	O
adenosine	rs1799971
,	O
guanosine	rs1799971
,	O
cytidine	rs1799971
,	O
and	rs1799971
thymidine	rs1799971
in	rs1799971
position	rs1799971
118	rs1799971
,	O
resulted	O
in	O
1	O
.	O
5	O
-	O
fold	O
lower	O
mRNA	O
levels	O
only	O
for	O
OPRM1	100770962
-	O
G118	rs1799971
,	O
and	O
more	O
than	O
10	O
-	O
fold	O
lower	O
OPRM1	100770962
protein	O
levels	O
,	O
measured	O
by	O
Western	O
blotting	O
and	O
receptor	O
binding	O
assay	O
.	O

After	O
transfection	O
and	O
inhibition	O
of	O
transcription	O
with	O
actinomycin	D003609
D	D003609
,	O
analysis	O
of	O
mRNA	O
turnover	O
failed	O
to	O
reveal	O
differences	O
in	O
mRNA	O
stability	O
between	O
A118	rs1799971
and	O
G118	rs1799971
alleles	O
,	O
indicating	O
a	O
defect	O
in	O
transcription	O
or	O
mRNA	O
maturation	O
.	O

These	O
results	O
indicate	O
that	O
OPRM1	100770962
-	O
G118	rs1799971
is	O
a	O
functional	O
variant	O
with	O
deleterious	O
effects	O
on	O
both	O
mRNA	O
and	O
protein	O
yield	O
.	O

Clarifying	O
the	O
functional	O
relevance	O
of	O
polymorphisms	O
associated	O
with	O
susceptibility	O
to	O
a	O
complex	O
disorder	O
such	O
as	O
drug	D019966
addiction	D019966
provides	O
a	O
foundation	O
for	O
clinical	O
association	O
studies	O
.	O
Peroxisomal	5468
proliferator	5468
activated	5468
receptor	5468
-	O
gamma	5468
deficiency	O
in	O
a	O
Canadian	O
kindred	O
with	O
familial	D052496
partial	D052496
lipodystrophy	D052496
type	D052496
3	D052496
(	O
FPLD3	D052496
)	O
.	O

BACKGROUND	O
:	O
Familial	D052496
partial	D052496
lipodystrophy	D052496
(	O
Dunnigan	D052496
)	O
type	D052496
3	D052496
(	O
FPLD3	D052496
,	O
Mendelian	D052496
Inheritance	D052496
in	D052496
Man	D052496
[	O
MIM	D052496
]	O
604367	D052496
)	O
results	O
from	O
heterozygous	O
mutations	O
in	O
PPARG	5468
encoding	O
peroxisomal	5468
proliferator	5468
-	O
activated	5468
receptor	5468
-	O
gamma	5468
.	O

Both	O
dominant	O
-	O
negative	O
and	O
haploinsufficiency	O
mechanisms	O
have	O
been	O
suggested	O
for	O
this	O
condition	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
Canadian	O
FPLD3	D052496
kindred	O
with	O
an	O
affected	O
mother	O
who	O
had	O
loss	O
of	O
fat	O
on	O
arms	O
and	O
legs	O
,	O
but	O
no	O
increase	O
in	O
facial	O
,	O
neck	O
,	O
suprascapular	O
or	O
abdominal	O
fat	O
.	O

She	O
had	O
profound	O
insulin	D007333
resistance	D007333
,	O
diabetes	D003920
,	O
severe	O
hypertriglyceridemia	D015228
and	O
relapsing	O
pancreatitis	D010195
,	O
while	O
her	O
pre	O
-	O
pubescent	O
daughter	O
had	O
normal	O
fat	O
distribution	O
but	O
elevated	O
plasma	O
triglycerides	D014280
and	O
C	D002096
-	O
peptide	D002096
and	O
depressed	O
high	D008076
-	O
density	D008076
lipoprotein	D008076
cholesterol	D008076
.	O

RESULTS	O
:	O
The	O
mother	O
and	O
daughter	O
were	O
each	O
heterozygous	O
for	O
PPARG	5468
nonsense	O
mutation	O
Y355X	p|SUB|Y|355|X
,	O
whose	O
protein	O
product	O
in	O
vitro	O
was	O
transcriptionally	O
inactive	O
with	O
no	O
dominant	O
-	O
negative	O
activity	O
against	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

In	O
addition	O
the	O
mutant	O
protein	O
appeared	O
to	O
be	O
markedly	O
unstable	O
.	O

CONCLUSION	O
:	O
Taken	O
together	O
with	O
previous	O
studies	O
of	O
human	9606
PPARG	5468
mutations	O
,	O
these	O
findings	O
suggest	O
that	O
PPAR	5468
-	O
gamma	5468
deficiency	O
due	O
either	O
to	O
haploinsufficiency	O
or	O
to	O
substantial	O
activity	O
loss	O
due	O
to	O
dominant	O
negative	O
interference	O
of	O
the	O
normal	O
allele	O
product	O
'	O
s	O
function	O
can	O
each	O
contribute	O
to	O
the	O
FPLD3	D052496
phenotype	O
.	O
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	C401859
in	O
refractory	O
mantle	D020522
cell	D020522
lymphoma	D020522
.	O

Mantle	D020522
cell	D020522
lymphoma	D020522
(	O
MCL	D020522
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	D008228
-	O
cell	D008228
non	D008228
-	O
Hodgkin	D008228
'	O
s	D008228
lymphoma	D008228
.	O

Patients	9606
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

However	O
,	O
a	O
38%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	D020522
treated	O
with	O
temsirolimus	C401859
,	O
a	O
mTOR	2475
inhibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	D020522
who	O
had	O
tumor	D009369
regression	O
two	O
months	O
after	O
temsirolimus	C401859
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	C401859
therapy	O
.	O

Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	C401859
inhibited	O
tumor	D009369
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	D009369
cells	O
.	O

Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	C401859
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	D009369
microvessel	O
density	O
and	O
of	O
VEGF	7422
expression	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	D009336
tissue	O
repair	O
,	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	C401859
therapy	O
.	O

Thus	O
,	O
temsirolimus	C401859
reduced	O
tumor	D009369
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsirolimus	C401859
on	O
tumor	D009369
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	D020522
resistant	O
to	O
conventional	O
chemotherapy	O
.	O
Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	D006470
volume	O
in	O
a	O
mouse	10090
model	O
of	O
warfarin	D014859
-	O
associated	O
intracerebral	D002543
hemorrhage	D002543
.	O

Warfarin	D014859
-	O
associated	O
intracerebral	D002543
hemorrhage	D002543
(	O
W	D014859
-	O
ICH	D002543
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	D020521
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	D014859
-	O
ICH	D002543
.	O

Using	O
a	O
mouse	10090
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	9606
prothrombin	C025667
complex	C025667
concentrate	C025667
(	O
PCC	C025667
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O

Male	O
CD	O
-	O
1	O
mice	10090
were	O
treated	O
with	O
warfarin	D014859
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
)	O
International	O
Normalized	O
Ratio	O
of	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
9	O
.	O

First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	9606
PCC	C025667
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	10090
.	O

Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	D017364
was	O
administered	O
to	O
induce	O
hemorrhage	D006470
in	O
the	O
right	O
striatum	O
.	O

Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	C025667
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i	O
.	O
v	O
.	O

(	O
n	O
=	O
12	O
per	O
group	O
)	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	D006470
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O

The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	C025667
-	O
treated	O
animals	O
(	O
6	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
2	O
microL	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

In	O
the	O
saline	O
group	O
,	O
45%	O
of	O
the	O
mice	10090
developed	O
large	O
hematomas	D006406
(	O
i	O
.	O
e	O
.	O
,	O
>	O
15	O
microL	O
)	O
.	O

In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	C025667
group	O
.	O

We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	C025667
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	D014859
-	O
ICH	D002543
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	9606
W	D014859
-	O
ICH	D002543
.	O
Role	O
of	O
stress	O
-	O
activated	O
OCT4A	5460
in	O
the	O
cell	O
fate	O
decisions	O
of	O
embryonal	D018236
carcinoma	D018236
cells	O
treated	O
with	O
etoposide	D005047
.	O

Tumor	O
cellular	O
senescence	O
induced	O
by	O
genotoxic	O
treatments	O
has	O
recently	O
been	O
found	O
to	O
be	O
paradoxically	O
linked	O
to	O
the	O
induction	O
of	O
""""	O
stemness	O
.	O
""""	O
This	O
observation	O
is	O
critical	O
as	O
it	O
directly	O
impinges	O
upon	O
the	O
response	O
of	O
tumors	D009369
to	O
current	O
chemo	O
-	O
radio	O
-	O
therapy	O
treatment	O
regimens	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
following	O
etoposide	D005047
(	O
ETO	D005047
)	O
treatment	O
embryonal	D018236
carcinoma	D018236
PA	9606
-	O
1	9606
cells	O
undergo	O
a	O
p53	7157
-	O
dependent	O
upregulation	O
of	O
OCT4A	5460
and	O
p21Cip1	1026
(	O
governing	O
self	O
-	O
renewal	O
and	O
regulating	O
cell	O
cycle	O
inhibition	O
and	O
senescence	O
,	O
respectively	O
)	O
.	O

Here	O
we	O
report	O
further	O
detail	O
on	O
the	O
relationship	O
between	O
these	O
and	O
other	O
critical	O
cell	O
-	O
fate	O
regulators	O
.	O

PA	9606
-	O
1	9606
cells	O
treated	O
with	O
ETO	D005047
display	O
highly	O
heterogeneous	O
increases	O
in	O
OCT4A	5460
and	O
p21Cip1	1026
indicative	O
of	O
dis	O
-	O
adaptation	O
catastrophe	O
.	O

Silencing	O
OCT4A	5460
suppresses	O
p21Cip1	1026
,	O
changes	O
cell	O
cycle	O
regulation	O
and	O
subsequently	O
suppresses	O
terminal	O
senescence	O
;	O
p21Cip1	1026
-	O
silencing	O
did	O
not	O
affect	O
OCT4A	5460
expression	O
or	O
cellular	O
phenotype	O
.	O

SOX2	6657
and	O
NANOG	79923
expression	O
did	O
not	O
change	O
following	O
ETO	D005047
treatment	O
suggesting	O
a	O
dissociation	O
of	O
OCT4A	5460
from	O
its	O
pluripotency	O
function	O
.	O

Instead	O
,	O
ETO	D005047
-	O
induced	O
OCT4A	5460
was	O
concomitant	O
with	O
activation	O
of	O
AMPK	5562
,	O
a	O
key	O
component	O
of	O
metabolic	O
stress	O
and	O
autophagy	O
regulation	O
.	O

p16ink4a	1029
,	O
the	O
inducer	O
of	O
terminal	O
senescence	O
,	O
underwent	O
autophagic	O
sequestration	O
in	O
the	O
cytoplasm	O
of	O
ETO	D005047
-	O
treated	O
cells	O
,	O
allowing	O
alternative	O
cell	O
fates	O
.	O

Accordingly	O
,	O
failure	O
of	O
autophagy	O
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
p16ink4a	1029
,	O
nuclear	O
disintegration	O
,	O
and	O
loss	O
of	O
cell	O
recovery	O
.	O

Together	O
,	O
these	O
findings	O
imply	O
that	O
OCT4A	5460
induction	O
following	O
DNA	O
damage	O
in	O
PA	9606
-	O
1	9606
cells	O
,	O
performs	O
a	O
cell	O
stress	O
,	O
rather	O
than	O
self	O
-	O
renewal	O
,	O
function	O
by	O
moderating	O
the	O
expression	O
of	O
p21Cip1	1026
,	O
which	O
alongside	O
AMPK	5562
helps	O
to	O
then	O
regulate	O
autophagy	O
.	O

Moreover	O
,	O
this	O
data	O
indicates	O
that	O
exhaustion	O
of	O
autophagy	O
,	O
through	O
persistent	O
DNA	O
damage	O
,	O
is	O
the	O
cause	O
of	O
terminal	O
cellular	O
senescence	O
.	O
Cisplatin	D002945
induces	O
tolerogenic	O
dendritic	O
cells	O
in	O
response	O
to	O
TLR	13982
agonists	O
via	O
the	O
abundant	O
production	O
of	O
IL	16153
-	O
10	16153
,	O
thereby	O
promoting	O
Th2	O
-	O
and	O
Tr1	O
-	O
biased	O
T	O
-	O
cell	O
immunity	O
.	O

Although	O
many	O
advantageous	O
roles	O
of	O
cisplatin	D002945
(	O
cis	D002945
-	O
diamminedichloroplatinum	D002945
(	O
II	O
)	O
,	O
CDDP	D002945
)	O
have	O
been	O
reported	O
in	O
cancer	D009369
therapy	O
,	O
the	O
immunomodulatory	O
roles	O
of	O
cisplatin	D002945
in	O
the	O
phenotypic	O
and	O
functional	O
alterations	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	D002945
on	O
the	O
functionality	O
of	O
DCs	O
and	O
the	O
changes	O
in	O
signaling	O
pathways	O
activated	O
upon	O
toll	13982
-	O
like	13982
receptor	13982
(	O
TLR	13982
)	O
stimulation	O
.	O

Cisplatin	D002945
-	O
treated	O
DCs	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
(	O
CD80	12519
,	O
CD86	12524
,	O
MHC	14961,14972
class	14961,14972
I	14961,14972
and	14961,14972
II	14961,14972
)	O
and	O
up	O
-	O
regulated	O
endocytic	O
capacity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Upon	O
stimulation	O
with	O
various	O
TLR	13982
agonists	O
,	O
cisplatin	D002945
-	O
treated	O
DCs	O
showed	O
markedly	O
increased	O
IL	16153
-	O
10	16153
production	O
through	O
activation	O
of	O
the	O
p38	26416
MAPK	26416
and	O
NF	18033
-	O
kappaB	18033
signaling	O
pathways	O
without	O
altering	O
the	O
levels	O
of	O
TNF	21926
-	O
alpha	21926
and	O
IL	16185
-	O
12p70	16185
,	O
indicating	O
the	O
cisplatin	D002945
-	O
mediated	O
induction	O
of	O
tolerogenic	O
DCs	O
.	O

This	O
effect	O
was	O
dependent	O
on	O
the	O
production	O
of	O
IL	16153
-	O
10	16153
from	O
DCs	O
,	O
as	O
neither	O
DCs	O
isolated	O
from	O
IL	16153
-	O
10	16153
-	O
/	O
-	O
mice	10090
nor	O
IL	16153
-	O
10	16153
-	O
neutralized	O
DCs	O
generated	O
tolerogenic	O
DCs	O
.	O

Interestingly	O
,	O
DCs	O
that	O
were	O
co	O
-	O
treated	O
with	O
cisplatin	D002945
and	O
lipopolysaccharide	D008070
(	O
LPS	D008070
)	O
exhibited	O
a	O
decreased	O
immunostimulatory	O
capacity	O
for	O
inducing	O
the	O
proliferation	O
of	O
Th1	O
-	O
and	O
Th17	O
-	O
type	O
T	O
cells	O
;	O
instead	O
,	O
these	O
DCs	O
contributed	O
to	O
Th2	O
-	O
type	O
T	O
cell	O
immunity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
investigations	O
revealed	O
a	O
unique	O
T	O
cell	O
population	O
,	O
IL	16153
-	O
10	16153
-	O
producing	O
CD3	12501
+	O
CD4	12504
+	O
LAG	16768
-	O
3	16768
+	O
CD49b	16398
+	O
CD25	16184
-	O
Foxp3	20371
-	O
Tr1	O
cells	O
,	O
that	O
was	O
significantly	O
increased	O
without	O
altering	O
the	O
Foxp3	20371
+	O
regulatory	O
T	O
cell	O
population	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
cisplatin	D002945
induces	O
immune	O
-	O
suppressive	O
tolerogenic	O
DCs	O
in	O
TLR	-
agonist	-
-	O
induced	O
inflammatory	D007249
conditions	O
via	O
abundant	O
IL	16153
-	O
10	16153
production	O
,	O
thereby	O
skewing	O
Th	O
cell	O
differentiation	O
towards	O
Th2	O
and	O
Tr1	O
cells	O
.	O

This	O
relationship	O
may	O
provide	O
cancer	D009369
cells	O
with	O
an	O
opportunity	O
to	O
evade	O
the	O
immune	O
system	O
.	O

Leukemia	16878,3976
inhibitory	16878,3976
factor	16878,3976
protects	O
the	O
lung	O
during	O
respiratory	D018357
syncytial	D018357
viral	D018357
infection	D018357
.	O

BACKGROUND	O
:	O
Respiratory	12814
syncytial	12814
virus	12814
(	O
RSV	12814
)	O
infects	O
the	O
lung	O
epithelium	O
where	O
it	O
stimulates	O
the	O
production	O
of	O
numerous	O
host	O
cytokines	O
that	O
are	O
associated	O
with	O
disease	O
burden	O
and	O
acute	D055371
lung	D055371
injury	D055371
.	O

Characterizing	O
the	O
host	O
cytokine	O
response	O
to	O
RSV	D018357
infection	D018357
,	O
the	O
regulation	O
of	O
host	O
cytokines	O
and	O
the	O
impact	O
of	O
neutralizing	O
an	O
RSV	12814
-	O
inducible	O
cytokine	O
during	O
infection	D007239
were	O
undertaken	O
in	O
this	O
study	O
.	O

METHODS	O
:	O
A549	9606
,	O
primary	O
human	9606
small	O
airway	O
epithelial	O
(	O
SAE	9606
)	O
cells	O
and	O
wild	O
-	O
type	O
,	O
TIR	106759
-	O
domain	106759
-	O
containing	106759
adapter	106759
-	O
inducing	106759
interferon	106759
-	O
b	106759
(	O
Trif	106759
)	O
and	O
mitochondrial	228607
antiviral	228607
-	O
signaling	228607
protein	228607
(	O
Mavs	228607
)	O
knockout	O
(	O
KO	O
)	O
mice	10090
were	O
infected	O
with	O
RSV	12814
and	O
cytokine	O
responses	O
were	O
investigated	O
by	O
ELISA	O
,	O
multiplex	O
analysis	O
and	O
qPCR	O
.	O

Neutralizing	O
anti	O
-	O
leukemia	3976
inhibitory	3976
factor	3976
(	O
LIF	3976
)	O
IgG	O
or	O
control	O
IgG	O
was	O
administered	O
to	O
a	O
group	O
of	O
wild	O
-	O
type	O
animals	O
prior	O
to	O
RSV	D018357
infection	D018357
.	O

RESULTS	O
AND	O
DISCUSSION	O
:	O
RSV	D018357
-	O
infected	D018357
A549	9606
and	O
SAE	9606
cells	O
release	O
a	O
network	O
of	O
cytokines	O
,	O
including	O
newly	O
identified	O
RSV	12814
-	O
inducible	O
cytokines	O
LIF	3976
,	O
migration	4282
inhibitory	4282
factor	4282
(	O
MIF	4282
)	O
,	O
stem	4254
cell	4254
factor	4254
(	O
SCF	4254
)	O
,	O
CCL27	10850
,	O
CXCL12	6387
and	O
stem	6320
cell	6320
growth	6320
factor	6320
beta	6320
(	O
SCGF	6320
-	O
b	6320
)	O
.	O

These	O
RSV	12814
-	O
inducible	O
cytokines	O
were	O
also	O
observed	O
in	O
the	O
airways	O
of	O
mice	10090
during	O
an	O
infection	D007239
.	O

To	O
identify	O
the	O
regulation	O
of	O
RSV	12814
inducible	O
cytokines	O
,	O
Mavs	228607
and	O
Trif	106759
deficient	O
animals	O
were	O
infected	O
with	O
RSV	12814
.	O

In	O
vivo	O
induction	O
of	O
airway	O
IL	16176
-	O
1b	16176
,	O
IL	16189
-	O
4	16189
,	O
IL	16191
-	O
5	16191
,	O
IL	16193
-	O
6	16193
,	O
IL	16160
-	O
12	16160
(	O
p40	16160
)	O
,	O
IFN	15978
-	O
g	15978
,	O
CCL2	20296
,	O
CCL5	20304
,	O
CCL3	20302
,	O
CXCL1	14825
,	O
IP	15945
-	O
10	15945
/	O
CXCL10	15945
,	O
IL	50929
-	O
22	50929
,	O
MIG	17329
/	O
CXCL9	17329
and	O
MIF	17319
were	O
dependent	O
on	O
Mavs	228607
expression	O
in	O
mice	10090
.	O

Loss	O
of	O
Trif	106759
expression	O
in	O
mice	10090
altered	O
the	O
RSV	12814
induction	O
of	O
IL	16176
-	O
1b	16176
,	O
IL	16191
-	O
5	16191
,	O
CXCL12	20315
,	O
MIF	17319
,	O
LIF	16878
,	O
CXCL12	20315
and	O
IFN	15978
-	O
g	15978
.	O

Silencing	O
of	O
retinoic	23586
acid	23586
-	O
inducible	23586
gene	23586
-	O
1	23586
(	O
RIG	23586
-	O
I	23586
)	O
expression	O
in	O
A549	9606
cells	O
had	O
a	O
greater	O
impact	O
on	O
RSV	12814
-	O
inducible	O
cytokines	O
than	O
melanoma	64135
differentiation	64135
-	O
associated	64135
protein	64135
5	64135
(	O
MDA5	64135
)	O
and	O
laboratory	79132
of	79132
genetics	79132
and	79132
physiology	79132
2	79132
(	O
LGP2	79132
)	O
,	O
and	O
Trif	148022
expression	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
LIF	16878
in	O
the	O
airways	O
during	O
RSV	D018357
infection	D018357
,	O
animals	O
were	O
treated	O
with	O
neutralizing	O
anti	O
-	O
LIF	16878
IgG	O
,	O
which	O
enhanced	O
RSV	12814
pathology	O
observed	O
with	O
increased	O
airspace	O
protein	O
content	O
,	O
apoptosis	O
and	O
airway	O
hyperresponsiveness	O
compared	O
to	O
control	O
IgG	O
treatment	O
.	O

CONCLUSIONS	O
:	O
RSV	D018357
infection	D018357
in	O
the	O
epithelium	O
induces	O
a	O
network	O
of	O
immune	O
factors	O
to	O
counter	O
infection	D007239
,	O
primarily	O
in	O
a	O
RIG	23586
-	O
I	23586
dependent	O
manner	O
.	O

Expression	O
of	O
LIF	16878,3976
protects	O
the	O
lung	O
from	O
lung	D055370
injury	D055370
and	O
enhanced	O
pathology	O
during	O
RSV	D018357
infection	D018357
.	O
Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	D004280
-	O
induced	O
myocardial	D017202
ischemia	D017202
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	D004280
-	O
induced	O
myocardial	D017202
ischemia	D017202
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	D004280
-	O
induced	O
myocardial	D017202
ischemia	D017202
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	D007511
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	9606
undergoing	O
Sestamibi	O
-	O
SPECT	O
/	O
dobutamine	D004280
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	D004280
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	9606
perfusion	O
defects	O
compatible	O
with	O
ischemia	D007511
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	D004280
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16%	O
to	O
79%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60%	O
to	O
68%	O
and	O
negative	O
predictive	O
value	O
from	O
54%	O
to	O
78%	O
,	O
and	O
specificity	O
decreased	O
from	O
90%	O
to	O
67%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	D017202
ischemia	D017202
,	O
especially	O
in	O
patients	9606
unable	O
to	O
exercise	O
.	O
Two	O
novel	O
mutations	O
,	O
L490R	rs80338886
and	O
V561X	rs80338887
,	O
of	O
the	O
transferrin	7036
receptor	7036
2	7036
gene	O
in	O
Japanese	O
patients	9606
with	O
hemochromatosis	D006432
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
low	O
prevalence	O
of	O
the	O
C282Y	rs1800562
mutation	O
of	O
the	O
HFE	3077
gene	O
in	O
Japan	O
means	O
that	O
the	O
genetic	O
background	O
of	O
hemochromatosis	D006432
in	O
Japanese	O
patients	9606
remains	O
unclear	O
.	O

In	O
a	O
previous	O
report	O
,	O
we	O
showed	O
that	O
3	O
patients	9606
from	O
one	O
family	O
had	O
an	O
AVAQ	p|DEL|594_597|AVAQ
594	p|DEL|594_597|AVAQ
-	O
597	p|DEL|594_597|AVAQ
deletion	p|DEL|594_597|AVAQ
of	O
the	O
transferrin	7036
receptor	7036
(	O
TfR2	7036
)	O
gene	O
.	O

This	O
suggests	O
that	O
the	O
TfR2	7036
gene	O
is	O
involved	O
in	O
hemochromatosis	D006432
in	O
Japanese	O
patients	9606
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Nine	O
patients	9606
clinically	O
diagnosed	O
with	O
hemochromatosis	D006432
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
samples	O
collected	O
with	O
informed	O
consent	O
.	O

The	O
HFE	3077
and	O
TfR2	7036
genes	O
were	O
analyzed	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
splicing	O
sites	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
mutations	O
in	O
the	O
HFE	3077
gene	O
.	O

In	O
the	O
TfR2	7036
gene	O
,	O
2	O
novel	O
mutations	O
,	O
1469T	rs80338886
-	O
>	O
G	rs80338886
(	O
L490R	rs80338886
)	O
and	O
1665delC	rs80338887
(	O
V561X	rs80338887
)	O
,	O
were	O
found	O
in	O
2	O
patients	9606
.	O

A	O
known	O
variation	O
,	O
714C	rs34242818
-	O
>	O
(	O
I238M	rs34242818
)	O
,	O
was	O
also	O
found	O
in	O
the	O
patient	9606
with	O
L490R	rs80338886
.	O

The	O
patient	9606
homozygous	O
for	O
both	O
L490R	rs80338886
and	O
I238M	rs34242818
presented	O
with	O
a	O
mild	O
manifestation	O
of	O
hemochromatosis	D006432
at	O
the	O
age	O
of	O
41	O
years	O
.	O

His	O
liver	O
was	O
cirrhotic	D008103
with	O
parenchymal	O
iron	D007501
deposits	O
and	O
the	O
result	O
of	O
a	O
glucose	D005947
tolerance	O
test	O
was	O
compatible	O
with	O
diabetes	D003920
mellitus	D003920
.	O

The	O
patient	9606
homozygous	O
for	O
V561X	rs80338887
had	O
severe	O
iron	D019190
overload	D019190
with	O
the	O
triad	O
of	O
cirrhosis	D008103
,	O
diabetes	D003920
mellitus	D003920
and	O
skin	D010859
pigmentation	D010859
at	O
the	O
age	O
of	O
58	O
years	O
.	O

INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
Taken	O
together	O
with	O
the	O
previous	O
report	O
,	O
5	O
of	O
our	O
12	O
patients	9606
with	O
hemochromatosis	D006432
manifesting	O
in	O
middle	O
age	O
had	O
mutations	O
in	O
the	O
TfR2	7036
gene	O
.	O

Thus	O
,	O
TfR2	7036
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hemochromatosis	D006432
in	O
Japan	O
.	O
Endothelial	O
NADPH	85431
oxidase	85431
4	85431
mediates	O
vascular	25589
endothelial	25589
growth	25589
factor	25589
receptor	25589
2	25589
-	O
induced	O
intravitreal	O
neovascularization	O
in	O
a	O
rat	10116
model	O
of	O
retinopathy	D012178
of	D012178
prematurity	D012178
.	O

PURPOSE	O
:	O
NADPH	114243,50507,66021,85431
oxidase	114243,50507,66021,85431
-	O
generated	O
reactive	D017382
oxygen	D017382
species	D017382
(	O
ROS	D017382
)	O
are	O
implicated	O
in	O
angiogenesis	O
.	O

Isoforms	O
of	O
NADPH	114243,50507,66021,85431
oxidase	114243,50507,66021,85431
NOX1	114243
,	O
NOX2	66021
,	O
and	O
NOX4	85431
are	O
reported	O
to	O
be	O
expressed	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Of	O
these	O
,	O
NOX1	114243
and	O
NOX2	66021
have	O
been	O
reported	O
to	O
contribute	O
to	O
intravitreal	O
neovascularization	O
(	O
IVNV	O
)	O
in	O
oxygen	D010100
-	O
induced	O
retinopathy	D012164
(	O
OIR	D012164
)	O
models	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
isoform	O
NOX4	85431
in	O
ECs	O
contributed	O
to	O
vascular	83785
endothelial	83785
growth	83785
factor	83785
(	O
VEGF	83785
)	O
-	O
induced	O
angiogenesis	O
and	O
IVNV	O
.	O

METHODS	O
:	O
Isoforms	O
of	O
NADPH	114243,50507,66021,85431
oxidase	114243,50507,66021,85431
MRNA	O
were	O
measured	O
in	O
several	O
types	O
of	O
cultured	O
vascular	O
ecs	O
:	O
human	9606
retinal	O
microvascular	O
ECs	O
(	O
hRMVECs	O
)	O
,	O
choroidal	O
ECs	O
(	O
CECs	O
)	O
,	O
and	O
human	9606
umbilical	O
vascular	O
ECs	O
(	O
HUVECs	O
)	O
using	O
real	O
-	O
time	O
PCR	O
.	O

Newborn	O
rat	10116
pups	O
and	O
dams	O
were	O
placed	O
into	O
an	O
OIR	D012164
model	O
that	O
cycled	O
oxygen	D010100
concentration	O
between	O
50%	O
and	O
10%	O
every	O
24	O
h	O
for	O
14	O
days	O
,	O
and	O
then	O
were	O
placed	O
in	O
room	O
air	O
(	O
RA	O
)	O
for	O
an	O
additional	O
4	O
days	O
(	O
rat	10116
OIR	D012164
model	O
)	O
.	O

NOX4	85431
expression	O
in	O
retinal	O
lysates	O
from	O
the	O
RA	O
-	O
raised	O
pups	O
at	O
postnatal	O
day	O
0	O
(	O
P0	O
)	O
,	O
P14	O
,	O
and	O
P18	O
was	O
determined	O
with	O
western	O
blots	O
.	O

STAT3	25125
activation	O
was	O
determined	O
as	O
the	O
ratio	O
of	O
phosphorylated	O
STAT3	25125
to	O
total	O
STAT3	25125
with	O
western	O
blot	O
analysis	O
of	O
retinal	O
lysates	O
from	O
pups	O
raised	O
in	O
RA	O
or	O
from	O
the	O
rat	10116
OIR	D012164
model	O
at	O
P18	O
.	O

Semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
NOX4	85431
colabeling	O
with	O
lectin	-
-	O
stained	O
retinal	O
ECs	O
was	O
determined	O
by	O
immunolabeling	O
of	O
retinal	O
cryosections	O
from	O
P18	O
pups	O
in	O
OIR	D012164
or	O
in	O
RA	O
.	O

In	O
hRMVECs	O
transfected	O
with	O
NOX4	50507
siRNA	O
and	O
treated	O
with	O
VEGF	7422
or	O
control	O
,	O
1	O
)	O
ROS	D017382
generation	O
was	O
measured	O
using	O
the	O
5	-
-	O
(	O
and	-
-	O
6	-
)	O
-	O
chloromethyl	-
-	O
2	-
'	O
,	O
7	-
'	O
-	O
dichlorodihydrofluorescein	-
diacetate	-
,	O
acetyl	-
ester	-
fluorescence	O
assay	O
and	O
2	O
)	O
phosphorylated	O
VEGF	3791
receptor	3791
2	3791
and	O
STAT3	6774
,	O
and	O
total	O
VEGFR2	3791
and	O
STAT3	6774
were	O
measured	O
in	O
western	O
blot	O
analyses	O
.	O

VEGF	7422
-	O
stimulated	O
hRMVEC	O
proliferation	O
was	O
measured	O
following	O
transfection	O
with	O
NOX4	50507
siRNA	O
or	O
STAT3	6774
siRNA	O
,	O
or	O
respective	O
controls	O
.	O

RESULTS	O
:	O
NOX4	50507
was	O
the	O
most	O
prevalent	O
isoform	O
of	O
NADPH	114243,50507,66021,85431
oxidase	114243,50507,66021,85431
in	O
vascular	O
ECs	O
.	O

NOX4	85431
expression	O
in	O
retinal	O
lysates	O
was	O
significantly	O
decreased	O
during	O
development	O
in	O
RA	O
.	O

Compared	O
to	O
RA	O
,	O
the	O
expression	O
of	O
retinal	O
NOX4	85431
increased	O
at	O
P18	O
.	O

At	O
p18	O
OIR	D012164
,	O
semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
lectin	-
and	O
NOX4	85431
colabeling	O
in	O
retinal	O
vascular	O
ECs	O
was	O
greater	O
in	O
retinal	O
cryosections	O
and	O
activated	O
STAT3	25125
was	O
greater	O
in	O
retinal	O
lysates	O
when	O
compared	O
to	O
the	O
RA	O
-	O
raised	O
pups	O
.	O

In	O
cultured	O
hRMVECs	O
,	O
knockdown	O
of	O
NOX4	50507
by	O
siRNA	O
transfection	O
inhibited	O
VEGF	7422
-	O
induced	O
ROS	D017382
generation	O
.	O

VEGF	7422
induced	O
a	O
physical	O
interaction	O
of	O
phosphorylated	O
-	O
VEGFR2	3791
and	O
NOX4	50507
.	O

Knockdown	O
of	O
NOX4	50507
:	O
1	O
)	O
reduced	O
VEGFR2	3791
activation	O
but	O
did	O
not	O
abolish	O
it	O
and	O
2	O
)	O
abolished	O
STAT3	6774
activation	O
in	O
response	O
to	O
VEGF	7422
.	O

Knockdown	O
of	O
either	O
NOX4	50507
or	O
STAT3	6774
inhibited	O
VEGF	7422
-	O
induced	O
EC	O
proliferation	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
in	O
a	O
model	O
representative	O
of	O
human	9606
retinopathy	D012178
of	D012178
prematurity	D012178
,	O
NOX4	85431
was	O
increased	O
at	O
a	O
time	O
point	O
when	O
IVNV	O
developed	O
.	O

VEGF	7422
-	O
activated	O
NOX4	50507
led	O
to	O
an	O
interaction	O
between	O
VEGF	7422
-	O
activated	O
VEGFR2	3791
and	O
NOX4	50507
that	O
mediated	O
EC	O
proliferation	O
via	O
activation	O
of	O
STAT3	6774
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NOX4	85431
may	O
regulate	O
VEGFR2	25589
-	O
mediated	O
IVNV	O
through	O
activated	O
STAT3	25125
.	O
MDMA	D018817
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	D003072
social	D003072
and	D003072
emotional	D003072
judgement	D003072
processes	D003072
.	O

In	O
recent	O
years	O
working	O
memory	D008569
deficits	D008569
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	D018817
(	O
3	D018817
,	O
4	D018817
-	O
methylenedioxymethamphetamine	D018817
,	O
ecstasy	D018817
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	D018817
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
""""	O
prefrontal	O
""""	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	D018817
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	D018817
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA	D018817
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	D018817
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	D018817
use	O
.	O
Successful	O
therapy	O
with	O
argatroban	C031942
for	O
superior	O
mesenteric	O
vein	D020246
thrombosis	D020246
in	O
a	O
patient	9606
with	O
congenital	D020152
antithrombin	D020152
deficiency	D020152
.	O

A	O
38	O
-	O
year	O
-	O
old	O
woman	9606
was	O
admitted	O
with	O
superior	D020246
mesenteric	D020246
vein	D020246
(	O
SMV	D020246
)	O
thrombosis	D020246
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O

The	O
plasma	O
antithrombin	462
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	462
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O

However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	2147
inhibitor	O
,	O
argatroban	C031942
.	O

Family	O
studies	O
of	O
antithrombin	462
activity	O
revealed	O
that	O
she	O
had	O
type	D025861
I	D025861
congenital	D025861
antithrombin	D025861
deficiency	D025861
.	O

A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	462
(	O
single	O
nucleotide	c|INS|7916_7917|T
T	c|INS|7916_7917|T
insertion	c|INS|7916_7917|T
at	c|INS|7916_7917|T
7916	c|INS|7916_7917|T
and	c|INS|7916_7917|T
7917	c|INS|7916_7917|T
,	O
Glu	p|SUB|E|272|X
272	p|SUB|E|272|X
to	p|SUB|E|272|X
stop	p|SUB|E|272|X
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O

Argatroban	C031942
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	D020152
antithrombin	D020152
deficiency	D020152
with	O
SMV	D020246
thrombosis	D020246
.	O
Mutational	O
analysis	O
of	O
CYP2C8	1558
in	O
hypertensive	D006973
patients	9606
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

WHAT	O
IS	O
KNOWN	O
AND	O
OBJECTIVE	O
:	O
CYP2C8	1558
is	O
involved	O
in	O
the	O
cytochrome	1558
P450	1558
(	O
CYP	1558
)	O
epoxygenase	1558
pathway	O
.	O

Arachidonic	D016718
acid	D016718
metabolites	O
such	O
as	O
epoxyeicosatrienenoic	-
acids	-
and	O
hydroxyeicosatetrenoic	-
acids	-
,	O
produced	O
may	O
have	O
a	O
role	O
in	O
hypertension	D006973
.	O

We	O
aimed	O
to	O
develop	O
a	O
medium	O
through	O
-	O
put	O
method	O
for	O
screening	O
samples	O
of	O
known	O
and	O
new	O
mutations	O
of	O
CYP2C8	1558
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
200	O
subjects	O
(	O
hypertensive	D006973
patients	9606
and	O
healthy	O
controls	O
)	O
were	O
screened	O
for	O
SNPs	O
in	O
CYP2C8	1558
using	O
DHPLC	O
.	O

Genotypes	O
and	O
allelic	O
frequencies	O
of	O
CYP2C8	1558
between	O
the	O
healthy	O
controls	O
and	O
patients	9606
with	O
hypertension	D006973
were	O
compared	O
.	O

RESULTS	O
AND	O
DISCUSSIONS	O
:	O
Six	O
variants	O
were	O
detected	O
and	O
two	O
were	O
new	O
;	O
T	c|DEL|5063|T
deletion	c|DEL|5063|T
at	c|DEL|5063|T
5063	c|DEL|5063|T
and	O
substitution	O
of	O
C	c|SUB|C|33468|T
to	c|SUB|C|33468|T
T	c|SUB|C|33468|T
at	c|SUB|C|33468|T
33468	c|SUB|C|33468|T
in	O
exon	O
8	O
.	O

Differences	O
in	O
variant	O
frequencies	O
were	O
detected	O
between	O
the	O
controls	O
and	O
hypertensive	D006973
patients	9606
.	O

The	O
controls	O
have	O
significantly	O
higher	O
prevalence	O
of	O
C35322C	c|SUB|C|35322|C
compared	O
to	O
the	O
patients	9606
.	O

The	O
functional	O
significance	O
of	O
the	O
SNP	O
at	O
35322	O
requires	O
further	O
study	O
.	O

Having	O
homozygous	O
C35322C	c|SUB|C|35322|C
could	O
be	O
a	O
protective	O
factor	O
for	O
hypertension	D006973
.	O

WHAT	O
IS	O
NEW	O
AND	O
CONCLUSION	O
:	O
Denaturing	O
high	O
performance	O
liquid	O
chromatography	O
is	O
useful	O
for	O
population	O
screening	O
to	O
identify	O
new	O
and	O
existing	O
SNPs	O
.	O

A	O
higher	O
frequency	O
of	O
the	O
C35322T	c|SUB|C|35322|T
SNP	O
was	O
observed	O
among	O
hypertensive	D006973
patients	9606
than	O
control	O
subjects	O
.	O

This	O
potentially	O
important	O
observation	O
requires	O
confirmation	O
and	O
the	O
clinical	O
significance	O
assessed	O
.	O
Voltage	7416,83529
-	O
Dependent	7416,83529
Anion	7416,83529
Channel	7416,83529
1	7416,83529
(	O
VDAC1	7416,83529
)	O
Participates	O
the	O
Apoptosis	O
of	O
the	O
Mitochondrial	D028361
Dysfunction	D028361
in	O
Desminopathy	C563319
.	O

Desminopathies	C563319
caused	O
by	O
the	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
desmin	1674
are	O
genetically	O
protein	O
aggregation	O
myopathies	D009135
.	O

Mitochondrial	D028361
dysfunction	D028361
is	O
one	O
of	O
pathological	O
changes	O
in	O
the	O
desminopathies	C563319
at	O
the	O
earliest	O
stage	O
.	O

The	O
molecular	O
mechanisms	O
of	O
mitochondria	D028361
dysfunction	D028361
in	O
desminopathies	C563319
remain	O
exclusive	O
.	O

VDAC1	7416
regulates	O
mitochondrial	O
uptake	O
across	O
the	O
outer	O
membrane	O
and	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
.	O

Relationships	O
between	O
desminopathies	C563319
and	O
Voltage	7416
-	O
dependent	7416
anion	7416
channel	7416
1	7416
(	O
VDAC1	7416
)	O
remain	O
unclear	O
.	O

Here	O
we	O
successfully	O
constructed	O
the	O
desminopathy	C563319
rat	10116
model	O
,	O
evaluated	O
with	O
conventional	O
stains	O
,	O
containing	O
hematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
,	O
Gomori	O
Trichrome	O
(	O
MGT	O
)	O
,	O
(	O
PAS	O
)	O
,	O
red	O
oil	O
(	O
ORO	O
)	O
,	O
NADH	O
-	O
TR	O
,	O
SDH	O
staining	O
and	O
immunohistochemistry	O
.	O

Immunofluorescence	O
results	O
showed	O
that	O
VDAC1	7416,83529
was	O
accumulated	O
in	O
the	O
desmin	1674,64362
highly	O
stained	O
area	O
of	O
muscle	O
fibers	O
of	O
desminopathy	C563319
patients	9606
or	O
desminopathy	C563319
rat	10116
model	O
compared	O
to	O
the	O
normal	O
ones	O
.	O

Meanwhile	O
apoptosis	O
related	O
proteins	O
bax	24887,581
and	O
ATF2	1386,81647
were	O
involved	O
in	O
desminopathy	C563319
patients	9606
and	O
desminopathy	C563319
rat	10116
model	O
,	O
but	O
not	O
bcl	24224,596
-	O
2	24224,596
,	O
bcl	24888,598
-	O
xl	24888,598
or	O
HK2	25059,3099
.	O
VDAC1	7416,83529
and	O
desmin	1674,64362
are	O
closely	O
relevant	O
in	O
the	O
tissue	O
splices	O
of	O
deminopathies	O
patients	9606
and	O
rats	10116
with	O
desminopathy	C563319
at	O
protein	O
lever	O
.	O

Moreover	O
,	O
apoptotic	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
desminopathies	C563319
,	O
like	O
bax	24887,581
,	O
ATF2	1386,81647
,	O
but	O
not	O
bcl	24224,596
-	O
2	24224,596
,	O
bcl	24888,598
-	O
xl	24888,598
or	O
HK2	25059,3099
.	O

This	O
pathological	O
analysis	O
presents	O
the	O
correlation	O
between	O
VDAC1	7416,83529
and	O
desmin	1674,64362
,	O
and	O
apoptosis	O
related	O
proteins	O
are	O
correlated	O
in	O
the	O
desminopathy	C563319
.	O

Furthermore	O
,	O
we	O
provide	O
a	O
rat	10116
model	O
of	O
desminopathy	C563319
for	O
the	O
investigation	O
of	O
desmin	64362
related	O
myopathy	D009135
.	O
The	O
cytogenetic	O
action	O
of	O
ifosfamide	D007069
,	O
mesna	D015080
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	9986
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	D007069
(	O
IFO	D007069
)	O
is	O
an	O
alkylating	D008357
nitrogen	D008357
mustard	D008357
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	D006470
cystitis	D003556
.	O

This	O
side	O
effect	O
of	O
IFO	D007069
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	D015080
2	D015080
-	O
sulfanylethanesulfonate	D015080
(	O
Mesna	D015080
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	D007069
and	O
Mesna	D015080
were	O
administrated	O
separately	O
on	O
rabbit	9986
'	O
s	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O

Mesna	D015080
'	O
s	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	D007069
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	D007069
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	D015080
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	D007069
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	D015080
significantly	O
reduces	O
IFO	D007069
'	O
s	O
genotoxicity	D030342
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O
Two	O
novel	O
mutations	O
of	O
the	O
PAX6	5080
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	9606
.	O

PURPOSE	O
:	O
Aniridia	D015783
(	O
AN	D015783
)	O
is	O
a	O
rare	O
congenital	D000013
panocular	D000013
disorder	D000013
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	5080
box	5080
homeotic	5080
gene	5080
6	5080
(	O
PAX6	5080
)	O
gene	O
.	O

The	O
PAX6	5080
gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	C537775
segment	C537775
malformations	C537775
including	O
Peters	C537884
anomaly	C537884
.	O

We	O
studied	O
the	O
PAX6	5080
gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	D015783
,	O
coloboma	D003103
of	D003103
iris	D003103
and	D003103
choroid	D003103
,	O
or	O
anterior	C537775
segment	C537775
malformations	C537775
.	O

PATIENTS	9606
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	9606
were	O
examined	O
clinically	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O

Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6	5080
gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
fragments	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O

RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	9606
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	D015783
,	O
coloboma	D003103
of	D003103
iris	D003103
and	D003103
choroids	D003103
,	O
and	O
the	O
anterior	C537775
segment	C537775
malformations	C537775
including	O
peters	C537884
anomaly	C537884
.	O

Sequencing	O
of	O
the	O
PAX6	5080
gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing	O
-	O
site	O
mutations	O
c	c|SUB|C|357-3|G
.	O
357	c|SUB|C|357-3|G
-	O
3C	c|SUB|C|357-3|G
>	O
G	c|SUB|C|357-3|G
(	O
p	p|FS|S|119||
.	O
Ser119fsX	p|FS|S|119||
)	O
were	O
identified	O
in	O
the	O
patients	9606
of	O
the	O
AN	D015783
group	O
.	O

A	O
novel	O
missense	O
mutation	O
c	c|SUB|T|643|C
.	O
643T	c|SUB|T|643|C
>	O
C	c|SUB|T|643|C
(	O
p	p|SUB|S|216|P
.	O
S216P	p|SUB|S|216|P
)	O
was	O
detected	O
in	O
the	O
anterior	C537775
segment	C537775
malformation	C537775
group	O
.	O

The	O
mutation	O
p	p|SUB|S|216|P
.	O
S216P	p|SUB|S|216|P
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	5080
caused	O
the	O
phenotype	O
of	O
Peters	C537884
anomaly	C537884
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O

Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6	5080
gene	O
and	O
DKFZ	-
p686k1684	-
gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	9606
from	O
the	O
AN	D015783
group	O
.	O

Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	D003103
of	D003103
iris	D003103
and	D003103
choroid	D003103
.	O

CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6	5080
gene	O
.	O
Polymorphisms	O
of	O
the	O
DNA	O
mismatch	4436
repair	4436
gene	O
HMSH2	4436
in	O
breast	D001943
cancer	D001943
occurence	O
and	O
progression	O
.	O

The	O
response	O
of	O
the	O
cell	O
to	O
DNA	O
damage	O
and	O
its	O
ability	O
to	O
maintain	O
genomic	O
stability	O
by	O
DNA	O
repair	O
are	O
crucial	O
in	O
preventing	O
cancer	D009369
initiation	D009369
and	O
progression	O
.	O

Therefore	O
,	O
polymorphism	O
of	O
DNA	O
repair	O
genes	O
may	O
affect	O
the	O
process	O
of	O
carcinogenesis	D063646
.	O

The	O
importance	O
of	O
genetic	O
variability	O
of	O
the	O
components	O
of	O
mismatch	4436
repair	4436
(	O
MMR	4436
)	O
genes	O
is	O
well	O
documented	O
in	O
colorectal	D015179
cancer	D015179
,	O
but	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
breast	D001943
cancer	D001943
.	O

hMSH2	4436
is	O
one	O
of	O
the	O
crucial	O
proteins	O
of	O
MMR	4436
.	O

We	O
performed	O
a	O
case	O
-	O
control	O
study	O
to	O
test	O
the	O
association	O
between	O
two	O
polymorphisms	O
in	O
the	O
hMSH2	4436
gene	O
:	O
an	O
A	rs17217772
-	O
-	O
>	O
G	rs17217772
transition	rs17217772
at	rs17217772
127	rs17217772
position	rs17217772
producing	O
an	O
Asn	rs17217772
-	O
-	O
>	O
Ser	rs17217772
substitution	rs17217772
at	rs17217772
codon	rs17217772
127	rs17217772
(	O
the	O
Asn127Ser	rs17217772
polymorphism	O
)	O
and	O
a	O
G	rs4987188
-	O
-	O
>	O
A	rs4987188
transition	rs4987188
at	rs4987188
1032	rs4987188
position	rs4987188
resulting	O
in	O
a	O
Gly	rs4987188
-	O
-	O
>	O
Asp	rs4987188
change	rs4987188
at	rs4987188
codon	rs4987188
322	rs4987188
(	O
the	O
Gly322Asp	rs4987188
polymorphism	O
)	O
and	O
breast	D001943
cancer	D001943
risk	O
and	O
cancer	D009369
progression	O
.	O

Genotypes	O
were	O
determined	O
in	O
DNA	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
150	O
breast	D001943
cancer	D001943
patients	9606
and	O
150	O
age	O
-	O
matched	O
women	9606
(	O
controls	O
)	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
allele	O
-	O
specific	O
PCR	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
studied	O
polymorphisms	O
and	O
breast	D001943
cancer	D001943
progression	O
evaluated	O
by	O
node	O
-	O
metastasis	O
,	O
tumor	D009369
size	O
and	O
Bloom	O
-	O
Richardson	O
grading	O
.	O

A	O
strong	O
association	O
between	O
breast	D001943
cancer	D001943
occurrence	O
and	O
the	O
Gly	O
/	O
Gly	O
phenotype	O
of	O
the	O
Gly322Asp	rs4987188
polymorphism	O
(	O
odds	O
ratio	O
8	O
.	O
39	O
;	O
95%	O
confidence	O
interval	O
1	O
.	O
44	O
-	O
48	O
.	O
8	O
)	O
was	O
found	O
.	O

Therefore	O
,	O
MMR	4436
may	O
play	O
a	O
role	O
in	O
the	O
breast	D001943
carcinogenesis	D001943
and	O
the	O
Gly322Asp	rs4987188
polymorphism	O
of	O
the	O
hMSH2	4436
gene	O
may	O
be	O
considered	O
as	O
a	O
potential	O
marker	O
in	O
breast	D001943
cancer	D001943
.	O
Vitamin	2638
D	2638
-	O
binding	2638
protein	2638
gene	O
polymorphism	O
association	O
with	O
IA	5798
-	O
2	5798
autoantibodies	O
in	O
type	D003922
1	D003922
diabetes	D003922
.	O

BACKGROUND	O
:	O
Vitamin	2638
D	2638
-	O
binding	2638
protein	2638
(	O
DBP	2638
)	O
is	O
the	O
main	O
systemic	O
transporter	O
of	O
1	D002117
.	O
25	D002117
(	O
OH	D002117
)	O
2D3	D002117
and	O
is	O
essential	O
for	O
its	O
cellular	O
endocytosis	O
.	O

There	O
are	O
two	O
known	O
polymorphisms	O
in	O
exon	O
11	O
of	O
the	O
DBP	2638
gene	O
resulting	O
in	O
amino	O
acid	O
variants	O
:	O
GAT	p|SUB|D|416|E
-	O
-	O
>	O
GAG	p|SUB|D|416|E
substitution	p|SUB|D|416|E
replaces	p|SUB|D|416|E
aspartic	p|SUB|D|416|E
acid	p|SUB|D|416|E
by	p|SUB|D|416|E
glutamic	p|SUB|D|416|E
acid	p|SUB|D|416|E
in	p|SUB|D|416|E
codon	p|SUB|D|416|E
416	p|SUB|D|416|E
;	O
and	O
ACG	p|SUB|T|420|K
-	O
-	O
>	O
AAG	p|SUB|T|420|K
substitution	p|SUB|T|420|K
in	p|SUB|T|420|K
codon	p|SUB|T|420|K
420	p|SUB|T|420|K
leads	O
to	O
an	O
exchange	O
of	O
threonine	p|SUB|T||K
for	p|SUB|T||K
lysine	p|SUB|T||K
.	O

These	O
DBP	2638
variants	O
lead	O
to	O
differences	O
in	O
the	O
affinity	O
for	O
1	D002117
.	O
25	D002117
(	O
OH	D002117
)	O
2D3	D002117
.	O

Correlations	O
between	O
DBP	2638
alleles	O
and	O
type	D003922
1	D003922
diabetes	D003922
have	O
been	O
described	O
in	O
different	O
populations	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
polymorphism	O
in	O
codon	O
416	O
of	O
the	O
DBP	2638
gene	O
for	O
an	O
association	O
with	O
autoimmune	O
markers	O
of	O
type	D003922
1	D003922
diabetes	D003922
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
present	O
analysis	O
was	O
a	O
case	O
control	O
study	O
.	O

110	O
patients	9606
,	O
68	O
controls	O
,	O
and	O
115	O
first	O
-	O
degree	O
relatives	O
were	O
genotyped	O
for	O
the	O
DBP	2638
polymorphism	O
in	O
codon	O
416	O
.	O

DNA	O
typing	O
of	O
DBP	2638
locus	O
was	O
performed	O
by	O
the	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
(	O
RFLP	O
)	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
Asp	O
/	O
Glu	O
and	O
Glu	O
/	O
Glu	O
were	O
significantly	O
increased	O
in	O
diabetic	D003920
subjects	O
with	O
detectable	O
IA	5798
-	O
2	5798
antibodies	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
DBP	2638
Glu	O
-	O
containing	O
genotype	O
was	O
not	O
accompanied	O
by	O
differences	O
in	O
the	O
prevalence	O
of	O
GAD65	2572
antibodies	O
.	O

These	O
finding	O
supports	O
a	O
role	O
of	O
the	O
vitamin	D014807
D	D014807
endocrine	O
system	O
in	O
the	O
autoimmune	O
process	O
of	O
type	D003922
1	D003922
diabetes	D003922
.	O
Deletion	O
of	O
endothelial	O
cell	O
-	O
specific	O
liver	20869
kinase	20869
B1	20869
increases	O
angiogenesis	O
and	O
tumor	D009369
growth	O
via	O
vascular	22339
endothelial	22339
growth	22339
factor	22339
.	O

Liver	20869
kinase	20869
B1	20869
(	O
LKB1	20869
)	O
is	O
a	O
serine	20869
/	O
threonine	20869
protein	20869
kinase	20869
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
.	O

It	O
was	O
first	O
identified	O
in	O
Peutz	D010580
-	O
Jeghers	D010580
syndrome	D010580
as	O
a	O
tumor	D009369
suppressor	O
gene	O
.	O

Whether	O
endothelial	O
LKB1	20869
regulates	O
angiogenesis	O
and	O
tumor	D009369
growth	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
endothelial	O
cell	O
-	O
specific	O
LKB1	20869
-	O
knockout	O
(	O
LKB1	20869
(	O
endo	O
-	O
/	O
-	O
)	O
)	O
mice	10090
by	O
crossbreeding	O
vascular	12562
endothelial	12562
-	O
cadherin	12562
-	O
Cre	O
mice	10090
with	O
LKB1	20869
(	O
flox	O
/	O
flox	O
)	O
mice	10090
.	O

Vascular	22339
endothelial	22339
growth	22339
factor	22339
(	O
VEGF	22339
)	O
level	O
was	O
highly	O
co	O
-	O
stained	O
in	O
endothelial	O
cells	O
but	O
not	O
in	O
macrophages	O
in	O
LKB1	20869
(	O
endo	O
-	O
/	O
-	O
)	O
mice	10090
.	O

Consistently	O
,	O
LKB1	20869
(	O
endo	O
-	O
/	O
-	O
)	O
mouse	10090
tissues	O
including	O
the	O
lung	O
,	O
skin	O
,	O
kidney	O
and	O
liver	O
showed	O
increased	O
vascular	O
permeability	O
.	O

Tumors	D009369
implanted	O
in	O
LKB1	20869
(	O
endo	O
-	O
/	O
-	O
)	O
mice	10090
but	O
not	O
macrophage	O
-	O
specific	O
LKB1	20869
-	O
knockout	O
mice	10090
grew	O
faster	O
and	O
showed	O
enhanced	O
vascular	O
permeability	O
and	O
increased	O
angiogenesis	O
as	O
compared	O
with	O
those	O
implanted	O
in	O
wild	O
-	O
type	O
mice	10090
.	O

Injection	O
of	O
VEGF	22339
-	O
neutralizing	O
antibody	O
but	O
not	O
the	O
isotype	O
-	O
matched	O
control	O
antibody	O
decreased	O
endothelial	O
-	O
cell	O
angiogenesis	O
and	O
tumor	D009369
growth	O
in	O
vivo	O
.	O

Furthermore	O
,	O
LKB1	20869
deletion	O
enhanced	O
mouse	10090
retinal	O
and	O
cell	O
angiogenesis	O
,	O
and	O
knockdown	O
of	O
VEGF	22339
by	O
small	O
-	O
interfering	O
RNA	O
decreased	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
.	O

Re	O
-	O
expression	O
of	O
LKB1	20869
or	O
knockdown	O
of	O
VEGF	16542
receptor	16542
2	16542
decreased	O
the	O
overproliferation	O
and	O
-	O
migration	O
observed	O
in	O
LKB1	20869
(	O
endo	O
-	O
/	O
-	O
)	O
cells	O
.	O

Mechanistically	O
,	O
LKB1	20869
could	O
bind	O
to	O
the	O
VEGF	22339
transcription	O
factor	O
,	O
specificity	20683
protein	20683
1	20683
(	O
Sp1	20683
)	O
,	O
which	O
then	O
inhibited	O
the	O
binding	O
of	O
Sp1	20683
to	O
the	O
VEGF	22339
promoter	O
to	O
reduce	O
VEGF	22339
expression	O
.	O

Endothelial	O
LKB1	20869
may	O
regulate	O
endothelial	O
angiogenesis	O
and	O
tumor	D009369
growth	O
by	O
modulating	O
Sp1	20683
-	O
mediated	O
VEGF	22339
expression	O
.	O
Urinary	D001749
bladder	D001749
cancer	D001749
in	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	D003520
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	D001749
cancer	D001749
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	D003520
,	O
in	O
patients	9606
with	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	9606
Register	O
a	O
cohort	O
of	O
1065	O
patients	9606
with	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	D009369
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	D001749
cancer	D001749
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	D003520
and	O
bladder	D001749
cancer	D001749
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	D001749
cancer	D001749
after	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	D001749
cancer	D001749
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	D003520
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	D001749
cancer	D001749
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	D003520
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	D001749
cancer	D001749
in	O
the	O
cohort	O
reached	O
10%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
,	O
and	O
a	O
history	O
of	O
bladder	D001749
cancer	D001749
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	D003520
and	O
the	O
risk	O
of	O
bladder	D001749
cancer	D001749
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	D014890
'	O
s	D014890
granulomatosis	D014890
.	O
Mutation	O
analysis	O
of	O
FOXF2	2295
in	O
patients	9606
with	O
disorders	D012734
of	D012734
sex	D012734
development	D012734
(	O
DSD	D012734
)	O
in	O
combination	O
with	O
cleft	D002972
palate	D002972
.	O

In	O
contrast	O
to	O
disorders	D012734
of	D012734
sexual	D012734
differentiation	D012734
caused	O
by	O
lack	O
of	O
androgen	D000728
production	O
or	O
inhibited	O
androgen	D000728
action	O
,	O
defects	O
affecting	O
development	O
of	O
the	O
bipotent	O
genital	O
anlagen	O
have	O
rarely	O
been	O
investigated	O
in	O
humans	9606
.	O

We	O
have	O
previously	O
documented	O
that	O
the	O
transcription	O
factor	O
FOXF2	2295
is	O
highly	O
expressed	O
in	O
human	9606
foreskin	O
.	O

Moreover	O
,	O
Foxf2	14238
knockout	O
mice	10090
present	O
with	O
cleft	D002972
palate	D002972
in	O
combination	O
with	O
hypoplasia	C537540
of	C537540
the	C537540
genital	C537540
tubercle	C537540
.	O

We	O
hypothesized	O
that	O
humans	9606
with	O
disorders	D012734
of	D012734
sex	D012734
development	D012734
(	O
DSD	D012734
)	O
in	O
combination	O
with	O
cleft	D002972
palate	D002972
could	O
have	O
mutations	O
in	O
the	O
FOXF2	2295
gene	O
.	O

Eighteen	O
children	O
with	O
DSD	D012734
and	O
cleft	D002972
palate	D002972
were	O
identified	O
in	O
the	O
L	O
beck	O
DSD	D012734
database	O
(	O
about	O
1	O
,	O
500	O
entries	O
)	O
.	O

Genomic	O
DNA	O
sequence	O
analysis	O
of	O
the	O
FOXF2	2295
gene	O
was	O
performed	O
and	O
compared	O
with	O
10	O
normal	O
female	O
and	O
10	O
normal	O
male	O
controls	O
,	O
respectively	O
.	O

Two	O
heterozygous	O
DNA	O
sequence	O
variations	O
were	O
solely	O
present	O
in	O
one	O
single	O
patient	9606
each	O
but	O
in	O
none	O
of	O
the	O
20	O
normal	O
controls	O
:	O
a	O
duplication	c|DUP||GCC|
of	c|DUP||GCC|
GCC	c|DUP||GCC|
(	O
c	c|DUP|97|GCC|9-10
.	O
97GCC	c|DUP|97|GCC|9-10
[	O
9	c|DUP|97|GCC|9-10
]	O
+	O
[	O
10	c|DUP|97|GCC|9-10
]	O
)	O
resulting	O
in	O
an	O
extra	O
alanine	O
within	O
exon	O
1	O
and	O
a	O
25	c|SUB|G|*25|A
*	O
G	c|SUB|G|*25|A
>	O
A	c|SUB|G|*25|A
substitution	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
.	O

Two	O
patients	9606
carried	O
a	O
c	rs72667003
.	O
262G	rs72667003
>	O
A	rs72667003
sequence	O
variation	O
predicting	O
for	O
an	O
Ala88Thr	rs72667003
exchange	O
which	O
was	O
also	O
detected	O
in	O
2	O
normal	O
controls	O
.	O

Two	O
silent	O
mutations	O
,	O
c	rs61753348
.	O
1272C	rs61753348
>	O
T	rs61753348
(	O
Ser424Ser	rs61753348
)	O
and	O
c	rs2293783
.	O
1284T	rs2293783
>	O
C	rs2293783
(	O
Tyr428Tyr	rs2293783
)	O
,	O
respectively	O
,	O
occurred	O
in	O
the	O
coding	O
region	O
of	O
exon	O
2	O
,	O
again	O
in	O
both	O
patients	9606
and	O
normal	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
majority	O
of	O
the	O
detected	O
sequence	O
alterations	O
were	O
polymorphisms	O
without	O
obvious	O
functional	O
relevance	O
.	O

However	O
,	O
it	O
cannot	O
be	O
excluded	O
that	O
the	O
2	O
unique	O
DNA	O
sequence	O
alterations	O
could	O
have	O
affected	O
FOXF2	2295
on	O
the	O
mRNA	O
or	O
protein	O
level	O
thus	O
contributing	O
to	O
the	O
observed	O
disturbances	O
in	O
genital	O
and	O
palate	O
development	O
.	O
Melanocortin	17202,25635,4160
-	O
4	17202,25635,4160
receptor	17202,25635,4160
activation	O
inhibits	O
c	116554,26419,5599
-	O
Jun	116554,26419,5599
N	116554,26419,5599
-	O
terminal	116554,26419,5599
kinase	116554,26419,5599
activity	O
and	O
promotes	O
insulin	16333,24505,3630
signaling	O
.	O

The	O
melanocortin	5443
system	O
is	O
crucial	O
to	O
regulation	O
of	O
energy	O
homeostasis	O
.	O

The	O
melanocortin	4160
receptor	4160
type	4160
4	4160
(	O
MC4R	4160
)	O
modulates	O
insulin	3630
signaling	O
via	O
effects	O
on	O
c	5599
-	O
Jun	5599
N	5599
-	O
terminal	5599
kinase	5599
(	O
JNK	5599
)	O
.	O

The	O
melanocortin	5443
agonist	O
NDP	C027756
-	O
MSH	C027756
dose	O
-	O
dependently	O
inhibited	O
JNK	5599
activity	O
in	O
HEK293	9606
cells	O
stably	O
expressing	O
the	O
human	9606
MC4R	4160
;	O
effects	O
were	O
reversed	O
by	O
melanocortin	4160
receptor	4160
antagonist	O
.	O

NDP	C027756
-	O
MSH	C027756
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
IRS	3667
-	O
1	3667
(	O
ser307	p|Allele|S|307
)	O
phosphorylation	O
,	O
effects	O
also	O
reversed	O
by	O
a	O
specific	O
melanocortin	4160
receptor	4160
antagonist	O
.	O

NDP	C027756
-	O
MSH	C027756
augmented	O
insulin	3630
-	O
stimulated	O
AKT	207
phosphorylation	O
in	O
vitro	O
.	O

The	O
melanocortin	5443
agonist	O
melanotan	C079282
II	C079282
increased	O
insulin	24505
-	O
stimulated	O
AKT	24185
phosphorylation	O
in	O
the	O
rat	10116
hypothalamus	O
in	O
vivo	O
.	O

NDP	C027756
-	O
MSH	C027756
increased	O
insulin	16333
-	O
stimulated	O
glucose	D005947
uptake	O
in	O
hypothalamic	O
GT1	10090
-	O
1	10090
cells	O
.	O

The	O
current	O
study	O
shows	O
that	O
the	O
melanocortinergic	O
system	O
interacts	O
with	O
insulin	16333,24505,3630
signaling	O
via	O
novel	O
effects	O
on	O
JNK	116554,26419,5599
activity	O
.	O
Recovery	O
of	O
tacrolimus	D016559
-	O
associated	O
brachial	D020968
neuritis	D020968
after	O
conversion	O
to	O
everolimus	D000068338
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
-	O
-	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	D016559
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	D020258
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	D001927
,	O
headaches	D006261
,	O
seizures	D012640
,	O
or	O
neurological	D009461
deficits	D009461
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	D009187
and	O
right	O
brachial	D020968
plexitis	D020968
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	D016559
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	D008775
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	D016559
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	D000068338
.	O
A	O
Taiwanese	O
boy	O
with	O
congenital	D052497
generalized	D052497
lipodystrophy	D052497
caused	O
by	O
homozygous	O
Ile262fs	p|FS|I|262||
mutation	O
in	O
the	O
BSCL2	26580
gene	O
.	O

Congenital	D052497
generalized	D052497
lipodystrophy	D052497
(	O
CGL	D052497
)	O
is	O
a	O
rare	O
autosomal	D030342
recessive	D030342
disease	D030342
that	O
is	O
characterized	O
by	O
a	O
near	O
-	O
complete	O
absence	O
of	O
adipose	O
tissue	O
from	O
birth	O
or	O
early	O
infancy	O
.	O

Mutations	O
in	O
the	O
BSCL2	26580
gene	O
are	O
known	O
to	O
result	O
in	O
CGL2	D052497
,	O
a	O
more	O
severe	O
phenotype	O
than	O
CGL1	D052497
,	O
with	O
earlier	O
onset	O
,	O
more	O
extensive	O
fat	O
loss	O
and	O
biochemical	O
changes	O
,	O
more	O
severe	O
intellectual	D008607
impairment	D008607
,	O
and	O
more	O
severe	O
cardiomyopathy	D009202
.	O

We	O
report	O
a	O
3	O
-	O
month	O
-	O
old	O
Taiwanese	O
boy	O
with	O
initial	O
presentation	O
of	O
a	O
lack	O
of	O
subcutaneous	O
fat	O
,	O
prominent	O
musculature	O
,	O
generalized	O
eruptive	D014973
xanthomas	D014973
,	O
and	O
extreme	O
hypertriglyceridemia	D015228
.	O

Absence	O
of	O
mechanical	O
adipose	O
tissue	O
in	O
the	O
orbits	O
and	O
scalp	O
was	O
revealed	O
by	O
head	O
magnetic	O
resonance	O
imaging	O
.	O

Hepatomegaly	D006529
was	O
noticed	O
,	O
and	O
histological	O
examination	O
of	O
a	O
liver	O
biopsy	O
specimen	O
suggested	O
severe	O
hepatic	D005234
steatosis	D005234
and	O
periportal	O
necrosis	D009336
.	O

However	O
,	O
echocardiography	O
indicated	O
no	O
sign	O
of	O
cardiomyopathy	D009202
and	O
he	O
showed	O
no	O
distinct	O
intellectual	D008607
impairment	D008607
that	O
interfered	O
with	O
daily	O
life	O
.	O

About	O
1	O
year	O
later	O
,	O
abdominal	O
computed	O
tomography	O
revealed	O
enlargement	D007674
of	D007674
kidneys	D007674
.	O

He	O
had	O
a	O
homozygous	O
insertion	O
of	O
a	O
nucleotide	O
,	O
783insG	c|INS|783|G
(	O
Ile262fs	p|FS|I|262||
mutation	O
)	O
,	O
in	O
exon	O
7	O
of	O
the	O
BSCL2	26580
gene	O
.	O

We	O
reviewed	O
the	O
genotype	O
of	O
CGL	D052497
cases	O
from	O
Japan	O
,	O
India	O
,	O
China	O
and	O
Taiwan	O
,	O
and	O
found	O
that	O
BSCL2	26580
is	O
a	O
major	O
causative	O
gene	O
for	O
CGL	D052497
in	O
Asian	O
.	O
Pleomorphic	5326
adenoma	5326
gene	5326
like	5326
-	O
2	5326
induces	O
epithelial	O
-	O
mesenchymal	O
transition	O
via	O
Wnt	7474
/	O
b	1499
-	O
catenin	1499
signaling	O
pathway	O
in	O
human	9606
colorectal	D015179
adenocarcinoma	D015179
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
critical	O
step	O
in	O
the	O
acquisition	O
of	O
metastatic	O
and	O
invasive	O
power	O
for	O
tumor	D009369
cells	O
.	O

Colorectal	D015179
adenocarcinoma	D015179
(	O
CRC	D015179
)	O
is	O
a	O
common	O
cancer	D009369
where	O
metastasis	D009362
is	O
directly	O
linked	O
to	O
patient	9606
survival	O
.	O

Recent	O
studies	O
show	O
that	O
pleomorphic	5326
adenoma	5326
gene	5326
like	5326
-	O
2	5326
(	O
PLAGL2	5326
)	O
could	O
induce	O
tumor	D009369
EMT	O
and	O
is	O
an	O
independent	O
predictive	O
factor	O
associated	O
with	O
poor	O
prognosis	O
in	O
cancer	D009369
.	O

In	O
the	O
present	O
study	O
,	O
we	O
confirmed	O
the	O
role	O
of	O
PLAGL2	5326
in	O
the	O
prognosis	O
of	O
CRC	D015179
patients	9606
and	O
provide	O
molecular	O
evidence	O
of	O
PLAGL2	5326
promoted	O
EMT	O
in	O
CRC	D015179
cell	O
line	O
SW480	9606
.	O

We	O
found	O
that	O
PLAGL2	5326
expression	O
was	O
upregulated	O
in	O
the	O
paraffin	D010232
-	O
embedded	O
CRC	D015179
tissues	O
compared	O
to	O
borderline	O
or	O
benign	O
tissues	O
.	O

Experimental	O
EMT	O
induced	O
by	O
PLAGL2	5326
plasmid	O
transfection	O
proved	O
PLAGL2	5326
protein	O
overexpression	O
could	O
enhance	O
the	O
cell	O
scratch	O
wound	O
-	O
healing	O
and	O
transwell	O
ability	O
and	O
significantly	O
upregulated	O
mesenchymal	O
marker	O
proteins	O
,	O
N	1000
-	O
cadherin	1000
and	O
vimentin	7431
and	O
concurrently	O
downregulated	O
epithelial	O
marker	O
of	O
E	999
-	O
cadherin	999
.	O

Subsequently	O
,	O
through	O
western	O
blot	O
assay	O
,	O
we	O
found	O
that	O
PLAGL2	5326
could	O
activate	O
the	O
wnt	7474
-	O
signaling	O
component	O
b	1499
-	O
catenin	1499
in	O
the	O
nuclei	O
.	O

More	O
CRC	D015179
cell	O
metastasis	D009362
to	O
the	O
lungs	O
was	O
observed	O
when	O
the	O
PLAGL2	5326
overexpressing	O
SW480	9606
cells	O
were	O
injected	O
into	O
the	O
tail	O
vein	O
of	O
rats	10116
,	O
compared	O
with	O
the	O
cell	O
control	O
and	O
PLAGL2	5326
silence	O
group	O
.	O

Our	O
findings	O
indicated	O
that	O
PLAGL2	5326
might	O
be	O
a	O
very	O
upstream	O
key	O
molecule	O
regulating	O
EMT	O
involved	O
in	O
Wnt	7474
/	O
b	1499
-	O
catenin	1499
signaling	O
pathway	O
.	O
Calcium	24247
sensing	24247
receptor	24247
protects	O
high	O
glucose	D005947
-	O
induced	O
energy	O
metabolism	D008659
disorder	D008659
via	O
blocking	O
gp78	361367
-	O
ubiquitin	O
proteasome	O
pathway	O
.	O

Diabetic	D058065
cardiomyopathy	D058065
(	O
DCM	D002311
)	O
is	O
a	O
major	O
complication	O
and	O
fatal	O
cause	O
of	O
the	O
patients	9606
with	O
diabetes	D003920
.	O

The	O
calcium	24247
sensing	24247
receptor	24247
(	O
CaSR	24247
)	O
is	O
a	O
G	24247
protein	24247
-	O
coupled	24247
receptor	24247
,	O
which	O
is	O
involved	O
in	O
maintaining	O
calcium	D002118
homeostasis	O
,	O
regulating	O
cell	O
proliferation	O
and	O
apoptosis	O
,	O
and	O
so	O
on	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
found	O
that	O
CaSR	24247
expression	O
,	O
intracellular	O
calcium	D002118
levels	O
and	O
cardiac	O
function	O
were	O
all	O
significantly	O
decreased	O
in	O
DCM	D002311
rats	10116
;	O
however	O
,	O
the	O
exact	O
mechanism	O
are	O
not	O
clear	O
yet	O
.	O

The	O
present	O
study	O
revealed	O
the	O
protective	O
role	O
of	O
CaSR	24247
in	O
myocardial	D009202
energy	D009202
metabolism	D009202
disorder	D009202
induced	O
by	O
high	O
glucose	D005947
(	O
HG	O
)	O
as	O
well	O
as	O
the	O
underlying	O
mechanism	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
HG	O
decreased	O
the	O
expression	O
of	O
CaSR	24247
,	O
mitochondrial	O
fusion	O
proteins	O
(	O
Mfn1	192647
,	O
Mfn2	64476
)	O
,	O
cell	O
gap	O
junction	O
related	O
proteins	O
(	O
Cx43	24392
,	O
beta	84353
-	O
catenin	84353
,	O
N	83501
-	O
cadherin	83501
)	O
,	O
and	O
intracellular	O
ATP	D000255
concentration	O
.	O

In	O
contrast	O
,	O
HG	O
increased	O
extracellular	O
ATP	D000255
concentration	O
,	O
the	O
expression	O
of	O
gp78	361367
,	O
mitochondrial	O
fission	O
proteins	O
(	O
Fis1	288584
,	O
Drp1	114114
)	O
,	O
and	O
the	O
ubiquitination	O
levels	O
of	O
Mfn1	192647
,	O
Mfn2	64476
and	O
Cx43	24392
.	O

Moreover	O
,	O
CaSR	24247
agonist	O
and	O
gp78	361367
-	O
siRNA	O
significantly	O
reduced	O
the	O
above	O
changes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
HG	O
induces	O
myocardial	D009202
energy	D009202
metabolism	D009202
disorder	D009202
via	O
decrease	O
of	O
CaSR	24247
expression	O
,	O
and	O
activation	O
of	O
gp78	361367
-	O
ubiquitin	O
proteasome	O
system	O
.	O

In	O
turn	O
,	O
these	O
effects	O
disrupt	O
the	O
structure	O
and	O
function	O
of	O
the	O
mitochondria	O
and	O
the	O
cell	O
gap	O
junction	O
,	O
result	O
in	O
the	O
reduced	O
ATP	D000255
synthesis	O
and	O
the	O
increased	O
ATP	D000255
leakage	O
.	O

Stimulation	O
of	O
CaSR	24247
significantly	O
attenuates	O
HG	O
-	O
induced	O
abnormal	D009202
myocardial	D009202
energy	D009202
metabolism	D009202
,	O
suggesting	O
CaSR	24247
would	O
be	O
a	O
promising	O
potential	O
therapeutic	O
target	O
for	O
DCM	D002311
.	O
Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	9606
with	O
inflammatory	D015212
bowel	D015212
disease	D015212
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self	O
-	O
antigens	O
have	O
been	O
associated	O
with	O
Crohn	D003424
'	O
s	D003424
disease	D003424
.	O

The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	2
that	O
underlies	O
Crohn	D003424
'	O
s	D003424
disease	D003424
,	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	2
.	O

It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	10333,10392,22900,64127,7096,7097,7099
immune	10333,10392,22900,64127,7096,7097,7099
receptor	10333,10392,22900,64127,7096,7097,7099
genes	O
(	O
nucleotide	64127
oligomerisation	64127
domain	64127
(	O
NOD	64127
)	O
2	64127
/	O
caspase	64127
recruitment	64127
domain	64127
(	O
CARD	64127
)	O
15	64127
,	O
NOD1	10392
/	O
CARD4	10392
,	O
TUCAN	22900
/	O
CARDINAL	22900
/	O
CARD8	22900
,	O
Toll	7099
-	O
like	7099
receptor	7099
(	O
TLR	7099
)	O
4	7099
,	O
TLR2	7097
,	O
TLR1	7096
and	O
TLR6	10333
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	D015212
bowel	D015212
disease	D015212
(	O
IBD	D015212
)	O
.	O

Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	9606
with	O
IBD	D015212
(	O
874	O
Crohn	D003424
'	O
s	D003424
disease	D003424
,	O
259	O
ulcerative	D003093
colitis	D003093
,	O
30	O
indeterminate	O
colitis	D003092
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti	O
-	O
Saccharomyces	4932
cerevisiae	4932
antibodies	O
(	O
gASCA	O
)	O
IgG	O
,	O
anti	O
-	O
laminaribioside	O
antibodies	O
(	O
ALCA	O
)	O
IgG	O
,	O
anti	O
-	O
chitobioside	O
antibodies	O
(	O
ACCA	O
)	O
IgA	O
,	O
anti	O
-	O
mannobioside	O
antibodies	O
(	O
AMCA	O
)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(	O
Omp	O
)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2	64127
/	O
CARD15	64127
,	O
TUCAN	22900
/	O
CARDINAL	22900
/	O
CARD8	22900
,	O
NOD1	10392
/	O
CARD4	10392
,	O
TLR4	7099
,	O
TLR1	7096
,	O
TLR2	7097
and	O
TLR6	10333
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
Crohn	D003424
'	O
s	D003424
disease	D003424
patients	9606
without	O
CARD15	64127
mutations	O
,	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	64127
variant	O
in	O
Crohn	D003424
'	O
s	D003424
disease	D003424
patients	9606
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66	O
.	O
1%	O
versus	O
51	O
.	O
5%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
ALCA	O
positivity	O
(	O
43	O
.	O
3%	O
versus	O
34	O
.	O
9%	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85	O
.	O
7	O
versus	O
51	O
.	O
8	O
ELISA	O
units	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
independent	O
of	O
ileal	O
involvement	O
.	O

A	O
gene	O
dosage	O
effect	O
,	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	9606
carrying	O
none	O
,	O
one	O
and	O
two	O
CARD15	64127
variants	O
,	O
respectively	O
,	O
was	O
seen	O
for	O
both	O
markers	O
.	O

Similarly	O
,	O
Crohn	D003424
'	O
s	D003424
disease	D003424
patients	9606
carrying	O
NOD1	10392
/	O
CARD4	10392
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild	O
-	O
type	O
patients	9606
(	O
63	O
.	O
8%	O
versus	O
55	O
.	O
2%	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O

An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	7099
D299G	rs4986790
and	O
TLR2	7097
P631H	p|SUB|P|631|H
variants	O
,	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23	O
.	O
4%	O
versus	O
35%	O
,	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
Omp	O
antibodies	O
(	O
20	O
.	O
5%	O
versus	O
34	O
.	O
6%	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Variants	O
in	O
innate	10333,10392,22900,64127,7096,7097,7099
immune	10333,10392,22900,64127,7096,7097,7099
receptor	10333,10392,22900,64127,7096,7097,7099
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	64127
and	O
TLR4	7099
variants	O
was	O
observed	O
.	O

These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	D015212
.	O
Serotonin	3362
6	3362
receptor	3362
gene	O
is	O
associated	O
with	O
methamphetamine	D008694
-	O
induced	O
psychosis	D011605
in	O
a	O
Japanese	O
population	O
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	D011605
disorders	D011605
such	O
as	O
schizophrenia	D012559
.	O

The	O
serotonin	3362
6	3362
(	O
5	3362
-	O
HT6	3362
)	O
receptor	3362
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	D014150
,	O
such	O
as	O
clozapine	D003024
and	O
olanzapine	D000077152
,	O
and	O
d	D003913
-	O
amphetamine	D003913
-	O
induced	O
hyperactivity	D006948
in	O
rats	10116
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5	D012702
-	O
HT6	D012702
receptor	D012702
antagonist	D012702
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d	D003913
-	O
amphetamine	D003913
or	O
phencyclidine	D010622
was	O
restored	O
by	O
5	D012702
-	O
HT6	D012702
receptor	D012702
antagonist	D012702
in	O
an	O
animal	O
study	O
using	O
rats	10116
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	D012559
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	3362
-	O
HT6	3362
receptors	3362
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	D011605
disorders	D011605
.	O

The	O
symptoms	O
of	O
methamphetamine	D008694
(	O
METH	D008694
)	O
-	O
induced	O
psychosis	D011605
are	O
similar	O
to	O
those	O
of	O
paranoid	D012563
type	D012563
schizophrenia	D012563
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5	3362
-	O
HT6	3362
gene	O
(	O
HTR6	3362
)	O
with	O
METH	D008694
-	O
induced	O
psychosis	D011605
.	O

METHOD	O
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	rs6693503
,	O
rs1805054	rs1805054
,	O
rs4912138	rs4912138
,	O
rs3790757	rs3790757
and	O
rs9659997	rs9659997
)	O
,	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case	O
-	O
control	O
samples	O
(	O
197	O
METH	D008694
-	O
induced	O
psychosis	D011605
patients	9606
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	D008694
dependence	O
patients	9606
.	O

RESULTS	O
:	O
rs6693503	rs6693503
was	O
associated	O
with	O
METH	D008694
-	O
induced	O
psychosis	D011605
patients	9606
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

Moreover	O
,	O
this	O
association	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
.	O

In	O
the	O
haplotype	O
-	O
wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	rs6693503
and	O
rs1805054	rs1805054
)	O
and	O
three	O
markers	O
(	O
rs6693503	rs6693503
,	O
rs1805054	rs1805054
and	O
rs4912138	rs4912138
)	O
in	O
HTR6	3362
and	O
METH	D008694
-	O
induced	O
psychosis	D011605
patients	9606
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	3362
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH	D008694
-	O
induced	O
psychosis	D011605
in	O
the	O
Japanese	O
population	O
.	O
Growth	2688
hormone	2688
dose	O
in	O
growth	D004393
hormone	D004393
-	O
deficient	D004393
adults	O
is	O
not	O
associated	O
with	O
IGF	3479
-	O
1	3479
gene	O
polymorphisms	O
.	O

AIMS	O
:	O
Several	O
SNPs	O
and	O
a	O
microsatellite	O
cytosine	O
-	O
adenine	O
repeat	O
promoter	O
polymorphism	O
of	O
the	O
IGF	3479
-	O
1	3479
gene	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
circulating	O
IGF	3479
-	O
1	3479
serum	O
concentrations	O
.	O

Variance	O
in	O
IGF	3479
-	O
1	3479
concentrations	O
due	O
to	O
genetic	O
variations	O
may	O
affect	O
different	O
response	O
to	O
growth	2688
hormone	2688
(	O
GH	2688
)	O
treatment	O
,	O
resulting	O
in	O
different	O
individually	O
required	O
GH	2688
-	O
doses	O
in	O
GH	D004393
-	O
deficient	D004393
patients	9606
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
if	O
the	O
IGF	3479
-	O
1	3479
gene	O
polymorphisms	O
are	O
associated	O
with	O
the	O
GH	2688
-	O
dose	O
of	O
GH	D004393
-	O
deficient	D004393
adults	O
.	O

MATERIALS	O
&	O
METHODS	O
:	O
A	O
total	O
of	O
nine	O
tagging	O
SNPs	O
,	O
five	O
additionally	O
selected	O
SNPs	O
and	O
a	O
cytosine	O
-	O
adenine	O
repeat	O
polymorphism	O
were	O
determined	O
in	O
133	O
German	O
adult	O
patients	9606
(	O
66	O
men	9606
,	O
67	O
women	9606
;	O
mean	O
age	O
45	O
.	O
4	O
years	O
+	O
/	O
-	O
13	O
.	O
1	O
standard	O
deviation	O
;	O
majority	O
Caucasian	O
)	O
with	O
GH	D004393
-	O
deficiency	D004393
(	O
GHD	D004393
)	O
of	O
different	O
origin	O
,	O
derived	O
from	O
the	O
prospective	O
Pfizer	O
International	O
Metabolic	O
Study	O
(	O
KIMS	O
)	O
Pharmacogenetics	O
Study	O
.	O

Patients	9606
received	O
GH	2688
-	O
treatment	O
for	O
12	O
months	O
with	O
finished	O
dose	O
-	O
titration	O
of	O
GH	2688
and	O
centralized	O
IGF	3479
-	O
1	3479
measurements	O
.	O

GH	2688
-	O
dose	O
after	O
1	O
year	O
of	O
treatment	O
,	O
IGF	3479
-	O
1	3479
concentrations	O
,	O
IGF	3479
-	O
1	3479
-	O
standard	O
deviation	O
score	O
(	O
SDS	O
)	O
,	O
the	O
IGF	3479
-	O
1	3479
:	O
GH	2688
ratio	O
and	O
anthropometric	O
data	O
were	O
analyzed	O
by	O
genotype	O
.	O

RESULTS	O
:	O
Except	O
for	O
rs1019731	rs1019731
,	O
which	O
showed	O
a	O
significant	O
difference	O
of	O
IGF	3479
-	O
1	3479
-	O
SDS	O
by	O
genotypes	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
all	O
polymorphisms	O
showed	O
no	O
associations	O
with	O
the	O
GH	2688
-	O
doses	O
,	O
IGF	3479
-	O
1	3479
concentrations	O
,	O
IGF	3479
-	O
1	3479
-	O
SDS	O
and	O
IGF	3479
-	O
1	3479
:	O
GH	2688
ratio	O
after	O
adjusting	O
for	O
the	O
confounding	O
variables	O
gender	O
,	O
age	O
and	O
BMI	O
.	O

CONCLUSION	O
:	O
IGF	3479
-	O
1	3479
gene	O
polymorphisms	O
were	O
not	O
associated	O
with	O
the	O
responsiveness	O
to	O
exogenous	O
GH	2688
in	O
GHD	D004393
.	O

Therefore	O
,	O
genetic	O
variations	O
of	O
the	O
IGF	3479
-	O
1	3479
gene	O
seem	O
not	O
to	O
be	O
major	O
influencing	O
factors	O
of	O
the	O
GH	2688
-	O
IGF	3479
-	O
axis	O
causing	O
variable	O
response	O
to	O
exogenous	O
GH	2688
-	O
treatment	O
.	O
Fine	O
mapping	O
and	O
identification	O
of	O
a	O
candidate	O
gene	O
SSH1	54434
in	O
disseminated	D017499
superficial	D017499
actinic	D017499
porokeratosis	D017499
.	O

Disseminated	D017499
superficial	D017499
actinic	D017499
porokeratosis	D017499
(	O
DSAP	D017499
)	O
is	O
an	O
uncommon	O
autosomal	O
dominant	O
chronic	O
keratinization	D007642
disorder	D007642
,	O
characterized	O
by	O
multiple	O
superficial	O
keratotic	D007642
lesions	D007642
surrounded	O
by	O
a	O
slightly	O
raised	O
keratotic	O
border	O
.	O

Thus	O
far	O
,	O
although	O
two	O
loci	O
for	O
DSAP	D017499
have	O
been	O
identified	O
,	O
the	O
genetic	O
basis	O
and	O
pathogenesis	O
of	O
this	O
disorder	O
have	O
not	O
been	O
elucidated	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
linkage	O
analysis	O
in	O
three	O
Chinese	O
affected	O
families	O
and	O
localized	O
the	O
gene	O
in	O
an	O
8	O
.	O
0	O
cM	O
interval	O
defined	O
by	O
D12S330	O
and	O
D12S354	O
on	O
chromosome	O
12	O
.	O

Upon	O
screening	O
30	O
candidate	O
genes	O
,	O
we	O
identified	O
a	O
missense	O
mutation	O
,	O
p	p|SUB|S|63|N
.	O
Ser63Asn	p|SUB|S|63|N
in	O
SSH1	54434
in	O
one	O
family	O
,	O
a	O
frameshift	O
mutation	O
,	O
p	p|FS|S|19|C|24
.	O
Ser19CysfsX24	p|FS|S|19|C|24
in	O
an	O
alternative	O
variant	O
(	O
isoform	O
f	O
)	O
of	O
SSH1	54434
in	O
another	O
family	O
,	O
and	O
a	O
frameshift	O
mutation	O
,	O
p	p|FS|P|63|P|54
.	O
Pro27ProfsX54	p|FS|P|63|P|54
in	O
the	O
same	O
alternative	O
variant	O
in	O
one	O
non	O
-	O
familial	O
case	O
with	O
DSAP	D017499
.	O

SSH1	54434
encodes	O
a	O
phosphatase	O
that	O
plays	O
a	O
pivotal	O
role	O
in	O
actin	O
dynamics	O
.	O

Our	O
data	O
suggested	O
that	O
cytoskeleton	O
disorganization	O
in	O
epidermal	O
cells	O
is	O
likely	O
associated	O
with	O
the	O
pathogenesis	O
of	O
DSAP	D017499
.	O
Atorvastatin	D000069059
protects	O
against	O
contrast	D007674
-	O
induced	D007674
nephropathy	D007674
via	O
anti	O
-	O
apoptosis	O
by	O
the	O
upregulation	O
of	O
Hsp27	24471
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Contrast	D007674
-	O
induced	D007674
nephropathy	D007674
(	O
CIN	D007674
)	O
is	O
an	O
iatrogenic	O
acute	D058186
renal	D058186
failure	D058186
occurring	O
following	O
the	O
intravascular	O
injection	O
of	O
iodinated	O
radiographic	O
contrast	O
medium	O
.	O

However	O
,	O
the	O
regulatory	O
mechanisms	O
for	O
CIN	D007674
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
atorvastatin	D000069059
protects	O
against	O
CIN	D007674
via	O
anti	O
-	O
apoptotic	O
effects	O
by	O
the	O
upregulation	O
of	O
Hsp27	24471
in	O
vivo	O
and	O
in	O
vitro	O
.	O

To	O
determine	O
whether	O
atorvastatin	D000069059
attenuated	O
CIN	D007674
,	O
the	O
inflammatory	D007249
response	O
and	O
apoptosis	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
a	O
rat	10116
model	O
of	O
iopamidol	D007479
-	O
induced	O
CIN	D007674
was	O
used	O
,	O
and	O
human	9606
embryonic	O
proximal	O
tubule	O
(	O
HK2	9606
)	O
cell	O
damage	O
was	O
assessed	O
.	O

The	O
rats	10116
were	O
assigned	O
into	O
four	O
groups	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
,	O
as	O
follows	O
:	O
Control	O
rats	10116
;	O
rats	10116
+	O
atorvastatin	D000069059
;	O
rats	10116
+	O
iopamidol	D007479
;	O
rats	10116
+	O
iopamidol	D007479
+	O
atorvastatin	D000069059
.	O

In	O
vitro	O
,	O
the	O
HK2	9606
cells	O
were	O
treated	O
with	O
iopamidol	D007479
in	O
the	O
presence	O
or	O
absence	O
of	O
atorvastatin	D000069059
,	O
heat	3315
shock	3315
protein	3315
(	O
Hsp	3315
)	O
27	3315
small	O
interfering	O
(	O
si	O
)	O
RNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	3315
.	O

The	O
renal	O
tissues	O
were	O
examined	O
histopathologically	O
and	O
collected	O
for	O
western	O
blot	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
atorvastatin	D000069059
ameliorated	O
the	O
apoptosis	D007674
and	D007674
deterioration	D007674
of	D007674
renal	D007674
function	D007674
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
atorvastatin	D000069059
reduced	O
the	O
iopamidol	D007479
-	O
induced	O
activity	O
of	O
B	24887
cell	24887
lymphoma	24887
-	O
2	24887
(	O
Bcl	24887
-	O
2	24887
)	O
-	O
associated	24887
X	24887
protein	24887
(	O
Bax	24887
)	O
/	O
caspase	25402
-	O
3	25402
and	O
increased	O
the	O
expression	O
of	O
Bcl	24224
-	O
2	24224
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Notably	O
,	O
following	O
treatment	O
with	O
Hsp27	3315
siRNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	3315
,	O
it	O
was	O
found	O
that	O
iopamidol	D007479
enhanced	O
or	O
weakened	O
the	O
upregulation	O
of	O
Bax	581
/	O
caspase	836
-	O
3	836
and	O
downregulation	O
of	O
Bcl	596
-	O
2	596
in	O
the	O
HK2	9606
cells	O
,	O
respectively	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
atorvastatin	D000069059
protected	O
against	O
contrast	D007674
-	O
induced	D007674
renal	D007674
tubular	D007674
cell	D007674
apoptosis	D007674
through	O
the	O
upregulation	O
of	O
Hsp27	24471
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Possible	O
neuroleptic	D009459
malignant	D009459
syndrome	D009459
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	D017374
and	O
alprazolam	D000525
.	O

A	O
74	O
-	O
year	O
-	O
old	O
man	9606
with	O
depressive	D003866
symptoms	D003866
was	O
admitted	O
to	O
a	O
psychiatric	D001523
hospital	O
due	O
to	O
insomnia	D007319
,	O
loss	D001068
of	D001068
appetite	D001068
,	O
exhaustion	O
,	O
and	O
agitation	D011595
.	O

Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	D017374
and	O
1	O
.	O
2	O
mg	O
alprazolam	D000525
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	D017374
and	O
alprazolam	D000525
treatment	O
,	O
the	O
patient	9606
exhibited	O
marked	O
psychomotor	D011596
retardation	D011596
,	O
disorientation	O
,	O
and	O
severe	O
muscle	D009127
rigidity	D009127
with	O
tremors	D014202
.	O

The	O
patient	9606
had	O
a	O
fever	D005334
(	O
38	O
.	O
2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	D001480
symptoms	D001480
.	O

Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	D003402
phosphokinase	D003402
(	O
2218	O
IU	O
/	O
L	O
)	O
,	O
aspartate	D001219
aminotransferase	D001219
(	O
134	O
IU	O
/	O
L	O
)	O
,	O
alanine	D000410
aminotransferase	D000410
(	O
78	O
IU	O
/	O
L	O
)	O
,	O
and	O
BUN	O
(	O
27	O
.	O
9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O

The	O
patient	9606
received	O
bromocriptine	D001971
and	O
diazepam	D003975
to	O
treat	O
his	O
symptoms	O
.	O

7	O
days	O
later	O
,	O
the	O
fever	D005334
disappeared	O
and	O
the	O
patient	9606
'	O
s	O
serum	O
CPK	D003402
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O

This	O
patient	9606
presented	O
with	O
symptoms	O
of	O
neuroleptic	D009459
malignant	D009459
syndrome	D009459
(	O
NMS	D009459
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	D009459
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	D017374
and	O
alprazolam	D000525
treatment	O
.	O

The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	9606
'	O
s	O
NMS	D009459
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O

The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	9606
was	O
suspected	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	D009459
should	O
be	O
noted	O
in	O
elderly	O
depressive	D003866
patients	9606
whose	O
symptoms	O
often	O
include	O
dehydration	D003681
,	O
agitation	D011595
,	O
malnutrition	D044342
,	O
and	O
exhaustion	O
.	O

Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	9606
who	O
suffer	O
from	O
depression	D003866
.	O
Whole	O
-	O
Organism	O
Developmental	O
Expression	O
Profiling	O
Identifies	O
RAB	189429
-	O
28	189429
as	O
a	O
Novel	O
Ciliary	O
GTPase	189429
Associated	O
with	O
the	O
BBSome	260219
and	O
Intraflagellar	O
Transport	O
.	O

Primary	O
cilia	O
are	O
specialised	O
sensory	O
and	O
developmental	O
signalling	O
devices	O
extending	O
from	O
the	O
surface	O
of	O
most	O
eukaryotic	O
cells	O
.	O

Defects	O
in	O
these	O
organelles	O
cause	O
inherited	D030342
human	D030342
disorders	D030342
(	O
ciliopathies	D000072661
)	O
such	O
as	O
retinitis	D012174
pigmentosa	D012174
and	O
Bardet	D020788
-	O
Biedl	D020788
syndrome	D020788
(	O
BBS	D020788
)	O
,	O
frequently	O
affecting	O
many	O
physiological	O
and	O
developmental	O
processes	O
across	O
multiple	O
organs	O
.	O

Cilium	O
formation	O
,	O
maintenance	O
and	O
function	O
depend	O
on	O
intracellular	O
transport	O
systems	O
such	O
as	O
intraflagellar	O
transport	O
(	O
IFT	O
)	O
,	O
which	O
is	O
driven	O
by	O
kinesin	177685
-	O
2	177685
and	O
IFT	O
-	O
dynein	172041
motors	O
and	O
regulated	O
by	O
the	O
Bardet	260219
-	O
Biedl	260219
syndrome	260219
(	O
BBS	260219
)	O
cargo	260219
-	O
adaptor	260219
protein	260219
complex	260219
,	O
or	O
BBSome	260219
.	O

To	O
identify	O
new	O
cilium	O
-	O
associated	O
genes	O
,	O
we	O
employed	O
the	O
nematode	O
C	6239
.	O

elegans	6239
,	O
where	O
ciliogenesis	O
occurs	O
within	O
a	O
short	O
timespan	O
during	O
late	O
embryogenesis	O
when	O
most	O
sensory	O
neurons	O
differentiate	O
.	O

Using	O
whole	O
-	O
organism	O
RNA	O
-	O
Seq	O
libraries	O
,	O
we	O
discovered	O
a	O
signature	O
expression	O
profile	O
highly	O
enriched	O
for	O
transcripts	O
of	O
known	O
ciliary	O
proteins	O
,	O
including	O
FAM	189695
-	O
161	189695
(	O
FAM161A	84140
orthologue	O
)	O
,	O
CCDC	112942
-	O
104	112942
(	O
CCDC104	112942
)	O
,	O
and	O
RPI	189281
-	O
1	189281
(	O
RP1	6101
/	O
RP1L1	94137
)	O
,	O
which	O
we	O
confirm	O
are	O
cilium	O
-	O
localised	O
in	O
worms	O
.	O

From	O
a	O
list	O
of	O
185	O
candidate	O
ciliary	O
genes	O
,	O
we	O
uncover	O
orthologues	O
of	O
human	9606
MAP9	79884
,	O
YAP	10413
,	O
CCDC149	91050
,	O
and	O
RAB28	9364
as	O
conserved	O
cilium	O
-	O
associated	O
components	O
.	O

Further	O
analyses	O
of	O
C	6239
.	O

elegans	6239
RAB	189429
-	O
28	189429
,	O
recently	O
associated	O
with	O
autosomal	O
-	O
recessive	O
cone	D000071700
-	O
rod	D000071700
dystrophy	D000071700
,	O
reveal	O
that	O
this	O
small	O
GTPase	189429
is	O
exclusively	O
expressed	O
in	O
ciliated	O
neurons	O
where	O
it	O
dynamically	O
associates	O
with	O
IFT	O
trains	O
.	O

Whereas	O
inactive	O
GDP	D006153
-	O
bound	O
RAB	189429
-	O
28	189429
displays	O
no	O
IFT	O
movement	O
and	O
diffuse	O
localisation	O
,	O
GTP	D006160
-	O
bound	O
(	O
activated	O
)	O
RAB	189429
-	O
28	189429
concentrates	O
at	O
the	O
periciliary	O
membrane	O
in	O
a	O
BBSome	260219
-	O
dependent	O
manner	O
and	O
undergoes	O
bidirectional	O
IFT	O
.	O

Functional	O
analyses	O
reveal	O
that	O
whilst	O
cilium	O
structure	O
,	O
sensory	O
function	O
and	O
IFT	O
are	O
seemingly	O
normal	O
in	O
a	O
rab	189429
-	O
28	189429
null	O
allele	O
,	O
overexpression	O
of	O
predicted	O
GDP	D006153
or	O
GTP	D006160
locked	O
variants	O
of	O
RAB	189429
-	O
28	189429
perturbs	O
cilium	O
and	O
sensory	O
pore	O
morphogenesis	O
and	O
function	O
.	O

Collectively	O
,	O
our	O
findings	O
present	O
a	O
new	O
approach	O
for	O
identifying	O
ciliary	O
proteins	O
,	O
and	O
unveil	O
RAB28	9364
,	O
a	O
GTPase	9364
most	O
closely	O
related	O
to	O
the	O
BBS	D020788
protein	O
RABL4	11020
/	O
IFT27	11020
,	O
as	O
an	O
IFT	O
-	O
associated	O
cargo	O
with	O
BBSome	260219
-	O
dependent	O
cell	O
autonomous	O
and	O
non	O
-	O
autonomous	O
functions	O
at	O
the	O
ciliary	O
base	O
.	O
Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	6716
gene	O
exon	O
4	O
in	O
a	O
male	D058490
pseudohermaphrodite	D058490
patient	9606
of	O
Chinese	O
origin	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5	6716
-	O
alpha	6716
-	O
reductase	6716
type	6716
2	6716
gene	O
(	O
SRD5A2	6716
)	O
analysis	O
in	O
a	O
male	D058490
pseudohermaphrodite	D058490
(	O
MPH	D058490
)	O
patient	9606
with	O
normal	O
testosterone	D013739
(	O
T	D013739
)	O
production	O
and	O
normal	O
androgen	367
receptor	367
(	O
AR	367
)	O
gene	O
coding	O
sequences	O
.	O

A	O
patient	9606
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
,	O
a	O
46	O
,	O
XY	O
karyotype	O
,	O
and	O
normal	O
T	D013739
secretion	O
under	O
human	D006063
chorionic	D006063
gonadotropin	D006063
(	O
hCG	D006063
)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O

Exons	O
1	O
-	O
8	O
of	O
the	O
AR	367
gene	O
and	O
exons	O
1	O
-	O
5	O
of	O
the	O
SRD5A2	6716
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O

AR	367
gene	O
coding	O
sequences	O
were	O
normal	O
.	O

SRD5A2	6716
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
,	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	c|DEL|CODON219|T
nucleotide	c|DEL|CODON219|T
deletion	c|DEL|CODON219|T
,	O
which	c|DEL|CODON219|T
predicts	c|DEL|CODON219|T
a	c|DEL|CODON219|T
frameshift	c|DEL|CODON219|T
mutation	c|DEL|CODON219|T
from	c|DEL|CODON219|T
codon	c|DEL|CODON219|T
219	c|DEL|CODON219|T
,	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
,	O
where	O
the	O
substitution	O
of	O
guanine	rs9332964
(	O
CGA	rs9332964
)	O
by	rs9332964
adenine	rs9332964
(	O
CAA	rs9332964
)	O
predicts	O
a	O
glutamine	rs9332964
replacement	rs9332964
of	rs9332964
arginine	rs9332964
(	O
R227Q	rs9332964
)	O
.	O

Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O

The	O
patient	9606
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	6716
mutations	O
,	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O

The	O
patient	9606
showed	O
an	O
R227Q	rs9332964
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	D058490
patients	9606
,	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
,	O
Tdel219	c|DEL|CODON219|T
.	O

Testis	O
morphology	O
showed	O
that	O
,	O
during	O
early	O
infancy	O
,	O
the	O
5	6716
-	O
alpha	6716
-	O
reductase	6716
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O
A	O
haplotype	O
-	O
based	O
analysis	O
of	O
the	O
PTPN22	26191
locus	O
in	O
type	D003922
1	D003922
diabetes	D003922
.	O

A	O
recent	O
addition	O
to	O
the	O
list	O
of	O
widely	O
confirmed	O
type	D003922
1	D003922
diabetes	D003922
risk	O
loci	O
is	O
the	O
PTPN22	26191
gene	O
encoding	O
a	O
lymphoid	26191
-	O
specific	26191
phosphatase	26191
(	O
Lyp	26191
)	O
.	O

However	O
,	O
evidence	O
supporting	O
a	O
role	O
for	O
PTPN22	26191
in	O
type	D003922
1	D003922
diabetes	D003922
derives	O
entirely	O
from	O
the	O
study	O
of	O
just	O
one	O
coding	O
single	O
nucleotide	O
polymorphism	O
,	O
1858C	rs2476601
/	O
T	rs2476601
.	O

In	O
the	O
current	O
study	O
,	O
the	O
haplotype	O
structure	O
of	O
the	O
PTPN22	26191
region	O
was	O
determined	O
,	O
and	O
individual	O
haplotypes	O
were	O
tested	O
for	O
association	O
with	O
type	D003922
1	D003922
diabetes	D003922
in	O
family	O
-	O
based	O
tests	O
.	O

The	O
1858T	rs2476601
risk	O
allele	O
occurred	O
on	O
only	O
a	O
single	O
haplotype	O
that	O
was	O
strongly	O
associated	O
with	O
type	D003922
1	D003922
diabetes	D003922
(	O
P	O
=	O
7	O
.	O
9	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
.	O

After	O
controlling	O
for	O
the	O
effects	O
of	O
this	O
allele	O
,	O
two	O
other	O
haplotypes	O
were	O
observed	O
to	O
be	O
weakly	O
associated	O
with	O
type	D003922
1	D003922
diabetes	D003922
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Sequencing	O
of	O
the	O
coding	O
region	O
of	O
PTPN22	26191
on	O
these	O
haplotypes	O
revealed	O
a	O
novel	O
variant	O
(	O
2250G	rs56048322
/	O
C	rs56048322
)	O
predicted	O
to	O
result	O
in	O
a	O
nonsynonymous	O
amino	O
acid	O
substitution	O
.	O

Analysis	O
of	O
PTPN22	26191
transcripts	O
from	O
a	O
subject	O
heterozygous	O
for	O
this	O
variant	O
indicated	O
that	O
it	O
interfered	O
with	O
normal	O
mRNA	O
splicing	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
after	O
exon	O
17	O
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
the	O
1858C	rs2476601
/	O
T	rs2476601
allele	O
is	O
the	O
major	O
risk	O
variant	O
for	O
type	D003922
1	D003922
diabetes	D003922
in	O
the	O
PTPN22	26191
locus	O
,	O
but	O
they	O
suggest	O
that	O
additional	O
infrequent	O
coding	O
variants	O
at	O
PTPN22	26191
may	O
also	O
contribute	O
to	O
type	D003922
1	D003922
diabetes	D003922
risk	O
.	O
Sepsis	D018805
-	O
induced	O
changes	O
in	O
amino	246235,25648,29642,84551
acid	246235,25648,29642,84551
transporters	246235,25648,29642,84551
and	O
leucine	D007930
signaling	O
via	O
mTOR	56718
in	O
skeletal	O
muscle	O
.	O

The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
sepsis	D018805
-	O
induced	O
leucine	D007930
(	O
Leu	D007930
)	O
resistance	O
in	O
skeletal	O
muscle	O
is	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
amino	246235,25648,29642,84551
acid	246235,25648,29642,84551
transporters	246235,25648,29642,84551
important	O
in	O
regulating	O
Leu	D007930
flux	O
or	O
an	O
impairment	O
in	O
the	O
formation	O
of	O
the	O
Leu	D007930
-	O
sensitive	O
mTOR	56718
-	O
Ragulator	295234,308869
complex	295234,308869
.	O

Sepsis	D018805
in	O
adult	O
male	O
rats	10116
decreased	O
basal	O
protein	O
synthesis	O
in	O
gastrocnemius	O
,	O
associated	O
with	O
a	O
reduction	O
in	O
mTOR	56718
activation	O
as	O
indicated	O
by	O
decreased	O
4E	116636
-	O
BP1	116636
and	O
S6K1	83840
phosphorylation	O
.	O

The	O
ability	O
of	O
oral	O
Leu	D007930
to	O
increase	O
protein	O
synthesis	O
and	O
mTOR	56718
kinase	O
after	O
1	O
h	O
was	O
largely	O
prevented	O
in	O
sepsis	D018805
.	O

Sepsis	D018805
increased	O
CAT1	25648
,	O
LAT2	84551
and	O
SNAT2	29642
mRNA	O
content	O
two	O
-	O
to	O
fourfold	O
,	O
but	O
only	O
the	O
protein	O
content	O
for	O
CAT1	25648
(	O
20	O
%	O
decrease	O
)	O
differed	O
significantly	O
.	O

Conversely	O
,	O
sepsis	D018805
decreased	O
the	O
proton	246235
-	O
assisted	246235
amino	246235
acid	246235
transporter	246235
(	O
PAT	246235
)	O
-	O
2	246235
mRNA	O
by	O
60	O
%	O
,	O
but	O
without	O
a	O
coordinate	O
change	O
in	O
PAT2	246235
protein	O
.	O

There	O
was	O
no	O
sepsis	D018805
or	O
Leu	D007930
effect	O
on	O
the	O
protein	O
content	O
for	O
RagA	117043,117044,297960,298514
-	O
D	117043,117044,297960,298514
,	O
LAMTOR	295234,308869
-	O
1	295234,308869
and	295234,308869
-	O
2	295234,308869
,	O
raptor	287871
,	O
Rheb	26954
or	O
mTOR	56718
in	O
muscle	O
.	O

The	O
binding	O
of	O
mTOR	56718
,	O
PRAS40	292887
and	O
RagC	298514
to	O
raptor	287871
did	O
not	O
differ	O
for	O
control	O
and	O
septic	O
muscle	O
in	O
the	O
basal	O
condition	O
;	O
however	O
,	O
the	O
Leu	D007930
-	O
induced	O
decrease	O
in	O
PRAS40	292887
raptor	287871
and	O
increase	O
in	O
RagC	298514
raptor	287871
seen	O
in	O
control	O
muscle	O
was	O
absent	O
in	O
sepsis	D018805
.	O

The	O
intracellular	O
Leu	D007930
concentration	O
was	O
increased	O
in	O
septic	O
muscle	O
,	O
compared	O
to	O
basal	O
control	O
conditions	O
,	O
and	O
oral	O
Leu	D007930
further	O
increased	O
the	O
intracellular	O
Leu	D007930
concentration	O
similarly	O
in	O
both	O
control	O
and	O
septic	O
rats	10116
.	O

Hence	O
,	O
while	O
alterations	O
in	O
select	O
amino	246235,25648,29642,84551
acid	246235,25648,29642,84551
transporters	246235,25648,29642,84551
are	O
not	O
associated	O
with	O
development	O
of	O
sepsis	D018805
-	O
induced	O
Leu	D007930
resistance	O
,	O
the	O
Leu	D007930
-	O
stimulated	O
binding	O
of	O
raptor	287871
with	O
RagC	298514
and	O
the	O
recruitment	O
of	O
mTOR	56718
/	O
raptor	287871
to	O
the	O
endosome	O
-	O
lysosomal	O
compartment	O
may	O
partially	O
explain	O
the	O
inability	O
of	O
Leu	D007930
to	O
fully	O
activate	O
mTOR	56718
and	O
muscle	O
protein	O
synthesis	O
.	O
Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	6657
and	O
CHX10	338917
genes	O
in	O
patients	9606
with	O
anophthalmia	D000853
/	O
microphthalmia	D008850
.	O

PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	6657
and	O
CHX10	338917
genes	O
have	O
been	O
reported	O
in	O
patients	9606
with	O
anophthalmia	D000853
and	O
/	O
or	O
microphthalmia	D008850
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
34	O
anophthalmic	D000853
/	O
microphthalmic	D008850
patient	9606
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	6657
and	O
CHX10	338917
.	O

METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	6657
and	O
CHX10	338917
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
)	O
,	O
five	O
unaffected	O
family	O
members	O
,	O
and	O
80	O
healthy	O
controls	O
.	O

Patient	9606
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O

Base	O
pair	O
changes	O
in	O
SOX2	6657
and	O
CHX10	338917
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	9606
samples	O
.	O

RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	6657
were	O
identified	O
in	O
this	O
cohort	O
.	O

Mutation	O
c	c|SUB|G|310|T
.	O
310	c|SUB|G|310|T
G	c|SUB|G|310|T
>	O
T	c|SUB|G|310|T
(	O
p	p|SUB|E|104|X
.	O

Glu104X	p|SUB|E|104|X
)	O
,	O
found	O
in	O
one	O
patient	9606
,	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
-	O
binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	p|SUB|E||X
acid	p|SUB|E||X
to	p|SUB|E||X
a	p|SUB|E||X
stop	p|SUB|E||X
codon	p|SUB|E||X
.	O

The	O
second	O
mutation	O
,	O
noted	O
in	O
two	O
affected	O
siblings	O
,	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c	rs587776776
.	O
549delC	rs587776776
(	O
p	rs587776776
.	O

Pro184ArgfsX19	rs587776776
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O

The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O

In	O
addition	O
,	O
a	O
novel	O
nucleotide	O
substitution	O
c	rs77677339
.	O
*	O
557G	rs77677339
>	O
A	rs77677339
was	O
identified	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
in	O
one	O
patient	9606
.	O

The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O

A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c	rs11915160
.	O

*	O
469	rs11915160
C	rs11915160
>	O
A	rs11915160
,	O
SNP	O
rs11915160	rs11915160
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	9606
.	O

Screening	O
of	O
CHX10	338917
identified	O
two	O
synonymous	O
sequence	O
variants	O
,	O
c	rs35435463
.	O
471	rs35435463
C	rs35435463
>	O
T	rs35435463
(	O
p	rs35435463
.	O
Ser157Ser	rs35435463
,	O
rs35435463	rs35435463
)	O
and	O
c	rs182972044
.	O
579	rs182972044
G	rs182972044
>	O
A	rs182972044
(	O
p	rs182972044
.	O

Gln193Gln	rs182972044
,	O
novel	O
SNP	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
sequence	O
variant	O
,	O
c	rs75395981
.	O
871	rs75395981
G	rs75395981
>	O
A	rs75395981
(	O
p	rs75395981
.	O

Asp291Asn	rs75395981
,	O
novel	O
SNP	O
)	O
.	O

The	O
non	O
-	O
synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
,	O
suggesting	O
non	O
-	O
causality	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	6657
in	O
ocular	O
development	O
.	O

Loss	O
of	O
SOX2	6657
function	O
results	O
in	O
severe	O
eye	D005124
malformation	D005124
.	O

CHX10	338917
was	O
not	O
implicated	O
with	O
microphthalmia	D008850
/	O
anophthalmia	D000853
in	O
our	O
patient	9606
cohort	O
.	O
Combination	O
of	O
the	O
histone	3065
deacetylase	3065
inhibitor	O
depsipeptide	D047630
and	O
5	D005472
-	O
fluorouracil	D005472
upregulates	O
major	3119
histocompatibility	3119
complex	3119
class	3119
II	3119
and	O
p21	1026
genes	O
and	O
activates	O
caspase	836,840
-	O
3	836,840
/	O
7	836,840
in	O
human	9606
colon	D003110
cancer	D003110
HCT	9606
-	O
116	9606
cells	O
.	O

Epigenetic	O
anticancer	O
drugs	O
such	O
as	O
histone	3065
deacetylase	3065
(	O
HDAC	3065
)	O
inhibitors	O
have	O
been	O
combined	O
with	O
existing	O
anticancer	O
drugs	O
for	O
synergistic	O
or	O
additive	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
a	O
very	O
low	O
concentration	O
of	O
depsipeptide	D047630
,	O
an	O
HDAC	3065
inhibitor	O
,	O
potentiated	O
the	O
antitumor	O
activity	O
of	O
5	D005472
-	O
fluorouracil	D005472
(	O
5	D005472
-	O
FU	D005472
)	O
in	O
a	O
human	9606
colon	D003110
cancer	D003110
cell	O
model	O
using	O
HCT	9606
-	O
116	9606
,	O
HT29	9606
,	O
and	O
SW48	9606
cells	O
via	O
the	O
inhibition	O
of	O
colony	O
formation	O
ability	O
or	O
cellular	O
viability	O
.	O

Exposure	O
to	O
a	O
combination	O
of	O
5	D005472
-	O
FU	D005472
(	O
1	O
.	O
75	O
uM	O
)	O
and	O
1	O
nM	O
depsipeptide	D047630
for	O
24	O
and	O
48	O
h	O
resulted	O
in	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
activated	O
caspase	836,840
-	O
3	836,840
/	O
7	836,840
,	O
while	O
5	D005472
-	O
FU	D005472
alone	O
failed	O
to	O
activate	O
caspase	836,840
-	O
3	836,840
/	O
7	836,840
.	O

Microarray	O
and	O
subsequent	O
gene	O
ontology	O
analyses	O
revealed	O
that	O
compared	O
to	O
5	D005472
-	O
FU	D005472
or	O
depsipeptide	D047630
alone	O
,	O
the	O
combination	O
treatment	O
of	O
5	D005472
-	O
FU	D005472
and	O
depsipeptide	D047630
upregulated	O
genes	O
related	O
to	O
cell	O
death	O
and	O
the	O
apoptotic	O
process	O
consistent	O
with	O
the	O
inhibition	O
of	O
colony	O
formation	O
and	O
caspase	836,840
-	O
3	836,840
/	O
7	836,840
activation	O
.	O

These	O
analyses	O
indicated	O
marked	O
upregulation	O
of	O
antigen	O
processing	O
and	O
presentation	O
of	O
peptide	O
or	O
polysaccharide	D011134
antigen	O
via	O
major	3123
histocompatibility	3123
complex	3123
(	O
MHC	3123
)	O
class	3123
(	O
GO	O
:	O
0002504	O
)	O
and	O
MHC	3123
protein	3123
complex	3123
(	O
GO	O
:	O
0042611	O
)	O
.	O

Compared	O
with	O
vehicle	O
controls	O
,	O
the	O
cells	O
treated	O
with	O
the	O
combination	O
of	O
5	D005472
-	O
FU	D005472
and	O
depsipeptide	D047630
showed	O
marked	O
induction	O
(	O
3	O
-	O
to	O
8	O
.	O
5	O
-	O
fold	O
)	O
of	O
expression	O
of	O
MHC	3119
class	3119
II	3119
genes	3119
,	O
but	O
not	O
of	O
MHC	3106
class	3106
I	3106
genes	3106
.	O

Furthermore	O
,	O
our	O
global	O
analysis	O
of	O
gene	O
expression	O
,	O
which	O
was	O
focused	O
on	O
genes	O
involved	O
in	O
the	O
molecular	O
regulation	O
of	O
MHC	3119
class	3119
II	3119
genes	3119
,	O
showed	O
enhancement	O
of	O
pro	O
-	O
apoptotic	O
PCAF	8850
and	O
CIITA	4261
after	O
the	O
combination	O
of	O
5	D005472
-	O
FU	D005472
and	O
depsipeptide	D047630
.	O

These	O
results	O
may	O
indicate	O
a	O
closer	O
relationship	O
between	O
elevation	O
of	O
MHC	3119
class	3119
II	3119
expression	O
and	O
cellular	O
apoptosis	O
induced	O
by	O
the	O
combination	O
of	O
depsipeptide	D047630
and	O
5	D005472
-	O
FU	D005472
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
combination	O
of	O
5	D005472
-	O
FU	D005472
and	O
depsipeptide	D047630
induces	O
human	9606
colon	D003110
cancer	D003110
cell	O
apoptosis	O
in	O
a	O
concerted	O
manner	O
with	O
the	O
induction	O
of	O
MHC	3119
class	3119
II	3119
gene	O
expression	O
.	O
MOL1	835209
is	O
required	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	3702
.	O

Plants	O
maintain	O
pools	O
of	O
pluripotent	O
stem	O
cells	O
which	O
allow	O
them	O
to	O
constantly	O
produce	O
new	O
tissues	O
and	O
organs	O
.	O

Stem	O
cell	O
homeostasis	O
in	O
shoot	O
and	O
root	O
tips	O
depends	O
on	O
negative	O
regulation	O
by	O
ligand	O
-	O
receptor	O
pairs	O
of	O
the	O
CLE	820713,821957,832170
peptide	820713,821957,832170
and	O
leucine	835209,836269
-	O
rich	835209,836269
repeat	835209,836269
receptor	835209,836269
-	O
like	835209,836269
kinase	835209,836269
(	O
LRR	835209,836269
-	O
RLK	835209,836269
)	O
families	O
.	O

However	O
,	O
regulation	O
of	O
the	O
cambium	O
,	O
the	O
stem	O
cell	O
niche	O
required	O
for	O
lateral	O
growth	O
of	O
shoots	O
and	O
roots	O
,	O
is	O
poorly	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
the	O
LRR	835209,836269
-	O
RLK	835209,836269
MOL1	835209
is	O
necessary	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	3702
thaliana	3702
.	O

By	O
employing	O
promoter	O
reporter	O
lines	O
,	O
we	O
reveal	O
that	O
MOL1	835209
is	O
active	O
in	O
a	O
domain	O
that	O
is	O
distinct	O
from	O
the	O
domain	O
of	O
the	O
positively	O
acting	O
CLE41	822075
/	O
PXY	836269
signaling	O
module	O
.	O

In	O
particular	O
,	O
we	O
show	O
that	O
MOL1	835209
acts	O
in	O
an	O
opposing	O
manner	O
to	O
the	O
CLE41	822075
/	O
PXY	836269
module	O
and	O
that	O
changing	O
the	O
domain	O
or	O
level	O
of	O
MOL1	835209
expression	O
both	O
result	O
in	O
disturbed	O
cambium	O
organization	O
.	O

Underlining	O
discrete	O
roles	O
of	O
MOL1	835209
and	O
PXY	836269
,	O
both	O
LRR	835209,836269
-	O
RLKs	835209,836269
are	O
not	O
able	O
to	O
replace	O
each	O
other	O
when	O
their	O
expression	O
domains	O
are	O
interchanged	O
.	O

Furthermore	O
,	O
MOL1	835209
but	O
not	O
PXY	836269
is	O
able	O
to	O
rescue	O
CLV1	843915
deficiency	O
in	O
the	O
shoot	O
apical	O
meristem	O
.	O

By	O
identifying	O
genes	O
mis	O
-	O
expressed	O
in	O
mol1	835209
mutants	O
,	O
we	O
demonstrate	O
that	O
MOL1	835209
represses	O
genes	O
associated	O
with	O
stress	O
-	O
related	O
ethylene	D005030
and	O
jasmonic	C011006
acid	C011006
hormone	O
signaling	O
pathways	O
which	O
have	O
known	O
roles	O
in	O
coordinating	O
lateral	O
growth	O
of	O
the	O
Arabidopsis	3702
stem	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
common	O
regulatory	O
mechanisms	O
in	O
different	O
plant	O
stem	O
cell	O
niches	O
are	O
adapted	O
to	O
specific	O
niche	O
anatomies	O
and	O
emphasize	O
the	O
importance	O
of	O
a	O
complex	O
spatial	O
organization	O
of	O
intercellular	O
signaling	O
cascades	O
for	O
a	O
strictly	O
bidirectional	O
tissue	O
production	O
.	O
R58fs	p|FS|R|58||
mutation	O
in	O
the	O
HGD	3081
gene	O
in	O
a	O
family	O
with	O
alkaptonuria	D000474
in	O
the	O
UAE	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
alkaptonuria	D000474
in	O
the	O
UAE	O
population	O
and	O
to	O
identify	O
the	O
genotype	O
of	O
affected	O
individuals	O
.	O

In	O
a	O
3	O
stage	O
sampling	O
technique	O
2981	O
pupils	O
from	O
Government	O
schools	O
in	O
Al	O
Ain	O
and	O
private	O
schools	O
in	O
Dubai	O
were	O
selected	O
to	O
take	O
part	O
in	O
the	O
study	O
,	O
of	O
whom	O
2857	O
provided	O
urine	O
samples	O
.	O

Urine	O
collected	O
was	O
analysed	O
for	O
homogentisic	D006713
acid	D006713
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
white	O
blood	O
cells	O
of	O
all	O
family	O
members	O
of	O
the	O
affected	O
case	O
following	O
standard	O
established	O
protocols	O
.	O

Specific	O
PRC	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
14	O
exons	O
of	O
the	O
HGD	3081
gene	O
with	O
the	O
flanking	O
intronic	O
sequences	O
including	O
the	O
splice	O
site	O
sequences	O
.	O

2857	O
children	O
returned	O
a	O
viable	O
urine	O
sample	O
,	O
of	O
which	O
one	O
was	O
highly	O
positive	O
for	O
homogentisic	D006713
acid	D006713
.	O

All	O
12	O
members	O
of	O
this	O
girl	O
'	O
s	O
family	O
were	O
studied	O
and	O
one	O
,	O
a	O
22	O
year	O
old	O
brother	O
,	O
was	O
found	O
to	O
excrete	O
HGA	D006713
.	O

Another	O
,	O
a	O
sister	O
who	O
had	O
not	O
provided	O
a	O
urine	O
sample	O
,	O
was	O
discovered	O
by	O
genetic	O
testing	O
.	O

There	O
were	O
no	O
complaints	O
of	O
joint	D018771
pain	D018771
or	O
other	O
symptoms	O
in	O
any	O
member	O
of	O
this	O
family	O
.	O

Parents	O
were	O
first	O
cousins	O
.	O

We	O
found	O
a	O
single	O
nucleotide	O
deletion	O
c	c|DEL|342|A
.	O
342delA	c|DEL|342|A
,	O
located	O
in	O
exon	O
3	O
,	O
which	O
resulted	O
in	O
a	O
frameshift	O
at	O
amino	O
acid	O
position	O
58	O
(	O
p	p|FS|R|58||
.	O
Arg58fs	p|FS|R|58||
or	O
p	p|FS|R|58||
.	O
R58fs	p|FS|R|58||
)	O
.	O

Alkaptonuria	D000474
may	O
be	O
more	O
common	O
than	O
it	O
is	O
thought	O
to	O
be	O
with	O
an	O
allele	O
prevalence	O
estimated	O
at	O
0	O
.	O
0107	O
(	O
95%	O
CI	O
0	O
.	O
000392	O
-	O
0	O
.	O
03473	O
)	O
.	O

The	O
R58fs	p|FS|R|58||
mutation	O
is	O
old	O
,	O
perhaps	O
having	O
occurred	O
several	O
thousand	O
years	O
ago	O
,	O
and	O
has	O
spread	O
over	O
a	O
large	O
geographical	O
area	O
.	O
5	D005472
-	O
Fluorouracil	D005472
cardiotoxicity	D066126
induced	O
by	O
alpha	C032348
-	O
fluoro	C032348
-	O
beta	C032348
-	O
alanine	C032348
.	O

Cardiotoxicity	D066126
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	D005472
-	O
fluorouracil	D005472
(	O
5	D005472
-	O
FU	D005472
)	O
treatment	O
for	O
malignancies	D009369
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	9606
with	O
5	D005472
-	O
FU	D005472
-	O
induced	O
cardiotoxicity	D066126
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	C032348
-	O
fluoro	C032348
-	O
beta	C032348
-	O
alanine	C032348
(	O
FBAL	C032348
)	O
was	O
observed	O
.	O

The	O
patient	9606
,	O
who	O
had	O
unresectable	O
colon	D003110
cancer	D003110
metastases	D009362
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O

After	O
admission	O
,	O
the	O
patient	9606
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	D005472
-	O
FU	D005472
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	D002637
pain	D002637
with	O
right	D002037
bundle	D002037
branch	D002037
block	D002037
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	C032348
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precordial	D002637
pain	D002637
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	D005472
-	O
FU	D005472
.	O

As	O
the	O
precordial	D002637
pain	D002637
in	O
this	O
patient	9606
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	D005472
-	O
FU	D005472
-	O
induced	O
cardiotoxicity	D066126
,	O
the	O
administration	O
of	O
5	D005472
-	O
FU	D005472
was	O
abandoned	O
.	O

Instead	O
,	O
oral	O
administration	O
of	O
S	C079198
-	O
1	C079198
(	O
a	O
derivative	O
of	O
5	D005472
-	O
FU	D005472
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S	C079198
-	O
1	C079198
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	-
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	D005472
-	O
FU	D005472
into	O
FBAL	C032348
.	O

The	O
serum	O
FBAL	C032348
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S	C079198
-	O
1	C079198
administration	O
.	O

Thereafter	O
,	O
no	O
cardiac	D006331
symptoms	D006331
were	O
observed	O
.	O

The	O
patient	9606
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S	C079198
-	O
1	C079198
treatment	O
.	O

The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	C032348
is	O
related	O
to	O
5	D005472
-	O
FU	D005472
-	O
induced	O
cardiotoxicity	D066126
.	O

S	C079198
-	O
1	C079198
may	O
be	O
administered	O
safely	O
to	O
patients	9606
with	O
5	D005472
-	O
FU	D005472
-	O
induced	O
cardiotoxicity	D066126
.	O
Hypoglycemic	O
Effect	O
of	O
Combined	O
Ghrelin	58991
and	O
Glucagon	14527
Receptor	14527
Blockade	O
.	O

Glucagon	2642
receptor	2642
(	O
GcgR	2642
)	O
blockade	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
insulin	3630
monotherapy	O
for	O
treating	O
type	D003922
1	D003922
diabetes	D003922
since	O
deletion	O
or	O
inhibition	O
of	O
GcgRs	2642
corrects	O
hyperglycemia	D006943
in	O
models	O
of	O
diabetes	D003920
.	O

The	O
factors	O
regulating	O
glycemia	D001786
in	O
a	O
setting	O
devoid	O
of	O
insulin	3630
and	O
glucagon	2641
function	O
remain	O
unclear	O
but	O
may	O
include	O
the	O
hormone	O
ghrelin	51738
.	O

Not	O
only	O
is	O
ghrelin	51738
release	O
controlled	O
by	O
glucose	D005947
but	O
also	O
ghrelin	51738
has	O
many	O
actions	O
that	O
can	O
raise	O
or	O
reduce	O
falls	O
in	O
blood	D001786
glucose	D001786
level	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
ghrelin	58991
rises	O
to	O
prevent	O
hypoglycemia	D007003
in	O
the	O
absence	O
of	O
glucagon	14526
function	O
.	O

Both	O
GcgR	14527
knockout	O
(	O
Gcgr	14527
(	O
-	O
/	O
-	O
)	O
)	O
mice	10090
and	O
db	O
/	O
db	O
mice	10090
that	O
were	O
administered	O
GcgR	14527
monoclonal	O
antibody	O
displayed	O
lower	O
blood	D001786
glucose	D001786
levels	O
accompanied	O
by	O
elevated	O
plasma	O
ghrelin	58991
levels	O
.	O

Although	O
treatment	O
with	O
the	O
pancreatic	O
b	O
-	O
cell	O
toxin	O
streptozotocin	D013311
induced	O
hyperglycemia	D006943
and	O
raised	O
plasma	O
ghrelin	58991
levels	O
in	O
wild	O
-	O
type	O
mice	10090
,	O
hyperglycemia	D006943
was	O
averted	O
in	O
similarly	O
treated	O
Gcgr	14527
(	O
-	O
/	O
-	O
)	O
mice	10090
and	O
the	O
plasma	O
ghrelin	58991
level	O
was	O
further	O
increased	O
.	O

Notably	O
,	O
administration	O
of	O
a	O
ghrelin	208188
receptor	208188
antagonist	O
further	O
reduced	O
blood	D001786
glucose	D001786
levels	O
into	O
the	O
markedly	O
hypoglycemic	O
range	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	D013311
-	O
treated	O
Gcgr	14527
(	O
-	O
/	O
-	O
)	O
mice	10090
.	O

A	O
lowered	O
blood	D001786
glucose	D001786
level	O
also	O
was	O
observed	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	D013311
-	O
treated	O
ghrelin	208188
receptor	208188
-	O
null	O
mice	10090
that	O
were	O
administered	O
GcgR	14527
monoclonal	O
antibody	O
.	O

These	O
data	O
suggest	O
that	O
when	O
glucagon	14526
activity	O
is	O
blocked	O
in	O
the	O
setting	O
of	O
type	D003922
1	D003922
diabetes	D003922
,	O
the	O
plasma	O
ghrelin	58991
level	O
rises	O
,	O
preventing	O
hypoglycemia	D007003
.	O
Star	64852
-	O
PAP	64852
,	O
a	O
poly	64852
(	O
A	64852
)	O
polymerase	64852
,	O
functions	O
as	O
a	O
tumor	D009369
suppressor	O
in	O
an	O
orthotopic	O
human	9606
breast	D001943
cancer	D001943
model	O
.	O

Star	64852
-	O
PAP	64852
is	O
a	O
noncanonical	O
poly	64852
(	O
A	64852
)	O
polymerase	64852
and	O
required	O
for	O
the	O
expression	O
of	O
a	O
select	O
set	O
of	O
mRNAs	O
.	O

However	O
,	O
the	O
pathological	O
role	O
of	O
Star	64852
-	O
PAP	64852
in	O
cancer	D009369
largely	O
remains	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
decreased	O
expression	O
of	O
Star	64852
-	O
PAP	64852
in	O
breast	D001943
cancer	D001943
cell	O
lines	O
and	O
tissues	O
.	O

Ectopic	O
Star	64852
-	O
PAP	64852
expression	O
inhibited	O
proliferation	O
as	O
well	O
as	O
colony	O
-	O
forming	O
ability	O
of	O
breast	D001943
cancer	D001943
cells	O
.	O

In	O
breast	D001943
cancer	D001943
patients	9606
,	O
high	O
levels	O
of	O
Star	64852
-	O
PAP	64852
correlated	O
with	O
an	O
improved	O
prognosis	O
.	O

Moreover	O
,	O
by	O
regulating	O
the	O
expression	O
of	O
BIK	638
(	O
BCL2	638
-	O
interacting	638
killer	638
)	O
,	O
Star	64852
-	O
PAP	64852
induced	O
apoptosis	O
of	O
breast	D001943
cancer	D001943
cells	O
through	O
the	O
mitochondrial	O
pathway	O
.	O

The	O
growth	O
of	O
breast	D001943
cancer	D001943
xenografts	O
in	O
NOD	O
/	O
SCID	D016511
mice	10090
was	O
also	O
inhibited	O
by	O
the	O
doxycycline	D004318
-	O
induced	O
Star	64852
-	O
PAP	64852
overexpression	O
.	O

Furthermore	O
,	O
Star	64852
-	O
PAP	64852
sensitized	O
breast	D001943
cancer	D001943
cells	O
to	O
chemotherapy	O
drugs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
mammary	O
epithelial	O
cells	O
,	O
Star	64852
-	O
PAP	64852
knockdown	O
partially	O
transformed	O
these	O
cells	O
and	O
induced	O
them	O
to	O
undergo	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
Star	64852
-	O
PAP	64852
possesses	O
tumor	D009369
-	O
suppressing	O
activity	O
and	O
can	O
be	O
a	O
valuable	O
target	O
for	O
developing	O
new	O
cancer	D009369
therapeutic	O
strategies	O
.	O
Chronic	O
treatment	O
with	O
metformin	D008687
suppresses	O
toll	29260
-	O
like	29260
receptor	29260
4	29260
signaling	O
and	O
attenuates	O
left	D018487
ventricular	D018487
dysfunction	D018487
following	O
myocardial	D009203
infarction	D009203
.	O

Acute	O
treatment	O
with	O
metformin	D008687
has	O
a	O
protective	O
effect	O
in	O
myocardial	D009203
infarction	D009203
by	O
suppression	O
of	O
inflammatory	D007249
responses	O
due	O
to	O
activation	O
of	O
AMP	65248
-	O
activated	65248
protein	65248
kinase	65248
(	O
AMPK	65248
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	D008687
on	O
cardiac	D006331
dysfunction	D006331
and	O
toll	29260
-	O
like	29260
receptor	29260
4	29260
(	O
TLR4	29260
)	O
activities	O
following	O
myocardial	D009203
infarction	D009203
and	O
their	O
relation	O
with	O
AMPK	65248
were	O
assessed	O
.	O

Male	O
Wistar	O
rats	10116
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	D007545
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	D008687
twice	O
daily	O
for	O
14	O
days	O
.	O

Isoproterenol	D007545
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	D009203
myocardial	D009203
infarction	D009203
.	O

Isoproterenol	D007545
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O

The	O
left	D018487
ventricular	D018487
dysfunction	D018487
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	D008687
.	O

Metfromin	D008687
markedly	O
lowered	O
isoproterenol	D007545
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	29260
mRNA	O
,	O
myeloid	301059
differentiation	301059
protein	301059
88	301059
(	O
MyD88	301059
)	O
,	O
tumor	24835
necrosis	24835
factor	24835
-	O
alpha	24835
(	O
TNF	24835
-	O
a	24835
)	O
,	O
and	O
interleukin	24498
6	24498
(	O
IL	24498
-	O
6	24498
)	O
in	O
the	O
heart	O
tissues	O
.	O

Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	24835
-	O
a	24835
and	O
IL	24498
-	O
6	24498
.	O

However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O

Phosphorylated	O
AMPKa	65248
(	O
p	O
-	O
AMPK	65248
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	D008687
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	D008687
reduces	O
post	O
-	O
myocardial	D009203
infarction	D009203
cardiac	D006331
dysfunction	D006331
and	O
suppresses	O
inflammatory	D007249
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	29260
activities	O
.	O

This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	D009203
myocardium	D009203
.	O
Identification	O
of	O
apolipoprotein	348
E	348
Guangzhou	O
(	O
arginine	p|SUB|R|150|P
150	p|SUB|R|150|P
proline	p|SUB|R|150|P
)	O
,	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	C567089
glomerulopathy	C567089
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Lipoprotein	C567089
glomerulopathy	C567089
(	O
LPG	C567089
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus	D013927
-	O
like	O
substances	O
in	O
markedly	O
dilated	D007674
glomerular	D007674
capillaries	D007674
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	348
E	348
(	O
apoE	348
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	348
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	C567089
,	O
but	O
LPG	C567089
may	O
not	O
be	O
caused	O
by	O
apoE	348
gene	O
mutations	O
in	O
Chinese	O
patients	9606
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	348
with	O
LPG	C567089
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
:	O
The	O
apoE	348
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	C567089
patients	9606
was	O
sequenced	O
.	O

The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	348
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18	O
-	O
T	O
vector	O
and	O
then	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	348
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	C567089
patients	9606
and	O
1	O
asymptomatic	O
family	O
member	O
.	O

Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	c|SUB|G|308|C
to	c|SUB|G|308|C
C	c|SUB|G|308|C
point	c|SUB|G|308|C
mutation	c|SUB|G|308|C
in	c|SUB|G|308|C
exon	c|SUB|G|308|C
4	c|SUB|G|308|C
(	O
base	c|SUB|G|308|C
308	c|SUB|G|308|C
)	O
of	O
the	O
apoE	348
gene	O
in	O
all	O
patients	9606
and	O
the	O
asymptomatic	O
family	O
member	O
.	O

This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	p|SUB|R|150|P
residue	p|SUB|R|150|P
for	p|SUB|R|150|P
arginine	p|SUB|R|150|P
residue	p|SUB|R|150|P
at	p|SUB|R|150|P
position	p|SUB|R|150|P
150	p|SUB|R|150|P
of	O
apoE	348
.	O

Those	O
patients	9606
were	O
all	O
heterozygotes	O
with	O
apoE	348
Guangzhou	O
.	O

One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	348
Guangzhou	O
,	O
although	O
he	O
did	O
not	O
have	O
proteinuria	D011507
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	348
(	O
arginine	p|SUB|R|150|P
150	p|SUB|R|150|P
proline	p|SUB|R|150|P
)	O
is	O
a	O
novel	O
apoE	348
variant	O
that	O
etiologically	O
related	O
to	O
LPG	C567089
.	O

This	O
variant	O
(	O
apoE	348
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	348
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	D008055
.	O
A	O
two	O
base	O
pair	O
deletion	O
in	O
the	O
PQBP1	10084
gene	O
is	O
associated	O
with	O
microphthalmia	D008850
,	O
microcephaly	D008831
,	O
and	O
mental	D008607
retardation	D008607
.	O

X	D038901
-	O
linked	D038901
mental	D038901
retardation	D038901
has	O
been	O
traditionally	O
divided	O
into	O
syndromic	O
(	O
S	O
-	O
XLMR	D038901
)	O
and	O
non	O
-	O
syndromic	O
forms	O
(	O
NS	O
-	O
XLMR	D038901
)	O
,	O
although	O
the	O
borderlines	O
between	O
these	O
phenotypes	O
begin	O
to	O
vanish	O
and	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
for	O
example	O
PQBP1	10084
,	O
can	O
cause	O
S	O
-	O
XLMR	D038901
as	O
well	O
as	O
NS	O
-	O
XLMR	D038901
.	O

Here	O
,	O
we	O
report	O
two	O
maternal	O
cousins	O
with	O
an	O
apparently	O
X	D038901
-	O
linked	D038901
phenotype	D038901
of	D038901
mental	D038901
retardation	D038901
(	O
MR	D008607
)	O
,	O
microphthalmia	D008850
,	O
choroid	D003103
coloboma	D003103
,	O
microcephaly	D008831
,	O
renal	D007674
hypoplasia	D007674
,	O
and	O
spastic	D010264
paraplegia	D010264
.	O

By	O
multipoint	O
linkage	O
analysis	O
with	O
markers	O
spanning	O
the	O
entire	O
X	O
-	O
chromosome	O
we	O
mapped	O
the	O
disease	O
locus	O
to	O
a	O
28	O
-	O
Mb	O
interval	O
between	O
Xp11	O
.	O
4	O
and	O
Xq12	O
,	O
including	O
the	O
BCOR	54880
gene	O
.	O

A	O
missense	O
mutation	O
in	O
BCOR	54880
was	O
described	O
in	O
a	O
family	O
with	O
Lenz	C537464
microphthalmia	C537464
syndrome	C537464
,	O
a	O
phenotype	O
showing	O
substantial	O
overlapping	O
features	O
with	O
that	O
described	O
in	O
the	O
two	O
cousins	O
.	O

However	O
,	O
no	O
mutation	O
in	O
the	O
BCOR	54880
gene	O
was	O
found	O
in	O
both	O
patients	9606
.	O

Subsequent	O
mutation	O
analysis	O
of	O
PQBP1	10084
,	O
located	O
within	O
the	O
delineated	O
linkage	O
interval	O
in	O
Xp11	O
.	O
23	O
,	O
revealed	O
a	O
2	O
-	O
bp	O
deletion	O
,	O
c	rs606231195
.	O
461_462delAG	rs606231195
,	O
that	O
cosegregated	O
with	O
the	O
disease	O
.	O

Notably	O
,	O
the	O
same	O
mutation	O
is	O
associated	O
with	O
the	O
Hamel	C537761
cerebropalatocardiac	C537761
syndrome	C537761
,	O
another	O
form	O
of	O
S	O
-	O
XLMR	D038901
.	O

Haplotype	O
analysis	O
suggests	O
a	O
germline	O
mosaicism	O
of	O
the	O
2	O
-	O
bp	O
deletion	O
in	O
the	O
maternal	O
grandmother	O
of	O
both	O
affected	O
individuals	O
.	O

In	O
summary	O
,	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
mutations	O
in	O
PQBP1	10084
are	O
associated	O
with	O
an	O
S	O
-	O
XLMR	D038901
phenotype	O
including	O
microphthalmia	D008850
,	O
thereby	O
further	O
extending	O
the	O
clinical	O
spectrum	O
of	O
phenotypes	O
associated	O
with	O
PQBP1	10084
mutations	O
.	O
Genetic	O
investigation	O
of	O
the	O
TSPYL1	7259
gene	O
in	O
sudden	D013398
infant	D013398
death	D013398
syndrome	D013398
.	O

BACKGROUND	O
:	O
Sudden	D013398
infant	D013398
death	D013398
syndrome	D013398
(	O
SIDS	D013398
)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	D003643
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O

Recently	O
,	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	C563856
infant	C563856
death	C563856
with	C563856
dysgenesis	C563856
of	C563856
the	C563856
testes	C563856
syndrome	C563856
(	O
SIDDT	C563856
)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	7259
gene	O
.	O

PURPOSE	O
:	O
The	O
study	O
'	O
s	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	7259
in	O
SIDS	D013398
.	O

METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	D013398
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O

RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
,	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O

No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	9606
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O

In	O
one	O
female	O
patient	9606
a	O
p	rs140756663
.	O
F366L	rs140756663
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
,	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O

A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
,	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
,	O
cannot	O
be	O
ruled	O
out	O
completely	O
.	O

Because	O
SIDDT	C563856
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	7259
mutations	O
,	O
this	O
heterozygous	O
exchange	O
cannot	O
solely	O
explain	O
the	O
sudden	D003645
death	D003645
in	O
this	O
child	O
.	O

The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	C563856
(	O
457_458insG	c|INS|457_458|G
)	O
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O

CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	7259
gene	O
and	O
SIDS	D013398
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O

Genetic	O
analysis	O
of	O
TSPYL1	7259
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	D013398
without	O
dysgenesis	D013733
of	D013733
the	D013733
testes	D013733
.	O
High	O
fat	D004041
diet	O
-	O
fed	O
obese	D009765
rats	10116
are	O
highly	O
sensitive	O
to	O
doxorubicin	D004317
-	O
induced	O
cardiotoxicity	D066126
.	O

Often	O
,	O
chemotherapy	O
by	O
doxorubicin	D004317
(	O
Adriamycin	D004317
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	D066126
in	O
patients	O
during	O
and	O
posttherapy	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	D004317
-	O
induced	O
cardiotoxicity	D066126
.	O

This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	D014280
and	O
increased	O
cardiac	O
fatty	D005227
-	O
acid	D005227
oxidation	O
,	O
ATP	D000255
synthesis	O
,	O
and	O
upregulated	O
JAK	84598
/	O
STAT3	25125
pathway	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40%	O
high	O
fat	D004041
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	D009765
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	10116
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	D004317
-	O
induced	O
cardiotoxicity	D066126
.	O

A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	D004317
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	D066126
,	O
cardiac	D006331
dysfunction	D006331
,	O
lipid	D008055
peroxidation	O
,	O
and	O
80%	O
mortality	O
in	O
the	O
obese	D009765
(	O
OB	D009765
)	O
rats	10116
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	D007674,D056486
or	D007674,D056486
hepatic	D007674,D056486
toxicity	D007674,D056486
.	O

Doxorubicin	D004317
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	D004317
and	O
doxorubicinol	C010013
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	D009765
hearts	O
.	O

Mechanistic	O
studies	O
revealed	O
that	O
OB	D009765
rats	10116
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	25708,54315
proteins	25708,54315
2	25708,54315
and	25708,54315
3	25708,54315
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	25747
proliferators	25747
activated	25747
receptor	25747
-	O
alpha	25747
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	246253
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	D005227
-	O
acid	D005227
oxidation	O
(	O
666	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400	O
.	O
2	O
+	O
/	O
-	O
11	O
.	O
8	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
OB	D009765
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	65248
-	O
alpha2	65248
protein	65248
kinase	65248
,	O
and	O
(	O
6	O
)	O
86%	O
drop	O
in	O
cardiac	O
ATP	D000255
levels	O
accompanied	O
by	O
decreased	O
ATP	D000255
/	O
ADP	D000244
ratio	O
after	O
doxorubicin	D004317
administration	O
.	O

Decreased	O
cardiac	O
erythropoietin	24335
and	O
increased	O
SOCS3	89829
further	O
downregulated	O
the	O
cardioprotective	O
JAK	84598
/	O
STAT3	25125
pathway	O
.	O

In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	D009765
rats	10116
are	O
highly	O
sensitized	O
to	O
doxorubicin	D004317
-	O
induced	O
cardiotoxicity	D066126
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	D000255
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	84598
/	O
STAT3	25125
pathway	O
.	O
Risks	O
and	O
benefits	O
of	O
COX	D052246
-	O
2	D052246
inhibitors	D052246
vs	O
non	O
-	O
selective	O
NSAIDs	D000894
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit?	O
A	O
retrospective	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	D009203
myocardial	D009203
infarction	D009203
(	O
AMI	D009203
)	O
with	O
COX	D052246
-	O
2	D052246
inhibitors	D052246
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	D000894
-	O
steroidal	D000894
anti	D000894
-	O
inflammatory	D000894
drugs	D000894
(	O
NSAIDs	D000894
)	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	D009203
and	O
GI	D006471
bleeding	D006471
among	O
elderly	O
patients	O
using	O
COX	D052246
-	O
2	D052246
inhibitors	D052246
,	O
NS	O
-	O
NSAIDs	D000894
and	O
acetaminophen	D000082
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	D000894
or	O
acetaminophen	D000082
during	O
1999	O
-	O
2002	O
.	O

Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O

RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	D001241
were	O
:	O
75	O
,	O
761	O
to	O
acetaminophen	D000082
,	O
42	O
,	O
671	O
to	O
rofecoxib	C116926
65	O
,	O
860	O
to	O
celecoxib	C105934
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NSAIDs	D000894
.	O

Among	O
users	O
of	O
aspirin	D001241
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxib	C116926
,	O
22	O
,	O
875	O
to	O
celecoxib	C105934
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	D000894
and	O
38	O
,	O
048	O
to	O
acetaminophen	D000082
.	O

Among	O
non	O
-	O
users	O
of	O
aspirin	D001241
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	D009203
/	O
GI	O
vs	O
the	O
acetaminophen	D000082
(	O
with	O
no	O
aspirin	D001241
)	O
group	O
were	O
:	O
rofecoxib	C116926
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
celecoxib	C105934
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
naproxen	D009288
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
diclofenac	D004008
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprofen	D007052
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
users	O
of	O
aspirin	D001241
,	O
they	O
were	O
:	O
rofecoxib	C116926
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celecoxib	C105934
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ibuprofen	D007052
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclofenac	D004008
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naproxen	D009288
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminophen	D000082
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	D001241
,	O
naproxen	D009288
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	D009203
/	O
GI	D006471
bleeding	D006471
.	O

The	O
AMI	D009203
/	O
GI	D005767
toxicity	D005767
of	O
celecoxib	C105934
was	O
similar	O
to	O
that	O
of	O
acetaminophen	D000082
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	C116926
and	O
NS	O
-	O
NSAIDs	D000894
.	O

Among	O
users	O
of	O
aspirin	D001241
,	O
both	O
celecoxib	C105934
and	O
naproxen	D009288
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O
In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	D058915
A2A	D058915
/	O
A1	D058915
receptor	D058915
antagonist	D058915
in	O
animal	O
models	O
of	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	D058915
A	D058915
(	O
2A	D058915
)	O
/	O
A	D058915
(	O
1	D058915
)	O
receptor	D058915
antagonist	D058915
in	O
several	O
animal	O
models	O
of	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
is	O
described	O
.	O

Discovery	O
and	O
scale	O
-	O
up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10	O
.	O
0%	O
to	O
30	O
.	O
5%	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	D058915
(	O
2A	D058915
)	O
/	O
A	D058915
(	O
1	D058915
)	O
receptor	D058915
antagonist	D058915
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	D010300
'	O
s	D010300
disease	D010300
including	O
mouse	10090
and	O
rat	10116
models	O
of	O
haloperidol	D006220
-	O
induced	O
catalepsy	D002375
,	O
mouse	10090
model	O
of	O
reserpine	D012110
-	O
induced	O
akinesia	D004409
,	O
rat	10116
6	D016627
-	O
hydroxydopamine	D016627
(	O
6	D016627
-	O
OHDA	D016627
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	D015632
-	O
treated	O
non	O
-	O
human	9606
primate	O
model	O
.	O
Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	9606
.	O

Mutations	O
in	O
the	O
GJB2	2706
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	D034381
hearing	D034381
impairment	D034381
in	O
Europe	O
.	O

Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O

Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	D034381
impairment	D034381
.	O

Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2	2706
-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	2706
gene	O
)	O
patients	9606
with	O
hearing	D034381
impairment	D034381
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	10804
and	O
GJB3	2707
)	O
and	O
in	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
of	O
GJB2	2706
including	O
the	O
splice	O
sites	O
.	O

Eleven	O
out	O
of	O
47	O
GJB2	2706
-	O
heterozygous	O
patients	9606
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-	O
3170G	c|SUB|G|-3170|A
>	O
A	c|SUB|G|-3170|A
in	O
the	O
5	O
'	O
UTR	O
region	O
of	O
GJB2	2706
.	O

One	O
out	O
of	O
these	O
11	O
patients	9606
showed	O
homozygous	O
-	O
3170G	c|SUB|G|-3170|A
>	O
A	c|SUB|G|-3170|A
genotype	O
in	O
combination	O
with	O
p	rs111033196
.	O
R127H	rs111033196
.	O

Next	O
to	O
the	O
GJB2	2706
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	10804
[	O
Delta	O
(	O
GJB6	10804
-	O
D13S1830	O
)	O
]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	2707
[	O
c	rs41310442
.	O
357C	rs41310442
>	O
T	rs41310442
,	O
c	rs35983826
.	O
798C	rs35983826
>	O
T	rs35983826
and	O
c	rs1805063
.	O
94C	rs1805063
>	O
T	rs1805063
(	O
p	rs1805063
.	O
R32W	rs1805063
)	O
]	O
which	O
are	O
unlikely	O
disease	O
-	O
causing	O
.	O

Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-	O
3170G	c|SUB|G|-3170|A
>	O
A	c|SUB|G|-3170|A
mutation	O
(	O
in	O
addition	O
to	O
c	rs80338939
.	O
35delG	rs80338939
)	O
in	O
patients	9606
with	O
hearing	D034381
impairment	D034381
.	O
Tumor	D009369
thymidylate	7298
synthase	7298
1494del6	c|DEL|1494|6
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	D015179
cancer	D015179
patients	9606
receiving	O
fluorouracil	D005472
-	O
based	O
adjuvant	O
treatment	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	D009369
thymidylate	7298
synthase	7298
(	O
TS	7298
)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	D015179
cancer	D015179
patients	9606
receiving	O
adjuvant	O
fluorouracil	D005472
(	O
FU	D005472
)	O
-	O
based	O
treatment	O
.	O

PATIENTS	9606
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty	O
-	O
nine	O
colorectal	D015179
cancer	D015179
patients	9606
homogeneously	O
treated	O
with	O
FU	D005472
plus	O
levamisole	D007978
or	O
leucovorin	D002955
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O

TS	7298
enhancer	O
region	O
,	O
3R	O
G	c|SUB|G||C
>	O
C	c|SUB|G||C
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
and	O
TS	7298
1494del6	c|DEL|1494|6
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh	O
-	O
frozen	O
normal	O
mucosa	O
and	O
tumor	D009369
.	O

Mutational	O
analyses	O
of	O
TS	7298
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	D009369
and	O
in	O
18	O
additional	O
metachronic	O
metastases	D009362
.	O

TS	7298
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	D009369
.	O

Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
,	O
differentiation	O
,	O
and	O
location	O
.	O

RESULTS	O
:	O
Tumor	D009369
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
26%	O
)	O
showed	O
that	O
the	O
3R	O
/	O
3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0	O
.	O
38	O
;	O
95%	O
CI	O
,	O
0	O
.	O
16	O
to	O
0	O
.	O
93	O
;	O
P	O
=	O
.	O
020	O
for	O
the	O
recessive	O
model	O
)	O
.	O

3R	O
G	c|SUB|G||C
>	O
C	c|SUB|G||C
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O

Tumor	D009369
TS	7298
1494del6	c|DEL|1494|6
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
36%	O
)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
,	O
based	O
on	O
an	O
additive	O
model	O
,	O
HR	O
=	O
0	O
.	O
42	O
;	O
95%	O
CI	O
,	O
0	O
.	O
22	O
to	O
0	O
.	O
82	O
;	O
P	O
=	O
.	O
0034	O
)	O
.	O

Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D	O
'	O
=	O
0	O
.	O
71	O
,	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
3R	O
/	O
-	O
6	O
base	O
pair	O
(	O
bp	O
)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R	O
/	O
+	O
6bp	O
(	O
HR	O
=	O
0	O
.	O
42	O
;	O
95%	O
CI	O
,	O
0	O
.	O
20	O
to	O
0	O
.	O
85	O
;	O
P	O
=	O
.	O
017	O
)	O
.	O

No	O
TS	7298
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	D009369
or	O
metastases	D009362
.	O

TS	7298
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O

CONCLUSION	O
:	O
Tumor	D009369
TS	7298
1494del6	c|DEL|1494|6
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU	D005472
-	O
based	O
adjuvant	O
treatment	O
of	O
colorectal	D015179
cancer	D015179
patients	9606
.	O
Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	D011692
aminonucleoside	D011692
nephrosis	D009401
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	D011507
starts	O
.	O

Using	O
puromycin	D011692
aminonucleoside	D011692
nephrosis	D009401
(	O
PAN	D009401
)	O
rats	10116
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	64563
,	O
a	81634
-	O
actinin	81634
,	O
dendrin	25113
,	O
and	O
plekhh2	313866
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O

Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O

Possible	O
effects	O
of	O
ACE	24310
inhibition	O
were	O
tested	O
.	O

RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	D011507
,	O
appeared	O
.	O

The	O
amount	O
of	O
nephrin	64563
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O

The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	D011507
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

Nephrin	64563
decreased	O
further	O
,	O
while	O
dendrin	25113
and	O
plekhh2	313866
also	O
decreased	O
but	O
a	81634
-	O
actinin	81634
remained	O
unchanged	O
.	O

ACE	24310
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O

CONCLUSIONS	O
:	O
PAN	D009401
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	D011507
.	O

This	O
was	O
preceded	O
by	O
altered	O
nephrin	64563
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O

The	O
novel	O
proteins	O
dendrin	25113
and	O
plekhh2	313866
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	D009401
,	O
whereas	O
a	81634
-	O
actinin	81634
was	O
unchanged	O
.	O
Intronic	O
deletions	O
in	O
the	O
SLC34A3	142680
gene	O
cause	O
hereditary	C562793
hypophosphatemic	C562793
rickets	C562793
with	C562793
hypercalciuria	C562793
.	O

CONTEXT	O
:	O
Hereditary	C562793
hypophosphatemic	C562793
rickets	C562793
with	C562793
hypercalciuria	C562793
(	O
HHRH	C562793
)	O
is	O
a	O
rare	O
metabolic	D008659
disorder	D008659
,	O
characterized	O
by	O
hypophosphatemia	D017674
and	O
rickets	D012279
/	O
osteomalacia	D010018
with	O
increased	O
serum	O
1	C097949
,	O
25	C097949
-	O
dihydroxyvitamin	C097949
D	C097949
[	O
1	C097949
,	O
25	C097949
-	O
(	O
OH	C097949
)	O
(	O
2	C097949
)	O
D	C097949
]	O
resulting	O
in	O
hypercalciuria	D053565
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
SLC34A3	142680
gene	O
,	O
which	O
encodes	O
sodium	142680
-	O
phosphate	142680
cotransporter	142680
type	142680
IIc	142680
,	O
are	O
responsible	O
for	O
the	O
occurrence	O
of	O
HHRH	C562793
.	O

DESIGN	O
AND	O
SETTING	O
:	O
Mutation	O
analysis	O
of	O
exons	O
and	O
adjacent	O
introns	O
in	O
the	O
SLC34A3	142680
gene	O
was	O
conducted	O
at	O
an	O
academic	O
research	O
laboratory	O
and	O
medical	O
center	O
.	O

PATIENTS	9606
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Members	O
of	O
two	O
unrelated	O
families	O
with	O
HHRH	C562793
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Two	O
affected	O
siblings	O
in	O
one	O
family	O
were	O
homozygous	O
for	O
a	O
101	c|DEL||101
-	O
bp	c|DEL||101
deletion	c|DEL||101
in	O
intron	O
9	O
.	O

Haplotype	O
analysis	O
of	O
the	O
SLC34A3	142680
locus	O
in	O
the	O
family	O
showed	O
that	O
the	O
two	O
deletions	O
are	O
on	O
different	O
haplotypes	O
.	O

An	O
unrelated	O
individual	O
with	O
HHRH	C562793
was	O
a	O
compound	O
heterozygote	O
for	O
an	O
85	c|DEL||85
-	O
bp	c|DEL||85
deletion	c|DEL||85
in	O
intron	O
10	O
and	O
a	O
G	c|SUB|G||A
-	O
to	c|SUB|G||A
-	O
A	c|SUB|G||A
substitution	O
at	O
the	O
last	O
nucleotide	O
in	O
exon	O
7	O
.	O

The	O
intron	O
9	O
deletion	O
(	O
and	O
likely	O
the	O
other	O
two	O
mutations	O
)	O
identified	O
in	O
this	O
study	O
causes	O
aberrant	O
RNA	O
splicing	O
.	O

Sequence	O
analysis	O
of	O
the	O
deleted	O
regions	O
revealed	O
the	O
presence	O
of	O
direct	O
repeats	O
of	O
homologous	O
sequences	O
.	O

CONCLUSION	O
:	O
HHRH	C562793
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
SLC34A3	142680
gene	O
.	O

Haplotype	O
analysis	O
suggests	O
that	O
the	O
two	O
intron	O
9	O
deletions	O
arose	O
independently	O
.	O

The	O
identification	O
of	O
three	O
independent	O
deletions	O
in	O
introns	O
9	O
and	O
10	O
suggests	O
that	O
the	O
SLC34A3	142680
gene	O
may	O
be	O
susceptible	O
to	O
unequal	O
crossing	O
over	O
because	O
of	O
sequence	O
misalignment	O
during	O
meiosis	O
.	O
The	O
association	O
between	O
tranexamic	D014148
acid	D014148
and	O
convulsive	D012640
seizures	D012640
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	9606
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	D012640
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	9606
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	D012640
seizure	D012640
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	D004409
involuntary	D004409
motor	D004409
movements	D004409
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	D012640
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9%	O
)	O
patients	9606
developed	O
postoperative	O
convulsive	D012640
seizures	D012640
.	O

Generalised	D012640
and	D012640
focal	D012640
seizures	D012640
were	O
identified	O
in	O
68	O
and	O
32	O
patients	9606
,	O
respectively	O
.	O

The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	D012640
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	9606
.	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	D012640
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	D001018
of	D001018
ascending	D001018
aorta	D001018
,	O
congestive	D006333
heart	D006333
failure	D006333
,	O
deep	O
hypothermic	D007035
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	D014148
acid	D014148
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	D014148
acid	D014148
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	D012640
(	O
OR	O
14	O
.	O
3	O
,	O
95%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Patients	9606
with	O
convulsive	D012640
seizures	D012640
had	O
2	O
.	O
5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	9606
without	O
convulsive	D012640
seizures	D012640
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	9606
with	O
convulsive	D012640
seizures	D012640
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	9606
without	O
seizures	D012640
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Convulsive	D012640
seizures	D012640
are	O
a	O
serious	O
postoperative	D011183
complication	D011183
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	D014148
acid	D014148
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	D012640
.	O
A	O
TSPO	12257
ligand	O
attenuates	O
brain	D001927
injury	D001927
after	O
intracerebral	D002543
hemorrhage	D002543
.	O

Intracerebral	D002543
hemorrhage	D002543
(	O
ICH	D002543
)	O
is	O
a	O
devastating	O
disease	O
without	O
effective	O
treatment	O
.	O

After	O
ICH	D002543
,	O
the	O
immediate	O
infiltration	O
of	O
leukocytes	O
and	O
activation	O
of	O
microglia	O
are	O
accompanied	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
of	O
the	O
18	O
-	O
kDa	O
translocator	12257
protein	12257
(	O
TSPO	12257
)	O
.	O

TSPO	12257
ligands	O
have	O
shown	O
anti	O
-	O
inflammatory	D007249
and	O
neuroprotective	O
properties	O
in	O
models	O
of	O
CNS	D002493
injury	D002493
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
impact	O
of	O
a	O
TSPO	12257
ligand	O
,	O
etifoxine	C002125
,	O
on	O
brain	D001927
injury	D001927
and	O
inflammation	D007249
in	O
2	O
mouse	10090
models	O
of	O
ICH	D002543
.	O

TSPO	706
was	O
up	O
-	O
regulated	O
in	O
Iba1	199
(	O
+	O
)	O
cells	O
from	O
brains	O
of	O
patients	9606
with	O
ICH	D002543
and	O
in	O
CD11b	16409
(	O
+	O
)	O
CD45	19264
(	O
int	O
)	O
cells	O
from	O
mice	10090
subjected	O
to	O
collagenase	D017364
-	O
induced	O
ICH	D002543
.	O

Etifoxine	C002125
significantly	O
reduced	O
neurodeficits	D001927
and	O
perihematomal	O
brain	D001929
edema	D001929
after	O
ICH	D002543
induction	O
by	O
injection	O
of	O
either	O
autologous	O
blood	O
or	O
collagenase	D017364
.	O

In	O
collagenase	D017364
-	O
induced	O
ICH	D002543
mice	10090
,	O
the	O
protection	O
of	O
etifoxine	C002125
was	O
associated	O
with	O
reduced	O
leukocyte	O
infiltration	O
into	O
the	O
brain	O
and	O
microglial	O
production	O
of	O
IL	16193
-	O
6	16193
and	O
TNF	21926
-	O
a	21926
.	O

Etifoxine	C002125
improved	O
blood	O
-	O
brain	O
barrier	O
integrity	O
and	O
diminished	O
cell	O
death	O
.	O

Notably	O
,	O
the	O
protective	O
effect	O
of	O
etifoxine	C002125
was	O
abolished	O
in	O
mice	10090
depleted	O
of	O
microglia	O
by	O
using	O
a	O
colony	12978
-	O
stimulating	12978
factor	12978
1	12978
receptor	12978
inhibitor	O
.	O

These	O
results	O
indicate	O
that	O
the	O
TSPO	12257
ligand	O
etifoxine	C002125
attenuates	O
brain	D001927
injury	D001927
and	O
inflammation	D007249
after	O
ICH	D002543
.	O

TSPO	12257
may	O
be	O
a	O
viable	O
therapeutic	O
target	O
that	O
requires	O
further	O
investigations	O
in	O
ICH	D002543
.	O
-	O
Li	O
,	O
M	O
.	O
,	O
Ren	O
,	O
H	O
.	O
,	O
Sheth	O
,	O
K	O
.	O

N	O
.	O
,	O
Shi	O
,	O
F	O
.	O
-	O
D	O
.	O
,	O
Liu	O
,	O
Q	O
.	O

A	O
TSPO	12257
ligand	O
attenuates	O
brain	D001927
injury	D001927
after	O
intracerebral	D002543
hemorrhage	D002543
.	O
Mechanisms	O
of	O
hypertension	D006973
induced	O
by	O
nitric	D009569
oxide	D009569
(	O
NO	D009569
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O

Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	D009569
oxide	D009569
(	O
NO	D009569
)	O
in	O
hypertension	D006973
is	O
a	O
hallmark	O
of	O
arterial	D018754
dysfunction	D018754
.	O

Experimental	O
hypertension	D006973
created	O
by	O
the	O
removal	O
of	O
NO	D009569
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O

These	O
include	O
augmented	O
endothelin	24323
-	O
1	24323
(	O
ET	24323
-	O
1	24323
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O

We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	D019335
-	O
nitro	D019335
-	O
L	D019335
-	O
arginine	D019335
(	O
LNNA	D019335
)	O
hypertension	D006973
through	O
these	O
mechanisms	O
.	O

Rats	10116
were	O
treated	O
with	O
the	O
NO	24598
synthase	24598
inhibitor	O
LNNA	D019335
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O

Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	10116
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	D019335
rats	10116
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O

Maximal	O
contraction	O
to	O
norepinephrine	D009638
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	D019335
compared	O
with	O
control	O
rats	10116
whereas	O
the	O
maximum	O
contraction	O
to	O
ET	24323
-	O
1	24323
was	O
significantly	O
reduced	O
(	O
54%	O
control	O
)	O
.	O

Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	D009638
(	O
37%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET	24323
-	O
1	24323
was	O
observed	O
.	O

Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	D019335
hypertension	D006973
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	D019335
.	O

The	O
superoxide	D013481
scavenger	O
tempol	C001803
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	10116
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	D019335
rats	10116
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	D018738
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	D019335
hypertensive	D006973
rats	10116
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	10116
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	D019335
rats	10116
had	O
higher	O
basal	O
levels	O
of	O
superoxide	D013481
compared	O
with	O
those	O
from	O
control	O
rats	10116
.	O

These	O
data	O
suggest	O
that	O
while	O
NO	D009569
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	D006973
.	O
Necrotising	D019115
fasciitis	D019115
after	O
bortezomib	D000069286
and	O
dexamethasone	D003907
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	9606
of	O
Waldenstrom	D008258
macroglobulinaemia	D008258
.	O

Bortezomib	D000069286
and	O
high	O
-	O
dose	O
dexamethasone	D003907
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	D001424
infections	D001424
in	O
patients	9606
with	O
B	O
-	O
cell	O
malignancies	D009369
.	O

However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	9606
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76	O
-	O
year	O
-	O
old	O
man	9606
with	O
Waldenstrom	D008258
macroglobulinaemia	D008258
who	O
suffered	O
necrotising	D019115
fasciitis	D019115
without	O
neutropenia	D009503
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	D000069286
,	O
high	O
-	O
dose	O
dexamethasone	D003907
and	O
rituximab	D000069283
.	O

Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	D001424
infections	D001424
related	O
to	O
bortezomib	D000069286
plus	O
high	O
-	O
dose	O
dexamethasone	D003907
in	O
elderly	O
patients	9606
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O
The	O
glycine	14664
transporter	14664
-	O
1	14664
inhibitor	O
SSR103800	-1
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	10090
.	O

Schizophrenia	D012559
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	D004298
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	14810
N	14810
-	O
methyl	14810
-	O
D	14810
-	O
aspartate	14810
(	O
NMDA	14810
)	O
receptor	14810
produce	O
schizophrenic	D012559
-	O
like	O
symptoms	O
in	O
humans	9606
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	14810
receptor	14810
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	14810
receptor	14810
.	O

Among	O
them	O
are	O
glycine	14664
transporter	14664
-	O
1	14664
(	O
GlyT1	14664
)	O
inhibitors	O
such	O
as	O
SSR103800	-1
,	O
which	O
indirectly	O
enhance	O
NMDA	14810
receptor	14810
function	O
by	O
increasing	O
the	O
glycine	D005998
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	14810
receptor	14810
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	-1
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	D006948
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	D000661
and	O
MK	D016291
-	O
801	D016291
)	O
or	O
transgenic	O
mice	10090
(	O
ie	O
,	O
NMDA	14810
Nr1	14810
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	13162
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	-1
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocked	O
hyperactivity	D006948
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	14810
receptor	14810
antagonist	O
,	O
MK	D016291
-	O
801	D016291
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	D006948
of	O
NMDA	14810
Nr1	14810
(	O
neo	O
-	O
/	O
-	O
)	O
mice	10090
.	O

In	O
contrast	O
,	O
SSR103800	-1
failed	O
to	O
affect	O
hyperactivity	D006948
induced	O
by	O
amphetamine	D000661
or	O
naturally	O
observed	O
in	O
dopamine	13162
transporter	13162
(	O
DAT	13162
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	10090
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	D006220
)	O
and	O
atypical	O
(	O
olanzapine	C076029
,	O
clozapine	D003024
and	O
aripiprazole	C094645
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	D006948
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	-1
did	O
not	O
produce	O
catalepsy	D002375
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	14664
inhibitor	O
,	O
SSR103800	-1
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	D004298
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O
Atrial	D001281
fibrillation	D001281
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	C535648
lymphoma	C535648
in	O
a	O
patient	9606
with	O
myotonic	D009223
dystrophy	D009223
(	O
Steinert	D009223
'	O
s	D009223
disease	D009223
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	C535648
lymphoma	C535648
and	O
myotonic	D009223
dystrophy	D009223
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	D009136
dystrophy	D009136
,	O
and	O
sudden	O
atrial	D001281
fibrillation	D001281
following	O
one	O
cycle	O
of	O
doxorubicin	D004317
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	9606
.	O

Atrial	D001281
fibrillation	D001281
or	O
other	O
cardiac	D001145
arrhythmias	D001145
are	O
unusual	O
complications	O
in	O
patients	9606
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	D066126
toxicity	D066126
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	D001145
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	9606
.	O
NOTCH1	4851
and	O
SOX10	6663
are	O
Essential	O
for	O
Proliferation	O
and	O
Radiation	O
Resistance	O
of	O
Cancer	D009369
Stem	O
-	O
Like	O
Cells	O
in	O
Adenoid	D003528
Cystic	D003528
Carcinoma	D003528
.	O

PURPOSE	O
:	O
Although	O
the	O
existence	O
of	O
cancer	D009369
stem	O
cells	O
(	O
CSC	O
)	O
in	O
adenoid	D003528
cystic	D003528
carcinoma	D003528
(	O
ACC	D003528
)	O
has	O
been	O
proposed	O
,	O
lack	O
of	O
assays	O
for	O
their	O
propagation	O
and	O
uncertainty	O
about	O
molecular	O
markers	O
prevented	O
their	O
characterization	O
.	O

Our	O
objective	O
was	O
to	O
isolate	O
CSC	O
from	O
ACC	D003528
and	O
provide	O
insight	O
into	O
signaling	O
pathways	O
that	O
support	O
their	O
propagation	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
To	O
isolate	O
CSC	O
from	O
ACC	D003528
and	O
characterize	O
them	O
,	O
we	O
used	O
ROCK	6093
inhibitor	O
-	O
supplemented	O
cell	O
culture	O
,	O
immunomagnetic	O
cell	O
sorting	O
,	O
andin	O
vitro	O
/	O
in	O
vivoassays	O
for	O
CSC	O
viability	O
and	O
tumorigenicity	O
.	O

RESULTS	O
:	O
We	O
identified	O
in	O
ACC	D003528
CD133	8842
-	O
positive	O
CSC	O
that	O
expressed	O
NOTCH1	4851
and	O
SOX10	6663
,	O
formed	O
spheroids	O
,	O
and	O
initiated	O
tumors	D009369
in	O
nude	O
mice	10090
.	O

CD133	8842
(	O
+	O
)	O
ACC	D003528
cells	O
produced	O
activated	O
NOTCH1	4851
(	O
N1ICD	4851
)	O
and	O
generated	O
CD133	8842
(	O
-	O
)	O
cells	O
that	O
expressed	O
JAG1	182
as	O
well	O
as	O
neural	O
differentiation	O
factors	O
NR2F1	7025
,	O
NR2F2	7026
,	O
and	O
p27Kip1	1027
.	O

Knockdowns	O
of	O
NOTCH1	4851
,	O
SOX10	6663
,	O
and	O
their	O
common	O
effector	O
FABP7	2173
had	O
negative	O
effects	O
on	O
each	O
other	O
,	O
inhibited	O
spheroidogenesis	O
,	O
and	O
induced	O
cell	O
death	O
pointing	O
at	O
their	O
essential	O
roles	O
in	O
CSC	O
maintenance	O
.	O

Downstream	O
effects	O
of	O
FABP7	2173
knockdown	O
included	O
suppression	O
of	O
a	O
broad	O
spectrum	O
of	O
genes	O
involved	O
in	O
proliferation	O
,	O
ribosome	O
biogenesis	O
,	O
and	O
metabolism	O
.	O

Among	O
proliferation	O
-	O
linked	O
NOTCH1	4851
/	O
FABP7	2173
targets	O
,	O
we	O
identified	O
SKP2	6502
and	O
its	O
substrate	O
p27Kip1	1027
.	O

A	O
g	55851
-	O
secretase	55851
inhibitor	O
,	O
DAPT	C419410
,	O
selectively	O
depleted	O
CD133	8842
(	O
+	O
)	O
cells	O
,	O
suppressed	O
N1ICD	4851
and	O
SKP2	6502
,	O
induced	O
p27Kip1	1027
,	O
inhibited	O
ACC	D003528
growthin	O
vivo	O
,	O
and	O
sensitized	O
CD133	8842
(	O
+	O
)	O
cells	O
to	O
radiation	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
establish	O
in	O
the	O
majority	O
of	O
ACC	D003528
the	O
presence	O
of	O
a	O
previously	O
uncharacterized	O
population	O
of	O
CD133	8842
(	O
+	O
)	O
cells	O
with	O
neural	O
stem	O
properties	O
,	O
which	O
are	O
driven	O
by	O
SOX10	6663
,	O
NOTCH1	4851
,	O
and	O
FABP7	2173
.	O

Sensitivity	O
of	O
these	O
cells	O
to	O
Notch	4851
inhibition	O
and	O
their	O
dependence	O
on	O
SKP2	6502
offer	O
new	O
opportunities	O
for	O
targeted	O
ACC	D003528
therapies	O
.	O
The	O
impact	O
of	O
PPARa	5465
activation	O
on	O
whole	O
genome	O
gene	O
expression	O
in	O
human	9606
precision	O
cut	O
liver	O
slices	O
.	O

BACKGROUND	O
:	O
Studies	O
in	O
mice	10090
have	O
shown	O
that	O
PPARa	19013
is	O
an	O
important	O
regulator	O
of	O
lipid	D008055
metabolism	O
in	O
liver	O
and	O
key	O
transcription	O
factor	O
involved	O
in	O
the	O
adaptive	O
response	O
to	O
fasting	O
.	O

However	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
role	O
of	O
PPARa	5465
in	O
human	9606
liver	O
.	O

METHODS	O
:	O
Here	O
we	O
set	O
out	O
to	O
study	O
the	O
function	O
of	O
PPARa	5465
in	O
human	9606
liver	O
via	O
analysis	O
of	O
whole	O
genome	O
gene	O
regulation	O
in	O
human	9606
liver	O
slices	O
treated	O
with	O
the	O
PPARa	5465
agonist	O
Wy14643	C006253
.	O

RESULTS	O
:	O
Quantitative	O
PCR	O
indicated	O
that	O
PPARa	5465
is	O
well	O
expressed	O
in	O
human	9606
liver	O
and	O
human	9606
liver	O
slices	O
and	O
that	O
the	O
classical	O
PPARa	5465
targets	O
PLIN2	123
,	O
VLDLR	7436
,	O
ANGPTL4	51129
,	O
CPT1A	1374
and	O
PDK4	5166
are	O
robustly	O
induced	O
by	O
PPARa	5465
activation	O
.	O

Transcriptomics	O
analysis	O
indicated	O
that	O
617	O
genes	O
were	O
upregulated	O
and	O
665	O
genes	O
were	O
downregulated	O
by	O
PPARa	5465
activation	O
(	O
q	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

Many	O
genes	O
induced	O
by	O
PPARa	5465
activation	O
were	O
involved	O
in	O
lipid	D008055
metabolism	O
(	O
ACSL5	51703
,	O
AGPAT9	84803
,	O
FADS1	3992
,	O
SLC27A4	10999
)	O
,	O
xenobiotic	O
metabolism	O
(	O
POR	5447
,	O
ABCC2	1244
,	O
CYP3A5	1577
)	O
or	O
the	O
unfolded	O
protein	O
response	O
,	O
whereas	O
most	O
of	O
the	O
downregulated	O
genes	O
were	O
involved	O
in	O
immune	O
-	O
related	O
pathways	O
.	O

Among	O
the	O
most	O
highly	O
repressed	O
genes	O
upon	O
PPARa	5465
activation	O
were	O
several	O
chemokines	4283,6355,6372,6376
(	O
e	O
.	O
g	O
.	O

CXCL9	4283
-	O
11	4283
,	O
CCL8	6355
,	O
CX3CL1	6376
,	O
CXCL6	6372
)	O
,	O
interferon	3458
g	3458
-	O
induced	O
genes	O
(	O
e	O
.	O
g	O
.	O

IFITM1	8519
,	O
IFIT1	3434
,	O
IFIT2	3433
,	O
IFIT3	3437
)	O
and	O
numerous	O
other	O
immune	O
-	O
related	O
genes	O
(	O
e	O
.	O
g	O
.	O

TLR3	7098
,	O
NOS2	4843
,	O
and	O
LCN2	3934
)	O
.	O

Comparative	O
analysis	O
of	O
gene	O
regulation	O
by	O
Wy14643	C006253
between	O
human	9606
liver	O
slices	O
and	O
primary	O
human	9606
hepatocytes	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
gene	O
expression	O
by	O
PPARa	5465
is	O
much	O
better	O
captured	O
by	O
liver	O
slices	O
as	O
compared	O
to	O
primary	O
hepatocytes	O
.	O

In	O
particular	O
,	O
PPARa	5465
activation	O
markedly	O
suppressed	O
immunity	O
/	O
inflammation	D007249
-	O
related	O
genes	O
in	O
human	9606
liver	O
slices	O
but	O
not	O
in	O
primary	O
hepatocytes	O
.	O

Finally	O
,	O
several	O
putative	O
new	O
target	O
genes	O
of	O
PPARa	5465
were	O
identified	O
that	O
were	O
commonly	O
induced	O
by	O
PPARa	5465
activation	O
in	O
the	O
two	O
human	9606
liver	O
model	O
systems	O
,	O
including	O
TSKU	25987
,	O
RHOF	54509
,	O
CA12	771
and	O
VSIG10L	147645
.	O

CONCLUSION	O
:	O
Our	O
paper	O
demonstrates	O
the	O
suitability	O
and	O
superiority	O
of	O
human	9606
liver	O
slices	O
over	O
primary	O
hepatocytes	O
for	O
studying	O
the	O
functional	O
role	O
of	O
PPARa	5465
in	O
human	9606
liver	O
.	O

Our	O
data	O
underscore	O
the	O
major	O
role	O
of	O
PPARa	5465
in	O
regulation	O
of	O
hepatic	O
lipid	D008055
and	O
xenobiotic	O
metabolism	O
in	O
human	9606
liver	O
and	O
reveal	O
a	O
marked	O
immuno	O
-	O
suppressive	O
/	O
anti	O
-	O
inflammatory	D007249
effect	O
of	O
PPARa	5465
in	O
human	9606
liver	O
slices	O
that	O
may	O
be	O
therapeutically	O
relevant	O
for	O
non	D065626
-	O
alcoholic	D065626
fatty	D065626
liver	D065626
disease	D065626
.	O
Curcumin	D003474
decreases	O
specificity	6667,6670,6671
protein	6667,6670,6671
expression	O
in	O
bladder	D001749
cancer	D001749
cells	O
.	O

Curcumin	D003474
is	O
the	O
active	O
component	O
of	O
tumeric	O
,	O
and	O
this	O
polyphenolic	O
compound	O
has	O
been	O
extensively	O
investigated	O
as	O
an	O
anticancer	O
drug	O
that	O
modulates	O
multiple	O
pathways	O
and	O
genes	O
.	O

In	O
this	O
study	O
,	O
10	O
to	O
25	O
micromol	O
/	O
L	O
curcumin	D003474
inhibited	O
253JB	9606
-	O
V	9606
and	O
KU7	9606
bladder	D001749
cancer	D001749
cell	O
growth	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
induction	O
of	O
apoptosis	O
and	O
decreased	O
expression	O
of	O
the	O
proapoptotic	332
protein	332
survivin	332
and	O
the	O
angiogenic	2321,7422
proteins	2321,7422
vascular	7422
endothelial	7422
growth	7422
factor	7422
(	O
VEGF	7422
)	O
and	O
VEGF	2321
receptor	2321
1	2321
(	O
VEGFR1	2321
)	O
.	O

Because	O
expression	O
of	O
survivin	332
,	O
VEGF	7422
,	O
and	O
VEGFR1	2321
are	O
dependent	O
on	O
specificity	6667,6670,6671
protein	6667,6670,6671
(	O
Sp	6667,6670,6671
)	O
transcription	6667,6670,6671
factors	6667,6670,6671
,	O
we	O
also	O
investigated	O
the	O
effects	O
of	O
curcumin	D003474
on	O
Sp	6667,6670,6671
protein	O
expression	O
as	O
an	O
underlying	O
mechanism	O
for	O
the	O
apoptotic	O
and	O
antiangiogenic	O
activity	O
of	O
this	O
compound	O
.	O

The	O
results	O
show	O
that	O
curcumin	D003474
induced	O
proteasome	5698
-	O
dependent	O
down	O
-	O
regulation	O
of	O
Sp1	6667
,	O
Sp3	6670
,	O
and	O
Sp4	6671
in	O
253JB	9606
-	O
V	9606
and	O
KU7	9606
cells	O
.	O

Moreover	O
,	O
using	O
RNA	O
interference	O
with	O
small	O
inhibitory	O
RNAs	O
for	O
Sp1	6667
,	O
Sp3	6670
,	O
and	O
Sp4	6671
,	O
we	O
observed	O
that	O
curcumin	D003474
-	O
dependent	O
inhibition	O
of	O
nuclear	4790
factor	4790
kappaB	4790
(	O
NF	4790
-	O
kappaB	4790
)	O
-	O
dependent	O
genes	O
,	O
such	O
as	O
bcl	596
-	O
2	596
,	O
survivin	332
,	O
and	O
cyclin	595
D1	595
,	O
was	O
also	O
due	O
,	O
in	O
part	O
,	O
to	O
loss	O
of	O
Sp	6667,6670,6671
proteins	O
.	O

Curcumin	D003474
also	O
decreased	O
bladder	D001749
tumor	D001749
growth	O
in	O
athymic	O
nude	O
mice	10090
bearing	O
KU7	9606
cells	O
as	O
xenografts	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
Sp1	20683
,	O
Sp3	20687
,	O
and	O
Sp4	20688
protein	O
levels	O
in	O
tumors	D009369
.	O

These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
one	O
of	O
the	O
underlying	O
mechanisms	O
of	O
action	O
of	O
curcumin	D003474
as	O
a	O
cancer	D009369
chemotherapeutic	O
agent	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
expression	O
of	O
Sp	6667,6670,6671
transcription	6667,6670,6671
factors	6667,6670,6671
in	O
bladder	D001749
cancer	D001749
cells	O
.	O
Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	D039141
muscular	D039141
dystrophy	D039141
.	O

BACKGROUND	O
:	O
Oculopharyngeal	D039141
muscular	D039141
dystrophy	D039141
(	O
OPMD	D039141
)	O
is	O
a	O
late	O
onset	O
autosomal	D030342
dominant	D030342
muscle	D030342
disorder	D030342
.	O

OPMD	D039141
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	C019529
tract	O
in	O
the	O
polyadenylate	8106
binding	8106
-	O
protein	8106
nuclear	8106
1	8106
(	O
PABPN1	8106
)	O
gene	O
.	O

We	O
identified	O
and	O
characterized	O
a	O
PABPN1	8106
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	D039141
.	O

METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	D039141
family	O
.	O

Genetic	O
alterations	O
in	O
the	O
PABPN1	8106
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	D039141
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	8106
gene	O
.	O

The	O
normal	O
(	O
GCG	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
6	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
(	O
GCA	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
3GCG	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
sequence	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
was	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
replaced	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
by	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
(	O
GCG	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
6	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
(	O
GCA	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
(	O
GCG	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
4	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
(	O
GCA	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
)	O
3GCG	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
due	O
to	O
an	O
insertion	c|INS|(GCG)4GCA
of	c|INS|(GCG)4GCA
(	O
GCG	c|INS|(GCG)4GCA
)	O
4GCA	c|INS|(GCG)4GCA
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	D039141
subjects	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	D039141
patients	9606
in	O
the	O
literature	O
,	O
an	O
insertion	c|INS|(GCG)4GCA
of	c|INS|(GCG)4GCA
(	O
GCG	c|INS|(GCG)4GCA
)	O
4GCA	c|INS|(GCG)4GCA
in	O
the	O
PABPN1	8106
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	D039141
subjects	O
.	O

The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross	O
-	O
over	O
of	O
two	O
PABPN1	8106
alleles	O
.	O
A	O
novel	O
mutation	O
(	O
E333D	p|SUB|E|333|D
)	O
in	O
the	O
thyroid	6955
hormone	6955
beta	6955
receptor	6955
causing	O
resistance	D018382
to	D018382
thyroid	D018382
hormone	D018382
syndrome	D018382
.	O

Resistance	D018382
to	D018382
thyroid	D018382
hormone	D018382
(	O
RTH	D018382
)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	D013963
hormones	D013963
(	O
TH	D013963
)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	1081
stimulating	1081
hormone	1081
(	O
TSH	1081
)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	D013963
.	O

The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	6955
hormone	6955
beta	6955
receptor	6955
(	O
TRbeta	6955
)	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	D018382
mutation	O
(	O
E333D	p|SUB|E|333|D
)	O
located	O
in	O
the	O
large	O
carboxy	O
-	O
terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	6955
.	O

The	O
mutation	O
was	O
identified	O
in	O
a	O
22	O
-	O
year	O
-	O
old	O
French	O
woman	9606
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	D050177
.	O

Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	D013974
(	O
T4	D013974
:	O
20	O
.	O
8	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
8	O
.	O
5	O
-	O
18	O
)	O
)	O
and	O
triiodothyronine	D014284
(	O
T3	D014284
:	O
5	O
.	O
7	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
1	O
.	O
4	O
-	O
4	O
)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	1081
level	O
of	O
4	O
.	O
7	O
mU	O
/	O
ml	O
(	O
normal	O
,	O
0	O
.	O
4	O
-	O
4	O
)	O
.	O

Her	O
father	O
and	O
her	O
brother	O
'	O
s	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	D018382
.	O

Direct	O
sequencing	O
of	O
the	O
TRbeta	6955
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A	c|SUB|A|1284|C
>	O
C	c|SUB|A|1284|C
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	p|SUB|E|333|D
acid	p|SUB|E|333|D
333	p|SUB|E|333|D
by	p|SUB|E|333|D
aspartic	p|SUB|E|333|D
acid	p|SUB|E|333|D
residue	O
(	O
E333D	p|SUB|E|333|D
)	O
.	O

Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	6955
mutant	O
were	O
conducted	O
.	O

We	O
found	O
that	O
the	O
E333D	p|SUB|E|333|D
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	D014284
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	6256
X	6256
receptor	6256
(	O
RXR	6256
)	O
when	O
bound	O
to	O
DNA	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
E333D	p|SUB|E|333|D
TRbeta	6955
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2	O
-	O
and	O
DR4	O
-	O
TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	9606
TSHalpha	1081
promoter	O
.	O

Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
TRbeta	6955
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(	O
F2	O
-	O
TRE	O
)	O
and	O
a	O
negative	O
(	O
TSHalpha	1081
)	O
promoter	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	p|SUB|E|333|D
TRbeta	6955
mutation	O
is	O
responsible	O
for	O
the	O
RTH	D018382
phenotype	O
in	O
the	O
proposita	O
'	O
s	O
family	O
.	O
Cloning	O
of	O
human	9606
very	37
-	O
long	37
-	O
chain	37
acyl	37
-	O
coenzyme	37
A	37
dehydrogenase	37
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	9606
.	O

Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	9606
mitochondrial	O
very	37
-	O
long	37
-	O
chain	37
acyl	37
-	O
coenzyme	37
A	37
dehydrogenase	37
(	O
VLCAD	37
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O

PCR	O
-	O
amplified	O
VLCAD	37
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	C536353
-	O
deficient	C536353
patients	9606
.	O

In	O
both	O
patients	9606
,	O
a	O
105	c|DEL|1078-1182|
-	O
bp	c|DEL|1078-1182|
deletion	c|DEL|1078-1182|
encompassing	c|DEL|1078-1182|
bases	c|DEL|1078-1182|
1078	c|DEL|1078-1182|
-	O
1182	c|DEL|1078-1182|
in	O
VLCAD	37
cDNA	O
was	O
identified	O
.	O

The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	37
pre	O
-	O
mRNA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	C536353
deficiency	C536353
.	O

Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	9606
VLCAD	37
was	O
performed	O
in	O
the	O
patients	9606
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	C536353
of	C536353
the	C536353
normal	C536353
VLCAD	C536353
protein	C536353
causes	O
impaired	O
long	D005227
-	O
chain	D005227
fatty	D005227
acid	D005227
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	9606
fibroblasts	O
.	O

In	O
patient	9606
fibroblasts	O
,	O
raising	O
VLCAD	37
activity	O
to	O
approximately	O
20%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	D019308
acid	D019308
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	C536353
deficiency	C536353
.	O
Haplotype	O
structure	O
of	O
the	O
beta	153,154,155
adrenergic	153,154,155
receptor	153,154,155
genes	O
in	O
US	O
Caucasians	O
and	O
African	O
Americans	O
.	O

The	O
beta	153,154,155
-	O
adrenergic	153,154,155
receptors	153,154,155
(	O
beta	153,154,155
-	O
AR	153,154,155
)	O
are	O
G	O
protein	O
-	O
coupled	O
receptors	O
activated	O
by	O
epinephrine	D004837
and	O
norepinephrine	D009638
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
their	O
physiological	O
functions	O
.	O

Previously	O
,	O
three	O
beta	153,154,155
-	O
AR	153,154,155
genes	O
(	O
ADRB1	153
,	O
ADRB2	154
and	O
ADRB3	155
)	O
were	O
resequenced	O
,	O
identifying	O
polymorphisms	O
that	O
were	O
used	O
in	O
genetic	O
association	O
studies	O
of	O
cardiovascular	D002318,D008659
and	D002318,D008659
metabolic	D002318,D008659
disorders	D002318,D008659
.	O

These	O
studies	O
have	O
produced	O
intriguing	O
but	O
inconsistent	O
results	O
,	O
potentially	O
because	O
the	O
known	O
functional	O
variants	O
:	O
ADRB1	153
Arg389Gly	p|SUB|R|389|G
and	O
Gly49Ser	p|SUB|G|49|S
,	O
ADRB2	154
Arg16Gly	p|SUB|R|16|G
and	O
Gln27Glu	p|SUB|Q|27|E
,	O
and	O
ADRB3	155
Arg64Trp	p|SUB|R|64|W
provided	O
an	O
incomplete	O
picture	O
of	O
the	O
total	O
functional	O
diversity	O
at	O
these	O
genes	O
.	O

Therefore	O
,	O
we	O
created	O
marker	O
panels	O
for	O
each	O
beta	153,154,155
-	O
AR	153,154,155
gene	O
that	O
included	O
the	O
known	O
functional	O
markers	O
and	O
also	O
other	O
markers	O
evenly	O
spaced	O
and	O
with	O
sufficient	O
density	O
to	O
identify	O
haplotype	O
block	O
structure	O
and	O
to	O
maximize	O
haplotype	O
diversity	O
.	O

A	O
total	O
of	O
27	O
markers	O
were	O
genotyped	O
in	O
96	O
US	O
Caucasians	O
and	O
96	O
African	O
Americans	O
.	O

In	O
both	O
populations	O
and	O
for	O
each	O
gene	O
,	O
a	O
single	O
block	O
with	O
little	O
evidence	O
of	O
historical	O
recombination	O
was	O
observed	O
.	O

For	O
each	O
gene	O
,	O
haplotype	O
captured	O
most	O
of	O
the	O
information	O
content	O
of	O
each	O
functional	O
locus	O
,	O
even	O
if	O
that	O
locus	O
was	O
not	O
genotyped	O
,	O
and	O
presumably	O
haplotype	O
would	O
capture	O
the	O
signal	O
from	O
unknown	O
functional	O
loci	O
whose	O
alleles	O
are	O
of	O
moderate	O
abundance	O
.	O

This	O
study	O
demonstrates	O
the	O
utility	O
of	O
using	O
beta	153,154,155
-	O
AR	153,154,155
gene	O
haplotype	O
maps	O
and	O
marker	O
panels	O
as	O
tools	O
for	O
linkage	O
studies	O
on	O
beta	153,154,155
-	O
AR	153,154,155
function	O
.	O
Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2	1585
/	O
CYP11B1	1584
locus	O
and	O
postoperative	O
hypertension	D006973
risk	O
in	O
the	O
patients	9606
with	O
aldosterone	D000236
-	O
producing	D000236
adenomas	D000236
.	O

OBJECTIVES	O
:	O
Hypertension	D006973
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O

Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	D006973
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	1584,1585
synthesis	1584,1585
genes	1584,1585
(	O
CYP11B2	1585
,	O
CYP11B1	1584
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	D006973
in	O
Chinese	O
patients	9606
undergoing	O
adrenalectomy	O
for	O
aldosterone	D000236
-	O
producing	D000236
adenomas	D000236
(	O
APA	D000236
)	O
.	O

METHODS	O
:	O
Ninety	O
-	O
three	O
patients	9606
with	O
APA	D000236
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	D006973
.	O

All	O
patients	9606
were	O
genotyped	O
for	O
rs1799998	rs1799998
(	O
C	rs1799998
-	O
344	rs1799998
T	rs1799998
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	rs4539
(	O
A2718G	rs4539
)	O
within	O
CYP11B2	1585
and	O
rs6410	rs6410
(	O
G22	rs6410
5A	rs6410
)	O
,	O
rs6387	rs6387
(	O
A2803G	rs6387
)	O
within	O
CYP11B1	1584
.	O

The	O
associations	O
between	O
CYPB11B2	1585
/	O
CYP11B1	1584
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	D006973
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O
CYP11B2	1585
-	O
CYP11B1	1584
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	D006973
in	O
Chinese	O
patients	9606
undergoing	O
adrenalectomy	O
with	O
APA	D000236
(	O
P	O
=	O
.	O
006	O
)	O
.	O

Specifically	O
,	O
the	O
rs4539	rs4539
(	O
AA	O
)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	D006973
(	O
P	O
=	O
.	O
002	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(	O
AGACT	O
)	O
,	O
H2	O
(	O
AGAWT	O
)	O
,	O
and	O
H3	O
(	O
AGAWC	O
)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	D006973
(	O
P	O
=	O
.	O
01	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
005	O
after	O
Bonferroni	O
correction	O
)	O
.	O

Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	D006973
included	O
duration	O
of	O
hypertension	D006973
(	O
P	O
<	O
.	O
0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	D006973
(	O
P	O
=	O
.	O
001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.	O
015	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rs4539	rs4539
(	O
AA	O
)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	D006973
for	O
Chinese	O
patients	9606
treated	O
by	O
adrenalectomy	O
with	O
APA	D000236
.	O

DNA	O
polymorphisms	O
at	O
CYP11B2	1584,1585
/	O
B1	1584,1585
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	D006973
of	O
patients	9606
with	O
APA	D000236
.	O
Analysis	O
of	O
skin	D012878
cancer	D012878
risk	O
factors	O
in	O
immunosuppressed	O
renal	O
transplant	O
patients	9606
shows	O
high	O
levels	O
of	O
UV	O
-	O
specific	O
tandem	O
CC	c|SUB|C||T
to	c|SUB|C||T
TT	c|SUB|C||T
mutations	O
of	O
the	O
p53	7157
gene	O
.	O

Immunosuppressed	O
renal	O
transplant	O
recipients	O
(	O
RTRs	O
)	O
are	O
predisposed	O
to	O
non	D012878
-	O
melanoma	D012878
skin	D012878
cancers	D012878
(	O
NMSCs	D012878
)	O
,	O
predominantly	O
squamous	D002294
cell	D002294
carcinomas	D002294
(	O
SCCs	D002294
)	O
.	O

We	O
have	O
analyzed	O
skin	D012871
lesions	D012871
from	O
RTRs	O
with	O
aggressive	O
tumors	D009369
for	O
p53	7157
gene	O
modifications	O
,	O
the	O
presence	O
of	O
Human	10566
Papillomas	10566
Virus	10566
(	O
HPV	10566
)	O
DNA	O
in	O
relation	O
to	O
the	O
p53	7157
codon	O
72	O
genotype	O
and	O
polymorphisms	O
of	O
the	O
XPD	2068
repair	O
gene	O
.	O

We	O
detected	O
24	O
p53	7157
mutations	O
in	O
15	O
/	O
25	O
(	O
60%	O
)	O
NMSCs	D012878
,	O
1	O
deletion	O
and	O
23	O
base	O
substitutions	O
,	O
the	O
majority	O
(	O
78%	O
)	O
being	O
UV	O
-	O
specific	O
C	c|SUB|C||T
to	c|SUB|C||T
T	c|SUB|C||T
transitions	O
at	O
bipyrimidine	O
sites	O
.	O

Importantly	O
,	O
35%	O
(	O
6	O
/	O
17	O
)	O
are	O
tandem	O
mutations	O
,	O
including	O
4	O
UV	O
signature	O
CC	c|SUB|C||T
to	c|SUB|C||T
TT	c|SUB|C||T
transitions	O
possibly	O
linked	O
to	O
modulated	O
DNA	O
repair	O
caused	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	D016572
A	D016572
(	O
CsA	D016572
)	O
.	O

We	O
found	O
8	O
p53	7157
mutations	O
in	O
7	O
/	O
17	O
(	O
41%	O
)	O
precancerous	D011230
actinic	D055623
keratosis	D055623
(	O
AK	D055623
)	O
,	O
suggesting	O
that	O
p53	7157
mutations	O
are	O
early	O
events	O
in	O
RTR	O
skin	D012878
carcinogenesis	D012878
.	O

Immunohistochemical	O
analysis	O
shows	O
a	O
good	O
correlation	O
between	O
p53	7157
accumulation	O
and	O
mutations	O
.	O

HPV	10566
DNA	O
was	O
detected	O
in	O
78%	O
of	O
skin	D012871
lesions	D012871
(	O
60%	O
Basal	D002280
Cell	D002280
Carcinomas	D002280
,	O
82%AK	O
and	O
79%	O
SCCs	D002294
)	O
.	O

Thus	O
,	O
immunosuppression	O
has	O
increased	O
the	O
risk	O
of	O
infections	D007239
by	O
HPVs	10566
,	O
predominantly	O
epidermodysplasia	D004819
verruciformis	D004819
,	O
speculated	O
to	O
play	O
a	O
role	O
in	O
skin	D012878
cancer	D012878
development	O
.	O

No	O
association	O
is	O
found	O
between	O
HPV	10566
status	O
and	O
p53	7157
mutation	O
.	O

Moreover	O
,	O
p53	7157
codon	O
72	O
or	O
frequencies	O
of	O
three	O
XPD	2068
genotypes	O
of	O
RTRs	O
are	O
comparable	O
with	O
control	O
populations	O
.	O

The	O
p53	7157
mutation	O
spectrum	O
,	O
presenting	O
a	O
high	O
level	O
of	O
CC	c|SUB|C||T
to	c|SUB|C||T
TT	c|SUB|C||T
mutations	O
,	O
shows	O
that	O
the	O
UV	O
component	O
of	O
sunlight	O
is	O
the	O
major	O
risk	O
factor	O
and	O
modulated	O
DNA	O
repair	O
by	O
immunosuppressive	O
drug	O
treatment	O
may	O
be	O
significant	O
in	O
the	O
skin	D012878
carcinogenesis	D012878
of	O
RTRs	O
.	O
Tumor	D009369
associated	O
antigen	O
recognition	O
by	O
autologous	O
serum	O
in	O
patients	9606
with	O
breast	D001943
cancer	D001943
.	O

Breast	D001943
cancer	D001943
accounts	O
for	O
30	O
-	O
40%	O
of	O
all	O
deaths	O
from	O
cancers	D009369
in	O
females	O
.	O

In	O
an	O
effort	O
to	O
identify	O
tumor	D009369
associated	O
antigens	O
that	O
may	O
be	O
useful	O
for	O
immunotherapy	O
,	O
we	O
utilized	O
serological	O
analysis	O
of	O
recombinant	O
cDNA	O
expression	O
libraries	O
(	O
SEREX	O
)	O
technique	O
to	O
identify	O
breast	D001943
cancer	D001943
-	O
associated	O
antigens	O
.	O

SEREX	O
screening	O
of	O
cDNA	O
expression	O
libraries	O
derived	O
from	O
3	O
breast	D001943
cancer	D001943
patients	9606
identified	O
a	O
total	O
of	O
88	O
positive	O
clones	O
(	O
bcg	O
-	O
1	O
to	O
bcg	O
-	O
88	O
)	O
,	O
including	O
27	O
hitherto	O
unknown	O
sequences	O
.	O

The	O
cDNA	O
sequences	O
and	O
mRNA	O
expression	O
patterns	O
were	O
characterized	O
.	O

Seroreactivity	O
of	O
the	O
SEREX	O
clones	O
were	O
determined	O
in	O
sera	O
from	O
75	O
breast	D001943
cancer	D001943
patients	9606
,	O
75	O
colon	D015179
cancer	D015179
patients	9606
,	O
and	O
25	O
healthy	O
donors	O
.	O

Expression	O
analysis	O
on	O
a	O
cDNA	O
panel	O
from	O
17	O
different	O
normal	O
tissues	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
revealed	O
tissue	O
restricted	O
mRNA	O
expression	O
of	O
2	O
of	O
the	O
27	O
unknown	O
antigens	O
.	O

Bcg	O
-	O
72	O
is	O
expressed	O
only	O
in	O
breast	O
,	O
prostate	O
and	O
thymus	O
,	O
while	O
bcg	O
-	O
84	O
is	O
expressed	O
at	O
moderate	O
levels	O
in	O
testis	O
,	O
spleen	O
and	O
breast	O
.	O

The	O
other	O
25	O
unknown	O
antigens	O
were	O
expressed	O
in	O
most	O
other	O
tissues	O
.	O

Serologic	O
assay	O
revealed	O
that	O
7	O
out	O
of	O
the	O
88	O
clones	O
showed	O
reactivity	O
to	O
at	O
least	O
one	O
serum	O
from	O
either	O
75	O
breast	O
or	O
75	O
colon	D015179
cancer	D015179
patients	9606
.	O

These	O
clones	O
did	O
not	O
react	O
with	O
sera	O
from	O
a	O
panel	O
of	O
25	O
healthy	O
adult	O
individuals	O
.	O

Our	O
results	O
demonstrate	O
the	O
utility	O
of	O
the	O
SEREX	O
approach	O
for	O
the	O
identification	O
of	O
potential	O
tumor	D009369
associated	O
antigens	O
in	O
human	9606
breast	D001943
cancer	D001943
.	O
The	O
M235T	rs699
polymorphism	O
of	O
the	O
angiotensinogen	183
gene	O
in	O
South	O
Indian	O
patients	9606
of	O
hypertrophic	D002312
cardiomyopathy	D002312
.	O

INTRODUCTION	O
:	O
Hypertrophic	D002312
cardiomyopathy	D002312
(	O
HCM	D002312
)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	D006331
disease	D006331
with	O
a	O
diverse	O
clinical	O
course	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	rs699
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	183
(	O
AGT	183
)	O
gene	O
with	O
HCM	D002312
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

Subjects	O
and	O
methods	O
.	O

One	O
-	O
hundred	O
and	O
fifty	O
HCM	D002312
(	O
90	O
sporadic	D002312
hypertrophic	D002312
cardiomyopathy	D002312
[	O
SHCM	D002312
]	O
and	O
60	O
familial	D024741
hypertrophic	D024741
cardiomyopathy	D024741
[	O
FHCM	D024741
]	O
)	O
patients	9606
and	O
165	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	D006973
and	O
left	D017379
ventricular	D017379
hypertrophy	D017379
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	183
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	rs699
to	rs699
threonine	rs699
substitution	rs699
at	rs699
codon	rs699
235	rs699
(	O
M235T	rs699
)	O
of	O
exon	O
2	O
,	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	-
.	O

RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
between	O
the	O
SHCM	D002312
patients	9606
and	O
controls	O
.	O

The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	D024741
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	183
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	D002312
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	D024741
.	O
Gankyrin	53380
induces	O
STAT3	20848
activation	O
in	O
tumor	D009369
microenvironment	O
and	O
sorafenib	D000077157
resistance	O
in	O
hepatocellular	D006528
carcinoma	D006528
.	O

Most	O
hepatocellular	D006528
carcinomas	D006528
(	O
HCC	D006528
)	O
develop	O
as	O
a	O
result	O
of	O
chronic	D007249
liver	D007249
inflammation	D007249
.	O

We	O
have	O
shown	O
that	O
the	O
oncoprotein	53380
gankyrin	53380
is	O
critical	O
for	O
inflammation	D007249
-	O
induced	O
tumorigenesis	D009369
in	O
the	O
colon	O
.	O

Although	O
the	O
in	O
vitro	O
function	O
of	O
gankyrin	5716
is	O
well	O
known	O
,	O
its	O
role	O
in	O
vivo	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
gankyrin	53380
in	O
the	O
tumor	D009369
microenvironment	O
of	O
mice	10090
with	O
liver	O
parenchymal	O
cell	O
-	O
specific	O
gankyrin	53380
ablation	O
(	O
Alb	11657
-	O
Cre	O
;	O
gankyrin	53380
(	O
f	O
/	O
f	O
)	O
)	O
and	O
gankyrin	53380
deletion	O
both	O
in	O
liver	O
parenchymal	O
and	O
non	O
-	O
parenchymal	O
cells	O
(	O
Mx1	17857
-	O
Cre	O
;	O
gankyrin	53380
(	O
f	O
/	O
f	O
)	O
)	O
.	O

Gankyrin	5716
upregulates	O
vascular	22339
endothelial	22339
growth	22339
factor	22339
expression	O
in	O
tumor	D009369
cells	O
.	O

Gankyrin	53380
binds	O
to	O
Src	15170
homology	15170
2	15170
domain	15170
-	O
containing	15170
protein	15170
tyrosine	15170
phosphatase	15170
-	O
1	15170
(	O
SHP	15170
-	O
1	15170
)	O
,	O
mainly	O
expressed	O
in	O
liver	O
non	O
-	O
parenchymal	O
cells	O
,	O
resulting	O
in	O
phosphorylation	O
and	O
activation	O
of	O
signal	20848
transducer	20848
and	20848
activator	20848
of	20848
transcription	20848
3	20848
(	O
STAT3	20848
)	O
.	O

Gankyrin	53380
deficiency	O
in	O
non	O
-	O
parenchymal	O
cells	O
,	O
but	O
not	O
in	O
parenchymal	O
cells	O
,	O
reduced	O
STAT3	20848
activity	O
,	O
interleukin	16193
(	O
IL	16193
)	O
-	O
6	16193
production	O
,	O
and	O
cancer	D009369
stem	O
cell	O
marker	O
(	O
Bmi1	12151
and	O
epithelial	17075
cell	17075
adhesion	17075
molecule	17075
[	O
EpCAM	17075
]	O
)	O
expression	O
,	O
leading	O
to	O
attenuated	O
tumorigenic	D009369
potential	O
.	O

Chronic	D007249
inflammation	D007249
enhances	O
gankyrin	5716
expression	O
in	O
the	O
human	9606
liver	O
.	O

Gankyrin	5716
expression	O
in	O
the	O
tumor	D009369
microenvironment	O
is	O
negatively	O
correlated	O
with	O
progression	O
-	O
free	O
survival	O
in	O
patients	9606
undergoing	O
sorafenib	D000077157
treatment	O
for	O
HCC	D006528
.	O

Thus	O
,	O
gankyrin	53380
appears	O
to	O
play	O
a	O
critical	O
oncogenic	O
function	O
in	O
tumor	D009369
microenvironment	O
and	O
may	O
be	O
a	O
potential	O
target	O
for	O
developing	O
therapeutic	O
and	O
preventive	O
strategies	O
against	O
HCC	D006528
.	O
Effects	O
of	O
the	O
cyclooxygenase	5743
-	O
2	5743
specific	O
inhibitor	O
valdecoxib	C406224
versus	O
nonsteroidal	D000894
antiinflammatory	D000894
agents	D000894
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	D013927
events	O
in	O
patients	9606
with	O
arthritis	D001168
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	D013927
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	5743
(	O
COX	5743
)	O
-	O
2	5743
-	O
specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	D000894
antiinflammatory	D000894
drugs	D000894
(	O
NSAIDs	D000894
)	O
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	C406224
,	O
a	O
new	O
COX	5743
-	O
2	5743
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	9606
with	O
osteoarthritis	D010003
and	O
rheumatoid	D001172
arthritis	D001172
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	D013927
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	D013927
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	C406224
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	D000894
(	O
diclofenac	D004008
75	O
mg	O
bid	O
,	O
ibuprofen	D007052
800	O
mg	O
tid	O
,	O
or	O
naproxen	D009288
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	D010003
and	O
rheumatoid	D001172
arthritis	D001172
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	9606
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low	O
-	O
dose	O
(	O
<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	D001241
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	D001241
(	O
n	O
=	O
6883	O
)	O
.	O

Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	D013927
events	O
were	O
similar	O
for	O
valdecoxib	C406224
,	O
NSAIDs	D000894
,	O
and	O
placebo	O
.	O

The	O
risk	O
of	O
serious	O
thrombotic	D013927
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	C406224
dose	O
.	O

Thrombotic	D013927
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	D001241
users	O
than	O
nonusers	O
of	O
aspirin	D001241
(	O
placebo	O
,	O
1	O
.	O
4%	O
vs	O
.	O

0%	O
;	O
valdecoxib	C406224
,	O
1	O
.	O
7%	O
vs	O
.	O

0	O
.	O
2%	O
;	O
NSAIDs	D000894
,	O
1	O
.	O
9%	O
vs	O
.	O

0	O
.	O
5%	O
)	O
.	O

The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	D001241
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	C406224
doses	O
.	O

Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	C406224
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	D013927
events	O
relative	O
to	O
nonselective	O
NSAIDs	D000894
or	O
placebo	O
in	O
osteoarthritis	D010003
and	O
rheumatoid	D001172
arthritis	D001172
patients	9606
in	O
controlled	O
clinical	O
trials	O
.	O
Metallothionein	4495
-	O
1	4495
as	O
a	O
biomarker	O
of	O
altered	O
redox	O
metabolism	O
in	O
hepatocellular	D006528
carcinoma	D006528
cells	O
exposed	O
to	O
sorafenib	D000077157
.	O

BACKGROUND	O
:	O
Sorafenib	D000077157
,	O
a	O
kinase	O
inhibitor	O
active	O
against	O
various	O
solid	O
tumours	D009369
,	O
induces	O
oxidative	O
stress	O
and	O
ferroptosis	O
,	O
a	O
new	O
form	O
of	O
oxidative	O
necrosis	D009336
,	O
in	O
some	O
cancer	D009369
cells	O
.	O

Clinically	O
-	O
applicable	O
biomarkers	O
that	O
reflect	O
the	O
impact	O
of	O
sorafenib	D000077157
on	O
the	O
redox	O
metabolism	O
of	O
cancer	D009369
cells	O
are	O
lacking	O
.	O

METHODS	O
:	O
We	O
used	O
gene	O
expression	O
microarrays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
immunoblot	O
,	O
protein	O
-	O
specific	O
ELISA	O
,	O
and	O
gene	O
reporter	O
constructs	O
encoding	O
the	O
enzyme	O
luciferase	O
to	O
study	O
the	O
response	O
of	O
a	O
panel	O
of	O
cancer	D009369
cells	O
to	O
sorafenib	D000077157
.	O

Tumour	D009369
explants	O
prepared	O
from	O
surgical	O
hepatocellular	D006528
carcinoma	D006528
(	O
HCC	D006528
)	O
samples	O
and	O
serum	O
samples	O
obtained	O
from	O
HCC	D006528
patients	9606
receiving	O
sorafenib	D000077157
were	O
also	O
used	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
genes	O
of	O
the	O
metallothionein	4495
-	O
1	4495
(	O
MT1	4495
)	O
family	O
are	O
induced	O
in	O
the	O
HCC	D006528
cell	O
line	O
Huh7	9606
exposed	O
to	O
sorafenib	D000077157
.	O

Sorafenib	D000077157
increased	O
the	O
expression	O
of	O
MT1G	4495
mRNA	O
in	O
a	O
panel	O
of	O
human	9606
cancer	D009369
cells	O
,	O
an	O
effect	O
that	O
was	O
not	O
observed	O
with	O
eight	O
other	O
clinically	O
-	O
approved	O
kinase	O
inhibitors	O
.	O

We	O
identified	O
the	O
minimal	O
region	O
of	O
the	O
MT1G	4495
promoter	O
that	O
confers	O
inducibility	O
by	O
sorafenib	D000077157
to	O
a	O
133	O
base	O
pair	O
region	O
containing	O
an	O
Anti	O
-	O
oxidant	O
Response	O
Element	O
(	O
ARE	O
)	O
and	O
showed	O
the	O
essential	O
role	O
of	O
the	O
transcription	O
factor	O
NRF2	4780
(	O
Nuclear	4780
factor	4780
erythroid	4780
2	4780
-	O
Related	4780
Factor	4780
2	4780
)	O
.	O

We	O
examined	O
the	O
clinical	O
relevance	O
of	O
our	O
findings	O
by	O
analysing	O
the	O
regulation	O
of	O
MT1G	4495
in	O
five	O
tumour	D009369
explants	O
prepared	O
from	O
surgical	O
HCC	D006528
samples	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
MT1	4495
increase	O
in	O
the	O
serum	O
of	O
some	O
HCC	D006528
patients	9606
receiving	O
sorafenib	D000077157
,	O
and	O
found	O
an	O
association	O
with	O
reduced	O
overall	O
survival	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
MT1	4495
constitute	O
a	O
biomarker	O
adapted	O
for	O
exploring	O
the	O
impact	O
of	O
sorafenib	D000077157
on	O
the	O
redox	O
metabolism	O
of	O
cancer	D009369
cells	O
.	O
Familial	O
glucocorticoid	2908
receptor	2908
haploinsufficiency	O
by	O
non	O
-	O
sense	O
mediated	O
mRNA	O
decay	O
,	O
adrenal	D000312
hyperplasia	D000312
and	O
apparent	C537422
mineralocorticoid	C537422
excess	C537422
.	O

Primary	O
glucocorticoid	C564221
resistance	C564221
(	O
OMIM	OMIM:138040
138040	OMIM:138040
)	O
is	O
a	O
rare	O
hereditary	D030342
disease	D030342
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	D005938
action	O
,	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	2908
receptor	2908
(	O
GR	2908
)	O
.	O

Investigation	O
of	O
adrenal	C538238
incidentalomas	C538238
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
)	O
,	O
prone	O
to	O
cortisol	C535280
resistance	C535280
,	O
bilateral	D000312
adrenal	D000312
hyperplasia	D000312
,	O
arterial	O
hypertension	D006973
and	O
hypokalemia	D007008
.	O

This	O
phenotype	O
exacerbated	O
over	O
time	O
,	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p	p|SUB|R|469|X
.	O
R469	p|SUB|R|469|X
[	O
R	p|SUB|R|469|X
,	O
X	p|SUB|R|469|X
]	O
reported	O
to	O
date	O
for	O
the	O
GR	2908
,	O
replacing	O
an	O
arginine	p|SUB|R|469|X
(	O
CGA	p|SUB|R|469|X
)	O
by	p|SUB|R|469|X
a	p|SUB|R|469|X
stop	p|SUB|R|469|X
(	O
TGA	p|SUB|R|469|X
)	O
at	p|SUB|R|469|X
amino	p|SUB|R|469|X
-	O
acid	p|SUB|R|469|X
469	p|SUB|R|469|X
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
receptor	O
.	O

In	O
vitro	O
,	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50	O
-	O
kDa	O
GR	2908
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
,	O
devoid	O
of	O
hormone	O
-	O
dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O

In	O
the	O
proband	O
'	O
s	O
fibroblasts	O
,	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O

The	O
absence	O
of	O
detectable	O
mutated	O
GR	2908
mRNA	O
was	O
accompanied	O
by	O
a	O
50%	O
reduction	O
in	O
wild	O
type	O
GR	2908
transcript	O
and	O
protein	O
.	O

This	O
reduced	O
GR	2908
expression	O
leads	O
to	O
a	O
significantly	O
below	O
-	O
normal	O
induction	O
of	O
glucocorticoid	D005938
-	O
induced	O
target	O
genes	O
,	O
FKBP5	2289
in	O
fibroblasts	O
.	O

We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	D005938
signaling	O
dysfunction	O
involved	O
GR	2908
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	2908
transcript	O
through	O
a	O
nonsense	O
-	O
mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine	D004640
-	O
treated	O
propositus	O
'	O
fibroblasts	O
.	O

GR	2908
haploinsufficiency	O
leads	O
to	O
hypertension	D006973
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	4306
receptor	4306
by	O
elevated	O
cortisol	D006854
rather	O
than	O
to	O
increased	O
mineralocorticoid	D008901
production	O
reported	O
in	O
primary	O
glucocorticoid	C564221
resistance	C564221
.	O

Indeed	O
,	O
apparent	C537422
mineralocorticoid	C537422
excess	C537422
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone	D013761
-	O
tetrahydrocortisol	D013760
ratio	O
in	O
affected	O
patients	9606
,	O
revealing	O
reduced	O
glucocorticoid	D005938
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b	3291
-	O
hydroxysteroid	3291
dehydrogenase	3291
type	3291
2	3291
,	O
a	O
GR	2908
regulated	O
gene	O
.	O

We	O
propose	O
thus	O
that	O
GR	2908
haploinsufficiency	O
compromises	O
glucocorticoid	D005938
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	D003480
,	O
incidentally	O
revealed	O
bilateral	D000312
adrenal	D000312
hyperplasia	D000312
and	O
mineralocorticoid	D008901
-	O
independent	O
hypertension	D006973
.	O
Genetic	O
alterations	O
in	O
primary	O
glioblastomas	D005909
in	O
Japan	O
.	O

Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	D005909
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	D009369
from	O
mainly	O
caucasian	O
patients	9606
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	D005909
in	O
Japanese	O
patients	9606
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	7157
mutations	O
in	O
16	O
of	O
73	O
(	O
22%	O
)	O
glioblastomas	D005909
and	O
PTEN	5728
mutations	O
in	O
13	O
of	O
63	O
(	O
21%	O
)	O
cases	O
analyzed	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
EGFR	1956
amplification	O
in	O
25	O
of	O
77	O
(	O
32%	O
)	O
cases	O
and	O
p16	1029
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(	O
42%	O
)	O
cases	O
.	O

Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(	O
69%	O
)	O
glioblastomas	D005909
.	O

The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	D005909
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O

As	O
previously	O
observed	O
for	O
glioblastomas	D005909
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	1956
amplification	O
and	O
p16	1029
deletion	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	7157
mutations	O
and	O
p16	1029
deletion	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
in	O
glioblastomas	D005909
in	O
Japan	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	D005909
patients	9606
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18	O
-	O
21	O
)	O
of	O
the	O
EGFR	1956
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(	O
3%	O
)	O
glioblastomas	D005909
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(	O
5%	O
)	O
glioblastomas	D005909
in	O
Switzerland	O
.	O

The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	p|SUB|Q|787|Q
787	p|SUB|Q|787|Q
CAG	p|SUB|Q|787|Q
/	O
CAA	p|SUB|Q|787|Q
(	O
Gln	p|SUB|Q||Q
/	O
Gln	p|SUB|Q||Q
)	O
in	O
glioblastomas	D005909
in	O
Japan	O
were	O
G	O
/	O
G	O
(	O
82	O
.	O
4%	O
)	O
,	O
G	O
/	O
A	O
(	O
10	O
.	O
8%	O
)	O
,	O
A	O
/	O
A	O
(	O
6	O
.	O
8%	O
)	O
,	O
corresponding	O
to	O
G	O
0	O
.	O
878	O
versus	O
A	O
0	O
.	O
122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	D005909
in	O
Switzerland	O
:	O
G	O
/	O
G	O
(	O
27	O
.	O
2%	O
)	O
,	O
G	O
/	O
A	O
(	O
28	O
.	O
4%	O
)	O
,	O
A	O
/	O
A	O
(	O
44	O
.	O
4%	O
)	O
,	O
corresponding	O
to	O
G	O
0	O
.	O
414	O
versus	O
A	O
0	O
.	O
586	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	D005909
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	1956
gene	O
.	O
Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	411
B	411
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	D009087
type	D009087
VI	D009087
patient	9606
.	O

Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p	p|SUB|R|315|X
.	O
R315X	p|SUB|R|315|X
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	411
B	411
(	O
ARSB	411
)	O
gene	O
in	O
a	O
mucopolysaccharidosis	D009087
type	D009087
VI	D009087
patient	9606
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O

Patient	9606
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	411
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c	c|DEL|899_1142|
.	O
899	c|DEL|899_1142|
-	O
1142del	c|DEL|899_1142|
.	O

As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	411
gene	O
.	O

This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g	g|DEL|99367_102002|
.	O
99367	g|DEL|99367_102002|
-	O
102002del	g|DEL|99367_102002|
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O

We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
in	O
13%	O
of	O
age	O
-	O
matched	O
Czech	O
children	O
with	O
primary	D008831
microcephaly	D008831
.	O

The	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
is	O
a	O
rare	O
autosomal	D043171
recessive	D043171
chromosomal	D043171
instability	D043171
disorder	D043171
characterized	O
by	O
early	O
growth	D006130
retardation	D006130
,	O
congenital	D008831
microcephaly	D008831
,	O
immunodeficiency	D007153
,	O
borderline	O
mental	O
development	O
,	O
and	O
a	O
high	O
tendency	O
to	O
lymphoreticular	D049932
malignancies	D049932
.	O

Most	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
patients	9606
are	O
of	O
Slavonic	O
origin	O
,	O
and	O
all	O
of	O
them	O
known	O
so	O
far	O
carry	O
a	O
founder	O
homozygous	O
5	c|DEL||5
nucleotide	c|DEL||5
deletion	c|DEL||5
in	O
the	O
NBS1	4683
gene	O
.	O

Microcephaly	D008831
was	O
present	O
in	O
100%	O
of	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
patients	9606
in	O
a	O
recent	O
large	O
international	O
cooperative	O
study	O
.	O

The	O
frequency	O
of	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
among	O
children	O
with	O
primary	D008831
microcephaly	D008831
was	O
not	O
known	O
.	O

Early	O
correct	O
diagnosis	O
of	O
the	O
syndrome	O
is	O
crucial	O
for	O
appropriate	O
preventive	O
care	O
and	O
therapy	O
.	O

We	O
tested	O
67	O
Czech	O
patients	9606
of	O
different	O
ages	O
with	O
simple	O
microcephaly	O
for	O
the	O
presence	O
of	O
the	O
most	O
common	O
mutation	O
in	O
the	O
NBS1	4683
gene	O
.	O

Three	O
new	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
cases	O
were	O
detected	O
in	O
this	O
cohort	O
,	O
representing	O
4	O
.	O
5%	O
of	O
the	O
cohort	O
.	O

All	O
these	O
newly	O
diagnosed	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
patients	9606
were	O
younger	O
than	O
10	O
months	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

They	O
were	O
all	O
born	O
within	O
a	O
2	O
.	O
5	O
-	O
year	O
period	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
67	O
children	O
in	O
the	O
cohort	O
were	O
born	O
within	O
this	O
2	O
.	O
5	O
-	O
year	O
period	O
,	O
representing	O
a	O
13%	O
incidence	O
of	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
.	O

Frequency	O
of	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
heterozygotes	O
among	O
infants	O
in	O
the	O
Czech	O
Republic	O
is	O
1	O
:	O
130	O
-	O
158	O
and	O
the	O
birth	O
rate	O
is	O
90	O
,	O
000	O
per	O
year	O
,	O
therefore	O
in	O
the	O
time	O
span	O
of	O
2	O
.	O
5	O
years	O
,	O
three	O
new	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
homozygotes	O
are	O
expected	O
to	O
be	O
born	O
.	O

Therefore	O
we	O
assume	O
that	O
by	O
DNA	O
testing	O
of	O
Czech	O
primary	O
microcephalic	O
children	O
it	O
is	O
possible	O
to	O
detect	O
all	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
patients	9606
to	O
be	O
expected	O
.	O

The	O
age	O
at	O
correct	O
diagnosis	O
was	O
lowered	O
from	O
7	O
.	O
1	O
years	O
at	O
the	O
time	O
before	O
DNA	O
testing	O
,	O
to	O
well	O
under	O
1	O
year	O
of	O
age	O
.	O

All	O
new	O
Nijmegen	D049932
breakage	D049932
syndrome	D049932
patients	9606
could	O
receive	O
appropriate	O
preventive	O
care	O
,	O
which	O
should	O
significantly	O
improve	O
their	O
life	O
expectancy	O
and	O
prognosis	O
.	O
CTR9	22083
/	O
PAF1c	22083,54624,76246
regulates	O
molecular	O
lineage	O
identity	O
,	O
histone	260423
H3K36	260423
trimethylation	O
and	O
genomic	O
imprinting	O
during	O
preimplantation	O
development	O
.	O

Genome	O
-	O
wide	O
epigenetic	O
reprogramming	O
is	O
required	O
for	O
successful	O
preimplantation	O
development	O
.	O

Inappropriate	O
or	O
deficient	O
chromatin	O
regulation	O
can	O
result	O
in	O
defective	O
lineage	O
specification	O
and	O
loss	O
of	O
genomic	O
imprinting	O
,	O
compromising	O
normal	O
development	O
.	O

Here	O
we	O
report	O
that	O
two	O
members	O
of	O
the	O
RNA	22083,54624,76246
polymerase	22083,54624,76246
II	22083,54624,76246
associated	22083,54624,76246
factor	22083,54624,76246
,	O
homolog	22083,54624,76246
(	O
Saccharomyces	22083,54624,76246
cerevisiae	22083,54624,76246
)	O
complex	22083,54624,76246
(	O
PAF1	22083,54624,76246
complex	22083,54624,76246
)	O
components	O
,	O
Ctr9	22083
and	O
Rtf1	76246
,	O
are	O
required	O
during	O
mammalian	O
preimplantation	O
development	O
.	O

We	O
demonstrate	O
that	O
Ctr9	22083
-	O
deficient	O
embryos	O
fail	O
to	O
correctly	O
specify	O
lineages	O
at	O
the	O
blastocyst	O
stage	O
.	O

Expression	O
of	O
some	O
lineage	O
specific	O
factors	O
is	O
markedly	O
reduced	O
in	O
Ctr9	22083
knockdown	O
embryos	O
,	O
including	O
Eomes	13813
,	O
Elf5	13711
and	O
Sox2	20674
,	O
while	O
others	O
are	O
inappropriately	O
expressed	O
(	O
Oct4	18999
,	O
Nanog	71950
,	O
Gata6	14465
,	O
Fgf4	14175
and	O
Sox17	20671
)	O
.	O

We	O
also	O
show	O
that	O
several	O
imprinted	O
genes	O
(	O
Mest	17294
,	O
Peg3	18616
,	O
Snrpn	20646
and	O
Meg3	17263
)	O
are	O
aberrantly	O
expressed	O
although	O
allele	O
specific	O
DNA	O
methylation	O
is	O
not	O
altered	O
.	O

We	O
document	O
a	O
loss	O
of	O
histone	260423
H3	260423
lysine	c|Allele|K|36
36	c|Allele|K|36
trimethylation	O
(	O
H3K36me3	260423
)	O
in	O
Ctr9	22083
-	O
deficient	O
embryos	O
and	O
confirm	O
that	O
knockdown	O
of	O
either	O
Setd2	235626
or	O
Rtf1	76246
results	O
in	O
similar	O
phenotypes	O
.	O

These	O
findings	O
show	O
that	O
the	O
PAF1	22083,54624,76246
complex	22083,54624,76246
is	O
required	O
for	O
mammalian	O
development	O
,	O
likely	O
through	O
regulation	O
of	O
H3K36me3	260423
,	O
and	O
indicate	O
functional	O
conservation	O
of	O
the	O
PAF1	22083,54624,76246
complex	22083,54624,76246
from	O
yeast	4932
to	O
mammals	O
in	O
vivo	O
.	O
Salidroside	C009172
Ameliorates	O
Renal	D007674
Interstitial	D007674
Fibrosis	D007674
by	O
Inhibiting	O
the	O
TLR4	21898,7099
/	O
NF	18033,4790
-	O
kappaB	18033,4790
and	O
MAPK	26413,5594
Signaling	O
Pathways	O
.	O

Salidroside	C009172
(	O
Sal	C009172
)	O
is	O
an	O
active	O
ingredient	O
that	O
is	O
isolated	O
from	O
Rhodiola	203015
rosea	203015
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
anti	O
-	O
inflammatory	D007249
activities	O
and	O
a	O
renal	O
protective	O
effect	O
.	O

However	O
,	O
the	O
role	O
of	O
Sal	C009172
on	O
renal	D007674
fibrosis	D007674
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Here	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
is	O
to	O
test	O
the	O
protective	O
effects	O
of	O
Sal	C009172
against	O
renal	D007674
interstitial	D007674
fibrosis	D007674
(	O
RIF	D007674
)	O
,	O
and	O
to	O
explore	O
the	O
underlying	O
mechanisms	O
using	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
the	O
unilateral	D014517
ureteric	D014517
obstruction	D014517
(	O
UUO	D014517
)	O
or	O
folic	D005492
acid	D005492
(	O
FA	D005492
)	O
-	O
induced	O
mice	10090
renal	D007674
interstitial	D007674
fibrosis	D007674
in	O
vivo	O
and	O
the	O
transforming	21803
growth	21803
factor	21803
(	O
TGF	21803
)	O
-	O
beta1	21803
-	O
stimulated	O
human	9606
proximal	O
tubular	O
epithelial	O
cell	O
(	O
HK	9606
-	O
2	9606
)	O
model	O
in	O
vitro	O
.	O

The	O
levels	O
of	O
kidney	O
functional	O
parameters	O
and	O
inflammatory	D007249
cytokines	O
in	O
serum	O
are	O
examined	O
.	O

The	O
degree	O
of	O
renal	D007674
damage	D007674
and	O
fibrosis	D005355
is	O
determined	O
by	O
histological	O
assessment	O
.	O

Immunohistochemistry	O
and	O
western	O
blotting	O
are	O
used	O
to	O
determine	O
the	O
mechanisms	O
of	O
Sal	C009172
against	O
RIF	D007674
.	O

Our	O
results	O
show	O
that	O
treatment	O
with	O
Sal	C009172
can	O
ameliorate	O
tubular	D007674
injury	D007674
and	O
deposition	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
(	O
including	O
collagen	1281,12825
SH	1281,12825
and	O
collagen	1277,1278,12842,12843
I	1277,1278,12842,12843
)	O
.	O

Furthermore	O
,	O
Sal	C009172
administration	O
significantly	O
suppresses	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
expression	O
of	O
alpha	11475,59
-	O
SMA	11475,59
,	O
vimentin	22352,7431
,	O
TGF	21803,7040
-	O
beta1	21803,7040
,	O
snail	20613,6615
,	O
slug	20583,6591
,	O
and	O
a	O
largely	O
restored	O
expression	O
of	O
E	12550,999
-	O
cadherin	12550,999
.	O

Additionally	O
,	O
Sal	C009172
also	O
reduces	O
the	O
levels	O
of	O
serum	O
biochemical	O
markers	O
(	O
serum	O
creatinine	D003404
,	O
Scr	O
;	O
blood	O
urea	D014508
nitrogen	D009584
,	O
BUN	O
;	O
and	O
uric	D014527
acid	D014527
,	O
UA	D014527
)	O
and	O
decreases	O
the	O
release	O
of	O
inflammatory	D007249
cytokines	O
(	O
IL	16176,3553
-	O
1beta	16176,3553
,	O
IL	16193,3569
-	O
6	16193,3569
,	O
TNF	21926,7124
-	O
alpha	21926,7124
)	O
.	O

Further	O
study	O
revealed	O
that	O
the	O
effect	O
of	O
Sal	C009172
on	O
renal	D007674
interstitial	D007674
fibrosis	D007674
is	O
associated	O
with	O
the	O
lower	O
expression	O
of	O
TLR4	21898,7099
,	O
p	O
-	O
IkappaBalpha	18035,4792
,	O
p	O
-	O
NF	18033,4790
-	O
kappaB	18033,4790
and	O
mitogen	26413,5594
-	O
activated	26413,5594
protein	26413,5594
kinases	26413,5594
(	O
MAPK	26413,5594
)	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
Sal	C009172
treatment	O
improves	O
kidney	O
function	O
,	O
ameliorates	O
the	O
deposition	O
of	O
the	O
ECM	O
components	O
and	O
relieves	O
the	O
protein	O
levels	O
of	O
EMT	O
markers	O
in	O
mouse	10090
kidneys	O
and	O
HK	9606
-	O
2	9606
cells	O
.	O

Furthermore	O
,	O
Sal	C009172
treatment	O
significantly	O
decreases	O
the	O
release	O
of	O
inflammatory	D007249
cytokines	O
and	O
inhibits	O
the	O
TLR4	21898,7099
/	O
NF	18033,4790
-	O
kappaB	18033,4790
and	O
MAPK	26413,5594
signaling	O
pathways	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
Sal	C009172
could	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
treating	O
renal	D007674
fibrosis	D007674
.	O
Neuregulin	3084
-	O
1	3084
beta	3084
and	O
neuregulin	3084
-	O
1	3084
alpha	3084
differentially	O
affect	O
the	O
migration	O
and	O
invasion	O
of	O
malignant	D018319
peripheral	D018319
nerve	D018319
sheath	D018319
tumor	D018319
cells	O
.	O

Malignant	D018319
peripheral	D018319
nerve	D018319
sheath	D018319
tumors	D018319
(	O
MPNSTs	D018319
)	O
are	O
the	O
most	O
common	O
malignancy	D009369
associated	O
with	O
neurofibromatosis	4763
Type	4763
1	4763
(	O
NF1	4763
)	O
.	O

These	O
Schwann	O
cell	O
lineage	O
-	O
derived	O
sarcomas	D012509
aggressively	O
invade	O
adjacent	O
nerve	O
and	O
soft	O
tissue	O
,	O
frequently	O
precluding	O
surgical	O
resection	O
.	O

Little	O
is	O
known	O
regarding	O
the	O
mechanisms	O
underlying	O
this	O
invasive	O
behavior	O
.	O

We	O
have	O
shown	O
that	O
MPNSTs	D018319
express	O
neuregulin	3084
-	O
1	3084
(	O
NRG	3084
-	O
1	3084
)	O
beta	3084
isoforms	O
,	O
which	O
promote	O
Schwann	O
cell	O
migration	O
during	O
development	O
,	O
and	O
NRG	3084
-	O
1	3084
alpha	3084
isoforms	O
,	O
whose	O
effects	O
on	O
Schwann	O
cells	O
are	O
poorly	O
understood	O
.	O

Hypothesizing	O
that	O
NRG	3084
-	O
1	3084
beta	3084
and	O
/	O
or	O
NRG	3084
-	O
1	3084
alpha	3084
promote	O
MPNST	D018319
invasion	O
,	O
we	O
found	O
that	O
NRG	3084
-	O
1	3084
beta	3084
promoted	O
MPNST	D018319
migration	O
in	O
a	O
substrate	O
-	O
specific	O
manner	O
,	O
markedly	O
enhancing	O
migration	O
on	O
laminin	16777
but	O
not	O
on	O
collagen	1277,1278
type	1277,1278
I	1277,1278
or	O
fibronectin	2335
.	O

The	O
NRG	3084
-	O
1	3084
receptors	O
erbB3	13867,2065
and	O
erbB4	13869,2066
were	O
present	O
in	O
MPNST	D018319
invadopodia	O
(	O
processes	O
mediating	O
invasion	O
)	O
,	O
partially	O
colocalized	O
with	O
focal	5747
adhesion	5747
kinase	5747
and	O
the	O
laminin	3688
receptor	3688
beta	3688
(	O
1	3688
)	O
-	O
integrin	3688
and	O
coimmunoprecipitated	O
with	O
beta	3688
(	O
1	3688
)	O
-	O
integrin	3688
.	O

NRG	3084
-	O
1	3084
beta	3084
stimulated	O
human	9606
and	O
murine	10090
MPNST	D018319
cell	O
migration	O
and	O
invasion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
three	O
-	O
dimensional	O
migration	O
assays	O
,	O
acting	O
as	O
a	O
chemotactic	O
factor	O
.	O

Both	O
baseline	O
and	O
NRG	3084
-	O
1	3084
beta	3084
-	O
induced	O
migration	O
were	O
erbB	13867,13869,2065,2066
-	O
dependent	O
and	O
required	O
the	O
action	O
of	O
MEK	26395,26396,5604,5605
1	26395,26396,5604,5605
/	O
2	26395,26396,5604,5605
,	O
SAPK	26419,5599
/	O
JNK	26419,5599
,	O
PI	30955,5290
-	O
3	30955,5290
kinase	30955,5290
,	O
Src	20779,6714
family	20779,6714
kinases	20779,6714
and	O
ROCK	19877,19878,6093,9475
-	O
I	19877,19878,6093,9475
/	O
II	19877,19878,6093,9475
.	O

In	O
contrast	O
,	O
NRG	3084
-	O
1	3084
alpha	3084
had	O
no	O
effect	O
on	O
the	O
migration	O
and	O
invasion	O
of	O
some	O
MPNST	D018319
lines	O
and	O
inhibited	O
the	O
migration	O
of	O
others	O
.	O

While	O
NRG	3084
-	O
1	3084
beta	3084
potently	O
and	O
persistently	O
activated	O
Erk	26413,26417,5594,5595
1	26413,26417,5594,5595
/	O
2	26413,26417,5594,5595
,	O
SAPK	26419,5599
/	O
JNK	26419,5599
,	O
Akt	11651,207
and	O
Src	20779,6714
family	20779,6714
kinases	20779,6714
,	O
NRG	3084
-	O
1	3084
alpha	3084
did	O
not	O
activate	O
Akt	11651,207
and	O
activated	O
these	O
other	O
kinases	O
with	O
kinetics	O
distinct	O
from	O
those	O
evident	O
in	O
NRG	3084
-	O
1	3084
beta	3084
-	O
stimulated	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
NRG	3084
-	O
1	3084
beta	3084
enhances	O
MPNST	D018319
migration	O
and	O
that	O
NRG	3084
-	O
1	3084
beta	3084
and	O
NRG	3084
-	O
1	3084
alpha	3084
differentially	O
modulate	O
this	O
process	O
.	O
Critical	O
role	O
of	O
neuronal	18164
pentraxin	18164
1	18164
in	O
mitochondria	O
-	O
mediated	O
hypoxic	D020925
-	O
ischemic	D020925
neuronal	D020925
injury	D020925
.	O

Developing	O
brain	O
is	O
highly	O
susceptible	O
to	O
hypoxic	D020925
-	O
ischemic	D020925
(	O
HI	D020925
)	O
injury	D020925
leading	O
to	O
severe	O
neurological	D009461
disabilities	D009461
in	O
surviving	O
infants	O
and	O
children	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
induction	O
of	O
neuronal	266777
pentraxin	266777
1	266777
(	O
NP1	266777
)	O
,	O
a	O
novel	O
neuronal	O
protein	O
of	O
long	O
-	O
pentraxin	O
family	O
,	O
following	O
HI	D020925
neuronal	D020925
injury	D020925
.	O

Here	O
,	O
we	O
investigated	O
how	O
this	O
specific	O
signal	O
is	O
propagated	O
to	O
cause	O
the	O
HI	D020925
neuronal	D020925
death	D020925
.	O

We	O
used	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
NP1	18164
knockout	O
(	O
NP1	18164
-	O
KO	O
)	O
mouse	10090
hippocampal	O
cultures	O
,	O
modeled	O
in	O
vitro	O
following	O
exposure	O
to	O
oxygen	D010100
glucose	D005947
deprivation	O
(	O
OGD	O
)	O
,	O
and	O
in	O
vivo	O
neonatal	O
(	O
P9	O
-	O
10	O
)	O
mouse	10090
model	O
of	O
HI	D020925
brain	D020925
injury	D020925
.	O

Our	O
results	O
show	O
induction	O
of	O
NP1	18164
in	O
primary	O
hippocampal	O
neurons	O
following	O
OGD	O
exposure	O
(	O
4	O
-	O
8	O
h	O
)	O
and	O
in	O
the	O
ipsilateral	O
hippocampal	O
CA1	12346
and	O
CA3	12350
regions	O
at	O
24	O
-	O
48	O
h	O
post	O
-	O
HI	O
compared	O
to	O
the	O
contralateral	O
side	O
.	O

We	O
also	O
found	O
increased	O
PTEN	19211
activity	O
concurrent	O
with	O
OGD	O
time	O
-	O
dependent	O
(	O
4	O
-	O
8	O
h	O
)	O
dephosphorylation	O
of	O
Akt	11651
(	O
Ser473	p|AellelS|473
)	O
and	O
GSK	56637
-	O
3b	56637
(	O
Ser9	p|AellelS|9
)	O
.	O

OGD	O
also	O
caused	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
Bad	12015
(	O
Ser136	p|AellelS|136
)	O
,	O
and	O
Bax	12028
protein	O
levels	O
.	O

Immunofluorescence	O
staining	O
and	O
subcellular	O
fractionation	O
analyses	O
revealed	O
increased	O
mitochondrial	O
translocation	O
of	O
Bad	12015
and	O
Bax	12028
proteins	O
from	O
cytoplasm	O
following	O
OGD	O
(	O
4	O
h	O
)	O
and	O
simultaneously	O
increased	O
release	O
of	O
Cyt	13063
C	13063
from	O
mitochondria	O
followed	O
by	O
activation	O
of	O
caspase	12367
-	O
3	12367
.	O

NP1	18164
protein	O
was	O
immunoprecipitated	O
with	O
Bad	12015
and	O
Bax	12028
proteins	O
;	O
OGD	O
caused	O
increased	O
interactions	O
of	O
NP1	18164
with	O
Bad	12015
and	O
Bax	12028
,	O
thereby	O
,	O
facilitating	O
their	O
mitochondrial	O
translocation	O
and	O
dissipation	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
D	O
(	O
m	O
)	O
)	O
.	O

This	O
NP1	18164
induction	O
preceded	O
the	O
increased	O
mitochondrial	O
release	O
of	O
cytochrome	13063
C	13063
(	O
Cyt	13063
C	13063
)	O
into	O
the	O
cytosol	O
,	O
activation	O
of	O
caspase	12367
-	O
3	12367
and	O
OGD	O
time	O
-	O
dependent	O
cell	O
death	O
in	O
WT	O
primary	O
hippocampal	O
neurons	O
.	O

In	O
contrast	O
,	O
in	O
NP1	18164
-	O
KO	O
neurons	O
there	O
was	O
no	O
translocation	O
of	O
Bad	12015
and	O
Bax	12028
from	O
cytosol	O
to	O
the	O
mitochondria	O
,	O
and	O
no	O
evidence	O
of	O
D	O
(	O
m	O
)	O
loss	O
,	O
increased	O
Cyt	13063
C	13063
release	O
and	O
caspase	12367
-	O
3	12367
activation	O
following	O
OGD	O
;	O
which	O
resulted	O
in	O
significantly	O
reduced	O
neuronal	D009410
death	D009410
.	O

Our	O
results	O
indicate	O
a	O
regulatory	O
role	O
of	O
NP1	18164
in	O
Bad	12015
/	O
Bax	12028
-	O
dependent	O
mitochondrial	O
release	O
of	O
Cyt	13063
C	13063
and	O
caspase	12367
-	O
3	12367
activation	O
.	O

Together	O
our	O
findings	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
NP1	18164
regulates	O
mitochondria	O
-	O
driven	O
hippocampal	O
cell	O
death	O
;	O
suggesting	O
NP1	18164
as	O
a	O
potential	O
therapeutic	O
target	O
against	O
HI	D020925
brain	D020925
injury	D020925
in	O
neonates	O
.	O
Repeated	O
otilonium	C013934
bromide	C013934
administration	O
prevents	O
neurotransmitter	D018377
changes	O
in	O
colon	O
of	O
rats	10116
underwent	O
to	O
wrap	O
restraint	O
stress	O
.	O

Otilonium	C013934
bromide	C013934
(	O
OB	C013934
)	O
is	O
a	O
spasmolytic	O
drug	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
irritable	D043183
bowel	D043183
syndrome	D043183
(	O
IBS	D043183
)	O
.	O

Its	O
efficacy	O
has	O
been	O
attributed	O
to	O
the	O
block	O
of	O
L	24239,83810
-	O
and	24239,83810
T	24239,83810
-	O
type	24239,83810
Ca	24239,83810
(	O
2	24239,83810
+	O
)	O
channels	24239,83810
and	O
muscarinic	1128,6869
and	1128,6869
tachykinin	1128,6869
receptors	1128,6869
in	O
the	O
smooth	O
muscle	O
.	O

Furthermore	O
,	O
in	O
healthy	O
rats	10116
,	O
repeated	O
OB	C013934
administration	O
modified	O
neurotransmitter	D018377
expression	O
and	O
function	O
suggesting	O
other	O
mechanisms	O
of	O
action	O
.	O

On	O
this	O
basis	O
,	O
we	O
investigated	O
whether	O
repeated	O
OB	C013934
treatment	O
prevented	O
the	O
functional	O
and	O
neurochemical	O
changes	O
observed	O
in	O
the	O
colon	O
of	O
rats	10116
underwent	O
to	O
wrap	O
restrain	O
stress	O
(	O
WRS	O
)	O
a	O
psychosocial	O
stressor	O
considered	O
suitable	O
to	O
reproduce	O
the	O
main	O
IBS	D043183
signs	O
and	O
symptoms	O
.	O

In	O
control	O
,	O
WRS	O
and	O
OB	C013934
/	O
WRS	O
rats	10116
functional	O
parameters	O
were	O
measured	O
in	O
vivo	O
and	O
morphological	O
investigations	O
were	O
done	O
ex	O
vivo	O
in	O
the	O
colon	O
.	O

The	O
results	O
showed	O
that	O
OB	C013934
counteracts	O
most	O
of	O
the	O
neurotransmitters	D018377
changes	O
caused	O
by	O
WRS	O
.	O

In	O
particular	O
,	O
the	O
drug	O
prevents	O
the	O
decrease	O
in	O
SP	24806
-	O
,	O
NK1r	24807
-	O
,	O
nNOS	24598
-	O
,	O
VIP	117064
-	O
,	O
and	O
S100b	25742
-	O
immunoreactivity	O
(	O
IR	O
)	O
and	O
the	O
increase	O
in	O
CGRP	24241
-	O
,	O
and	O
CRF1r	58959
-	O
IR	O
.	O

On	O
the	O
contrary	O
,	O
OB	C013934
does	O
not	O
affect	O
the	O
increase	O
in	O
CRF2r	64680
-	O
IR	O
neurons	O
observed	O
in	O
WRS	O
rats	10116
and	O
does	O
not	O
interfere	O
with	O
the	O
mild	O
mucosal	D052016
inflammation	D052016
due	O
to	O
WRS	O
.	O

Finally	O
,	O
OB	C013934
per	O
se	O
increases	O
the	O
Mr2	81645
expression	O
in	O
the	O
muscle	O
wall	O
and	O
decreases	O
the	O
number	O
of	O
the	O
myenteric	O
ChAT	290567
-	O
IR	O
neurons	O
.	O

Functional	O
findings	O
show	O
a	O
significantly	O
reduction	O
in	O
the	O
number	O
of	O
spontaneous	O
abdominal	O
contraction	O
in	O
OB	C013934
treated	O
rats	10116
.	O

The	O
ability	O
of	O
OB	C013934
to	O
block	O
L	24239
-	O
type	24239
Ca	24239
(	O
2	24239
+	O
)	O
channels	24239
,	O
also	O
expressed	O
by	O
enteric	O
neurons	O
,	O
might	O
represent	O
a	O
possible	O
mechanism	O
through	O
which	O
OB	C013934
exerts	O
its	O
actions	O
.	O
Lack	O
of	O
association	O
of	O
C	1234
-	O
C	1234
chemokine	1234
receptor	1234
5	1234
DD32	c|DEL||32
deletion	c|DEL||32
status	O
with	O
rheumatoid	D001172
arthritis	D001172
,	O
systemic	D008180
lupus	D008180
erythematosus	D008180
,	O
lupus	D008181
nephritis	D008181
,	O
and	O
disease	O
severity	O
.	O

OBJECTIVE	O
:	O
C	1234
-	O
C	1234
chemokine	1234
receptor	1234
5	1234
(	O
CCR5	1234
)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	D007249
.	O

A	O
32	c|DEL||32
base	c|DEL||32
-	O
pair	c|DEL||32
(	O
DD32	c|DEL||32
)	O
deletion	c|DEL||32
in	O
the	O
CCR5	1234
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O

This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	D001327
diseases	D001327
.	O

We	O
investigated	O
whether	O
the	O
DD32	c|DEL||32
deletion	c|DEL||32
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	9606
with	O
rheumatoid	D001172
arthritis	D001172
(	O
RA	D001172
)	O
,	O
systemic	D008180
lupus	D008180
erythematosus	D008180
(	O
SLE	D008180
)	O
,	O
and	O
lupus	D008181
nephritis	D008181
(	O
LN	D008181
)	O
;	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	D001172
patients	9606
,	O
97	O
SLE	D008180
patients	9606
,	O
113	O
LN	D008181
patients	9606
,	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	1234
DD32	c|DEL||32
deletion	c|DEL||32
.	O

Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	9606
and	O
controls	O
.	O

Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

The	O
genotype	O
frequencies	O
of	O
patients	9606
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5	1234
/	O
DD32	c|DEL||32
,	O
DD32	c|DEL||32
/	O
DD32	c|DEL||32
:	O
RA	D001172
18	O
.	O
3%	O
and	O
1	O
.	O
2%	O
,	O
respectively	O
;	O
SLE	D008180
17	O
.	O
5%	O
and	O
2	O
.	O
1%	O
;	O
LN	D008181
13	O
.	O
3%	O
and	O
1	O
.	O
8%	O
;	O
controls	O
20	O
.	O
0%	O
and	O
2	O
.	O
8%	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
for	O
lower	O
DD32	c|DEL||32
deletion	c|DEL||32
allele	O
frequency	O
in	O
LN	D008181
patients	9606
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	1234
status	O
and	O
disease	O
severity	O
in	O
RA	D001172
,	O
SLE	D008180
,	O
or	O
LN	D008181
.	O

CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	D008181
cannot	O
be	O
excluded	O
,	O
the	O
CCR5	1234
DD32	c|DEL||32
deletion	c|DEL||32
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	D001172
,	O
SLE	D008180
,	O
or	O
LN	D008181
.	O

No	O
significant	O
effect	O
of	O
the	O
DD32	c|DEL||32
deletion	c|DEL||32
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O
Cocaine	D003042
causes	O
memory	D007859,D008569
and	D007859,D008569
learning	D007859,D008569
impairments	D007859,D008569
in	O
rats	10116
:	O
involvement	O
of	O
nuclear	81736
factor	81736
kappa	81736
B	81736
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	D000077236
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	D003042
toxicity	D064420
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	D003042
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	81736
factor	81736
kappa	81736
B	81736
(	O
NFkappaB	81736
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	D064420
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	81736
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	24598
nitric	24598
oxide	24598
synthase	24598
(	O
nNOS	24598
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	D000077236
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	D019970
addiction	D019970
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	D003042
administration	O
in	O
rats	10116
.	O

NFkappaB	81736
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	D003042
treated	O
rats	10116
,	O
as	O
well	O
as	O
GSH	D005978
concentration	O
and	O
glutathione	D005978
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	24598
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	D003042
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	81736
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	24598
activity	O
and	O
the	O
decrease	O
of	O
glutathione	D005978
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	81736
in	O
the	O
alterations	O
induced	O
by	O
cocaine	D003042
.	O

Topiramate	D000077236
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O
D90A	rs80265967
-	O
SOD1	6647
mediated	O
amyotrophic	D000690
lateral	D000690
sclerosis	D000690
:	O
a	O
single	O
founder	O
for	O
all	O
cases	O
with	O
evidence	O
for	O
a	O
Cis	O
-	O
acting	O
disease	O
modifier	O
in	O
the	O
recessive	O
haplotype	O
.	O

More	O
than	O
100	O
different	O
heterozygous	O
mutations	O
in	O
copper	6647
/	O
zinc	6647
superoxide	6647
dismutase	6647
(	O
SOD1	6647
)	O
have	O
been	O
found	O
in	O
patients	9606
with	O
amyotrophic	D000690
lateral	D000690
sclerosis	D000690
(	O
ALS	D000690
)	O
,	O
a	O
fatal	O
neurodegenerative	D019636
disease	D019636
.	O

Uniquely	O
,	O
D90A	rs80265967
-	O
SOD1	6647
has	O
been	O
identified	O
in	O
recessive	O
,	O
dominant	O
and	O
apparently	O
sporadic	O
pedigrees	O
.	O

The	O
phenotype	O
of	O
homozygotes	O
is	O
stereotyped	O
with	O
an	O
extended	O
survival	O
,	O
whereas	O
that	O
of	O
affected	O
heterozygotes	O
varies	O
.	O

The	O
frequency	O
of	O
D90A	rs80265967
-	O
SOD1	6647
is	O
50	O
times	O
higher	O
in	O
Scandinavia	O
(	O
2	O
.	O
5%	O
)	O
than	O
elsewhere	O
,	O
though	O
ALS	D000690
prevalence	O
is	O
not	O
raised	O
there	O
.	O

Our	O
earlier	O
study	O
indicated	O
separate	O
founders	O
for	O
recessive	O
and	O
dominant	O
/	O
sporadic	O
ALS	D000690
and	O
we	O
proposed	O
a	O
disease	O
-	O
modifying	O
factor	O
linked	O
to	O
the	O
recessive	O
mutation	O
.	O

Here	O
we	O
have	O
doubled	O
our	O
sample	O
set	O
and	O
employed	O
novel	O
markers	O
to	O
characterise	O
the	O
mutation	O
'	O
s	O
origin	O
and	O
localise	O
any	O
modifying	O
factor	O
.	O

Linkage	O
disequilibrium	O
analysis	O
indicates	O
that	O
D90A	rs80265967
homozygotes	O
and	O
heterozygotes	O
share	O
a	O
rare	O
haplotype	O
and	O
are	O
all	O
descended	O
from	O
a	O
single	O
ancient	O
founder	O
(	O
alpha	O
0	O
.	O
974	O
)	O
c	O
.	O
895	O
generations	O
ago	O
.	O

Homozygotes	O
arose	O
subsequently	O
only	O
c	O
.	O
63	O
generations	O
ago	O
(	O
alpha	O
0	O
.	O
878	O
)	O
.	O

Recombination	O
has	O
reduced	O
the	O
region	O
shared	O
by	O
recessive	O
kindreds	O
to	O
97	O
-	O
265	O
kb	O
around	O
SOD1	6647
,	O
excluding	O
all	O
neighbouring	O
genes	O
.	O

We	O
propose	O
that	O
a	O
cis	O
-	O
acting	O
regulatory	O
polymorphism	O
has	O
arisen	O
close	O
to	O
D90A	rs80265967
-	O
SOD1	6647
in	O
the	O
recessive	O
founder	O
,	O
which	O
decreases	O
ALS	D000690
susceptibility	O
in	O
heterozygotes	O
and	O
slows	O
disease	O
progression	O
.	O
Spirulina	551299
lipopolysaccharides	D008070
inhibit	O
tumor	D009369
growth	O
in	O
a	O
Toll	21898
-	O
like	21898
receptor	21898
4	21898
-	O
dependent	O
manner	O
by	O
altering	O
the	O
cytokine	O
milieu	O
from	O
interleukin	16171
-	O
17	16171
/	O
interleukin	83430
-	O
23	83430
to	O
interferon	15978
-	O
g	15978
.	O

Th17	O
cells	O
and	O
the	O
cytokine	O
they	O
produce	O
,	O
interleukin	16171,3605
(	O
IL	16171,3605
)	O
-	O
17	16171,3605
,	O
play	O
an	O
important	O
role	O
in	O
tumor	D009369
progression	O
in	O
humans	9606
and	O
in	O
mice	10090
.	O

IL	16193
-	O
6	16193
and	O
IL	83430
-	O
23	83430
are	O
critical	O
cytokines	O
for	O
the	O
differentiation	O
and	O
propagation	O
of	O
Th17	O
cells	O
,	O
respectively	O
.	O

Bacterial	O
lipopolysaccharides	D008070
(	O
LPS	D008070
)	O
are	O
known	O
to	O
stimulate	O
immune	O
cells	O
to	O
produce	O
such	O
inflammatory	-
cytokines	-
.	O

Contrary	O
to	O
Escherichia	562
coli	562
(	O
E	562
.	O

coli	562
)	O
LPS	D008070
,	O
LPS	D008070
from	O
Spirulina	551299
has	O
low	O
toxicity	D064420
and	O
barely	O
induces	O
in	O
vivo	O
production	O
of	O
IL	16193
-	O
6	16193
and	O
IL	83430
-	O
23	83430
in	O
mice	10090
.	O

We	O
examined	O
the	O
antitumor	O
effects	O
of	O
Spirulina	551299
LPS	D008070
compared	O
to	O
E	562
.	O

coli	562
LPS	D008070
in	O
an	O
MH134	10090
hepatoma	D006528
model	O
.	O

Administration	O
of	O
Spirulina	551299
LPS	D008070
suppressed	O
tumor	D009369
growth	O
in	O
C3H	O
/	O
HeN	O
mice	10090
,	O
but	O
not	O
in	O
Toll	21898
-	O
like	21898
receptor	21898
4	21898
(	O
TLR4	21898
)	O
-	O
mutant	O
C3H	O
/	O
HeJ	O
mice	10090
,	O
by	O
reducing	O
serum	O
levels	O
of	O
IL	16171
-	O
17	16171
and	O
IL	83430
-	O
23	83430
,	O
while	O
increasing	O
interferon	15978
(	O
IFN	15978
)	O
-	O
g	15978
levels	O
.	O

The	O
antitumor	O
activity	O
and	O
IFN	15978
-	O
g	15978
production	O
were	O
mediated	O
by	O
T	O
cells	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
Spirulina	551299
LPS	D008070
impaired	O
the	O
antigen	O
-	O
presenting	O
function	O
that	O
supports	O
the	O
generation	O
of	O
IL	16171
-	O
17	16171
-	O
producing	O
cells	O
in	O
a	O
toll	21898
-	O
like	21898
receptor	21898
(	O
TLR	21898
)	O
4	21898
-	O
dependent	O
manner	O
.	O

Of	O
note	O
,	O
injection	O
of	O
anti	O
-	O
IL	16171
-	O
17	16171
antibody	O
in	O
tumor	D009369
-	O
bearing	O
C3H	O
/	O
HeN	O
mice	10090
in	O
the	O
absence	O
of	O
Spirulina	551299
LPS	D008070
markedly	O
suppressed	O
tumor	D009369
growth	O
and	O
augmented	O
IFN	15978
-	O
g	15978
responses	O
.	O

Thus	O
,	O
our	O
results	O
support	O
the	O
notion	O
that	O
IFN	15978
-	O
g	15978
and	O
IL	16171
-	O
17	16171
/	O
IL	83430
-	O
23	83430
mutually	O
regulate	O
Th17	O
and	O
Th1	O
responses	O
in	O
tumor	D009369
-	O
bearing	O
hosts	O
,	O
and	O
Spirulina	551299
LPS	D008070
modulates	O
the	O
balance	O
of	O
the	O
IFN	15978
-	O
g	15978
-	O
IL	16171
-	O
17	16171
/	O
IL	83430
-	O
23	83430
axis	O
towards	O
IFN	15978
-	O
g	15978
production	O
,	O
which	O
leads	O
to	O
tumor	D009369
inhibition	O
.	O

Furthermore	O
,	O
Spirulina	551299
LPS	D008070
effectively	O
inhibited	O
the	O
spontaneous	O
development	O
of	O
mammary	D001943
tumors	D001943
.	O

This	O
study	O
has	O
important	O
implications	O
for	O
the	O
exploitation	O
of	O
TLR	21898
-	O
based	O
immunomodulators	O
for	O
cancer	D009369
immunotherapy	O
.	O
Myotonic	13400
dystrophy	13400
protein	13400
kinase	13400
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	D002118
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	D009223
dystrophy	D009223
(	O
DM	D009223
)	O
,	O
the	O
most	O
prevalent	O
muscular	D009135
disorder	D009135
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	13400
protein	13400
kinase	13400
;	O
DMPK	13400
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	13400
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	D002118
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	D002118
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	D000255
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	13400
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	10090
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	13400
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	D002118
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	D002118
+	O
and	O
Na	D012964
+	O
channels	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	D002118
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	D000109
or	O
high	O
external	O
K	D011188
+	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	D002118
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	D002118
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	D002118
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	-
+	O
/	O
K	-
+	O
ATPase	-
and	O
sarcoplasmic	D053498
reticulum	D053498
Ca2	D053498
+	O
-	O
ATPase	D053498
are	O
affected	O
by	O
DMPK	13400
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	13400
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	D001260
-	O
telangiectasia	D001260
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	D001260
-	O
telangiectasia	D001260
(	O
A	D001260
-	O
T	D001260
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	472
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10%	O
-	O
15%	O
of	O
A	D001260
-	O
T	D001260
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	c|INS||137
-	O
bp	c|INS||137
insertion	c|INS||137
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
second	O
A	D001260
-	O
T	D001260
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	9606
.	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	9606
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	9606
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	D002524
ataxia	D002524
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	D001260
-	O
T	D001260
patients	9606
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	D001260
-	O
T	D001260
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	472
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
.	O
Omitting	O
fentanyl	D005283
reduces	O
nausea	D009325
and	O
vomiting	D014839
,	O
without	O
increasing	O
pain	D010146
,	O
after	O
sevoflurane	C009250
for	O
day	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	C009250
,	O
postoperative	D020250
nausea	D020250
and	D020250
vomiting	D020250
occurs	O
frequently	O
.	O

Fentanyl	D005283
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	D010149,D020250
nausea	D010149,D020250
and	D010149,D020250
vomiting	D010149,D020250
and	D010149,D020250
pain	D010149,D020250
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	C009250
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	D005283
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	D003907
in	O
addition	O
to	O
fentanyl	D005283
.	O

RESULTS	O
:	O
Omission	O
of	O
fentanyl	D005283
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	D020250
nausea	D020250
and	D020250
vomiting	D020250
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	D014839
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	D009325
prior	O
to	O
discharge	O
from	O
20%	O
and	O
17%	O
with	O
fentanyl	D005283
and	O
fentanyl	D005283
-	O
dexamethasone	D003907
,	O
respectively	O
,	O
to	O
5%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24%	O
and	O
31%	O
to	O
7%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethasone	D003907
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	D020250
nausea	D020250
and	D020250
vomiting	D020250
.	O

Combining	O
the	O
two	O
fentanyl	D005283
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	D020250
nausea	D020250
and	D020250
vomiting	D020250
and	O
nausea	D009325
prior	O
to	O
discharge	O
from	O
35%	O
and	O
33%	O
to	O
22%	O
and	O
19%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	D009325
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42%	O
to	O
27%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pain	D010146
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	D005283
.	O

Fentanyl	D005283
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	C009250
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	D012131
depression	D012131
,	O
hypotension	D007022
and	O
bradycardia	D001919
.	O

CONCLUSION	O
:	O
As	O
fentanyl	D005283
exacerbated	O
postoperative	D020250
nausea	D020250
and	D020250
vomiting	D020250
without	O
an	O
improvement	O
in	O
postoperative	D010149
pain	D010149
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	C009250
in	O
day	O
surgery	O
.	O
Aconitine	D000157
-	O
induced	O
Ca2	D002118
+	O
overload	O
causes	O
arrhythmia	D001145
and	O
triggers	O
apoptosis	O
through	O
p38	81649
MAPK	81649
signaling	O
pathway	O
in	O
rats	10116
.	O

Aconitine	D000157
is	O
a	O
major	O
bioactive	O
diterpenoid	-
alkaloid	-
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	D012964
(	O
+	O
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	D066126
of	O
aconitine	D000157
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	D002118
(	O
2	D002118
+	O
)	O
in	O
aconitine	D000157
poisoning	D011041
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	D002118
(	O
2	D002118
+	O
)	O
signaling	O
in	O
aconitine	D000157
poisoning	D011041
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	D002118
(	O
2	D002118
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	10116
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	D001145
in	O
conscious	O
freely	O
moving	O
rats	10116
.	O

To	O
investigate	O
effects	O
of	O
aconitine	D000157
on	O
myocardial	D009202
injury	D009202
,	O
we	O
performed	O
cytotoxicity	D064420
assay	O
in	O
neonatal	O
rat	10116
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	24533
dehydrogenase	24533
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	10116
.	O

The	O
results	O
showed	O
that	O
aconitine	D000157
resulted	O
in	O
myocardial	D009202
injury	D009202
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	-1
-	O
biotin	D001710
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	D000157
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca	D002118
(	O
2	D002118
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	D000157
promoted	O
Ca	D002118
(	O
2	D002118
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	D002118
(	O
2	D002118
+	O
)	O
handling	O
proteins	O
.	O

The	O
expression	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
revealed	O
that	O
pro	O
-	O
apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
BCL	24224
-	O
2	24224
expression	O
was	O
downregulated	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	81649
family	O
members	O
,	O
especially	O
the	O
P	O
-	O
P38	81649
/	O
P38	81649
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	D000157
significantly	O
aggravates	O
Ca	D002118
(	O
2	D002118
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	D001145
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	81649
mitogen	81649
-	O
activated	81649
protein	81649
kinase	81649
.	O
Coenzyme	C024989
Q10	C024989
treatment	O
ameliorates	O
acute	O
cisplatin	D002945
nephrotoxicity	D007674
in	O
mice	10090
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	C024989
Q10	C024989
was	O
investigated	O
in	O
mice	10090
with	O
acute	D058186
renal	D058186
injury	D058186
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O

injection	O
of	O
cisplatin	D002945
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Coenzyme	C024989
Q10	C024989
treatment	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O
p	O
.	O
)	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	D002945
administration	O
.	O

Coenzyme	C024989
Q10	C024989
significantly	O
reduced	O
blood	D001806
urea	D001806
nitrogen	D001806
and	O
serum	O
creatinine	D003404
levels	O
which	O
were	O
increased	O
by	O
cisplatin	D002945
.	O

Coenzyme	C024989
Q10	C024989
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	O
glutathione	D005978
level	O
and	O
superoxide	20655
dismutase	20655
activity	O
)	O
,	O
suppressed	O
lipid	D008055
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	21926
necrosis	21926
factor	21926
-	O
alpha	21926
,	O
nitric	D009569
oxide	D009569
and	O
platinum	D010984
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	D012643
and	O
zinc	D015032
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	D002945
administration	O
.	O

Also	O
,	O
histopathological	O
renal	D007674
tissue	D007674
damage	D007674
mediated	O
by	O
cisplatin	D002945
was	O
ameliorated	O
by	O
coenzyme	C024989
Q10	C024989
treatment	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	C024989
Q10	C024989
significantly	O
decreased	O
the	O
cisplatin	D002945
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	18125
oxide	18125
synthase	18125
,	O
nuclear	18033
factor	18033
-	O
kappaB	18033
,	O
caspase	12367
-	O
3	12367
and	O
p53	22060
in	O
renal	O
tissue	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	C024989
Q10	C024989
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	D002945
nephrotoxicity	D007674
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O
U87MG	9606
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	9606
cancer	D009369
cell	O
line	O
.	O

U87MG	9606
is	O
a	O
commonly	O
studied	O
grade	D005909
IV	D005909
glioma	D005909
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1	O
,	O
700	O
publications	O
over	O
four	O
decades	O
.	O

In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	D009369
genome	O
sequencing	O
,	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50	O
-	O
base	O
mate	O
paired	O
strategy	O
with	O
a	O
1	O
.	O
4kb	O
mean	O
insert	O
library	O
.	O

A	O
total	O
of	O
1	O
,	O
014	O
,	O
984	O
,	O
286	O
mate	O
-	O
end	O
and	O
120	O
,	O
691	O
,	O
623	O
single	O
-	O
end	O
two	O
-	O
base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O

All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
,	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O

The	O
aligned	O
sequence	O
reads	O
and	O
mate	O
-	O
pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
,	O
1	O
,	O
315	O
structural	O
variations	O
(	O
>	O
100	O
bp	O
)	O
,	O
191	O
,	O
743	O
small	O
(	O
<	O
21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(	O
indels	O
)	O
,	O
and	O
2	O
,	O
384	O
,	O
470	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
.	O

Among	O
these	O
observations	O
,	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	5728
was	O
robustly	O
identified	O
,	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O

Data	O
were	O
compared	O
to	O
219	O
,	O
187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93	O
.	O
83%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99	O
.	O
99%	O
sequence	O
accuracy	O
.	O

Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	D009369
cell	O
line	O
due	O
to	O
small	O
indels	O
,	O
large	O
deletions	O
,	O
and	O
translocations	O
.	O

In	O
total	O
,	O
512	O
genes	O
were	O
homozygously	O
mutated	O
,	O
including	O
154	O
by	O
SNVs	O
,	O
178	O
by	O
small	O
indels	O
,	O
145	O
by	O
large	O
microdeletions	O
,	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O

Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
,	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O

These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	D009369
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O

The	O
sequence	O
analysis	O
of	O
U87MG	9606
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O
A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
hPER2	8864
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O

The	O
PERIOD2	8864
(	O
PER2	8864
)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
human	9606
PER2	8864
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	C565789
sleep	C565789
phase	C565789
syndrome	C565789
(	O
ASPS	C565789
)	O
.	O

We	O
have	O
investigated	O
three	O
other	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	8864
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
C	c|SUB|C|-1228|T
-	O
1228T	c|SUB|C|-1228|T
)	O
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
(	O
C111G	c|SUB|C|111|G
)	O
,	O
and	O
one	O
missense	O
mutation	O
(	O
G3853A	c|SUB|G|3853|A
)	O
causing	O
a	O
glycine	p|SUB|G||Q
to	p|SUB|G||Q
glutamine	p|SUB|G||Q
substitution	O
in	O
the	O
predicted	O
protein	O
.	O

Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n	O
=	O
35	O
for	O
each	O
group	O
)	O
.	O

Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111G	c|Allele|G|111
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(	O
0	O
.	O
14	O
)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(	O
0	O
.	O
03	O
)	O
(	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
two	O
-	O
sided	O
P	O
value	O
=	O
0	O
.	O
031	O
,	O
odds	O
ratio	O
=	O
5	O
.	O
67	O
)	O
.	O

No	O
significant	O
difference	O
in	O
111G	c|Allele|G|111
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O

Computer	O
prediction	O
indicated	O
that	O
the	O
C111G	c|SUB|C|111|G
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O

The	O
PER2	8864
111G	c|Allele|G|111
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	C565789
.	O
RNASEL	6041
and	O
RNASEL	6041
-	O
inhibitor	O
variation	O
and	O
prostate	D011471
cancer	D011471
risk	O
in	O
Afro	O
-	O
Caribbeans	O
.	O

BACKGROUND	O
:	O
Afro	O
-	O
Caribbeans	O
from	O
Tobago	O
are	O
at	O
high	O
risk	O
of	O
developing	O
prostate	D011471
cancer	D011471
.	O

This	O
elevated	O
risk	O
of	O
prostate	D011471
cancer	D011471
is	O
shared	O
by	O
populations	O
of	O
African	O
ancestry	O
living	O
in	O
diverse	O
environments	O
in	O
the	O
Western	O
hemisphere	O
.	O

Variation	O
in	O
the	O
ribonuclease	6041
L	6041
(	O
RNASEL	6041
)	O
gene	O
has	O
recently	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
prostate	D011471
cancer	D011471
.	O

However	O
,	O
whether	O
RNASEL	6041
variation	O
contributes	O
to	O
the	O
increased	O
risk	O
of	O
prostate	D011471
cancer	D011471
observed	O
in	O
populations	O
of	O
African	O
ancestry	O
remains	O
unclear	O
.	O

METHODS	O
:	O
We	O
resequenced	O
the	O
positional	O
candidate	O
gene	O
RNASEL	6041
in	O
48	O
prostate	D011471
cancer	D011471
cases	O
and	O
genotyped	O
the	O
previously	O
reported	O
R462Q	rs486907
and	O
D541E	rs627928
polymorphisms	O
in	O
230	O
prostate	D011471
cancer	D011471
cases	O
and	O
458	O
controls	O
.	O

We	O
also	O
examined	O
the	O
inhibitor	O
of	O
RNASEL	6041
(	O
ABCE1	6059
)	O
for	O
variation	O
associated	O
with	O
prostate	D011471
cancer	D011471
risk	O
.	O

RESULTS	O
:	O
We	O
found	O
no	O
evidence	O
of	O
association	O
between	O
R462Q	rs486907
and	O
D541E	rs627928
polymorphisms	O
and	O
prostate	D011471
cancer	D011471
risk	O
in	O
our	O
case	O
/	O
control	O
analysis	O
.	O

A	O
novel	O
variant	O
(	O
K294E	rs143544690
)	O
was	O
identified	O
in	O
a	O
single	O
heterozygous	O
individual	O
with	O
prostate	D011471
cancer	D011471
.	O

We	O
also	O
observed	O
a	O
20	c|INDEL|1109|20
bp	c|INDEL|1109|20
insertion	c|INDEL|1109|20
/	O
deletion	c|INDEL|1109|20
polymorphism	c|INDEL|1109|20
1	c|INDEL|1109|20
,	O
109	c|INDEL|1109|20
bp	c|INDEL|1109|20
upstream	c|INDEL|1109|20
of	c|INDEL|1109|20
the	c|INDEL|1109|20
initiation	c|INDEL|1109|20
codon	c|INDEL|1109|20
,	O
but	O
this	O
variant	O
was	O
not	O
associated	O
with	O
prostate	D011471
cancer	D011471
.	O

We	O
identified	O
16	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ABCE1	6059
gene	O
,	O
only	O
3	O
of	O
which	O
had	O
a	O
minor	O
allele	O
frequency	O
>	O
5%	O
.	O

A	O
common	O
A	c|SUB|A|-1071|G
/	O
G	c|SUB|A|-1071|G
transition	c|SUB|A|-1071|G
-	O
1	c|SUB|A|-1071|G
,	O
071	c|SUB|A|-1071|G
bp	c|SUB|A|-1071|G
from	O
the	O
transcriptional	O
start	O
site	O
was	O
genotyped	O
and	O
showed	O
no	O
evidence	O
of	O
association	O
with	O
prostate	D011471
cancer	D011471
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
common	O
variation	O
in	O
the	O
putative	O
prostate	D011471
cancer	D011471
susceptibility	O
gene	O
,	O
RNASEL	6041
,	O
or	O
its	O
inhibitor	O
does	O
not	O
contribute	O
significantly	O
to	O
prostate	D011471
cancer	D011471
risk	O
in	O
this	O
Afro	O
-	O
Caribbean	O
population	O
.	O
Hepatic	O
but	O
not	O
brain	O
iron	D007501
is	O
rapidly	O
chelated	O
by	O
deferasirox	D000077588
in	O
aceruloplasminemia	C536004
due	O
to	O
a	O
novel	O
gene	O
mutation	O
.	O

BACKGROUND	O
_	O
#	O
38	O
;	O
AIMS	O
:	O
Aceruloplasminemia	C536004
is	O
a	O
rare	O
autosomal	D020271
recessive	D020271
neurodegenerative	D020271
disease	D020271
associated	O
with	O
brain	O
and	O
liver	O
iron	D007501
accumulation	O
which	O
typically	O
presents	O
with	O
movement	D009069
disorders	D009069
,	O
retinal	D012162
degeneration	D012162
,	O
and	O
diabetes	D003920
mellitus	D003920
.	O

Ceruloplasmin	1356
is	O
a	O
multi	O
-	O
copper	O
ferroxidase	-
that	O
is	O
secreted	O
into	O
plasma	O
and	O
facilitates	O
cellular	O
iron	D007501
export	O
and	O
iron	D007501
binding	O
to	O
transferrin	7018
.	O

RESULTS	O
:	O
A	O
novel	O
homozygous	O
ceruloplasmin	1356
gene	O
mutation	O
,	O
c	c|SUB|G|2554+1|T
.	O
2554	c|SUB|G|2554+1|T
+	O
1G	c|SUB|G|2554+1|T
>	O
T	c|SUB|G|2554+1|T
,	O
was	O
identified	O
as	O
the	O
cause	O
of	O
aceruloplasminemia	C536004
in	O
three	O
affected	O
siblings	O
.	O

Two	O
siblings	O
presented	O
with	O
movement	D009069
disorders	D009069
and	O
diabetes	D003920
.	O

Complementary	O
DNA	O
sequencing	O
showed	O
that	O
this	O
mutation	O
causes	O
skipping	O
of	O
exon	O
14	O
and	O
deletion	c|DEL|809_852|
of	c|DEL|809_852|
amino	c|DEL|809_852|
acids	c|DEL|809_852|
809	c|DEL|809_852|
-	O
852	c|DEL|809_852|
while	O
preserving	O
the	O
open	O
reading	O
frame	O
.	O

Western	O
blotting	O
of	O
liver	O
extracts	O
and	O
sera	O
of	O
affected	O
patients	9606
showed	O
retention	O
of	O
the	O
abnormal	O
protein	O
in	O
the	O
liver	O
.	O

Aceruloplasminemia	C536004
was	O
associated	O
with	O
severe	O
brain	O
and	O
liver	O
iron	D019190
overload	D019190
,	O
where	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
iron	D007501
hormone	O
hepcidin	57817
was	O
increased	O
,	O
corresponding	O
to	O
the	O
degree	O
of	O
iron	D019190
overload	D019190
.	O

Hepatic	O
iron	D007501
concentration	O
normalized	O
after	O
3	O
and	O
5months	O
of	O
iron	D007501
chelation	O
therapy	O
with	O
deferasirox	D000077588
,	O
which	O
was	O
also	O
associated	O
with	O
reduced	O
insulin	3630
demands	O
.	O

During	O
short	O
term	O
treatment	O
there	O
was	O
no	O
clinical	O
or	O
imaging	O
evidence	O
for	O
significant	O
effects	O
on	O
brain	O
iron	D019190
overload	D019190
.	O

CONCLUSIONS	O
:	O
Aceruloplasminemia	C536004
can	O
show	O
an	O
incomplete	O
clinical	O
penetrance	O
but	O
is	O
invariably	O
associated	O
with	O
iron	D007501
accumulation	O
in	O
the	O
liver	O
and	O
in	O
the	O
brain	O
.	O

Iron	D007501
accumulation	O
in	O
aceruloplasminemia	C536004
is	O
a	O
result	O
of	O
defective	O
cellular	O
iron	D007501
export	O
,	O
where	O
hepcidin	57817
regulation	O
is	O
appropriate	O
for	O
the	O
degree	O
of	O
iron	D019190
overload	D019190
.	O

Iron	D007501
chelation	O
with	O
deferasirox	D000077588
was	O
effective	O
in	O
mobilizing	O
hepatic	O
iron	D007501
but	O
has	O
no	O
effect	O
on	O
brain	O
iron	D007501
.	O
Aberrant	O
caveolin	857
-	O
1	857
-	O
mediated	O
Smad	4086,4090,4093
signaling	O
and	O
proliferation	O
identified	O
by	O
analysis	O
of	O
adenine	rs587777017
474	rs587777017
deletion	rs587777017
mutation	O
(	O
c	rs587777017
.	O
474delA	rs587777017
)	O
in	O
patient	9606
fibroblasts	O
:	O
a	O
new	O
perspective	O
on	O
the	O
mechanism	O
of	O
pulmonary	D006976
hypertension	D006976
.	O

A	O
heterozygous	O
caveolin	857
-	O
1	857
c	rs587777017
.	O
474delA	rs587777017
mutation	O
has	O
been	O
identified	O
in	O
a	O
family	O
with	O
heritable	O
pulmonary	D000081029
arterial	D000081029
hypertension	D000081029
(	O
PAH	D000081029
)	O
.	O

This	O
frameshift	O
mutation	O
leads	O
to	O
a	O
caveolin	857
-	O
1	857
protein	O
that	O
contains	O
all	O
known	O
functional	O
domains	O
but	O
has	O
a	O
change	O
in	O
only	O
the	O
final	O
20	O
amino	O
acids	O
of	O
the	O
C	O
-	O
terminus	O
.	O

Here	O
we	O
studied	O
how	O
this	O
mutation	O
alters	O
caveolin	857
-	O
1	857
function	O
,	O
using	O
patient	9606
-	O
derived	O
fibroblasts	O
.	O

Transmission	O
electron	O
microscopy	O
showed	O
that	O
fibroblasts	O
carrying	O
the	O
c	rs587777017
.	O
474delA	rs587777017
mutation	O
form	O
typical	O
caveolae	O
.	O

Expression	O
of	O
mutated	O
caveolin	857
-	O
1	857
in	O
caveolin	12389
-	O
1	12389
-	O
null	O
mouse	10090
fibroblasts	O
failed	O
to	O
induce	O
formation	O
of	O
caveolae	O
due	O
to	O
retention	O
of	O
the	O
mutated	O
protein	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

However	O
,	O
coexpression	O
of	O
wild	O
-	O
type	O
caveolin	857
-	O
1	857
with	O
mutated	O
caveolin	857
-	O
1	857
restored	O
the	O
ability	O
to	O
form	O
caveolae	O
.	O

Importantly	O
,	O
fibroblasts	O
carrying	O
the	O
mutation	O
showed	O
twofold	O
increase	O
in	O
proliferation	O
rate	O
associated	O
with	O
hyperphosphorylation	O
of	O
Smad1	4086,4090,4093
/	O
5	4086,4090,4093
/	O
8	4086,4090,4093
.	O

This	O
mutation	O
impaired	O
the	O
antiproliferative	O
function	O
of	O
caveolin	857
-	O
1	857
.	O

Inhibition	O
of	O
type	657,658,90,94
I	657,658,90,94
TGFb	657,658,90,94
receptors	657,658,90,94
ALK1	657,658,90,94
/	O
2	657,658,90,94
/	O
3	657,658,90,94
/	O
6	657,658,90,94
responsible	O
for	O
phosphorylation	O
of	O
Smad1	4086,4090,4093
/	O
5	4086,4090,4093
/	O
8	4086,4090,4093
reduced	O
the	O
hyperproliferation	O
seen	O
in	O
c	rs587777017
.	O
474delA	rs587777017
fibroblasts	O
.	O

These	O
results	O
demonstrate	O
the	O
critical	O
role	O
of	O
the	O
final	O
20	O
amino	O
acids	O
of	O
caveolin	857
-	O
1	857
in	O
modulating	O
fibroblast	O
proliferation	O
by	O
dampening	O
Smad	4086,4090,4093
signaling	O
and	O
suggest	O
that	O
augmented	O
Smad	4086,4090,4093
signaling	O
and	O
fibroblast	O
hyperproliferation	O
are	O
contributing	O
factors	O
in	O
the	O
pathogenesis	O
of	O
PAH	D000081029
in	O
patients	9606
with	O
caveolin	857
-	O
1	857
c	rs587777017
.	O
474delA	rs587777017
mutation	O
.	O
Mutations	O
in	O
N	8473
-	O
acetylglucosamine	8473
(	O
O	8473
-	O
GlcNAc	8473
)	O
transferase	8473
in	O
patients	9606
with	O
X	D038901
-	O
linked	D038901
intellectual	D038901
disability	D038901
.	O

N	8473
-	O
Acetylglucosamine	8473
(	O
O	8473
-	O
GlcNAc	8473
)	O
transferase	8473
(	O
OGT	8473
)	O
regulates	O
protein	O
O	8473
-	O
GlcNAcylation	8473
,	O
an	O
essential	O
and	O
dynamic	O
post	O
-	O
translational	O
modification	O
.	O

The	O
O	8473
-	O
GlcNAc	8473
modification	O
is	O
present	O
on	O
numerous	O
nuclear	O
and	O
cytosolic	O
proteins	O
and	O
has	O
been	O
implicated	O
in	O
essential	O
cellular	O
functions	O
such	O
as	O
signaling	O
and	O
gene	O
expression	O
.	O

Accordingly	O
,	O
altered	O
levels	O
of	O
protein	O
O	8473
-	O
GlcNAcylation	8473
have	O
been	O
associated	O
with	O
developmental	D003147
defects	D003147
and	O
neurodegeneration	D019636
.	O

However	O
,	O
mutations	O
in	O
the	O
OGT	8473
gene	O
have	O
not	O
yet	O
been	O
functionally	O
confirmed	O
in	O
humans	9606
.	O

Here	O
,	O
we	O
report	O
on	O
two	O
hemizygous	O
mutations	O
in	O
OGT	8473
in	O
individuals	O
with	O
X	D038901
-	O
linked	D038901
intellectual	D038901
disability	D038901
(	O
XLID	D038901
)	O
and	O
dysmorphic	O
features	O
:	O
one	O
missense	O
mutation	O
(	O
p	rs1114167891
.	O
Arg284Pro	rs1114167891
)	O
and	O
one	O
mutation	O
leading	O
to	O
a	O
splicing	O
defect	O
(	O
c	c|SUB|T463-6|G
.	O
463	c|SUB|T463-6|G
-	O
6T	c|SUB|T463-6|G
>	O
G	c|SUB|T463-6|G
)	O
.	O

Both	O
mutations	O
reside	O
in	O
the	O
tetratricopeptide	O
repeats	O
of	O
OGT	8473
that	O
are	O
essential	O
for	O
substrate	O
recognition	O
.	O

We	O
observed	O
slightly	O
reduced	O
levels	O
of	O
OGT	8473
protein	O
and	O
reduced	O
levels	O
of	O
its	O
opposing	O
enzyme	O
O	10724
-	O
GlcNAcase	10724
in	O
both	O
patient	9606
-	O
derived	O
fibroblasts	O
,	O
but	O
global	O
O	8473
-	O
GlcNAc	8473
levels	O
appeared	O
to	O
be	O
unaffected	O
.	O

Our	O
data	O
suggest	O
that	O
mutant	O
cells	O
attempt	O
to	O
maintain	O
global	O
O	8473
-	O
GlcNAcylation	8473
by	O
down	O
-	O
regulating	O
O	10724
-	O
GlcNAcase	10724
expression	O
.	O

We	O
also	O
found	O
that	O
the	O
c	c|SUB|T463-6|G
.	O
463	c|SUB|T463-6|G
-	O
6T	c|SUB|T463-6|G
>	O
G	c|SUB|T463-6|G
mutation	O
leads	O
to	O
aberrant	O
mRNA	O
splicing	O
,	O
but	O
no	O
stable	O
truncated	O
protein	O
was	O
detected	O
in	O
the	O
corresponding	O
patient	9606
-	O
derived	O
fibroblasts	O
.	O

Recombinant	O
OGT	8473
bearing	O
the	O
p	rs1114167891
.	O
Arg284Pro	rs1114167891
mutation	O
was	O
prone	O
to	O
unfolding	O
and	O
exhibited	O
reduced	O
glycosylation	O
activity	O
against	O
a	O
complex	O
array	O
of	O
glycosylation	O
substrates	O
and	O
proteolytic	O
processing	O
of	O
the	O
transcription	O
factor	O
host	3054
cell	3054
factor	3054
1	3054
,	O
which	O
is	O
also	O
encoded	O
by	O
an	O
XLID	D038901
-	O
associated	O
gene	O
.	O

We	O
conclude	O
that	O
defects	O
in	O
O	8473
-	O
GlcNAc	8473
homeostasis	O
and	O
host	3054
cell	3054
factor	3054
1	3054
proteolysis	O
may	O
play	O
roles	O
in	O
mediation	O
of	O
XLID	D038901
in	O
individuals	O
with	O
OGT	8473
mutations	O
.	O
Cardiovascular	D002318
complications	D002318
associated	O
with	O
terbutaline	D013726
treatment	O
for	O
preterm	D007752
labor	D007752
.	O

Severe	O
cardiovascular	D002318
complications	D002318
occurred	O
in	O
eight	O
of	O
160	O
patients	9606
treated	O
with	O
terbutaline	D013726
for	O
preterm	D007752
labor	D007752
.	O

Associated	O
corticosteroid	D000305
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O

Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O
Long	O
-	O
term	O
oral	O
galactose	D005690
treatment	O
prevents	O
cognitive	D003072
deficits	D003072
in	O
male	O
Wistar	O
rats	10116
treated	O
intracerebroventricularly	O
with	O
streptozotocin	D013311
.	O

Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	D003704
of	O
sporadic	O
Alzheimer	D000544
'	O
s	D000544
disease	D000544
(	O
sAD	D000544
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	24954
-	O
receptor	24954
(	O
IR	24954
)	O
system	O
followed	O
by	O
decreased	O
glucose	D005947
transport	O
via	O
glucose	D005947
transporter	O
GLUT4	25139
and	O
decreased	O
glucose	D005947
metabolism	O
in	O
brain	O
cells	O
.	O

An	O
alternative	O
source	O
of	O
energy	O
is	O
d	D005690
-	O
galactose	D005690
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	D005947
-	O
glucose	D005947
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	24505
-	O
independent	O
GLUT3	25551
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	D005947
via	O
the	O
Leloir	O
pathway	O
.	O

Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	D005690
induce	O
memory	D008569
deterioration	D008569
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	D005690
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	D005690
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	D003072
deficits	D003072
in	O
streptozotocin	D013311
-	O
induced	O
(	O
STZ	D013311
-	O
icv	O
)	O
rat	10116
model	O
of	O
sAD	D000544
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O

One	O
month	O
of	O
oral	O
galactose	D005690
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	D013311
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	D013311
-	O
icv	O
-	O
induced	O
cognitive	D003072
deficits	D003072
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	D005690
was	O
independent	O
of	O
the	O
rat	10116
age	O
and	O
of	O
the	O
galactose	D005690
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Additionally	O
,	O
oral	O
galactose	D005690
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	D005690
in	O
the	O
blood	O
.	O

The	O
increase	O
of	O
galactose	D005690
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	D005690
dose	O
.	O

Oral	O
galactose	D005690
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	D003072
deficits	D003072
associated	O
with	O
glucose	D018149
hypometabolism	D018149
in	O
AD	D000544
.	O
Biophysical	O
and	O
functional	O
characterization	O
of	O
hippocalcin	3208
mutants	O
responsible	O
for	O
human	9606
dystonia	D004421
.	O

Dystonia	D004421
is	O
a	O
neurological	D009069
movement	D009069
disorder	D009069
that	O
forces	O
the	O
body	O
into	O
twisting	O
,	O
repetitive	O
movements	O
or	O
sometimes	O
painful	O
abnormal	O
postures	O
.	O

With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
,	O
the	O
homozygous	O
mutations	O
T71N	rs775863165
and	O
A190T	rs550921485
in	O
the	O
neuronal	3208
calcium	3208
sensor	3208
(	O
NCS	3208
)	O
hippocalcin	3208
were	O
identified	O
as	O
the	O
genetic	O
cause	O
of	O
primary	D004421
isolated	D004421
dystonia	D004421
(	O
DYT2	3208
dystonia	D004421
)	O
.	O

However	O
,	O
the	O
effect	O
of	O
these	O
mutations	O
on	O
the	O
physiological	O
role	O
of	O
hippocalcin	3208
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Using	O
a	O
multidisciplinary	O
approach	O
,	O
we	O
demonstrated	O
that	O
hippocalcin	3208
oligomerises	O
in	O
a	O
calcium	D002118
-	O
dependent	O
manner	O
and	O
binds	O
to	O
voltage	783
-	O
gated	783
calcium	783
channels	783
.	O

Mutations	O
T71N	rs775863165
and	O
A190T	rs550921485
in	O
hippocalcin	3208
did	O
not	O
affect	O
stability	O
,	O
calcium	D002118
-	O
binding	O
affinity	O
or	O
translocation	O
to	O
cellular	O
membranes	O
(	O
Ca2	D000069285
+	O
/	O
myristoyl	O
switch	O
)	O
.	O

We	O
obtained	O
the	O
first	O
crystal	O
structure	O
of	O
hippocalcin	3208
and	O
alignment	O
with	O
other	O
NCS	3208
proteins	O
showed	O
significant	O
variability	O
in	O
the	O
orientation	O
of	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
molecule	O
,	O
the	O
region	O
expected	O
to	O
be	O
important	O
for	O
target	O
binding	O
.	O

We	O
demonstrated	O
that	O
the	O
disease	O
-	O
causing	O
mutations	O
did	O
not	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
,	O
however	O
both	O
mutants	O
showed	O
a	O
defect	O
in	O
oligomerisation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
an	O
increased	O
calcium	D002118
influx	O
in	O
KCl	D011189
-	O
depolarised	O
cells	O
expressing	O
mutated	O
hippocalcin	3208
,	O
mostly	O
driven	O
by	O
N	774
-	O
type	774
voltage	774
-	O
gated	774
calcium	774
channels	774
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
dystonia	D004421
-	O
causing	O
mutations	O
strongly	O
affect	O
hippocalcin	3208
cellular	O
functions	O
which	O
suggest	O
a	O
central	O
role	O
for	O
perturbed	O
calcium	D002118
signalling	O
in	O
DYT2	3208
dystonia	D004421
.	O
Primary	D016543
malignant	D016543
lymphoma	D016543
of	D016543
the	D016543
brain	D016543
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	11102
tumor	D009369
suppressor	O
gene	O
.	O

Ten	O
primary	D016543
central	D016543
nervous	D016543
system	D016543
lymphomas	D016543
(	O
PCNSL	D016543
,	O
brain	D016543
lymphomas	D016543
)	O
were	O
examined	O
for	O
p14	11102
gene	O
exon	O
1beta	O
deletion	O
,	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
,	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot	O
-	O
based	O
methylation	O
assay	O
.	O

In	O
Southern	O
blot	O
analysis	O
,	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
,	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
,	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O

Thus	O
,	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	11102
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
,	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O

In	O
addition	O
,	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	D009369
,	O
we	O
detected	O
a	O
missense	O
mutation	O
(	O
L50R	p|SUB|L|50|R
)	O
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O

Methylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p14	11102
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O

Our	O
observation	O
of	O
frequent	O
p14	11102
gene	O
abnormalities	O
(	O
90%	O
)	O
and	O
inactivation	O
(	O
40	O
-	O
60%	O
)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	D008223
lymphoma	D008223
in	O
which	O
p14	11102
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
,	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	D063646
between	O
PCNSL	D016543
and	O
systemic	D008223
lymphoma	D008223
.	O
Learning	D007859,D008569
and	D007859,D008569
memory	D007859,D008569
deficits	D007859,D008569
in	O
ecstasy	D018817
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	D018817
users	O
display	O
impairments	D007859,D008569
in	D007859,D008569
learning	D007859,D008569
and	D007859,D008569
memory	D007859,D008569
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	D018817
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	D018817
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	D002188
use	O
of	O
the	O
ecstasy	D018817
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	D002188
users	O
(	O
Nestor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O

Deficits	D007859,D008569
in	D007859,D008569
learning	D007859,D008569
and	D007859,D008569
memory	D007859,D008569
:	O
parahippocampal	O
hyperactivity	D006948
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	D002188
users	O
.	O

Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecstasy	D018817
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	D002188
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	D018817
-	O
specific	O
hyperactivity	D006948
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy	D018817
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	D018817
and	O
cannabis	D002188
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy	D018817
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	D002188
use	O
.	O

These	O
ecstasy	D018817
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	D020258
effects	O
of	O
ecstasy	D018817
.	O
Variation	O
in	O
the	O
CXCR1	3577
gene	O
(	O
IL8RA	3577
)	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
chronic	D055113
periodontitis	D055113
.	O

BACKGROUND	O
:	O
The	O
chemokine	3577
receptor	3577
1	3577
CXCR	3577
-	O
1	3577
(	O
or	O
IL8R	3577
-	O
alpha	3577
)	O
is	O
a	O
specific	O
receptor	O
for	O
the	O
interleukin	3576
8	3576
(	O
IL	3576
-	O
8	3576
)	O
,	O
which	O
is	O
chemoattractant	O
for	O
neutrophils	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
inflammatory	D007249
response	O
.	O

The	O
polymorphism	O
rs2234671	rs2234671
at	O
position	O
Ex2	rs2234671
+	O
860G	rs2234671
>	O
C	rs2234671
of	O
the	O
CXCR1	3577
gene	O
causes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
(	O
S276T	rs2234671
)	O
.	O

This	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
seemed	O
to	O
be	O
functional	O
as	O
it	O
was	O
associated	O
with	O
decreased	O
lung	D008175
cancer	D008175
risk	O
.	O

Previous	O
studies	O
of	O
our	O
group	O
found	O
association	O
of	O
haplotypes	O
in	O
the	O
IL8	3576
and	O
in	O
the	O
CXCR2	3579
genes	O
with	O
the	O
multifactorial	O
disease	O
chronic	D055113
periodontitis	D055113
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
polymorphism	O
rs2234671	rs2234671
in	O
395	O
Brazilian	O
subjects	O
with	O
and	O
without	O
chronic	D055113
periodontitis	D055113
.	O

FINDINGS	O
:	O
Similar	O
distribution	O
of	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
observed	O
between	O
the	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphism	O
rs2234671	rs2234671
in	O
the	O
CXCR1	3577
gene	O
was	O
not	O
associated	O
with	O
the	O
susceptibility	O
to	O
chronic	D055113
periodontitis	D055113
in	O
the	O
studied	O
Brazilian	O
population	O
.	O
Disease	O
-	O
associated	O
mutations	O
in	O
human	9606
BICD2	23299
hyperactivate	O
motility	O
of	O
dynein	1778
-	O
dynactin	1639
.	O

Bicaudal	23299
D2	23299
(	O
BICD2	23299
)	O
joins	O
dynein	1778
with	O
dynactin	1639
into	O
a	O
ternary	O
complex	O
(	O
termed	O
DDB	1639,1778,23299
)	O
capable	O
of	O
processive	O
movement	O
.	O

Point	O
mutations	O
in	O
the	O
BICD2	23299
gene	O
have	O
been	O
identified	O
in	O
patients	9606
with	O
a	O
dominant	O
form	O
of	O
spinal	D009134
muscular	D009134
atrophy	D009134
,	O
but	O
how	O
these	O
mutations	O
cause	O
disease	O
is	O
unknown	O
.	O

To	O
investigate	O
this	O
question	O
,	O
we	O
have	O
developed	O
in	O
vitro	O
motility	O
assays	O
with	O
purified	O
DDB	1639,1778,76895
and	O
BICD2	76895
'	O
s	O
membrane	O
vesicle	O
partner	O
,	O
the	O
GTPase	5870
Rab6a	5870
.	O

Rab6a	5870
-	O
GTP	5870
,	O
either	O
in	O
solution	O
or	O
bound	O
to	O
artificial	O
liposomes	O
,	O
released	O
BICD2	76895
from	O
an	O
autoinhibited	O
state	O
and	O
promoted	O
robust	O
dynein	1778
-	O
dynactin	1639
transport	O
.	O

In	O
these	O
assays	O
,	O
BICD2	76895
mutants	O
showed	O
an	O
enhanced	O
ability	O
to	O
form	O
motile	O
DDB	1639,1778,23299
complexes	O
.	O

Increased	O
retrograde	O
transport	O
by	O
BICD2	76895
mutants	O
also	O
was	O
observed	O
in	O
cells	O
using	O
an	O
inducible	O
organelle	O
transport	O
assay	O
.	O

When	O
overexpressed	O
in	O
rat	10116
hippocampal	O
neurons	O
,	O
the	O
hyperactive	O
BICD2	76895
mutants	O
decreased	O
neurite	O
growth	O
.	O

Our	O
results	O
reveal	O
that	O
dominant	O
mutations	O
in	O
BICD2	76895
hyperactivate	O
DDB	1639,1778,23299
motility	O
and	O
suggest	O
that	O
an	O
imbalance	O
of	O
minus	O
versus	O
plus	O
end	O
-	O
directed	O
microtubule	O
motility	O
in	O
neurons	O
may	O
underlie	O
spinal	D009134
muscular	D009134
atrophy	D009134
.	O
Glucose	D005947
metabolism	O
in	O
patients	O
with	O
schizophrenia	D012559
treated	O
with	O
atypical	O
antipsychotic	D014150
agents	D014150
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	D005947
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	D003920
mellitus	D003920
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	D012559
treated	O
with	O
certain	O
atypical	O
antipsychotic	D014150
agents	D014150
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	D005947
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	D003920
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	D003024
and	O
olanzapine	C076029
)	O
and	O
risperidone	D018967
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	D005947
tolerance	O
test	O
.	O

DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	D012559
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	D005947
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O

Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	D005947
tolerance	O
test	O
.	O

Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	D012559
or	O
schizoaffective	D011618
disorder	D011618
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	D003024
,	O
olanzapine	C076029
,	O
or	O
risperidone	D018967
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	D005947
and	O
fasting	O
serum	O
insulin	D007328
levels	O
,	O
insulin	O
sensitivity	O
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	D007333
resistance	D007333
,	O
and	O
glucose	D005947
effectiveness	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	D014150
agent	D014150
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
months	O
(	O
clozapine	D003024
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
months	O
(	O
olanzapine	C076029
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risperidone	D018967
)	O
.	O

Fasting	O
serum	O
insulin	D007328
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozapine	D003024
>	O
olanzapine	C076029
>	O
risperidone	D018967
)	O
with	O
significant	O
differences	O
between	O
clozapine	D003024
and	O
risperidone	D018967
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzapine	C076029
and	O
risperidone	D018967
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	O
sensitivity	O
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
clozapine	D003024
<	O
olanzapine	C076029
<	O
risperidone	D018967
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	D003024
and	O
olanzapine	C076029
exhibiting	O
significant	O
insulin	D007333
resistance	D007333
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	D018967
(	O
clozapine	D003024
vs	O
risperidone	D018967
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olanzapine	C076029
vs	O
risperidone	D018967
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	D007333
resistance	D007333
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clozapine	D003024
>	O
olanzapine	C076029
>	O
risperidone	D018967
)	O
(	O
clozapine	D003024
vs	O
risperidone	D018967
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanzapine	C076029
vs	O
risperidone	D018967
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	D005947
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clozapine	D003024
<	O
olanzapine	C076029
<	O
risperidone	D018967
)	O
with	O
significant	O
differences	O
between	O
clozapine	D003024
and	O
risperidone	D018967
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzapine	C076029
and	O
risperidone	D018967
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	D003024
-	O
and	O
olanzapine	C076029
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	D007333
resistance	D007333
and	O
impairment	O
of	O
glucose	D005947
effectiveness	O
compared	O
with	O
risperidone	D018967
-	O
treated	O
subjects	O
.	O

Patients	O
taking	O
clozapine	D003024
and	O
olanzapine	C076029
must	O
be	O
examined	O
for	O
insulin	D007333
resistance	D007333
and	O
its	O
consequences	O
.	O
Debrisoquine	D003647
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta	154
-	O
2	154
receptor	154
pharmacodynamics	O
of	O
metoprolol	D008790
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	D008790
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	D003647
/	O
sparteine	D013034
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta	153
-	O
1	153
adrenoceptor	153
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	D008790
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta	154
-	O
2	154
adrenoceptor	154
antagonism	O
by	O
metoprolol	D008790
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	D008790
of	O
terbutaline	D013726
-	O
induced	O
hypokalemia	D007008
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	D008790
and	O
the	O
active	O
S	O
-	O
isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	D008790
plasma	O
concentrations	O
resulting	O
in	O
half	O
-	O
maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0	O
.	O
5	O
mg	O
of	O
terbutaline	D013726
s	O
.	O
c	O
.	O

on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	D008790
p	O
.	O
o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	D013726
dose	O
(	O
0	O
.	O
75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	D011188
,	O
terbutaline	D013726
,	O
metoprolol	D008790
(	O
racemic	O
,	O
R	O
-	O
and	O
S	O
-	O
isomer	O
)	O
,	O
and	O
alpha	C029504
-	O
hydroxymetoprolol	C029504
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	D008790
.	O

In	O
PMs	O
,	O
metoprolol	D008790
increased	O
the	O
terbutaline	D013726
area	O
under	O
the	O
plasma	O
concentration	O
vs	O
.	O

time	O
curve	O
(	O
+	O
67%	O
)	O
.	O

Higher	O
metoprolol	D008790
/	O
alpha	C029504
-	O
hydroxymetoprolol	C029504
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R	O
-	O
/	O
S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	D008790
potency	O
with	O
higher	O
racemic	O
metoprolol	D008790
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+	O
/	O
-	O
7	O
ng	O
.	O
ml	O
-	O
1	O
)	O
than	O
EMs	O
(	O
42	O
+	O
/	O
-	O
8	O
ng	O
.	O
ml	O
-	O
1	O
,	O
P	O
less	O
than	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Dexrazoxane	D064730
protects	O
against	O
myelosuppression	D001855
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	D005047
and	O
daunorubicin	D003630
but	O
not	O
doxorubicin	D004317
.	O

PURPOSE	O
:	O
The	O
anthracyclines	D018943
daunorubicin	D003630
and	O
doxorubicin	D004317
and	O
the	O
epipodophyllotoxin	D011034
etoposide	D005047
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	D001855
and	O
cardiac	D066126
toxicity	D066126
limit	O
their	O
use	O
.	O

Dexrazoxane	D064730
(	O
ICRF	D064730
-	O
187	D064730
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	D018943
-	O
induced	O
cardiotoxicity	D066126
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	D006402
toxicity	D006402
following	O
coadministration	O
of	O
dexrazoxane	D064730
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	9606
and	O
murine	10090
blood	O
progenitor	O
cells	O
to	O
etoposide	D005047
,	O
daunorubicin	D003630
,	O
and	O
doxorubicin	D004317
+	O
/	O
-	O
dexrazoxane	D064730
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	10090
were	O
treated	O
with	O
etoposide	D005047
,	O
daunorubicin	D003630
,	O
and	O
doxorubicin	D004317
,	O
with	O
or	O
without	O
dexrazoxane	D064730
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	D064730
reduced	O
myelosuppression	D001855
and	O
weight	D015431
loss	D015431
from	O
daunorubicin	D003630
and	O
etoposide	D005047
in	O
mice	10090
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	D064730
neither	O
reduced	O
myelosuppression	D001855
,	O
weight	D015431
loss	D015431
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	D064420
from	O
doxorubicin	D004317
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	D064730
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	D004317
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	D003630
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	D005047
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	D064730
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	D009362
combining	O
dexrazoxane	D064730
and	O
high	O
doses	O
of	O
etoposide	D005047
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	D006402
toxicity	D006402
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	D064420
chemotherapy	O
.	O
GATA4	2626
mutations	O
in	O
486	O
Chinese	O
patients	9606
with	O
congenital	D006331
heart	D006331
disease	D006331
.	O

Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	2626
gene	O
in	O
some	O
types	O
of	O
congenital	D006331
heart	D006331
disease	D006331
(	O
CHD	D006331
)	O
.	O

However	O
,	O
the	O
prevalence	O
of	O
GATA4	2626
mutations	O
in	O
CHD	D006331
and	O
the	O
correlation	O
between	O
the	O
GATA4	2626
genotype	O
and	O
CHD	D006331
phenotype	O
have	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	2626
gene	O
in	O
486	O
CHD	D006331
patients	9606
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
,	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O

Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
(	O
46delS	|DEL|46|S
)	O
,	O
two	O
small	O
insertion	O
mutations	O
(	O
118	|INS|118_119|A
-	O
119insA	|INS|118_119|A
and	O
125	|INS|125_126|AA
-	O
126insAA	|INS|125_126|AA
)	O
,	O
and	O
six	O
non	O
-	O
synonymous	O
mutations	O
(	O
A6V	rs199922907
,	O
P163S	rs387906769
,	O
E359K	rs368489876
,	O
P407Q	rs115099192
,	O
S429T	p|SUB|S|429|T
and	O
A442V	rs146017816
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	9606
(	O
nine	O
with	O
ventricular	D006345
septal	D006345
defect	D006345
,	O
two	O
with	O
Tetralogy	D013771
of	D013771
Fallot	D013771
,	O
and	O
one	O
with	O
endocardial	D004694
cushion	D004694
defect	D004694
)	O
.	O

Of	O
them	O
,	O
two	O
patients	9606
carrying	O
E359K	rs368489876
mutation	O
were	O
from	O
two	O
generations	O
in	O
one	O
family	O
with	O
ventricular	D006345
septal	D006345
defect	D006345
(	O
VSD	D006345
)	O
.	O

Interestingly	O
,	O
a	O
nucleotide	O
insertion	O
of	O
c	c|INS|1146+25|A
.	O
1146	c|INS|1146+25|A
+	O
25insA	c|INS|1146+25|A
in	O
exon	O
6	O
was	O
detected	O
in	O
five	O
VSD	D006345
patients	9606
,	O
but	O
not	O
in	O
486	O
normal	O
healthy	O
controls	O
.	O

Our	O
findings	O
are	O
useful	O
in	O
understanding	O
the	O
prevalence	O
of	O
GATA4	2626
mutations	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	2626
genotype	O
and	O
the	O
CHD	D006331
phenotype	O
in	O
Chinese	O
patients	9606
.	O
Two	O
novel	O
mutations	O
of	O
the	O
TSH	7252
-	O
beta	7252
subunit	O
gene	O
underlying	O
congenital	D003409
central	D003409
hypothyroidism	D003409
undetectable	O
in	O
neonatal	O
TSH	7252
screening	O
.	O

CONTEXT	O
:	O
Patients	9606
with	O
TSH	7252
-	O
beta	7252
subunit	O
defects	O
and	O
congenital	D003409
hypothyroidism	D003409
are	O
missed	O
by	O
TSH	7252
-	O
based	O
neonatal	O
screening	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
report	O
the	O
molecular	O
consequences	O
of	O
a	O
novel	O
splice	O
-	O
junction	O
mutation	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
TSH	7252
-	O
beta	7252
subunit	O
gene	O
found	O
in	O
two	O
patients	9606
with	O
congenital	D003409
central	D003409
hypothyroidism	D003409
and	O
conventional	O
treatment	O
-	O
resistant	O
anemia	D000740
.	O

RESULTS	O
:	O
Patient	9606
1	O
had	O
a	O
homozygous	O
G	c|SUB|G||A
to	c|SUB|G||A
A	c|SUB|G||A
nucleotide	O
change	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
of	O
exon	O
/	O
intron	O
2	O
.	O

This	O
resulted	O
in	O
a	O
silent	O
change	O
at	O
codon	O
34	O
of	O
the	O
mature	O
protein	O
.	O

In	O
vitro	O
splicing	O
assays	O
showed	O
that	O
the	O
mutant	O
minigene	O
dramatically	O
affected	O
pre	O
-	O
mRNA	O
processing	O
,	O
causing	O
exon	O
2	O
to	O
be	O
completely	O
skipped	O
.	O

The	O
putative	O
product	O
from	O
a	O
new	O
out	O
-	O
of	O
-	O
frame	O
translational	O
start	O
point	O
in	O
exon	O
3	O
is	O
expected	O
to	O
yield	O
a	O
nonsense	O
25	O
-	O
amino	O
-	O
acid	O
peptide	O
.	O

In	O
patient	9606
2	O
,	O
sequence	O
analysis	O
revealed	O
a	O
compound	O
heterozygosis	O
for	O
the	O
already	O
reported	O
313delT	c|DEL|313|T
(	O
C105Vfs114X	p|FS|C|105|V|114
)	O
mutation	O
and	O
for	O
a	O
second	O
novel	O
mutation	O
in	O
exon	O
3	O
,	O
substituting	O
G	c|SUB|G|323|A
for	c|SUB|G|323|A
A	c|SUB|G|323|A
at	c|SUB|G|323|A
cDNA	c|SUB|G|323|A
nucleotide	c|SUB|G|323|A
position	c|SUB|G|323|A
323	c|SUB|G|323|A
,	O
resulting	O
in	O
a	O
C88Y	p|SUB|C|88|Y
change	O
.	O

This	O
cysteine	O
residue	O
is	O
conserved	O
among	O
all	O
dimeric	O
pituitary	O
and	O
placental	O
glycoprotein	122876
hormone	122876
-	O
beta	122876
subunits	122876
.	O

Data	O
from	O
in	O
silico	O
analysis	O
confirmed	O
that	O
the	O
C88Y	p|SUB|C|88|Y
mutation	O
would	O
affect	O
subunit	O
conformation	O
.	O

Indeed	O
,	O
two	O
different	O
bioinformatics	O
approaches	O
,	O
PolyPhen	O
and	O
SIFT	O
analysis	O
,	O
predicted	O
C88Y	p|SUB|C|88|Y
to	O
be	O
a	O
damaging	O
substitution	O
.	O

CONCLUSIONS	O
:	O
In	O
isolated	O
TSH	D007037
deficiency	D007037
,	O
the	O
exact	O
molecular	O
diagnosis	O
is	O
mandatory	O
for	O
diagnosis	O
of	O
isolated	C566321
pituitary	C566321
deficiency	C566321
,	O
delineation	O
of	O
prognosis	O
,	O
and	O
genetic	O
counseling	O
.	O

Moreover	O
,	O
diagnosis	O
of	O
central	D007037
hypothyroidism	D007037
should	O
be	O
considered	O
in	O
the	O
face	O
of	O
severe	O
infant	O
anemia	D000740
of	O
uncertain	O
etiology	O
.	O
Characterization	O
of	O
a	O
novel	O
BCHE	590
""""	O
silent	O
""""	O
allele	O
:	O
point	O
mutation	O
(	O
p	p|SUB|V|204|D
.	O
Val204Asp	p|SUB|V|204|D
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	D001049
with	O
suxamethonium	D013390
.	O

Butyrylcholinesterase	C537417
deficiency	C537417
is	O
characterized	O
by	O
prolonged	O
apnea	D001049
after	O
the	O
use	O
of	O
muscle	-
relaxants	-
(	O
suxamethonium	D013390
or	O
mivacurium	D000077590
)	O
in	O
patients	9606
who	O
have	O
mutations	O
in	O
the	O
BCHE	590
gene	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	D055191
block	D055191
after	O
administration	O
of	O
suxamethonium	D013390
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	590
variant	O
(	O
c	c|SUB|T|695|A
.	O
695T	c|SUB|T|695|A
>	O
A	c|SUB|T|695|A
,	O
p	p|SUB|V|204|D
.	O
Val204Asp	p|SUB|V|204|D
)	O
.	O

Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
""""	O
silent	O
""""	O
phenotype	O
.	O

Low	O
activity	O
of	O
patient	9606
plasma	O
butyrylcholinesterase	590
with	O
butyrylthiocholine	D002092
(	O
BTC	D002092
)	O
and	O
benzoylcholine	D001588
,	O
and	O
values	O
of	O
dibucaine	D003992
and	O
fluoride	D005459
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O

Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	590
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	9606
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	590
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
p	p|SUB|V|204|D
.	O
Val204Asp	p|SUB|V|204|D
/	O
p	rs1799807
.	O
Asp70Gly	rs1799807
-	O
p	rs1803274
.	O
Ala539Thr	rs1803274
BChE	590
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	D002092
as	O
the	O
substrate	O
.	O

Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	D002092
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	D013390
.	O

Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	p|SUB|V|204|D
.	O
Val204Asp	p|SUB|V|204|D
is	O
disruption	O
of	O
hydrogen	O
bonding	O
between	O
Gln223	p|Allele|Q|223
and	O
Glu441	p|Allele|E|2441
,	O
leading	O
Ser198	p|Allele|S|198
and	O
His438	p|Allele|H|438
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	p|SUB|A|204|D
.	O
Ala204Asp	p|SUB|A|204|D
/	O
p	rs1799807
.	O
Asp70Gly	rs1799807
-	O
p	rs1803274
.	O
Ala539Thr	rs1803274
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O
The	O
promoter	O
of	O
inducible	O
nitric	4843
oxide	4843
synthase	4843
implicated	O
in	O
glaucoma	D005901
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O

PURPOSE	O
:	O
Nitric	D009569
oxide	D009569
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	9606
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	D009422
and	D009422
non	D009422
-	O
neurological	D009422
disorders	D009422
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	4843
Oxide	4843
Synthase	4843
,	O
iNOS	4843
,	O
and	O
the	O
neuropathological	D005901
disorder	D005901
glaucoma	D005901
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	D001766
in	O
the	O
world	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	4843
and	O
primary	D005902
open	D005902
angle	D005902
glaucoma	D005902
,	O
POAG	D005902
,	O
and	O
to	O
find	O
the	O
functional	O
element	O
(	O
s	O
)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion	O
/	O
deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	4843
were	O
genotyped	O
in	O
200	O
POAG	D005902
patients	9606
and	O
200	O
age	O
-	O
matched	O
controls	O
.	O

Also	O
,	O
the	O
CCTTT	O
-	O
microsatellite	O
was	O
examined	O
for	O
its	O
protein	O
-	O
binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
between	O
patients	9606
and	O
controls	O
.	O

(	O
CCTTT	c|DUP||CCTTT|14
)	O
14	c|DUP||CCTTT|14
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter	O
-	O
construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	D005902
patients	9606
,	O
while	O
(	O
CCTTT	c|DUP||CCTTT|10
)	O
10	c|DUP||CCTTT|10
and	O
(	O
CCTTT	c|DUP||CCTTT|13
)	O
13	c|DUP||CCTTT|13
were	O
less	O
common	O
.	O

In	O
EMSA	O
,	O
the	O
(	O
CCTTT	c|DUP||CCTTT|14
)	O
14	c|DUP||CCTTT|14
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	4843
with	O
POAG	D005902
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O
Severe	O
form	O
of	O
thyroid	D018382
hormone	D018382
resistance	D018382
in	O
a	O
patient	9606
with	O
homozygous	O
/	O
hemizygous	O
mutation	O
of	O
T3	7068
receptor	7068
gene	O
.	O

Resistance	D018382
to	D018382
thyroid	D018382
hormone	D018382
syndrome	D018382
(	O
RTH	D018382
)	O
is	O
a	O
rare	O
disorder	O
,	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Patients	9606
with	O
RTH	D018382
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	D013971
or	O
rarely	O
with	O
hypothyroidism	D007037
.	O

Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	7068
hormone	7068
receptor	7068
beta	7068
gene	O
(	O
TR	7068
-	O
beta	7068
)	O
.	O

We	O
present	O
a	O
patient	9606
with	O
RTH	D018382
found	O
to	O
be	O
homo	O
-	O
/	O
hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR	7068
-	O
beta	7068
gene	O
.	O

The	O
single	O
nucleotide	O
substitution	O
I280S	p|SUB|I|280|S
(	O
1123T	g|SUB|T|1123|G
-	O
-	O
>	O
G	g|SUB|T|1123|G
)	O
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

The	O
I280S	p|SUB|I|280|S
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	9606
.	O

The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	D008607
intellectual	D008607
development	D008607
,	O
hyperkinetic	D006948
behaviour	O
,	O
tachycardia	D013610
,	O
hearing	D006311,D014786
and	D006311,D014786
visual	D006311,D014786
impairment	D006311,D014786
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	p|SUB|I|280|S
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR	7068
-	O
beta	7068
.	O
The	O
androgen	11835
receptor	11835
confers	O
protection	O
against	O
diet	O
-	O
induced	O
atherosclerosis	D050197
,	O
obesity	D009765
,	O
and	O
dyslipidemia	D050171
in	O
female	O
mice	10090
.	O

Androgens	D000728
have	O
important	O
cardiometabolic	O
actions	O
in	O
males	O
,	O
but	O
their	O
metabolic	O
role	O
in	O
females	O
is	O
unclear	O
.	O

To	O
determine	O
the	O
physiologic	O
androgen	11835
receptor	11835
(	O
AR	11835
)	O
-	O
dependent	O
actions	O
of	O
androgens	D000728
on	O
atherogenesis	D050197
in	O
female	O
mice	10090
,	O
we	O
generated	O
female	O
AR	11835
-	O
knockout	O
(	O
ARKO	11835
)	O
mice	10090
on	O
an	O
atherosclerosis	D050197
-	O
prone	O
apolipoprotein	11816
E	11816
(	O
apoE	11816
)	O
-	O
deficient	O
background	O
.	O

After	O
8	O
weeks	O
on	O
a	O
high	O
-	O
fat	O
diet	O
,	O
but	O
not	O
on	O
a	O
normal	O
chow	O
diet	O
,	O
atherosclerosis	D050197
in	O
aorta	O
was	O
increased	O
in	O
ARKO	11835
females	O
(	O
+	O
59%	O
vs	O
.	O

control	O
apoE	11816
-	O
deficient	O
mice	10090
with	O
intact	O
AR	11835
gene	O
)	O
.	O

They	O
also	O
displayed	O
increased	O
body	O
weight	O
(	O
+	O
18%	O
)	O
,	O
body	O
fat	O
percentage	O
(	O
+	O
62%	O
)	O
,	O
and	O
hepatic	O
triglyceride	100035834
levels	O
,	O
reduced	O
insulin	16334
sensitivity	O
,	O
and	O
a	O
marked	O
atherogenic	D050197
dyslipidemia	D050171
(	O
serum	O
cholesterol	D002784
,	O
+	O
52%	O
)	O
.	O

Differences	O
in	O
atherosclerosis	D050197
,	O
body	O
weight	O
,	O
and	O
lipid	D008055
levels	O
between	O
ARKO	11835
and	O
control	O
mice	10090
were	O
abolished	O
in	O
mice	10090
that	O
were	O
ovariectomized	O
before	O
puberty	O
,	O
consistent	O
with	O
a	O
protective	O
action	O
of	O
ovarian	O
androgens	D000728
mediated	O
via	O
the	O
AR	11835
.	O

Furthermore	O
,	O
the	O
AR	11835
agonist	O
dihydrotestosterone	D013196
reduced	O
atherosclerosis	D050197
(	O
-	O
41%	O
;	O
thoracic	O
aorta	O
)	O
,	O
subcutaneous	O
fat	O
mass	O
(	O
-	O
44%	O
)	O
,	O
and	O
cholesterol	D002784
levels	O
(	O
-	O
35%	O
)	O
in	O
ovariectomized	O
mice	10090
,	O
reduced	O
hepatocyte	O
lipid	D008055
accumulation	O
in	O
hepatoma	D006528
cells	O
in	O
vitro	O
,	O
and	O
regulated	O
mRNA	O
expression	O
of	O
hepatic	O
genes	O
pivotal	O
for	O
lipid	D008055
homeostasis	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
AR	11835
protects	O
against	O
diet	O
-	O
induced	O
atherosclerosis	D050197
in	O
female	O
mice	10090
and	O
propose	O
that	O
this	O
is	O
mediated	O
by	O
modulation	O
of	O
body	O
composition	O
and	O
lipid	D008055
metabolism	O
.	O
Macular	D003317
corneal	D003317
dystrophy	D003317
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	4166
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	4166
sulfotransferase	4166
gene	4166
(	O
CHST6	4166
)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	D003317
corneal	D003317
dystrophy	D003317
(	O
MCD	D003317
)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O

METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O

The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(	O
LM	O
)	O
and	O
an	O
electron	O
microscope	O
(	O
EM	O
)	O
separately	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
,	O
and	O
the	O
coding	O
region	O
of	O
CHST6	4166
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O

RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	D007501
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O

Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O

The	O
compound	O
heterozygous	O
mutations	O
,	O
c	c|SUB|C|892|T
.	O
892C	c|SUB|C|892|T
>	O
T	c|SUB|C|892|T
and	O
c	c|SUB|T|1072|C
.	O
1072T	c|SUB|T|1072|C
>	O
C	c|SUB|T|1072|C
,	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	4166
in	O
three	O
patients	9606
.	O

The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	p|SUB|Q|298|X
codon	p|SUB|Q|298|X
for	p|SUB|Q|298|X
glutamine	p|SUB|Q|298|X
at	p|SUB|Q|298|X
codon	p|SUB|Q|298|X
298	p|SUB|Q|298|X
(	O
p	p|SUB|Q|298|X
.	O
Q298X	p|SUB|Q|298|X
)	O
and	O
a	O
missense	O
mutation	O
at	O
codon	p|SUB|Y|358|H
358	p|SUB|Y|358|H
,	O
tyrosine	p|SUB|Y|358|H
to	p|SUB|Y|358|H
histidine	p|SUB|Y|358|H
(	O
p	p|SUB|Y|358|H
.	O
Y358H	p|SUB|Y|358|H
)	O
.	O

The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O

These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O

CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	4166
function	O
,	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	D007632
sulfate	D007632
(	O
KS	D007632
)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O

It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	1277
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O
